FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Pavanello, C
   Mosca, L
   Cigoli, MS
   Cavallari, U
   Mombelli, G
   Romeo, S
   Calabresi, L
AF Pavanello, C.
   Mosca, L.
   Cigoli, M. S.
   Cavallari, U.
   Mombelli, G.
   Romeo, S.
   Calabresi, L.
TI PLASMA LP(A) LEVELS CORRELATE WITH CARDIOVASCULAR DISEASE BEYOND
   LDL-CHOLESTEROL IN AN ITALIAN COHORT OF FH
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pavanello, C.; Calabresi, L.] Univ Milan, Ctr E Grossi Paoletti, Dip Sci Farmacol & Biomol, Milan, Italy.
   [Mosca, L.; Cigoli, M. S.; Cavallari, U.] ASST Grande Osped Metropolitano Niguarda, Dip Med Lab, SS Genet Med, Milan, Italy.
   [Mombelli, G.] ASST Grande Osped Metropolitano Niguarda, Ctr Dislipidemie, SSD Diag & Cure Terr Mal Cardiache, Milan, Italy.
   [Romeo, S.] Sahlgrenska Ctr Cardiovasc & Metab Res, Dept Mol & Clin Med, Dept Cardiolog, Gothenburg, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.3.202
BP E163
EP E163
DI 10.1016/j.atherosclerosis.2018.06.489
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600501
DA 2019-10-28
ER

PT J
AU Pecherina, T
   Kastalap, V
   Barbarash, O
AF Pecherina, T.
   Kastalap, V.
   Barbarash, O.
TI CLINICAL CASE OF A PATIENT WITH A FAMILY HETEROZYGOUS
   HYPERCHOLESTEROLEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pecherina, T.; Kastalap, V.; Barbarash, O.] Sci Res Inst Complex Problems Cardiovasc Dis, Kemerovo, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.498
BP E246
EP E246
DI 10.1016/j.atherosclerosis.2018.06.781
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600793
DA 2019-10-28
ER

PT J
AU Pek, SLT
   Chan, EZL
   Lee, ZY
   Ang, KKL
   Ou, AY
   Qi, XG
   Ng, LF
   Wong, JW
   Yeoh, LY
   Lim, SC
   Sum, CF
   Tavintharan, S
AF Pek, S. L. T.
   Chan, E. Z. L.
   Lee, Z. Y.
   Ang, K. K. L.
   Ou, A. Y.
   Qi, X. G.
   Ng, L. F.
   Wong, J. W.
   Yeoh, L. Y.
   Lim, S. C.
   Sum, C. F.
   Tavintharan, S.
TI CLINICAL AND GENETIC PROFILES IN TYPE 2 DIABETES PATIENTS WITH MODERATE
   TO SEVERE HYPERTRIGLYCERIDEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pek, S. L. T.; Chan, E. Z. L.; Lee, Z. Y.; Ang, K. K. L.; Ou, A. Y.; Qi, X. G.; Ng, L. F.; Wong, J. W.; Lim, S. C.; Tavintharan, S.] Khoo Teck Puat Hosp, Clin Res Unit, Singapore, Singapore.
   [Lim, S. C.; Sum, C. F.; Tavintharan, S.] Admiralty Med Ctr, Diabet Ctr, Singapore, Singapore.
   [Yeoh, L. Y.; Lim, S. C.; Sum, C. F.; Tavintharan, S.] Khoo Teck Puat Hosp, Dept Med, Singapore, Singapore.
   [Lim, S. C.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.3.321
BP E197
EP E197
DI 10.1016/j.atherosclerosis.2018.06.608
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600620
DA 2019-10-28
ER

PT J
AU Pellegrin, M
   Bouzourene, K
   Aubert, J
   Mazzolai, L
AF Pellegrin, M.
   Bouzourene, K.
   Aubert, J.
   Mazzolai, L.
TI ROLE OF CD4+T CELLS IN ANGIOTENSIN II-INDUCED ATHEROSCLEROSIS AND PLAQUE
   VULNERABILITY IN 2-KIDNEY, 1-CLIP APOE-/-MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pellegrin, M.; Bouzourene, K.; Aubert, J.; Mazzolai, L.] Univ Hosp Lausanne, Div Angiol, Lausanne, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.032
BP E113
EP E113
DI 10.1016/j.atherosclerosis.2018.06.317
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600329
DA 2019-10-28
ER

PT J
AU Pereira, A
   Abrao, T
   Saldanha, A
   Gason, V
   Fonseca, L
   Santos, R
   Martinez, T
AF Pereira, A.
   Abrao, T.
   Saldanha, A.
   Gason, V.
   Fonseca, L.
   Santos, R.
   Martinez, T.
TI AGE DEPENDANT ASSOCIATION OF URIC ACID AND HYPERTENSION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pereira, A.; Abrao, T.; Fonseca, L.; Santos, R.; Martinez, T.] Sao Paulo Heart Inst, Sao Paulo, Brazil.
   [Saldanha, A.; Gason, V.] BP A Beneficiencia Portuguesa, Sao Paulo, Brazil.
OI Leme da Rocha Martinez, Tania/0000-0002-1027-6954
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.516
BP E250
EP E251
DI 10.1016/j.atherosclerosis.2018.06.797
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600808
DA 2019-10-28
ER

PT J
AU Pereira, A
   Sposito, A
   Fonseca, L
   Saldanha, A
   Gazon, V
   Fo, RS
   Elias, MC
   Martinez, T
AF Pereira, A.
   Sposito, A.
   Fonseca, L.
   Saldanha, A.
   Gazon, V.
   Santos Fo, R.
   Elias, M. C.
   Martinez, T.
TI BODY MASS INDEX AND SALT INTAKE MAY LACK CLUSTERING WITH OTHER RISK
   MARKERS FOR HYPERTENSION IN YOUNG AND MIDDLE ADULTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pereira, A.; Fonseca, L.; Santos Fo, R.; Elias, M. C.; Martinez, T.] Sao Paulo Heart Inst InCor, Sao Paulo, Brazil.
   [Sposito, A.] Campinas Univ, Campinas, SP, Brazil.
   [Saldanha, A.; Gazon, V.] BP A Beneficiencia Portuguesa Sao Paulo, Sao Paulo, Brazil.
RI da Rocha Martinez, Tania Leme/M-6547-2019; Martinez, Tania L
   R/L-4271-2018; Sposito, Andrei C/G-4116-2013
OI da Rocha Martinez, Tania Leme/0000-0002-1027-6954; Sposito, Andrei
   C/0000-0001-7127-2052
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.396
BP E218
EP E218
DI 10.1016/j.atherosclerosis.2018.06.683
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600695
DA 2019-10-28
ER

PT J
AU Perello, E
   Savall, E
   Martinez-hervas, E
   Civera, M
   Real, JT
   Ascaso, JF
AF Perello, E.
   Savall, E.
   Martinez-hervas, S.
   Civera, M.
   Real, J. T.
   Ascaso, J. F.
TI POSTPRANDIAL INTERLEUKIN RESPONSE AFTER AN ORAL FAT LOAD TEST IN
   PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Perello, E.; Savall, E.; Martinez-hervas, S.; Civera, M.; Real, J. T.; Ascaso, J. F.] Univ Valencia, Hosp Clin Univ CIBERDEM, Valencia, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.027
BP E111
EP E112
DI 10.1016/j.atherosclerosis.2018.06.312
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600324
DA 2019-10-28
ER

PT J
AU Perez, JVV
   Hoppstadter, J
   Bruscoli, S
   Riccardi, C
   Kiemer, AK
AF Perez, J. V. Valbuena
   Hoppstaedter, J.
   Bruscoli, S.
   Riccardi, C.
   Kiemer, A. K.
TI STATIN-INDUCED MYOPATHY: ROLE OF THE GLUCOCORTICOID-INDUCED LEUCINE
   ZIPPER
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Perez, J. V. Valbuena; Hoppstaedter, J.; Kiemer, A. K.] Saarland Univ, Dept Pharmaceut Biol, Saarbrucken, Germany.
   [Hoppstaedter, J.; Bruscoli, S.; Riccardi, C.] Univ Perugia, Dept Med, Sect Pharmacol, Perugia, Italy.
RI Riccardi, Carlo/N-4610-2014; Kiemer, Alexandra K./I-9300-2012
OI Riccardi, Carlo/0000-0001-9257-3997; Kiemer, Alexandra
   K./0000-0002-7224-9900
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG22.4
BP E54
EP E55
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600160
DA 2019-10-28
ER

PT J
AU Lopez, CP
   Almagro, F
   Brea, A
   Sanchez-Chaparro, MA
   Muniz, O
   Alvarez-Sala, L
   Ariza, MJ
   Valdivielso, P
AF Perez Lopez, C.
   Almagro, F.
   Brea, A.
   Sanchez-Chaparro, M. A.
   Muniz, O.
   Alvarez-Sala, L.
   Ariza, M. J.
   Valdivielso, P.
TI SEQUENCE VARIANTS IN THE GPIHBP1 GENE IN PATIENTS WITH SEVERE
   HYPERTRIGLYCERIDEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Perez Lopez, C.; Sanchez-Chaparro, M. A.; Valdivielso, P.] Hosp Virgen Victoria, Malaga, Spain.
   [Almagro, F.] Donostia Ospitalea, San Sebastian, Spain.
   [Brea, A.] Hosp San Pedro, Logrono, Spain.
   [Muniz, O.] Hosp Virgen Rocio, Seville, Spain.
   [Alvarez-Sala, L.] Hosp Gregorio Maranon, Madrid, Spain.
   [Ariza, M. J.] Lab Lipidos & Arteriosclerosis CIMES, Malaga, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.2.184
BP E157
EP E158
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600483
DA 2019-10-28
ER

PT J
AU Perez-calahorra, S
   Mateo-Gallego, R
   Plana, N
   Pedro-Botet, J
   Suarez-Tembra, M
   Sanchez-Hernandez, RM
   Almagro, F
   Ascaso, JF
   Ortega, E
   Lahoz, C
   Valdivielso, P
   Civeira, F
AF Perez-calahorra, S.
   Mateo-Gallego, R.
   Plana, N.
   Pedro-Botet, J.
   Suarez-Tembra, M.
   Sanchez-Hernandez, R. M.
   Almagro, F.
   Ascaso, J. F.
   Ortega, E.
   Lahoz, C.
   Valdivielso, P.
   Civeira, F.
TI VARIATION OF THE CONCENTRATION OF LIPOPROTEIN (A) ACCORDING TO
   CONCENTRATION OF TRIGLYCERIDES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Perez-calahorra, S.; Mateo-Gallego, R.; Civeira, F.] Hosp Univ Miguel Servet, Unidad Lipidos, IIS Aragon, CIBERCV, Zaragoza, Spain.
   [Plana, N.] Univ Rovira & Virgili, Unitat Med Vasc & Metab, St Joan Univ IISPV, CIBERDEM, Tarragona, Spain.
   [Pedro-Botet, J.] Dept Endocrinol & Nutr, Lipid & Vasc Risk Unit, Barcelona, Spain.
   [Suarez-Tembra, M.] Hosp San Rafael, Unidad Lipidos, La Coruna, Spain.
   [Sanchez-Hernandez, R. M.] Hosp Univ Insular Materno Infantil, Serv Endocrinol & Nutr, Las Palmas Gran Canarias, Spain.
   [Almagro, F.] Hosp Donostia, Unidad Lipidos, San Sebastian, Spain.
   [Ascaso, J. F.] Hosp Univ Valencia, Serv Endocrinol, Valencia, Spain.
   [Ortega, E.] Hosp Clin CIBEROBN, Lipid Clin, Endocrinol & Nutr Serv, Inst Invest Biomed August Pi Sunyer, Barcelona, Spain.
   [Lahoz, C.] Hosp Carlos III, Unidad Lipid, Madrid, Spain.
   [Valdivielso, P.] Univ Malaga HVirgen Victoria, Dept Med & Dermatol, Lipid & Atherosclerosis Lab, CIMES, Malaga, Spain.
RI MASANA, LUIS/M-7002-2019
OI MASANA, LUIS/0000-0002-0789-4954
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.3.204
BP E163
EP E164
DI 10.1016/j.atherosclerosis.2018.06.491
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600503
DA 2019-10-28
ER

PT J
AU Peri, C
   Zocchi, M
   Mitro, N
   Caruso, D
   De Fabiani, E
   Crestani, M
AF Peri, C.
   Zocchi, M.
   Mitro, N.
   Caruso, D.
   De Fabiani, E.
   Crestani, M.
TI STUDYING THE EPIGENETIC BASIS OF AGE RELATED AND CARDIOMETABOLIC
   DISEASES IN HUMANIZED MOUSE MODELS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Peri, C.; Zocchi, M.; Mitro, N.; Caruso, D.; De Fabiani, E.; Crestani, M.] Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy.
FU EUEuropean Union (EU) [FP7-HUMAN-602757]
FX EU FP7-HUMAN-602757
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.4.292
BP E189
EP E189
DI 10.1016/j.atherosclerosis.2018.06.579
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600591
DA 2019-10-28
ER

PT J
AU Petelina, T
   Musikhina, N
   Gapon, L
   Sharoyan, U
AF Petelina, T.
   Musikhina, N.
   Gapon, L.
   Sharoyan, U.
TI THE ROLE OF STATINS IN PREVENTION OF ACUTE CORONARY EVENTS IN PATIENTS
   WITH CORONARY HEART DISEASE BEFORE AND AFTER CORONARY ANGIOPLASTY AND
   STENTING
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Petelina, T.; Musikhina, N.; Gapon, L.; Sharoyan, U.] Tomsk Natl Res Med Ctr, Tyumen Cardiol Res Ctr, Tyumen, Russia.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.2.414
BP E223
EP E223
DI 10.1016/j.atherosclerosis.2018.06.701
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600713
DA 2019-10-28
ER

PT J
AU Petrov, I
   Dumitrescu, A
   Ceska, R
   Zafrir, B
   Wozakowska-Kaplon, B
   Fabryova, L
   Pintaric, H
   Bridges, I
   Petkova, R
AF Petrov, I.
   Dumitrescu, A.
   Ceska, R.
   Zafrir, B.
   Wozakowska-Kaplon, B.
   Fabryova, L.
   Pintaric, H.
   Bridges, I.
   Petkova, R.
TI CLINICAL MANAGEMENT OF HIGH AND VERY HIGH RISK PATIENTS WITH
   HYPERLIPIDEMIA IN CENTRAL AND EASTERN EUROPE: AN OBSERVATIONAL STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Petrov, I.] Heart & Vasc Inst, City Clin, Cardiol Angiol & Electrophysiol Dept, Sofia, Bulgaria.
   [Dumitrescu, A.] Univ Med & Farm Timisoara, CardioPrevent Fdn, Timisoara, Romania.
   [Ceska, R.] Charles Univ Prague, Ctr Prevent Cardiol, Dept Internal Med 3, Prague, Czech Republic.
   [Zafrir, B.] Lady Davis Carmel Med Ctr, Dept Cardiovasc Med, Haifa, Israel.
   [Wozakowska-Kaplon, B.] Jan Kochanowski Univ Humanities & Sci, Cardiol Clin, Swietokrzyskie, Poland.
   [Fabryova, L.] MED PED Ctr, Lipid Clin, Dept Diabet & Metab Disorders, Bratislava, Slovakia.
   [Pintaric, H.] Univ Zagreb, Fac Dent, Dept Internal Med, Grad Zagreb, Croatia.
   [Bridges, I.] Amgen Ltd, Cambridge, England.
   [Petkova, R.] Amgen Bulgaria EOOD, Sofia, Bulgaria.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.467
BP E237
EP E237
DI 10.1016/j.atherosclerosis.2018.06.750
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600762
DA 2019-10-28
ER

PT J
AU Piljac, A
   Ljubic, S
   Jazbec, A
   Iovrencic, MV
   Duvnjak, LS
AF Piljac, A.
   Ljubic, S.
   Jazbec, A.
   Iovrencic, M. Vucic
   Duvnjak, L. Smircic
TI ADIPONECTIN AND HIGH-DENSITY LIPOPROTEIN ARE CLOSELY RELATED TO FATTY
   LIVER, YET CYSTATIN C EMERGES AS AN IMPORTANT FACTOR IN THE PREDICTION
   OF DIABETIC NEPHROPATHY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Piljac, A.; Ljubic, S.; Duvnjak, L. Smircic] Merkur Univ Hosp, Vuk Vrhovac Univ Clin, Zagreb, Croatia.
   [Jazbec, A.] Univ Zagreb, Zagreb, Croatia.
   [Iovrencic, M. Vucic] Merkur Univ Hosp, Dept Lab Med, Zagreb, Croatia.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.4.337
BP E201
EP E202
DI 10.1016/j.atherosclerosis.2018.06.624
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600636
DA 2019-10-28
ER

PT J
AU Pinegina, N
   Loguinova, M
   Vagida, M
   Shpektor, A
   Vasilieva, E
   Margolis, L
AF Pinegina, N.
   Loguinova, M.
   Vagida, M.
   Shpektor, A.
   Vasilieva, E.
   Margolis, L.
TI CORRELATIONS OF PHENOTYPIC COMPOSITION OF MONOCYTES AND
   MONOCYTE-PLATELET COMPLEXES AND IN-HOSPITAL COMPLICATIONS IN PATIENTS
   WITH ACUTE MYOCARDIAL INFARCTION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pinegina, N.; Loguinova, M.; Vagida, M.; Shpektor, A.; Vasilieva, E.] Moscow State Univ Med & Dent, Lab Atherothrombosis, Moscow, Russia.
   [Margolis, L.] NICHD, NIH, Program Phys Biol, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG40.3
BP E88
EP E89
DI 10.1016/j.atherosclerosis.2018.06.244
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600258
DA 2019-10-28
ER

PT J
AU Pirazzi, C
   Sandstedt, J
   Hakansson, L
   Gustafsson, C
   Wiklund, O
   Romeo, S
   Mancina, R
AF Pirazzi, C.
   Sandstedt, J.
   Hakansson, L.
   Gustafsson, C.
   Wiklund, O.
   Romeo, S.
   Mancina, R.
TI IDENTIFICATION OF A NEW GENETIC DETERMINANT OF FAMILIAL
   HYPERCHOLESTEROLEMIA (FH)
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pirazzi, C.; Sandstedt, J.; Hakansson, L.; Gustafsson, C.; Romeo, S.] Sahgrenksa Univ Hosp, Dept Cardiol, Gothenburg, Sweden.
   [Wiklund, O.; Romeo, S.; Mancina, R.] Wallenberg Lab Cardiovasc & Metab Res, Gothenburg, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.245
BP E175
EP E175
DI 10.1016/j.atherosclerosis.2018.06.532
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600544
DA 2019-10-28
ER

PT J
AU Pirim, D
   Coban, N
   Erkan, AF
   Ekici, B
   Erginel-Unaltuna, N
   Diker, IY
   Ozuynuk, AS
AF Pirim, D.
   Coban, N.
   Erkan, A. F.
   Ekici, B.
   Erginel-Unaltuna, N.
   Diker, I. Y.
   Ozuynuk, A. S.
TI A NOVEL MIRSNP AT THE IGF1 3 ' UTR MAY MODULATE THE MIRNA-MEDIATED GENE
   EXPRESSION IN CARDIOVASCULAR DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pirim, D.; Coban, N.; Erkan, A. F.; Ekici, B.; Erginel-Unaltuna, N.; Diker, I. Y.; Ozuynuk, A. S.] Uludag Univ, Bursa, Turkey.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.4.295
BP E190
EP E190
DI 10.1016/j.atherosclerosis.2018.06.582
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600594
DA 2019-10-28
ER

PT J
AU Pitha, J
   Pithova, P
   Stavek, P
   Hubacek, JA
   Auzky, O
   Houdkova, R
   Eisenreichova, S
   Neskudla, T
   Pelikanova, T
   Kvapil, M
AF Pitha, J.
   Pithova, P.
   Stavek, P.
   Hubacek, J. A.
   Auzky, O.
   Houdkova, R.
   Eisenreichova, S.
   Neskudla, T.
   Pelikanova, T.
   Kvapil, M.
TI CONNEXIN 37 GENE POLYMORPHISM AND ATHEROSCLEROTIC CHANGES IN WOMEN WITH
   DIABETES TYPE 1 AND 2
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pitha, J.; Pithova, P.; Kvapil, M.] Charles Univ Prague, Fac Hosp Motol, Fac Med 2, Clin Internal Med, Prague, Czech Republic.
   [Stavek, P.; Hubacek, J. A.; Auzky, O.; Houdkova, R.] Inst Clin & Expt Med, Lab Atherosclerosis Res, Ctr Med Expt, Prague, Czech Republic.
   [Eisenreichova, S.; Neskudla, T.; Pelikanova, T.] Inst Clin & Expt Med, Ctr Diabetol, Prague, Czech Republic.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.2.276
BP E184
EP E185
DI 10.1016/j.atherosclerosis.2018.06.563
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600575
DA 2019-10-28
ER

PT J
AU Plochberger, B
   Roehrl, C
   Preiner, J
   Karner, A
   Axmann, M
   Novacek, J
   Sezgin, E
   Eggeling, C
   Hinterndorfer, P
   Schuetz, GJ
   Stangl, H
AF Plochberger, B.
   Roehrl, C.
   Preiner, J.
   Karner, A.
   Axmann, M.
   Novacek, J.
   Sezgin, E.
   Eggeling, C.
   Hinterndorfer, P.
   Schuetz, G. J.
   Stangl, H.
TI INTERACTION OF LIPOPROTEIN PARTICLES WITH LIPID BILAYER-MEMBRANES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Plochberger, B.; Preiner, J.; Karner, A.] Upper Austria Univ Appl Sci, Linz, Austria.
   [Roehrl, C.; Axmann, M.; Stangl, H.] Med Univ Vienna, Inst Med Chem, Vienna, Austria.
   [Novacek, J.] CEITEC, Brno, Czech Republic.
   [Sezgin, E.; Eggeling, C.] Univ Oxford, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
   [Hinterndorfer, P.] Johannes Kepler Univ Linz, Inst Biophys, Linz, Austria.
   [Schuetz, G. J.] TU Wien, Inst Appl Phys, Vienna, Austria.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG3.6
BP E23
EP E23
DI 10.1016/j.atherosclerosis.2018.06.054
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600068
DA 2019-10-28
ER

PT J
AU Pojskic, L
   Stimjanin, E
   Selimovic, H
   Pojskic, B
AF Pojskic, L.
   Stimjanin, E.
   Selimovic, H.
   Pojskic, B.
TI FAMILIAL HYPERCHOLESTEROLEMIA IN HOSPITAL SCREENING PROGRAM IN BOSNIA
   AND HERZEGOVINA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pojskic, L.; Stimjanin, E.; Selimovic, H.; Pojskic, B.] Cantonal Hosp Zenica, Zenica, Bosnia & Herceg.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.253
BP E178
EP E178
DI 10.1016/j.atherosclerosis.2018.06.540
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600552
DA 2019-10-28
ER

PT J
AU Poledne, R
   Lesna, IK
   Hovingh, GH
   Kastelein, JJP
AF Poledne, R.
   Lesna, I. Kralova
   Hovingh, G. H.
   Kastelein, J. J. P.
TI MACROPHAGES OF ADIPOSE TISSUE MIGHT AFFECT LIFE EXPECTANCY OF FH
   INDIVIDUALS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Poledne, R.; Lesna, I. Kralova] Ctr Med Expt, Inst Clin & Expt Med, Prague, Czech Republic.
   [Hovingh, G. H.; Kastelein, J. J. P.] Univ Amsterdam, Acad Med Ctr, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.2.042
BP E116
EP E116
DI 10.1016/j.atherosclerosis.2018.06.328
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600340
DA 2019-10-28
ER

PT J
AU Porsch, FS
   Kiss, M
   Tsiantoulas, D
   Ozsvar-Kozma, M
   Goederle, L
   Nitschke, L
   Binder, CJ
AF Porsch, F. S.
   Kiss, M.
   Tsiantoulas, D.
   Ozsvar-Kozma, M.
   Goederle, L.
   Nitschke, L.
   Binder, C. J.
TI CD22 DEFICIENCY REDUCES PLASMA TRIGLYCERIDE LEVELS WITHOUT AFFECTING
   ATHEROSCLEROTIC LESION SIZE IN FEMALE LDLR-/- MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Porsch, F. S.; Kiss, M.; Tsiantoulas, D.; Ozsvar-Kozma, M.; Goederle, L.; Binder, C. J.] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
   [Kiss, M.; Tsiantoulas, D.; Ozsvar-Kozma, M.; Goederle, L.; Binder, C. J.] Austrian Acad Sci CeMM, Ctr Mol Med, Vienna, Austria.
   [Nitschke, L.] Univ Erlangen Nurnberg, Dept Biol, Div Genet, Erlangen, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG15.4
BP E44
EP E45
DI 10.1016/j.atherosclerosis.2018.06.114
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600128
DA 2019-10-28
ER

PT J
AU Porsgaard, T
   Povlsen, GK
   Langhi, C
   Nygaard, H
   Marcher, H
   Jappe, MB
   Alsted, TJ
AF Porsgaard, T.
   Povlsen, G. K.
   Langhi, C.
   Nygaard, H.
   Marcher, H.
   Jappe, M. B.
   Alsted, T. J.
TI THE HYPERGLYCEMIC, DYSLIPIDEMIC SYRIAN GOLDEN HAMSTER IS A POTENTIAL
   MODEL FOR STUDYING ANTI-DIABETIC TREATMENTS AND LIPID MODULATING
   INTERVENTIONS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Porsgaard, T.; Nygaard, H.; Marcher, H.; Jappe, M. B.; Alsted, T. J.] Novo Nordisk, Global Res, Insulin Pharmacol, Malov, Denmark.
   [Povlsen, G. K.; Langhi, C.] Novo Nordisk, Global Res, Insulin Metab & Safety Biol, Malov, Denmark.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.160
BP E151
EP E151
DI 10.1016/j.atherosclerosis.2018.06.447
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600459
DA 2019-10-28
ER

PT J
AU Perez, ABP
   Rodriguez, PV
   Suarez, SR
   Fuentetaja, RS
   Cid, RD
   Armesto, RA
   Diaz, JLD
AF Porto Perez, A. B.
   Vazquez Rodriguez, P.
   Ruanova Suarez, S.
   Suarez Fuentetaja, R.
   De la Fuente Cid, R.
   Argueso Armesto, R.
   Diaz Diaz, J. L.
TI HYPERTRANSAMINASEMIA AND HEPATIC STEATOSIS: CHARACTERISTICS AND
   TEMPORARY EVOLUTION IN A COHORT OF FAMILIAL COMBINED HYPERLIPIDAEMIA
   PATIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Porto Perez, A. B.; Vazquez Rodriguez, P.; Ruanova Suarez, S.; Suarez Fuentetaja, R.; De la Fuente Cid, R.; Argueso Armesto, R.; Diaz Diaz, J. L.] Complexo Hosp Univ A Coruna, La Coruna, Spain.
RI Diaz, Jose Luis JLDD Diaz/Q-2523-2015
OI Diaz, Jose Luis JLDD Diaz/0000-0002-9194-495X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.1.301
BP E191
EP E192
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600600
DA 2019-10-28
ER

PT J
AU Posadas-sanchez, R
   Angeles-Martinez, J
   Perez-Hernandez, N
   Rodriguez-Perez, JM
   Lopez-Bautista, F
   Flores-Dominguez, C
   Fragoso, JM
   Posadas-Romero, C
   Vargas-Alarcon, G
AF Posadas-sanchez, R.
   Angeles-Martinez, J.
   Perez-Hernandez, N.
   Rodriguez-Perez, J. M.
   Lopez-Bautista, F.
   Flores-Dominguez, C.
   Fragoso, J. M.
   Posadas-Romero, C.
   Vargas-Alarcon, G.
TI INTERLEUKIN 10 GENE POLYMORPHISMS ARE ASSOCIATED WITH A DECREASED RISK
   OF DEVELOPING PREMATURE CORONARY ARTERY DISEASE AND SOME CLINICAL AND
   METABOLIC PARAMETERS. THE GEA STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Posadas-sanchez, R.; Lopez-Bautista, F.; Posadas-Romero, C.] Inst Nacl Cardiol Ignacio Chavez, Dept Endocrinol, Cuidad De Mexico, Mexico.
   [Angeles-Martinez, J.; Perez-Hernandez, N.; Rodriguez-Perez, J. M.; Flores-Dominguez, C.; Fragoso, J. M.; Vargas-Alarcon, G.] Inst Nacl Cardiol Ignacio Chavez, Dept Mol Biol, Cuidad De Mexico, Mexico.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.024
BP E110
EP E110
DI 10.1016/j.atherosclerosis.2018.06.309
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600321
DA 2019-10-28
ER

PT J
AU Poussin, C
   Spinelli, SL
   Curran, TM
   Baglia, LA
   Berg, R
   Ansari, S
   Guedj, E
   Medlin, LF
   Ivanov, NV
   Picavet, P
   Phipps, RP
   Peitsch, MC
   Hoeng, J
AF Poussin, C.
   Spinelli, S. L.
   Curran, T. M.
   Baglia, L. A.
   Berg, R.
   Ansari, S.
   Guedj, E.
   Medlin, L. Fedlin
   Ivanov, N. V.
   Picavet, P.
   Phipps, R. P.
   Peitsch, M. C.
   Hoeng, J.
TI A CLINICAL RESEARCH INVESTIGATION ON THE EFFECTS OF CIGARETTE SMOKING,
   E-CIGARETTE VAPING AND SMOKING CESSATION ON VASCULAR CELL BIOLOGY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Poussin, C.; Ansari, S.; Guedj, E.; Medlin, L. Fedlin; Ivanov, N. V.; Picavet, P.; Peitsch, M. C.; Hoeng, J.] Philip Morris Int R&D, Neuchatel, Switzerland.
   [Spinelli, S. L.; Curran, T. M.; Baglia, L. A.; Berg, R.; Phipps, R. P.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.463
BP E236
EP E236
DI 10.1016/j.atherosclerosis.2018.06.747
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600759
DA 2019-10-28
ER

PT J
AU Pramfalk, C
   Ahmed, O
   Larsson, L
   Hardfeldt, J
   Pedrelli, M
   Vedin, L
   Steffensen, K
   Tellez, M
   Delbes, A
   Denis, R
   Luquet, S
   Eriksson, M
   Parini, P
AF Pramfalk, C.
   Ahmed, O.
   Larsson, L.
   Hardfeldt, J.
   Pedrelli, M.
   Vedin, L.
   Steffensen, K.
   Tellez, M.
   Delbes, A.
   Denis, R.
   Luquet, S.
   Eriksson, M.
   Parini, P.
TI GENETIC DEPLETION OF THE SOAT2 GENE DIMINISHES DIET-INDUCED HEPATIC
   STEATOSIS AND IMPROVES GLUCOSE TOLERANCE IN MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Pramfalk, C.; Ahmed, O.; Larsson, L.; Hardfeldt, J.; Pedrelli, M.; Vedin, L.; Steffensen, K.; Parini, P.] Karolinska Inst, Dept Lab Med, Stockholm, Sweden.
   [Ahmed, O.] Khartoum Univ, Dept Biochem, Fac Med, Khartoum, Sudan.
   [Tellez, M.; Delbes, A.; Denis, R.; Luquet, S.] Paris Diderot Univ, Sorbonne Paris Cite, CNRS UMR 8251, Paris, France.
   [Eriksson, M.; Parini, P.] Karolinska Inst, Dept Med, Stockholm, Sweden.
OI Denis, Raphael/0000-0002-7677-7460
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG4.6
BP E25
EP E25
DI 10.1016/j.atherosclerosis.2018.06.060
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600074
DA 2019-10-28
ER

PT J
AU Prus, Y
   Sergienko, I
   Ansheles, A
AF Prus, Y.
   Sergienko, I.
   Ansheles, A.
TI MYOCARDIAL PERFUSION ABNORMALITIES AND SEVERITY OF ATHEROSCLEROTIC
   CAROTID ARTERY LESIONS IN PATIENTS WITH DIFFERENT PROBABILITY OF FH
   DIAGNOSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Prus, Y.; Sergienko, I.; Ansheles, A.] Natl Med Res Ctr Cardiol, Moscow, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.8.120
BP E139
EP E139
DI 10.1016/j.atherosclerosis.2018.06.408
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600420
DA 2019-10-28
ER

PT J
AU Puertas-gonzalez, JA
   Maresma, MF
   Miquel, AP
   Vilagut, FT
   Corral, IS
   Lafuente, H
   Alia-ramos, P
   Moraes, MC
   Ingles, EC
   Bonnin, RR
   Pinto-sala, X
   Candas-estebanez, B
AF Puertas-gonzalez, J. A.
   Fanlo Maresma, M.
   Padro Miquel, A.
   Trias Vilagut, F.
   Sarasa Corral, I.
   Lafuente, H.
   Alia-ramos, P.
   Carratini Moraes, M.
   Corbella Ingles, E.
   Rigo Bonnin, R.
   Pinto-sala, X.
   Candas-estebanez, B.
TI PREVALENCE OF RISK ALLELES OF POLYGENIC HYPERTRIGLYCERIDEMIA AND
   ASSOCIATION WITH MAXIMUM TRIGLYCERIDE SERUM CONCENTRATION ON SOUTHERN
   BARCELONA METROPOLITAN AREA POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Puertas-gonzalez, J. A.; Padro Miquel, A.; Alia-ramos, P.; Carratini Moraes, M.; Rigo Bonnin, R.; Candas-estebanez, B.] Hosp Univ Bellvitge, Clin Lab, Mol Genet, Barcelona, Spain.
   [Fanlo Maresma, M.; Trias Vilagut, F.; Sarasa Corral, I.; Lafuente, H.; Corbella Ingles, E.; Pinto-sala, X.] Hosp Univ Bellvitge, Cardiovasc Risk Unit, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.2.274
BP E184
EP E184
DI 10.1016/j.atherosclerosis.2018.06.561
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600573
DA 2019-10-28
ER

PT J
AU Grifol, NP
   Jin, L
   Estruch, M
   Pascale, B
   Quesada, JLS
   Gonzalez, SB
AF Puig Grifol, N.
   Jin, L.
   Estruch, M.
   Pascale, B.
   Sanchez Quesada, J. L.
   Benitez Gonzalez, S.
TI ROLE OF SPHINGOLIPIDS IN THE INFLAMMATORY AND APOPTOTIC EFFECTS OF
   LDL(-) ON MONOCYTES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Puig Grifol, N.; Jin, L.; Estruch, M.; Pascale, B.; Sanchez Quesada, J. L.; Benitez Gonzalez, S.] Hosp Santa Creu & Sant Pau, IIB St Pau, Res Inst, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG8.4
BP E32
EP E32
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600096
DA 2019-10-28
ER

PT J
AU Qayyum, F
   Lauridsen, BK
   Frikke-Schmidt, R
   Nordestgaard, BG
   Tybjaerg-Hansen, A
AF Qayyum, F.
   Lauridsen, B. K.
   Frikke-Schmidt, R.
   Nordestgaard, B. G.
   Tybjaerg-Hansen, A.
TI STATIN TREATMENT, GENETIC INHIBITION OF HMGCR AND RISK OF SYMPTOMATIC
   GALLSTONE DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Qayyum, F.; Lauridsen, B. K.; Frikke-Schmidt, R.; Tybjaerg-Hansen, A.] Rigshosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Nordestgaard, B. G.] Herlev & Gentofte Hosp, Dept Clin Biochem, Copenhagen, Denmark.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG9.4
BP E35
EP E35
DI 10.1016/j.atherosclerosis.2018.06.087
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600101
DA 2019-10-28
ER

PT J
AU Qi, YF
   Zhu, Q
   Ni, XQ
   Lu, WW
   Zhang, JS
   Ren, JL
   Wu, DI
   Chen, Y
   Zhang, LS
   Yu, YR
   Tang, CS
AF Qi, Y. F.
   Zhu, Q.
   Ni, X. Q.
   Lu, W. W.
   Zhang, J. S.
   Ren, J. L.
   Wu, D. I.
   Chen, Y.
   Zhang, L. S.
   Yu, Y. R.
   Tang, C. S.
TI INTERMEDIN REDUCES NEOINTIMA FORMATION BY REGULATING VASCULAR SMOOTH
   MUSCLE CELL PHENOTYPE VIA CAMP/PKA PATHWAY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Qi, Y. F.; Zhu, Q.; Ni, X. Q.; Lu, W. W.; Zhang, J. S.; Ren, J. L.; Wu, D. I.; Chen, Y.; Zhang, L. S.; Yu, Y. R.; Tang, C. S.] Peking Univ, Hlth Sci Ctr, Beijing, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG16:2
BP E46
EP E46
DI 10.1016/j.atherosclerosis.2018.06.118
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600132
DA 2019-10-28
ER

PT J
AU Navarro, GMQ
   Alcala-diaz, JF
   Perez-corral, I
   Torres-pena, JD
   Fernandez-gandara, C
   Perez-jimenez, F
   Delgado-lista, J
   Lopez-miranda, J
AF Quintana Navarro, G. M.
   Alcala-diaz, J. F.
   Perez-corral, I.
   Torres-pena, J. D.
   Fernandez-gandara, C.
   Perez-jimenez, F.
   Delgado-lista, J.
   Lopez-miranda, J.
TI LONG-TERM ADHERENCE TO TWO HEALTHY DIETS IN CORONARY PATIENTS AFTER FIVE
   YEARS OF DIETARY INTERVENTION: CORDIOPREV STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Quintana Navarro, G. M.; Alcala-diaz, J. F.; Perez-corral, I.; Torres-pena, J. D.; Fernandez-gandara, C.; Perez-jimenez, F.; Delgado-lista, J.; Lopez-miranda, J.] Univ Cordoba, Reina SofIa Univ Hosp, IMIBIC, Lipids & Atherosclerosis Unit, Cordoba, Spain.
   [Quintana Navarro, G. M.; Alcala-diaz, J. F.; Perez-corral, I.; Torres-pena, J. D.; Fernandez-gandara, C.; Perez-jimenez, F.; Delgado-lista, J.; Lopez-miranda, J.] Inst Hlth CarlosIII, Spanish Biomed Res Ctr Physiopathol Obes & Nutr C, Madrid, Spain.
RI Alcala-Diaz, Juan F./Q-4455-2019
OI Alcala-Diaz, Juan F./0000-0002-4572-3611
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG33.5
BP E74
EP E74
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600221
DA 2019-10-28
ER

PT J
AU Rademakers, T
   Manca, M
   Orban, T
   Jin, H
   Frissen, HJM
   Ruhle, F
   Hautvast, P
   Sikkink, CJ
   Peutz-Kootstra, CJ
   Heeneman, S
   Daemen, MJ
   Stoll, M
   van Zandvoort, MA
   Dequiedt, F
   van Buul, JD
   Biessen, EA
AF Rademakers, T.
   Manca, M.
   Orban, T.
   Jin, H.
   Frissen, H. J. M.
   Ruehle, F.
   Hautvast, P.
   Sikkink, C. J.
   Peutz-Kootstra, C. J.
   Heeneman, S.
   Daemen, M. J.
   Stoll, M.
   van Zandvoort, M. A.
   Dequiedt, F.
   van Buul, J. D.
   Biessen, E. A.
TI ENDOTHELIAL BETA-2 SPECTRIN: A CRITICAL PLAQUE STIFFNESS DEPENDENT
   REGULATOR OF MICROVESSEL LEAKAGE IN HUMAN ATHEROSCLEROTIC PLAQUE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rademakers, T.; Manca, M.; Jin, H.; Frissen, H. J. M.; Hautvast, P.; Peutz-Kootstra, C. J.; Heeneman, S.; Biessen, E. A.] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Pathol, Maastricht, Netherlands.
   [Rademakers, T.; van Buul, J. D.] Sanquin Res & Landsteiner Lab, Lab Mol Cell Biol, Dept Plasma Prot, Amsterdam, Netherlands.
   [Orban, T.; Dequiedt, F.] Univ Liege, GIGA, Lab Prot Signaling & Interact, Liege, Belgium.
   [Ruehle, F.; Stoll, M.] Maastricht Univ, Dept Cardiogenet, Maastricht, Netherlands.
   [Ruehle, F.; Stoll, M.] Univ Munster, Inst Human Genet, Genet Epidemiol, Munster, Germany.
   [Sikkink, C. J.] Zuyderland Med Ctr, Dept Surg, Sittard Geleen, Netherlands.
   [Daemen, M. J.] Acad Med Ctr, Dept Pathol, Amsterdam, Netherlands.
   [van Zandvoort, M. A.] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Mol Cell Biol, Maastricht, Netherlands.
   [Biessen, E. A.] Rhein Westfal TH Aachen, Inst Mol Cardiovasc Res, Aachen, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.086
BP E129
EP E129
DI 10.1016/j.atherosclerosis.2018.06.373
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600385
DA 2019-10-28
ER

PT J
AU Rahman, M
   Steuer, J
   Gilgren, P
   Liu, A
   Frostegard, J
AF Rahman, M.
   Steuer, J.
   Gilgren, P.
   Liu, A.
   Frostegard, J.
TI AN INHIBITOR TO MITOCHONDRIAL REACTIVE OXYGEN SPECIES INHIBITED
   PRO-INFLAMMATORY EFFECT IN ATHEROSCLEROTIC PLAQUES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rahman, M.; Liu, A.; Frostegard, J.] Karolinska Inst, Dept Environm Med, Stockholm, Sweden.
   [Steuer, J.; Gilgren, P.] Karolinska Inst Hosp, Dept Vasc Surg, Stockholm, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.028
BP E112
EP E112
DI 10.1016/j.atherosclerosis.2018.06.313
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600325
DA 2019-10-28
ER

PT J
AU Rajkovic, J
   Peric, M
   Stanisic, J
   Rakocevic, J
   Novakovic, R
   Djokic, V
   Labudovic-Borovic, M
   Tepavcevic, S
   Kanjuh, V
   Heinle, H
   Gojkovic-Bukarica, LJ
AF Rajkovic, J.
   Peric, M.
   Stanisic, J.
   Rakocevic, J.
   Novakovic, R.
   Djokic, V.
   Labudovic-Borovic, M.
   Tepavcevic, S.
   Kanjuh, V.
   Heinle, H.
   Gojkovic-Bukarica, L. J.
TI INVOLVEMENT OF ATP-SENSITIVE AND LARGE-CONDUTANCE CALCIUM-ACTIVATED
   POTASSIUM CHANNELS IN PINACIDIL EFFECTS ON THE ISOLATED INTERNAL MAMMARY
   ARTERY GRAFTS FROM PATIENTS WITH TYPE-2 DIABETES MELLITUS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rajkovic, J.; Novakovic, R.; Djokic, V.; Gojkovic-Bukarica, L. J.] Med Fac, Inst Pharmacol Clin Pharmacol & Toxicol, Belgrade, Serbia.
   [Peric, M.] Dedinje Cardiovasc Inst, Belgrade, Serbia.
   [Stanisic, J.; Tepavcevic, S.] Vinca Inst Nucl Sci, Lab Mol Biol & Endocrinol, Belgrade, Serbia.
   [Rakocevic, J.; Labudovic-Borovic, M.] Med Fac, Inst Histol & Embryol, Belgrade, Serbia.
   [Kanjuh, V.] Serbian Acad Arts & Sci, Belgrade, Serbia.
   [Heinle, H.] Inst Physiol, Tubingen, Germany.
OI Stanisic, Jelena/0000-0002-4365-9169
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.6.101
BP E133
EP E133
DI 10.1016/j.atherosclerosis.2018.06.389
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600401
DA 2019-10-28
ER

PT J
AU Rallidis, L
   Kotakos, C
   Vilaeti, A
   Katsimardos, A
   Grassos, C
   Moutsatou, P
   Iliodromitis, E
AF Rallidis, L.
   Kotakos, C.
   Vilaeti, A.
   Katsimardos, A.
   Grassos, C.
   Moutsatou, P.
   Iliodromitis, E.
TI HOMOCYSTEINE IS AN INDEPENDENT PREDICTOR OF LONG-TERM CARDIOVASCULAR
   MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE IN THE ERA OF
   STATINS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rallidis, L.; Vilaeti, A.; Katsimardos, A.; Moutsatou, P.; Iliodromitis, E.] Univ Gen Hosp Attikon, Athens, Greece.
   [Kotakos, C.] 251 Air Force Gen Hosp, Athens, Greece.
   [Grassos, C.] KAT Gen Hosp Attica, Athens, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.476
BP E239
EP E240
DI 10.1016/j.atherosclerosis.2018.06.759
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600771
DA 2019-10-28
ER

PT J
AU Ramin-Mangata, S
   Thedrez, A
   Cariou, B
   Scharfmann, R
   Nobecourt, E
   Lambert, G
AF Ramin-Mangata, S.
   Thedrez, A.
   Cariou, B.
   Scharfmann, R.
   Nobecourt, E.
   Lambert, G.
TI LDL RECEPTOR (LDLR) EXPRESSION AND LDL UPTAKE IN HUMAN PANCREATIC BETA
   CELLS ARE REGULATED BY STATINS AND PCSK9-CONSEQUENCE FOR
   GLUCOSE-STIMULATED INSULIN SECRETION (GSIS)
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ramin-Mangata, S.; Nobecourt, E.; Lambert, G.] Univ La Reunion, INSERM, UMR DeTROI, St Denis, Reunion, France.
   [Thedrez, A.; Cariou, B.] Univ Nantes, CNRS, INSERM, Inst Thorax, Nantes, France.
   [Scharfmann, R.] Univ Paris 05, INSERM, Inst Cochin, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG3.2
BP E22
EP E22
DI 10.1016/j.atherosclerosis.2018.06.050
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600064
DA 2019-10-28
ER

PT J
AU Rather, R
   Dhawan, V
AF Rather, R.
   Dhawan, V.
TI AQUEOUS TERMINALIA ARJUNA EXTRACT INDUCED DIFFERENTIAL PROTEIN
   EXPRESSION IN HYPERCHOLESTEROLEMIC RABBITS: A PROTEOMIC BASED STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rather, R.] Wachemo Univ, Hossaina, Ethiopia.
   [Dhawan, V.] PGIMER, Chandigarh, India.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W7:3
BP E7
EP E8
DI 10.1016/j.atherosclerosis.2018.06.907
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600024
DA 2019-10-28
ER

PT J
AU Rathod, K
   Koganti, S
   Mathur, A
   Wragg, A
   Jones, D
AF Rathod, K.
   Koganti, S.
   Mathur, A.
   Wragg, A.
   Jones, D.
TI CULPRIT LESION VERSUS MULTI-VESSEL INTERVENTION IN PATIENTS WITH
   CARDIOGENIC SHOCK COMPLICATING MYOCARDIAL INFARCTION: INCIDENCE AND
   OUTCOMES FROM THE LONDON HEART ATTACK GROUP
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rathod, K.; Koganti, S.; Mathur, A.; Wragg, A.; Jones, D.] St Bartholomews Hosp, Barts Heart Ctr, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG7:6
BP E31
EP E31
DI 10.1016/j.atherosclerosis.2018.06.078
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600092
DA 2019-10-28
ER

PT J
AU Rathod, K
   Koganti, S
   Mathur, A
   Wragg, A
   Jones, D
AF Rathod, K.
   Koganti, S.
   Mathur, A.
   Wragg, A.
   Jones, D.
TI COMPLETE VERSUS CULPRIT ONLY LESION INTERVENTION IN ACS PATIENTS WITH
   MULTI-VESSEL DISEASE: INCIDENCE AND OUTCOMES FROM THE LONDON HEART
   ATTACK GROUP
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rathod, K.; Koganti, S.; Mathur, A.; Wragg, A.; Jones, D.] St Bartholomews Hosp, Barts Heart Ctr, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.458
BP E234
EP E235
DI 10.1016/j.atherosclerosis.2018.06.742
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600754
DA 2019-10-28
ER

PT J
AU Rauch, U
   Bengtsson, E
   Goncalves, I
   Hultgardh-Nilsson, A
AF Rauch, U.
   Bengtsson, E.
   Goncalves, I.
   Hultgardh-Nilsson, A.
TI DOES THE FIBROUS CAP STRIKE BACK? MOLECULES IMPLICATED IN
   MECHANOTRANSDUCTION IN ATHEROSCLEROTIC PLAQUES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rauch, U.; Hultgardh-Nilsson, A.] Dept Expt Med Sci, Lund, Sweden.
   [Bengtsson, E.] Dept Clin Sci, Malmo, Sweden.
   [Goncalves, I.] Dept Cardiol, Clin Sci, Malmo, Sweden.
RI Bengtsson, Eva/AAA-1968-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.6.100
BP E133
EP E133
DI 10.1016/j.atherosclerosis.2018.06.388
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600400
DA 2019-10-28
ER

PT J
AU Rawther, T
   Torres, LFC
   Rye, KA
   Tabet, F
AF Rawther, T.
   Torres, L. F. Cuesta
   Rye, K. A.
   Tabet, F.
TI REGULATION OF LIPOPROTEIN(A) EXPRESSION BY MICRORNAS IN HUMAN HEPATOMA
   CELL LINE HEP3B
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rawther, T.; Torres, L. F. Cuesta; Rye, K. A.; Tabet, F.] Univ New South Wales Australia, Sch Med Sci Mech Dis & Translat Res, Sydney, NSW, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.3.192
BP E160
EP E160
DI 10.1016/j.atherosclerosis.2018.06.479
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600491
DA 2019-10-28
ER

PT J
AU Ray, K
   Stoekenbroek, RM
   Kallend, D
   Leiter, LA
   Landmesser, U
   Scott-Wright, R
   Wijngaard, P
   Kastelein, JJP
AF Ray, K.
   Stoekenbroek, R. M.
   Kallend, D.
   Leiter, L. A.
   Landmesser, U.
   Scott-Wright, R.
   Wijngaard, P.
   Kastelein, J. J. P.
TI EFFECT OF AN RNAI THERAPEUTIC TARGETING PCSK9 ON ATHEROGENIC
   LIPOPROTEINS: PRE-SPECIFIED SECONDARY ENDPOINTS IN ORION 1
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ray, K.] Imperial Colllege, Dept Primary Care & Publ Hlth, Imperial Ctr Cardiovasc Dis Prevent, London, England.
   [Stoekenbroek, R. M.; Kastelein, J. J. P.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
   [Kallend, D.; Wijngaard, P.] Med Co, Parsippany, NJ USA.
   [Leiter, L. A.] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Div Endocrinol & Metab, Toronto, ON, Canada.
   [Landmesser, U.] Charite Univ Med Berlin, Dept Cardiol, Berlin Inst Hlth, Berlin, Germany.
   [Landmesser, U.] German Ctr Cardiovac Resear, Berlin, Germany.
   [Scott-Wright, R.] Mayo Clin, Dept Cardiol, Rochester, MN USA.
RI Ray, Kausik/Z-2055-2019
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA LB2:2
BP E9
EP E9
DI 10.1016/j.atherosclerosis.2018.06.911
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600028
DA 2019-10-28
ER

PT J
AU Raz, O
   Rosenzweig, T
   Rogovsky, O
   Shapira, I
   Berliner, S
AF Raz, O.
   Rosenzweig, T.
   Rogovsky, O.
   Shapira, I.
   Berliner, S.
TI EFFECT OF HIGH COMPLEX CARBOHYDRATE DIET ON WEIGHT REDUCTION AND THE
   METABOLIC AND INFLAMMATORY MARKERS IN POSTMENOPAUSAL WOMEN
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Raz, O.] Ariel Univ, Ariel, Israel.
   [Rosenzweig, T.; Rogovsky, O.; Shapira, I.; Berliner, S.] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.5.355
BP E206
EP E206
DI 10.1016/j.atherosclerosis.2018.06.641
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600653
DA 2019-10-28
ER

PT J
AU Razgildina, N
   Panteleeva, A
   Miroshnikova, V
   Pobozheva, I
   Polyakova, E
   Berkovitch, O
   Belyaeva, O
   Baranova, E
   Pchelina, S
AF Razgildina, N.
   Panteleeva, A.
   Miroshnikova, V.
   Pobozheva, I.
   Polyakova, E.
   Berkovitch, O.
   Belyaeva, O.
   Baranova, E.
   Pchelina, S.
TI OMENTIN1 GENE EXPRESSION IN EPICARDIAL AND SUBCUTANEOUS ADIPOSE TISSUE
   DURING OBESITY RELATED CORONARY HEART DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Razgildina, N.; Panteleeva, A.; Miroshnikova, V.; Pchelina, S.] Petersburg Nucl Phys Inst, St Petersburg, Russia.
   [Panteleeva, A.; Pobozheva, I.; Polyakova, E.; Berkovitch, O.; Belyaeva, O.; Baranova, E.; Pchelina, S.] First Pavlov State Med Univ St Petersburg, St Petersburg, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.7.239
BP E173
EP E174
DI 10.1016/j.atherosclerosis.2018.06.526
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600538
DA 2019-10-28
ER

PT J
AU Reeskamp, LF
   Hartgers, ML
   Peter, J
   Dallinga-Thie, GM
   Grefhorst, A
   Zuurbier, LCA
   Defesche, JC
   Hovingh, GK
AF Reeskamp, L. F.
   Hartgers, M. L.
   Peter, J.
   Dallinga-Thie, G. M.
   Grefhorst, A.
   Zuurbier, L. C. A.
   Defesche, J. C.
   Hovingh, G. K.
TI A DEEP INTRONIC VARIANT IN LDLR CAUSING FAMILIAL HYPERCHOLESTEROLEMIA:
   TIME TO WIDEN THE SCOPE?
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Reeskamp, L. F.; Hartgers, M. L.; Hovingh, G. K.] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
   [Peter, J.; Dallinga-Thie, G. M.; Grefhorst, A.] Acad Med Ctr, Dept Expt Vasc Med, Amsterdam, Netherlands.
   [Zuurbier, L. C. A.; Defesche, J. C.] Acad Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA LB1:4
BP E4
EP E4
DI 10.1016/j.atherosclerosis.2018.06.894
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600011
DA 2019-10-28
ER

PT J
AU Ressia, A
   Dell'Oca, N
   Reyes, X
   Fernandez, G
   Stoll, M
AF Ressia, A.
   Dell'Oca, N.
   Reyes, X.
   Fernandez, G.
   Stoll, M.
TI CUMULATIVE LDL-C BURDEN AS A CVD RISK PREDICTOR ON FAMILIAL
   HYPERCHOLESTEROLEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ressia, A.; Dell'Oca, N.; Reyes, X.; Fernandez, G.; Stoll, M.] Comis Honoraria Salud Cardiovasc CHSCV, Montevideo, Uruguay.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG36:5
BP E81
EP E82
DI 10.1016/j.atherosclerosis.2018.06.226
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600240
DA 2019-10-28
ER

PT J
AU Revnic, CR
   Ginghina, C
   Revnic, F
   Voinea, S
AF Revnic, C. R.
   Ginghina, C.
   Revnic, F.
   Voinea, S.
TI BIOCHEMICAL STUDIES OF POLYMORPHONUCLEAR CELLS(PMN) ACTIVITY IN PATIENTS
   WITH ACUTE CORONARY SYNDROMES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Revnic, C. R.; Voinea, S.] UMF Carol Davila, Bucharest, Romania.
   [Ginghina, C.] CC Iliescu Inst, Bucharest, Romania.
   [Revnic, F.] NIGG Ana Aslan, Bucharest, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.039
BP E115
EP E115
DI 10.1016/j.atherosclerosis.2018.06.324
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600336
DA 2019-10-28
ER

PT J
AU Revnic, CR
   Ginghina, C
   Revnic, F
   Paltineanu, B
   Voinea, S
AF Revnic, C. R.
   Ginghina, C.
   Revnic, F.
   Paltineanu, B.
   Voinea, S.
TI EVALUATION OF APOPTOSIS IN LYMPHOCYTES FROM PATIENTS WITH ACUTE CORONARY
   SYNDROMES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Revnic, C. R.; Voinea, S.] UMF Carol Davila, Bucharest, Romania.
   [Ginghina, C.] CC Iliescu Inst, Bucharest, Romania.
   [Revnic, F.] NIGG Ana Aslan, Bucharest, Romania.
   [Paltineanu, B.] UMF Tg Mures, Bucharest, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.038
BP E114
EP E115
DI 10.1016/j.atherosclerosis.2018.06.323
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600335
DA 2019-10-28
ER

PT J
AU Revnic, CR
   Revnic, F
   Paltineanu, B
   Voinea, S
AF Revnic, C. R.
   Revnic, F.
   Paltineanu, B.
   Voinea, S.
TI PHYSIOLOGICAL STUDIES OF CARDIAC CONTRACTILITY OF RABBIT HEART WITH
   EXPERIMENTAL HYPERTHYROIDISM
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Revnic, C. R.; Voinea, S.] UMF Carol Davila, Bucharest, Romania.
   [Revnic, F.] NIGG Ana Aslan, Bucharest, Romania.
   [Paltineanu, B.] UMF Tg Mures, Targu Mures, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.7.117
BP E138
EP E138
DI 10.1016/j.atherosclerosis.2018.06.405
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600417
DA 2019-10-28
ER

PT J
AU Rhew, JY
   Kim, W
   Cho, JH
AF Rhew, J. Y.
   Kim, W.
   Cho, J. H.
TI EFFECTS OF STATIN THERAPY ON CLINICAL OUTCOMES AFTER ACUTE MYOCARDIAL
   INFARCTION IN PATIENTS WITH ADVANCED RENAL DYSFUNCTION: A PROPENSITY
   SCORE-MATCHED ANALYSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Kim, W.] Kyung Hee Univ Hosp, Seoul, South Korea.
   [Rhew, J. Y.] Jeonju Presbyterian Hosp, Jeonju, South Korea.
   [Cho, J. H.] St Garolo Hosp, Sunchon, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.498BI
BP E246
EP E246
DI 10.1016/j.atherosclerosis.2018.06.782
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600794
OA Green Published
DA 2019-10-28
ER

PT J
AU Ricci, MA
   Scavizzi, M
   Ministrini, S
   Migliola, EN
   De Vuono, S
   Lupattelli, G
AF Ricci, M. A.
   Scavizzi, M.
   Ministrini, S.
   Migliola, E. Nulli
   De Vuono, S.
   Lupattelli, G.
TI MORBID OBESITY AND HYPERTENSION: THE ROLE OF PERI-RENAL FAT
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ricci, M. A.; Scavizzi, M.; Ministrini, S.; Migliola, E. Nulli; De Vuono, S.; Lupattelli, G.] Osped S Maria Misericordia, Dept Med, Internal Med, Perugia, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG34.4
BP E77
EP E77
DI 10.1016/j.atherosclerosis.2018.06.212
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600226
DA 2019-10-28
ER

PT J
AU Martin, SR
   Jimenez, JMD
   Garcia, JFC
   Munoz-Torrero, JFS
AF Rico Martin, S.
   De Nicolas Jimenez, J. M.
   Calderon Garcia, J. F.
   Sanchez Munoz-Torrero, J. F.
TI ANKLE-BRACHIAL DIFFERENCE PULSE WAVE VELOCITY (ABD-PWV) MEASURED WITH A
   NEW DEVICE CORRELATES WITH CAROTID INTIMA-MEDIA THIKNESS (IMT)
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rico Martin, S.; Calderon Garcia, J. F.] Univ Extremadura, Nursing & Therapy Occupat Coll, Caceres, Spain.
   [De Nicolas Jimenez, J. M.] Extremadura Hlth Serv, Hlth Ctr, Zona Ctr, Caceres, Spain.
   [Sanchez Munoz-Torrero, J. F.] Hosp San Pedro Alcantara, Extremadura Hlth Serv, Dept Internal Med, Caceres, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.472
BP E238
EP E239
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600767
DA 2019-10-28
ER

PT J
AU Martin, SR
   Jimenez, JMD
   Garcia, JFC
   Munoz-torrero, JFS
AF Rico Martin, S.
   De Nicolas Jimenez, J. M.
   Calderon Garcia, J. F.
   Sanchez Munoz-torrero, J. F.
TI ANKLE-BRACHIAL DIFFERENCE PULSE WAVE VELOCITY (ABD-PWV) MEASURED WITH A
   NEW DEVICE IS RELATED TO THE PRESENCE OF ATHEROSCLEROTIC CAROTID PLAQUES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rico Martin, S.; Calderon Garcia, J. F.] Univ Extremadura, Nursing & Therapy Occupat Collegue, Caceres, Spain.
   [De Nicolas Jimenez, J. M.] Extremadura Hlth Serv, Hlth Ctr, Zona Ctr, Caceres, Spain.
   [Sanchez Munoz-torrero, J. F.] Hosp San Pedro Alcantara, Extremadura Hlth Serv, Dept Internal Med, Caceres, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.474
BP E239
EP E239
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600769
DA 2019-10-28
ER

PT J
AU Rinne, P
   Kadiri, J
   Velasco-Delgado, M
   Nuutinen, S
   Rami, M
   Savontaus, E
   Steffens, S
AF Rinne, P.
   Kadiri, J.
   Velasco-Delgado, M.
   Nuutinen, S.
   Rami, M.
   Savontaus, E.
   Steffens, S.
TI MELANOCORTIN 1 RECEPTOR DEFICIENCY PROMOTES ATHEROSCLEROSIS IN
   APOLIPOPROTEIN E-/- MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rinne, P.; Kadiri, J.; Velasco-Delgado, M.; Nuutinen, S.; Savontaus, E.] Univ Turku, Inst Biomed, Turku, Finland.
   [Rami, M.] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Prevent IPEK, Munich, Germany.
RI Rinne, Petteri/N-7099-2019; Hollmen, Maija/B-5831-2017
OI Hollmen, Maija/0000-0002-3250-7653
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W8:4
BP E12
EP E12
DI 10.1016/j.atherosclerosis.2018.06.917
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600034
DA 2019-10-28
ER

PT J
AU Rioja, J
   Perez-Lopez, C
   Ariza, MJ
   Lamiquiz, I
   Muniz, O
   Ruiz-Ocana, P
   Carbayo, JA
   Mangas, A
   Alvarez-Sala, L
   Valdivielso, P
AF Rioja, J.
   Perez-Lopez, C.
   Ariza, M. J.
   Lamiquiz, I.
   Muniz, O.
   Ruiz-Ocana, P.
   Carbayo, J. A.
   Mangas, A.
   Alvarez-Sala, L.
   Valdivielso, P.
TI IDENTIFICATION OF CASES WITH LIPOPROTEIN LIPASE DEFICIENCY IN PATIENTS
   WITH SEVERE HYPERTRIGLYCERIDEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rioja, J.; Ariza, M. J.] Univ Malaga, Med & Dermatol Dept, Lipids & Atherosclerosis Lab, CIMES, Malaga, Spain.
   [Perez-Lopez, C.; Valdivielso, P.] Univ Hosp Virgen Victoria, Internal Med Dept, Malaga, Spain.
   [Lamiquiz, I.] Univ Zaragoza, Univ Hosp Miguel Servet, CIBERCV, IIS Aragon, Zaragoza, Spain.
   [Muniz, O.] Univ Hosp Virgen Rocio, Internal Med Dept, Seville, Spain.
   [Ruiz-Ocana, P.] Puerta Mar Puerto Real Hosp, Paedriat Endocrinol Unit, Cadiz, Spain.
   [Carbayo, J. A.] Quiron Salud Hosp, Lipids Unit, Albacete, Spain.
   [Mangas, A.] Univ Hosp Puerta Mar, Internal Med Dept, Cadiz, Spain.
   [Alvarez-Sala, L.] Univ Hosp Gregorio Maranon, Internal Med Dept, Madrid, Spain.
OI Ruiz-Ocana, Pablo/0000-0003-0395-6828
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG25:2
BP E59
EP E59
DI 10.1016/j.atherosclerosis.2018.06.160
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600174
DA 2019-10-28
ER

PT J
AU Ritsch, A
   Duerr, A
   Kahler, P
   Hunjadi, M
   Stojakovic, T
   Zewinger, S
   Speer, T
   Silbernagl, G
   Scharnagl, H
   Kleber, M
   Marz, W
AF Ritsch, A.
   Duerr, A.
   Kahler, P.
   Hunjadi, M.
   Stojakovic, T.
   Zewinger, S.
   Speer, T.
   Silbernagl, G.
   Scharnagl, H.
   Kleber, M.
   Maerz, W.
TI INDEPENDENT EFFECTS OF KIDNEY FUNCTION AND CHOLERSTEROL EFFLUX ON
   CARDIOVASCULAR MORTALITY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ritsch, A.; Duerr, A.; Kahler, P.; Hunjadi, M.] Med Univ Innsbruck, Innsbruck, Austria.
   [Stojakovic, T.; Silbernagl, G.; Scharnagl, H.; Maerz, W.] Med Univ Graz, Graz, Austria.
   [Zewinger, S.; Speer, T.] Saarland Univ, Med Ctr, Homburg, Germany.
   [Kleber, M.; Maerz, W.] Heidelberg Univ, Mannheim, Germany.
   [Maerz, W.] Synlab Acad, Mannheim, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG6.6
BP E28
EP E28
DI 10.1016/j.atherosclerosis.2018.06.072
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600086
DA 2019-10-28
ER

PT J
AU Urbina, AR
   Rull, A
   Llanos, JO
   Quesada, JLS
AF Rivas Urbina, A.
   Rull, A.
   Ordonez Llanos, J.
   Sanchez Quesada, J. L.
TI APOLIPOPROTEIN J-DERIVED MIMETIC PEPTIDE D-[113-122]APOJ BINDS TO LDL
   AND RETARDS ITS SPONTANEOUS AGGREGATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rivas Urbina, A.; Rull, A.; Ordonez Llanos, J.; Sanchez Quesada, J. L.] Hosp St Pau IIB St Pau, Res Inst, Barcelona, Spain.
   [Ordonez Llanos, J.] Univ Autonoma Barcelona, Cerdanyola Del Valles, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.159
BP E150
EP E151
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600458
DA 2019-10-28
ER

PT J
AU Rizos, C
   Barkas, F
   Athyros, V
   Antza, C
   Attilakos, A
   Elisaf, M
   Zacharis, E
   Rallidis, L
   Kiouri, E
   Kolovou, G
   Loulakakis, M
   Boufidou, A
   Skoumas, I
   Liberopoulos, E
AF Rizos, C.
   Barkas, F.
   Athyros, V.
   Antza, C.
   Attilakos, A.
   Elisaf, M.
   Zacharis, E.
   Rallidis, L.
   Kiouri, E.
   Kolovou, G.
   Loulakakis, M.
   Boufidou, A.
   Skoumas, I.
   Liberopoulos, E.
TI CARBOHYDRATE METABOLISM IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA:
   DATA FROM THE HELLAS-FH REGISTRY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rizos, C.; Barkas, F.; Elisaf, M.; Liberopoulos, E.] Univ Ioannina, Med Sch, Dept Internal Med, Ioannina, Greece.
   [Athyros, V.; Antza, C.] Aristotle Univ Thessaloniki, Med Sch, Dept Internal Med, Thessaloniki, Greece.
   [Attilakos, A.] Univ Athens, Med Sch, Dept Pediat, Athens, Greece.
   [Zacharis, E.; Loulakakis, M.] Univ Gen Hosp Heraklion, Cardiol Clin, Iraklion, Greece.
   [Rallidis, L.; Kiouri, E.] Univ Athens, Med Sch, Dept Med, Athens, Greece.
   [Kolovou, G.] Onassis Cardiac Surg Ctr, Cardiol Clin, Athens, Greece.
   [Boufidou, A.] AHEPA Univ, Cardiol Clin, Gen Hosp, Thessaloniki, Greece.
   [Skoumas, I.] Hippokrateion Hosp, Cardiol Clin, Athens, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.246
BP E176
EP E176
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600545
DA 2019-10-28
ER

PT J
AU Rizos, C
   Athyros, V
   Antza, C
   Attilakos, A
   Elisaf, M
   Zacharis, E
   Rallidis, L
   Katsiki, N
   KiourI, E
   Kolovou, G
   Loulakakis, M
   Boufidou, A
   Skoumas, I
   Florentin, M
   Liberopoulos, E
AF Rizos, C.
   Athyros, V.
   Antza, C.
   Attilakos, A.
   Elisaf, M.
   Zacharis, E.
   Rallidis, L.
   Katsiki, N.
   Kiour, E., I
   Kolovou, G.
   Loulakakis, M.
   Boufidou, A.
   Skoumas, I.
   Florentin, M.
   Liberopoulos, E.
TI THE ACHIEVEMENT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TARGET IN
   SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: THE ROLE OF PCSK9
   INHIBITORS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rizos, C.; Elisaf, M.; Florentin, M.; Liberopoulos, E.] Univ Ioannina, Med Sch, Dept Internal Med, Ioannina, Greece.
   [Athyros, V.; Antza, C.; Katsiki, N.] Aristotle Univ Thessaloniki, Med Sch, Dept Internal Med, Thessaloniki, Greece.
   [Attilakos, A.] Univ Athens, Med Sch, Dept Pediat, Athens, Greece.
   [Zacharis, E.; Loulakakis, M.] Univ Gen Hosp Heraklion, Cardiol Clin, Iraklion, Greece.
   [Rallidis, L.; Kiour, E., I] Univ Athens, Med Sch, Dept Med, Athens, Greece.
   [Kolovou, G.] Onassis Cardiac Surg Ctr, Cardiol Clin, Athens, Greece.
   [Boufidou, A.] AHEPA Univ Gen Hosp, Cardiol Clin, Thessaloniki, Greece.
   [Skoumas, I.] Hippokrateion Hosp, Cardiol Clin, Athens, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.247
BP E176
EP E176
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600546
DA 2019-10-28
ER

PT J
AU Rizos, C
   Athyros, V
   Garoufi, A
   Elisaf, M
   Kolovou, G
   Kotsis, V
   Bilianou, E
   Rallidis, L
   Skalides, E
   Skoumas, I
   Tziomalos, K
   Chrousos, G
   Liberopoulos, E
AF Rizos, C.
   Athyros, V.
   Garoufi, A.
   Elisaf, M.
   Kolovou, G.
   Kotsis, V.
   Bilianou, E.
   Rallidis, L.
   Skalides, E.
   Skoumas, I.
   Tziomalos, K.
   Chrousos, G.
   Liberopoulos, E.
TI CARDIOVASCULAR PROFILE AND TREATMENT OF PATIENTS WITH FAMILIAL
   HYPERCHOLESTEROLEMIA IN GREECE: PRELIMINARY DATA FROM THE HELLENIC
   REGISTRY HELLAS-FH
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rizos, C.; Elisaf, M.; Liberopoulos, E.] Univ Ioannina, Med Sch, Dept Internal Med, Ioannina, Greece.
   [Athyros, V.; Kotsis, V.; Tziomalos, K.] Aristotle Univ Thessaloniki, Med Sch, Dept Internal Med, Thessaloniki, Greece.
   [Garoufi, A.; Chrousos, G.] Univ Athens, Med Sch, Dept Pediat, Athens, Greece.
   [Kolovou, G.] Onassis Cardiac Surg Ctr, Cardiol Clin, Athens, Greece.
   [Bilianou, E.] Tzaneio Gen Hosp, Cardiol Clin, Piraeus, Greece.
   [Rallidis, L.] Univ Athens, Med Sch, Dept Med, Athens, Greece.
   [Skalides, E.] Univ Gen Hosp Heraklion, Cardiol Clin, Iraklion, Greece.
   [Skoumas, I.] Hippokrateion Hosp, Cardiol Clin, Athens, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG37:5
BP E83
EP E83
DI 10.1016/j.atherosclerosis.2018.06.231
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600245
DA 2019-10-28
ER

PT J
AU Leal, CR
   Cebada, RT
   Benitez, JS
   Rodriguez, ES
   Guerrero, PP
   Blasco, ER
   Perez, SP
AF Rodriguez Leal, C.
   Toro Cebada, R.
   Soto Benitez, J.
   Sanchez Rodriguez, E.
   Perez Guerrero, P.
   Ruiz Blasco, E.
   Pascual Perez, S.
TI CARDIOVASCULAR PROFILE OF PATIENTS ADMITTED IN MEDICINE INTERNAL. DO WE
   COLLECT THE RISK FACTORS CARDIOVASCULAR IN CLINICAL HISTORY?
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rodriguez Leal, C.; Soto Benitez, J.; Sanchez Rodriguez, E.; Perez Guerrero, P.; Ruiz Blasco, E.; Pascual Perez, S.] Hosp Univ Puerta Mar, Cadiz, Spain.
   [Toro Cebada, R.] Univ Cadiz, Cardiol, Cadiz, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.3.420
BP E224
EP E224
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600719
DA 2019-10-28
ER

PT J
AU Leal, CR
   Cebada, RT
   Benitez, JS
   Gomez, AD
   Gomez, NC
   Racero, IT
   Rojas, AM
AF Rodriguez Leal, C.
   Toro Cebada, R.
   Soto Benitez, J.
   Diaz Gomez, A.
   Caro Gomez, N.
   Tinoco Racero, I.
   Mangas Rojas, A.
TI WHAT IS THE CARDIOVASCULAR PROFILE OF THE PATIENT HOSPITALIZED WITH
   CHRONIC OBLITERANT ARTERIOPATHY?
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rodriguez Leal, C.; Soto Benitez, J.; Diaz Gomez, A.; Caro Gomez, N.; Tinoco Racero, I.; Mangas Rojas, A.] Hosp Univ Puerta Mar, Cadiz, Spain.
   [Toro Cebada, R.] Univ Cadiz, Cardiol, Cadiz, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.475
BP E239
EP E239
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600770
DA 2019-10-28
ER

PT J
AU Leal, CR
   Cebada, RT
   Benitez, JS
   Gomez, NC
   Rodriguez, ES
   Racero, IT
   Moreno, ADS
   Rojas, AM
AF Rodriguez Leal, C.
   Toro Cebada, R.
   Soto Benitez, J.
   Caro Gomez, N.
   Sanchez Rodriguez, E.
   Tinoco Racero, I.
   Santos Moreno, A. De los
   Mangas Rojas, A.
TI CARDIOVASCULAR PROFILE IN HOSPITALIZED PATIENTS WITH AN ISCHEMIC EVENT
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rodriguez Leal, C.; Soto Benitez, J.; Caro Gomez, N.; Sanchez Rodriguez, E.; Tinoco Racero, I.; Santos Moreno, A. De los; Mangas Rojas, A.] Hosp Univ Puerta MAR, Cadiz, Spain.
   [Toro Cebada, R.] Univ Cadiz, Cardiol, Cadiz, Spain.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.376
BP E212
EP E212
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600675
DA 2019-10-28
ER

PT J
AU Leal, CR
   Cebada, RT
   Benitez, JS
   Gomez, NC
   Blasco, ER
   Gestoso, AC
   Gomez, AD
   Rojas, AM
AF Rodriguez Leal, C.
   Toro Cebada, R.
   Soto Benitez, J.
   Caro Gomez, N.
   Ruiz Blasco, E.
   Caceres Gestoso, A.
   Diaz Gomez, A.
   Mangas Rojas, A.
TI CARDIOVASCULAR PROFILE OF PATIENTS WITH ACCIDENT CEREBROVASCULAR
   HOSPITALIZED IN INTERNAL MEDICINE SERVICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rodriguez Leal, C.; Soto Benitez, J.; Caro Gomez, N.; Ruiz Blasco, E.; Caceres Gestoso, A.; Diaz Gomez, A.; Mangas Rojas, A.] Hosp Univ Puerta Del Mar, Cadiz, Spain.
   [Toro Cebada, R.] Univ Cadiz, Cardiol, Cadiz, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.481
BP E241
EP E241
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600776
DA 2019-10-28
ER

PT J
AU Rodriguez-calvo, R
   Bosquet, A
   Girona, J
   Guaita-esteruelas, S
   Heras, M
   Saavedra-Garcia, P
   Martinez-micaelo, N
   Masana, L
AF Rodriguez-calvo, R.
   Bosquet, A.
   Girona, J.
   Guaita-esteruelas, S.
   Heras, M.
   Saavedra-Garcia, P.
   Martinez-micaelo, N.
   Masana, L.
TI BMS309403 DECREASES FATTY ACID-INDUCED ENDOPLASMIC RETICULUM
   STRESS-ASSOCIATED INFLAMMATION IN SKELETAL MUSCLE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rodriguez-calvo, R.; Bosquet, A.; Girona, J.; Guaita-esteruelas, S.; Heras, M.; Saavedra-Garcia, P.; Martinez-micaelo, N.; Masana, L.] Univ Rovira & Virgili, Inst Invest Sanit Pere Virgili, CIBERDEM, Reus, Spain.
RI MASANA, LUIS/M-7002-2019
OI MASANA, LUIS/0000-0002-0789-4954
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.3.319
BP E197
EP E197
DI 10.1016/j.atherosclerosis.2018.06.606
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600618
DA 2019-10-28
ER

PT J
AU Rodriguez-fortunez, P
   Blasco, M
   Diaz, A
   Rodriguez-de Miguel, M
   Orera-pena, L
AF Rodriguez-fortunez, P.
   Blasco, M.
   Diaz, A.
   Rodriguez-de Miguel, M.
   Orera-pena, L.
TI MANAGEMENT OF CARDIOVASCULAR RISK AND TREATMENT IN PATIENTS WITH
   ATHEROGENIC DYSLIPIDEMIA. PERSPECTIVE OF PRIMARY CARE PHYSICIANS. AVANZA
   STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rodriguez-fortunez, P.; Rodriguez-de Miguel, M.; Orera-pena, L.] MYLAN Med Dept, Madrid, Spain.
   [Blasco, M.] CS Delicias Sur, Zaragoza, Spain.
   [Diaz, A.] CS Bembibre, Leon, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.3.417
BP E223
EP E223
DI 10.1016/j.atherosclerosis.2018.06.704
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600716
DA 2019-10-28
ER

PT J
AU Rodriguez-Fortunez, P
   Franch-Nadal, J
   Fornos-Perez, J
   Orera-Pena, L
   de Miguel, MR
AF Rodriguez-Fortunez, P.
   Franch-Nadal, J.
   Fornos-Perez, J.
   Orera-Pena, L.
   Rodriguez de Miguel, M.
TI TELEMEDICINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE SPANISH
   HEALTH SYSTEM. ENREDA2 STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rodriguez-Fortunez, P.; Orera-Pena, L.; Rodriguez de Miguel, M.] MYLAN Med Dept, Madrid, Spain.
   [Franch-Nadal, J.] CS Drassanes Raval Sud, Barcelona, Spain.
   [Fornos-Perez, J.] Working Grp Diabet SEFAC, Pontevedra, Spain.
RI Franch-Nadal, Josep/AAC-1945-2019
OI Franch-Nadal, Josep/0000-0002-5175-1555
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG29.5
BP E67
EP E68
DI 10.1016/j.atherosclerosis.2018.06.186
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600200
DA 2019-10-28
ER

PT J
AU Romanov, V
   Mitchenko, O
   Chulaevska, I
   ILLuschina, A
AF Romanov, V.
   Mitchenko, O.
   Chulaevska, I.
   ILLuschina, A.
TI ATHEROGENIC POTENTIAL OF SUBCLINICAL HYPOTHYROIDISM AND CARDIOVASCULAR
   RISK IN WOMEN WITH HYPERTENSION AND HYPOTHYROIDISM
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Romanov, V.; Mitchenko, O.; Chulaevska, I.; ILLuschina, A.] Inst Cardiol, Kiev, Ukraine.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.2.413
BP E222
EP E222
DI 10.1016/j.atherosclerosis.2018.06.700
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600712
DA 2019-10-28
ER

PT J
AU Romanova, V
AF Romanova, V.
TI PREGNANCY-ASSOCIATED PLASMA PROTEIN A AS THE CRITERION OF CORONARY
   ARTERY DISEASE DESTABILIZATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Romanova, V.] Natl Pirogov Mem Med Univ, Vinnytsya, Ukraine.
RI Romanova, Valentyna/C-2059-2017
OI Romanova, Valentyna/0000-0002-1881-2811
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.074
BP E125
EP E126
DI 10.1016/j.atherosclerosis.2018.06.361
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600373
DA 2019-10-28
ER

PT J
AU Roncero-Ramos, I
   Lopez-Moreno, J
   Jimenez-Lucena, R
   Gomez-Delgado, F
   Vals-Delgado, C
   Delgado-Lista, J
   Camargo, A
   Lopez-Miranda, J
AF Roncero-Ramos, I.
   Lopez-Moreno, J.
   Jimenez-Lucena, R.
   Gomez-Delgado, F.
   Vals-Delgado, C.
   Delgado-Lista, J.
   Camargo, A.
   Lopez-Miranda, J.
TI MEDITERRANEAN DIET, GLUCOSE HOMEOSTASIS AND INFLAMMASOME GENETIC
   VARIANTS: THE CORDIOPREV STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Roncero-Ramos, I.; Lopez-Moreno, J.; Jimenez-Lucena, R.; Gomez-Delgado, F.; Vals-Delgado, C.; Delgado-Lista, J.; Camargo, A.; Lopez-Miranda, J.] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Lipids & Atherosclerosis Unit,Nutrigen GC9, Cordoba, Spain.
   [Roncero-Ramos, I.; Lopez-Moreno, J.; Jimenez-Lucena, R.; Gomez-Delgado, F.; Vals-Delgado, C.; Delgado-Lista, J.; Camargo, A.; Lopez-Miranda, J.] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain.
RI Camargo, Antonio/G-9720-2015
OI Camargo, Antonio/0000-0002-0415-4184
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG31.1
BP E70
EP E70
DI 10.1016/j.atherosclerosis.2018.06.193
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600207
DA 2019-10-28
ER

PT J
AU Rosloniec, E
   Gocal, M
   Mika, P
AF Rosloniec, E.
   Gocal, M.
   Mika, P.
TI DO CLAUDICANTS UNDERESTIMATE THEIR WALKING DISTANCE?
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rosloniec, E.; Gocal, M.; Mika, P.] Univ Phys Educ, Dept Clin Rehabil, Krakow, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.487
BP E242
EP E243
DI 10.1016/j.atherosclerosis.2018.06.770
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600782
DA 2019-10-28
ER

PT J
AU Rosloniec, E
   Wiecek, M
   Mika, P
AF Rosloniec, E.
   Wiecek, M.
   Mika, P.
TI THE EFFECTS OF NORDIC WALKING TRAINING ON BLOOD ANTIOXIDANT DEFENCE IN
   PATIENTS WITH INTERMITTENT CLAUDICATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rosloniec, E.; Mika, P.] Univ Phys Educ, Dept Clin Rehabil, Krakow, Poland.
   [Wiecek, M.] Univ Phys Educ, Dept Physiol & Biochem, Krakow, Poland.
RI Wiecek, Magdalena/U-2339-2019
OI Wiecek, Magdalena/0000-0002-5390-3049
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.029
BP E112
EP E112
DI 10.1016/j.atherosclerosis.2018.06.314
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600326
DA 2019-10-28
ER

PT J
AU Rosloniec, E
   Kulik, A
   Nowobilski, R
   Mika, P
AF Rosloniec, E.
   Kulik, A.
   Nowobilski, R.
   Mika, P.
TI PSYCHIATRIC MORBIDITY IN PATIENTS WITH INTERMITTENT CLAUDICATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rosloniec, E.; Mika, P.] Univ Phys Educ, Dept Clin Rehabil, Krakow, Poland.
   [Kulik, A.] Univ Sch Phys Educ Poznan, Fac Phys Educ Gorzow Wielkopolski, Gorzow Wielkopolski, Poland.
   [Nowobilski, R.] Jagiellonian Univ, Inst Physiotherapy, Krakow, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.483
BP E241
EP E242
DI 10.1016/j.atherosclerosis.2018.06.766
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600778
DA 2019-10-28
ER

PT J
AU Rossi, N
   Falchi, M
   Bourbon, M
   Visconti, A
AF Rossi, N.
   Falchi, M.
   Bourbon, M.
   Visconti, A.
TI WHOLE GENOME SEQUENCING ASSOCIATION STUDIES OF LIPIDS LEVELS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rossi, N.; Bourbon, M.] Inst Nacl Saude Doutor Ricardo Jorge, Lisbon, Portugal.
   [Falchi, M.; Visconti, A.] Kings Coll London, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG46.1
BP E102
EP E102
DI 10.1016/j.atherosclerosis.2018.06.278
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600292
DA 2019-10-28
ER

PT J
AU Rovira-Llopis, S
   Banuls, C
   Diaz-Morales, N
   Escribano-Lopez, I
   Lopez-Domenech, S
   Iannantuoni, F
   de Maranon, AM
   Abad-Jimenez, Z
   Rocha, M
   Victor, VM
   Hernandez-Mijares, A
AF Rovira-llopis, S.
   Banuls, C.
   Diaz-Morales, N.
   Escribano-Lopez, I.
   Lopez-Domenech, S.
   Iannantuoni, F.
   de Maranon, A. M.
   Abad-Jimenez, Z.
   Rocha, M.
   Victor, V. M.
   Hernandez-Mijares, A.
TI REDUCED TESTOSTERONE LEVELS ARE RELATED TO IMPAIRED METABOLIC PROFILE,
   SMALLER HDL AND LDL SUBFRACTIONS AND ENHANCED INFLAMMATION AND
   LEUKOCYTE-ENDOTHELIUM INTERACTIONS IN TYPE 2 DIABETIC MEN
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rovira-llopis, S.; Banuls, C.; Diaz-Morales, N.; Escribano-Lopez, I.; Lopez-Domenech, S.; Iannantuoni, F.; de Maranon, A. M.; Abad-Jimenez, Z.; Rocha, M.; Victor, V. M.; Hernandez-Mijares, A.] Univ Hosp Doctor Peset FISABIO, Serv Endocrinol & Nutr, Valencia, Spain.
   [Rocha, M.; Victor, V. M.] Univ Valencia, Dept Pharmacol, CIBER Hepat & Digest Dis, CIBER Res Grp CB06 04 0071, Valencia, Spain.
   [Victor, V. M.] Univ Valencia, Dept Physiol, Valencia, Spain.
   [Hernandez-Mijares, A.] Univ Valencia, Dept Med, Valencia, Spain.
RI victor, victor/Q-4843-2019
FU European Regional Development Fund (EDRF "A way to build Europe"); 
   [PI15/1424];  [PI16/1083];  [PI16/00301];  [UGP15-220];  [UGP15-193]
FX This study was financed by grants PI15/1424, PI16/1083, PI16/00301,
   UGP15-220, UGP15-193 and European Regional Development Fund (EDRF "A way
   to build Europe").
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.3.325
BP E198
EP E198
DI 10.1016/j.atherosclerosis.2018.06.612
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600624
DA 2019-10-28
ER

PT J
AU Ruhanen, H
   Haridas, PAN
   Zhou, Y
   Jauhiainen, M
   Kakela, R
   Olkkonen, VM
AF Ruhanen, H.
   Haridas, P. A. Nidhina
   Zhou, Y.
   Jauhiainen, M.
   Kakela, R.
   Olkkonen, V. M.
TI ANGPTL3 KNOCK-DOWN ALTERS HEPATOCYTE LIPID PROFILE AND METABOLISM
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ruhanen, H.; Haridas, P. A. Nidhina; Jauhiainen, M.; Olkkonen, V. M.] Minerva Fdn, Helsinki, Finland.
   [Zhou, Y.] Cardiff Univ, Syst Immun Univ Res Inst, Cardiff, S Glam, Wales.
   [Zhou, Y.] Cardiff Univ, Div Infect & Immun, Cardiff, S Glam, Wales.
   [Kakela, R.] Univ Helsinki, Dept Biosci, Helsinki, Finland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG28.1
BP E64
EP E64
DI 10.1016/j.atherosclerosis.2018.06.176
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600190
DA 2019-10-28
ER

PT J
AU Aixa, AR
   Rodriguez-Gallego, E
   Gomez, J
   Domingo, P
   Ferrando-Martinez, S
   Peraire, J
   Vilades, C
   Veloso, S
   Lopez-Dupla, M
   Beltran-Debon, R
   Alba, V
   Vargas, M
   Castellano, A
   Leal, M
   Pacheco, Y
   Ruiz-Mateos, E
   Gutierrez, F
   Vidal, F
AF Rull Aixa, A.
   Rodriguez-Gallego, E.
   Gomez, J.
   Domingo, P.
   Ferrando-Martinez, S.
   Peraire, J.
   Vilades, C.
   Veloso, S.
   Lopez-Dupla, M.
   Beltran-Debon, R.
   Alba, V.
   Vargas, M.
   Castellano, A.
   Leal, M.
   Pacheco, Y.
   Ruiz-Mateos, E.
   Gutierrez, F.
   Vidal, F.
TI CIRCULATING METABOLOMIC PROFILE INDICATES MITOCHONDRIAL DYSFUNCTION IN
   HIV-DYSLIPIDEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rull Aixa, A.; Rodriguez-Gallego, E.; Gomez, J.; Peraire, J.; Vilades, C.; Veloso, S.; Lopez-Dupla, M.; Beltran-Debon, R.; Alba, V.; Vargas, M.; Castellano, A.; Vidal, F.] Univ Rovira & Virgili, Hosp Univ Joan XXIII IISPV, Tarragona, Spain.
   [Gomez, J.] Univ Rovira & Virgili, Dept Elect Engn, Metabol Platform, IISPV, Tarragona, Spain.
   [Domingo, P.] Hosp Santa Creu & Sant Pau, Infect Dis Unit, Barcelona, Spain.
   [Ferrando-Martinez, S.] NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Leal, M.; Pacheco, Y.; Ruiz-Mateos, E.] Virgen Rocio Univ Hosp CSIC Uni, Inst Biomed Seville, IBiS, Lab Immunovirol, Seville, Spain.
   [Gutierrez, F.] Hosp Gen Elche, Infect Dis Unit, Alicante, Spain.
   [Gutierrez, F.] Univ Miguel Hernandez, Alicante, Spain.
RI Beltran-Debon, Raul/A-9287-2014
OI Beltran-Debon, Raul/0000-0001-9691-1906
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.153
BP E149
EP E149
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600452
DA 2019-10-28
ER

PT J
AU Rundblad, A
   Holven, KB
   Bruheim, I
   Myhrstad, MC
   Ulven, SM
AF Rundblad, A.
   Holven, K. B.
   Bruheim, I.
   Myhrstad, M. C.
   Ulven, S. M.
TI EFFECTS OF LEAN AND FATTY FISH AND KRILL OIL ON GENE EXPRESSION IN
   PERIPHERAL BLOOD MONONUCLEAR CELLS AND LIPOPROTEIN SUBCLASSES: A
   RANDOMIZED CONTROLLED TRIAL
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Rundblad, A.; Myhrstad, M. C.] Oslo & Akershus Univ Coll, Dept Nursing & Hlth Promot, Oslo, Norway.
   [Holven, K. B.; Ulven, S. M.] Univ Oslo, Dept Nutr, Oslo, Norway.
   [Holven, K. B.] Oslo Univ Hosp, Natl Advisory Unit Familial Hypercholesterolemia, Oslo, Norway.
   [Bruheim, I.] Rimfrost AS, Fosnavaag, Norway.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG33.3
BP E73
EP E73
DI 10.1016/j.atherosclerosis.2018.06.205
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600219
DA 2019-10-28
ER

PT J
AU Ruuth, M
   Nguyen, SD
   Vihervaara, T
   Hilvo, M
   Uusitupa, M
   Schwab, U
   Savolainen, M
   Jauhiainen, M
   Kakela, R
   Baruch, A
   Laaksonen, R
   Kovanen, PT
   Oorni, K
AF Ruuth, M.
   Nguyen, S. D.
   Vihervaara, T.
   Hilvo, M.
   Uusitupa, M.
   Schwab, U.
   Savolainen, M.
   Jauhiainen, M.
   Kakela, R.
   Baruch, A.
   Laaksonen, R.
   Kovanen, P. T.
   Oorni, K.
TI SUSCEPTIBILITY OF LDL PARTICLES TO AGGREGATE DEPENDS ON PARTICLE
   LIPIDOME, IS MODIFIABLE, AND ASSOCIATES WITH FUTURE CARDIOVASCULAR
   DEATHS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ruuth, M.] Univ Helsinki, Wihuri Res Inst, Helsinki, Finland.
   [Ruuth, M.] Univ Helsinki, Fac Med, Res Program Unit, Helsinki, Finland.
   [Nguyen, S. D.; Kovanen, P. T.; Oorni, K.] Wihuri Res Inst, Helsinki, Finland.
   [Vihervaara, T.; Hilvo, M.; Laaksonen, R.] Zora Biosci, Espoo, Finland.
   [Uusitupa, M.; Schwab, U.] Inst Publ Hlth & Clin Nutr, Sch Med, Kuopio, Finland.
   [Schwab, U.] Kuopio Univ Hosp, Inst Clin Med, Internal Med, Kuopio, Finland.
   [Savolainen, M.] Univ Oulu, Oulu, Finland.
   [Savolainen, M.] Oulu Univ Hosp, Med Res Ctr, Oulu, Finland.
   [Jauhiainen, M.] Minerva Fdn, Helsinki, Finland.
   [Jauhiainen, M.] Natl Inst Hlth & Welf, Helsinki, Finland.
   [Kakela, R.] Univ Helsinki, Helsinki Univ Lipid Unit, Dept Biosci, Helsinki, Finland.
   [Baruch, A.] Genentech Res & Early Dev, San Francisco, CA USA.
   [Laaksonen, R.] Univ Tampere, Finnish Cardiovasc Res Ctr, Tampere, Finland.
   [Laaksonen, R.] Univ Hosp, Finnish Clin Biobank Tampere, Tampere, Finland.
RI Ruuth, Maija/P-6767-2019
OI Ruuth, Maija/0000-0001-8903-0617
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG8.3
BP E32
EP E32
DI 10.1016/j.atherosclerosis.2018.06.081
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600095
DA 2019-10-28
ER

PT J
AU Ryzhkova, A
   Sazonova, M
   Sazonova, M
   Nikitina, N
   Galitsyna, E
   Melnichenko, A
   Demakova, N
   Shkurat, T
   Sobenin, I
AF Ryzhkova, A.
   Sazonova, M.
   Sazonova, M.
   Nikitina, N.
   Galitsyna, E.
   Melnichenko, A.
   Demakova, N.
   Shkurat, T.
   Sobenin, I.
TI INVESTIGATION OF MUTATIONS M.3256C > T AND M.12315G > A IN WOMEN WITH
   ASYMPTOMATIC ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Galitsyna, E.; Melnichenko, A.; Demakova, N.; Shkurat, T.] Southern Fed Univ, Rostov Na Donu, Russia.
   [Ryzhkova, A.; Sazonova, M.; Nikitina, N.; Sobenin, I.] Natl Med Res Ctr Cardiol, Moscow, Russia.
   [Sazonova, M.; Sazonova, M.] Inst Gen Pathol & Pathophysiol, Moscow, Russia.
RI Sobenin, Igor A/J-4282-2013; Sazonova, Margarita A/O-9685-2017;
   Melnichenko, Alexandra A/V-5783-2018
OI Sobenin, Igor A/0000-0003-0978-6444; Sazonova, Margarita
   A/0000-0002-8610-4593; 
FU Russian Science FoundationRussian Science Foundation (RSF) [15-15-10022]
FX This study was supported by Russian Science Foundation, grant
   #15-15-10022.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.528
BP E254
EP E254
DI 10.1016/j.atherosclerosis.2018.06.809
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600820
DA 2019-10-28
ER

PT J
AU Sabrina, P
   Magenta, A
   D'Agostino, M
   Martino, F
   Barilla, F
   Satta, N
   Frias, M
   Gencer, B
   Mach, F
   Vuilleumier, N
AF Sabrina, P.
   Magenta, A.
   D'Agostino, M.
   Martino, F.
   Barilla, F.
   Satta, N.
   Frias, M.
   Gencer, B.
   Mach, F.
   Vuilleumier, N.
TI ANTI-APOLIPOPROTEIN A1 (APOA1) AUTOANTIBODIES DISRUPT THE CHOLESTEROL
   PATHWAY VIA SREBP-2 AND DECREASE CIRCULATING MIR-33A IN
   HYPERCHOLESTEROLAEMIC CHILDREN
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sabrina, P.; Satta, N.; Frias, M.; Vuilleumier, N.] Geneva Univ Hosp, Dept Genet & Lab Med, Div Lab Med, Geneva, Switzerland.
   [Satta, N.; Vuilleumier, N.] Geneva Univ Hosp, Dept Human Prot Sci, Geneva, Switzerland.
   [Magenta, A.; D'Agostino, M.] Fdn Luigi Maria Monti, Ist Dermopat Immacolata IRCCS, Vasc Pathol Lab, Rome, Italy.
   [Martino, F.] Sapienza Univ Rome, Dept Pediat, Ctr Clin Lipid Res, Rome, Italy.
   [Barilla, F.] Sapienza Univ, Dept Cardiovasc Resp Nephrol Anesthesiol & Geriat, Rome, Italy.
   [Frias, M.] Univ Geneva, Fac Med, Dept Internal Med Special, Geneva, Switzerland.
   [Gencer, B.; Mach, F.] Geneva Univ Hosp, Div Cardiol, Geneva, Switzerland.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG14:2
BP E42
EP E43
DI 10.1016/j.atherosclerosis.2018.06.107
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600120
DA 2019-10-28
ER

PT J
AU Sachdev, V
   Leopold, C
   Bauer, R
   Patankar, JV
   Iqbal, J
   Obrowsky, S
   Doktorova, M
   Scheicher, B
   Goeritzer, M
   Kolb, D
   Turnbull, AV
   Zimmer, A
   Hoefler, G
   Hussain, MM
   Groen, AK
   Kratky, D
AF Sachdev, V.
   Leopold, C.
   Bauer, R.
   Patankar, J. V.
   Iqbal, J.
   Obrowsky, S.
   Doktorova, M.
   Scheicher, B.
   Goeritzer, M.
   Kolb, D.
   Turnbull, A. V.
   Zimmer, A.
   Hoefler, G.
   Hussain, M. M.
   Groen, A. K.
   Kratky, D.
TI NOVEL ROLE OF A TRIGLYCERIDE-SYNTHESIZING ENZYME: DGAT1 AT THE CROSSROAD
   BETWEEN TRIGLYCERIDE AND CHOLESTEROL METABOLISM
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sachdev, V.; Leopold, C.; Bauer, R.; Patankar, J. V.; Obrowsky, S.; Goeritzer, M.; Kratky, D.] Med Univ Graz, Inst Mol Biol & Biochem, Graz, Austria.
   [Bauer, R.] Univ Med Ctr Hamburg Eppendorf, Ctr Expt Med, Hamburg, Germany.
   [Patankar, J. V.] Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC, Canada.
   [Iqbal, J.; Hussain, M. M.] Suny Downstate Med Ctr, Dept Cell Biol, New York, NY USA.
   [Doktorova, M.; Groen, A. K.] Univ Groningen, Univ Med, Dept Pediat, Ctr Liver Digest & Metab Dis, Groningen, Netherlands.
   [Scheicher, B.; Zimmer, A.] Karl Franzens Univ Graz, Inst Pharmaceut Sci, Graz, Austria.
   [Kolb, D.] Med Univ Graz, Inst Cell Biol Histol & Embryol, Graz, Austria.
   [Turnbull, A. V.] AstraZeneca R&D, Molndal, Sweden.
   [Hoefler, G.] Med Univ Graz, Inst Pathol, Graz, Austria.
RI Sachdev, Vinay/D-1029-2018; Iqbal, Jahangir/B-3903-2014
OI Sachdev, Vinay/0000-0002-6221-4376; Iqbal, Jahangir/0000-0002-9021-2271
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W9:5
BP E10
EP E11
DI 10.1016/j.atherosclerosis.2018.06.915
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600032
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Sadovnikov, P
   Urazgildeeva, S
   Nizhegorodcev, M
   Olkhovik, A
   Nokhrin, D
   Muzalevskaya, M
   Shugurova, I
   Malenkovskaya, D
   Tregubov, A
   Konovalova, T
   Gurevich, V
AF Sadovnikov, P.
   Urazgildeeva, S.
   Nizhegorodcev, M.
   Olkhovik, A.
   Nokhrin, D.
   Muzalevskaya, M.
   Shugurova, I.
   Malenkovskaya, D.
   Tregubov, A.
   Konovalova, T.
   Gurevich, V.
TI AGE AND GENDER PECULIARITIES OF LIPID SPECTRUM IN RUSSIAN URBAN
   POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Urazgildeeva, S.; Tregubov, A.; Konovalova, T.; Gurevich, V.] St Petersburg State Univ, Med Fac, Clin Sci & Educ Ctr Cardioil, St Petersburg, Russia.
   [Urazgildeeva, S.; Muzalevskaya, M.; Malenkovskaya, D.; Tregubov, A.; Konovalova, T.; Gurevich, V.] Sokolov Hosp, Ctr Atherosclerosis & Lipid Disorders, St Petersburg, Russia.
   [Sadovnikov, P.; Nizhegorodcev, M.; Olkhovik, A.] Ltd Liabil Co, Res & Prod Firm HELIX, St Petersburg, Russia.
   [Nokhrin, D.] Chelyabinsk State Univ, Biol Fac, Dept Microbiol Immunol & Gen Biol, Chelyabinsk, Russia.
   [Urazgildeeva, S.; Shugurova, I.] Ctr Cardiac Med Chernaya Rechka, St Petersburg, Russia.
   [Gurevich, V.] North Western State Med Univ, Chair Hosp Therapy & Cardiol, St Petersburg, Russia.
RI Tregubov, Aleksey V./J-4075-2013; Urazgildeeva, Soreya/H-9319-2013
OI Urazgildeeva, Soreya/0000-0003-3046-372X
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.3.419
BP E224
EP E224
DI 10.1016/j.atherosclerosis.2018.06.706
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600718
DA 2019-10-28
ER

PT J
AU Saely, CH
   Vonbank, A
   Lins, C
   Zanolin, D
   Leiherer, A
   Mader, A
   Larcher, B
   Muendlein, A
   Drexel, H
AF Saely, C. H.
   Vonbank, A.
   Lins, C.
   Zanolin, D.
   Leiherer, A.
   Mader, A.
   Larcher, B.
   Muendlein, A.
   Drexel, H.
TI TYPE 2 DIABETES, CHRONIC KIDNEY DISEASE, AND MORTALITY IN PATIENTS WITH
   ESTABLISHED CARDIOVASCULAR DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Saely, C. H.; Vonbank, A.; Lins, C.; Zanolin, D.; Leiherer, A.; Mader, A.; Larcher, B.; Muendlein, A.; Drexel, H.] VIVIT Inst, Feldkirch, Austria.
   [Saely, C. H.; Vonbank, A.] Acad Teaching Hosp, Feldkirch, Austria.
   [Saely, C. H.; Vonbank, A.; Leiherer, A.; Muendlein, A.; Drexel, H.] Private Univ Principal Liechtenstein, Triesen, Liechtenstein.
   [Leiherer, A.] Med Cent Lab, Feldkirch, Austria.
   [Drexel, H.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.
   [Drexel, H.] Univ Hosp Bern, Swiss Cardiovasc Ctr, Bern, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.4.340
BP E202
EP E203
DI 10.1016/j.atherosclerosis.2018.06.627
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600639
DA 2019-10-28
ER

PT J
AU Sage, A
   Bagchi-Chakraborty, J
   Tsiantoulas, D
   Harrison, J
   Clatworthy, MR
   Masters, L
   Smith, KGC
   Binder, CJ
   Mallat, Z
AF Sage, A.
   Bagchi-Chakraborty, J.
   Tsiantoulas, D.
   Harrison, J.
   Clatworthy, M. R.
   Masters, L.
   Smith, K. G. C.
   Binder, C. J.
   Mallat, Z.
TI FC GAMMA RECEPTOR IIB CONTROLS HUMORAL RESPONSES TO ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sage, A.; Bagchi-Chakraborty, J.; Tsiantoulas, D.; Harrison, J.; Clatworthy, M. R.; Masters, L.; Smith, K. G. C.; Mallat, Z.] Univ Cambridge, Dept Med, Cambridge, England.
   [Tsiantoulas, D.; Binder, C. J.] Med Univ Vienna, Vienna, Austria.
   [Tsiantoulas, D.; Binder, C. J.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria.
   [Mallat, Z.] Paris Cardiovasc Res Ctr, INSERM, U970, Paris, France.
   [Mallat, Z.] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA FC1.2
BP E6
EP E6
DI 10.1016/j.atherosclerosis.2018.06.902
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600019
DA 2019-10-28
ER

PT J
AU Sailer, S
   Haller, V
   Bernscherer, T
   Hunjadi, M
   Wanitschek, M
   Alber, H
   Ritsch, A
AF Sailer, S.
   Haller, V.
   Bernscherer, T.
   Hunjadi, M.
   Wanitschek, M.
   Alber, H.
   Ritsch, A.
TI ALTERED CETP CONCENTRATION AND HDL FUNCTION IN CAD PATIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sailer, S.; Haller, V.; Bernscherer, T.; Hunjadi, M.; Ritsch, A.] Med Univ Innsbruck, Dept Internal Med, Innsbruck, Austria.
   [Wanitschek, M.; Alber, H.] Med Univ Innsbruck, Dept Cardiol, Innsbruck, Austria.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.6.230
BP E171
EP E171
DI 10.1016/j.atherosclerosis.2018.06.517
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600529
DA 2019-10-28
ER

PT J
AU Saliba-Gustafsson, P
   Pedrelli, M
   Werngren, O
   Parini, P
   Ehrenborg, E
AF Saliba-Gustafsson, P.
   Pedrelli, M.
   Werngren, O.
   Parini, P.
   Ehrenborg, E.
TI THE INTERCONNECTION BETWEEN LXR ACTIVATION AND AUTOPHAGY IN PRIMARY
   HUMAN MACROPHAGES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Saliba-Gustafsson, P.; Werngren, O.; Ehrenborg, E.] Karolinska Inst, Ctr Mol Med, Dept Med, Cardiovasc Med Unit, Stockholm, Sweden.
   [Pedrelli, M.; Parini, P.] Karolinska Inst, Dept Lab Med, Div Clin Chem, Stockholm, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.2.045
BP E117
EP E117
DI 10.1016/j.atherosclerosis.2018.06.331
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600343
DA 2019-10-28
ER

PT J
AU Saliba-gustafsson, P
   Pedrelli, M
   Werngren, O
   Parini, P
   Ehrenborg, E
AF Saliba-gustafsson, P.
   Pedrelli, M.
   Werngren, O.
   Parini, P.
   Ehrenborg, E.
TI THE LIPID-DROPLET ASSOCIATED PROTEIN PERILIPIN 2 (PLIN2) PLAYS A CENTRAL
   ROLE IN LIPID ACCUMULATION AND CHOLESTEROL EFFLUX VIA EFFECTS ON LXR
   SIGNALING IN HUMAN MACROPHAGES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Saliba-gustafsson, P.; Werngren, O.; Ehrenborg, E.] Karolinska Inst, Cardiovasc Med Unit, Dept Med CMM, Karolinska Univ Hosp, Stockholm, Sweden.
   [Pedrelli, M.; Parini, P.] Karolinska Inst, Div Clin Chem, Dept Lab Med, Karolinska Univ Hosp, Stockholm, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG8.2
BP E32
EP E32
DI 10.1016/j.atherosclerosis.2018.06.080
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600094
DA 2019-10-28
ER

PT J
AU Salzmann, M
   Mussbacher, M
   Schrottmaier, WC
   Pointner, JB
   Hoesel, B
   Resch, U
   Bleichert, S
   Moser, M
   Assinger, A
   Schmid, JA
AF Salzmann, M.
   Mussbacher, M.
   Schrottmaier, W. C.
   Pointner, J. B.
   Hoesel, B.
   Resch, U.
   Bleichert, S.
   Moser, M.
   Assinger, A.
   Schmid, J. A.
TI kappa B KINASE 2 IMPAIRS PLATELET ACTIVATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Salzmann, M.; Mussbacher, M.; Hoesel, B.; Resch, U.; Bleichert, S.; Moser, M.; Assinger, A.; Schmid, J. A.] Med Univ Vienna, Inst Vasc Biol & Thrombosis Res, Vienna, Austria.
   [Schrottmaier, W. C.] Dept Clin Microbiol, Immunol Unit, Umea, Sweden.
   [Pointner, J. B.] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.
   [Pointner, J. B.] Univ Hosp Solna, Stockholm, Sweden.
RI Schmid, Johannes/C-7659-2009
OI Schmid, Johannes/0000-0002-6586-3507
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG42.3
BP E94
EP E95
DI 10.1016/j.atherosclerosis.2018.06.256
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600270
DA 2019-10-28
ER

PT J
AU Sanchez, R
   Nasir, K
   Klimchak, A
   Kuznik, A
   Joulain, F
   Briggs, A
AF Sanchez, R.
   Nasir, K.
   Klimchak, A.
   Kuznik, A.
   Joulain, F.
   Briggs, A.
TI MODELING THE POPULATION HEALTH BENEFITS OF LDL-C REDUCTION WITH
   ALIROCUMAB AMONG CARDIOVASCULAR DISEASE/HETEROZYGOUS FAMILIAL
   HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LDL-C
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sanchez, R.; Kuznik, A.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
   [Nasir, K.] Baptist Hlth South Florida, Ctr Healthcare Adv & Outcomes, Miami, FL USA.
   [Klimchak, A.] Axtria, Berkeley Hts, NJ USA.
   [Joulain, F.] Sanofi, Paris, France.
   [Briggs, A.] Univ Glasgow, HEHTA, Glasgow, Lanark, Scotland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG45.2
BP E100
EP E100
DI 10.1016/j.atherosclerosis.2018.06.273
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600287
DA 2019-10-28
ER

PT J
AU Ramos, AS
   Martinez, MC
   Ibarretxe, D
   Tomasini, R
   Anglada, J
   Plana, N
   Brea, A
   Valdivielso, P
AF Sanchez Ramos, A.
   Casanas Martinez, M.
   Ibarretxe, D.
   Tomasini, R.
   Anglada, J.
   Plana, N.
   Brea, A.
   Valdivielso, P.
TI LYSOSOMAL ACID LIPASE DEFICIENCY (LAL-D) : REPORT OF NEW FOUR SPANISH
   UNRELATED CASES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sanchez Ramos, A.; Valdivielso, P.] Hosp Virgen de la Victoria, Malaga, Spain.
   [Casanas Martinez, M.; Brea, A.] Hosp San Pedro, Logrono, Spain.
   [Ibarretxe, D.; Plana, N.] Hosp San Joan, Reus, Spain.
   [Tomasini, R.; Anglada, J.] Mutua Terrasa, Terrassa, Spain.
RI MASANA, LUIS/M-7002-2019
OI MASANA, LUIS/0000-0002-0789-4954
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.3.281
BP E186
EP E186
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600580
DA 2019-10-28
ER

PT J
AU Fernandez, CS
   Bautista, R
   Maldonado, JG
   Repiso, CG
   Tome, M
   Olivera, WO
   Almeida, JMG
   Morata, AR
   Fuentes, EG
   Sanchez, LG
AF Santiago Fernandez, C.
   Bautista, R.
   Gomez Maldonado, J.
   Gutierrez Repiso, C.
   Tome, M.
   Oliva Olivera, W.
   Garcia Almeida, J. M.
   Rodriguez Morata, A.
   Garcia Fuentes, E.
   Garrido Sanchez, L.
TI DIFFERENTIAL EXPRESSION OF THE MIRNA ACCORDING TO TWO DIFFERENT TYPES OF
   OIL IN HUVECS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Santiago Fernandez, C.; Garcia Fuentes, E.] Virgen de la Victoria Hosp, Dept Gastroenterol, IBIMA, Malaga, Spain.
   [Bautista, R.] Univ Malaga, Dept Bioinformat SCBI, Malaga, Spain.
   [Gomez Maldonado, J.] Univ Malaga, Dept Genom & Ultraseuencing SCBI, Malaga, Spain.
   [Gutierrez Repiso, C.; Oliva Olivera, W.; Garcia Almeida, J. M.; Garrido Sanchez, L.] Virgen de la Victoria Hosp, Dept Endocrinol & Nutr, IBIMA, Malaga, Spain.
   [Tome, M.] Reg Univ Hosp, Dept Endocrinol & Nutr, IBIMA, Malaga, Spain.
   [Oliva Olivera, W.; Garcia Almeida, J. M.; Garcia Fuentes, E.; Garrido Sanchez, L.] Inst Salud Carlos III, CIBER Physiopathol Obes & Nutr CIBERObn, Malaga, Spain.
   [Rodriguez Morata, A.] Virgen de la Victoria Hosp, IBIMA, Dept Angiol & Vasc Surg, Malaga, Spain.
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III [PI14/01306];
   FEDER fundsEuropean Union (EU)
FX This work was supported in part by a grant from the Instituto de Salud
   Carlos III (PI14/01306) and has been co-funded by FEDER funds.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.069
BP E124
EP E124
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600368
DA 2019-10-28
ER

PT J
AU Hernandez, AS
   Gonzalez, PJM
   Lorenzo, MM
   Heredero, A
   Aldamiz-echevarria, G
   Vivanco, F
   Llamas, GA
AF Santiago Hernandez, A.
   Martinez Gonzalez, P. J.
   Martin Lorenzo, M.
   Heredero, A.
   Aldamiz-echevarria, G.
   Vivanco, F.
   Alvarez Llamas, G.
TI NOVEL MARKER PANEL OF 10 METABOLITES FOR A BETTER IDENTIFICATION OF
   PATIENTS WITH HIGH CV RISK
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Santiago Hernandez, A.; Martinez Gonzalez, P. J.; Martin Lorenzo, M.; Vivanco, F.; Alvarez Llamas, G.] UAM, IIS Fdn Jimenez Diaz, Dept Immunol, Madrid, Spain.
   [Heredero, A.; Aldamiz-echevarria, G.] UAM, Fdn Jimenez Diaz, Dept Cardiac Surg, Madrid, Spain.
   [Vivanco, F.] UCM, Dept Biochem & Mol Biol 1, Madrid, Spain.
RI Alvarez-Llamas, Gloria/C-8938-2015
OI Alvarez-Llamas, Gloria/0000-0002-3313-721X
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.486
BP E242
EP E242
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600781
DA 2019-10-28
ER

PT J
AU Sanz, AMB
   Lamiquiz-Moneo, I
   Martin, C
   Mateo-Gallego, R
   Cenarro, A
   Civeira, F
AF Sanz, A. M. Bea
   Lamiquiz-Moneo, I.
   Martin, C.
   Mateo-Gallego, R.
   Cenarro, A.
   Civeira, F.
TI APOE GENE VARIANTS IN PRIMARY HYPERLIPIDEMIAS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sanz, A. M. Bea; Lamiquiz-Moneo, I.; Mateo-Gallego, R.; Cenarro, A.; Civeira, F.] Hosp Univ Miguel Servet, IIS Aragon, CIBERCV, Zaragoza, Spain.
   [Martin, C.] Univ Pais Vasco Euskal Herriko Unibertsitatea, Dept Bioquim & Biol Mol 2, Bilbao, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.3.278
BP E185
EP E185
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600577
DA 2019-10-28
ER

PT J
AU Saripo, V
   Gilis, D
   Nesterovics, G
   Upena-Roze, A
   Zvaigzne, L
   Erglis, A
   Latkovskis, G
AF Saripo, V.
   Gilis, D.
   Nesterovics, G.
   Upena-Roze, A.
   Zvaigzne, L.
   Erglis, A.
   Latkovskis, G.
TI PREVALENCE OF PREMATURE ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS
   INCLUDED IN THE LATVIAN REGISTRY OF FAMILIAL HYPERCHOLESTEROLEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Saripo, V.; Nesterovics, G.] Univ Latvia, Fac Med, Riga, Latvia.
   [Gilis, D.; Upena-Roze, A.; Zvaigzne, L.] Pauls Stradins Clin Univ Hosp, Latvian Ctr Cardiol, Riga, Latvia.
   [Erglis, A.; Latkovskis, G.] Univ Latvia, Inst Cardiol & Regenerat Med, Riga, Latvia.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.257
BP E179
EP E179
DI 10.1016/j.atherosclerosis.2018.06.544
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600556
DA 2019-10-28
ER

PT J
AU Satny, M
   Grauova, B
   Kasalova, E
   Schwarzova, L
   Snejdrlova, M
   Stulc, T
   Tumova, E
   Tvrdikova, E
   Vaclova, M
   Zemankova, P
   Zlatohlavek, L
   Vrablik, M
   Ceska, R
AF Satny, M.
   Grauova, B.
   Kasalova, E.
   Schwarzova, L.
   Snejdrlova, M.
   Stulc, T.
   Tumova, E.
   Tvrdikova, E.
   Vaclova, M.
   Zemankova, P.
   Zlatohlavek, L.
   Vrablik, M.
   Ceska, R.
TI FAMILIAL DYSBETALIPOPROTEINEMIA - YES, OR NO? - RETROSPECTIVE PATIENT
   STUDY OF THE CENTER FOR PREVENTIVE CARDIOLOGY OF THE 3RD INTERNAL CLINIC
   FIRST FACULTY OF MEDICINE AND GENERAL UNIVERSITY HOSPITAL
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Satny, M.; Grauova, B.; Kasalova, E.; Schwarzova, L.; Snejdrlova, M.; Stulc, T.; Tumova, E.; Tvrdikova, E.; Vaclova, M.; Zlatohlavek, L.; Vrablik, M.; Ceska, R.] Gen Univ Hosp, Fac Med 1, Internal Clin 3, Prague, Czech Republic.
   [Satny, M.; Grauova, B.; Kasalova, E.; Schwarzova, L.; Snejdrlova, M.; Stulc, T.; Tumova, E.; Tvrdikova, E.; Vaclova, M.; Zemankova, P.; Zlatohlavek, L.; Vrablik, M.; Ceska, R.] Gen Univ Hosp, Prague, Czech Republic.
   [Zemankova, P.] Gen Univ Hosp, Inst Biochem & Expt Oncol, Fac Med 1, Prague, Czech Republic.
FU  [AZV 15-27277A]
FX Supported by grant AZV 15-27277A.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.250
BP E177
EP E177
DI 10.1016/j.atherosclerosis.2018.06.537
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600549
DA 2019-10-28
ER

PT J
AU Satta, N
   Pagano, S
   Montecucco, F
   Gencer, B
   Mach, F
   Kaiser, L
   Calmy, A
   Vuilleumier, N
AF Satta, N.
   Pagano, S.
   Montecucco, F.
   Gencer, B.
   Mach, F.
   Kaiser, L.
   Calmy, A.
   Vuilleumier, N.
TI ANTI-APOLIPOPROTEIN A-1 AUTOANTIBODIES ARE ASSOCIATED WITH
   IMMUNODEFICIENCY AND SYSTEMIC INFLAMMATION IN HIV PATIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Satta, N.; Pagano, S.; Vuilleumier, N.] Geneva Univ Hosp, Dept Genet & Lab Med, Div Lab Med, 4 Rue Gabrielle Perret Gentil, CH-1205 Geneva, Switzerland.
   [Satta, N.; Pagano, S.; Vuilleumier, N.] Univ Geneva, Dept Human Prot Sci, Clin Chem & Prote Grp, Geneva, Switzerland.
   [Montecucco, F.] Univ Genoa, Dept Internal Med, Lab Phagocyte Physiopathol & Inflammat, Med Clin 1, 6 Viale Benedetto 15, I-16132 Genoa, Italy.
   [Montecucco, F.] IRCCS AOU San Martino IST, Largo Benzi 10, I-16143 Genoa, Italy.
   [Montecucco, F.] Univ Genoa, Ctr Excellence Biomed Res, 9 Viale Benedetto 15, I-16132 Genoa, Italy.
   [Gencer, B.; Mach, F.] Univ Geneva, Dept Med Specialties, Fdn Med Res, Div Cardiol, 64 Ave Roseraie, CH-1211 Geneva, Switzerland.
   [Kaiser, L.; Calmy, A.] Geneva Univ Hosp, Div Infect Dis, Geneva, Switzerland.
   [Kaiser, L.; Calmy, A.] Geneva Univ Hosp, Lab Med, Geneva, Switzerland.
   [Kaiser, L.; Calmy, A.] Univ Geneva, Fac Med, Geneva, Switzerland.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG12.5
BP E39
EP E40
DI 10.1016/j.atherosclerosis.2018.06.099
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600112
DA 2019-10-28
ER

PT J
AU Savarino, F
   Lo Gullo, A
   Carrio, JR
   Aragona, CO
   Suarez, A
   Atzeni, F
   Saitta, A
   Mandraffino, G
AF Savarino, F.
   Lo Gullo, A.
   Carrio, J. R.
   Aragona, C. O.
   Suarez, A.
   Atzeni, F.
   Saitta, A.
   Mandraffino, G.
TI SUBCLINICAL IMPAIRMENT OF MYOCARDIAL AND ENDOTHELIAL FUNCTIONALITY IN
   VERY EARLY PSORIATIC AND RHEUMATOID ARTHRITIS PATIENTS: ASSOCIATION WITH
   VITAMIN D, INFLAMMATION AND ACTIVITY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Savarino, F.; Lo Gullo, A.; Aragona, C. O.; Atzeni, F.; Saitta, A.; Mandraffino, G.] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
   [Carrio, J. R.; Suarez, A.] Univ Oviedo, Dept Funct Biol, Fac Med, Area Immunol, Oviedo, Spain.
   [Carrio, J. R.; Suarez, A.] Inst Invest Sanitaria Principado Asturias, Oviedo, Spain.
   [Atzeni, F.] Sackler Fac Med, Dept Neurol, Robert & Martha Harden Chair Mental & Neurol Dis, Tel Aviv, Israel.
RI Mandraffino, Giuseppe/J-1242-2019; Gullo, Alberto Lo/AAC-2766-2019
OI Mandraffino, Giuseppe/0000-0003-0272-2237; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG21.3
BP E52
EP E52
DI 10.1016/j.atherosclerosis.2018.06.139
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600153
DA 2019-10-28
ER

PT J
AU Savvinova, P
   Kalinskaya, A
   Shpektor, A
   Vasilieva, E
AF Savvinova, P.
   Kalinskaya, A.
   Shpektor, A.
   Vasilieva, E.
TI CLOT FORMATION AND FIBRINOLYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROME
   AND HEALTHY VOLUNTEERS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Savvinova, P.; Kalinskaya, A.; Shpektor, A.] Moscow State Univ Med & Dent, Cardiol Dept, Moscow, Russia.
   [Kalinskaya, A.; Shpektor, A.; Vasilieva, E.] Moscow State Univ Med & Dent, Lab Atherothrombosis, Moscow, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.11.148
BP E147
EP E148
DI 10.1016/j.atherosclerosis.2018.06.435
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600447
DA 2019-10-28
ER

PT J
AU Sazonova, MA
   Sinyov, VV
   Ryzhkova, AI
   Sazonova, MD
   Zhelankin, AV
   Khasanova, ZB
   Postnov, AY
   Orekhov, AN
   Sobenin, IA
AF Sazonova, M. A.
   Sinyov, V. V.
   Ryzhkova, A. I.
   Sazonova, M. D.
   Zhelankin, A. V.
   Khasanova, Z. B.
   Postnov, A. Y.
   Orekhov, A. N.
   Sobenin, I. A.
TI DETECTION OF HOMOPLASMIC MTDNA MUTATIONS BY NGS METHOD IN PATIENTS WITH
   CAROTID ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sazonova, M. A.; Ryzhkova, A. I.; Sazonova, M. D.; Orekhov, A. N.; Sobenin, I. A.] Inst Gen Pathol & Pathophysiol, Lab Angiopathol, Moscow, Russia.
   [Sinyov, V. V.; Zhelankin, A. V.; Khasanova, Z. B.; Postnov, A. Y.; Sobenin, I. A.] Natl Med Res Ctr Cardiol, Lab Med Genet, Moscow, Russia.
   [Orekhov, A. N.] Skolkovo Innovat Ctr, Inst Atherosclerosis Res, Moscow, Russia.
RI Sobenin, Igor A/J-4282-2013; Orekhov, Alexander N/J-4838-2013
OI Sobenin, Igor A/0000-0003-0978-6444; Orekhov, Alexander
   N/0000-0002-6495-1628
FU Russian Science FoundationRussian Science Foundation (RSF) [14-14-01038]
FX This study was supported by Russian Science Foundation, grant
   #14-14-01038.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.085
BP E128
EP E128
DI 10.1016/j.atherosclerosis.2018.06.371
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600383
DA 2019-10-28
ER

PT J
AU Sazzli, K
   Ikhwan, TGM
   Sidik, TGA
   Gunavathy, S
   Alan, FYY
   Azman, WAW
AF Sazzli, K.
   Ikhwan, T. G. Mohd
   Sidik, T. G. Abu Bakar
   Gunavathy, S.
   Alan, F. Yean Yip
   Azman, W. A. Wan
TI MORTALITY AND LIPID TRENDS IN ACS POPULATIONS: A STUDY FROM THE
   MALAYSIAN NATIONAL CARDIOVASCULAR DISEASE DATABASE - ACUTE CORONARY
   SYNDROME (NCVD-ACS) REGISTRY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sazzli, K.] Univ Teknol MARA, Fac Med, Selangor, Malaysia.
   [Ikhwan, T. G. Mohd; Sidik, T. G. Abu Bakar; Gunavathy, S.] Natl Heart Assoc Malaysia, Kuala Lumpur, Malaysia.
   [Alan, F. Yean Yip] Sarawak Gen Hosp, Clin Res Ctr, Sarawak, Malaysia.
   [Azman, W. A. Wan] Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.409
BP E221
EP E221
DI 10.1016/j.atherosclerosis.2018.06.696
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600708
DA 2019-10-28
ER

PT J
AU Scarinzi, P
   Bigolin, P
   Simoni, F
   Benvegnu, L
   Antonucci, A
   Biolo, M
   Panzavolta, C
   Bertocco, S
   Zambon, S
   Fabris, F
   Manzato, E
   Previato, L
   Zambon, A
AF Scarinzi, P.
   Bigolin, P.
   Simoni, F.
   Benvegnu, L.
   Antonucci, A.
   Biolo, M.
   Panzavolta, C.
   Bertocco, S.
   Zambon, S.
   Fabris, F.
   Manzato, E.
   Previato, L.
   Zambon, A.
TI ULTRASONOGRAPHIC DETECTION OF XANTHOMAS IN ACHILLES TENDON OF PATIENTS
   WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Scarinzi, P.; Bigolin, P.; Benvegnu, L.; Antonucci, A.; Biolo, M.; Panzavolta, C.; Bertocco, S.; Zambon, S.; Fabris, F.; Manzato, E.; Previato, L.; Zambon, A.] Univ Padua, Dipartimento Med, Padua, Italy.
   [Simoni, F.] Osped Dolo, Dolo, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.8.123
BP E140
EP E140
DI 10.1016/j.atherosclerosis.2018.06.411
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600423
DA 2019-10-28
ER

PT J
AU Schilperoort, M
   van Dam, AD
   Hoeke, G
   Kooijman, S
   Christian, M
   Rensen, PCN
AF Schilperoort, M.
   van Dam, A. D.
   Hoeke, G.
   Kooijman, S.
   Christian, M.
   Rensen, P. C. N.
TI IDENTIFICATION OF GPR120 AS A NOVEL TARGET TO ACTIVATE BROWN ADIPOSE
   TISSUE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Schilperoort, M.; van Dam, A. D.; Hoeke, G.; Kooijman, S.; Rensen, P. C. N.] Leiden Univ, Med Ctr, Dept Med, Div Endocrinol, Leiden, Netherlands.
   [Christian, M.] Univ Warwick, Dept Metab & Vasc Hlth, Coventry, W Midlands, England.
RI Rensen, Patrick/Y-5528-2019; Rensen, Patrick C.N./D-7176-2018
OI Rensen, Patrick/0000-0002-8455-4988; Rensen, Patrick
   C.N./0000-0002-8455-4988
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W12:2
BP E14
EP E15
DI 10.1016/j.atherosclerosis.2018.06.925
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600042
DA 2019-10-28
ER

PT J
AU Schilperoort, M
   van der Berg, R
   Coomans, CP
   Meijer, JH
   Biermasz, N
   Kooijman, S
   Rensen, PCN
AF Schilperoort, M.
   van der Berg, R.
   Coomans, C. P.
   Meijer, J. H.
   Biermasz, N.
   Kooijman, S.
   Rensen, P. C. N.
TI DISRUPTION OF THE BIOLOGICAL CLOCK AGGRAVATES ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Schilperoort, M.; van der Berg, R.; Biermasz, N.; Kooijman, S.; Rensen, P. C. N.] Leiden Univ, Med Ctr, Dept Med, Div Endocrinol, Leiden, Netherlands.
   [Coomans, C. P.; Meijer, J. H.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Lab Neurophysiol, Leiden, Netherlands.
RI Rensen, Patrick C.N./D-7176-2018; Rensen, Patrick/Y-5528-2019
OI Rensen, Patrick C.N./0000-0002-8455-4988; Rensen,
   Patrick/0000-0002-8455-4988
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W11:5
BP E13
EP E14
DI 10.1016/j.atherosclerosis.2018.06.923
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600040
DA 2019-10-28
ER

PT J
AU Schinzari, F
   Tesauro, M
   Veneziani, A
   Baroni, A
   Mores, N
   Cardillo, C
AF Schinzari, F.
   Tesauro, M.
   Veneziani, A.
   Baroni, A.
   Mores, N.
   Cardillo, C.
TI SECRETORY CHANGES AND INFLAMMATION ARE ASSOCIATED WITH VASCULAR
   DYSFUNCTION IN OBESE PATIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Veneziani, A.; Baroni, A.; Mores, N.; Cardillo, C.] Univ Cattolica Sacro Cuore, Rome, Italy.
   [Schinzari, F.] Policlin A Gemelli, Rome, Italy.
   [Tesauro, M.] Univ Tor Vergata, Rome, Italy.
RI schinzari, francesca/AAB-9982-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.3.056
BP E120
EP E120
DI 10.1016/j.atherosclerosis.2018.06.342
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600354
DA 2019-10-28
ER

PT J
AU Schiopu, A
   Marinkovic, G
   DeCamp, L
   Winkler, L
   Nilsson, J
   Jovinge, S
AF Schiopu, A.
   Marinkovic, G.
   DeCamp, L.
   Winkler, L.
   Nilsson, J.
   Jovinge, S.
TI THE S100A8/A9 ALARMIN STIMULATES MYELOID CELL RESPONSE AND PROMOTES
   CARDIAC REPAIR AFTER MYOCARDIAL INFARCTION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Schiopu, A.; Marinkovic, G.; Nilsson, J.] Lund Univ, Expt Cardiovasc Res, Lund, Sweden.
   [DeCamp, L.; Winkler, L.; Jovinge, S.] Van Andel Inst, Grand Rapids, MI USA.
   [Jovinge, S.] Spectrum Hlth Hosp, Fredrik Meijer Heart & Vasc Inst, Grand Rapids, MI USA.
   [Jovinge, S.] Stanford Univ, CardioVasc Inst, Palo Alto, CA 94304 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA FC1.6
BP E7
EP E7
DI 10.1016/j.atherosclerosis.2018.06.906
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600023
DA 2019-10-28
ER

PT J
AU Schnitzler, JG
   Hoogeveen, RM
   Nicorescu, I
   Versloot, M
   Stroes, ESG
   Kroon, J
AF Schnitzler, J. G.
   Hoogeveen, R. M.
   Nicorescu, I.
   Versloot, M.
   Stroes, E. S. G.
   Kroon, J.
TI TARGETING LIPOPROTEIN(A)-INDUCED ENDOTHELIAL CELL METABOLIC CHANGES IN
   ORDER TO REDUCE INFLAMMATION, LEUKOCYTE EXTRAVASATION AND THEREBY
   ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Schnitzler, J. G.; Nicorescu, I.; Versloot, M.; Kroon, J.] Acad Med Ctr, Dept Expt Vasc Med, Amsterdam, Netherlands.
   [Hoogeveen, R. M.; Stroes, E. S. G.; Kroon, J.] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG11.5
BP E37
EP E37
DI 10.1016/j.atherosclerosis.2018.06.093
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600107
DA 2019-10-28
ER

PT J
AU Scicali, R
   Rosenbaum, D
   Di Pino, A
   Giral, P
   Cluzel, P
   Redheuil, A
   Piro, S
   Rabuazzo, AM
   Purrello, F
   Bruckert, E
   Gallo, A
AF Scicali, R.
   Rosenbaum, D.
   Di Pino, A.
   Giral, P.
   Cluzel, P.
   Redheuil, A.
   Piro, S.
   Rabuazzo, A. M.
   Purrello, F.
   Bruckert, E.
   Gallo, A.
TI AN INCREASED WAIST-TO-HIP RATIO IS A KEY DETERMINANT OF ATHEROSCLEROTIC
   BURDEN IN OVERWEIGHT SUBJECTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Scicali, R.; Di Pino, A.; Piro, S.; Rabuazzo, A. M.; Purrello, F.] Dept Clin & Expt Med, Catania, Italy.
   [Rosenbaum, D.; Giral, P.; Cluzel, P.; Redheuil, A.; Bruckert, E.; Gallo, A.] UPMC Univ Paris 06, Sorbonne Univ, INSERM 1146, Paris, France.
RI Piro, Salvatore/H-9353-2012; Scicali, Roberto/L-9587-2019
OI Piro, Salvatore/0000-0002-1781-0902; Scicali,
   Roberto/0000-0002-7023-3649
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.5.362
BP E208
EP E208
DI 10.1016/j.atherosclerosis.2018.06.648
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600660
DA 2019-10-28
ER

PT J
AU Scrimali, C
   Spina, R
   Ingrassia, V
   Cefalu, AB
   Valenti, V
   Altieri, GI
   Noto, D
   Brucato, F
   Misiano, G
   Giammanco, A
   Barbagallo, CM
   Ganci, A
   Fayer, F
   Averna, MR
AF Scrimali, C.
   Spina, R.
   Ingrassia, V.
   Cefalu, A. B.
   Valenti, V.
   Altieri, G. I.
   Noto, D.
   Brucato, F.
   Misiano, G.
   Giammanco, A.
   Barbagallo, C. M.
   Ganci, A.
   Fayer, F.
   Averna, M. R.
TI DETECTION OF COPY NUMBER VARIATIONS (CNVS) IN LDLR GENE BY NEXT
   GENERATION SEQUENCING IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Scrimali, C.; Spina, R.; Ingrassia, V.; Cefalu, A. B.; Valenti, V.; Altieri, G. I.; Noto, D.; Brucato, F.; Misiano, G.; Giammanco, A.; Barbagallo, C. M.; Ganci, A.; Fayer, F.; Averna, M. R.] Biomed Dept Internal Med, Palermo, Italy.
RI Noto, Davide/AAA-9208-2019; Giammanco, Andrea/O-5017-2019; Cefalu',
   Angelo B/K-9491-2016
OI Giammanco, Andrea/0000-0001-9640-8294; Cefalu', Angelo
   B/0000-0003-1259-8284
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.172
BP E154
EP E154
DI 10.1016/j.atherosclerosis.2018.06.459
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600471
DA 2019-10-28
ER

PT J
AU Duarte, JS
   Ferrinho, C
   Bello, C
   Azinheira, J
   Vasconcelos, C
AF Sequeira Duarte, J.
   Ferrinho, C.
   Bello, C.
   Azinheira, J.
   Vasconcelos, C.
TI RISCK FACTORS CONTROL IN TYPE 2 DIABETIC PATIENTS WITH PERIPHERIAL
   ARTERY DISEASE. TWELVE YEARS EXPERIENCE OF A CENTER
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sequeira Duarte, J.; Ferrinho, C.; Bello, C.; Vasconcelos, C.] CHLO Endocrinol, Lisbon, Portugal.
   [Azinheira, J.] CHLO Clin Pathol, Lisbon, Portugal.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.4.347
BP E204
EP E204
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600645
DA 2019-10-28
ER

PT J
AU Seres, I
   Szentimrei, R
   Szentpeteri, A
   Varga, VE
   Harangi, M
   Fulop, P
   Lorincz, H
   Nemes, B
   Paragh, G
AF Seres, I.
   Szentimrei, R.
   Szentpeteri, A.
   Varga, V. E.
   Harangi, M.
   Fulop, P.
   Lorincz, H.
   Nemes, B.
   Paragh, G.
TI PIGMENT EPITHELIUM-DERIVED FACTOR (PEDF) AND LIPID PARAMETERS IN
   PATIENTS WITH END STAGE RENAL FAILURE BEFORE AND AFTER KIDNEY
   ALLOTRASPLANTATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Seres, I.; Szentimrei, R.; Szentpeteri, A.; Varga, V. E.; Harangi, M.; Fulop, P.; Lorincz, H.; Paragh, G.] Univ Debrecen, Fac Med, Dept Internal Med, Debrecen, Hungary.
   [Nemes, B.] Univ Debrecen, Fac Med, Dept Organ Transplantat, Inst Surg, Debrecen, Hungary.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.520
BP E252
EP E252
DI 10.1016/j.atherosclerosis.2018.06.801
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600812
DA 2019-10-28
ER

PT J
AU Shakhtshneider, E
   Ivanoshchuk, D
   Makarenkova, K
   Orlov, P
   Timoshchenko, O
   Bazhan, S
   Voevoda, M
AF Shakhtshneider, E.
   Ivanoshchuk, D.
   Makarenkova, K.
   Orlov, P.
   Timoshchenko, O.
   Bazhan, S.
   Voevoda, M.
TI CLINICAL CASE: THE DEVELOPMENT OF HETEROZYGOUS FAMILIAL
   HYPERCHOLESTEROLEMIA IN A PATIENT WITH RS879255191 IN LDLR GENE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shakhtshneider, E.; Ivanoshchuk, D.; Makarenkova, K.; Orlov, P.; Timoshchenko, O.; Bazhan, S.; Voevoda, M.] RAS, SB, Branch ICG, Inst Internal & Prevent Med, Novosibirsk, Russia.
RI Ivanoshchuk, Dinara/N-2325-2018; Shakhtshneider, Elena/E-9453-2015
OI Shakhtshneider, Elena/0000-0001-6108-1025
FU RFBRRussian Foundation for Basic Research (RFBR) [N17-06-01045/17]
FX The reported study was partially supported by RFBR, research project
   N17-06-01045/17.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.256
BP E179
EP E179
DI 10.1016/j.atherosclerosis.2018.06.543
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600555
DA 2019-10-28
ER

PT J
AU Shakhtshneider, E
   Ivanoshchuk, D
   Orlov, P
   Shcherbakova, L
   Malyutina, S
   Ragino, Y
   Voevoda, M
AF Shakhtshneider, E.
   Ivanoshchuk, D.
   Orlov, P.
   Shcherbakova, L.
   Malyutina, S.
   Ragino, Y.
   Voevoda, M.
TI ASSOCIATION OF POLYMORPHISM THE APOE GENE WITH CARDIOVASCULAR RISK
   FACTORS AND UNFAVORABLE LONG-TERM PROGNOSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shakhtshneider, E.; Ivanoshchuk, D.; Orlov, P.; Shcherbakova, L.; Malyutina, S.; Ragino, Y.; Voevoda, M.] RAS, SB, ICG, Inst Internal & Prevent Med Branch, Novosibirsk, Russia.
RI Ivanoshchuk, Dinara/N-2325-2018; Shakhtshneider, Elena/E-9453-2015
OI Shakhtshneider, Elena/0000-0001-6108-1025
FU RFBRRussian Foundation for Basic Research (RFBR) [N17-06-01045/17]
FX The reported study was partially supported by RFBR, research project
   N17-06-01045/17.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.264
BP E181
EP E181
DI 10.1016/j.atherosclerosis.2018.06.551
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600563
DA 2019-10-28
ER

PT J
AU Sharma, V
AF Sharma, V.
TI BENEFICIAL EFFECT OF LAUGHTER YOGA AND CLAPPING EXERCISE IN CORONARY
   HEART DISEASE (CHD) PATIENTS IN SOUTH DELHI METRO POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sharma, V.] Shri Maha Maya Vaishnav Devi Mandir Res Inst, Delhi, India.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.485
BP E242
EP E242
DI 10.1016/j.atherosclerosis.2018.06.768
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600780
DA 2019-10-28
ER

PT J
AU Shcherbakova, N
   Meshkov, A
   Ershova, A
   Zharikova, A
   Kiseleva, A
   Khlebus, E
   Shalnova, S
   Boytsov, S
   Drapkina, O
AF Shcherbakova, N.
   Meshkov, A.
   Ershova, A.
   Zharikova, A.
   Kiseleva, A.
   Khlebus, E.
   Shalnova, S.
   Boytsov, S.
   Drapkina, O.
TI THE RESULTS OF EXOME SEQUENCING OF PARTICIPANTS OF EPIDEMIOLOGICAL STUDY
   WITH AND WITHOUT ISCHEMIC HEART DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shcherbakova, N.; Meshkov, A.; Ershova, A.; Zharikova, A.; Kiseleva, A.; Khlebus, E.; Shalnova, S.; Drapkina, O.] Natl Res Ctr Prevent Med, Moscow, Russia.
   [Boytsov, S.] Cardiol Res & Prod Ctr, Moscow, Russia.
RI Shalnova, Svetlana/D-3824-2016; Drapkina, Oxana/G-8443-2016; Khlebus,
   Eleonora/X-1674-2019
OI Drapkina, Oxana/0000-0002-4453-8430; Khlebus,
   Eleonora/0000-0002-8355-8960
NR 0
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.3.284
BP E187
EP E187
DI 10.1016/j.atherosclerosis.2018.06.571
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600583
DA 2019-10-28
ER

PT J
AU Okuda, LS
   Iborra, RT
   Pinto, PR
   Patel, M
   Machado, UF
   Rye, KA
   Passarelli, M
AF Shimabukuro Okuda, L.
   Tallada Iborra, R.
   Ramos Pinto, P.
   Patel, M.
   Fabres Machado, U.
   Rye, K. A.
   Passarelli, M.
TI ADVANCED GLYCATED APOAIV IS LESS EFFICIENT IN REDUCING INFLAMMATION IN
   MACROPHAGES AND UNABLE TO PREVENT THE REDUCTION IN ABCA1 AND ABCG1 MRNA
   INDUCED BY LPS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shimabukuro Okuda, L.; Tallada Iborra, R.; Ramos Pinto, P.; Passarelli, M.] Univ Sao Paulo, Hosp Clin HCFMUSP, Lab Lipides, Fac Med, LIM10, Sao Paulo, Brazil.
   [Patel, M.; Rye, K. A.] Univ New South Wales, Sch Med Sci, Fac Med, Lipid Res Grp, Sydney, NSW, Australia.
   [Fabres Machado, U.] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo, Brazil.
RI Iborra, Rodrigo T Tallada/I-6339-2017; Iborra, Rodrigo
   Tallada/Q-4122-2019
OI Iborra, Rodrigo T Tallada/0000-0002-3772-4200; Iborra, Rodrigo
   Tallada/0000-0002-3772-4200
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.5.216
BP E167
EP E167
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600515
DA 2019-10-28
ER

PT J
AU Shiomi, M
   Takeda, H
   Irino, Y
   Yamada, S
   Kuniyoshi, N
   Ying, Y
   Koike, T
   Izumi, Y
   Shinohara, M
   Bamba, T
   Ishida, T
AF Shiomi, M.
   Takeda, H.
   Irino, Y.
   Yamada, S.
   Kuniyoshi, N.
   Ying, Y.
   Koike, T.
   Izumi, Y.
   Shinohara, M.
   Bamba, T.
   Ishida, T.
TI DEVELOPMENT OF MARKERS FOR PROGRESSION OF CORONARY PLAQUES USING WHHLMI
   RABBITS, AN ANIMAL MODEL OF FAMILIAL HYPERCHOLESTEROLEMIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shiomi, M.; Irino, Y.; Yamada, S.; Kuniyoshi, N.; Ying, Y.; Koike, T.; Shinohara, M.; Ishida, T.] Kobe Univ, Grad Sch Med, Kobe, Hyogo, Japan.
   [Takeda, H.; Izumi, Y.; Bamba, T.] Kyushu Univ, Fukuoka, Fukuoka, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.502
BP E247
EP E247
DI 10.1016/j.atherosclerosis.2018.06.786
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600797
DA 2019-10-28
ER

PT J
AU Shipman, K
   Shipman, A
   Maghsoodi, N
AF Shipman, K.
   Shipman, A.
   Maghsoodi, N.
TI STATIN THERAPY AND THE RISK OF HERPES VIRUS REACTIVATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shipman, K.] Western Sussex NHS Trust, Worthing, England.
   [Shipman, A.] Portsmouth Hosp NHS Trust, Portsmouth, Hants, England.
   [Maghsoodi, N.] Surrey & Sussex Healthcare NHS Trust, Redhill, Surrey, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.4.433
BP E228
EP E228
DI 10.1016/j.atherosclerosis.2018.06.720
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600732
DA 2019-10-28
ER

PT J
AU Shishkova, V
   Remennik, A
   Valyaeva, V
   Adasheva, T
AF Shishkova, V.
   Remennik, A.
   Valyaeva, V.
   Adasheva, T.
TI STUDY OF ASSOCIATIONS OF POLYMORPHIC VARIANTS OF LIPID AND CARBOHYDRATE
   METABOLISM GENES, VASCULAR INFLAMMATION AND NEUROTRANSMITTER SYSTEMS
   WITH THE DEVELOPMENT OF THE FIRST ISCHEMIC STROKE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shishkova, V.; Remennik, A.; Valyaeva, V.; Adasheva, T.] Ctr Spech Patol & Neurorehabil, Moscow, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.3.285
BP E187
EP E187
DI 10.1016/j.atherosclerosis.2018.06.572
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600584
DA 2019-10-28
ER

PT J
AU Shklianka, I
   Zharinov, O
   Mikhaliev, K
   Yepanchintseva, O
AF Shklianka, I.
   Zharinov, O.
   Mikhaliev, K.
   Yepanchintseva, O.
TI PERIOPERATIVE STATINS PREVENT EARLY COMPLICATIONS OF THE SURGICAL
   REVASCULARIZATION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shklianka, I.; Yepanchintseva, O.] Minist Ukraine, Polyclin Dept, Heart Inst Healthcare, Kiev, Ukraine.
   [Zharinov, O.] Shupyk Natl Med Acad Postgrad Educ, Dept Funct Diagnost, Kiev, Ukraine.
   [Mikhaliev, K.] Sci & Pract Ctr Prevent & Clin Med, Dept Internal Med, Kiev, Ukraine.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG38:3
BP E84
EP E84
DI 10.1016/j.atherosclerosis.2018.06.233
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600247
DA 2019-10-28
ER

PT J
AU Shurkevich, N
   Vetoshkin, A
   Gapon, L
   Gubin, D
AF Shurkevich, N.
   Vetoshkin, A.
   Gapon, L.
   Gubin, D.
TI CIRCADIAN INFLUENCE ON ATHEROSCLEROSIS IN EXTREME NORTH CONDITIONS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shurkevich, N.; Gapon, L.] Russian Acad Sci, Tomsk Natl Res Med Ctr, Tyumen Cardiol Res Ctr, Tomsk, Russia.
   [Vetoshkin, A.] Gazprom Dobycha Yamburg LLC, Med Unit, Yamburg, Russia.
   [Gubin, D.] Russian Acad Sci, Tomsk Natl Res Med Ctr, Tyumen Cardiol Res Ctr, Tomsk, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.364
BP E209
EP E209
DI 10.1016/j.atherosclerosis.2018.06.651
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600663
DA 2019-10-28
ER

PT J
AU Shuumarjav, U
   Kotani, K
   Taniguchi, N
AF Shuumarjav, U.
   Kotani, K.
   Taniguchi, N.
TI ETHNIC DIFFERECES OF ATHEROSCLEROTIC PARAMETERS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Shuumarjav, U.] Mongolian Natl Univ Med Sci, Ulaanbaatar, Mongolia.
   [Kotani, K.; Taniguchi, N.] Jichi Med Univ, Dept Clin Med, Shimotsuke, Tochigi, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.471
BP E238
EP E238
DI 10.1016/j.atherosclerosis.2018.06.754
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600766
DA 2019-10-28
ER

PT J
AU Sigal, A
   Tavoni, TM
   Freitas, FR
   Silva, BMO
   Brandao, LG
   Maranhao, RC
AF Sigal, A.
   Tavoni, T. M.
   Freitas, F. R.
   Silva, B. M. O.
   Brandao, L. G.
   Maranhao, R. C.
TI LIPID TRANSFERS TO HDL ARE DIMINISHED IN WOMEN WITH OVERT HYPOTHYROIDISM
   AFTER TOTAL THYROIDECTOMY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sigal, A.; Freitas, F. R.; Silva, B. M. O.; Maranhao, R. C.] Med Sch Hosp, Heart Inst, Sao Paulo, Brazil.
   [Tavoni, T. M.; Maranhao, R. C.] Univ Sao Paulo, Fac Pharmaceut Sci, Sao Paulo, Brazil.
   [Brandao, L. G.] Univ Sao Paulo, Med Sch Hosp, Dept Head & Neck Surg, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.5.217
BP E167
EP E167
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600516
DA 2019-10-28
ER

PT J
AU Simionov, L
AF Simionov, L.
TI THE DYNAMICS OF THE INFLAMMATORY STATUS BIOMARKER UNDER THE TREATMENT
   WITH NEBIVOLOL IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY DEPENDING ON
   THE STENT'S LENGTH
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Simionov, L.] Inst Cardiol, Kishinev, Moldova.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.005
BP E105
EP E105
DI 10.1016/j.atherosclerosis.2018.06.290
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600302
DA 2019-10-28
ER

PT J
AU Simionov, L
   Ivanov, V
   Dumanschi, C
   Sapojnic, N
   Ceasovschih, A
   Ulmanu, A
AF Simionov, L.
   Ivanov, V.
   Dumanschi, C.
   Sapojnic, N.
   Ceasovschih, A.
   Ulmanu, A.
TI THE CORRELATION BETWEEN ENDOTHELIAL DYSFUNCTION AND THE TREATMENT WITH
   NEBIVOLOL IN PATIENTS WITH DIABETES AND ANGINA PECTORIS UNDERGOING
   CORONARY ANGIOPLASTY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Simionov, L.; Ivanov, V.; Dumanschi, C.; Sapojnic, N.; Ceasovschih, A.; Ulmanu, A.] Inst Cardiol, Kishinev, Moldova.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.3.050
BP E118
EP E118
DI 10.1016/j.atherosclerosis.2018.06.336
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600348
DA 2019-10-28
ER

PT J
AU Simionov, L
AF Simionov, L.
TI EFFECTS OF NEBIVOLOL COMBINED WITH RAMIPRIL VS NEBIVOLOL ASSOCIATED
   AMLODIPINE AND RAMIPRIL ON BIOMARKER OF ENDOTHELIAL DYSFUNCTION IN
   PACIENTS WITH ANGINA PECTORIS AND ESSENTIAL HYPERTENSION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Simionov, L.] Inst Cardiol, Kishinev, Moldova.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.3.052
BP E119
EP E119
DI 10.1016/j.atherosclerosis.2018.06.338
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600350
DA 2019-10-28
ER

PT J
AU Simionov, L
   Ivanov, V
AF Simionov, L.
   Ivanov, V.
TI THE EVOLUTION OF THE OXIDATIVE STRESS BIOMARKERS UNDER THE TREATMENT
   WITH NEBIVOLOL VS BISOPROLOL IN PATIENTS WITH STABLE ANGINA PECTORIS
   UNDERGOING CORONARY ANGIOPLASTY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Simionov, L.; Ivanov, V.] Inst Cardiol, Kishinev, Moldova.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.6.093
BP E131
EP E131
DI 10.1016/j.atherosclerosis.2018.06.381
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600393
DA 2019-10-28
ER

PT J
AU Sinyov, V
   Sazonova, MA
   Ryzhkova, AI
   Doroshchuk, AD
   Kuzmin, AV
   Sazonova, M
   Khasanova, ZB
   Orekhov, AN
   Sobenin, IA
AF Sinyov, V.
   Sazonova, M. A.
   Ryzhkova, A. I.
   Doroshchuk, A. D.
   Kuzmin, A. V.
   Sazonova, M.
   Khasanova, Z. B.
   Orekhov, A. N.
   Sobenin, I. A.
TI CELLULAR RESPIRATION IN CYTOPLASMIC HYBRIDS WITH DIFFERENT HETEROPLASMY
   LEVELS OF MITOCHONDRIAL GENOME MUTATIONS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sinyov, V.; Sazonova, M. A.; Ryzhkova, A. I.; Doroshchuk, A. D.; Kuzmin, A. V.; Sazonova, M.; Khasanova, Z. B.; Sobenin, I. A.] Minist Healthcare, Fed State Budget Org Natl Med Res Ctr Cardiol, Moscow, Russia.
   [Sinyov, V.; Sazonova, M. A.; Orekhov, A. N.; Sobenin, I. A.] Inst Gen Pathol & Pathophysiol, Moscow, Russia.
   [Orekhov, A. N.] Skolkovo Innovat Ctr, Inst Atherosclerosis Res, Moscow, Russia.
RI Sobenin, Igor A/J-4282-2013; Orekhov, Alexander N/J-4838-2013; Sazonova,
   Margarita A/O-9685-2017
OI Sobenin, Igor A/0000-0003-0978-6444; Orekhov, Alexander
   N/0000-0002-6495-1628; Sazonova, Margarita A/0000-0002-8610-4593
FU Russian Science FoundationRussian Science Foundation (RSF) [1414-01038]
FX This work was supported by the Russian Science Foundation (Grant
   #1414-01038).
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.529
BP E254
EP E254
DI 10.1016/j.atherosclerosis.2018.06.810
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600821
DA 2019-10-28
ER

PT J
AU Sirenko, O
   Kuryata, O
AF Sirenko, O.
   Kuryata, O.
TI CAROTID ATHEROSCLEROSIS IN FEMALES WITH LOW-ACTIVITY RHEUMATOID
   ARTHRITIS AND ITS PREDICTORS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sirenko, O.; Kuryata, O.] SE Dnipropetrovsk Med Acad, Dnipro, Ukraine.
RI Sirenko, Oksana/I-9149-2017; Kuryata, Olexandr/J-1005-2017
OI Sirenko, Oksana/0000-0003-4728-8614; Kuryata,
   Olexandr/0000-0001-7642-0077
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.3.057
BP E120
EP E120
DI 10.1016/j.atherosclerosis.2018.06.343
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600355
DA 2019-10-28
ER

PT J
AU Skolnikova, E
   Sedova, L
   Krenova, D
   Kren, V
   Seda, O
AF Skolnikova, E.
   Sedova, L.
   Krenova, D.
   Kren, V.
   Seda, O.
TI EARLY LIFE PROGRAMMING WITH SUCROSE INTERFERES WITH LIPID PROFILES OF
   SHR RATS IN TWO SUBSEQUENT GENERATIONS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Skolnikova, E.; Sedova, L.; Krenova, D.; Kren, V.; Seda, O.] Charles Univ Prague, Fac Med 1, Inst Biol & Med Genet, Prague, Czech Republic.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG32.1
BP E72
EP E72
DI 10.1016/j.atherosclerosis.2018.06.199
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600213
DA 2019-10-28
ER

PT J
AU Skorepa, P
   Fortunato, J
   Blaha, V
   Horacek, JM
AF Skorepa, P.
   Fortunato, J.
   Blaha, V.
   Horacek, J. M.
TI SERUM CONCENTRATION OF NON-ESTERIFIED FATTY ACIDS (NEFAS) IN
   NON-SURGICAL CRITICALLY ILL PATIENTS: THE IMPACT OF SPECIFIC TYPES OF
   TOTAL PARENTERAL NUTRITION (TPN)
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Skorepa, P.; Horacek, J. M.] Univ Def, Fac Mil Hlth Sci, Dpt Mil Internal Med & Mil Hyg, Hradec Kralove, Czech Republic.
   [Skorepa, P.; Fortunato, J.; Blaha, V.] Univ Hosp, Dpt Internal Med Metab Care & Gerontol 3, Hradec Kralove, Czech Republic.
   [Skorepa, P.; Fortunato, J.; Blaha, V.; Horacek, J. M.] Charles Univ Prague, Hradec Kralove, Czech Republic.
   [Horacek, J. M.] Univ Hosp, Dpt Internal Med & Haematol 4, Hradec Kralove, Czech Republic.
FU Specific research project - Parenteral nutrition and Long-term
   organization development plan 1011, AZV CR [FVZ201510, 17-28882A,
   17-29241A]
FX Supported by Specific research project FVZ201510 - Parenteral nutrition
   and Long-term organization development plan 1011, AZV CR c. 17-28882A,
   17-29241A.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.166
BP E152
EP E153
DI 10.1016/j.atherosclerosis.2018.06.453
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600465
DA 2019-10-28
ER

PT J
AU Slastnikova, E
   Sadykova, D
   Shakirova, A
   Khabibrakhmanova, Z
   Krinitskaya, N
   Pecheritsa, O
   Galimova, L
AF Slastnikova, E.
   Sadykova, D.
   Shakirova, A.
   Khabibrakhmanova, Z.
   Krinitskaya, N.
   Pecheritsa, O.
   Galimova, L.
TI HYPERCHOLESTEROLEMIA AND DIABETES MELLITUS TYPE I: CLINICAL CASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Slastnikova, E.; Sadykova, D.; Shakirova, A.; Khabibrakhmanova, Z.] KSMA, Branch Campus FSBEI FPE RMACPE MOH Russia, Kazan, Russia.
   [Krinitskaya, N.; Pecheritsa, O.; Galimova, L.] Childrens Republ Clin Hosp, Kazan, Russia.
RI Sadykova, Dinara I/O-6946-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.3.334
BP E201
EP E201
DI 10.1016/j.atherosclerosis.2018.06.621
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600633
DA 2019-10-28
ER

PT J
AU Sleptsov, A
   Nazarenko, M
   Skryabin, N
   Denisov, E
   Tashireva, L
   Lebedev, I
   Puzyrev, V
AF Sleptsov, A.
   Nazarenko, M.
   Skryabin, N.
   Denisov, E.
   Tashireva, L.
   Lebedev, I.
   Puzyrev, V.
TI GENOMIC ALTERATIONS IN CELLS INVOLVED IN THE ATHEROSCLEROTIC PROCESS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sleptsov, A.; Nazarenko, M.; Skryabin, N.; Lebedev, I.; Puzyrev, V.] Russia Acad Sci, Tomsk Natl Res Med Ctr, Res Inst Med Genet, Tomsk, Russia.
   [Denisov, E.; Tashireva, L.] Russia Acad Sci, Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia.
RI Lebedev, Igor/O-2470-2019; Nazarenko, Maria S/A-7917-2014; Puzyrev,
   Valery P/S-3144-2016; Denisov, Evgeny/C-8662-2012; Lebedev, Igor
   N/K-7454-2012; Sleptcov, Alexei/A-8163-2014; Skryabin, Nikolay
   Alekseevich/A-7862-2014
OI Lebedev, Igor/0000-0002-0482-8046; Nazarenko, Maria
   S/0000-0002-0673-4094; Puzyrev, Valery P/0000-0002-2113-4556; Lebedev,
   Igor N/0000-0002-0482-8046; Sleptcov, Alexei/0000-0003-3226-1750;
   Skryabin, Nikolay Alekseevich/0000-0002-2491-3141
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.6.103
BP E134
EP E134
DI 10.1016/j.atherosclerosis.2018.06.391
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600403
DA 2019-10-28
ER

PT J
AU Slutter, B
   Depuydt, M
   van Duijn, J
   Bot, I
   Wezel, A
   Koppejan, H
   Toes, R
   Kuiper, J
AF Slutter, B.
   Depuydt, M.
   van Duijn, J.
   Bot, I.
   Wezel, A.
   Koppejan, H.
   Toes, R.
   Kuiper, J.
TI MASSCYTOMETRY IDENTIFIES CD8 T-CELL DIVERSITY IN HUMAN ATHEROSCLEROTIC
   LESIONS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Slutter, B.; Depuydt, M.; van Duijn, J.; Bot, I.; Kuiper, J.] Leiden Acad Ctr Drug Res, Leiden, Netherlands.
   [Wezel, A.] HMC Westeinde, The Hague, Netherlands.
   [Koppejan, H.; Toes, R.] Leiden Univ, Med Ctr, Leiden, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W7:4
BP E8
EP E8
DI 10.1016/j.atherosclerosis.2018.06.908
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600025
DA 2019-10-28
ER

PT J
AU Smolenskaya, O
   Suslov, S
   Shimkevich, A
AF Smolenskaya, O.
   Suslov, S.
   Shimkevich, A.
TI THE RISK FACTORS FOR CARDIOVASCULAR DISEASE AND THE VASCULAR AGE OF THE
   POPULATION OF HEALTHY MEN ARE 40 TO 60 YEARS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Smolenskaya, O.; Suslov, S.; Shimkevich, A.] Ural State Med Univ, Ekaterinburg, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.3.431
BP E227
EP E228
DI 10.1016/j.atherosclerosis.2018.06.718
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600730
DA 2019-10-28
ER

PT J
AU Snip, OSC
   Hoekstra, M
   Zhao, Y
   Calpe-Berdiel, L
   Vulve, J
   Escola-Gil, JC
   Foks, A
   Van der Sluis, RJ
   Blanco-Vaca, F
   Van Berkel, TJC
   Kuivenhoven, J
   Van Eck, M
AF Snip, O. S. C.
   Hoekstra, M.
   Zhao, Y.
   Calpe-Berdiel, L.
   Vulve, J.
   Escola-Gil, J. Carles
   Foks, A.
   Van der Sluis, R. J.
   Blanco-Vaca, F.
   Van Berkel, T. J. C.
   Kuivenhoven, J.
   Van Eck, M.
TI REDUCED SYSTEMIC INFLAMMATION AND INCREASED REVERSE CHOLESTEROL
   TRANSPORT TOGETHER DRIVE LEUKOCYTE ABCA1-MEDIATED PROTECTION AGAINST
   ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Snip, O. S. C.; Hoekstra, M.; Zhao, Y.; Calpe-Berdiel, L.; Foks, A.; Van der Sluis, R. J.; Van Berkel, T. J. C.; Van Eck, M.] Leiden Acad Ctr Drug Res, Div BioTherapeut, Leiden, Netherlands.
   [Vulve, J.; Escola-Gil, J. Carles; Blanco-Vaca, F.] IIB St Pau, Barcelona, Spain.
   [Vulve, J.; Escola-Gil, J. Carles; Blanco-Vaca, F.] CIBER Diabet Enfermedades Metabololican Asociadas, Barcelona, Spain.
   [Blanco-Vaca, F.] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Barcelona, Spain.
   [Kuivenhoven, J.] Univ Amsterdam, Dept Vasc Med, Acad Med Ctr, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG14.5
BP E43
EP E44
DI 10.1016/j.atherosclerosis.2018.06.110
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600124
DA 2019-10-28
ER

PT J
AU Sobotka, O
   Stankova, P
   Kucera, O
   Endlicher, R
   Nozickova, K
   Cervinkova, Z
AF Sobotka, O.
   Stankova, P.
   Kucera, O.
   Endlicher, R.
   Nozickova, K.
   Cervinkova, Z.
TI CHANGES IN LIVER ENERGY METABOLISM DURING THE PROGRESSION OF NAFLD
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sobotka, O.; Stankova, P.; Kucera, O.; Endlicher, R.; Nozickova, K.; Cervinkova, Z.] Charles Univ Prague, Fac Med Hradec Kralove, Hradec Kralove, Czech Republic.
   [Sobotka, O.] Univ Hosp, Dept Internal Med Metab & Gerontol 3, Hradec Kralove, Czech Republic.
FU INTER-COST LTC [17044]; PROGRESS [Q40/02]; AZV CR [17-28882A, 17-31754A]
FX This work was supported by grants INTER-COST LTC 17044; PROGRESS Q40/02
   and AZV CR No. 17-28882A and 17-31754A.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG28.3
BP E65
EP E65
DI 10.1016/j.atherosclerosis.2018.06.178
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600192
DA 2019-10-28
ER

PT J
AU Sopic, M
   Mihajlovic, M
   Ninic, A
   Bogavac-Stanojevic, N
   Stepanovic, Z
   Vekic, J
   Zeljkovic, A
   Janac, J
   Kalimanovska-Spasojevic, V
   Jelic-Ivanovic, Z
AF Sopic, M.
   Mihajlovic, M.
   Ninic, A.
   Bogavac-Stanojevic, N.
   Stepanovic, Z.
   Vekic, J.
   Zeljkovic, A.
   Janac, J.
   Kalimanovska-Spasojevic, V.
   Jelic-ivanovic, Z.
TI ADIPOR1 POLYMORPHISM G.202940846G > C (RS7539542) IS ASSOCIATED WITH
   HIGHER CARDIOVASCULAR RISK IN MIDDLE-AGED POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sopic, M.; Mihajlovic, M.; Ninic, A.; Bogavac-Stanojevic, N.; Vekic, J.; Zeljkovic, A.; Janac, J.; Kalimanovska-Spasojevic, V.; Jelic-ivanovic, Z.] Univ Belgrade, Fac Pharm, Dept Med Biochem, Belgrade, Serbia.
   [Stepanovic, Z.] Medigrp Gen Hosp, Belgrade, Serbia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.504
BP E248
EP E248
DI 10.1016/j.atherosclerosis.2018.06.788
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600799
DA 2019-10-28
ER

PT J
AU Sorokin, A
   Kotani, K
   Dey, A
   Harrington, C
   Lerman, J
   Chung, J
   Rodante, J
   Bluemke, D
   Chen, M
   Playford, M
   Mehta, N
AF Sorokin, A.
   Kotani, K.
   Dey, A.
   Harrington, C.
   Lerman, J.
   Chung, J.
   Rodante, J.
   Bluemke, D.
   Chen, M.
   Playford, M.
   Mehta, N.
TI PSORIASIS SPECIFIC CHANGES IN OXIDIZED LIPOPROTEINS AND ITS ASSOCIATION
   WITH NON-CALCIFIED CORONARY PLAQUE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sorokin, A.; Dey, A.; Harrington, C.; Lerman, J.; Chung, J.; Rodante, J.; Bluemke, D.; Chen, M.; Playford, M.; Mehta, N.] Natl Heart Lung & Blood Inst, Sect Inflammat & Cardiometab Dis, Bethesda, MD USA.
   [Kotani, K.] Jichi Med Univ, Div Community & Family Med, Shimotsuke, Japan.
RI Mehta, Nehal N/W-4669-2019
OI Mehta, Nehal N/0000-0003-4939-5130
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.510
BP E249
EP E249
DI 10.1016/j.atherosclerosis.2018.06.793
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600804
DA 2019-10-28
ER

PT J
AU Sousa, B
AF Sousa, B.
TI MEDITERRANEAN DIET, A WAY TO REDUCE ATHEROSCLEROSIS: THE ADHERENCE IN A
   PORTUGUESE SAMPLE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sousa, B.] Univ Lusofona Humanidades & Tecnol, Sch Sci & Hlth Technol, Lisbon, Portugal.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.5.358
BP E207
EP E207
DI 10.1016/j.atherosclerosis.2018.06.644
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600656
DA 2019-10-28
ER

PT J
AU Stanimirovic, J
   Panic, A
   Obradovic, M
   Zafirovic, S
   Isenovic, ER
AF Stanimirovic, J.
   Panic, A.
   Obradovic, M.
   Zafirovic, S.
   Isenovic, E. R.
TI IGF-1 AMELIORATES DETRIMENTAL EFFECTS OF OBESITY IN RAT HEART BY
   PROMOTING AKT AND FOXO1
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Stanimirovic, J.; Panic, A.; Obradovic, M.; Zafirovic, S.; Isenovic, E. R.] Vinca Inst Nucl Sci, Dept Radiobiol & Mol Genet, Belgrade, Serbia.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.7.114
BP E137
EP E137
DI 10.1016/j.atherosclerosis.2018.06.402
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600414
DA 2019-10-28
ER

PT J
AU Stanisic, J
   Koricanac, G
   Stojiljkovic, M
   Culafic, T
   Romic, S
   Kostic, M
   Pantelic, M
   Tepavcevic, S
AF Stanisic, J.
   Koricanac, G.
   Stojiljkovic, M.
   Culafic, T.
   Romic, S.
   Kostic, M.
   Pantelic, M.
   Tepavcevic, S.
TI DISTURBANCES IN CARDIAC INSULIN SIGNALING AND NITRIC OXIDE SYNTHASE IN
   OVARIECTOMIZED RATS ON FRUCTOSE DIET CAN BE PREVENTED BY LOW INTENSITY
   EXERCISE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Stanisic, J.; Koricanac, G.; Stojiljkovic, M.; Culafic, T.; Romic, S.; Kostic, M.; Pantelic, M.; Tepavcevic, S.] Vinca Inst Nucl Sci, Lab Mol Biol & Endocrinol, Belgrade, Serbia.
OI Stanisic, Jelena/0000-0002-4365-9169
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.3.320
BP E197
EP E197
DI 10.1016/j.atherosclerosis.2018.06.607
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600619
DA 2019-10-28
ER

PT J
AU Stepanova, M
   Oishi, Y
   Kirichenko, T
   Orekhov, A
AF Stepanova, M.
   Oishi, Y.
   Kirichenko, T.
   Orekhov, A.
TI MONOCYTE ACTIVATION: CELLULAR TEST FOR DEVELOPMENT OF DIAGNOSTICS AND
   THERAPY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Stepanova, M.; Orekhov, A.] Inst Gen Pathol & Pathophysiol, Moscow, Russia.
   [Oishi, Y.] Tokyo Med & Dent Univ, Tokyo, Japan.
   [Kirichenko, T.] Natl Med Res Ctr Cardiol, Moscow, Russia.
RI Kirichenko, Tatiana V./R-8560-2017; Orekhov, Alexander N/J-4838-2013
OI Kirichenko, Tatiana V./0000-0002-2899-9202; Orekhov, Alexander
   N/0000-0002-6495-1628
FU RFBRRussian Foundation for Basic Research (RFBR) [18-54-50007]
FX The study was funded by RFBR according to the research project
   (application # 18-54-50007).
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.2.049
BP E118
EP E118
DI 10.1016/j.atherosclerosis.2018.06.335
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600347
DA 2019-10-28
ER

PT J
AU Stojanovic, M
   Radenkovic, M
AF Stojanovic, M.
   Radenkovic, M.
TI OMEGA-3 FATTY ACIDS ARE CAPABLE TO DECREASE THE LIPOPROTEIN-ASSOCIATED
   PHOSPHOLIPASE A2 BLOOD LEVEL
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Stojanovic, M.; Radenkovic, M.] Univ Belgrade, Med Fac, Dept Pharmcol Clin Pharmacol & Toxicol, Belgrade, Serbia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.465
BP E237
EP E237
DI 10.1016/j.atherosclerosis.2018.06.749
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600761
DA 2019-10-28
ER

PT J
AU Stolarikova, E
   Kopecky, J
   Velebova, K
   Veleba, J
   Belinova, L
   Malinska, H
   Segetova, M
   Melenovsky, V
   Pelikanova, T
AF Stolarikova, E.
   Kopecky, J.
   Velebova, K.
   Veleba, J.
   Belinova, L.
   Malinska, H.
   Segetova, M.
   Melenovsky, V.
   Pelikanova, T.
TI THE EFFECT OF METFORMIN ON ENERGETIC METABOLISM IN PATIENTS WITH TYPE 2
   DIABETES/PREDIABETES AND CHRONIC HEART FAILURE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Stolarikova, E.; Kopecky, J.; Velebova, K.; Veleba, J.; Belinova, L.; Pelikanova, T.] Inst Clin & Expt Med, Diabetol Ctr, Prague, Czech Republic.
   [Segetova, M.; Melenovsky, V.] Inst Clin & Expt Med, Cardiac Ctr, Prague, Czech Republic.
   [Malinska, H.] Inst Clin & Expt Med, Expt Med Ctr, Prague, Czech Republic.
RI Melenovsky, Vojtech/T-9422-2019
OI Melenovsky, Vojtech/0000-0001-8921-7078
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.3.313
BP E195
EP E195
DI 10.1016/j.atherosclerosis.2018.06.600
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600612
DA 2019-10-28
ER

PT J
AU Strandkjaer, N
   Frikke-Schmidt, R
   Hansen, M
   Kamstrup, P
   Tybjaerg-Hansen, A
   Nordestgaard, B
   Tabor, A
   Sundberg, K
   Bundgaard, H
   Iversen, K
AF Strandkjaer, N.
   Frikke-Schmidt, R.
   Hansen, Mk.
   Kamstrup, Pr.
   Tybjaerg-Hansen, A.
   Nordestgaard, B.
   Tabor, A.
   Sundberg, K.
   Bundgaard, H.
   Iversen, K.
TI A COMPARISON OF CHOLESTEROL LEVELS IN UMBILICAL CORD BLOOD AND IN
   NEONATAL BLOOD - THE COMPARE STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Strandkjaer, N.; Hansen, Mk.; Iversen, K.] Herlev Hosp, Univ Copenhagen Hosp, Dept Cardiol, Copenhagen, Denmark.
   [Frikke-Schmidt, R.; Tybjaerg-Hansen, A.] Rigshosp, Univ Copenhagen Hosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Kamstrup, Pr.; Nordestgaard, B.] Herlev Hosp, Univ Copenhagen Hosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Tabor, A.; Sundberg, K.; Bundgaard, H.] Rigshosp, Univ Copenhagen Hosp, Dept Obstet, Copenhagen, Denmark.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG41.3
BP E92
EP E92
DI 10.1016/j.atherosclerosis.2018.06.250
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600264
DA 2019-10-28
ER

PT J
AU Strembitska, A
   Salt, IP
   Baillie, G
AF Strembitska, A.
   Salt, I. P.
   Baillie, G.
TI THE EFFECT OF EXPERIMENTAL HYPERGLYCAEMIA ON ENDOTHELIAL FUNCTION AND
   MITOCHONDRIAL ACTIVITY IN HUMAN AORTIC ENDOTHELIAL CELLS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Strembitska, A.; Salt, I. P.; Baillie, G.] Univ Glasgow, Glasgow, Lanark, Scotland.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.063
BP E122
EP E122
DI 10.1016/j.atherosclerosis.2018.06.350
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600362
DA 2019-10-28
ER

PT J
AU Su, T
AF Su, T.
TI POSITIVE ASSOCIATION BETWEEN SMALL DENSE LOW-DENSITY LIPOPROTEIN
   CHOLESTEROL CONCENTRATION AND BIOMARKERS OF INFLAMMATION, THROMBOSIS,
   AND PREDIABETES IN NON-DIABETIC ADULTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Su, T.] Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei, Taiwan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.525
BP E253
EP E253
DI 10.1016/j.atherosclerosis.2018.06.806
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600817
DA 2019-10-28
ER

PT J
AU Suciu, M
   Vlaia, L
   Andor, M
   Vlaia, V
   Tomescu, M
   Cristescu, C
AF Suciu, M.
   Vlaia, L.
   Andor, M.
   Vlaia, V.
   Tomescu, M.
   Cristescu, C.
TI IMPACT OF DIFFERENT DOSES OF ROSUVASTATIN THERAPY ON FUNCTIONAL AND
   STRUCTURAL MARKERS OF ENDOTHELIUM DAMAGE IN HYPERTENSIVE PATIENTS
   DETERMINED BY SMOKING STATUS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Suciu, M.; Vlaia, L.; Vlaia, V.; Cristescu, C.] Victor Babes Univ Med & Pharm, Fac Pharm, Timisoara, Romania.
   [Andor, M.; Tomescu, M.] Victor Babes Univ Med & Pharm, Fac Med, Timisoara, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.410
BP E222
EP E222
DI 10.1016/j.atherosclerosis.2018.06.697
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600709
DA 2019-10-28
ER

PT J
AU Suciu, M
   Vlaia, L
   Suciu, L
   Dragan, L
   Vlaia, V
   Voicu, M
   Buda, V
   Mabda, CM
   Andor, M
   Negres, S
   Cristescu, C
AF Suciu, M.
   Vlaia, L.
   Suciu, L.
   Dragan, L.
   Vlaia, V.
   Voicu, M.
   Buda, V.
   Mabda, C. M.
   Andor, M.
   Negres, S.
   Cristescu, C.
TI EXPLORING THE KNOWLEDGE, THE REASONS AND THE PREVALENCE OF THE
   CONTRAINDICATED USE OF COMBINED ORAL CONTRACEPTIVES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Suciu, M.; Vlaia, L.; Suciu, L.; Dragan, L.; Vlaia, V.; Voicu, M.; Buda, V.; Mabda, C. M.; Andor, M.; Cristescu, C.] Victor Babes Univ Med & Pharm, Timisoara, Romania.
   [Negres, S.] Carol Davila Univ Med & Pharm, Bucharest, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.399
BP E219
EP E219
DI 10.1016/j.atherosclerosis.2018.06.686
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600698
DA 2019-10-28
ER

PT J
AU Suciu, M
   Vlaia, L
   Andor, M
   Vlaia, V
   Negres, S
   Cristescu, C
AF Suciu, M.
   Vlaia, L.
   Andor, M.
   Vlaia, V.
   Negres, S.
   Cristescu, C.
TI KNOWLEDGE, ATTITUDES AND PRACTICES ON SELF-MONITORING BLOOD PRESSURE AND
   BLOOD GLUCOSE LEVEL IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE II
   DIABETES MELLITUS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Suciu, M.; Vlaia, L.; Andor, M.; Vlaia, V.; Cristescu, C.] Victor Babes Univ Med & Pharm, Timisoara, Romania.
   [Negres, S.] Carol Davila Univ Med & Pharm, Bucharest, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.404
BP E220
EP E220
DI 10.1016/j.atherosclerosis.2018.06.691
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600703
DA 2019-10-28
ER

PT J
AU Sukhorukov, V
   Zakiev, E
   Nikiforov, N
   Oishi, Y
   Zhelankin, A
   Sobenin, I
   Makeev, V
   Kontush, A
   Le Goff, W
   Foxx, K
   Kruth, H
   Jin, X
   Bukrinsky, M
   Orekhov, A
AF Sukhorukov, V.
   Zakiev, E.
   Nikiforov, N.
   Oishi, Y.
   Zhelankin, A.
   Sobenin, I.
   Makeev, V.
   Kontush, A.
   Le Goff, W.
   Foxx, K.
   Kruth, H.
   Jin, X.
   Bukrinsky, M.
   Orekhov, A.
TI TRANSCRIPTOME ANALYSIS OF HUMAN MACROPHAGES REVEALS GENES REGULATING
   CELLULAR CHOLESTEROL EFFLUX
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sukhorukov, V.; Nikiforov, N.; Orekhov, A.] Inst Gen Pathol & Pathophysiol, Dept Angiopathol, Moscow, Russia.
   [Zakiev, E.; Kontush, A.; Le Goff, W.] UPMC, INSERM, UMR 1166, ICAN, Paris, France.
   [Oishi, Y.] Tokyo Med & Dent Univ, Dept Cellular & Mol Med, Tokyo, Japan.
   [Zhelankin, A.] Fed Res & Clin Ctr Phys Chem Med, Dept Mol Biol & Genet, Moscow, Russia.
   [Sobenin, I.] Natl Med Res Ctr Cardiol, Dept Med Genet, Moscow, Russia.
   [Makeev, V.] Vavilov Inst Gen Genet, Dept Syst Biol, Moscow, Russia.
   [Foxx, K.] Kalen Biomed LLC, Montgomery Village, MD USA.
   [Kruth, H.; Jin, X.] NIH, Div Intramural Res, Bldg 10, Bethesda, MD 20892 USA.
   [Bukrinsky, M.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC USA.
RI Sobenin, Igor A/J-4282-2013; Sukhorukov, Vasily/H-6545-2016; Le Goff,
   Wilfried/N-6326-2017; Le Goff, Wilfried/N-7593-2019; Orekhov, Alexander
   N/J-4838-2013
OI Sobenin, Igor A/0000-0003-0978-6444; Sukhorukov,
   Vasily/0000-0002-0312-3773; Le Goff, Wilfried/0000-0002-7611-9644; Le
   Goff, Wilfried/0000-0002-7611-9644; Orekhov, Alexander
   N/0000-0002-6495-1628
FU Russian Science FoundationRussian Science Foundation (RSF) [14-15-00112]
FX This work was supported by Russian Science Foundation (Grant #
   14-15-00112).
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG19.1
BP E48
EP E48
DI 10.1016/j.atherosclerosis.2018.06.127
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600141
DA 2019-10-28
ER

PT J
AU Sulkava, M
   Levula, M
   Lyytikainen, LP
   Pashupati, PM
   Klopp, N
   Illig, T
   Seppala, I
   Kholova, I
   Laaksonen, R
   Jarvinen, O
   Mennander, A
   Kahonen, M
   Miettinen, M
   Lehtimaki, T
   Oksala, N
   Raitoharju, E
AF Sulkava, M.
   Levula, M.
   Lyytikainen, L. P.
   Pashupati, P. Mishra
   Klopp, N.
   Illig, T.
   Seppala, I.
   Kholova, I.
   Laaksonen, R.
   Jarvinen, O.
   Mennander, A.
   Kahonen, M.
   Miettinen, M.
   Lehtimaki, T.
   Oksala, N.
   Raitoharju, E.
TI FORMYL PEPTIDE RECEPTORS 1-3 AND ANNEXIN 1 IN ATHEROSCLEROTIC PLAQUES -
   TAMPERE VASCULAR STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sulkava, M.; Levula, M.; Lyytikainen, L. P.; Pashupati, P. Mishra; Seppala, I.; Laaksonen, R.; Jarvinen, O.; Mennander, A.; Kahonen, M.; Miettinen, M.; Lehtimaki, T.; Raitoharju, E.] Tampere Univ Hosp, Dept Clin Chem, Fimlab Labs, Finnish Cardiovasc Res Ctr Tampere, Tampere, Finland.
   [Sulkava, M.; Levula, M.; Lyytikainen, L. P.; Pashupati, P. Mishra; Seppala, I.; Kholova, I.; Laaksonen, R.; Jarvinen, O.; Mennander, A.; Kahonen, M.; Miettinen, M.; Lehtimaki, T.; Oksala, N.; Raitoharju, E.] Univ Tampere, Fac Med & Life Sci, Tampere, Finland.
   [Klopp, N.; Illig, T.] German Res Ctr Environm Hlth GmbH, Res Unit Mol Epidemiol, Helmholtz Zentrum Munchen, Munich, Germany.
   [Jarvinen, O.; Mennander, A.] Tampere Univ Hosp, Ctr Heart, Dept Cardiac Surg, Tampere, Finland.
   [Oksala, N.] Tampere Univ Hosp, Div Vasc Surg, Dept Surg, Tampere, Finland.
   [Kahonen, M.] Tampere Univ Hosp, Dept Clin Physiol, Tampere, Finland.
   [Miettinen, M.] Univ Tampere, Adult Stem Cell Grp, BioMediTech, Fac Med & Life Sci, Tampere, Finland.
   [Klopp, N.; Illig, T.] Hannover Med Sch, Hannover Unified Biobank, Hannover, Germany.
   [Kholova, I.] Tampere Univ Hosp, Dept Pathol, Fimlab Labs, Tampere, Finland.
   [Klopp, N.] Hannover Med Sch, Dept Human Genet, Hannover, NH, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.002
BP E104
EP E105
DI 10.1016/j.atherosclerosis.2018.06.287
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600299
DA 2019-10-28
ER

PT J
AU Sundholm, J
   Litwin, L
   Koivusalo, SB
   Rono, K
   Eriksson, JG
   Sarkola, T
AF Sundholm, J.
   Litwin, L.
   Koivusalo, S. B.
   Rono, K.
   Eriksson, J. G.
   Sarkola, T.
TI MATERNAL GESTATIONAL DIABETES AND OBESITY, IMPACT ON CAROTID ARTERY
   STIFFNESS AND INTIMA-MEDIA THICKNESS IN THE OFFSPRING - RADIEL STUDY 6
   YEARS FOLLOW-UP
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sundholm, J.; Litwin, L.; Sarkola, T.] Univ Helsinki, Childrens Hosp, Helsinki, Finland.
   [Sundholm, J.; Litwin, L.; Koivusalo, S. B.; Rono, K.; Eriksson, J. G.] Helsinki Univ Hosp, Helsinki, Finland.
   [Litwin, L.] SMDZ, Dept Congenital Heart Defects & Pediat Cardiol, Zabrze, Poland.
   [Koivusalo, S. B.; Rono, K.] Univ Helsinki, Womens Hosp, Helsinki, Finland.
   [Eriksson, J. G.] Univ Helsinki, Helsinki, Finland.
   [Eriksson, J. G.] Folkhalsan Res Ctr, Helsinki, Finland.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG10.3
BP E18
EP E19
DI 10.1016/j.atherosclerosis.2018.06.039
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600053
DA 2019-10-28
ER

PT J
AU Sundholm, J
   Litwin, L
   Rono, K
   Koivusalo, SB
   Eriksson, JG
   Sarkola, T
AF Sundholm, J.
   Litwin, L.
   Rono, K.
   Koivusalo, S. B.
   Eriksson, J. G.
   Sarkola, T.
TI MUSCULAR ARTERY MORPHOLOGY IS ASSOCIATED WITH LEAN BODY MASS IN CHILDREN
   OF MOTHERS WITH OBESITY AND GDM - RADIEL STUDY 6 YEARS FOLLOW-UP
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sundholm, J.; Litwin, L.; Sarkola, T.] Univ Helsinki, Childrens Hosp, Helsinki, Finland.
   [Sundholm, J.; Litwin, L.; Rono, K.; Koivusalo, S. B.; Eriksson, J. G.; Sarkola, T.] Helsinki Univ Hosp, Helsinki, Finland.
   [Litwin, L.] SMDZ, Dept Congenital Heart Defects & Pediat Cardiol, Zabrze, Poland.
   [Rono, K.; Koivusalo, S. B.] Univ Helsinki, Womens Hosp, Helsinki, Finland.
   [Eriksson, J. G.] Univ Helsinki, Helsinki, Finland.
   [Eriksson, J. G.] Folkhalsan Res Ctr, Helsinki, Finland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.6.102
BP E134
EP E134
DI 10.1016/j.atherosclerosis.2018.06.390
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600402
DA 2019-10-28
ER

PT J
AU Sustar, U
   Lainscek, D
   Horvat, S
AF Sustar, U.
   Lainscek, D.
   Horvat, S.
TI EFFECT OF PALMITATE AND TST GENE ON INFLAMMATION AND INSULIN RESISTANCE
   IN ADIPOCYTES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sustar, U.] Natl Inst Chem, Dept Synthet Biol & Immunol, Ljubljana, Slovenia.
   [Lainscek, D.; Horvat, S.] Univ Ljubljana, Dept Anim Sci, Biotech Fac, Ljubljana, Slovenia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG31.6
BP E71
EP E71
DI 10.1016/j.atherosclerosis.2018.06.198
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600212
DA 2019-10-28
ER

PT J
AU Nunes, VS
   Cazita, PM
   Catanozi, S
   Nakandakare, ER
   Quintao, ECR
AF Sutti Nunes, V.
   Miralda Cazita, P.
   Catanozi, S.
   Nakandakare, E. R.
   Quintao, E. C. R.
TI CHOLESTEROL CONTENT AND SYNTHESIS IN THE BRAIN OF APOE KNOCKOUT MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sutti Nunes, V.; Miralda Cazita, P.; Catanozi, S.; Nakandakare, E. R.; Quintao, E. C. R.] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Lab Lipides,LIM 10, Sao Paulo, Brazil.
RI Cazita, Patricia M/C-1066-2012; Nunes, Valeria S./G-4778-2012
OI Nunes, Valeria S./0000-0002-6769-5412
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.154
BP E149
EP E149
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600453
DA 2019-10-28
ER

PT J
AU Szamosi, T
AF Szamosi, T.
TI TREATMENT OF PEDIATRIC PATIENTS WITH HOMOZYGOTE FAMILIAL
   HYPERCHOLESTEROLEMIA (HEFH)
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Szamosi, T.] Semmelweis Univ, Med Fac, Pediat Dept 2, Budapest, Hungary.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.11.149
BP E148
EP E148
DI 10.1016/j.atherosclerosis.2018.06.436
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600448
DA 2019-10-28
ER

PT J
AU Szentimrei, R
   Harangi, M
   Szentpeteri, A
   Varga, V
   Lorincz, H
   Seres, I
   Nemes, B
   Paragh, G
AF Szentimrei, R.
   Harangi, M.
   Szentpeteri, A.
   Varga, V.
   Lorincz, H.
   Seres, I.
   Nemes, B.
   Paragh, G.
TI CHANGES IN NT-PROCNP LEVELS IN PATIENTS WITH END STAGE RENAL FAILURE
   BEFORE AND AFTER KIDNEY ALLOTRASPLANTATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Szentimrei, R.; Harangi, M.; Szentpeteri, A.; Varga, V.; Lorincz, H.; Seres, I.; Paragh, G.] Univ Debrecen, Dept Internal Med, Fac Med, Debrecen, Hungary.
   [Nemes, B.] Univ Debrecen, Fac Med, Inst Surg, Dept Organ Transplantat, Debrecen, Hungary.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.6.521
BP E252
EP E252
DI 10.1016/j.atherosclerosis.2018.06.802
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600813
DA 2019-10-28
ER

PT J
AU Sztanek, FSF
   Lorincz, H
   Banyai, D
   Sandor, P
   Molnar, A
   Seres, I
   Paragh, G
AF Sztanek, F. S. Ferenc
   Lorincz, Hajnalka
   Banyai, Dora
   Sandor, Petra
   Molnar, Agnes
   Seres, Ildiko
   Paragh, Gyorgy
TI CHANGES OF OXIDATIVE STRESS MARKERS AFTER TREATMENT OF DIABETIC
   NEUROPATHY WITH ALPHA-LIPOIC ACID
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Sztanek, F. S. Ferenc; Lorincz, Hajnalka; Banyai, Dora; Sandor, Petra; Molnar, Agnes; Seres, Ildiko; Paragh, Gyorgy] Univ Debrecen, Dept Internal Med, Bldg A, Debrecen, Hungary.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.4.348
BP E204
EP E205
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600646
DA 2019-10-28
ER

PT J
AU Takata, K
   Honda, S
   Sidharta, S
   Duong, M
   Shishikura, D
   Kim, S
   Andrews, J
   Bartolo, B
   Pisaltis, P
   Bursill, C
   Worthley, M
   Nicholls, S
AF Takata, K.
   Honda, S.
   Sidharta, S.
   Duong, M.
   Shishikura, D.
   Kim, S.
   Andrews, J.
   Bartolo, B.
   Pisaltis, P.
   Bursill, C.
   Worthley, M.
   Nicholls, S.
TI A BENEFICIAL ROLE OF ATP-BINDING CASSETTE TRANSPORTER G1-MEDIATED
   CHOLESTEROL EFFLUX CAPACITY IN REGRESSION OF CORONARY LIPID CONTENT
   ASSESSED BY NEAR-INFRARED SPECTROSCOPY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Takata, K.; Honda, S.; Duong, M.; Shishikura, D.; Kim, S.; Andrews, J.; Bartolo, B.; Pisaltis, P.; Bursill, C.; Worthley, M.; Nicholls, S.] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
   [Sidharta, S.; Pisaltis, P.; Worthley, M.] Royal Adelaide Hosp, Adelaide, SA, Australia.
   [Pisaltis, P.; Bursill, C.; Worthley, M.; Nicholls, S.] Univ Adelaide, Adelaide, SA, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG2.1
BP E20
EP E20
DI 10.1016/j.atherosclerosis.2018.06.043
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600057
DA 2019-10-28
ER

PT J
AU Iborra, RT
   Machado-Lima, A
   Okuda, LS
   Minanni, C
   Mello, M
   Nakandakare, ER
   Machado, UF
   Correa-Gianella, MLC
   Passarelli, M
AF Tallada Iborra, R.
   Machado-Lima, A.
   Okuda, L. S.
   Minanni, C.
   Mello, M.
   Nakandakare, E. R.
   Machado, U. F.
   Correa-Gianella, M. L. C.
   Passarelli, M.
TI IMPROVEMENT OF GLYCEMIC CONTROL RESTORES ABCA-1 IN MACROPHAGES INCUBATED
   WITH ALBUMIN ISOLATED FROM DIABETIC SUBJECTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tallada Iborra, R.; Okuda, L. S.; Minanni, C.; Mello, M.; Nakandakare, E. R.; Passarelli, M.] Univ Sao Paulo, Fac Med, Lab Lipides LIM 10, Sao Paulo, Brazil.
   [Machado-Lima, A.] Univ Sao Judas Tadeu, Sao Paulo, Brazil.
   [Machado, U. F.; Correa-Gianella, M. L. C.] Univ Sao Paulo, ICB, Dept Fisiol & Biofis, Sao Paulo, Brazil.
   [Correa-Gianella, M. L. C.] Univ Nove Julho, Programa Posgrad Med, Sao Paulo, Brazil.
RI Iborra, Rodrigo Tallada/Q-4122-2019; Iborra, Rodrigo T
   Tallada/I-6339-2017
OI Iborra, Rodrigo Tallada/0000-0002-3772-4200; Iborra, Rodrigo T
   Tallada/0000-0002-3772-4200
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG6.4
BP E27
EP E28
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600084
DA 2019-10-28
ER

PT J
AU Tanianskii, D
   Pigarevsky, PV
   Maltceva, SV
   Denisenko, AD
AF Tanianskii, D.
   Pigarevsky, P. V.
   Maltceva, S. V.
   Denisenko, A. D.
TI IMMUNOHISTOCHEMICAL DETECTION OF ADIPONECTIN IN ATHEROSCLEROTIC PLAQUE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tanianskii, D.; Denisenko, A. D.] Inst Expt Med, Dept Biochem, St Petersburg, Russia.
   [Tanianskii, D.] Inst Highly Pure Biopreparat, St Petersburg, Russia.
   [Pigarevsky, P. V.; Maltceva, S. V.] Inst Expt Med, Dept Morphol, St Petersburg, Russia.
   [Denisenko, A. D.] St Petersburg State Univ, St Petersburg, Russia.
RI Tanyanskiy, Dmitry/G-3307-2015
OI Tanyanskiy, Dmitry/0000-0002-5321-8834
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.6.105
BP E134
EP E135
DI 10.1016/j.atherosclerosis.2018.06.393
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600405
DA 2019-10-28
ER

PT J
AU Tarvala, U
   El Matary, R
   Nightingale, T
   Poston, R
AF Tarvala, U.
   El Matary, R.
   Nightingale, T.
   Poston, R.
TI DECREASE IN VON-WILLEBRAND FACTOR PROTEIN IN THE ENDOTHELIUM OF HUMAN
   CORONARY ATHEROSCLEROTIC PLAQUES: POSSIBLE MECHANISMS AND ROLE IN
   THROMBOSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tarvala, U.; El Matary, R.; Nightingale, T.; Poston, R.] Queen Mary Univ London, Ctr Microvasc Res, London, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG42:4
BP E95
EP E95
DI 10.1016/j.atherosclerosis.2018.06.257
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600271
DA 2019-10-28
ER

PT J
AU Tavoni, TM
   Vinagre, CG
   Freitas, FR
   Mesquita, CH
   Vinagre, JC
   Mariani, AC
   Kalil, R
   Maranhao, RC
AF Tavoni, T. M.
   Vinagre, C. G.
   Freitas, F. R.
   Mesquita, C. H.
   Vinagre, J. C.
   Mariani, A. C.
   Kalil-Filho, R.
   Maranhao, R. C.
TI PLASMA CLEARANCE OF CHYLOMICRON REMNANTS IS DELAYED IN AGED SUBJECTS: A
   STUDY WITH ARTIFICIAL EMULSIONS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tavoni, T. M.; Maranhao, R. C.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Analyses, Sao Paulo, Brazil.
   [Vinagre, C. G.; Mariani, A. C.] Univ Santo Amaro, Sao Paulo, Brazil.
   [Freitas, F. R.; Vinagre, J. C.; Kalil-Filho, R.; Maranhao, R. C.] Univ Sao Paulo, Med Sch Hosp, Heart Inst InCor, Sao Paulo, Brazil.
   [Mesquita, C. H.] Inst Nucl Res, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.2.181
BP E157
EP E157
DI 10.1016/j.atherosclerosis.2018.06.468
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600480
DA 2019-10-28
ER

PT J
AU Tchitashvili, G
   Kakauridze, N
   Buadze, T
   Gaiozishvili, M
   Lezhava, T
AF Tchitashvili, G.
   Kakauridze, N.
   Buadze, T.
   Gaiozishvili, M.
   Lezhava, T.
TI ASSOCIATION OF GENES POLYMORPHISMS WITH WARFARIN DOSE REQUIREMENT IN
   GEORGIAN POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tchitashvili, G.] Ivane Javakhishvili Tbilisi State Univ, Dept Biol, Div Genet, Tbilisi, Georgia.
   [Kakauridze, N.; Gaiozishvili, M.] Tbilisi State Med Univ, Fac Med, Dept Internal Med, Tbilisi, Georgia.
   [Buadze, T.; Lezhava, T.] Ivane Javakhishvili Tbilisi State Univ, Tbilisi, Georgia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.11.145
BP E147
EP E147
DI 10.1016/j.atherosclerosis.2018.06.432
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600444
DA 2019-10-28
ER

PT J
AU Terentes-Printzios, D
   Vlachopoulos, C
   Koutagiar, I
   Ioakeimidis, N
   Aznaouridis, K
   Xaplanteris, P
   Georgakopoulos, C
   Tousoulis, D
AF Terentes-Printzios, D.
   Vlachopoulos, C.
   Koutagiar, I.
   Ioakeimidis, N.
   Aznaouridis, K.
   Xaplanteris, P.
   Georgakopoulos, C.
   Tousoulis, D.
TI DYSLIPIDEMIA ACCELERATES VASCULAR AGING
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Terentes-Printzios, D.; Vlachopoulos, C.; Koutagiar, I.; Ioakeimidis, N.; Aznaouridis, K.; Xaplanteris, P.; Georgakopoulos, C.; Tousoulis, D.] Hippokrateion Hosp, Hypertens & Cardiometab Unit, Dept Cardiol 1, Athens Med Sch, Athens, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG41.6
BP E93
EP E93
DI 10.1016/j.atherosclerosis.2018.06.253
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600267
DA 2019-10-28
ER

PT J
AU Tesarova, S
   Blaha, V
   Ceska, R
   Dvorakova, J
   Freiberger, T
   Horak, P
   Hyanek, J
   Kyselak, O
   Nussbaumerova, B
   Soska, V
   Urbanek, R
   Vaclova, M
   Vaverkova, H
   Vrablik, M
   Vyroubal, P
   Zemek, S
   Zlatohlavek, L
AF Tesarova, S.
   Blaha, V.
   Ceska, R.
   Dvorakova, J.
   Freiberger, T.
   Horak, P.
   Hyanek, J.
   Kyselak, O.
   Nussbaumerova, B.
   Soska, V.
   Urbanek, R.
   Vaclova, M.
   Vaverkova, H.
   Vrablik, M.
   Vyroubal, P.
   Zemek, S.
   Zlatohlavek, L.
TI GENERAL CHARACTERISTICS OF PACIENTS WITH HOMOZYGOUS FORM OF FAMILIAL
   HYPERCHOLESTEROLAEMIA IN THE CZECH REPUBLIC
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tesarova, S.; Ceska, R.; Horak, P.; Vaclova, M.; Vrablik, M.; Zlatohlavek, L.] Charles Univ Prague, Fac Med 1, Med Dept 3, Prague, Czech Republic.
   [Tesarova, S.; Ceska, R.; Horak, P.; Vaclova, M.; Vrablik, M.; Zlatohlavek, L.] Gen Univ Hosp Prague, Prague, Czech Republic.
   [Blaha, V.; Vyroubal, P.] Teaching Hosp, Dept Metab Care & Gerontol, Hradec Kralove, Czech Republic.
   [Dvorakova, J.; Hyanek, J.] Na Homolce Hosp, Metab Outpatient Unit, Dept Clin Biochem, Prague, Czech Republic.
   [Freiberger, T.] Ctr Cardiovasc Surg & Transplantat, Brno, Czech Republic.
   [Nussbaumerova, B.] Teaching Hosp Pilsen, Internal Dept 2, Plzen, Czech Republic.
   [Kyselak, O.; Soska, V.] St Anna Hosp, Dept Clin Biochem, Brno, Czech Republic.
   [Vaverkova, H.] Med Fac, Dept Internal Med 3, Olomouc, Czech Republic.
   [Vaverkova, H.] Univ Hosp Olomouc, Olomouc, Czech Republic.
   [Zemek, S.] Lipid Clin Uherske Hradiste, Uherske Hradiste, Czech Republic.
   [Urbanek, R.] Lipid Clin Zlin, Zlin, Czech Republic.
FU AZV Czech Republic [15-28277A]
FX Supported by grant of AZV Czech Republic No. 15-28277A
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.1.254
BP E178
EP E178
DI 10.1016/j.atherosclerosis.2018.06.541
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600553
DA 2019-10-28
ER

PT J
AU Theofilatos, D
   Fotakis, P
   Valanti, E
   Sanoudou, D
   Zannis, V
   Kardassis, D
AF Theofilatos, D.
   Fotakis, P.
   Valanti, E.
   Sanoudou, D.
   Zannis, V.
   Kardassis, D.
TI HDL INDUCES THE EXPRESSION OF ANGIOPOIETIN LIKE 4 (ANGPTL4) GENE IN
   ENDOTHELIAL CELLS VIA A PI3K/AKT/FOXO1 SIGNALING PATHWAY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Theofilatos, D.; Kardassis, D.] Univ Crete, Sch Med, Iraklion, Greece.
   [Theofilatos, D.; Kardassis, D.] IMBB FORTH, Iraklion, Greece.
   [Fotakis, P.] Columbia Univ, Sch Med, New York, NY USA.
   [Valanti, E.; Sanoudou, D.] Univ Athens, Sch Med, Athens, Greece.
   [Zannis, V.] Boston Univ, Med Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG11.4
BP E36
EP E37
DI 10.1016/j.atherosclerosis.2018.06.092
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600106
DA 2019-10-28
ER

PT J
AU Timofeeva, S
   Butenko, E
   Derevyanchuk, K
   Shkurat, T
AF Timofeeva, S.
   Butenko, E.
   Derevyanchuk, K.
   Shkurat, T.
TI ASSOCIATION OF HETEROPLASMY LEVEL OF MITOHONDRIAL MUTATION M.13513G > IN
   GENEMT-ND5 WITH CAROTID ATHEROSCLEROSIS IN RUSSIAN POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Timofeeva, S.; Butenko, E.; Derevyanchuk, K.; Shkurat, T.] Southern Fed Univ, Rostov Na Donu, Russia.
FU Ministry of education and science of the Russian FederationMinistry of
   Education and Science, Russian Federation [6.6762.2017/BT]
FX The study was performed on the equipment of the Center of collective use
   "High technologies" (Southern Federal University) in the framework of
   the basic part of the Ministry of education and science of the Russian
   Federation state task, project No. 6.6762.2017/BT.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.3.283
BP E186
EP E187
DI 10.1016/j.atherosclerosis.2018.06.570
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600582
DA 2019-10-28
ER

PT J
AU Tinahones, F
   Laufs, U
   Cariou, B
   Yang, J
   Louie, MJ
   Thompson, D
   Leiter, LA
AF Tinahones, F.
   Laufs, U.
   Cariou, B.
   Yang, J.
   Louie, M. J.
   Thompson, D.
   Leiter, L. A.
TI ALIROCUMAB EFFICACY AND SAFETY BY BODY MASS INDEX: POOLED ANALYSIS FROM
   10 PHASE 3 ODYSSEY TRIALS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tinahones, F.] Malaga Univ, Hosp Virgen Victoria, CIBERobn, IBIMA, Malaga, Spain.
   [Laufs, U.] Univ Klinikum Saarlandes, Homburg, Germany.
   [Cariou, B.] Inst Thorax, Nantes, France.
   [Yang, J.] Sanofi, Bridgewater, MA USA.
   [Louie, M. J.; Thompson, D.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
   [Leiter, L. A.] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG22.3
BP E53
EP E54
DI 10.1016/j.atherosclerosis.2018.06.145
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600159
DA 2019-10-28
ER

PT J
AU TIsdall, AR
   Crowley, V
AF TIsdall, A. Rakovac
   Crowley, V.
TI A CASE-FINDING STRATEGY FOR FAMILIAL HYPERCHOLESTEROLAEMIA IN IRISH
   HOSPITALS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [TIsdall, A. Rakovac; Crowley, V.] St James Hosp, Biochem Dept, Dublin, Ireland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG36.3
BP E81
EP E81
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600238
DA 2019-10-28
ER

PT J
AU Tmoyan, N
   Ezhov, M
   Afanasieva, O
   Afanasieva, M
   Balakhonova, T
   Pokrovsky, S
AF Tmoyan, N.
   Ezhov, M.
   Afanasieva, O.
   Afanasieva, M.
   Balakhonova, T.
   Pokrovsky, S.
TI HIGH LIPOPROTEIN(A) LEVEL IS A PREDICTOR OF SEVERE CAROTID
   ATHEROSCLEROSIS AND ISCHEMIC STROKE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tmoyan, N.; Ezhov, M.; Afanasieva, O.; Afanasieva, M.; Balakhonova, T.; Pokrovsky, S.] FSBI Cardiol Natl Med Res Ctr MoH RF, Moscow, Russia.
RI Ezhov, Marat/M-5598-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.3.188
BP E159
EP E159
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600487
DA 2019-10-28
ER

PT J
AU Tmoyan, N
   Ezhov, M
   Afanasieva, O
   Klesareva, E
   Afanasieva, M
   Razova, O
   Pokrovsky, S
AF Tmoyan, N.
   Ezhov, M.
   Afanasieva, O.
   Klesareva, E.
   Afanasieva, M.
   Razova, O.
   Pokrovsky, S.
TI LIPOPROTEIN(A), APOLIPOPROTEIN( A) PHENOTYPES AND MULTISITE
   ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tmoyan, N.; Ezhov, M.; Afanasieva, O.; Klesareva, E.; Afanasieva, M.; Razova, O.; Pokrovsky, S.] Natl Med Res Cardiol Ctr, Moscow, Russia.
RI Ezhov, Marat/M-5598-2019; Klesareva, Elena Aleksandrovna/M-2852-2018
OI Klesareva, Elena Aleksandrovna/0000-0002-0682-8699
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.3.189
BP E159
EP E159
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600488
DA 2019-10-28
ER

PT J
AU Tmoyan, N
   Ezhov, M
   Afanasieva, O
   Klesareva, E
   Pogorelova, O
   Tripoten, M
   Afanasieva, M
   Razova, O
   Pokrovsky, S
AF Tmoyan, N.
   Ezhov, M.
   Afanasieva, O.
   Klesareva, E.
   Pogorelova, O.
   Tripoten, M.
   Afanasieva, M.
   Razova, O.
   Pokrovsky, S.
TI THE ROLE OF LIPOPROTEIN(A) AND APOLIPOPROTEIN(A) PHENOTYPES IN SEVERE
   ATHEROSCLEROSIS OF CORONARY, CAROTID AND LOWER LIMBS ARTERIES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tmoyan, N.; Ezhov, M.; Afanasieva, O.; Klesareva, E.; Pogorelova, O.; Tripoten, M.; Afanasieva, M.; Razova, O.; Pokrovsky, S.] Natl Med Res Cardiol Ctr, Moscow, Russia.
RI Klesareva, Elena Aleksandrovna/M-2852-2018; Ezhov, Marat/M-5598-2019;
   Tmoyan, Narek/E-3371-2018
OI Klesareva, Elena Aleksandrovna/0000-0002-0682-8699; Tmoyan,
   Narek/0000-0002-3617-9343
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.3.200
BP E162
EP E162
DI 10.1016/j.atherosclerosis.2018.06.487
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600499
DA 2019-10-28
ER

PT J
AU Tokgozoglu, L
   Ural, D
   Kayikcioglu, M
   Kilickap, U
   Goksuluk, H
   Karaaslan, D
AF Tokgozoglu, L.
   Ural, D.
   Kayikcioglu, M.
   Kilickap, U.
   Goksuluk, H.
   Karaaslan, D.
TI TEMPORAL TRENDS IN OBESITY AND STATUS OF DYSLIPIDEMIA IN TURKEY: A
   META-ANALYSIS OF EPIDEMIOLOGICAL STUDIES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tokgozoglu, L.] Hacettepe Univ, Sch Med, Ankara, Turkey.
   [Ural, D.; Karaaslan, D.] Koc Univ, Sch Med, Istanbul, Turkey.
   [Kayikcioglu, M.] Ege Univ, Sch Med, Izmir, Turkey.
   [Kilickap, U.; Goksuluk, H.] Ankara Univ, Sch Med, Ankara, Turkey.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.3.430
BP E227
EP E227
DI 10.1016/j.atherosclerosis.2018.06.717
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600729
DA 2019-10-28
ER

PT J
AU Cebada, RT
   Gonzalez, P
   Blasco-turrion, S
   Granados, AL
   Mesa, MD
   Toro, C
   Quezada-feijoo, M
   Ramos, M
   Lopez-ayala, R
   Rosa, F
   Rosa, S
   Mangas, A
AF Toro Cebada, R.
   Gonzalez, P.
   Blasco-turrion, S.
   Lopez Granados, A.
   Mesa, M. D.
   Toro, C.
   Quezada-feijoo, M.
   Ramos, M.
   Lopez-ayala, R.
   Rosa, F.
   Rosa, S.
   Mangas, A.
TI ECHOCARDIOGRAPHIC PATTERNS IN IDIOPATHIC AND FAMILIAL DILATED
   CARDIOMYOPATHY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Toro Cebada, R.; Toro, C.; Rosa, F.; Rosa, S.; Mangas, A.] Univ Cadiz, Med Sch Cadiz, Cadiz, Spain.
   [Gonzalez, P.; Blasco-turrion, S.] Hosp Univ Puerto Real, Cadiz, Spain.
   [Lopez Granados, A.; Mesa, M. D.] Hosp Univ Reina Sofia, Cordoba, Spain.
   [Quezada-feijoo, M.; Ramos, M.; Lopez-ayala, R.] Hosp Cruz Roja, Madrid, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.489
BP E243
EP E243
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600784
DA 2019-10-28
ER

PT J
AU Cebada, RT
   Blasco-Turrion, S
   Gonzalez, P
   Pena, LP
   Ponce, FJM
   Longobardo, FR
   Rojas, AM
AF Toro Cebada, R.
   Blasco-Turrion, S.
   Gonzalez, P.
   Pena Pena, L.
   Morales Ponce, F. J.
   Rosa Longobardo, F.
   Mangas Rojas, A.
TI IMPLICATION OF ECHOCARDIOGRAPHY IN THE FOLLOW-UP OF FAMILIAL
   CARDIOMYOPATHIES SECONDARY TO MUTATION OF THE LMNA GENE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Toro Cebada, R.] Med Sch, Cadiz, Spain.
   [Blasco-Turrion, S.] Univ Hosp Puerto Real, Cadiz, Spain.
   [Gonzalez, P.; Pena Pena, L.] Univ Hosp Virgen del Rocio, Seville, Spain.
   [Morales Ponce, F. J.] Univ Hosp Puerto Real Cadiz SPAIN, Inst Invest & Innovac Ciencias Biomed Cadiz, Cadiz, Spain.
   [Rosa Longobardo, F.] Inst Invest & Innovac Ciencias Biomed Cadiz INiBI, Cadiz, Spain.
   [Mangas Rojas, A.] Med Sch Cadiz SPAIN, Inst Invest & Innovac Ciencias Biomed Cadiz, Cadiz, Spain.
RI Morales, Francisco J/J-1863-2017
OI Morales, Francisco J/0000-0002-4689-7461
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.460
BP E235
EP E236
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600756
DA 2019-10-28
ER

PT J
AU Tosheska-Trajkovska, K
   Labudovic, D
   Jovanova, S
   Kostovska, I
   Bosilkova, G
   Topuzovska, S
AF Tosheska-Trajkovska, K.
   Labudovic, D.
   Jovanova, S.
   Kostovska, I.
   Bosilkova, G.
   Topuzovska, S.
TI CHOLESTERYL ESTER TRANSFER PROTEIN, LECITHIN CHOLESTEROL
   ACYLTRANSFERASE, LOW DENSITY LIPOPROTEIN PARTICLE SIZE AND INTIMA MEDIA
   THICKNESS IN PATIENTS WITH CORONARY HEART DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tosheska-Trajkovska, K.; Labudovic, D.; Kostovska, I.; Bosilkova, G.; Topuzovska, S.] Univ Ss Cyril & Methodius, Med Fac, Inst Med & Expt Biochem, Skopje, Macedonia.
   [Jovanova, S.] Univ Ss Cyril & Methodius, Med Fac, Univ Clin Cardiol, Skopje, Macedonia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.6.227
BP E170
EP E170
DI 10.1016/j.atherosclerosis.2018.06.514
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600526
DA 2019-10-28
ER

PT J
AU Toth, A
   Erdei, J
   Balogh, E
   Nyakundi, B
   Banyai, E
   Ryffel, B
   Paragh, G
   Cordero, M
   Jeney, V
AF Toth, A.
   Erdei, J.
   Balogh, E.
   Nyakundi, B.
   Banyai, E.
   Ryffel, B.
   Paragh, Gy.
   Cordero, M.
   Jeney, V.
TI INDUCTION OF NLRP3 INFLAMMASOME ACTIVATION BY HEME IN HUMAN ENDOTHELIAL
   CELLS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Toth, A.; Erdei, J.; Balogh, E.; Nyakundi, B.; Banyai, E.; Paragh, Gy.; Jeney, V.] Fac Med, Dept Internal Med, Debrecen, Hungary.
   [Ryffel, B.] Natl Ctr Sci Res Expt & Mol Immunol & Neurogenet, Orleans, France.
   [Ryffel, B.] Univ Cape Town, Inst Mol Med, Cape Town, South Africa.
   [Cordero, M.] Biomed Res Ctr, Inst Nutr & Food Technol, Dept Physiol, Granada, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG11.2
BP E36
EP E36
DI 10.1016/j.atherosclerosis.2018.06.090
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600104
OA Green Published
DA 2019-10-28
ER

PT J
AU Toyoshima, MTK
   Santos-Bezerra, DP
   Machado-Lima, A
   Goes, MFS
   Caramelli, B
   Correa-Giannella, MLC
   Passarelli, M
AF Toyoshima, M. T. K.
   Santos-Bezerra, D. P.
   Machado-Lima, A.
   Goes, M. F. S.
   Caramelli, B.
   Correa-Giannella, M. L. C.
   Passarelli, M.
TI IN TYPE 1 DIABETES MELLITUS IMPAIRED VASCULAR FUNCTION RELATES TO THE
   EXPRESSION OF MYD88 IN LYMPHOMONONUCLEAR CELLS BUT NOT TO DIETARY
   ADVANCED GLYCATION END-PRODUCTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Toyoshima, M. T. K.; Passarelli, M.] Univ Sao Paulo, Lab Lipides LIM10, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, Brazil.
   [Toyoshima, M. T. K.] Inst Canc Estado Sao Paulo Octavio Frias de Olive, Hosp Clini, Serv Oncoendocrinol, Sao Paulo, Brazil.
   [Santos-Bezerra, D. P.; Correa-Giannella, M. L. C.] Univ Sao Paulo, Fac Med, Lab Carboidratos & Radioimunoensaio LIM18, Hosp Clin HCFMUSP, Sao Paulo, Brazil.
   [Machado-Lima, A.] Univ Sao Judas Tadeu, Sao Paulo, Brazil.
   [Goes, M. F. S.] Hosp Clin HCFMUSP, Fac Med, Lab Aterosclerose, Inst Coracao, Sao Paulo, Brazil.
   [Caramelli, B.] Hosp Clin HCFMUSP Facul, Unidade Med Interdisciplinar Cardiol UnMic, Inst Coracao, Sao Paulo, Brazil.
   [Correa-Giannella, M. L. C.] Univ Nove Julho, Programa Posgrad Med, Sao Paulo, SP, Brazil.
RI Santos-Bezerra, Daniele/K-7579-2015; Caramelli, Bruno/B-9916-2008
OI Santos-Bezerra, Daniele/0000-0003-3464-8166; Caramelli,
   Bruno/0000-0001-6718-8456
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2015/21072-5]
FX FAPESP(2015/21072-5)
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG27.3
BP E63
EP E63
DI 10.1016/j.atherosclerosis.2018.06.172
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600186
DA 2019-10-28
ER

PT J
AU Trambowicz, K
   Gorzelak-Pabis, P
   Durma, A
   Pypec, A
   Lis, E
   Rozmarynowska, I
   Jurzak, N
   Ignaczak, M
   Broncel, M
AF Trambowicz, K.
   Gorzelak-Pabis, P.
   Durma, A.
   Pypec, A.
   Lis, E.
   Rozmarynowska, I.
   Jurzak, N.
   Ignaczak, M.
   Broncel, M.
TI STATIN USE AND SLEEP DISTURBANCE - OWN EXPERIENCE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Trambowicz, K.; Gorzelak-Pabis, P.; Durma, A.; Pypec, A.; Lis, E.; Rozmarynowska, I.; Jurzak, N.; Ignaczak, M.; Broncel, M.] Med Univ Lodz, Dept Internal Dis & Clin Pharmacol, Lodz, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.4.438
BP E229
EP E229
DI 10.1016/j.atherosclerosis.2018.06.725
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600737
DA 2019-10-28
ER

PT J
AU Trautwein, E
   Koppenol, W
   deJong, A
   Hiemstra, H
   Vermeer, M
   Noakes, M
   Luscombe-Marsh, N
AF Trautwein, E.
   Koppenol, W.
   deJong, A.
   Hiemstra, H.
   Vermeer, M.
   Noakes, M.
   Luscombe-Marsh, N.
TI PLANT STEROLS LOWERS BOTH FASTING LDL-CHOLESTEROL AND TRIGLYCERIDES IN
   DYSLIPIDAEMIC INDIVIDUALS WITH OR AT RISK OF DEVELOPING TYPE 2 DIABETES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Trautwein, E.; Koppenol, W.; deJong, A.; Hiemstra, H.; Vermeer, M.] Unilever R&D, Vlaardingen, Netherlands.
   [Noakes, M.; Luscombe-Marsh, N.] CSIRO Food Nutriton & Bioprod, Adelaide, SA, Australia.
RI Luscombe-Marsh, Natalie/F-4082-2019
OI Luscombe-Marsh, Natalie/0000-0001-9690-4722
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.3.324
BP E198
EP E198
DI 10.1016/j.atherosclerosis.2018.06.611
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600623
DA 2019-10-28
ER

PT J
AU Tremblay, K
   Brisson, D
   Gaudet, D
AF Tremblay, K.
   Brisson, D.
   Gaudet, D.
TI LIPOPROTEIN LIPASE GENE REPLACEMENT THERAPY LONG-TERM EFFECT ON FAMILIAL
   HYPERCHYLOMICRONEMIA GENE EXPRESSION PROFILE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tremblay, K.; Brisson, D.] Univ Montreal, Community Genet Ctr, Chicoutimi, PQ, Canada.
   [Gaudet, D.] ECOGENE 21, Chicoutimi, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG9.3
BP E34
EP E34
DI 10.1016/j.atherosclerosis.2018.06.086
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600100
DA 2019-10-28
ER

PT J
AU Trusca, VG
   Dumitrescu, M
   Fenyo, IM
   Tudorache, IF
   Gafencu, AV
AF Trusca, V. G.
   Dumitrescu, M.
   Fenyo, I. M.
   Tudorache, I. F.
   Gafencu, A. V.
TI BISPHENOL A EXERTS PRO-ATHEROGENIC EFFECTS THROUGH NF-KB ACTIVATION AND
   DOWN-REGULATION OF APOLIPOPROTEIN A1 EXPRESSION IN HEPATOCYTES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Trusca, V. G.; Dumitrescu, M.; Fenyo, I. M.; Tudorache, I. F.; Gafencu, A. V.] Inst Cellular Biol & Pathol Nicolae Simionescu, Bucharest, Romania.
RI Fenyo, Ioana Madalina/H-5517-2013
OI Fenyo, Ioana Madalina/0000-0003-3898-0940
FU CNCS - UEFISCDI [PN-II-RU-TE-2014-4-2660]; Romanian Academy
FX This work was supported by CNCS - UEFISCDI (PN-II-RU-TE-2014-4-2660) and
   Romanian Academy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.2.275
BP E184
EP E184
DI 10.1016/j.atherosclerosis.2018.06.562
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600574
DA 2019-10-28
ER

PT J
AU Tsai, W
   Chou, C
AF Tsai, W.
   Chou, C.
TI INCREASED BLOOD PRESSURE VARIABILITY WAS ASSOCIATED WITH FUTURE KIDNEY
   DISEASE IN ESSENTIAL HYPERTENSION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tsai, W.] Natl Cheng Kung Univ, Med Coll, Tainan, Taiwan.
   [Chou, C.] Sinlau Christian Hospita, Tainan, Taiwan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.2.303
BP E192
EP E192
DI 10.1016/j.atherosclerosis.2018.06.590
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600602
DA 2019-10-28
ER

PT J
AU Tsujikawa, L
   Kulikowski, E
   Calosing, C
   Wasiak, S
   Gilham, D
   Halliday, C
   Johansson, J
   Sweeney, M
   Wong, N
AF Tsujikawa, L.
   Kulikowski, E.
   Calosing, C.
   Wasiak, S.
   Gilham, D.
   Halliday, C.
   Johansson, J.
   Sweeney, M.
   Wong, N.
TI APABETALONE (RVX-208) ATTENUATES HYPERGLYCEMIA AND TMAO INDUCED ADHESION
   OF THP-1 MONOCYTES TO HUVEC ENDOTHELIAL CELLS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tsujikawa, L.; Kulikowski, E.; Calosing, C.; Wasiak, S.; Gilham, D.; Halliday, C.; Wong, N.] Resverlogix Corp, Calgary, AB, Canada.
   [Johansson, J.; Sweeney, M.] Resverlogix Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.5.215
BP E167
EP E167
DI 10.1016/j.atherosclerosis.2018.06.502
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600514
DA 2019-10-28
ER

PT J
AU Tsukui, D
   Kimura, Y
   Yanagida, T
   Kono, H
AF Tsukui, D.
   Kimura, Y.
   Yanagida, T.
   Kono, H.
TI REDUCED ATHEROSCLEROSIS IN MICE WITH CONDITIONAL DELETION OF SPLEEN
   TYROSINE KINASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tsukui, D.; Kimura, Y.; Yanagida, T.; Kono, H.] Teikyo Univ, Sch Med, Dept Internal Med, Tokyo, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG15.5
BP E45
EP E45
DI 10.1016/j.atherosclerosis.2018.06.115
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600129
DA 2019-10-28
ER

PT J
AU Tudorache, I
   Trusca, V
   Gafencu, A
AF Tudorache, I.
   Trusca, V.
   Gafencu, A.
TI BENZO(A)PYRENE - ACTIVATED AHR REGULATES APOLIPOPROTEINS EXPRESSION IN
   HEPATOCYTES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tudorache, I.; Trusca, V.; Gafencu, A.] ICBP, Bucharest, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.179
BP E156
EP E156
DI 10.1016/j.atherosclerosis.2018.06.466
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600478
DA 2019-10-28
ER

PT J
AU Tudorache, I
   Trusca, V
   Gafencu, A
AF Tudorache, I.
   Trusca, V.
   Gafencu, A.
TI BENZO(A)PYRENE - ACTIVATED AHR REGULATES APOLIPOPROTEINS EXPRESSION IN
   HEPATOCYTES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tudorache, I.; Trusca, V.; Gafencu, A.] ICBP Nicolae Simionescu, Bucharest, Romania.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.176
BP E155
EP E155
DI 10.1016/j.atherosclerosis.2018.06.463
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600475
DA 2019-10-28
ER

PT J
AU Tzani, A
   Konstantopoulos, P
   Doulamis, IP
   Daskalopoulou, A
   Liakea, A
   Korou, ML
   Iliopoulos, DC
   Kavantzas, N
   Stamatelopoulos, KS
   Perrea, DN
AF Tzani, A.
   Konstantopoulos, P.
   Doulamis, I. P.
   Daskalopoulou, A.
   Liakea, A.
   Korou, M. L.
   Iliopoulos, D. C.
   Kavantzas, N.
   Stamatelopoulos, K. S.
   Perrea, D. N.
TI PEROXISOME PROLIFERATIVE ACTIVATING FACTOR-ALPHA MEDIATED EFFECTS OF
   CHIOS MASTIC GUM (CMG) ON AN EXPERIMENTAL MODEL OF DIET-INDUCED
   ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tzani, A.; Konstantopoulos, P.; Doulamis, I. P.; Daskalopoulou, A.; Korou, M. L.; Iliopoulos, D. C.; Perrea, D. N.] Natl & Kapodist, Med Sch Athens, Lab Expt Surg & Surg Res NS Christeas, Athens, Greece.
   [Liakea, A.; Kavantzas, N.] Univ Athens, Med Sch Athens, Dept Pathol, Athens, Greece.
   [Stamatelopoulos, K. S.] Natl & Kapodistrian, Med Sch, Dept Clin Therapeut, Vasc Lab,Alexandra Hosp, Athens, Greece.
RI Doulamis, Ilias P/H-6836-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG33.1
BP E73
EP E73
DI 10.1016/j.atherosclerosis.2018.06.203
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600217
DA 2019-10-28
ER

PT J
AU Tzani, A
   Daskalopoulou, A
   Doulamis, IP
   Konstantopoulos, P
   Antoranz, A
   Minia, A
   Marinos, G
   Alexopoulos, L
   Perrea, DN
AF Tzani, A.
   Daskalopoulou, A.
   Doulamis, I. P.
   Konstantopoulos, P.
   Antoranz, A.
   Minia, A.
   Marinos, G.
   Alexopoulos, L.
   Perrea, D. N.
TI PPAR-ALPHA INDEPENDENT ANTI-INFLAMMATORY EFFECTS OF FENOFIBRATE IN A
   TRANSGENIC MODEL OF ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Tzani, A.; Daskalopoulou, A.; Doulamis, I. P.; Konstantopoulos, P.; Perrea, D. N.] Natl & Kapodistri, Med Sch Athens, Lab Expt Surg & Surg Res NS Christeas, Athens, Greece.
   [Antoranz, A.; Minia, A.; Alexopoulos, L.] Protatonce Ltd, Athens, Greece.
   [Marinos, G.] Univ Athens, Laiko Gen Hosp, Athens, Greece.
   [Alexopoulos, L.] Natl Tech Univ Athens, Dept Mech Engn, Athens, Greece.
RI Doulamis, Ilias P/H-6836-2019
OI Antoranz, Asier/0000-0001-7284-610X
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.2.047
BP E117
EP E118
DI 10.1016/j.atherosclerosis.2018.06.333
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600345
DA 2019-10-28
ER

PT J
AU Ueda, T
AF Ueda, T.
TI PERIPHERAL MICROVASCULAR DYSFUNCTION IN SUBJECTS WITH TYPE2 DIABETES IN
   ACCORDANCE WITH ABSENCE OR PRESENCE OF CORONARY ARTERY DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Ueda, T.] JR Hiroshima Hosp, Dept Cardiol, Hiroshima, Japan.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.3.051
BP E118
EP E119
DI 10.1016/j.atherosclerosis.2018.06.337
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600349
DA 2019-10-28
ER

PT J
AU Uzokov, J
   Alyavi, B
AF Uzokov, J.
   Alyavi, B.
TI COMBINATION LIPID LOWERING THERAPY WITH ROSUVASTATIN AND EZETIMIBE IN
   DYSLIPIDEMIC PATIENTS WITH STABLE CORONARY ARTERY DISEASE AND METABOLIC
   SYNDROME
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Uzokov, J.; Alyavi, B.] Republican Specialized Sci Pract Med Ctr Therapy, Tashkent, Uzbekistan.
RI Uzokov, Jamol/R-6346-2016
OI Uzokov, Jamol/0000-0003-4452-3391
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.4.444
BP E231
EP E231
DI 10.1016/j.atherosclerosis.2018.06.729
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600741
DA 2019-10-28
ER

PT J
AU Vakhtangadze, T
   Motsonelidze, T
   Gakhokidze, N
   Gegechkory, S
AF Vakhtangadze, T.
   Motsonelidze, T.
   Gakhokidze, N.
   Gegechkory, S.
TI CAROTID ARTERY INTIMA-MEDIA THICKENING IN PREGNANCY: ASSOCIATION WITH
   RISK-FACTORS, PARITY, OFFSPRING BIRTH WEIGHT, CLINICAL DATA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vakhtangadze, T.] Tbilisi State Med Univ, Tbilisi, Georgia.
   [Motsonelidze, T.] St Joakime & St Anna Med Ctr, Tbilisi, Georgia.
   [Gakhokidze, N.] Highest Med Sch AIETY, Tbilisi, Georgia.
   [Gegechkory, S.] Caucasus Int Univ, Tbilisi, Georgia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.477
BP E240
EP E240
DI 10.1016/j.atherosclerosis.2018.06.760
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600772
DA 2019-10-28
ER

PT J
AU Valdivielso-Felices, P
   Sanchez-Chaparro, MA
   Ramos, CFL
   Catalina-Romero, C
   Quevedo-Aguado, L
   Martinez-Munoz, P
   Calvo-Bonacho, E
AF Valdivielso-Felices, P.
   Sanchez-Chaparro, M. A.
   Fernandez-Labandera Ramos, C.
   Catalina-Romero, C.
   Quevedo-Aguado, L.
   Martinez-Munoz, P.
   Calvo-Bonacho, E.
TI CLINICAL UTILITY OF A NEW PREDICTIVE MODEL OF CARDIOVASCULAR RISK IN A
   YOUNG AND MIDDLE-AGED WORKING POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Valdivielso-Felices, P.; Sanchez-Chaparro, M. A.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Hosp Virgen Victoria Malaga, Malaga, Spain.
   [Fernandez-Labandera Ramos, C.; Catalina-Romero, C.; Quevedo-Aguado, L.; Martinez-Munoz, P.; Calvo-Bonacho, E.] Ibermutuamur Mutua Colaboradora Seguridad Social, Madrid, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG29.4
BP E67
EP E67
DI 10.1016/j.atherosclerosis.2018.06.185
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600199
DA 2019-10-28
ER

PT J
AU Van der Heijden, C
   Keating, ST
   Joosten, LAB
   Netea, MG
   Riksen, NP
AF Van der Heijden, C.
   Keating, S. T.
   Joosten, L. A. B.
   Netea, M. G.
   Riksen, N. P.
TI ALDOSTERONE INDUCES LONG-TERM PRO-ATHEROGENIC CHANGES IN PRIMARY HUMAN
   MACROPHAGES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Van der Heijden, C.; Keating, S. T.; Joosten, L. A. B.; Netea, M. G.; Riksen, N. P.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.
   [Netea, M. G.] Univ Bonn, Life & Med Sci Inst LIMES, Dept Genom & Immunoregulat, Bonn, Germany.
RI Riksen, Niels P/G-8260-2015; Keating, Samuel/P-9388-2019
OI Riksen, Niels P/0000-0001-9197-8124; Keating, Samuel/0000-0002-8288-1408
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG10:6
BP E19
EP E20
DI 10.1016/j.atherosclerosis.2018.06.042
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600056
DA 2019-10-28
ER

PT J
AU Van Eyk, H
   Blauw, LL
   Bizino, MB
   Wang, Y
   Rosendaal, FR
   van Dijk, KW
   de Mutsert, R
   Jazet, IM
   Smit, JWA
   Lamb, HJ
   Rensen, PCN
AF Van Eyk, H.
   Blauw, L. L.
   Bizino, M. B.
   Wang, Y.
   Rosendaal, F. R.
   van Dijk, K. Willems
   de Mutsert, R.
   Jazet, I. M.
   Smit, J. W. A.
   Lamb, H. J.
   Rensen, P. C. N.
TI CIRCULATING CETP IS NOT RELATED TO THE HEPATIC TRIGLYCERIDE CONTENT:
   LESSONS FROM A LIRAGLUTIDE INTERVENTION TRIAL AND A POPULATION-BASED
   COHORT
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Van Eyk, H.; Blauw, L. L.; Bizino, M. B.; Wang, Y.; van Dijk, K. Willems; Jazet, I. M.; Rensen, P. C. N.] Leiden Univ, Med Ctr, Dept Med, Div Endocrinol, Leiden, Netherlands.
   [Blauw, L. L.; Rosendaal, F. R.; de Mutsert, R.] Leiden Univ, Med Ctr, Dept Epidemiol, Leiden, Netherlands.
   [Bizino, M. B.; Lamb, H. J.] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands.
   [van Dijk, K. Willems] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands.
   [Smit, J. W. A.] Radboud Univ Nijmegen, Med Ctr, Dept Med, Nijmegen, Netherlands.
RI Rensen, Patrick/Y-5528-2019; Wang, Yanan/C-4143-2019; van Dijk, Ko
   Willems/A-1798-2008; Rensen, Patrick C.N./D-7176-2018
OI Rensen, Patrick/0000-0002-8455-4988; Wang, Yanan/0000-0002-0327-0458;
   van Dijk, Ko Willems/0000-0002-2172-7394; Rensen, Patrick
   C.N./0000-0002-8455-4988
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG25:5
BP E60
EP E60
DI 10.1016/j.atherosclerosis.2018.06.163
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600177
DA 2019-10-28
ER

PT J
AU Varaeva, Y
   Starodubova, A
   Kosyura, S
   Livantsova, E
AF Varaeva, Y.
   Starodubova, A.
   Kosyura, S.
   Livantsova, E.
TI THE SHORT-TERM EFFECT OF DIFFERENT WEIGHT LOSS DIETARY APPROACHES ON
   LIPID PROFILES IN REAL LIFE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Varaeva, Y.; Starodubova, A.; Kosyura, S.; Livantsova, E.] Fed Res Ctr Nutr Biotechnol & Food Safety, Moscow, Russia.
   [Starodubova, A.; Kosyura, S.] Pirogov Russian Natl Res Med Univ RNRMU, Moscow, Russia.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.5.359
BP E207
EP E208
DI 10.1016/j.atherosclerosis.2018.06.645
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600657
DA 2019-10-28
ER

PT J
AU Vargas-Alarcon, G
   Posadas-Sanchez, R
   Perez-Hernandez, N
   Rodriguez-Perez, JM
   Fragoso, JM
   Posadas-Romero, C
AF Vargas-Alarcon, G.
   Posadas-Sanchez, R.
   Perez-Hernandez, N.
   Rodriguez-Perez, J. M.
   Fragoso, J. M.
   Posadas-Romero, C.
TI THE MRE11A RS13447720 AND RS499952 POLYMORPHISMS ARE ASSOCIATED WITH
   DECREASED RISK OF DEVELOPING SUBCLINICAL ATHEROSCLEROSIS AND WITH SOME
   CARDIOVASCULAR RISK FACTORS. THE GEA MEXICAN STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vargas-Alarcon, G.; Posadas-Sanchez, R.; Perez-Hernandez, N.; Rodriguez-Perez, J. M.; Fragoso, J. M.; Posadas-Romero, C.] Inst Nacl Cardiol Ignacio Chavez, Mexico City, DF, Mexico.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.084
BP E128
EP E128
DI 10.1016/j.atherosclerosis.2018.06.370
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600382
DA 2019-10-28
ER

PT J
AU Vasilkova, V
   Mokhort, T
   Pchelin, I
   Bayrasheva, V
   Zmailik, M
   Naumenko, E
AF Vasilkova, V.
   Mokhort, T.
   Pchelin, I.
   Bayrasheva, V.
   Zmailik, M.
   Naumenko, E.
TI RELATIONSHIP BETWEEN LEFT VENTRICULAR HYPERTROPHY AND CARDIOVASCULAR
   RISK FACTORS IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vasilkova, V.] Gomel State Med Univ, Gomel, BELARUS.
   [Mokhort, T.] Belarusian State Med Univ, Minsk, BELARUS.
   [Pchelin, I.] St Petersburg State Univ, St Petersburg, Russia.
   [Bayrasheva, V.] Fed Almazov North West Med Res Ctr, St Petersburg, Russia.
   [Zmailik, M.; Naumenko, E.] Republican Res Ctr Radiat Med & Human Ecol, Gomel, BELARUS.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.379
BP E213
EP E213
DI 10.1016/j.atherosclerosis.2018.06.666
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600678
DA 2019-10-28
ER

PT J
AU Rodriguez, PV
   Perez, ABP
   Armesto, RA
   Fuentetaja, RS
   Cid, RD
   Suarez, SR
   Diaz, JLD
AF Vazquez Rodriguez, P.
   Porto Perez, A. B.
   Argueso Armesto, R.
   Suarez Fuentetaja, R.
   De la Fuente Cid, R.
   Ruanova Suarez, S.
   Diaz Diaz, J. L.
TI HYPERTRANSAMINASEMIA (HT) IN A COHORT WITH FAMILIAL COMBINED
   HYPERLIPIDEMIA (FCH): PREVALENCE AND RISK FACTORS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vazquez Rodriguez, P.; Porto Perez, A. B.; Argueso Armesto, R.; Suarez Fuentetaja, R.; De la Fuente Cid, R.; Ruanova Suarez, S.; Diaz Diaz, J. L.] Complexo Hosp Univ A Coruna, La Coruna, Spain.
RI Diaz, Jose Luis JLDD Diaz/Q-2523-2015
OI Diaz, Jose Luis JLDD Diaz/0000-0002-9194-495X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.163
BP E151
EP E152
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600462
DA 2019-10-28
ER

PT J
AU Veca, V
   Barsotti, F
   Bellofatto, I
   Lupattelli, G
   Siepi, D
   Vacca, C
   Ricci, MA
   Natali, C
   Vaudo, G
AF Veca, V.
   Barsotti, F.
   Bellofatto, I.
   Lupattelli, G.
   Siepi, D.
   Vacca, C.
   Ricci, M. A.
   Natali, C.
   Vaudo, G.
TI INTERLEUKIN 17 AND PRE-CLINICAL VASCULAR DAMAGE IN METABOLIC SYNDROME
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Veca, V.; Barsotti, F.; Lupattelli, G.; Siepi, D.; Ricci, M. A.; Natali, C.; Vaudo, G.] Univ Perugia, Dept Med, Internal Med, Perugia, Italy.
   [Bellofatto, I.] Trent Cardiac Ctr NHS, Nottinghamn, Italy.
   [Vacca, C.] Univ Perugia, Pharmacol Sect, Dept Expt Med, Perugia, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.026
BP E111
EP E111
DI 10.1016/j.atherosclerosis.2018.06.311
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600323
DA 2019-10-28
ER

PT J
AU Veca, V
   Gandolfo, V
   Natali, C
   Barsotti, F
   Lupattelli, G
   Siepi, D
   Ricci, MA
   Vaudo, G
AF Veca, V.
   Gandolfo, V.
   Natali, C.
   Barsotti, F.
   Lupattelli, G.
   Siepi, D.
   Ricci, M. A.
   Vaudo, G.
TI PRE-CLINICAL VASCULAR DAMAGE IN METABOLIC SYNDROME: CORRELATION BETWEEN
   NAFLD AND CAROTID DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Veca, V.; Gandolfo, V.; Natali, C.; Barsotti, F.; Lupattelli, G.; Siepi, D.; Ricci, M. A.; Vaudo, G.] Univ Perugia, Dept Med, Internal Med, Perugia, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.1.300
BP E191
EP E191
DI 10.1016/j.atherosclerosis.2018.06.587
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600599
DA 2019-10-28
ER

PT J
AU Velagapudi, V
   Poti, F
   Feuerborn, R
   Yalcinkaya, M
   Rohrer, L
   Nofer, J
   von Eckardstein, A
AF Velagapudi, V.
   Poti, F.
   Feuerborn, R.
   Yalcinkaya, M.
   Rohrer, L.
   Nofer, J.
   von Eckardstein, A.
TI DIFFERERENTIAL AND ANTAGONISTIC REGULATION OF TRANSENDOTHELIAL TRANSPORT
   OF HDL AND LDL BY SPHINGOSINE-1-PHOSPHATE RECEPTORS 1 AND 3
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Velagapudi, V.; Yalcinkaya, M.; Rohrer, L.; von Eckardstein, A.] Univ Zurich, Zurich, Switzerland.
   [Velagapudi, V.; Yalcinkaya, M.; Rohrer, L.; von Eckardstein, A.] Univ Hosp Zurich, Zurich, Switzerland.
   [Poti, F.] Univ Parma, Parma, Italy.
   [Poti, F.] Univ Modena, Modena, Italy.
   [Feuerborn, R.; Nofer, J.] Univ Munster, Munster, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA LB1:2
BP E3
EP E3
DI 10.1016/j.atherosclerosis.2018.06.892
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600009
DA 2019-10-28
ER

PT J
AU Veno, SK
   Bork, CS
   Jakobsen, MU
   Lundbye-Christensen, S
   Bach, FW
   Overvad, K
   Schmidt, EB
AF Veno, S. K.
   Bork, C. S.
   Jakobsen, M. U.
   Lundbye-Christensen, S.
   Bach, F. W.
   Overvad, K.
   Schmidt, E. B.
TI EPA AND DHA IN ADIPOSE TISSUE AND THE RISK OF ISCHEMIC STROKE -A DANISH
   CASE-COHORT STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Veno, S. K.; Bork, C. S.; Schmidt, E. B.] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark.
   [Jakobsen, M. U.] Tech Univ Denmark, Natl Food Inst, Div Diet Dis Prevent & Toxicol, Lyngby, Denmark.
   [Lundbye-Christensen, S.] Aalborg Univ Hosp, Unit Clin Biostat, Aalborg, Denmark.
   [Bach, F. W.] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark.
   [Overvad, K.] Aarhus Univ, Sect Epidemiol, Dept Publ Hlth, Aarhus, Denmark.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W10:5
BP E12
EP E13
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600037
DA 2019-10-28
ER

PT J
AU Verbeek, R
   Boekholdt, SM
   Luben, R
   Stroes, ESG
   Khaw, KT
   Hovingh, GK
AF Verbeek, R.
   Boekholdt, S. M.
   Luben, R.
   Stroes, E. S. G.
   Khaw, K. -T.
   Hovingh, G. K.
TI THE EFFECT OF LONG-TERM LOW LIPOPROTEINS ON NEUROCOGNITIVE FUNCTION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Verbeek, R.; Stroes, E. S. G.; Hovingh, G. K.] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
   [Boekholdt, S. M.] Acad Med Ctr, Dept Cardiol, Amsterdam, Netherlands.
   [Luben, R.; Khaw, K. -T.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
RI Luben, Robert N/H-5519-2015
OI Luben, Robert N/0000-0002-5088-6343
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG29.6
BP E68
EP E68
DI 10.1016/j.atherosclerosis.2018.06.187
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600201
DA 2019-10-28
ER

PT J
AU Vershinina, E
   Repin, A
AF Vershinina, E.
   Repin, A.
TI LOADING DOSES STATINS FOR PREVENTION OF CI-AKI AT THE ELECTIVE PCI
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vershinina, E.; Repin, A.] Tomsk NRMC, Cardiol Res Inst, Tomsk, Russia.
RI Vershinina, Elena O/L-9929-2016; Repin, Alexey/AAB-9393-2019
OI Vershinina, Elena O/0000-0002-2665-9108; 
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.2.302
BP E192
EP E192
DI 10.1016/j.atherosclerosis.2018.06.589
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600601
DA 2019-10-28
ER

PT J
AU Verweij, S
   Stiekema, L
   Delewi, R
   Zheng, K
   Moens, SB
   Kroon, J
   Versloot, M
   Piek, J
   Verberne, H
   Stroes, E
AF Verweij, S.
   Stiekema, L.
   Delewi, R.
   Zheng, K.
   Moens, S. Bernelot
   Kroon, J.
   Versloot, M.
   Piek, J.
   Verberne, H.
   Stroes, E.
TI PROLONGED HEMATOPOIETIC AND MYELOID CELLULAR RESPONSE IN PATIENTS AFTER
   A MYOCARDIAL INFARCTION MEASURED WITH 18F-DPA-714 PET/CT
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Verweij, S.; Stiekema, L.; Zheng, K.; Moens, S. Bernelot; Stroes, E.] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
   [Delewi, R.; Piek, J.] Acad Med Ctr, Dept Cardiol, Amsterdam, Netherlands.
   [Kroon, J.; Versloot, M.] Acad Med Ctr, Dept Expt Med, Amsterdam, Netherlands.
   [Verberne, H.] Acad Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG13.4
BP E41
EP E41
DI 10.1016/j.atherosclerosis.2018.06.103
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600116
DA 2019-10-28
ER

PT J
AU Vicen, M
   Varejckova, M
   Havelek, R
   Dolezelova, E
   Prasnicka, A
   Nachtigal, P
AF Vicen, M.
   Varejckova, M.
   Havelek, R.
   Dolezelova, E.
   Prasnicka, A.
   Nachtigal, P.
TI OXYSTEROLS OF VARIOUS ORIGIN AFFECT MEMBRANE ENDOGLIN EXPRESSION
   DIFFERENTLY IN HUMAN AORTIC ENDOTHELIAL CELLS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vicen, M.; Varejckova, M.; Dolezelova, E.; Prasnicka, A.; Nachtigal, P.] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Biol & Med Sci, Hradec Kralove, Czech Republic.
   [Havelek, R.] Charles Univ Prague, Fac Med Hradec Kralove, Dept Med Biochem, Hradec Kralove, Czech Republic.
RI Vicen, Matej/S-8443-2017
OI Vicen, Matej/0000-0002-7568-6989
FU Grant Agency of Charles University [GAUK 1158413C, 1216217]; Czech
   Health Research Council [AZV CR 17-31754A];  [SVV/2016/260293]
FX This work was supported by grants from Grant Agency of Charles
   University (GAUK 1158413C, 1216217), SVV/2016/260293 and Czech Health
   Research Council (AZV CR 17-31754A).
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.007
BP E106
EP E106
DI 10.1016/j.atherosclerosis.2018.06.292
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600304
DA 2019-10-28
ER

PT J
AU Vieira, O
AF Vieira, O.
TI LYSOSOMAL EXOCYTOSIS INDUCED BY A NOVEL IDENTIFIED FAMILY OF LIPIDS
   PLAYS A CRITICAL ROLE IN ATHEROGENESIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vieira, O.] Univ Nova Lisboa, Cedoc Nova Med Sch, Lisbon, Portugal.
RI Vieira, Otilia V/O-8660-2017
OI Vieira, Otilia V/0000-0003-4924-1780
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.2.046
BP E117
EP E117
DI 10.1016/j.atherosclerosis.2018.06.332
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600344
DA 2019-10-28
ER

PT J
AU Vishnolia, KK
   Tarhbalouti, K
   Wrobel, S
   Aherrahrou, Z
   Erdmann, J
AF Vishnolia, K. K.
   Tarhbalouti, K.
   Wrobel, S.
   Aherrahrou, Z.
   Erdmann, J.
TI STUDIES IN ZEBRAFISH ANNOTATE CNNM2 AND NT5C2 AS THE MOST LIKELY CAUSAL
   GENES AT THE BLOOD PRESSURE LOCUS ON CHROMOSOME 10Q24.32
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vishnolia, K. K.; Tarhbalouti, K.; Wrobel, S.; Aherrahrou, Z.; Erdmann, J.] Univ Lubeck, Inst Cardiogenet, Lubeck, Germany.
   [Vishnolia, K. K.; Tarhbalouti, K.; Wrobel, S.; Aherrahrou, Z.; Erdmann, J.] DZHK German Res Ctr Cardiovasc Res, Partner Site Hamburg Lubeck Kiel, D-23562 Lubeck, Lubeck, Germany.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG20.5
BP E51
EP E51
DI 10.1016/j.atherosclerosis.2018.06.136
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600150
DA 2019-10-28
ER

PT J
AU Vitverova, B
   Blazickova, K
   Najmanova, I
   Vicen, M
   Pericacho, M
   Nachtigal, P
AF Vitverova, B.
   Blazickova, K.
   Najmanova, I.
   Vicen, M.
   Pericacho, M.
   Nachtigal, P.
TI HIGH SOLUBLE ENDOGLIN LEVELS ACCOMPANIED BY MILD HYPERCHOLESTEROLEMIA
   ARE A RISK FACTOR FOR THE DEVELOPMENT OF ENDOTHELIAL DYSFUNCTION IN MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vitverova, B.; Blazickova, K.; Najmanova, I.; Vicen, M.; Nachtigal, P.] Charles Univ Prague, Dept Biol & Med Sci, Fac Pharm, Hradec Kralove, Czech Republic.
   [Pericacho, M.] Univ Salamanca, Renal & Cardiovasc Physiopathol Unit, Dept Physiol & Pharmacol, Salamanca, Spain.
RI Vicen, Matej/S-8443-2017
OI Vicen, Matej/0000-0002-7568-6989
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.068
BP E124
EP E124
DI 10.1016/j.atherosclerosis.2018.06.355
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600367
DA 2019-10-28
ER

PT J
AU Vlachopoulos, C
   Spanoudi, F
   Michalis, L
   Parthenakis, F
   Richter, D
   Triposkiadis, F
   Tsougos, E
   Hahalis, G
AF Vlachopoulos, C.
   Spanoudi, F.
   Michalis, L.
   Parthenakis, F.
   Richter, D.
   Triposkiadis, F.
   Tsougos, E.
   Hahalis, G.
TI REAL-WORLD EVIDENCE ON LDL-C GOAL ATTAINMENT RATE AND LIPID MANAGEMENT
   PATTERNS POST-ACS IN GREECE: THE POST-ACUTE CORONARY SYNDROME STUDY
   (PACSS)
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vlachopoulos, C.] Univ Athens, Sch Med, Dept Cardiol, Hippokrat Hosp, Athens, Greece.
   [Spanoudi, F.] Ind & Commercial SA, Merck Sharp & Dohme Pharmaceut, Athens, Greece.
   [Michalis, L.] Univ Ioannina, Dept Cardiol, Ioannina, Greece.
   [Parthenakis, F.] Univ Hosp Heraklion, Dept Cardiol, Iraklion, Greece.
   [Richter, D.] Athens Euroclin, Dept Cardiol 2, Athens, Greece.
   [Triposkiadis, F.] Univ Hosp Larissa, Dept Cardiol, Larisa, Greece.
   [Tsougos, E.] Henry Dunant Hosp Ctr, Dept Cardiol 2, Athens, Greece.
   [Hahalis, G.] Univ Hosp Patra, Dept Cardiol, Patras, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG41.5
BP E92
EP E93
DI 10.1016/j.atherosclerosis.2018.06.252
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600266
DA 2019-10-28
ER

PT J
AU Vlacil, A
   Vollmeister, E
   Bertrams, W
   Schosser, F
   Oberoi, R
   Schutt, J
   Schmeck, B
   Schieffer, B
   Grote, K
AF Vlacil, A.
   Vollmeister, E.
   Bertrams, W.
   Schoesser, F.
   Oberoi, R.
   Schuett, J.
   Schmeck, B.
   Schieffer, B.
   Grote, K.
TI NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN-CONTAINING PROTEIN
   (NOD)-RECEPTORS 1 AND 2 REGULATE MICRORNA EXPRESSION IN ENDOTHELIAL
   CELLS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vlacil, A.; Oberoi, R.; Schuett, J.; Grote, K.] Philipps Univ Marburg, Biomed Res Ctr BMFZ, Expt Cardiol, Marburg, Germany.
   [Schoesser, F.; Schieffer, B.] Univ Klinikum Marburg, Cardiol, Marburg, Germany.
   [Vollmeister, E.; Bertrams, W.; Schmeck, B.] Philipps Univ Marburg, Biomed Res Ctr BMFZ, Inst Lung Res, Marburg, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.078
BP E126
EP E127
DI 10.1016/j.atherosclerosis.2018.06.365
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600377
DA 2019-10-28
ER

PT J
AU Vlacil, A
   Schutt, H
   Schutt, J
   Oberoi, R
   Tietge, U
   Schieffer, B
   Grote, K
AF Vlacil, A.
   Schuett, H.
   Schuett, J.
   Oberoi, R.
   Tietge, U.
   Schieffer, B.
   Grote, K.
TI IMPACT OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN-CONTAINING
   PROTEINS (NOD) 1 AND 2 ON EXPERIMENTAL ATHEROSCLEROSIS AND LIPID
   METABOLISM
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vlacil, A.; Schuett, J.; Oberoi, R.; Grote, K.] Philipps Univ Marburg, Expt Cardiol, Biomed Res Ctr BMFZ, Marburg, Germany.
   [Schuett, H.; Schieffer, B.] Univ Klinikum Marburg, Cardiol, Marburg, Germany.
   [Tietge, U.] Univ Groningen, Ctr Liver Digest & Metab Dis CLDM, Groningen, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG11.3
BP E36
EP E36
DI 10.1016/j.atherosclerosis.2018.06.091
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600105
DA 2019-10-28
ER

PT J
AU Vladimirov, S
   Gojkovic, T
   Zeljkovic, A
   Jelic-Ivanovic, Z
   Miljkovic, M
   Bogavac-Stanojevic, N
   Stepanovic, Z
   Spasojevic-Kalimanovska, V
AF Vladimirov, S.
   Gojkovic, T.
   Zeljkovic, A.
   Jelic-Ivanovic, Z.
   Miljkovic, M.
   Bogavac-Stanojevic, N.
   Stepanovic, Z.
   Spasojevic-Kalimanovska, V.
TI ASSOCIATION OF CHOLESTEROL HOMEOSTASIS PARAMETERS WITH CARDIOVASCULAR
   RISK FACTORS IN HEALTHY POPULATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vladimirov, S.; Gojkovic, T.; Zeljkovic, A.; Jelic-Ivanovic, Z.; Miljkovic, M.; Bogavac-Stanojevic, N.; Spasojevic-Kalimanovska, V.] Univ Belgrade, Fac Pharm, Dept Med Biochem, Belgrade, Serbia.
   [Stepanovic, Z.] Gen Hosp Medigrp, Belgrade, Serbia.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG39.3
BP E86
EP E86
DI 10.1016/j.atherosclerosis.2018.06.238
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600252
DA 2019-10-28
ER

PT J
AU Vlaicu, S
   Tatomir, A
   Boodhoo, D
   Tegla, CA
   Rus, V
   Rus, H
AF Vlaicu, S.
   Tatomir, A.
   Boodhoo, D.
   Tegla, C. A.
   Rus, V.
   Rus, H.
TI RGC-32 MEDIATES EXTRACELLULAR MATRIX PRODUCTION IN HUMAN ATHEROSCLEROTIC
   LESIONS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vlaicu, S.] Iuliu Hatieganu Univ Med & Pharm, Dept Internal Med, Cluj Napoca, Romania.
   [Vlaicu, S.; Tatomir, A.; Boodhoo, D.; Tegla, C. A.; Rus, H.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA.
   [Rus, V.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
   [Rus, H.] Maryland Hlth Care Syst Vet Adm, Baltimore, MD USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.072
BP E125
EP E125
DI 10.1016/j.atherosclerosis.2018.06.359
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600371
DA 2019-10-28
ER

PT J
AU Vuilleumier, N
   Anderson, JLC
   Pagano, S
   Virzi, J
   Dullaart, RPF
   Kuipers, F
   Bakker, SJL
   Tietge, UJF
AF Vuilleumier, N.
   Anderson, J. L. C.
   Pagano, S.
   Virzi, J.
   Dullaart, R. P. F.
   Kuipers, F.
   Bakker, S. J. L.
   Tietge, U. J. F.
TI AUTOANTIBODIES TO APOLIPOPROTEIN A-I AS INDEPENDENT PREDICTORS OF
   CARDIOVASCULAR MORTALITY IN RENAL TRANSPLANT RECIPIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Vuilleumier, N.; Pagano, S.; Virzi, J.] Geneva Univ Hosp, Div Lab Med, Dept Genet & Lab Med, Geneva, Switzerland.
   [Anderson, J. L. C.; Kuipers, F.; Tietge, U. J. F.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands.
   [Dullaart, R. P. F.] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, Groningen, Netherlands.
   [Bakker, S. J. L.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG43.6
BP E97
EP E98
DI 10.1016/j.atherosclerosis.2018.06.265
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600279
DA 2019-10-28
ER

PT J
AU Wachsmann, A
   Maga, P
   Mikolajczyk, T
   Partyka, L
   Maga, M
   Krzanowski, M
AF Wachsmann, A.
   Maga, P.
   Mikolajczyk, T.
   Partyka, L.
   Maga, M.
   Krzanowski, M.
TI SUBSETS OF CD8+T LYMPHOCYTE - EARLY REACTANTS IN POST-ANGIOPLASTY INJURY
   OF ARTERIES IN PATIENTS WITH PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Wachsmann, A.; Maga, P.; Partyka, L.; Krzanowski, M.] Jagiellonian Univ, Dept Angiol, Coll Med, Krakow, Poland.
   [Mikolajczyk, T.] Jagiellonian Univ, Dept Internal & Agr Med, Coll Med, Krakow, Poland.
   [Maga, M.] Jagiellonian Univ, Coll Med, Krakow, Poland.
RI Partyka, Lukasz/F-9567-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG12:2
BP E38
EP E38
DI 10.1016/j.atherosclerosis.2018.06.096
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600110
DA 2019-10-28
ER

PT J
AU Wadey, K
   Cameron, O
   Brittan, JL
   Hellin, N
   Johnson, JL
   Jenkinson, HF
   Nobbs, AH
   George, SJ
AF Wadey, K.
   Cameron, O.
   Brittan, J. L.
   Hellin, N.
   Johnson, J. L.
   Jenkinson, H. F.
   Nobbs, A. H.
   George, S. J.
TI PERIODONTAL PATHOGENS ENHANCE WNT/< BETA >-CATENIN SIGNALLING AND
   THEREBY MAY EXACERBATE ATHEROGENESIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Wadey, K.; Cameron, O.; Johnson, J. L.; George, S. J.] Univ Bristol, Translat Hlth Sci, Bristol, Avon, England.
   [Brittan, J. L.; Hellin, N.; Jenkinson, H. F.; Nobbs, A. H.] Univ Bristol, Sch Oral & Dent Sci, Bristol, Avon, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG12.6
BP E40
EP E40
DI 10.1016/j.atherosclerosis.2018.06.100
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600113
DA 2019-10-28
ER

PT J
AU Walus-miarka, M
   Idzior-Walus, B
   Kapusta, M
   Trojak, A
   Miarka, P
   Malecki, MT
AF Walus-miarka, M.
   Idzior-Walus, B.
   Kapusta, M.
   Trojak, A.
   Miarka, P.
   Malecki, M. T.
TI FIBROBLAST GROWTH FACTOR 21 SERUM CONCENTRATIONS IN PATIENTS WITH
   NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND TYPE 2 DIABETES MELLITUS
   (DM2).
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Walus-miarka, M.; Idzior-Walus, B.; Trojak, A.; Malecki, M. T.] Jagiellonian Univ, Dept Metab Dis, Krakow, Poland.
   [Kapusta, M.] Jagiellonian Univ, Depertment Biochem, Krakow, Poland.
   [Miarka, P.] Jagiellonian Univ, Depertment Nephrol, Krakow, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P2.1.162
BP E151
EP E151
DI 10.1016/j.atherosclerosis.2018.06.449
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600461
DA 2019-10-28
ER

PT J
AU Waters, D
   Fayyad, R
   Colhoun, H
   Demicco, D
   Bangalore, S
AF Waters, D.
   Fayyad, R.
   Colhoun, H.
   Demicco, D.
   Bangalore, S.
TI BODY WEIGHT VARIABILITY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH
   TYPE 2 DIABETES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Waters, D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Fayyad, R.; Demicco, D.] Pfizer Inc, New York, NY USA.
   [Colhoun, H.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland.
   [Bangalore, S.] NYU, Sch Med, Div Cardiol, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W10:4
BP E12
EP E12
DI 10.1016/j.atherosclerosis.2018.06.919
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600036
DA 2019-10-28
ER

PT J
AU Weisell, J
   Ruotsalainen, AK
   Rysa, J
AF Weisell, J.
   Ruotsalainen, A. -K.
   Rysa, J.
TI INCREMENT OF CHONDROCYTE-LIKE CELLS IN AORTIC VALVES IN
   HYPERCHOLESTEROLAEMIC MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Weisell, J.; Ruotsalainen, A. -K.; Rysa, J.] Univ Eastern Finland, Sch Pharm, Kuopio, Finland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.5.088
BP E130
EP E130
DI 10.1016/j.atherosclerosis.2018.06.376
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600388
DA 2019-10-28
ER

PT J
AU West, N
   Corrigan, J
   Brown, A
   Owen, R
   Hoole, S
   Blatcher, S
   Proudfoot, D
AF West, N.
   Corrigan, J.
   Brown, A.
   Owen, R.
   Hoole, S.
   Blatcher, S.
   Proudfoot, D.
TI CORONARY ARTERY INFLAMMATORY BIOMARKER EXPRESSION DOES NOT CORRELATE
   WITH SYSTEMIC ELEVATION OF BIOMARKERS OR OF HSCRP
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [West, N.; Brown, A.; Hoole, S.] Papworth Hosp, Dept Cardiol, Cambridge, England.
   [Corrigan, J.; Owen, R.; Blatcher, S.] Plaquetec Ltd, Cambridge, England.
   [Proudfoot, D.] Babraham Inst, Cambridge, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG12:4
BP E38
EP E39
DI 10.1016/j.atherosclerosis.2018.06.098
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600123
DA 2019-10-28
ER

PT J
AU Westerterp, M
   Fotakis, P
   Ouimet, M
   Bochem, AE
   Zhang, H
   Molusky, MM
   Wang, W
   Abramowicz, S
   Wang, N
   Welch, CL
   Reilly, MP
   Stroes, ES
   Moore, KJ
   Tall, AR
AF Westerterp, M.
   Fotakis, P.
   Ouimet, M.
   Bochem, A. E.
   Zhang, H.
   Molusky, M. M.
   Wang, W.
   Abramowicz, S.
   Wang, N.
   Welch, C. L.
   Reilly, M. P.
   Stroes, E. S.
   Moore, K. J.
   Tall, A. R.
TI CHOLESTEROL EFFLUX PATHWAYS SUPPRESS INFLAMMASOME ACTIVATION, NEUTROPHIL
   EXTRACELLULAR TRAP FORMATION, AND ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Westerterp, M.] Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands.
   [Fotakis, P.; Zhang, H.; Molusky, M. M.; Wang, W.; Abramowicz, S.; Wang, N.; Welch, C. L.; Reilly, M. P.; Tall, A. R.] Columbia Univ, Dept Med, New York, NY USA.
   [Ouimet, M.; Moore, K. J.] NYU, Dept Med, 550 1St Ave, New York, NY 10016 USA.
   [Bochem, A. E.; Stroes, E. S.] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W1:3
BP E1
EP E1
DI 10.1016/j.atherosclerosis.2018.06.885
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600002
DA 2019-10-28
ER

PT J
AU Wierzbicki, A
   Kohli, M
   Patel, K
   McMahon, Z
   Ramachandran, R
   Crook, M
   Reynolds, T
AF Wierzbicki, A.
   Kohli, M.
   Patel, K.
   McMahon, Z.
   Ramachandran, R.
   Crook, M.
   Reynolds, T.
TI PRO-PROTEIN SUBTILISIN KEXIN-9 (PCSK9) INHIBITION IN PRACTICE: LIPID
   CLINIC EXPERIENCE IN 2 CONTRASTING UK CENTRES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Wierzbicki, A.; Kohli, M.; McMahon, Z.; Ramachandran, R.; Crook, M.] Guys Hosp, London, England.
   [Wierzbicki, A.; Kohli, M.; McMahon, Z.; Ramachandran, R.; Crook, M.] St Thomas Hosp, London, England.
   [Patel, K.; Reynolds, T.] Queens Hosp, Burton Upon Trent, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG45.3
BP E100
EP E100
DI 10.1016/j.atherosclerosis.2018.06.274
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600288
DA 2019-10-28
ER

PT J
AU Wierzbicki, A
   Viljoen, A
   Viljoen, S
   Martin, S
   Crook, M
   Reynolds, T
AF Wierzbicki, A.
   Viljoen, A.
   Viljoen, S.
   Martin, S.
   Crook, M.
   Reynolds, T.
TI REVIEW OF REFERRAL CRITERIA TO LIPID CLINICS AND OUTCOMES OF TREATMENT
   IN 4 UK CENTRES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Wierzbicki, A.; Crook, M.] Guys & St Thomas Hosp, London, England.
   [Viljoen, A.; Viljoen, S.] East Hertfordshire Hosp, Stevenage, Herts, England.
   [Martin, S.] Northwest Anglia Hosp, Peterborough, Cambs, England.
   [Reynolds, T.] Queens Hosp, Burton Upon Trent, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.473
BP E239
EP E239
DI 10.1016/j.atherosclerosis.2018.06.756
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600768
DA 2019-10-28
ER

PT J
AU Willecke, F
   Pfeiffer, K
   Anto-Michel, N
   Gissler, MC
   Mullick, A
   Hoppe, N
   Zirlik, A
AF Willecke, F.
   Pfeiffer, K.
   Anto-Michel, N.
   Gissler, M. C.
   Mullick, A.
   Hoppe, N.
   Zirlik, A.
TI ATHEROSCLEROSIS PROGRESSION AND REGRESSION INDUCED BY LDLR ANTISENSE AND
   LDLR SENSE OLIGONUCLEOTIDES IN MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Willecke, F.; Pfeiffer, K.; Anto-Michel, N.; Gissler, M. C.; Mullick, A.; Hoppe, N.; Zirlik, A.] Univ Heart Ctr Freiburg Bad Krozingen, Dept Cardiol & Angiol 1, Freiburg, Germany.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG19.3
BP E49
EP E49
DI 10.1016/j.atherosclerosis.2018.06.129
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600143
DA 2019-10-28
ER

PT J
AU Williams, H
   Johnson, J
   George, S
AF Williams, H.
   Johnson, J.
   George, S.
TI WISP-1/CCN4 PROTECTS AGAINST ATHROSCLEROSIS IN ATHEROPRONE MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Williams, H.; Johnson, J.; George, S.] Univ Bristol, Bristol Med Sch, Translat Hlth Sci, Bristol, Avon, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W5:5
BP E5
EP E5
DI 10.1016/j.atherosclerosis.2018.06.900
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600017
DA 2019-10-28
ER

PT J
AU Woo, CC
   Wongsurawat, T
   Lin, XY
   Sorokin, V
AF Woo, C. C.
   Wongsurawat, T.
   Lin, X. Y.
   Sorokin, V.
TI THE MIRNA 30B-5P TARGETING MRNA MBNL1 LEADS TO PROMYOGENIC VSMC
   PHENOTYPE MODULATION IN MYOCARDIAL INFARCTION PATIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Woo, C. C.; Sorokin, V.] Natl Univ Singapore, Singapore, Singapore.
   [Wongsurawat, T.] Bioinformat Inst, Agcy Sci Technol & Res A STAR, Singapore, Singapore.
   [Wongsurawat, T.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
   [Lin, X. Y.; Sorokin, V.] Natl Univ Heart Ctr, Singapore, Singapore.
RI Wongsurawat, Thidathip/K-5590-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG16:4
BP E46
EP E46
DI 10.1016/j.atherosclerosis.2018.06.119
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600133
DA 2019-10-28
ER

PT J
AU Worthmann, A
   John, C
   Ruhlemann, MC
   Baguhl, M
   Schlein, C
   Heinsen, FA
   Heine, M
   Mineo, C
   Fischer, M
   Scheja, L
   Franke, A
   Shaul, PW
   Heeren, J
AF Worthmann, A.
   John, C.
   Ruehlemann, M. C.
   Baguhl, M.
   Schlein, C.
   Heinsen, F. A.
   Heine, M.
   Mineo, C.
   Fischer, M.
   Scheja, L.
   Franke, A.
   Shaul, P. W.
   Heeren, J.
TI INCREASED HEPATIC BILE ACID PRODUCTION SHAPES THE GUT MICROBIOME AFTER
   COLD INDUCED BROWN ADIPOSE TISSUE ACTIVATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Worthmann, A.; John, C.; Baguhl, M.; Schlein, C.; Heine, M.; Scheja, L.; Heeren, J.] Univ Med Ctr Hamburg Eppendorf, Dept Biochem & Mol Cell Biol, Hamburg, Germany.
   [Ruehlemann, M. C.; Heinsen, F. A.; Franke, A.] Univ Kiel, IKMB, Kiel, Germany.
   [Mineo, C.; Shaul, P. W.] Univ Texas Southwestern Med Ctr Dallas, Ctr Pulm & Vasc Biol, Dallas, TX 75390 USA.
   [Fischer, M.] Univ Hamburg, Hamburg Sch Food Sci, Hamburg, Germany.
RI Ruhlemann, Malte/AAA-6528-2019
OI Ruhlemann, Malte/0000-0002-0685-0052
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA W12:3
BP E15
EP E15
DI 10.1016/j.atherosclerosis.2018.06.926
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600043
DA 2019-10-28
ER

PT J
AU Xu, Y
   Si, SY
   L, JQ
   W, X
   Li, YZ
   Z, X
   I, C
   J, XH
AF Xu, Y.
   Si, Sh. Y.
   L, J. Q.
   W, X.
   Li, Y. Zh
   Z, X.
   I, Ch
   J, X. H.
TI THE ANTI-INFLAMMATORY EFFECT OF R3 IN ATHEROSCLEROSIS IS ASSOCIATED WITH
   INHIBITION OF NLRP3 INFLAMMASOME
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 CAMS, Inst Med Biotechnol, Beijing, Peoples R China.
   PUMC, Beijing, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG6.1
BP E27
EP E27
DI 10.1016/j.atherosclerosis.2018.06.067
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600081
DA 2019-10-28
ER

PT J
AU Yalcinkaya, M
   Cardner, M
   Goetze, S
   Hunjadi, M
   Ritsch, A
   Hartung, J
   Landmesser, U
   Liebisch, G
   Wollscheid, B
   Beerenwinkel, N
   Rohrer, L
   Von Eckardstein, A
AF Yalcinkaya, M.
   Cardner, M.
   Goetze, S.
   Hunjadi, M.
   Ritsch, A.
   Hartung, J.
   Landmesser, U.
   Liebisch, G.
   Wollscheid, B.
   Beerenwinkel, N.
   Rohrer, L.
   Von Eckardstein, A.
TI A SYSTEMS BIOLOGICAL APPROACH TO THE ANTI-ATHEROGENICITY OF HIGH DENSITY
   LIPOPROTEINS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Yalcinkaya, M.; Rohrer, L.; Von Eckardstein, A.] Inst Clin Chem, Zurich, Switzerland.
   [Yalcinkaya, M.; Rohrer, L.; Von Eckardstein, A.] Univ Zurich Hosp, Zurich, Switzerland.
   [Cardner, M.; Beerenwinkel, N.] ETHZ Basel, BSSE, Basel, Switzerland.
   [Goetze, S.; Wollscheid, B.] ETHZ Zurich, HEST, Zurich, Switzerland.
   [Hunjadi, M.; Ritsch, A.] Univ Med Innsbruck, Dept Internal Med, Inssbruck, Austria.
   [Hartung, J.; Landmesser, U.] Univ Med Charite Berlin, Dept Cardiol, Berlin, Germany.
   [Liebisch, G.] Univ Regensburg, Inst Clin Chem, Regensburg, Germany.
RI Hartung, Johannes Jakob/D-1604-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.4.061
BP E121
EP E122
DI 10.1016/j.atherosclerosis.2018.06.348
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600360
DA 2019-10-28
ER

PT J
AU Yamagishi, T
AF Yamagishi, T.
TI ANTIATHEROSCLEROTIC EFFECTS OF SGLT2 INHIBITORS IN TYPE 2 DIABETIC
   PATIENTS WITH OBESITY AND HYPERTENSION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Yamagishi, T.] Tohoku Kosai Hosp, Sendai, Miyagi, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG26:6
BP E62
EP E62
DI 10.1016/j.atherosclerosis.2018.06.169
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600183
DA 2019-10-28
ER

PT J
AU Yano, S
   Tobita, H
   Uno, C
   Ishibashi, Y
   Mishima, S
   Nagai, A
AF Yano, S.
   Tobita, H.
   Uno, C.
   Ishibashi, Y.
   Mishima, S.
   Nagai, A.
TI REACTIVE HYPEREMIA INDEX IS SUITABLE FOR SCREENING ENDOTHELIAL
   DYSFUNCTION ESPECIALLY IN OBESE SUBJECTS WITH NON-ALCOHOLIC HEPATITIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Yano, S.; Tobita, H.; Uno, C.; Ishibashi, Y.; Mishima, S.; Nagai, A.] Shimane Univ, Fac Med, Izumo, Shimane, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.1.299
BP E191
EP E191
DI 10.1016/j.atherosclerosis.2018.06.586
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600598
DA 2019-10-28
ER

PT J
AU Yano, S
   Notsu, Y
   Yamaguchi, K
   Abe, T
   Yamada, K
   Nagai, A
   Tanabe, K
   Nabika, T
AF Yano, S.
   Notsu, Y.
   Yamaguchi, K.
   Abe, T.
   Yamada, K.
   Nagai, A.
   Tanabe, K.
   Nabika, T.
TI PLASMA LEVEL OF TRIMETHYLAMINE-N-OXIDE IS NOT CORRELATED TO THE
   INTIMA-MEDIA THICKNESS IN JAPANESE; SHIMANE COHRE STUDY
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Yano, S.; Notsu, Y.; Yamaguchi, K.; Yamada, K.; Nagai, A.; Tanabe, K.; Nabika, T.] Shimane Univ, Sch Med, Izumo, Shimane, Japan.
   [Yano, S.; Abe, T.; Nabika, T.] Ctr Community Based Healthcare Res & Educ CoHRE, Izumo, Shimane, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG10.5
BP E19
EP E19
DI 10.1016/j.atherosclerosis.2018.06.041
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600055
DA 2019-10-28
ER

PT J
AU Yubero-serrano, E
   Lopez-moreno, J
   Garcia-rios, A
   Fernandez-gandara, C
   Rangel-zuniga, O
   Delgado-lista, J
   Perez-martinez, P
   Lopez-miranda, J
AF Yubero-serrano, E.
   Lopez-moreno, J.
   Garcia-rios, A.
   Fernandez-gandara, C.
   Rangel-zuniga, O.
   Delgado-lista, J.
   Perez-martinez, P.
   Lopez-miranda, J.
TI DIET PATTERN EFFECT ON ENDOTHELIAL DAMAGE AND REGENERATIVE CAPACITY
   PROCESSES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Yubero-serrano, E.; Lopez-moreno, J.; Garcia-rios, A.; Fernandez-gandara, C.; Rangel-zuniga, O.; Delgado-lista, J.; Perez-martinez, P.; Lopez-miranda, J.] Maimonides Biomed Res Inst Cordoba, Lipid & Atherosclerosis Unit, Cordoba, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG33.6
BP E74
EP E75
DI 10.1016/j.atherosclerosis.2018.06.208
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600222
DA 2019-10-28
ER

PT J
AU Zaidi, H
   Byrkjeland, R
   Akra, S
   Solheim, S
   Arnesen, H
   Seljeflot, I
   Opstad, T
AF Zaidi, H.
   Byrkjeland, R.
   Akra, S.
   Solheim, S.
   Arnesen, H.
   Seljeflot, I.
   Opstad, T.
TI EFFECTS OF LONG-TERM EXERCISE TRAINING ON INFLAMMASOME-RELATED MEDIATORS
   IN PATIENTS WITH T2DM AND CAD
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zaidi, H.; Byrkjeland, R.; Akra, S.; Solheim, S.; Arnesen, H.; Seljeflot, I.; Opstad, T.] Oslo Univ Hosp, Ctr Clin Heart Res, Dept Cardiol, Oslo, Norway.
   [Byrkjeland, R.; Akra, S.; Solheim, S.; Arnesen, H.; Seljeflot, I.; Opstad, T.] Oslo Univ Hosp, Ctr Heart Failure Res, Oslo, Norway.
   [Byrkjeland, R.; Solheim, S.; Arnesen, H.; Seljeflot, I.; Opstad, T.] Univ Oslo, Fac Med, Oslo, Norway.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG22:1
BP E53
EP E53
DI 10.1016/j.atherosclerosis.2018.06.143
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600157
DA 2019-10-28
ER

PT J
AU Zakiev, E
   Ma, F
   Rached, F
   Lhomme, M
   Sukhorukov, V
   Serrano, CV
   Santos, RD
   Chapman, MJ
   Orekhov, A
   Kontush, A
AF Zakiev, E.
   Ma, F.
   Rached, F.
   Lhomme, M.
   Sukhorukov, V.
   Serrano, C. V.
   Santos, R. D.
   Chapman, M. J.
   Orekhov, A.
   Kontush, A.
TI UNSATURATED, LOW-ABUNDANT SPECIES OF HDL (LYSO) PHOSPHOLIPIDS ARE MOST
   AFFECTED BY ST SEGMENT ELEVATION MYOCARDIAL INFARCTION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zakiev, E.; Ma, F.; Rached, F.; Sukhorukov, V.; Chapman, M. J.; Kontush, A.] INSERM, UMR ICAN 1166, Natl Inst Hlth & Med Res, Paris, France.
   [Sukhorukov, V.; Orekhov, A.] Inst Gen Pathol & Pathophysiol, Moscow, Russia.
   [Rached, F.; Serrano, C. V.; Santos, R. D.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Lhomme, M.] ICAN, Paris, France.
   [Orekhov, A.] Inst Atherosclerosis Res, Moscow, Russia.
RI chapman, john/Y-2742-2019; Santos, Raul D./A-1170-2010; Sukhorukov,
   Vasily/H-6545-2016; Orekhov, Alexander N/J-4838-2013
OI Santos, Raul D./0000-0002-9860-6582; Sukhorukov,
   Vasily/0000-0002-0312-3773; Orekhov, Alexander N/0000-0002-6495-1628
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG23:4
BP E56
EP E57
DI 10.1016/j.atherosclerosis.2018.06.152
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600166
DA 2019-10-28
ER

PT J
AU Zalesskaia, I
   Korotenko, O
   Djumagulova, A
   Kydyralieva, R
   Ten, V
   Neliubova, T
AF Zalesskaia, I.
   Korotenko, O.
   Djumagulova, A.
   Kydyralieva, R.
   Ten, V.
   Neliubova, T.
TI COMPLEX ASSESSMENT OF THE PSYCHO-SOCIAL STATUS IN KYRGYZS WITH CORONARY
   HEART DISEASE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zalesskaia, I.; Korotenko, O.; Djumagulova, A.; Kydyralieva, R.] Natl Ctr Cardiol & Internal Dis, Bishkek, Kyrgyzstan.
   [Ten, V.; Neliubova, T.] Kyrgyz Russian Slav Univ, Bishkek, Kyrgyzstan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.395
BP E218
EP E218
DI 10.1016/j.atherosclerosis.2018.06.682
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600694
DA 2019-10-28
ER

PT J
AU Cervantes, AZ
   Lopez, B
   Torrent-Fontbona, F
   Pozo-Alonso, A
   Paluzie, G
   Garcia-Vilches, J
   Flores, AG
   Massa, R
   Martin-Urda, A
   Capella, D
AF Zamora Cervantes, A.
   Lopez, B.
   Torrent-Fontbona, F.
   Pozo-Alonso, A.
   Paluzie, G.
   Garcia-Vilches, J.
   Garcia Flores, A.
   Massa, R.
   Martin-Urda, A.
   Capella, D.
TI "CLINICAL DECISION SUPPORT SYSTEM" WITH "SMART DATA ANALYSIS" CAN
   IMPROVE DETECTION AND TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA AND
   HIGH VASCULAR RISK PATIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zamora Cervantes, A.] Hosp Blanes, TransLab UDG, Lipid Unit, Girona, Spain.
   [Lopez, B.; Torrent-Fontbona, F.; Pozo-Alonso, A.] Univ Girona, Control Engn & Intelligent Syst Grp, Girona, Spain.
   [Paluzie, G.; Garcia-Vilches, J.] Corp Salut Maresme & Selva, Girona, Spain.
   [Garcia Flores, A.; Massa, R.] Hosp Blanes, Girona, Spain.
   [Martin-Urda, A.] Hosp Palamos, Serv Salut Integrats Baix Emporda, Girona, Spain.
   [Capella, D.] Univ Girona, Dept Med Sci, Fac Med, Girona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.499BI
BP E246
EP E247
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600891
DA 2019-10-28
ER

PT J
AU Zanolin, D
   Saely, CH
   Vonbank, A
   Lins, C
   Leiherer, A
   Mader, A
   Larcher, B
   Muendlein, A
   Drexel, H
AF Zanolin, D.
   Saely, C. H.
   Vonbank, A.
   Lins, C.
   Leiherer, A.
   Mader, A.
   Larcher, B.
   Muendlein, A.
   Drexel, H.
TI PRO-B-TYPE NATRIURETIC PEPTIDE STRONGLY PREDICTS ALL CAUSE AND
   CARDIOVASCULAR MORTALITY IN PERIPHERAL ARTERIAL DISEASE PATIENTS WITH AS
   WELL AS IN THOSE WITHOUT TYPE 2 DIABETES
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zanolin, D.; Saely, C. H.; Vonbank, A.; Lins, C.; Leiherer, A.; Mader, A.; Larcher, B.; Muendlein, A.; Drexel, H.] VIVIT Inst, Feldkirch, Austria.
   [Saely, C. H.; Vonbank, A.; Mader, A.; Larcher, B.] Acad Teaching Hosp, Feldkirch, Austria.
   [Saely, C. H.; Vonbank, A.; Leiherer, A.; Mader, A.; Larcher, B.; Muendlein, A.; Drexel, H.] Private Univ Principal Liechtenstein, Triesen, Liechtenstein.
   [Leiherer, A.] Med Cent Lab, Feldkirch, Austria.
   [Drexel, H.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.
   [Drexel, H.] Univ Hosp, Swiss Cardiovasc Ctr, Bern, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P4.4.341
BP E203
EP E203
DI 10.1016/j.atherosclerosis.2018.06.628
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600640
DA 2019-10-28
ER

PT J
AU Zarubin, A
   Markov, A
   Sharysh, D
   Barbarash, O
   Nazarenko, M
   Puzyrev, V
AF Zarubin, A.
   Markov, A.
   Sharysh, D.
   Barbarash, O.
   Nazarenko, M.
   Puzyrev, V.
TI ACCOUNTING LEUKOCYTE INFILTRATION IN GENOME-WIDE DNA METHYLATION STUDIES
   OF ATHEROSCLEROTIC PLAQUE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zarubin, A.; Markov, A.; Nazarenko, M.; Puzyrev, V.] Russian Acad Sci, Tomsk Natl Res Med Ctr, Res Inst Med Genet, Tomsk, Russia.
   [Zarubin, A.; Sharysh, D.; Nazarenko, M.; Puzyrev, V.] Siberian State Med Univ, Tomsk, Russia.
   [Barbarash, O.; Nazarenko, M.] Fed State Budgetary Sci Inst, Res Inst Complex Issues Cardiovasc Dis, Kemerovo, Russia.
RI Nazarenko, Maria S/A-7917-2014; Puzyrev, Valery P/S-3144-2016; Markov,
   Anton V/A-8252-2014
OI Nazarenko, Maria S/0000-0002-0673-4094; Puzyrev, Valery
   P/0000-0002-2113-4556; Markov, Anton V/0000-0002-5824-6439
FU Russian Scientific FoundationRussian Science Foundation (RSF)
   [17-75-10146]
FX The study is supported by a grant of Russian Scientific Foundation
   (17-75-10146).
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P3.4.294
BP E190
EP E190
DI 10.1016/j.atherosclerosis.2018.06.581
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600593
DA 2019-10-28
ER

PT J
AU Zhadan, A
   Romanenko, O
   Tseluyko, V
AF Zhadan, A.
   Romanenko, O.
   Tseluyko, V.
TI INFLUENCE OF CAD ON HEART REMODELING AT PATIENTS WITH MITRAL VALVE
   REGURGITATION
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zhadan, A.; Romanenko, O.; Tseluyko, V.] Kharkiv Med Acad Postgrad Educ, Kharkov, Ukraine.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.5.478
BP E240
EP E240
DI 10.1016/j.atherosclerosis.2018.06.761
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600773
DA 2019-10-28
ER

PT J
AU Zheng, KH
   Pawade, T
   Kroon, J
   Hjortnaes, J
   Verbeek, R
   Arsenault, BJ
   Rogers, MA
   Aikawa, E
   Stroes, ESG
   Tsimikas, S
   Boekholdt, SM
   Dweck, MR
AF Zheng, K. H.
   Pawade, T.
   Kroon, J.
   Hjortnaes, J.
   Verbeek, R.
   Arsenault, B. J.
   Rogers, M. A.
   Aikawa, E.
   Stroes, E. S. G.
   Tsimikas, S.
   Boekholdt, S. M.
   Dweck, M. R.
TI LIPOPROTEIN(A) IS ASSOCIATED WITH INCREASED CALCIFICATION AND DISEASE
   PROGRESSION IN AORTIC STENOSIS PATIENTS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zheng, K. H.; Kroon, J.; Verbeek, R.; Stroes, E. S. G.; Boekholdt, S. M.] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands.
   [Pawade, T.; Dweck, M. R.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland.
   [Hjortnaes, J.] Univ Med Ctr Utrecht, Dept Cardiothorac Surg, Utrecht, Netherlands.
   [Arsenault, B. J.] Laval Univ Quebec, Heart & Lung Inst, Dept Med, Quebec City, PQ, Canada.
   [Rogers, M. A.; Aikawa, E.] Harvard Med Sch, Div Cardiovasc Med, Boston, MA USA.
   [Tsimikas, S.] Univ Calif San Diego, Div Cardiovasc Med, Sulpizio Cardiovasc Ctr, San Diego, CA 92103 USA.
RI Aikawa, Elena/L-6173-2019
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG1.5
BP E18
EP E18
DI 10.1016/j.atherosclerosis.2018.06.036
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600050
DA 2019-10-28
ER

PT J
AU Zhetisheva, R
   Kovaleva, M
   Kamenihina, I
   Isaykina, T
   Shogenova, M
   Karpov, A
   Kovalev, L
   Naumov, V
AF Zhetisheva, R.
   Kovaleva, M.
   Kamenihina, I.
   Isaykina, T.
   Shogenova, M.
   Karpov, A.
   Kovalev, L.
   Naumov, V.
TI TRANSGELIN AS A PROMISING MARKER FOR THE STUDY OF IMMUNE STATUS IN
   ATHEROSCLEROSIS
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zhetisheva, R.; Shogenova, M.; Karpov, A.; Naumov, V.] Natl Med Res Cardiol Ctr, Moscow, Russia.
   [Kovaleva, M.; Kamenihina, I.; Isaykina, T.; Kovalev, L.] Russian Acad Sci, Bach Inst Biochem, Res Ctr Biotechnol, Moscow, Russia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P1.1.021
BP E109
EP E110
DI 10.1016/j.atherosclerosis.2018.06.306
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600318
DA 2019-10-28
ER

PT J
AU Zhou, E
   Hoeke, G
   Eibergen, AC
   Wang, Z
   Havinga, RH
   Groen, AK
   Boon, MR
   Rensen, PCN
   Berbee, JFP
   Wang, Y
AF Zhou, E.
   Hoeke, G.
   Eibergen, A. C.
   Wang, Z.
   Havinga, R. H.
   Groen, A. K.
   Boon, M. R.
   Rensen, P. C. N.
   Berbee, J. F. P.
   Wang, Y.
TI BILE ACID SEQUESTRANT COLESEVELAM ENHANCES BENEFICIAL EFFECTS OF BROWN
   FAT ACTIVATION ON CHOLESTEROL METABOLISM IN APOE*3-LEIDEN.CETP MICE
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zhou, E.; Hoeke, G.; Eibergen, A. C.; Wang, Z.; Boon, M. R.; Rensen, P. C. N.; Berbee, J. F. P.; Wang, Y.] Leiden Univ, Med Ctr, Dept Med, Div Endocrinol, Leiden, Netherlands.
   [Zhou, E.; Hoeke, G.; Eibergen, A. C.; Wang, Z.; Boon, M. R.; Rensen, P. C. N.; Berbee, J. F. P.; Wang, Y.] Einthoven Lab, Leiden, Netherlands.
   [Havinga, R. H.; Groen, A. K.] Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands.
   [Groen, A. K.] Dept Vasc Med, Groningen, Netherlands.
RI Wang, Yanan/C-4143-2019; Rensen, Patrick C.N./D-7176-2018; Rensen,
   Patrick/Y-5528-2019
OI Wang, Yanan/0000-0002-0327-0458; Rensen, Patrick
   C.N./0000-0002-8455-4988; Rensen, Patrick/0000-0002-8455-4988
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG4.1
BP E23
EP E23
DI 10.1016/j.atherosclerosis.2018.06.055
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600069
DA 2019-10-28
ER

PT J
AU Zimetti, F
   Freitas, WM
   Campos, AM
   Daher, M
   Adorni, MP
   Bernini, F
   Sposito, AC
   Zanotti, I
AF Zimetti, F.
   Freitas, W. M.
   Campos, A. M.
   Daher, M.
   Adorni, M. P.
   Bernini, F.
   Sposito, A. C.
   Zanotti, I.
TI CHOLESTEROL EFFLUX CAPACITY OF HEALTHY OCTOGENARIANS DOES NOT ASSOCIATE
   WITH CORONARY CALCIUM, PLAQUE VULNERABILITY AND TELOMERE LENGTH
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zimetti, F.; Adorni, M. P.; Bernini, F.; Zanotti, I.] Univ Parma, Dept Food & Drug, Parma, Italy.
   [Freitas, W. M.; Campos, A. M.; Daher, M.; Sposito, A. C.] Univ Estadual Campinas, Fac Med Sci, Cardiol Div, Campinas, SP, Brazil.
RI Sposito, Andrei C/G-4116-2013
OI Sposito, Andrei C/0000-0001-7127-2052
NR 0
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA SAG6.5
BP E28
EP E28
DI 10.1016/j.atherosclerosis.2018.06.071
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600085
DA 2019-10-28
ER

PT J
AU Zivotic, I
   Duric, T
   Stankovic, A
   Stankovic, G
   Milasinovic, D
   Dekleva, M
   Nikolic, NM
   Alavantic, D
   Zivkovic, M
AF Zivotic, I.
   Duric, T.
   Stankovic, A.
   Stankovic, G.
   Milasinovic, D.
   Dekleva, M.
   Nikolic, N. Markovic
   Alavantic, D.
   Zivkovic, M.
TI HACD4 HAPLOTYPE CONFERS RISK OF MYOCARDIAL INFARCTION AMONG MALES IN THE
   POPULATION OF SERBIA
SO ATHEROSCLEROSIS
LA English
DT Meeting Abstract
CT 86th Congress of the European-Atherosclerosis-Society (EAS)
CY MAY 05-08, 2018
CL Lisbon, PORTUGAL
SP European Atherosclerosis Soc
C1 [Zivotic, I.; Duric, T.; Stankovic, A.; Alavantic, D.; Zivkovic, M.] Univ Belgrade, VINCA Inst Nucl Sci, Belgrade, Serbia.
   [Stankovic, G.; Milasinovic, D.] Clin Ctr Serbia, Belgrade, Serbia.
   [Dekleva, M.; Nikolic, N. Markovic] Univ Belgrade, Clin Ctr Zvezdara, Fac Med, Belgrade, Serbia.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD AUG
PY 2018
VL 275
MA P5.1.370
BP E210
EP E211
DI 10.1016/j.atherosclerosis.2018.06.657
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GR3RP
UT WOS:000442512600669
DA 2019-10-28
ER

PT J
AU Chen, WJ
   Chen, YH
   Hsu, YJ
   Lin, KH
   Yeh, YH
AF Chen, Wei-Jan
   Chen, Ying-Hwa
   Hsu, Yu-Juei
   Lin, Kwang-Huei
   Yeh, Yung-Hsin
TI MicroRNA-132 targeting PTEN contributes to cilostazol-promoted vascular
   smooth muscle cell differentiation
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cilostazol; Differentiation; microRNA; PTEN; Vascular smooth muscle cell
ID TUMOR-SUPPRESSOR; INTERMITTENT CLAUDICATION; NEOINTIMA FORMATION; CREB;
   PROLIFERATION; EXPRESSION; MIR-132; INHIBITION; MECHANISMS; INDUCTION
AB Background and aims: Cilostazol, beyond its antiplatelet effect, is also capable of promoting vascular smooth muscle cell (VSMC) differentiation. The aim of this study was to explore the potential role of PTEN, known to associate with VSMC differentiation, and its related microRNA (miRNA) in cilostazol-dependent effects.
   Methods and results: Microarray analysis in balloon-injured rat carotid arteries comparing with and without balloon injury revealed that miR-132 was differentially expressed. Bioinformatic analysis predicts PTEN as a novel target of miR-132. Western blot and quantitative real-time reverse transcription-polymerase chain reaction along with in situ hybridization documented that cilostazol treatment enhanced PTEN and reduced miR-132 expression in the neointima of balloon-injured arteries. Treatment of cultured rat VSMCs with cilostazol resulted in the up-regulation of PTEN mRNA and the down-regulation of miR-132, supporting an in vitro relevance. Co-transfection experiments showed that transfection of miR-132 mimic into VSMCs suppressed PTEN 3'UTR activities, further reflecting that PTEN is the direct target of miR-132. Over-expression of miR-132 in VSMCs led to an attenuation of cilostazol-induced PTEN and its downstream VSMC differentiation marker (calponin) expression, confirming the critical role of miR-132 in VSMC differentiation. Transient transfection studies demonstrated that cilostazol reduced the activity of miR-132 promoter, which was mediated via cyclic AMP response element-binding protein. Notably, the use of lentivirus to over-express miR-132 in the neointima of balloon-injured arteries could reverse the effect of cilostazol in vivo.
   Conclusions: These results suggest that miR-132 by targeting PTEN may be an important regulator in mediating cilostazol actions on VSMC differentiation. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Chen, Wei-Jan; Yeh, Yung-Hsin] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Div Cardiol, Taoyuan, Taiwan.
   [Chen, Ying-Hwa] Natl Yang Ming Univ, Coll Med, Taipei Vet Gen Hosp, Div Cardiol,Dept Internal Med, Taipei, Taiwan.
   [Hsu, Yu-Juei] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Nephrol, Taipei, Taiwan.
   [Lin, Kwang-Huei] Chang Gung Univ, Liver Res Ctr, Chang Gung Mem Hosp, Dept Biochem,Coll Med, Taoyuan, Taiwan.
RP Chen, WJ (reprint author), Chang Gung Univ, Chang Gung Mem Hosp, Div Cardiol, 5,Fu Shin Rd, Taoyuan 333, Taiwan.; Hsu, YJ (reprint author), Triserv Gen Hosp, Div Nephrol, Natl Def Med Ctr, 325,Sect 2,Cheng Kung Rd, Taipei 114, Taiwan.
EM wjchen@adm.cgmh.org.tw; yujuei@mail2000.com.tw
FU Chang Gung Research Grant Foundation [CMRPG381531-3]; National Science
   CouncilNational Science Council of Taiwan [NSC-98-2314-B-182A-085-MY2]
FX This work was supported by grants from the Chang Gung Research Grant
   Foundation [CMRPG381531-3]; and National Science Council Grants
   [NSC-98-2314-B-182A-085-MY2].
NR 36
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 1
EP 7
DI 10.1016/j.atherosclerosis.2018.04.030
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600001
PM 29738818
DA 2019-10-28
ER

PT J
AU Carnevale, R
   Nocella, C
   Pignatelli, P
   Bartimoccia, S
   Stefanini, L
   Basili, S
   Novo, M
   D'Amico, A
   Cammisotto, V
   Pastori, D
   Violi, F
AF Carnevale, Roberto
   Nocella, Cristina
   Pignatelli, Pasquale
   Bartimoccia, Simona
   Stefanini, Lucia
   Basili, Stefania
   Novo, Marta
   D'Amico, Alessandra
   Cammisotto, Vittoria
   Pastori, Daniele
   Violi, Francesco
TI Blood hydrogen peroxide break-down activity in healthy subjects and in
   patients at risk of cardiovascular events
SO ATHEROSCLEROSIS
LA English
DT Article
DE Hydrogen peroxide; Assay; Antioxidant; Atrial fibrillation;
   Cardiovascular events
ID OXIDATIVE STRESS; GLUTATHIONE-PEROXIDASE; INHIBITION
AB Background and aims: Antioxidant status has been shown to be associated with cardiovascular events (CVEs). The aim of the study was to develop an assay measuring serum hydrogen peroxide (H2O2) breakdown activity (HBA) of healthy subjects (HS) and to validate it in a cohort of patients with atrial fibrillation (AF).
   Methods: We developed the HBA assay in 121 HS and validated it in 842 AF patients. The occurrence of CVEs was registered and correlated with HBA in AF during a median follow-up of 30.6 months (3226 patient-years). A combined endpoint of CVEs included fatal/non-fatal ischemic stroke and myocardial infarction, cardiovascular death and transient ischemic attack.
   Results: In HS, median HBA was 61.2% [IQR: 52.9-69.4]. AF patients disclosed lower HBA than 30 HS balanced for age and sex (48.6% [IQR: 24.7-65.1] vs. 59.4% [IQR: 49.2-66.2], p < 0.001). During a mean follow-up of 30.6 months (3226 patient-years), 168 CVEs occurred (5.2%/year). A multivariable Cox's proportional hazards regression analysis showed that age group 3 (71-80 years, HR: 5.419, p = 0.020), age group 4 (>80 years, HR: 9.783, p = 0.002), diabetes (HR: 1.464, p = 0.049), previous cardiac events (HR: 1.887, p = 0.001) and HBA (below median, HR: 2.313, p < 0.001) predicted CVEs.
   Conclusions: We developed an easy assay to measure serum HBA, which was associated with CVEs in AF patients. This assay may represent an additional useful tool for cardiovascular risk stratification and should be validated in other high-risk populations. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Carnevale, Roberto; D'Amico, Alessandra] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Corso Repubbl 79, Latina, Italy.
   [Pignatelli, Pasquale; Bartimoccia, Simona; Stefanini, Lucia; Basili, Stefania; Novo, Marta; Cammisotto, Vittoria; Pastori, Daniele; Violi, Francesco] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Atherothrombosis Ctr, Clin Med 1, Rome, Italy.
   [Nocella, Cristina] IRCCS NeuroMed, Dept AngioCardioNeurol, I-86077 Pozzilli, IS, Italy.
RP Carnevale, R (reprint author), Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Corso Repubbl 79, Latina, Italy.
EM roberto.carnevale@uniroma1.it
RI Cammisotto, Vittoria/W-5910-2019; Pastori, Daniele/J-7087-2016;
   stefanini, lucia/K-3992-2016; Basili, Stefania/K-4024-2016; Carnevale,
   Roberto/K-1472-2016
OI Pastori, Daniele/0000-0001-6357-5213; stefanini,
   lucia/0000-0001-7420-301X; Basili, Stefania/0000-0002-6987-1926;
   Carnevale, Roberto/0000-0002-6216-9595
NR 19
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 29
EP 34
DI 10.1016/j.atherosclerosis.2018.04.025
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600005
PM 29747088
DA 2019-10-28
ER

PT J
AU Al Rifai, M
   Martin, SS
   McEvoy, JW
   Nasir, K
   Blankstein, R
   Yeboah, J
   Miedema, M
   Shea, SJ
   Polak, JE
   Ouyang, P
   Blumenthal, RS
   Bittencourt, M
   Bensenor, I
   Santos, RD
   Duncan, BB
   Santos, IS
   Lotufo, PA
   Blaha, MJ
AF Al Rifai, Mahmoud
   Martin, Seth S.
   McEvoy, John W.
   Nasir, Khurram
   Blankstein, Ron
   Yeboah, Joseph
   Miedema, Michael
   Shea, Steven J.
   Polak, Joseph E.
   Ouyang, Pamela
   Blumenthal, Roger S.
   Bittencourt, Marcio
   Bensenor, Isabela
   Santos, Raul D.
   Duncan, Bruce B.
   Santos, Itamar S.
   Lotufo, Paulo A.
   Blaha, Michael J.
TI The prevalence and correlates of subclinical atherosclerosis among
   adults with low-density lipoprotein cholesterol < 70 mg/dL: The
   Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal
   Study of Adult Health (ELSA-Brasil)
SO ATHEROSCLEROSIS
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; LDL-CHOLESTEROL; CARDIOVASCULAR-DISEASE;
   RISK-FACTORS; CIGARETTE-SMOKING; STATIN THERAPY; PULSE PRESSURE;
   YOUNG-ADULTS; CALCIFICATION; METAANALYSIS
AB Background and aims: The prevalence and correlates of subclinical atherosclerosis when low-density lipoprotein cholesterol (LDL-C) levels are low remain unclear. Therefore, we examined the association of cardiovascular risk factors and subclinical atherosclerosis among individuals with untreated LDL-C <70 mg/dL.
   Methods: We included participants from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohorts. To optimize accuracy, LDL-C was calculated by the validated Martin/Hopkins equation that uses an adjustable factor for the ratio of triglycerides to very low-density lipoprotein cholesterol. We defined subclinical atherosclerosis as a coronary artery calcium (CAC) score >0 in the combined cohort or common carotid intima media thickness (cIMT) in the 4th quartile, using cohort-specific cIMT distributions at baseline. Logistic regression models examined the cross-sectional associations of cardiovascular risk factors and subclinical atherosclerosis.
   Results: Among 9411 participants not on lipid lowering therapy, 263 (3%) had LDL-C <70 mg/dL (MESA: 206, ELSA: 57). Mean age in this population was 58 (SD 12) years, with 43% men, and 41% Black. The prevalence of CAC >0 in those with untreated LDL-C<70 mg/dL was 30%, and 18% were in 4th quartile of cIMT. In demographically adjusted models, only ever smoking was significantly associated with both CAC and cIMT. Similar results were obtained in risk factor-adjusted models (smoking: OR, 2.29; 95% CI, 1.10 -4.80 and OR, 3.44; 95% CI, 1.41-8.37 for CAC and cIMT, respectively).
   Conclusions: Among middle-aged to older individuals with untreated LDL-C <70 mg/dL, subclinical atherosclerosis remains moderately common and is associated with cigarette smoking. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Al Rifai, Mahmoud; Martin, Seth S.; McEvoy, John W.; Nasir, Khurram; Blumenthal, Roger S.; Blaha, Michael J.] Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD 21287 USA.
   [Al Rifai, Mahmoud] Univ Kansas, Sch Med, Dept Internal Med, Wichita, KS 67214 USA.
   [Nasir, Khurram] Baptist Hlth South Florida, Ctr Prevent & Wellness, Miami, FL USA.
   [Blankstein, Ron] Brigham & Womens Hosp, Dept Med, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA.
   [Blankstein, Ron] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
   [Yeboah, Joseph] Wake Forest Baptist Hlth, Dept Cardiol, Winston Salem, NC USA.
   [Miedema, Michael] Minneapolis Heart Inst Fdn, Minneapolis, MS USA.
   [Shea, Steven J.] Columbia Univ, Dept Med, New York, NY USA.
   [Shea, Steven J.] Columbia Univ, Dept Epidemiol, New York, NY USA.
   [Polak, Joseph E.] Tufts Univ, Sch Med, Dept Radiol, Boston, MA 02111 USA.
   [Ouyang, Pamela] Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD USA.
   [Bittencourt, Marcio; Bensenor, Isabela; Santos, Raul D.; Santos, Itamar S.; Lotufo, Paulo A.] Univ Sao Paulo, Sch Med, Univ Hosp, Ctr Clin & Epidemiol Res, Sao Paulo, Brazil.
   [Bensenor, Isabela; Santos, Itamar S.; Lotufo, Paulo A.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Santos, Raul D.] Univ Sao Paulo, Med Sch Hosp, Lipid Clin Heart Inst InCor, Sao Paulo, Brazil.
   [Duncan, Bruce B.] Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil.
RP Blaha, MJ (reprint author), Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Baltimore, MD 21287 USA.
EM mblaha1@jhmi.edu
RI Santos, Itamar S/K-7055-2012; Santos, Raul D./A-1170-2010; Santos,
   Itamar/M-2208-2019; Bittencourt, Marcio/C-1444-2011
OI Santos, Itamar S/0000-0003-3212-8466; Santos, Raul
   D./0000-0002-9860-6582; Santos, Itamar/0000-0003-3212-8466; Bittencourt,
   Marcio/0000-0002-3711-1754
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [HHSN268201500003I,
   N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163,
   N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168,
   N01-HC-95169]; National Center for Research ResourcesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Research Resources (NCRR) [UL1-TR-000040,
   UL1-TR-001079]; Brazilian Ministry of Health (Science and Technology
   Department); Brazilian Ministry of Science and Technology (Financiadora
   de Estudos e Projetos) [01 06 0115.00 SP, FAPESP (11/12256-4)];
   Brazilian Ministry of Science and Technology (CNPq National Research
   Council) [01 06 0115.00 SP, FAPESP (11/12256-4)]; National Heart, Lung,
   and Blood Institute (NHLBI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [5P50HL120163]; FDA Center for Tobacco
   Products (CTP)United States Department of Health & Human Services
FX The MESA study was supported by contracts HHSN268201500003I,
   N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163,
   N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168,
   and N01-HC-95169 from the National Heart, Lung, and Blood Institute and
   grants UL1-TR-000040 and UL1-TR-001079 from the National Center for
   Research Resources. The authors thank the other investigators, the
   staff, and the participants of the MESA study for their valuable
   contributions. A full list of participating MESA investigators and
   institutions can be found at http://www.mesa-nhlbi.org.; The ELSA-Brasil
   baseline study was supported by the Brazilian Ministry of Health
   (Science and Technology Department) and the Brazilian Ministry of
   Science and Technology (Financiadora de Estudos e Projetos and CNPq
   National Research Council) (grants 01 06 0115.00 SP and FAPESP
   (11/12256-4)). The authors thank the research team of the ELSA-Brasil
   baseline study for their contribution.; Research reported in this work
   was supported by grant number 5P50HL120163 from the National Heart,
   Lung, and Blood Institute (NHLBI) and FDA Center for Tobacco Products
   (CTP). The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the NIH or the Food and
   Drug Administration.
NR 27
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 61
EP 66
DI 10.1016/j.atherosclerosis.2018.04.021
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600010
PM 29751286
DA 2019-10-28
ER

PT J
AU O'Keeffe, LM
   Howe, LD
   Fraser, A
   Hughes, AD
   Wade, KH
   Anderson, EL
   Lawlor, DA
   Erzurumluoglu, AM
   Davey-Smith, G
   Rodriguez, S
   Stergiakouli, E
AF O'Keeffe, Linda M.
   Howe, Laura D.
   Fraser, Abigail
   Hughes, Alun D.
   Wade, Kaitlin H.
   Anderson, Emma L.
   Lawlor, Debbie A.
   Erzurumluoglu, A. Mesut
   Davey-Smith, George
   Rodriguez, Santiago
   Stergiakouli, Evie
TI Associations of Y chromosomal haplogroups with cardiometabolic risk
   factors and subclinical vascular measures in males during childhood and
   adolescence
SO ATHEROSCLEROSIS
LA English
DT Article
DE Y chromosome; Childhood; Adolescence; Cardiometabolic; Vascular
ID CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; YOUNG-ADULTS; MEN; DYSLIPIDEMIA;
   TRAJECTORIES; PREVENTION; MORTALITY; PREGNANCY; TRACKING
AB Background and aims: Males have greater cardiometabolic risk than females, though the reasons for this are poorly understood. The aim of this study was to examine the association between common Y chromosomal haplogroups and cardiometabolic risk during early life.
   Methods: In a British birth cohort, we examined the association of Y chromosomal haplogroups with trajectories of cardiometabolic risk factors from birth to 18 years and with carotid-femoral pulse wave velocity, carotid intima media thickness and left ventricular mass index at age 18. Haplogroups were grouped according to their phylogenetic relatedness into categories of R, I, E, J, G and all other haplogroups combined (T, Q, H, L, C, N and O). Risk factors included BMI, fat and lean mass, systolic blood pressure (SBP), diastolic blood pressure, pulse rate, triglycerides, high density lipoprotein cholesterol (HDL-c), non-HDL-c and c-reactive protein. Analyses were performed using multilevel models and linear regression, as appropriate.
   Results: Y chromosomal haplogroups were not associated with any cardiometabolic risk factors from birth to 18 years. For example, at age 18, the difference in SBP comparing each haplogroup with haplogroup R was -0.39mmHg (95% Confidence Interval (CI): -0.75, 1.54) for haplogroup I, 2.56mmHg (95% CI: -0.76, 5.89) for haplogroup E, -0.02 mmHg (95% CI: -2.87, 2.83) for haplogroup J, 1.28 mmHg (95% CI: -4.70, 2.13) for haplogroup G and -2.75mmHg (95% CI: -6.38, 0.88) for all other haplogroups combined.
   Conclusions: Common Y chromosomal haplogroups are not associated with cardiometabolic risk factors during childhood and adolescence or with subclinical cardiovascular measures at age 18. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [O'Keeffe, Linda M.; Howe, Laura D.; Fraser, Abigail; Wade, Kaitlin H.; Anderson, Emma L.; Lawlor, Debbie A.; Davey-Smith, George; Rodriguez, Santiago; Stergiakouli, Evie] Univ Bristol, MRC Integrat Epidemiol Unit, Oakfield House, Bristol BS8 2BN, Avon, England.
   [O'Keeffe, Linda M.; Howe, Laura D.; Fraser, Abigail; Wade, Kaitlin H.; Anderson, Emma L.; Lawlor, Debbie A.; Davey-Smith, George; Rodriguez, Santiago; Stergiakouli, Evie] Univ Bristol Sch Med, Populat Hlth Sci, Oakfield House, Bristol BS8 2BN, Avon, England.
   [Hughes, Alun D.] UCL, Inst Cardiovasc Sci, MRC Unit Lifelong Hlth & Aging, London WC1E 6BT, England.
   [Erzurumluoglu, A. Mesut] Univ Leicester, Genet Epidemiol Grp, Dept Hlth Sci, Ctr Med, Univ Rd, Leicester LE1 7RH, Leics, England.
   [Stergiakouli, Evie] Univ Bristol, Sch Oral & Dent Sci, Bristol, Avon, England.
RP O'Keeffe, LM (reprint author), Univ Bristol, MRC Integrat Epidemiol Unit, Oakfield House, Bristol BS8 2BN, Avon, England.
EM Linda.akeeffe@bristol.ac.uk
RI Hughes, Alun/N-3781-2013; Erzurumluoglu, A. Mesut/Z-1850-2018; Smith,
   George Davey/Y-7521-2019; Erzurumluoglu, A. Mesut/Q-7026-2019
OI Hughes, Alun/0000-0001-5432-5271; Erzurumluoglu, A.
   Mesut/0000-0003-1322-8138; Smith, George Davey/0000-0002-1407-8314;
   Erzurumluoglu, A. Mesut/0000-0003-1322-8138; O'Keeffe,
   Linda/0000-0002-0003-0774; Stergiakouli, Evangelia/0000-0003-3586-0927;
   Fraser, Abigail/0000-0002-7741-9470; Lawlor, Debbie
   A/0000-0002-6793-2262; Howe, Laura/0000-0003-3357-2796; Rodriguez,
   Santiago/0000-0001-6551-932X; Wade, Kaitlin/0000-0003-3362-6280; s,
   hema/0000-0002-3440-9475
FU Medical Research CouncilMedical Research Council UK (MRC); University of
   Bristol [MC_UU_12013/6, MC_UU_12013/9]; UK Medical Research Council
   Population Health Scientist fellowship [MR/M014509/1]; Career
   Development Awards from the United Kingdom Medical Research Council
   [MR/M020894/1, MR/M009351/1]; United Kingdom Medical Research
   CouncilMedical Research Council UK (MRC) [MC_UU_12013/5, MC_UU_12019/1];
   British Heart FoundationBritish Heart Foundation [PG/15/75/31748,
   CS/15/6/31468, CS/13/1/30327]; Wellcome TrustWellcome Trust
   [086676/7/08/Z]; National Institute for Health Research University
   College London Hospitals Biomedical Research Centre
FX The MRC Integrative Epidemiology Unit at the University of Bristol is
   supported by the Medical Research Council and the University of Bristol
   [MC_UU_12013/6, MC_UU_12013/9]. LMOK is supported by a UK Medical
   Research Council Population Health Scientist fellowship (MR/M014509/1).
   LDH and AF are supported by Career Development Awards from the United
   Kingdom Medical Research Council (grants MR/M020894/1 and MR/M009351/1,
   respectively). LMOK, LDH, AF, KHW, ELA, DAL, GDS, SR, and ES work in a
   unit that receives funds from the United Kingdom Medical Research
   Council (grant MC_UU_12013/5). AH received support from the British
   Heart Foundation (PG/15/75/31748, CS/15/6/31468, CS/13/1/30327), the
   Wellcome Trust (086676/7/08/Z), the National Institute for Health
   Research University College London Hospitals Biomedical Research Centre
   and works in a unit that receives funds from the United Kingdom Medical
   Research Council (Programme Code MC_UU_12019/1). All the funding sources
   had no role in the study design, collection, analysis, or interpretation
   of the data, writing the manuscript, or the decision to submit the paper
   for publication.
NR 43
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 94
EP 103
DI 10.1016/j.atherosclerosis.2018.04.027
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600014
PM 29753233
OA Green Published
DA 2019-10-28
ER

PT J
AU Nahon, JE
   Hoekstra, M
   Havik, SR
   Van Santbrink, PJ
   Dallinga-Thie, GM
   Kuivenhoven, JA
   Geerling, JJ
   Van Eck, M
AF Nahon, Joya E.
   Hoekstra, Menno
   Havik, Stefan R.
   Van Santbrink, Peter J.
   Dallinga-Thie, Geesje M.
   Kuivenhoven, Jan-Albert
   Geerling, Janine J.
   Van Eck, Miranda
TI Proteoglycan 4 regulates macrophage function without altering
   atherosclerotic lesion formation in a murine bone marrow-specific
   deletion model
SO ATHEROSCLEROSIS
LA English
DT Article
DE Proteoglycan 4; Proteoglycans; Macrophage function; Bone marrow
   transplantation; Atherosclerosis
ID HEPARAN-SULFATE PROTEOGLYCANS; SMOOTH-MUSCLE-CELLS; LIPOPROTEINS;
   VERSICAN; LDL; APOLIPOPROTEIN; METABOLISM; BIGLYCAN; PERLECAN; LUBRICIN
AB Background and aims: Proteoglycan 4 (Prg4) has a high structural similarity with the established atherosclerosis-modulating proteoglycan versican, but its role in atherogenesis is still unknown. Therefore, the impact of Prg4 deficiency on macrophage function in vitro and atherosclerosis susceptibility in vivo was investigated.
   Methods: The presence and localization of Prg4 was studied in atherosclerotic lesions. Furthermore, the effect of Prg4 deficiency on macrophage foam cell formation, cholesterol efflux and lipopolysaccharide (LPS) response was determined. Finally, susceptibility for atherosclerotic lesion formation was investigated in bone marrow-specific Prg4 knockout (KO) mice.
   Results: Prg4 mRNA expression was induced 91-fold (p<0.001) in murine initial atherosclerotic lesions and Prg4 protein co-localized with human lesional macrophages. Murine Prg4 KO macrophages showed increased foam cell formation (+2.1-fold, p<0.01). In parallel, the expression of the cholesterol efflux genes ATP-binding cassette transporter A1 and scavenger receptor type B1 was lower (-35%, p<0.05;40%, p<0.05) in Prg4 KO macrophages. This translated into an impaired cholesterol efflux to high-density lipoprotein (-13%, p<0.001) and apolipoprotein A1 (-8%, p<0.05). Furthermore, Prg4 KO macrophages showed an impaired LPS-induced rise in TNF alpha secretion as compared to wild-type controls (-31%, p<0.001), indicating a reduced inflammatory response. Combined, these pro-and anti-atherogenic effects did not translate into a significant difference in atherosclerotic lesion formation upon bone marrowspecific deletion of Prg4 in low-density lipoprotein receptor KO mice.
   Conclusions: Prg4 is present in macrophages in both murine and human atherosclerotic lesions and critically influences macrophage function, but deletion of Prg4 in bone marrow-derived cells does not affect atherosclerotic lesion development. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Nahon, Joya E.; Hoekstra, Menno; Van Santbrink, Peter J.; Geerling, Janine J.; Van Eck, Miranda] Leiden Acad Ctr Drug Res, Div BioTherapeut, Leiden, Netherlands.
   [Havik, Stefan R.; Dallinga-Thie, Geesje M.] Acad Med Ctr Amsterdam, Dept Expt Vasc Med, Amsterdam, Netherlands.
   [Kuivenhoven, Jan-Albert] Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands.
RP Nahon, JE (reprint author), Leiden Acad Ctr Drug Res, Div BioTherapeut, Leiden, Netherlands.
EM j.e.nahon@lacdr.leidenuniv.nl
OI dallinga-thie, geesje/0000-0001-5412-5923; Hoekstra,
   Menno/0000-0001-7463-2893
FU Netherlands CardioVascular Research Initiative: the Dutch Heart
   Foundation; Dutch Federation of University Medical Centres; Netherlands
   Organisation for Health Research and DevelopmentNetherlands Organization
   for Health Research and Development; Royal Netherlands Academy of
   Sciences [CVON2011-19]; Netherlands Organisation for Scientific Research
   (VICI Grant)Netherlands Organization for Scientific Research (NWO)
   [91813603]; Dutch Heart FoundationNetherlands Heart Foundation
   [2012T080, 2007T056]
FX We acknowledge the support from the Netherlands CardioVascular Research
   Initiative: "the Dutch Heart Foundation, Dutch Federation of University
   Medical Centres, the Netherlands Organisation for Health Research and
   Development and the Royal Netherlands Academy of Sciences" for the
   GENIUS project "Generating the best evidence-based pharmaceutical
   targets for atherosclerosis" (CVON2011-19 to M. v.E.). This study was
   supported by the Netherlands Organisation for Scientific Research (VICI
   Grant 91813603 to M. v.E.) and Dutch Heart Foundation grant 2012T080
   awarded to M.H; M. v.E. is an Established Investigator of the Dutch
   Heart Foundation (Grant 2007T056).
NR 45
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 120
EP 127
DI 10.1016/j.atherosclerosis.2018.05.008
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600017
PM 29772480
DA 2019-10-28
ER

PT J
AU Yamaguchi, J
   Kawada-Watanabe, E
   Koyanagi, R
   Arashi, H
   Sekiguchi, H
   Nakao, K
   Tobaru, T
   Tanaka, H
   Oka, T
   Endo, Y
   Saito, K
   Uchida, T
   Matsui, K
   Ogawa, H
   Hagiwara, N
AF Yamaguchi, Junichi
   Kawada-Watanabe, Erisa
   Koyanagi, Ryo
   Arashi, Hiroyuki
   Sekiguchi, Haruki
   Nakao, Koichi
   Tobaru, Tetsuya
   Tanaka, Hiroyuki
   Oka, Toshiaki
   Endo, Yasuhiro
   Saito, Katsumi
   Uchida, Tatsuro
   Matsui, Kunihiko
   Ogawa, Hiroshi
   Hagiwara, Nobuhisa
TI Baseline serum sitosterol level as predictor of adverse clinical events
   in acute coronary syndrome patients with dyslipidaemia: A sub-analysis
   of HIJ-PROPER
SO ATHEROSCLEROSIS
LA English
DT Article
DE Sitosterol; Ezetimibe; Pitavastatin; Lipid-lowering; Acute coronary
   syndrome
ID DENSITY-LIPOPROTEIN CHOLESTEROL; RANDOMIZED CONTROLLED-TRIAL;
   PRECISE-IVUS TRIAL; STATIN THERAPY; CARDIOVASCULAR EVENTS;
   MYOCARDIAL-INFARCTION; PLANT STEROLS; HEART-DISEASE; EZETIMIBE;
   METABOLISM
AB Background and aims: We aimed to examine the effect of serum sitosterol, a cholesterol absorption marker, on clinical outcomes in acute coronary syndrome patients with dyslipidaemia.
   Methods: This is a sub-analysis of the HIJ-PROPER trial that assesses the effect of aggressive low-density lipoprotein cholesterol (LDL-C) lowering treatment with pitavastatin + ezetimibe in 1734 acute coronary syndrome (ACS) patients with dyslipidaemia. Patients were divided into two groups based on sitosterol level at enrolment (cut-off value was 2.2 mu g/mL; a median of baseline sitosterol level), and clinical outcomes were examined.
   Results: The mean LDL-C level after 3 years in the low sitosterol group was 84.8 +/- 20.1 mg/dL with pitavastatin-monotherapy and 64.6 +/- 20.3 mg/dL with pitavastatin + ezetimibe, while corresponding values in the high sitosterol group were 91.0 +/- 22.9 mg/dL and 71.1 +/- 23.3 mg/dL, respectively. In the high sitosterol group, the Kaplan-Meier event rate for the primary endpoint at 3 years was 26.0% in the pitavastatin + ezetimibe group, as compared with 34.3% in the pitavastatin-monotherapy group (hazard ratio, 0.71; 95% confidence interval, 0.56-0.91; p = 0.006, p-value for interaction = 0.010). However, in the low sitosterol group, there was no significant reduction of the primary endpoint by pitavastatin + ezetimibe therapy.
   Conclusions: Aggressive lipid-lowering treatment with ezetimibe had a positive effect on clinical outcomes in the high sitosterol subset of ACS patients with dyslipidaemia, but not in the low sitosterol subset. This effect was independent of LDL-C reduction and suggests that sitosterol measurement on admission in ACS patients might contribute to a "personalised" lipid-lowering approach. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Yamaguchi, Junichi; Kawada-Watanabe, Erisa; Koyanagi, Ryo; Arashi, Hiroyuki; Sekiguchi, Haruki; Ogawa, Hiroshi; Hagiwara, Nobuhisa] Tokyo Womens Med Univ, Heart Inst Japan, Dept Cardiol, Tokyo 1628666, Japan.
   [Nakao, Koichi] Saisei Kai Kumamoto Hosp, Kumamoto 8614193, Japan.
   [Tobaru, Tetsuya] Sakakibara Heart Inst, Tokyo 1830003, Japan.
   [Tanaka, Hiroyuki] Tokyo Metropolitan Tama Med Ctr, Tokyo 1835111, Japan.
   [Oka, Toshiaki] Seirei Hamamatsu Gen Hosp, Shizuoka 4308558, Japan.
   [Endo, Yasuhiro] Saisei Kai Kurihashi Hosp, Saitama 3491105, Japan.
   [Saito, Katsumi] Nishiarai Heart Ctr, Tokyo 1230845, Japan.
   [Uchida, Tatsuro] Cardiovasc Ctr Sendai, Sendai, Miyagi 9813133, Japan.
   [Matsui, Kunihiko] Kumamoto Univ Hosp, Dept Gen & Community Med, Kumamoto 8608556, Japan.
RP Yamaguchi, J (reprint author), Tokyo Womens Med Univ, Heart Inst Japan, Dept Cardiol, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM j.yamaguchi0110@gmall.com
OI Sekiguchi, Haruki/0000-0003-0821-4815
FU Japan Research Promotion Society for Cardiovascular Diseases
FX This trial was funded by the Japan Research Promotion Society for
   Cardiovascular Diseases.
NR 31
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 139
EP 145
DI 10.1016/j.atherosclerosis.2018.04.036
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600019
PM 29772482
DA 2019-10-28
ER

PT J
AU Feng, TT
   Liu, P
   Wang, X
   Luo, JQ
   Zuo, X
   Jiang, XH
   Liu, C
   Li, YZ
   Li, N
   Chen, MH
   Zhu, NY
   Han, XW
   Liu, C
   Xu, YN
   Si, SY
AF Feng, Tingting
   Liu, Peng
   Wang, Xiao
   Luo, Jinque
   Zuo, Xuan
   Jiang, Xinhai
   Liu, Chang
   Li, Yongzhen
   Li, Ni
   Chen, Minghua
   Zhu, Ningyu
   Han, Xiaowan
   Liu, Chao
   Xu, Yanni
   Si, Shuyi
TI SIRT1 activator E1231 protects from experimental atherosclerosis and
   lowers plasma cholesterol and triglycerides by enhancing ABCA1
   expression
SO ATHEROSCLEROSIS
LA English
DT Article
DE SIRT1; LXR alpha; ABCA1; Cholesterol and lipid metabolism
ID APOLIPOPROTEIN E-DEFICIENT; CALORIE RESTRICTION; APOE(-/-) MICE;
   LXR-ALPHA; RECEPTOR; IDENTIFICATION; MACROPHAGES; EFFLUX; MECHANISM;
   OVEREXPRESSION
AB Background and aims: Sirtuin 1 (SIRT1) is a nicotinamide adenine dinucleotide-dependent protein deacetylase. Recent studies have demonstrated that enhancing SIRT1 expression or activity may modulate cholesterol and lipid metabolism. However, pharmacological and molecular regulators for SIRT1 are scarce. Here, we aimed to find novel small molecule modulators of SIRT1 to regulate cholesterol and lipid metabolism.
   Methods: A high-throughput screening assay was established to identify SIRT1 activators. Surface plasmon resonance and immunoprecipitation were performed to confirm the interaction of E1231 with SIRT1. Cholesterol assay was performed to demonstrate the in vitro effect of E1231. The in vivo effect of E1231 was evaluated in experimental models.
   Results: E1231, a piperazine 1,4-diamide compound, was identified as a SIRT1 activator with EC50 value of 0.83 mu M. E1231 interacted with recombinant human SIRT1 protein and deacetylated liver X receptoralpha (LXR alpha). E1231 increased ATP-binding cassette transporter A1 (ABCA1) expression in RAW 264.7 cells dependent on SIRT1 and LXRa. E1231 promoted cholesterol efflux and inhibited lipid accumulation in RAW 264.7 cells via SIRT1 and ABCA1. In the golden hamster hyperlipidemia model, E1231 treatment decreased total cholesterol and triglyceride levels in both serum and the liver, while increased cholesterol content in feces. Moreover, E1231 increased ABCA1 and SIRT1 protein expression in the liver. In ApoE(-/-) mice, E1231 treatment reduced atherosclerotic plaque development compared with untreated ApoE(-/-) mice.
   Conclusions: We identified a novel SIRT1 activator E1231 and elucidated its beneficial effects on lipid and cholesterol metabolism. Our study suggests that E1231 might be developed as a novel drug for treating atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Feng, Tingting; Liu, Peng; Wang, Xiao; Luo, Jinque; Zuo, Xuan; Jiang, Xinhai; Liu, Chang; Li, Yongzhen; Li, Ni; Chen, Minghua; Zhu, Ningyu; Han, Xiaowan; Liu, Chao; Xu, Yanni; Si, Shuyi] Chinese Acad Med Sci, Inst Med Biotechnol, NHC Key Lab Biotechnol Antibiot, Beijing 100050, Peoples R China.
   [Feng, Tingting; Liu, Peng; Wang, Xiao; Luo, Jinque; Zuo, Xuan; Jiang, Xinhai; Liu, Chang; Li, Yongzhen; Li, Ni; Chen, Minghua; Zhu, Ningyu; Han, Xiaowan; Liu, Chao; Xu, Yanni; Si, Shuyi] Peking Union Med Coll, Beijing 100050, Peoples R China.
   [Feng, Tingting] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Clin Pharm, Shanghai 201620, Peoples R China.
   [Li, Ni] CAMS, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Beijing 100050, Peoples R China.
RP Xu, YN; Si, SY (reprint author), Chinese Acad Med Sci, Inst Med Biotechnol, NHC Key Lab Biotechnol Antibiot, Beijing 100050, Peoples R China.; Xu, YN; Si, SY (reprint author), Peking Union Med Coll, Beijing 100050, Peoples R China.
EM xuyanniwendeng@hotmail.com; sisyimb@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81573482, 81621064, 81703503, 81273515, 81503065];
   Health and Medical Creation Program of CAMS [2016-I2M-1-011]; Key New
   Drug Creation and Manufacturing Program [2018ZX09711001-003-006,
   2018ZX09735001-002-001]
FX This work was supported by the National Natural Science Foundation of
   China (grant numbers 81573482, 81621064, 81703503, 81273515 and
   81503065), the Health and Medical Creation Program of CAMS (grant
   numbers 2016-I2M-1-011), and the Key New Drug Creation and Manufacturing
   Program (grant No. 2018ZX09711001-003-006 and 2018ZX09735001-002-001).
NR 50
TC 3
Z9 3
U1 4
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 172
EP 181
DI 10.1016/j.atherosclerosis.2018.04.039
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600024
PM 29787963
DA 2019-10-28
ER

PT J
AU Colombo, M
   Looker, HC
   Farran, B
   Agakov, F
   Brosnan, MJ
   Welsh, P
   Sattar, N
   Livingstone, S
   Durrington, PN
   Betteridge, DJ
   McKeigue, PM
   Colhoun, HM
AF Colombo, Marco
   Looker, Helen C.
   Farran, Bassam
   Agakov, Felix
   Brosnan, M. Julia
   Welsh, Paul
   Sattar, Naveed
   Livingstone, Shona
   Durrington, Paul N.
   Betteridge, D. John
   McKeigue, Paul M.
   Colhoun, Helen M.
TI Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide
   as independent predictors for cardiovascular disease in type 2 diabetes
SO ATHEROSCLEROSIS
LA English
DT Article
DE Epidemiology; Type 2 diabetes mellitus; Apolipoprotein; Cardiovascular
   disease
ID CORONARY-HEART-DISEASE; CARDIAC TROPONIN-T; ATHEROSCLEROSIS RISK;
   ATORVASTATIN; COMMUNITIES; POPULATION; MORTALITY; PROTEIN; EVENTS;
   CHOLESTEROL
AB Background and aims: Developing sparse panels of biomarkers for cardiovascular disease in type 2 diabetes would enable risk stratification for clinical decision making and selection into clinical trials. We examined the individual and joint performance of five candidate biomarkers for incident cardiovascular disease (CVD) in type 2 diabetes that an earlier discovery study had yielded.
   Methods: Apolipoprotein CIII (apoCIII), N-terminal prohormone B-type natriuretic peptide (NT-proBNP), high sensitivity Troponin T (hsTnT), Interleukin-6, and Interleukin-15 were measured in baseline serum samples from the Collaborative Atorvastatin Diabetes trial (CARDS) of atorvastatin versus placebo. Among 2105 persons with type 2 diabetes and median age of 62.9 years (range 39.2-77.3), there were 144 incident CVD (acute coronary heart disease or stroke) cases during the maximum 5-year follow up. We used Cox Proportional Hazards models to identify biomarkers associated with incident CVD and the area under the receiver operating characteristic curves (AUROC) to assess overall model prediction.
   Results: Three of the biomarkers were singly associated with incident CVD independently of other risk factors; NT-proBNP (Hazard Ratio per standardised unit 2.02, 95% Confidence Interval [CI] 1.63, 2.50), apoCIII (1.34, 95% CI 1.12, 1.60) and hsTnT (1.40, 95% CI 1.16, 1.69). When combined in a single model, only NT-proBNP and apoCIII were independent predictors of CVD, together increasing the AUROC using Framingham risk variables from 0.661 to 0.745.
   Conclusions: The biomarkers NT-proBNP and apoCIII substantially increment the prediction of CVD in type 2 diabetes beyond that obtained with the variables used in the Framingham risk score. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Colombo, Marco; Farran, Bassam; Agakov, Felix; McKeigue, Paul M.; Colhoun, Helen M.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   [Looker, Helen C.] NIH, Diabet Epidemiol & Clin Res Sect, 1550 E Indian Sch Rd, Phoenix, AZ 85014 USA.
   [Agakov, Felix] Pharmat Ltd, Edinburgh Bioquarter, 9 Little France Rd, Edinburgh EH16 4UX, Midlothian, Scotland.
   [Brosnan, M. Julia] Pfizer Inc, New York, NY USA.
   [Welsh, Paul; Sattar, Naveed] Univ Glasgow, Glasgow, Lanark, Scotland.
   [Livingstone, Shona] Univ Dundee, Diabet Epidemiol Unit, Mackenzie Bldg,Kirsty Semple Way, Dundee DD2 4BF, Scotland.
   [Durrington, Paul N.] Univ Manchester, Cardiovasc Res Grp, 46 Grafton St, Manchester M13 9NT, Lancs, England.
   [Betteridge, D. John] Univ Coll London Hosp, London, England.
   [Colhoun, Helen M.] NHS Fife, Kirkcaldy, England.
RP Colhoun, HM (reprint author), Western Gen Hosp, MRC, Inst Genet & Mol Med, AXA Chair Med Informat & Life Course Epidemiol, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.
EM helen.colhoun@igmm.ed.ac.uk
RI Welsh, Paul/H-5249-2019
OI Welsh, Paul/0000-0002-7970-3643; Colombo, Marco/0000-0001-6672-0623
FU Innovative Medicine Initiative [IMI/115006]; Diabetes UKDiabetes UK; UK
   Department of Health; Pfizer UKPfizer; Pfizer Inc.Pfizer
FX This work was funded by the Innovative Medicine Initiative under grant
   agreement no IMI/115006 (the SUMMIT consortium). The original CARDS
   Trial was funded by Diabetes UK, the UK Department of Health, Pfizer UK
   and Pfizer Inc. (manufacturers of atorvastatin).
NR 45
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 182
EP 190
DI 10.1016/j.atherosclerosis.2018.05.014
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600025
PM 29793175
OA Green Accepted, Other Gold, Green Published
DA 2019-10-28
ER

PT J
AU Nakagawa, K
   Nakashima, Y
AF Nakagawa, Kazunori
   Nakashima, Yutaka
TI Pathologic intimal thickening in human atherosclerosis is formed by
   extracellular accumulation of plasma-derived lipids and dispersion of
   intimal smooth muscle cells
SO ATHEROSCLEROSIS
LA English
DT Article
DE Pathologic intimal thickening; Humans; Coronary atherosclerosis;
   Plasma-derived lipids; Lipid pool; Smooth muscle cells; Dispersion
ID HUMAN CORONARY-ARTERIES; AMERICAN-HEART-ASSOCIATION; LIPOPROTEIN
   RETENTION; VASCULAR-LESIONS; FATTY STREAKS; HUMAN AORTA; PROTEOGLYCANS;
   PLAQUES; KEY; PROGRESSION
AB Background and aims: Pathologic intimal thickening (PIT) is an important stage of atherosclerosis that leads to atheroma. The present study aimed to clarify the pathogenesis of PIT in humans.
   Methods: Coronary arteries were obtained from 43 autopsy subjects aged 15-49 years. Non-atherosclerotic intima and atherosclerotic intimal lesions were classified into four groups, i.e. diffuse intimal thickening, fatty infiltration, fatty streak, and PIT, and the number and density of macrophages and smooth muscle cells (SMCs) were determined. Components of the lesions and proliferative and apoptotic activities of macrophages and SMCs were investigated by immunohistochemistry and TUNEL assay.
   Results: Extracellular lipids accumulated mildly in the fatty infiltration and fatty streak, and abundantly in the PIT to form the lipid pool. The extracellular lipids co-localized with apolipoprotein B and fibrinogen. Macrophage foam cells accumulated in the fatty streak and PIT, but no TUNEL-positive macrophages were detected in any lesion. No significant difference in the number of SMCs was found between the four groups, but the density of SMCs decreased in the fatty streak and PIT. The decrease correlated with an increase in the number of macrophages, and the accumulation of extracellular lipids in the lipid pool. Neither Ki-67-positive nor TUNEL-positive SMCs were detected in any lesion.
   Conclusions: In PIT in human atherosclerosis, the lipid pool is formed by infiltration and deposition of plasma-derived lipids. Intimal SMCs are dispersed in association with macrophage infiltration and lipid pool formation without undergoing significant proliferation or death. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Nakagawa, Kazunori] Kyushu Univ, Grad Sch Med Sci, Pathophysiol & Expt Pathol, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
   [Nakashima, Yutaka] Japanese Red Cross Fukuoka Hosp, Div Pathol, Minami Ku, 3-1-1 Ogusu, Fukuoka, Fukuoka 8158555, Japan.
   [Nakashima, Yutaka] SRL Fukuoka Lab, 2-1-8 Naka, Fukuoka, Fukuoka 8160906, Japan.
RP Nakashima, Y (reprint author), SRL Fukuoka Lab, 2-1-8 Naka, Fukuoka, Fukuoka 8160906, Japan.
EM kazun@med.kyushu-u.ac.jp; yutaka.nakashima@miraca.com
FU JSPS KAKENHI GrantMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP26670177];
   Foundation for the Advancement of Clinical Medicine, Fukuoka, Japan
FX This work was supported by JSPS KAKENHI Grant Number JP26670177 (to
   K.N.) and by The Foundation for the Advancement of Clinical Medicine
   (2013-2014), Fukuoka, Japan (to Y.N.).
NR 35
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 235
EP 242
DI 10.1016/j.atherosclerosis.2018.03.039
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600034
PM 29622338
DA 2019-10-28
ER

PT J
AU Schmitz, B
   Nelis, P
   Rolfes, F
   Alnawaiseh, M
   Klose, A
   Kruger, M
   Eter, N
   Brand, SM
   Alten, F
AF Schmitz, Boris
   Nelis, Pieter
   Rolfes, Florian
   Alnawaiseh, Maged
   Klose, Andreas
   Krueger, Michael
   Eter, Nicole
   Brand, Stefan-Martin
   Alten, Florian
TI Effects of high-intensity interval training on optic nerve head and
   macular perfusion using optical coherence tomography angiography in
   healthy adults
SO ATHEROSCLEROSIS
LA English
DT Article
DE Optical coherence tomography angiography (OCTA); High-intensity interval
   training (HIIT); Ophthalmology; Retinal blood flow; Physical exercise
ID FOVEAL AVASCULAR ZONE; PHYSICAL-ACTIVITY; OCT; REPEATABILITY; DENSITY;
   REPRODUCIBILITY; TECHNOLOGY; EXERCISE; DISEASE; IMPACT
AB Background and aims: High-intensity interval training (HIIT) has been identified to be efficient for increasing health-related fitness in general and in lifestyle-induced chronic diseases such as hypertension, obesity and metabolic syndrome. This study aimed to evaluate HIIT effects on optic nerve head (ONH) and macular perfusion in healthy adults using optical coherence tomography angiography (OCTA).
   Methods: Fifty-eight healthy participants (22.0 +/- 2.02 years, 40 females (69.0%)) performed a 4-week HIIT with two exercise sessions/week: Group 1, 4 x 30 HIIT, running at maximal speed (all-out) for 4 x 30 s with 30 s active recovery, Group 2, 8 x 15 HIIT, running at maximal speed (all-out) for 8 x 15 s with 15 s active recovery. OCTA of the ONH and the macula was performed at baseline and follow-up to detect changes of the foveal avascular zone (FAZ). Flow density was evaluated in the superficial and deep plexus of the central macula, in the radial peripapillary capillary layer, the nerve head layer of the disc region and of the peripapillary region.
   Results: The mean deep FAZ area and flow density of the superficial layer decreased by 14.00 +/- 13.02% and 1.26 +/- 3.20%, respectively, in response to overall HIIT (pre vs. post p < 0.0001; p = 0.0041). The flow density of the nerve head layer in the peripapillary area showed an overall increase by 1.94 +/- 2.39% (pre vs post p < 0.0001). All other parameters showed no difference.
   Conclusions: HIIT may be performed to induce changes in ophthalmic measures such as FAZ and nerve head perfusion. OCTA imaging of the central retina and the ONH could represent a sensitive tool for the early detection of systemic vascular changes. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Schmitz, Boris; Rolfes, Florian; Brand, Stefan-Martin] Univ Hosp Muenster, Mol Genet Cardiovasc Dis, Inst Sports Med, Munster, Germany.
   [Nelis, Pieter; Alnawaiseh, Maged; Eter, Nicole; Alten, Florian] Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
   [Klose, Andreas; Krueger, Michael] Univ Munster, Dept Phys Educ & Sports Hist, Munster, Germany.
RP Alten, F (reprint author), Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM florian.alten@ukmuenster.de
RI Schmitz, Boris/M-3205-2019
OI Schmitz, Boris/0000-0001-7041-7424
FU BayerBayer AG
FX Florian Alten received travel grants from Bayer, Nicole Eter is a
   consultant to Heidelberg Engineering, Novartis, Bayer, Sanofi Aventis,
   Allergan, Bausch and Lomb.
NR 47
TC 5
Z9 5
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 8
EP 15
DI 10.1016/j.atherosclerosis.2018.04.028
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600002
PM 29747089
DA 2019-10-28
ER

PT J
AU Kostner, KM
   Kostner, GM
   Wierzbicki, AS
AF Kostner, Karam M.
   Kostner, Gert M.
   Wierzbicki, Anthony S.
TI Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate
SO ATHEROSCLEROSIS
LA English
DT Review
DE Lipoprotein (a); Epidemiology; Assay; Cardiovascular disease; Treatment
ID CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; APOA GENE-EXPRESSION;
   HUMAN ATHEROSCLEROTIC LESIONS; CARDIOVASCULAR RISK-FACTOR; AORTIC-VALVE
   STENOSIS; OXIDIZED PHOSPHOLIPIDS; PLASMA LIPOPROTEIN(A);
   MYOCARDIAL-INFARCTION; ARTERY-DISEASE
AB Lipoprotein (a) (Lp(a)) is a cholesterol-rich lipoprotein known since 1963. In spite of extensive research on Lp(a), there are still numerous gaps in our knowledge relating to its function, biosynthesis and catabolism. One reason for this might be that apo(a), the characteristic glycoprotein of Lp(a), is expressed only in primates. Results from experiments using transgenic animals therefore may need verification in humans. Studies on Lp(a) are also handicapped by the great number of isoforms of apo(a) and the heterogeneity of apo(a)-containing fractions in plasma. Quantification of Lp(a) in the clinical laboratory for a long time has not been standardized. Starting from its discovery, reports accumulated that Lp(a) contributed to the risk of cardiovascular disease (CVD), myocardial infarction (MI) and stroke. Early reports were based on case control studies but in the last decades a great deal of prospective studies have been published that highlight the increased risk for CVD and MI in patients with elevated Lp(a). Final answers to the question of whether Lp(a) is ready for wider clinical use will come from intervention studies with novel selective Lp(a) lowering medications that are currently underway. This article expounds arguments for and against this proposition from currently available data. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Kostner, Karam M.] Mater Hosp, Dept Cardiol, Brisbane, Qld, Australia.
   [Kostner, Karam M.] Univ Queensland, Brisbane, Qld, Australia.
   [Kostner, Gert M.] Med Univ Graz, Dept Mol Biol & Biochem, Gottfried Schatz Res Ctr Cell Signaling, Graz, Austria.
   [Wierzbicki, Anthony S.] Guys & St Thomas Hosp, Dept Metab Med Chem Pathol, London, England.
RP Wierzbicki, AS (reprint author), St Thomas Hosp, Dept Chem Pathol, Lambeth Palace Rd, London SE1 7EH, England.
EM Anthony.wierzbicki@kcl.ac.uk
OI Kostner, Gerhard/0000-0002-2615-6017
NR 91
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 16
EP 22
DI 10.1016/j.atherosclerosis.2018.04.032
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600003
PM 29747086
DA 2019-10-28
ER

PT J
AU Talbot, CPJ
   Plat, J
   Joris, PJ
   Konings, M
   Kusters, YHAM
   Schalkwijk, CG
   Ritsch, A
   Mensink, RP
AF Talbot, Charlotte P. J.
   Plat, Jogchum
   Joris, Peter J.
   Konings, Maurice
   Kusters, Yvo H. A. M.
   Schalkwijk, Casper G.
   Ritsch, Andreas
   Mensink, Ronald P.
TI HDL cholesterol efflux capacity and cholesteryl ester transfer are
   associated with body mass, but are not changed by diet-induced weight
   loss: A randomized trial in abdominally obese men
SO ATHEROSCLEROSIS
LA English
DT Article
DE High-density lipoprotein; Abdominal obesity; Diet-induced weight loss;
   Cholesterol efflux; CETP-Activity
ID DENSITY-LIPOPROTEIN CHOLESTEROL; TRANSFER PROTEIN CETP; C-REACTIVE
   PROTEIN; MESSENGER-RNA; NORMOLIPIDEMIC SUBJECTS; INSULIN-RESISTANCE;
   ADIPOSE-TISSUE; PLASMA; WOMEN; REDUCTION
AB Background and aims: Obesity is associated with a lower HDL-mediated cholesterol efflux from macrophages and a higher CETP (cholesteryl ester transfer protein) activity, but effects of weight loss are not clear. In addition, associations with visceral and subcutaneous adipose tissue are not known. We therefore investigated effects of diet-induced weight loss on HDL-mediated cholesterol efflux and cholesterol ester (CE) transfer in abdominally obese men. Differences between normal-weight and abdominally obese men were also examined.
   Methods: Twenty-five apparently healthy, normal-weight men (waist circumference: <94 cm) and 52 abdominally obese men (waist circumference: 102-110 cm) were included. Abdominally obese subjects were randomly allocated to a dietary weight-loss intervention group or a noeweight loss control group. Individuals from the intervention group followed a very-low-calorie diet for 6 weeks to obtain a waist circumference below 102 cm, followed by a 2-week weight-stable period. Cholesterol efflux was measured in BODIPY-labeled murine J774 macrophages. CE transfer was measured by quantifying the transfer of CE from radiolabeled exogenous HDL to apoB-containing lipoproteins.
   Results: Cholesterol efflux capacity was 9 percentage point (pp) lower in abdominally obese than in normal-weight men (p <= 0.001), while CE transfer was 5 pp higher (p <= 0.01). Diet-induced weight-loss of 10.3 kg did not change cholesterol efflux and CE transfer. In addition, stepwise regression analysis did not suggest that the different fat depots are differently related to efflux capacity and CE transfer.
   Conclusions: After a 2-week weight-stable period, dietary weight loss of 10 kg did not improve ABCA1-mediated cholesterol efflux and CE transfer in abdominally obese men. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Talbot, Charlotte P. J.; Plat, Jogchum; Joris, Peter J.; Konings, Maurice; Mensink, Ronald P.] Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Nutr & Movement Sci, Univ Singel 50, NL-6229 ER Maastricht, Netherlands.
   [Kusters, Yvo H. A. M.; Schalkwijk, Casper G.] Maastricht Univ, Med Ctr, Sch Cardiovasc Dis, Dept Internal Med,CARIM, Maastricht, Netherlands.
   [Ritsch, Andreas] Innsbruck Med Univ, Innsbruck, Austria.
RP Talbot, CPJ (reprint author), Maastricht Univ, NUTRIM Sch Nutr & Translat Res Metab, Dept Nutr & Movement Sci, Univ Singel 50, NL-6229 ER Maastricht, Netherlands.
EM c.talbot@maastrichtuniversity.nl
OI Ritsch, Andreas/0000-0002-0417-5161
FU TI Food and Nutrition [CH001, CH002]
FX The present study is funded by research grants CH001 and CH002 from TI
   Food and Nutrition, a public-private partnership on precompetitive
   research in food and nutrition. The public partners are responsible for
   the study design, data collection and analysis, decision to publish, and
   preparation of the manuscript. The private partners have contributed to
   the project through regular discussions.
NR 53
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 23
EP 28
DI 10.1016/j.atherosclerosis.2018.04.029
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600004
PM 29747087
DA 2019-10-28
ER

PT J
AU Blasco-Colmenares, E
   Moreno-Franco, B
   Latre, ML
   Mur-Vispe, E
   Pocovi, M
   Jarauta, E
   Civeira, F
   Laclaustra, M
   Casasnovas, JA
   Guallar, E
AF Blasco-Colmenares, Elena
   Moreno-Franco, Belen
   Latre, Montserrat Leon
   Mur-Vispe, Eusebio
   Pocovi, Miguel
   Jarauta, Estibaliz
   Civeira, Fernando
   Laclaustra, Martin
   Casasnovas, Jose A.
   Guallar, Eliseo
TI Sleep duration and subclinical atherosclerosis: The Aragon Workers'
   Health Study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Sleep duration; Self-reported sleep duration; Subclinical
   atherosclerosis; Coronary artery calcification; Carotid artery disease;
   Femoral artery disease
ID PHYSICAL-ACTIVITY QUESTIONNAIRE; INTIMA-MEDIA THICKNESS; EPIDEMIOLOGIC
   EVIDENCE; ARTERY-DISEASE; METAANALYSIS; CORONARY; RISK; ASSOCIATION;
   VALIDATION; QUALITY
AB Background and aims: Few studies have evaluated the association of sleep duration with subclinical atherosclerosis, and with heterogeneous findings. We evaluated the association of sleep duration with the presence of coronary, carotid, and femoral subclinical atherosclerosis in healthy middle-age men with low prevalence of clinical comorbidities.
   Methods: We performed a cross-sectional analysis of 1968 men, 40-60 years of age, participating in the Aragon Workers' Health Study (AWHS). Duration of sleep during a typical work week was assessed by questionnaire. Coronary artery calcium scores (CACS) was assessed by computed tomography and the presence of carotid plaque and femoral plaque by ultrasound.
   Results: In fully adjusted models, the odds ratios (95% CI) for CACS >0 comparing sleep durations of <= 5, 6, and >= 8 h with 7 h were 1.34 (0.98-1.85), 1.35 (1.08-1.69) and 1.21 (0.90-1.62), respectively (p = 0.04). A similar U-shaped association was observed for CACS >= 100 and for CACS. The corresponding odds ratios for the presence of at least one carotid plaque were <= 5, 6, and >= 8 h with 7 h were 1.23 (0.88-1.72), 1.09 (0.86-1.38), and 0.86 (0.63-1.17), respectively (p = 0.31), and for the presence of at least one femoral plaque were 1.25 (0.87-1.80), 1.19 (0.93-1.51) and 1.17 (0.86-1.61), respectively (p = 0.39).
   Conclusions: Middle-aged men reporting 7 h of sleep duration had the lowest prevalence of subclinical coronary atherosclerosis as assessed by CACs. Our results support that men with very short or very long sleep durations are at increased risk of atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Blasco-Colmenares, Elena; Guallar, Eliseo] Johns Hopkins Univ, Sch Med, Div Internal Med, Baltimore, MD USA.
   [Blasco-Colmenares, Elena; Guallar, Eliseo] Johns Hopkins Univ, Sch Med, Dept Med, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA.
   [Moreno-Franco, Belen; Latre, Montserrat Leon; Pocovi, Miguel; Jarauta, Estibaliz; Civeira, Fernando; Laclaustra, Martin; Casasnovas, Jose A.] Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon, CIBER Cardiovasc, Zaragoza, Spain.
   [Moreno-Franco, Belen; Latre, Montserrat Leon; Pocovi, Miguel; Civeira, Fernando; Casasnovas, Jose A.] Univ Zaragoza, Zaragoza, Spain.
   [Mur-Vispe, Eusebio] Opel Spain, Prevent Dept, Figueruelas, Spain.
   [Guallar, Eliseo] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Moreno-Franco, B (reprint author), Hosp Univ Miguel Servet, Inst Invest Sanitaria Aragon, CIBER Cardiovasc, Zaragoza, Spain.
EM mbmoreno@unizar.es
RI Lenguas, Jose Antonio Casasnovas/F-4038-2010; Laclaustra,
   Martin/C-6709-2015
OI Lenguas, Jose Antonio Casasnovas/0000-0002-9887-2629; Civeira,
   Fernando/0000-0001-7043-0952; Laclaustra, Martin/0000-0003-3963-0846
FU CIBER CV; Carlos III Research Institute [IIS16/0114, PI14/00009,
   PI13/02686]; European Regional Development Fund "Investing in your
   future"European Union (EU); Agencia Aragonesa para la Investigacion y el
   Desarrollo (ARAID)
FX This study was supported in part by CIBER CV and grants IIS16/0114,
   PI14/00009 and PI13/02686 from the Carlos III Research Institute
   (co-supported by the European Regional Development Fund "Investing in
   your future"). Martin Laclaustra research activity is funded by Agencia
   Aragonesa para la Investigacion y el Desarrollo (ARAID).
NR 32
TC 1
Z9 1
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 35
EP 40
DI 10.1016/j.atherosclerosis.2018.05.003
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600006
PM 29751282
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Humphries, SE
   Cooper, JA
   Seed, M
   Capps, N
   Durrington, PN
   Jones, B
   McDowell, IFW
   Soran, H
   Neil, HAW
AF Humphries, S. E.
   Cooper, J. A.
   Seed, M.
   Capps, N.
   Durrington, P. N.
   Jones, B.
   McDowell, I. F. W.
   Soran, H.
   Neil, H. A. W.
CA Simon Broome Familial Hyperlipida
TI Coronary heart disease mortality in treated familial
   hypercholesterolaemia: Update of the UK Simon Broome FH register
SO ATHEROSCLEROSIS
LA English
DT Article
DE Heterozygous familial hypercholesterolemia; Coronary mortality; Cancer
   mortality; Dutch lipid clinic network score
ID DENSITY-LIPOPROTEIN CHOLESTEROL; GENERAL-POPULATION; RISK; MUTATIONS;
   DIAGNOSIS; PLASMA; SPECTRUM; COHORT; SCORE
AB Background and aims: Patients with familial hypercholesterolaemia (FH) have an elevated risk of coronary heart disease (CHD). Here we compare changes in CHD mortality in patients with heterozygous (FH) pre 1992, before lipid-lowering therapy with statins was used routinely, and in the periods 1992-2008 and 2008-2016.
   Methods: 1903 Definite (DFH) and 1650 Possible (PFH) patients (51% women) aged 20-79 years, recruited from 21 lipid clinics in the United Kingdom and followed prospectively between 1980 and 2016 for 67,060 person-years. The CHD standardised mortality ratio (SMR) compared to the population in England and Wales was calculated (with 95% Confidence intervals).
   Results: There were 585 deaths, including 252 from CHD. Overall, the observed 2.4-fold excess coronary mortality for treated DFH post-1991 was significantly higher than the 1.78 excess for PFH (35% 95% CI 3%-76%). In patients with DFH and established coronary disease, there was a significant excess coronary mortality in all time periods, but in men it was reduced from a 4.83-fold excess (2.32-8.89) pre-1992 to 4.66 (3.46-6.14) in 1992-2008 and 2.51 (1.01-5.17) post-2008, while in women the corresponding values were 7.23 (2.65-15.73), 4.42 (2.70-6.82) and 6.34 (2.06-14.81). Primary prevention in men with DFH resulted in a progressive reduction in coronary mortality over the three time-periods, with no excess mortality evident post-2008 (0.89 (0.29-2.08)), although in women the excess persisted (post-2008 3.65 (1.75-6.72)).
   Conclusions: The results confirm the benefit of statin treatment in reducing CHD mortality, but suggest that FH patients with pre-existing CHD and women with FH may not be treated adequately. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Humphries, S. E.; Cooper, J. A.] UCL, Ctr Cardiovasc Genet, Inst Cardiovasc Sci, Univ St, London WC1E 6JJ, England.
   [Seed, M.] Univ London, Imperial Coll Fac Med, Dept Cardiol, Charing Cross Campus, London, England.
   [Capps, N.] Princess Royal Hosp, Shrewsbury & Telford Hosp NHS Trust, Dept Clin Biochem, Telford, Shrops, England.
   [Durrington, P. N.] Univ Manchester, Sch Clin & Lab Sci, Cardiovasc Res Grp, Manchester, Lancs, England.
   [Jones, B.] Imperial Coll London, Sect Invest Med, London, England.
   [McDowell, I. F. W.] Univ Hosp Wales, Dept Med Biochem & Immunol, Cardiff, S Glam, Wales.
   [Soran, H.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester, Lancs, England.
   [Neil, H. A. W.] Univ Oxford Wolfson Coll, Oxford, England.
RP Humphries, SE (reprint author), UCL, Cardiovasc Genet, BHF Labs, Inst Cardiovasc Sci, Rayne Bldg,5 Univ St, London WC1E 6JJ, England.
EM steve.humphries@ucl.ac.uk
OI Jones, Benjamin/0000-0003-0461-2584
FU Pfizer LtdPfizer; Astra ZenecaAstraZeneca; Schering-Plough Ltd.Merck &
   CompanySchering Plough Corporation; British Heart FoundationBritish
   Heart Foundation [RG3008, RG008/08]; NIHR Clinical Lectureship; UCLH
   NIHR BRC
FX The Simon Broome FH register was previously supported by an unrestricted
   educational grant from Pfizer Ltd, and has previously received support
   from Astra Zeneca and Schering-Plough Ltd. HAWN and SEH would like to
   acknowledge grants RG3008 and RG008/08 from the British Heart
   Foundation, BJ the support of an NIHR Clinical Lectureship and SEH the
   support of the UCLH NIHR BRC. The sponsors had no involvement in any
   aspect of the study or publication.
NR 26
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 41
EP 46
DI 10.1016/j.atherosclerosis.2018.04.040
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600007
PM 29751283
OA Green Published, Other Gold
DA 2019-10-28
ER

PT J
AU Fujino, Y
   Attizzani, GE
   Tahara, S
   Wang, W
   Takagi, K
   Naganuma, T
   Yabushita, H
   Tanaka, K
   Sato, T
   Watanabe, Y
   Mitomo, S
   Kurita, N
   Ishiguro, H
   Nakamura, S
   Hozawa, K
   Bezerra, HG
   Yamagishi, S
   Nakamura, S
AF Fujino, Yusuke
   Attizzani, Guilherme E.
   Tahara, Satoko
   Wang, Wei
   Takagi, Kensuke
   Naganuma, Toru
   Yabushita, Hiroto
   Tanaka, Kentaro
   Sato, Tomohiko
   Watanabe, Yusuke
   Mitomo, Satoru
   Kurita, Naoyuki
   Ishiguro, Hisaaki
   Nakamura, Shotaro
   Hozawa, Koji
   Bezerra, Hiram G.
   Yamagishi, Sho-ichi
   Nakamura, Sunao
TI Association of skin autofluorescence with plaque vulnerability evaluated
   by optical coherence tomography in patients with cardiovascular disease
SO ATHEROSCLEROSIS
LA English
DT Article
DE Optical coherence tomography; Advanced glycation end products;
   Cardiovascular disease; Skin autofluorescence
ID GLYCATION END-PRODUCTS; VASCULAR COMPLICATIONS; ARTERY-DISEASE; PLASMA
AB Background and aims: Accumulation of advanced glycation end products (AGEs)can be measured non-invasively by skin autofluorescence (SAF) whose values are elevated in patients with cardiovascular disease (CVD). Optical coherence tomography (OCT) is an intravascular imaging modality that could allow visualization of plaque composition. We aim to examine the relationship between SAF and plaque composition evaluated by frequency-domain OCT in patients with CVD.
   Methods: We prospectively enrolled 108 patients with CVD, who underwent OCT images during percutaneous coronary intervention (PCI). We divided the population into two groups: high SAF group (greater than or equal to 2.6) and low SAF one (less than 2.6). OCT findings were then compared between high and low SAF groups.
   Results: The high SAF group showed much more thin cap fibroatheroma (TCFA), and calcified or ruptured plaques compared to the low SAF group. In multivariable analysis, low-density lipoprotein-cholesterol (LDL) (odds ratio: 1.15; 95% confidence interval: 1.00 to 1.32; p = 0.043), TG (OR for 10 mg/dl increase: 1.04; 95% confidence interval: 1.01 to 1.13; p = 0.016), and SAF (4.28; 1.86 to 9.84; p < 0.001) were independent correlates of TCFA, whereas SAF (2.61; 1.02 to 6.70; p = 0.047), estimated glomerular filtration rate (0.68; 0.49 to 0.93; p = 0.017) and LDL (1.19; 1.01 to 1.41; p = 0.037) were independent predictors of ruptured plaques. SAF and diabetes were independently associated with calcified plaques.
   Conclusions: High SAF were associated with plaque vulnerability in patients with CVD, thus suggesting the clinical utility of SAF measurement in identifying high-risk patients for future cardiovascular events. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Fujino, Yusuke; Tahara, Satoko; Takagi, Kensuke; Naganuma, Toru; Yabushita, Hiroto; Tanaka, Kentaro; Sato, Tomohiko; Watanabe, Yusuke; Mitomo, Satoru; Kurita, Naoyuki; Ishiguro, Hisaaki; Nakamura, Shotaro; Hozawa, Koji; Nakamura, Sunao] New Tokyo Hosp, Dept Cardiol, 1270 Wanagaya, Matsudo, Chiba 2702232, Japan.
   [Attizzani, Guilherme E.; Bezerra, Hiram G.] Case Western Reserve Univ, Harrington Heart & Vasc Inst, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
   [Wang, Wei] Univ Mississippi, Med Ctr, Ctr Biostat & Bioinformat, Jackson, MS 39216 USA.
   [Yamagishi, Sho-ichi] Kurume Univ, Sch Med, Dept Pathophysiol & Therapeut Diabet Vasc Complic, Kurume, Fukuoka, Japan.
RP Fujino, Y (reprint author), New Tokyo Hosp, Dept Cardiol, 1270 Wanagaya, Matsudo, Chiba 2702232, Japan.
EM yusuke.fujina1979@gmail.com
OI Yabushita, Hiroto/0000-0003-0440-024X
NR 36
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 47
EP 53
DI 10.1016/j.atherosclerosis.2018.03.001
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600008
PM 29751284
DA 2019-10-28
ER

PT J
AU Weng, S
   Kai, J
   Tranter, J
   Leonardi-Bee, J
   Qureshi, N
AF Weng, Stephen
   Kai, Joe
   Tranter, Jennifer
   Leonardi-Bee, Jo
   Qureshi, Nadeem
TI Improving identification and management of familial
   hypercholesterolaemia in primary care: Pre- and post-intervention study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Primary health care; Familial hypercholesterolaemia; Family health;
   Medical genetics
ID CORONARY-HEART-DISEASE; RISK-ASSESSMENT; HISTORY; TOOL; DEPRIVATION;
   GUIDANCE
AB Background and aims: Familial hypercholesterolaemia (FH) is a major cause of premature heart disease but remains unrecognised in most patients. This study investigated if a systematic primary care-based approach to identify and manage possible FH improves recommended best clinical practice.
   Methods: Pre- and post-intervention study in six UK general practices (population 45,033), which invited patients with total cholesterol >7.5 mmol/L to be assessed for possible FH. Compliance with national guideline recommendations to identify and manage possible FH (repeat cholesterol; assess family history of heart disease; identify secondary causes and clinical features; reduce total & LDL-cholesterol; statin prescribing; lifestyle advice) was assessed by calculating the absolute difference in measures of care pre- and six months post-intervention.
   Results: The intervention improved best clinical practice in 118 patients consenting to assessment (of 831 eligible patients): repeat cholesterol test (+75.4%, 95% CI 66.9-82.3); family history of heart disease assessed (+35.6%, 95% CI 27.0-44.2); diagnosis of secondary causes (+7.7%, 95% CI 4.1-13.9), examining clinical features (+6.0%, 95% CI 2.9-11.7). For 32 patients diagnosed with possible FH using Simon-Broome criteria, statin prescription significantly improved (18.8%, 95% CI 8.9-35.3), with nonsignificant mean reductions in cholesterol post-intervention (total: -0.16 mmol/L, 95% CI -0.78-0.46; LDL: -0.12 mmol/L, 95% CI -0.81-0.57).
   Conclusions: Within six months, this simple primary care intervention improved both identification and management of patients with possible FH, in line with national evidence-based guidelines. Replicating and sustaining this approach across the country could lead to substantial improvement in health outcomes for these individuals with very high cardiovascular risk. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Weng, Stephen; Kai, Joe; Tranter, Jennifer; Qureshi, Nadeem] Univ Nottingham, Sch Med, NIHR Sch Primary Care Res, Div Primary Care, Nottingham, England.
   [Leonardi-Bee, Jo] Univ Nottingham, Sch Med, Div Epidemiol & Publ Hlth, Nottingham, England.
RP Weng, S (reprint author), Univ Nottingham, Div Primary Care, 1403 Tower,Univ Pk, Nottingham NG7 2RD, England.
EM stephen.weng@nottingham.ac.uk
OI Qureshi, Nadeem/0000-0003-4909-0644; Kai, Joe/0000-0001-9040-9384; Weng,
   Stephen/0000-0002-5281-9590
FU Division of Primary, University of Nottingham; National Institute for
   Health Research School of Primary Care Research [NIHR-SPCR FR2-95]
FX This work was supported by the Division of Primary, University of
   Nottingham and funded by National Institute for Health Research School
   of Primary Care Research (NIHR-SPCR FR2-95).
NR 33
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 54
EP 60
DI 10.1016/j.atherosclerosis.2018.04.037
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600009
PM 29751285
OA Green Accepted
DA 2019-10-28
ER

PT J
AU do Vale, GT
   Simplicio, JA
   Gonzaga, NA
   Yokota, R
   Ribeiro, AA
   Casarini, DE
   de Martinis, BS
   Tirapelli, CR
AF do Vale, Gabriel T.
   Simplicio, Janaina A.
   Gonzaga, Natalia A.
   Yokota, Rodrigo
   Ribeiro, Amanda A.
   Casarini, Dulce E.
   de Martinis, Bruno S.
   Tirapelli, Carlos R.
TI Nebivolol prevents vascular oxidative stress and hypertension in rats
   chronically treated with ethanol
SO ATHEROSCLEROSIS
LA English
DT Article
DE Ethanol; Nebivolol; Hypertension; beta 1-adrenergic receptors; Oxidative
   stress
ID OXYGEN SPECIES GENERATION; SMOOTH-MUSCLE-CELLS; REDUCES VENTRICULAR
   HYPERTROPHY; ANGIOTENSIN TYPE-1 RECEPTOR; NITRIC-OXIDE SYNTHASE;
   ALCOHOL-CONSUMPTION; BLOOD-PRESSURE; DENSITY-LIPOPROTEIN; ACTIVATION;
   MECHANISMS
AB Background and aims: Chronic ethanol consumption is associated with hypertension and atherosclerosis. Vascular oxidative stress is described as an important mechanism whereby ethanol predisposes to atherosclerosis. We hypothesized that nebivolol would prevent ethanol-induced hypertension and vascular oxidative stress.
   Methods: Male Wistar rats were treated with ethanol 20% (vol./vol.) or nebivolol (10 mg/kg/day, p. o., gavage), a selective beta(1)-adrenergic receptor antagonist.
   Results: Ethanol-induced increase in blood pressure and in the circulating levels of adrenaline and noradrenaline was prevented by nebivolol. Similarly, nebivolol prevented ethanol-induced increase in plasma levels of renin, angiotensin I and II. Chronic ethanol consumption increased the aortic levels of superoxide anion (O-2(-)), thiobarbituric acid reactive species (TBARS) as well as the expression of Nox1 and nitrotyrosine immunostaining in the rat aorta. Treatment with nebivolol prevented these responses. The decrease in aortic levels of nitrate/nitrite (NOx) induced by ethanol was prevented by the treatment with nebivolol. Finally, nebivolol attenuated ethanol-induced increase in phenylephrine- and noradrenaline-induced contraction of endothelium-intact and endothelium-denuded aortic rings.
   Conclusions: The novelty of our study is that nebivolol prevented ethanol-induced hypertension and vascular oxidative stress. Additionally, we showed that the sympathetic nervous system (SNS) and the renin-angiotensin system (RAS) are important endogenous mediators of the cardiovascular effects of ethanol. (C) 2018 Elsevier B.V. All rights reserved.
C1 [do Vale, Gabriel T.; Simplicio, Janaina A.; Gonzaga, Natalia A.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Pharmacol, Ribeirao Preto, SP, Brazil.
   [Yokota, Rodrigo; Ribeiro, Amanda A.; Casarini, Dulce E.] Univ Fed Sao Paulo, Div Nephrol, Dept Med, Sao Paulo, Brazil.
   [de Martinis, Bruno S.] Univ Sao Paulo, Dept Chem, Fac Philosophy Sci & Letters Ribeirao Preto, Sao Paulo, Brazil.
   [do Vale, Gabriel T.; Simplicio, Janaina A.; Gonzaga, Natalia A.; Tirapelli, Carlos R.] Univ Sao Paulo, Sch Nursing Ribeirao Preto, Lab Pharmacol, Dept Psychiat Nursing & Human Sci, Sao Paulo, Brazil.
RP Tirapelli, CR (reprint author), Univ Sao Paulo, Escola Enfermagem Ribeirao Preto, Lab Farmacol, Ave Bandeirantes 3900, BR-14040 Ribeirao Preto, SP, Brazil.
EM crtirapelli@eerp.usp.br
RI De Martinis, Bruno/I-5388-2012; Vale, Gabriel/O-2695-2017; Gonzaga,
   Natalia/D-6517-2017
OI De Martinis, Bruno/0000-0002-2702-5190; Vale,
   Gabriel/0000-0002-8626-9240; Gonzaga, Natalia/0000-0003-1511-3318;
   Yokota, Rodrigo/0000-0002-1778-2278; Casarini, Dulce/0000-0003-1912-4292
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [302981/2013-6]; Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2015/22046-8]
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brazil (grant number 302981/2013-6) and
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Brazil (grant
   number 2015/22046-8).
NR 50
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 67
EP 76
DI 10.1016/j.atherosclerosis.2018.04.041
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600011
PM 29753230
DA 2019-10-28
ER

PT J
AU Pedard, M
   Quirie, A
   Totoson, P
   Verhoeven, F
   Gamier, P
   Tessier, A
   Demougeot, C
   Marie, C
AF Pedard, Martin
   Quirie, Aurore
   Totoson, Perle
   Verhoeven, Frank
   Gamier, Philippe
   Tessier, Anne
   Demougeot, Celine
   Marie, Christine
TI Vascular brain-derived neurotrophic factor pathway in rats with
   adjuvant-induced arthritis: Effect of anti-rheumatic drugs
SO ATHEROSCLEROSIS
LA English
DT Article
DE Vascular BDNF; Adjuvant-induced arthritis; Anti-rheumatic drugs
ID IMPROVES ENDOTHELIAL FUNCTION; NERVE GROWTH-FACTOR;
   RHEUMATOID-ARTHRITIS; CARDIOVASCULAR RISK; TNF-ALPHA; BDNF; DYSFUNCTION;
   RECEPTORS; DISEASE; TRKB
AB Background and aims: In rheumatoid arthritis, the control of both disease activity and standard cardiovascular (CV) risk factors is expected to attenuate the increased CV risk. Evidence that brain-derived neurotrophic factor (BDNF) plays a role in vascular biology led us to investigate the vascular BDNF pathway in arthritis rats as well as the interaction between endothelial nitric oxide (NO) and BDNF production.
   Methods: The aortic BDNF pathway was studied in rats with adjuvant-induced arthritis, (AIA) using Western blot and immunohistochemical analysis. Control of arthritis score was achieved by administration (for 3 weeks) of an equipotent dosage of etanercept, prednisolone, methotrexate, celecoxib or diclofenac. Aortas were exposed to an NO donor or an NO synthase inhibitor and vasoreactivity experiments were performed using LM22A-4 as a TrkB agonist.
   Results: Vascular BDNF and full length tropomyosin-related kinase B receptor (TrkB-FL) were higher in AIA than in control rats. These changes coincided with decreased endothelial immunoreactivity in BDNF and pTrkBtyr816 and were disconnected from arthritis score. Among anti-rheumatic drugs, only prednisolone and methotrexate prevented AIA-induced vascular BDNF loss. The effect of AIA on aortic BDNF levels was reversed by an NO donor and reproduced by an NOS inhibitor. Finally, LM22A-4 induced both NO-dependent vasodilation and phosphorylation of endothelial NO synthase at serine 1177.
   Conclusions: Our study identified changes in the BDNF/TrkB pathway as a disease activity-independent component of AIA-associated changes in endothelial phenotype. It provides new perspectives in the understanding and management of the high CV risk reported in rheumatoid arthritis. (C) 2018 Elsevier B. V. All rights reserved.
C1 [Pedard, Martin; Quirie, Aurore; Gamier, Philippe; Tessier, Anne; Marie, Christine] Univ Bourgogne Franche Comte, UFR Sci Sante, INSERM CAPS UMR1093, F-21000 Dijon, France.
   [Pedard, Martin] CHRU, Serv Neurol, Dijon, France.
   [Totoson, Perle; Verhoeven, Frank; Demougeot, Celine] Univ Bourgogne Franche Comte, PEPITE EA4267, FHU INCREASE, F-25030 Besancon, France.
RP Marie, C (reprint author), INSERM U1093, FR Sci Sante, 7 Blvd Jeanne dArc, F-21000 Dijon, France.
EM chmarie@u-bourgogne.fr
RI ; PEDARD, Martin/G-7477-2018
OI Garnier, Philippe/0000-0002-7877-3113; QUIRIE,
   Aurore/0000-0002-8926-1834; Verhoeven, Frank/0000-0003-2708-2918;
   PEDARD, Martin/0000-0003-1258-7825; tessier, anne/0000-0001-6655-5074;
   marie, christine/0000-0003-3724-0713
FU Universities of Bourgogne; INSERMInstitut National de la Sante et de la
   Recherche Medicale (Inserm); Franche Comte
FX This work was supported by funding from the Universities of Bourgogne
   and Franche Comte and INSERM.
NR 43
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 77
EP 85
DI 10.1016/j.atherosclerosis.2018.05.004
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600012
PM 29753231
DA 2019-10-28
ER

PT J
AU Ding, N
   Kwak, L
   Ballew, SH
   Jaar, B
   Hoogeveen, RC
   Ballantyne, CM
   Sharrett, AR
   Folsom, AR
   Heiss, G
   Salameh, M
   Coresh, J
   Hirsch, AT
   Selvin, E
   Matsushita, K
AF Ding, Ning
   Kwak, Lucia
   Ballew, Shoshana H.
   Jaar, Bernard
   Hoogeveen, Ron C.
   Ballantyne, Christie M.
   Sharrett, A. Richey
   Folsom, Aaron R.
   Heiss, Gerardo
   Salameh, Maya
   Coresh, Josef
   Hirsch, Alan T.
   Selvin, Elizabeth
   Matsushita, Kunihiro
TI Traditional and nontraditional glycemic markers and risk of peripheral
   artery disease: The Atherosclerosis Risk in Communities (ARIC) study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Peripheral artery disease; Diabetes; Glycemic markers; Foot care
ID GLYCATED ALBUMIN; MICROVASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE;
   DIABETIC CONTROL; KIDNEY-FUNCTION; FRUCTOSAMINE; MORTALITY;
   1,5-ANHYDROGLUCITOL; GLUCOSE; HYPERGLYCEMIA
AB Background and aims: Traditional glycemic markers, fasting glucose and hemoglobin A1c (HbA1c), predict incident peripheral artery disease (PAD). However, it is unknown whether nontraditional glycemic markers, fructosamine, glycated albumin, and 1,5-anhydroglucitol, are associated with PAD and whether these glycemic markers demonstrate particularly strong associations with severe PAD, critical limb ischemia (CLI).
   Methods: We quantified the associations of these five glycemic markers with incident PAD (hospitalizations with PAD diagnosis or leg revascularization) in 11,634 ARIC participants using Cox regression models. Participants were categorized according to diabetes diagnosis and clinical cut-points of glycemic markers (nontraditional glycemic markers were categorized according to percentiles corresponding to the HbA1c cut-points).
   Results: Over a median follow-up of 20.7 years, there were 392 cases of PAD (133 were CLI with tissue loss). HbA1c was more strongly associated with incident PAD than fasting glucose, with adjusted hazard ratios (HR) 6.00 (95% CI, 3.73-9.66) for diagnosed diabetes with HbA1c >= 7% and 3.53 (2.39-5.22) for no diagnosed diabetes with HbA1c >= 6.5% compared to no diagnosed diabetes with HbA1c <5.7%. Three nontraditional glycemic markers demonstrated risk gradients intermediate between HbA1c and fasting glucose and their risk gradients were substantially attenuated after adjusting for HbA1c. All glycemic markers consistently demonstrated stronger associations with CLI than PAD without CLI (p for difference <0.02 for all glycemic markers).
   Conclusions: Nontraditional glycemic markers were associated with incident PAD independent of fasting glucose but not necessarily HbA1c. Our results also support the importance of glucose metabolism in the progression to CLI. (C) 2018 Elsevier B. V. All rights reserved.
C1 [Ding, Ning; Kwak, Lucia; Ballew, Shoshana H.; Jaar, Bernard; Sharrett, A. Richey; Coresh, Josef; Selvin, Elizabeth; Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Jaar, Bernard; Salameh, Maya; Coresh, Josef; Selvin, Elizabeth; Matsushita, Kunihiro] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Hoogeveen, Ron C.; Ballantyne, Christie M.] Baylor Coll Med, Houston, TX 77030 USA.
   [Folsom, Aaron R.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA.
   [Heiss, Gerardo] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
   [Hirsch, Alan T.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.
RP Matsushita, K (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.
EM kmatsus5@jhu.edu
OI Ballew, Shoshana/0000-0002-7547-3764; Jaar, Bernard/0000-0003-1210-7115;
   Hoogeveen, Ron/0000-0003-2399-4653
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R21HL133694]; Federal
   funds from the National Heart, Lung, and Blood Institute, National
   Institutes of Health, Department of Health and Human Services
   [HHSN268201700001I, HHSN 268201700003I, HHSN268201700005I,
   HHSN268201700004I, HHSN2682017000021]
FX K.M. was supported by a grant from the National Heart, Lung, and Blood
   Institute (R21HL133694). The Atherosclerosis Risk in Communities study
   has been funded in whole or in part with Federal funds from the National
   Heart, Lung, and Blood Institute, National Institutes of Health,
   Department of Health and Human Services, under Contract nos.
   (HHSN268201700001I, HHSN 268201700003I, HHSN268201700005I,
   HHSN268201700004I, HHSN2682017000021).
NR 44
TC 2
Z9 3
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 86
EP 93
DI 10.1016/j.atherosclerosis.2018.04.042
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600013
PM 29753232
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Dong, SY
   Yan, ST
   Wang, ML
   Li, ZB
   Fang, LQ
   Zeng, Q
AF Dong, Sheng-Yong
   Yan, Shuang-Tong
   Wang, Man-Liu
   Li, Zhi-Bing
   Fang, Lian-Qing
   Zeng, Qiang
TI Associations of body weight and weight change with cardiovascular events
   and mortality in patients with coronary heart disease
SO ATHEROSCLEROSIS
LA English
DT Article
DE Coronary heart disease; Body weight; Obesity; Weight change; Mortality;
   Cardiovascular event
ID MASS INDEX; ARTERY-DISEASE; PROGNOSTIC IMPORTANCE; OBESITY PARADOX;
   OLDER-ADULTS; ALL-CAUSE; OVERWEIGHT; OUTCOMES; RISK; MEN
AB Background and aims: It is recommended that patients with coronary heart disease (CHD) pursue a normal body weight, while the effects of body weight and weight change on prognosis are still controversial. The present study was to assess these effects using a large-scale population with CHD in China.
   Methods: A total of 5276 patients with CHD were included from Jan 2000 to Dec 2014. Baseline and endpoint weights were measured. Outcomes including mortality and cardiovascular events were obtained.
   Results: Relative to patients with normal weight, risks for adverse outcomes were lowest in overweight patients and similar in obese patients. Hazard ratios (HRs) and 95% confidence interval (95% CI) for allcause death were 1.42 (1.06, 1.91) if overweight turned into normal weight and were 2.01 (1.28, 3.16) or 5.33 (2.81, 10.1) if obese turned into overweight or normal weight. Death risk increased with the extent of weight loss and moderate or large weight gain (p<0.05 for all). Similar results were found when risks for cardiovascular mortality and events were considered. Furthermore, these results remained significant when the patients were stratified by several covariates and even when several definitions of weight change were considered.
   Conclusions: Obesity did not increase adverse outcome risks in patients with CHD. Both weight loss and weight gain increased adverse outcome risks regardless of baseline body weight. The findings suggest that maintaining a stable weight may be a better strategy for the reduction of risks for cardiovascular outcomes and all-cause death in patients with CHD. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Dong, Sheng-Yong; Fang, Lian-Qing] PLA, Healthcare Dept, Agcy Off Adm, 2 Aimin St, Beijing 100034, Peoples R China.
   [Yan, Shuang-Tong; Li, Zhi-Bing] Chinese Peoples Liberat Army Gen Hosp, Dept Geriatr Endocrinol, Beijing 100853, Peoples R China.
   [Wang, Man-Liu] Peking Univ Tsinghua Univ Joint Ctr Life Sci, Beijing, Peoples R China.
   [Wang, Man-Liu] Peking Univ, Adv Acad Interdisciplinary Sci, Beijing 100871, Peoples R China.
   [Zeng, Qiang] Chinese Peoples Liberat Army Gen Hosp, Hlth Management Inst, 28 Fuzing Rd, Beijing 100853, Peoples R China.
RP Dong, SY (reprint author), PLA, Healthcare Dept, Agcy Off Adm, 2 Aimin St, Beijing 100034, Peoples R China.; Zeng, Q (reprint author), Chinese Peoples Liberat Army Gen Hosp, Hlth Management Inst, 28 Fuzing Rd, Beijing 100853, Peoples R China.
EM dsynh@126.com; zq301@126.com
NR 42
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 104
EP 111
DI 10.1016/j.atherosclerosis.2018.05.007
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600015
PM 29763769
DA 2019-10-28
ER

PT J
AU Lindbohm, J
   Korja, M
   Jousilahti, P
   Salomaa, V
   Kaprio, J
AF Lindbohm, Joni
   Korja, Miikka
   Jousilahti, Pekka
   Salomaa, Veikko
   Kaprio, Jaakko
TI Adverse lipid profile elevates risk for subarachnoid hemorrhage: A
   prospective population-based cohort study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Subarachnoid hemorrhage; Lipid profile; Epidemiology; Risk factors;
   Missing data
ID DENSITY-LIPOPROTEIN CHOLESTEROL; SACCULAR INTRACRANIAL ANEURYSM;
   HOSPITAL DISCHARGE REGISTER; MYOCARDIAL-INFARCTION; SERUM-LIPIDS;
   STROKE; MORTALITY; RUPTURE; DEATH; APOLIPOPROTEINS
AB Background and aims: Studies report that both high and low total cholesterol (TC) elevates SAH risk. There are few prospective studies on high-density lipoproteins (HDL-C) and low-density lipoproteins (LDL-C), and apparently none concerns apolipoproteins A and B. We aimed to clarify the association between lipid profile and SAH risk.
   Methods: The National FINRISK study provided risk-factor data recorded at enrolment between 1972 and 2007. During 1.52 million person-years of follow-up until 2014, 543 individuals suffered from incident hospitalized SAH or outside-hospital-fatal SAH. Cox proportional hazards model was used to calculate the hazard ratios and multiple imputation predicted ApoA1, ApoB, and LDL-C values for cohorts from a time before apolipoprotein-measurement methods were available.
   Results: One SD elevation (1.28 mmol/l) in TC elevated SAH risk in men (hazard ratio (HR) 1.15 (95% CIs 1.00-1.32)). Low HDL-C levels increased SAH risk, as each SD decrease (0.37 mmol/l) in HDL-C raised the risk in women (HR 1.29 (95% CIs 1.07-1.55)) and men (HR 1.20 (95% CIs 1.14-1.27)). Each SD increase (0.29 g/l) in ApoA1 decreased SAH risk in women (HR 0.85 (95% CIs 0.74-0.97)) and men (HR 0.88 (95% CIs 0.76-1.02)). LDL-C (SD 1.07 mmol/l) and ApoB (SD 0.28 g/l) elevated SAH risk in men with HR 1.15 (95% CIs 1.01-1.31) and HR 1.26 (95% CIs 1.10-1.44) per one SD increase. Age did not change these findings.
   Conclusions: An adverse lipid profile seems to elevate SAH risk similar to its effect in other cardiovascular diseases, especially in men. Whether SAH incidence diminishes with increasing statin use remains to be studied. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lindbohm, Joni; Kaprio, Jaakko] Univ Helsinki, Dept Publ Hlth, POB 20, FI-00014 Helsinki, Finland.
   [Lindbohm, Joni; Korja, Miikka] Univ Helsinki, Dept Neurosurg, POB 266, FI-00029 Helsinki, Finland.
   [Lindbohm, Joni; Korja, Miikka] Helsinki Univ Hosp, POB 266, FI-00029 Helsinki, Finland.
   [Kaprio, Jaakko] Inst Mol Med FIMM, POB 20, FI-00014 Helsinki, Finland.
   [Jousilahti, Pekka; Salomaa, Veikko] Natl Inst Hlth & Welf, Dept Hlth, POB 30, FI-00271 Helsinki, Finland.
RP Lindbohm, J (reprint author), Univ Helsinki, Dept Publ Hlth, POB 20, FI-00014 Helsinki, Finland.
EM joni.lindbohm@helsinki.fi
RI ; Korja, Miikka/E-4292-2016
OI Kaprio, Jaakko/0000-0002-3716-2455; Korja, Miikka/0000-0002-4463-6954
FU Department of Public Health at the University of Helsinki; Maire Taponen
   foundation; Ahvenainen foundation; Yrjo Jahnsson foundation; Academy of
   FinlandAcademy of Finland [265240, 263278]
FX This work was supported by the Department of Public Health at the
   University of Helsinki. JVL would like to thank the Maire Taponen, the
   Ahvenainen, and the Yrjo Jahnsson foundations for research grants.
   Jaakko Kaprio has been supported by the Academy of Finland (grants
   265240 & 263278). These foundations and funders played no role in
   conducting research or in data analysis.
NR 47
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 112
EP 119
DI 10.1016/j.atherosclerosis.2018.05.011
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600016
PM 29772479
OA Green Published
DA 2019-10-28
ER

PT J
AU Zhang, YZ
   Wang, L
   Zhang, JJ
   Xiong, XM
   Zhang, D
   Tang, XM
   Luo, XJ
   Ma, QL
   Peng, J
AF Zhang, Yin-Zhuang
   Wang, Lei
   Zhang, Jie-Jie
   Xiong, Xiao-Ming
   Zhang, Di
   Tang, Xuan-Meng
   Luo, Xiu-Ju
   Ma, Qi-Lin
   Peng, Jun
TI Vascular peroxide 1 promotes ox-LDL-induced programmed necrosis in
   endothelial cells through a mechanism involving beta-catenin signaling
SO ATHEROSCLEROSIS
LA English
DT Article
DE Vascular peroxide 1; Programmed necrosis; Endothelium; Hyperlipidemia;
   beta-Catenin
ID REGULATED NECROSIS; INDUCED SENESCENCE; HYPERTENSIVE-RATS; NECROPTOSIS;
   ATHEROSCLEROSIS; DYSFUNCTION; APOPTOSIS; DISEASE; DEATH; INFLAMMATION
AB Background and aims: Vascular peroxidase 1 (VPO1) plays a key role in mediation of cardiovascular oxidative injury. This study aims to determine whether VPO1 can promote programmed necrosis of endothelial cells and the underlying mechanisms.
   Methods and results: Human umbilical vein endothelial cells (HUVECs) were incubated with oxidized low-density lipoprotein (ox-LDL, 100 mu g/mL) for 48 h to induce cell injury, which showed an elevation in cell necrosis (reflected by the increased propidium iodide (PI) positive-staining cells, LDH release and decreased cell viability), concomitant with an increase in programmed necrosis-relevant proteins including receptor-interacting protein kinase 1/3 (RIPK1/3), p-RIPK3 and mixed lineage kinase domain like (MLKL); these phenomena were attenuated by necrostatin-1(Nec-1) and RIPK3 siRNA. Meanwhile, VP01 was up-regulated in ox-LDL-treated endothelial cells accompanied by a decrease in GSK-3 beta activity and p-beta-catenin levels, and an elevation of beta-catenin levels; these phenomena were reversed in the presence of VP01 siRNA or hypochlorous acid (HOCI) inhibitor; replacement of ox-LDL with HOCI could also induce endothelial programmed necrosis and activate the beta-catenin signaling; beta-catenin inhibitor could also suppress ox-LDL-induced RIPK-dependent necrosis. In hyperlipidemic patients, the plasma level of VP01 was obviously increased concomitant with an elevation in plasma levels of RIPK1, RIPK3 and MLKL, and they were positively correlated.
   Conclusions: VP01 plays an important role in promotion of endothelial programmed necrosis under hyperlipidemic conditions through activation of beta-catenin signaling. It may serve as a novel therapeutic target for prevention of endothelial dysfunction in hyperlipidemia. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zhang, Yin-Zhuang; Wang, Lei; Ma, Qi-Lin] Cent S Univ, Xiangya Hosp, Dept Cardiovasc Med, Changsha 410008, Hunan, Peoples R China.
   [Zhang, Jie-Jie; Xiong, Xiao-Ming; Peng, Jun] Cent S Univ, Dept Pharmacol, Xiangya Sch Pharmaceut Sci, Changsha 410078, Hunan, Peoples R China.
   [Zhang, Di] Cent S Univ, Xiangya Hosp 3, Dept Lab Med, Changsha 410013, Hunan, Peoples R China.
   [Tang, Xuan-Meng; Luo, Xiu-Ju] Cent S Univ, Xiangya Sch Med, Dept Lab Med, Changsha 410013, Hunan, Peoples R China.
   [Peng, Jun] Cent S Univ, Sch Pharmaceut Sci, Hunan Prov Key Lab Cardiovasc Res, Changsha 410078, Hunan, Peoples R China.
RP Ma, QL (reprint author), Cent S Univ, Xiangya Hosp, Dept Cardiovasc Med, Changsha 410008, Hunan, Peoples R China.; Peng, J (reprint author), Cent S Univ, Dept Pharmacol, Xiangya Sch Pharmaceut Sci, Changsha 410078, Hunan, Peoples R China.
EM mqilin2004@163.com; Junpeng@csu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81370250, 81373409]; Major Research Plan of the
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91439104]; Foundation of China Hunan Provincial
   Science and Technology Department [2015SK2027]
FX This work was supported by National Natural Science Foundation of China
   (No. 81370250 to Qi-Lin Ma; No. 81373409 to Jun Peng), the Major
   Research Plan of the National Natural Science Foundation of China (No.
   91439104 to Jun Peng), Foundation of China Hunan Provincial Science and
   Technology Department (No. 2015SK2027).
NR 35
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 128
EP 138
DI 10.1016/j.atherosclerosis.2018.04.031
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600018
PM 29772481
DA 2019-10-28
ER

PT J
AU Zhu, ZB
   Zhong, CK
   Xu, T
   Wang, AL
   Peng, YB
   Xu, T
   Peng, H
   Chen, CS
   Wang, JC
   Li, QW
   Geng, DQ
   Sun, YX
   Li, YQ
   Zhang, YH
   He, J
AF Zhu, Zhengbao
   Zhong, Chongke
   Xu, Tian
   Wang, Aili
   Peng, Yanbo
   Xu, Tan
   Peng, Hao
   Chen, Chung-Shivan
   Wang, Jinchao
   Li, Qunwei
   Geng, Deqin
   Sun, Yingxian
   Li, Yongqiu
   Zhang, Yonghong
   He, Jiang
TI Prognostic significance of serum cystatin C in acute ischemic stroke
   patients according to lipid component levels
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cystatin C; Lipid component; Ischemic stroke; Prognosis; Functional
   outcome
ID GLOMERULAR-FILTRATION-RATE; CHRONIC KIDNEY-DISEASE; CREATININE; RISK;
   MARKER; IMPACT; DEATH
AB Background and aims: Serum cystatin C (CysC) is associated with the risk of ischemic stroke and may predict cardiovascular events and death after ischemic stroke onset. However, the association between serum CysC and functional outcome in ischemic stroke patients remains unclear, and whether lipid component level influences the relationship between them has not been studied.
   Methods: A total of 3348 ischemic patients from China Antihypertensive Trial in Acute Ischemic Stroke were included in the study. Serum CysC was used to calculate estimated glomerular filtration rate (eGFR(CysC)) at baseline. The primary outcome was poor functional outcome (modified Rankin Scale score >= 3) at one year after ischemic stroke. Secondary outcomes were death, stroke recurrence, vascular events and combination of the aforementioned outcomes.
   Results: The association between eGFR(CysC) and primary outcome was appreciably modified by low density lipoprotein cholesterol (LDL-C) (p(interaction) = 0.048). Low eGFR(CysC) was associated with primary outcome only in ischemic stroke patients with LDL-C >= 4.14 mmol/l rather than all patients. The multi variable adjusted odds ratio (95% confidence interval) of poor functional outcome associated with low eGFR(CysC) was 3.94 (1.04-14.98) and a positive linear dose-response relationship between them was observed among patients with LDL-C >= 4.14 mmol/l (p for linearity = 0.021). Subgroup analyses further confirmed these associations. There was no association between eGFR based on serum creatinine and poor functional outcome of stroke.
   Conclusions: Low eGFR(CysC) may be an independent predictor for 1-year poor functional outcome in ischemic stroke patients with LDL-C >= 4.14 mmol/l. Further studies are needed to replicate our findings and to clarify the potential mechanisms. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zhu, Zhengbao; Zhong, Chongke; Xu, Tian; Wang, Aili; Xu, Tan; Peng, Hao; Zhang, Yonghong] Soochow Univ, Sch Publ Hlth, Dept Epidemiol, Med Coll, Suzhou, Jiangsu, Peoples R China.
   [Zhu, Zhengbao; Zhong, Chongke; Xu, Tian; Wang, Aili; Xu, Tan; Peng, Hao; Zhang, Yonghong] Soochow Univ, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Med Coll, Suzhou, Jiangsu, Peoples R China.
   [Zhong, Chongke; Chen, Chung-Shivan; He, Jiang] Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, 1440 Canal St,Suite 2000, New Orleans, LA 70112 USA.
   [Xu, Tian] Nantong Univ, Affiliated Hosp, Dept Neurol, Nantong, Jiangsu, Peoples R China.
   [Peng, Yanbo] Hebei United Univ, Affiliated Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China.
   [Wang, Jinchao] Yutian Cty Hosp, Dept Neurol, Tangshan, Hebei, Peoples R China.
   [Li, Qunwei] Taishan Med Coll, Sch Publ Hlth, Dept Epidemiol, Tai An, Shandong, Peoples R China.
   [Geng, Deqin] Xuzhou Med Coll, Affiliated Hosp, Dept Neurol, Xuzhou, Jiangsu, Peoples R China.
   [Sun, Yingxian] China Med Univ, Affiliated Hosp 1, Dept Cardiol, Shenyang, Liaoning, Peoples R China.
   [Li, Yongqiu] Tangshan Workers Hosp, Dept Neurol, Tangshan, Hebei, Peoples R China.
   [He, Jiang] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA.
RP He, J (reprint author), Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, 1440 Canal St,Suite 2000, New Orleans, LA 70112 USA.; Zhang, YH (reprint author), Soochow Univ, Sch Publ Hlth, Med Coll, 199 Renai Rd,Ind Pk Dist, Suzhou 215123, Peoples R China.
EM yhzhang@suda.edu.cn; jhe@tulane.edu
RI Peng, Hao/I-1134-2014
OI Peng, Hao/0000-0001-6277-662X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81320108026]; Project of the Priority Academic
   Program Development of Jiangsu Higher Education Institutions, China;
   Tulane University in New Orleans, Louisiana; Collins C. Diboll Private
   Foundation in New Orleans, Louisiana
FX This study was supported by the National Natural Science Foundation of
   China (grants: 81320108026) and a Project of the Priority Academic
   Program Development of Jiangsu Higher Education Institutions, China;
   Tulane University and Collins C. Diboll Private Foundation, both in New
   Orleans, Louisiana.
NR 30
TC 0
Z9 2
U1 1
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 146
EP 151
DI 10.1016/j.atherosclerosis.2018.05.015
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600020
PM 29778943
DA 2019-10-28
ER

PT J
AU Hobaus, C
   Tscharre, M
   Herz, CT
   Pesau, G
   Wrba, T
   Koppensteiner, R
   Schernthaner, GH
AF Hoebaus, Clemens
   Tscharre, Maximilian
   Herz, Carsten Thilo
   Pesau, Gerfried
   Wrba, Thomas
   Koppensteiner, Renate
   Schernthaner, Gerit-Holger
TI YKL-40 levels increase with declining ankle-brachial index and are
   associated with long-term cardiovascular mortality in peripheral
   arterial disease patients
SO ATHEROSCLEROSIS
LA English
DT Article
DE YKL-40; CHI3L1; Cardiovascular mortality; Peripheral arterial disease;
   Atherosclerosis
ID SERUM YKL-40; CHITINASE FAMILY; MATRIX PROTEIN; MARKER; INFLAMMATION;
   CHITOTRIOSIDASE; GLYCOPROTEIN; GRANULES; MEMBER
AB Background and aims: YKL-40 is an inflammatory marker secreted by macrophages and is expressed in atherosclerotic plaques. YKL-40 increases in coronary artery disease (CAD) with poor coronary collateral vessel development. Higher levels are linked to reduced survival in CAD patients. Studies evaluating YKL40 in patients with peripheral arterial disease (PAD) are scarce. This study aims to elucidate a possible link between YKL-40 and PAD severity as well as cardiovascular long-term mortality.
   Methods: YKL-40 was measured at baseline in 365 elderly PAD patients (age 69 +/- 10.4, 33.7% women, Fontaine stage I-II) by bead-based multiplex assay. Patients were followed for seven years to assess long-term cardiovascular and all-cause survival by Kaplan-Meier and Cox regression.
   Results: YKL-40 levels were associated with declining ankle-brachial index (ABI) in PAD patients without Moenckeberg's mediasclerosis (R = -0.189, p = 0.002). PAD patients with mediasclerosis exhibited higher YKL-40 levels (p = 0.002). Baseline YKL-40 levels were significantly associated with cardiovascular mortality (HR 1.52 (1.21-1.91), p < 0.001) and all-cause mortality (HR 1.45 (1.20-1.75), p < 0.001) over a seven-year observation period. After multivariable adjustment for gender, patient age, known carotid artery disease, known coronary artery disease, smoking status, systolic blood pressure, HbA1c, low density lipoprotein cholesterol, estimated glomerular filtration rate, aspartate aminotransferase, and Creactive protein, YKL-40 remained significantly associated with cardiovascular (HR 1.34 (1.02-1.75), p = 0.033) and all-cause mortality (HR 1.25 (1.01-1.55), p = 0.039).
   Conclusions: Increased YKL-40 levels are independently associated with poor long-term cardiovascular survival in peripheral arterial disease patients. Furthermore, YKL-40 correlates with patients' ABI in PAD in the absence of mediasclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hoebaus, Clemens; Pesau, Gerfried; Koppensteiner, Renate; Schernthaner, Gerit-Holger] Med Univ Vienna, Div Angiol, Med 2, Spitalgasse 23, A-1090 Vienna, Austria.
   [Tscharre, Maximilian] Wilhelminenspital Stadt Wien, Med Dept 3, Cardiol & Intens Care Med, Montleartstr 37, A-1160 Vienna, Austria.
   [Herz, Carsten Thilo] Med Univ Vienna, Div Endocrinol & Metab, Med 3, Spitalgasse 23, A-1090 Vienna, Austria.
   [Wrba, Thomas] Med Univ Vienna, IT Syst & Commun IT4Sci, Spitalgasse 23, A-1090 Vienna, Austria.
RP Schernthaner, GH (reprint author), Med Univ Vienna, Dept Internal Med 2, Div Angiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM gerit.schernthaner@meduniwien.ac.at
OI Herz, Carsten T./0000-0003-0888-6275; Hobaus,
   Clemens/0000-0002-9704-1452
FU Medical University Vienna, Vienna, Austria
FX Funding was provided by Medical University Vienna, Vienna, Austria.
NR 34
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 152
EP 156
DI 10.1016/j.atherosclerosis.2018.05.006
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600021
PM 29783062
DA 2019-10-28
ER

PT J
AU Santoro, F
   Costantino, MD
   Guastafierro, F
   Triggiani, G
   Ferraretti, A
   Tarantino, N
   Saguner, A
   Di Biase, M
   Brunetti, ND
AF Santoro, Francesco
   Costantino, Maria Domenica
   Guastafierro, Francesca
   Triggiani, Giuseppe
   Ferraretti, Armando
   Tarantino, Nicola
   Saguner, Ardan
   Di Biase, Matteo
   Brunetti, Natale Daniele
TI Inflammatory patterns in Takotsubo cardiomyopathy and acute coronary
   syndrome: A propensity score matched analysis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Acute coronary syndrome; Inflammation; Interleukins; Prognosis;
   Takotsubo cardiomyopathy
ID ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; ANGIOGRAPHIC FINDINGS;
   TAKO-TSUBO; STRESS; INTERLEUKIN-6; PATHOPHYSIOLOGY; MACROPHAGES;
   ACTIVATION; EVENTS
AB Background and aims: Systemic inflammatory activation can be observed in both Takotsubo cardiomyopathy (TTC) and acute coronary syndrome (ACS). The aim of this study was therefore to compare circulating cytokine levels during the acute and subacute phase of TTC and ACS.
   Methods: One hundred thirty-six consecutive patients were enrolled in the study; after a propensity score matching, 32 TTC patients were compared with 32 subjects with ACS. Clinical baseline features and circulating levels of interleukin(IL)-1 beta, IL-1 alpha, IL-2, IL-4, IL-6, IL-8, IL-10, IFN-gamma, MCP1, EGF, VEGF, TNF-alpha were obtained at admission (t(0)) and after 120 h (t(1)).
   Results: At t(0), several circulating IL levels were higher in subjects with TTC (IL-2 2 vs. 0.5 pg/ml, IL-4 1.5 vs. 0.82 pg/ml, IL-10 3.34 vs. 1.62 pg/ml, TNF-alpha 5 vs. 2.3 pg/ml, IFN-gamma 0.92 vs. 0.32 pg/ml, EGF 84.8 vs. 10.7 pg/ml, p < 0.05 in all cases), while IL-6 levels were higher in patients with ACS (25.4 vs. 12.4 pg/ml p <1/4> 0.03). At t(1), IL-2 and EGF levels were still higher in patients with TTC vs. those with ACS (IL-2 4.6 vs. 0.72 pg/ml, p = 0.01; EGF 36.3 vs. 18.5 pg/ml, p = 0.03), while IL-6 serum levels were higher in ACS patients (19.6 vs. 7.35 pg/ml, p = 0.02).
   Conclusions: Different inflammatory patterns can be observed during the acute and subacute phase of TTC when compared to ACS. Increased levels of anti-inflammatory interleukins can be found during the acute phase of TTC while ACS is featured by higher levels of IL-6 during the acute and sub-acute phase. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Santoro, Francesco; Guastafierro, Francesca; Triggiani, Giuseppe; Ferraretti, Armando; Tarantino, Nicola; Brunetti, Natale Daniele] Univ Foggia, Dept Med & Surg Sci, Foggia, Italy.
   [Santoro, Francesco] Asklepios Klin St Georg, Dept Cardiol, Hamburg, Germany.
   [Saguner, Ardan] Univ Heart Ctr Zurich, Dept Cardiol, Zurich, Switzerland.
   [Di Biase, Matteo] GVM Care & Res, Santa Maria Hosp, Dept Cardiol, Bari, Italy.
RP Brunetti, ND (reprint author), Viale Pinto 1, I-71122 Foggia, Italy.
EM natale.brunetti@unifg.it
RI Brunetti, Natale Daniele/S-9131-2019
OI Brunetti, Natale Daniele/0000-0001-9610-7408; Santoro,
   Francesco/0000-0001-9909-6513; Ferraretti, Armando/0000-0003-2586-721X
NR 32
TC 3
Z9 3
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 157
EP 161
DI 10.1016/j.atherosclerosis.2018.05.017
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600022
PM 29783063
DA 2019-10-28
ER

PT J
AU Wewege, MA
   Thom, JM
   Rye, KA
   Parmenter, BJ
AF Wewege, Michael A.
   Thom, Jeanette M.
   Rye, Kerry-Anne
   Parmenter, Belinda J.
TI Aerobic, resistance or combined training: A systematic review and
   meta-analysis of exercise to reduce cardiovascular risk in adults with
   metabolic syndrome
SO ATHEROSCLEROSIS
LA English
DT Review
DE Physical activity; Prevention; Cardiovascular disease; Metabolic
   disease; Prescription
ID BLOOD-PRESSURE; PEDRO SCALE; NHANES-III; QUALITY; WOMEN; DIET;
   RELIABILITY; PREVALENCE; COMPONENTS; INTENSITY
AB Background and aims: Exercise is beneficial to individuals with metabolic syndrome (MetS). An understudied group, who represent the majority of the MetS population, are individuals who have not developed diabetes. This review examined aerobic, resistance and combined (aerobic thorn resistance) exercise for cardiovascular risk factors in MetS without diabetes.
   Methods: Eight electronic databases were searched up to September 2017 for randomised controlled trials >4 weeks in duration that compared an exercise intervention to the non-exercise control in MetS without diabetes. MetS criteria, cardiorespiratory fitness and cardiovascular risk factors were metaanalysed in a random effects model.
   Results: Eleven studies with 16 interventions were included (12 aerobic, 4 resistance). Aerobic exercise significantly improved waist circumference -3.4 cm (p < 0.01), fasting glucose -0.15 mmol/L (p = 0.03), high-density cholesterol 0.05 mmol/L (p = 0.02), triglycerides -0.29 mmol/L (p < 0.01), diastolic blood pressure -1.6mmHg (p = 0.01), and cardiorespiratory fitness 4.2 ml/kg/min (p < 0.01), among other outcomes. No significant effects were determined following resistance exercise possibly due to limited data. Sub-analyses suggested that aerobic exercise progressed to vigorous intensity, and conducted 3 days/week for -12 weeks offered larger and more widespread improvements.
   Conclusions: Aerobic exercise following current guidelines offers widespread benefits to individuals with MetS without diabetes. More studies on resistance/combined exercise programs in MetS are required to improve the quality of evidence. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Wewege, Michael A.; Thom, Jeanette M.; Rye, Kerry-Anne; Parmenter, Belinda J.] Univ New South Wales, Fac Med, Sch Med Sci, Sydney, NSW 2052, Australia.
RP Wewege, MA (reprint author), Univ New South Wales, Fac Med, Sch Med Sci, Sydney, NSW 2052, Australia.
EM m.wewege@unsw.edu.au
RI Wewege, Michael/K-7937-2019
OI Parmenter, Belinda/0000-0001-8013-5658; Thom,
   Jeanette/0000-0002-6575-3711; Wewege, Michael/0000-0002-3283-2149
FU Australian Government Research Training Program (RTP)
   ScholarshipAustralian GovernmentDepartment of Industry, Innovation and
   Science
FX Michael Wewege was supported by an Australian Government Research
   Training Program (RTP) Scholarship.
NR 58
TC 5
Z9 5
U1 1
U2 20
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 162
EP 171
DI 10.1016/j.atherosclerosis.2018.05.002
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600023
PM 29783064
DA 2019-10-28
ER

PT J
AU de Vries, JK
   Balder, JW
   Pena, MJ
   Denig, P
   Smit, AJ
AF de Vries, Jeroen K.
   Balder, Jan W.
   Pena, Michelle J.
   Denig, Petra
   Smit, Andries J.
TI Non-LDL dyslipidemia is prevalent in the young and determined by
   lifestyle factors and age: The LifeLines cohort
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiovascular risk management; Cohort study; Dyslipidemia; Lifestyle;
   Non-LDL cholesterol; Population study; Obesity
ID DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK-FACTORS;
   HDL-CHOLESTEROL; REMNANT CHOLESTEROL; PHYSICAL-ACTIVITY; BLOOD-PRESSURE;
   DISEASE; LIPIDS; METAANALYSIS; ASSOCIATION
AB Background and aims: Non-LDL dyslipidemia (NLD) confers cardiovascular risk, and prevalence rates appear to be high in elderly populations. Small cohorts have identified several lifestyle, anthropometric, and medical factors associated with NLD. We aimed to assess sex-and age-specific prevalence of NLD in a contemporary population cohort (n = 167 729), and to identify independent determinants of NLD, focusing on lifestyle, anthropometric, and medical factors.
   Methods: The prevalence of NLD was assessed per 10-year age intervals in adults without cardiovascular disease not using lipid-modifying drugs from the Dutch LifeLines cohort. NLD was defined as low HDL-cholesterol or high triglycerides or high remnant cholesterol as per guideline cut-off values. Multivariable regression was used to identify factors independently associated with NLD. Determinants included age, smoking, alcohol use, physical activity, diet, BMI, diabetes mellitus (DM), chronic kidney disease, and in women, menopausal state and oral contraceptive use.
   Results: NLD occurred in 15-19% of women and 13-30% of men in this cohort, with the highest prevalence of 30% in 35-55 year old men. In most age groups, the prevalence in women was lower than in men. Obesity (both sexes: Odds ratio (OR) 5.3, 95% confidence interval (95% CI) 5.0-5.7), current smoking (men: OR 1.8, 95% CI 1.7-1.9; women OR 2.2, 95% CI 2.1-2.3), and DM (men: OR 2.2, 95% CI 1.8-2.6; women: OR 2.7, 95% CI 2.3-3.1) were strongly associated with NLD.
   Conclusions: NLD already occurs frequently at an early age. Modifiable lifestyle choices, obesity, and DM were strong determinants of NLD. Public health efforts could substantially contribute to decrease NLD. (C) 2018 Elsevier B.V. All rights reserved.
C1 [de Vries, Jeroen K.; Smit, Andries J.] Univ Groningen, Univ Med Ctr Groningen, Vasc Med Div, Dept Internal Med, POB 30-001, NL-9700 RB Groningen, Netherlands.
   [Balder, Jan W.] Univ Groningen, Univ Med Ctr Groningen, Mol Genet Div, Dept Pediat, POB 30-001, NL-9700 RB Groningen, Netherlands.
   [Pena, Michelle J.; Denig, Petra] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, POB 30-001, NL-9700 RB Groningen, Netherlands.
   [de Vries, Jeroen K.] Antonius Hosp Sneek, Dept Internal Med, Sneek, Netherlands.
RP de Vries, JK (reprint author), Univ Groningen, Univ Med Ctr Groningen, Vasc Med Div, Dept Internal Med, POB 30-001, NL-9700 RB Groningen, Netherlands.; de Vries, JK (reprint author), Antonius Hosp Sneek, Dept Internal Med, Sneek, Netherlands.
EM j.devries@antonius-sneek.nl
FU Merck Sharp DohmeMerck & Company
FX This work was partially supported by an unrestricted grant from Merck
   Sharp & Dohme.
NR 41
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 191
EP 198
DI 10.1016/j.atherosclerosis.2018.05.016
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600026
PM 29793176
DA 2019-10-28
ER

PT J
AU Shen, ZX
   Yang, QZ
   Li, C
   Du, LJ
   Sun, XN
   Liu, Y
   Sun, JY
   Gu, HH
   Sun, YM
   Wang, J
   Duan, SZ
AF Shen, Zhu-Xia
   Yang, Qing-Zhen
   Li, Chao
   Du, Lin-Juan
   Sun, Xue-Nan
   Liu, Yan
   Sun, Jian-Yong
   Gu, Hui-Hui
   Sun, Yu-Min
   Wang, Jun
   Duan, Sheng-Zhong
TI Myeloid peroxisome proliferator-activated receptor gamma deficiency
   aggravates myocardial infarction in mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Ppar gamma; Myocardial infarction; Cardiac function; NADPH oxidase;
   Macrophage; Inflammation
ID MACROPHAGE PPAR-GAMMA; INSULIN-RESISTANCE; MONOCYTE SUBSETS; NADPH
   OXIDASE; IMMUNE CELLS; ATHEROSCLEROSIS; PIOGLITAZONE; MUSCLE; APOPTOSIS;
   KNOCKOUT
AB Background and aims: Agonists of peroxisome proliferator-activated receptor gamma (Pparg) have been demonstrated to reduce the risk of myocardial infarction (MI) in clinical trials and animal experiments. However, the cellular and molecular mechanisms are not completely understood. We aimed to reveal the functions of myeloid Pparg in MI and explore the potential mechanisms in this study.
   Methods: Myeloid Pparg knockout (MPGKO) mice (n = 12) and control mice (n = 8) underwent coronary artery ligation to induce MI. Another cohort of MPGKO mice and control mice underwent coronary artery ligation and were then treated with IgG or neutralizing antibodies against interleukin (IL)-1 beta. Infarct size was determined by TTC staining and cardiac function was measured using echocardiography. Conditioned media from GW9662-or vehicle-treated macrophages were used to treat H9C2 cardiomyocyte cell line. Gene expression was analyzed using quantitative PCR. Reactive oxygen species were measured using flow cytometry.
   Results: Myeloid Pparg deficiency significantly increased myocardial infarct size. Cardiac hypertrophy was also exacerbated in MPGKO mice, with upregulation of beta-myosin heavy chain (Mhc) and brain natriuretic peptide (Bnp) and downregulation of alpha-Mhc in the non-infarcted zone. Conditioned media from GW9662-treated macrophages increased expression of beta-Mhc and Bnp in H9C2 cells. Echocardiographic measurements showed that MPGKO mice had worsen cardiac dysfunction after MI. Myeloid Pparg deficiency increased gene expression of NADPH oxidase subunits (Nox2 and Nox4) in the non-infarcted zone after MI. Conditioned media from GW9662-treated macrophages increased reactive oxygen species in H9C2 cells. Expression of inflammatory genes such as IL-1 beta and IL-6 was upregulated in the non-infarcted zone of MPGKO mice after MI. With the injection of neutralizing antibodies against IL-1 beta, control mice and MPGKO mice had comparable cardiac function and expression of inflammatory genes after MI.
   Conclusions: Myeloid Pparg deficiency exacerbates MI, likely through increased oxidative stress and cardiac inflammation. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Shen, Zhu-Xia; Li, Chao; Du, Lin-Juan; Sun, Xue-Nan; Liu, Yan; Sun, Jian-Yong; Duan, Sheng-Zhong] Shanghai Jiao Tong Univ, Lab Oral Microbiota & System Dis, Shanghai Key Lab Stomatol,Sch Med, Natl Clin Res Ctr Stomatol,Peoples Hosp 9,Sch Sto, Shanghai 200125, Peoples R China.
   [Shen, Zhu-Xia; Li, Chao; Du, Lin-Juan; Sun, Xue-Nan; Liu, Yan; Sun, Jian-Yong; Duan, Sheng-Zhong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Res Inst Stomatol, Natl Clin Res Ctr Stomatol,Peoples Hosp 9,Sch Sto, Shanghai 200125, Peoples R China.
   [Shen, Zhu-Xia; Gu, Hui-Hui; Sun, Yu-Min; Wang, Jun] Fudan Univ, Jingan Dist Ctr Hosp Shanghai, Dept Cardiol, Shanghai 200040, Peoples R China.
   [Yang, Qing-Zhen; Li, Chao; Du, Lin-Juan; Sun, Xue-Nan] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.
RP Duan, SZ (reprint author), Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Res Ctr, 115 Jinzun Rd, Shanghai 200125, Peoples R China.
EM duansz@shsmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81725003, 31671181, 91739303]; Shanghai Summit &
   Plateau Discipline Developing Projects; Natural Science Foundation of
   ShanghaiNatural Science Foundation of Shanghai [18ZR1432800]; Shanghai
   Municipal Commission of Health and Family Planning [201740176]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81725003, 31671181, 91739303), the Shanghai Summit
   & Plateau Discipline Developing Projects, the Natural Science Foundation
   of Shanghai (18ZR1432800), and Shanghai Municipal Commission of Health
   and Family Planning (201740176).
NR 57
TC 3
Z9 3
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 199
EP 205
DI 10.1016/j.atherosclerosis.2018.05.005
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600027
PM 29800789
DA 2019-10-28
ER

PT J
AU Tziomalos, K
   Sofogianni, A
   Angelopoulou, SM
   Christou, K
   Kostaki, S
   Papagianni, M
   Satsoglou, S
   Spanou, M
   Savopoulos, C
   Hatzitolios, AI
AF Tziomalos, Konstantinos
   Sofogianni, Areti
   Angelopoulou, Stella-Maria
   Christou, Konstantinos
   Kostaki, Stavroula
   Papagianni, Marianthi
   Satsoglou, Sarantis
   Spanou, Marianna
   Savopoulos, Christos
   Hatzitolios, Apostolos I.
TI Left ventricular hypertrophy assessed by electrocardiogram is associated
   with more severe stroke and with higher in-hospital mortality in
   patients with acute ischemic stroke
SO ATHEROSCLEROSIS
LA English
DT Article
DE Ischemic stroke; Left ventricular hypertrophy; Electrocardiogram;
   Sokolow-Lyon index; Cornell voltage-duration product
ID BLOOD-PRESSURE; RISK-FACTORS; CARDIOVASCULAR HEALTH; SYSTEMIC
   HYPERTENSION; ATRIAL-FIBRILLATION; MASS MEASUREMENTS; AGE;
   ECHOCARDIOGRAPHY; PREVALENCE; PREDICTORS
AB Background and aims: Left ventricular hypertrophy (LVH), assessed by electrocardiogram (ECG), is associated with increased risk for stroke. However, few studies that evaluated whether ECG-detected LVH predicts ischemic stroke severity and outcome. We aimed to evaluate these associations.
   Methods: We prospectively studied 922 patients consecutively admitted with acute ischemic stroke (age 79.6 +/- 6.9 years). Stroke severity was assessed at admission with the National Institutes of Health Stroke Scale (NIHSS). Severe stroke was defined as NIHSS >= 5. LVH was evaluated with the Sokolow-Lyon index and the Cornell voltage-duration product criteria in an ECG obtained at admission. The outcome was assessed with dependency at discharge (modified Rankin scale 2-5) and in-hospital mortality.
   Results: Independent predictors of severe stroke were age (relative risk (RR) per year 1.07, 95% confidence interval (CI) 1.03-1.11, p< 0.001), female gender (RR 0.36, 95% CI 0.17-0.76, p< 0.01), atrial fibrillation (RR 2.07, 95% CI 1.30-3.29, p< 0.005), chronic kidney disease (RR 2.38, 95% CI 1.04-5.44, p< 0.05), heart rate (RR per 1/min 1.02, 95% CI 1.01-1.04, p< 0.005), glucose levels (RR 1.012, 95% CI 1.006-1.018, p< 0.001), high-density lipoprotein cholesterol levels (RR 0.976, 95% CI 0.960-0.993, p< 0.005) and LVH defined according to the Cornell voltage-duration product criteria (RR 2.08, 95% CI 1.12-3.86, p< 0.05). Independent predictors of dependency at discharge were age (RR per year 1.08, 95% CI 1.03-1.13, p< 0.001), past smoking (RR versus no smoking 0.42, 95% 0.19-0.89, p< 0.05), history of ischemic stroke (RR 2.13, 95% CI 1.23-3.71, p< 0.01) and NIHSS at admission (RR 1.48, 95% CI 1.35-1.63, p< 0.001). Independent predictors of in-hospital mortality were glucose levels (RR 1.014, 95% CI 1.003-1.025, p< 0.05), NIHSS at admission (RR 1.29, 95% CI 1.19-1.41, p< 0.001) and LVH according to the Cornell voltageduration product criteria (RR 4.95, 95% CI 1.09-22.37, p< 0.05).
   Conclusions: LVH according to the Cornell voltage-duration product criteria appears to be associated with more severe stroke and with higher in-hospital mortality in patients with acute ischemic stroke. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Tziomalos, Konstantinos; Sofogianni, Areti; Angelopoulou, Stella-Maria; Christou, Konstantinos; Kostaki, Stavroula; Papagianni, Marianthi; Satsoglou, Sarantis; Spanou, Marianna; Savopoulos, Christos; Hatzitolios, Apostolos I.] Aristotle Univ Thessaloniki, AHEPA Hosp, Med Sch, Propedeut Dept Internal Med 1, Thessaloniki, Greece.
RP Tziomalos, K (reprint author), AHEPA Hosp, Propedeut Dept Internal Med 1, 1 Stilponos Kyriakidi St, Thessaloniki 54636, Greece.
EM ktziomal@auth.gr
OI Tziomalos, Konstantinos/0000-0002-3172-1594
NR 42
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 206
EP 211
DI 10.1016/j.atherosclerosis.2018.05.030
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600028
PM 29800790
DA 2019-10-28
ER

PT J
AU Machado, GP
   de Araujo, GN
   Carpes, CK
   Lech, M
   Mariani, S
   Valle, FH
   Bergoli, LCC
   Goncalves, SC
   Wainstein, RV
   Wainstein, MV
AF Machado, Guilherme Pinheiro
   de Araujo, Gustavo Neves
   Carpes, Christian Kunde
   Lech, Mateus
   Mariani, Stefani
   Valle, Felipe Homem
   Corsetti Bergoli, Luiz Carlos
   Goncalves, Sandro Cadaval
   Wainstein, Rodrigo V.
   Wainstein, Marco V.
TI Comparison of neutrophil-to-lymphocyte ratio and mean platelet volume in
   the prediction of adverse events after primary percutaneous coronary
   intervention in patients with ST-elevation myocardial infarction
SO ATHEROSCLEROSIS
LA English
DT Article
DE Myocardial infarction; Percutaneous coronary intervention; Mortality;
   Mean platelet volume; Neutrophil-to-lymphocyte ratio
ID NEUTROPHIL/LYMPHOCYTE RATIO; ATHEROSCLEROSIS; RISK; MORTALITY; DISEASE
AB Background and aims: Elevated neutrophil-to-lymphocyte ratio (NLR) and mean platelet volume (MPV) are indirect inflammatory markers. There is some evidence that both are associated with worse outcomes in ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI). The aim of the present study was to compare the capacity of NLR and MPV to predict adverse events after primary PCI.
   Methods: In a prospective cohort study, 625 consecutive patients with STEMI, who underwent primary PCI, were followed. Receiver operating characteristic (ROC) curve analysis was performed to calculate the area under the curve (AUC) for the occurrence of procedural complications, mortality and major adverse cardiovascular events (MACE).
   Results: Mean age was 60.7 (+/- 12.1) years, 67.5% were male. The median of NLR was 6.17 (3.8-9.4) and MPV was 10.7 (10.0-11.3). In multivariate analysis, both NLR and MPV remained independent predictors of no-reflow (relative risk [RR] = 2.26; 95% confidence interval [95% CI] = 1.16-4.32; p = 0.01 and RR = 2.68; 95% CI = 1.40-5.10; p < 0.01, respectively), but only NLR remained an independent predictor of in-hospital MACE (RR = 1.01; 95% CI = 1.00-1.06; p = 0.02). The AUC for in-hospital MACE was 0.57 for NLR (95% CI = 0.53-0.60; p = 0.03) and 0.56 for MPV (95% CI = 0.52-0.60; p = 0.07). However, when AUC were compared with DeLong test, there was no statistically significant difference for these outcomes (p > 0.05). NLR had an excellent negative predictive value (NPV) of 96.7 for no-reflow and 89.0 for inhospital MACE.
   Conclusions: Despite no difference in the ROC curve comparison with MPV, only NLR remained an independent predictor for in-hospital MACE. A low NLR has an excellent NPV for no-reflow and in-hospital MACE, and this could be of clinical relevance in the management of low-risk patients. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Machado, Guilherme Pinheiro; de Araujo, Gustavo Neves; Carpes, Christian Kunde; Lech, Mateus; Mariani, Stefani; Wainstein, Marco V.] Univ Fed Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
   [de Araujo, Gustavo Neves; Valle, Felipe Homem; Corsetti Bergoli, Luiz Carlos; Goncalves, Sandro Cadaval; Wainstein, Rodrigo V.; Wainstein, Marco V.] Hosp Clin Porto Alegre, Cardiol Div, Porto Alegre, RS, Brazil.
RP Machado, GP (reprint author), Hosp Clin Porto Alegre, Ramiro Barcelos 2350, BR-90035 Porto Alegre, RS, Brazil.
EM gpmachado89@gmail.com
RI Goncalves, Sandro Cadaval/W-5228-2019; Machado, Guilherme
   Pinheiro/N-6679-2017
OI Machado, Guilherme Pinheiro/0000-0002-5514-2562
NR 24
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 212
EP 217
DI 10.1016/j.atherosclerosis.2018.05.022
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600029
PM 29803159
DA 2019-10-28
ER

PT J
AU Peyracchia, M
   De Lio, G
   Montrucchio, C
   Omede, P
   d'Ettore, G
   Calcagno, A
   Vullo, V
   Cerrato, E
   Pennacchi, M
   Sardella, G
   Manga, P
   GrossoMarra, W
   Vullo, F
   Fedele, F
   Biondi-Zoccai, G
   Moretti, C
   Vachiat, A
   Bonora, S
   Rinaldi, M
   Mancone, M
   D'Ascenzo, F
AF Peyracchia, Mattia
   De Lio, Giulia
   Montrucchio, Chiara
   Omede, Pierluigi
   d'Ettore, Gabriella
   Calcagno, Andrea
   Vullo, Vincenzo
   Cerrato, Enrico
   Pennacchi, Mauro
   Sardella, Gennaro
   Manga, Pravin
   GrossoMarra, Walter
   Vullo, Francesco
   Fedele, Francesco
   Biondi-Zoccai, Giuseppe
   Moretti, Claudio
   Vachiat, Ahmed
   Bonora, Stefano
   Rinaldi, Mauro
   Mancone, Massimo
   D'Ascenzo, Fabrizio
TI Evaluation of coronary features of HIV patients presenting with ACS: The
   CUORE, a multicenter study
SO ATHEROSCLEROSIS
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; T-CELL COUNT;
   ANTIRETROVIRAL THERAPY; VASCULAR CALCIFICATION; ENDOTHELIAL FUNCTION;
   INFECTED PATIENTS; 1,25-DIHYDROXYVITAMIN D-3; PRIMARY PREVENTION;
   HEART-DISEASE
AB Background and aims: The risk of recurrence of myocardial infarction (MI) in HIV patients presenting with acute coronary syndrome (ACS) is well known, but there is limited evidence about potential differences in coronary plaques compared to non-HIV patients.
   Methods: In this multicenter case-control study, HIV patients presenting with ACS, with intravascularultrasound (IVUS) data, enrolled between February 2015 and June 2017, and undergoing highly active antiretroviral therapy (HAART), were retrospectively compared to non-HIV patients presenting with ACS, before and after propensity score with matching, randomly selected from included centers. Primary endpoint was the prevalence of multivessel disease. Secondary end-points were the prevalence of abnormal features at IVUS, the incidence of major-acute-cardiovascular-events (MACE), a composite end point of cardiovascular death, MI, target lesion revascularization (TLR), stent thrombosis (ST), non-cardiac death and target vessel revascularization (TVR). For each end-point, a subgroup analysis was conducted in HIV patients with CD4 cell count < 200/mm(3).
   Results: Before propensity score, 66 HIV patients and 120 non-HIV patients were selected, resulting in 20 and 40 after propensity score. Patients with multivessel disease were 11 and 17, respectively (p = 0.56). IVUS showed a lower plaque burden (71% vs. 75%, p < 0.001) and a higher prevalence of hyperechoic non-calcified plaques (100% vs. 35%, p < 0.05) in HIV patients; a higher prevalence of hypoechoic plaques (7% vs. 0%, p < 0.05), a higher incidence of MACE (17.4% vs. 9.1% vs. l' 8.0%, p < 0.05), MI recurrence (17.2% vs. 0.0% vs. 2.3%, p < 0.05), and ST (6.7% vs. 0.3% vs. 03%, p < 0.05) in HIV patients with CD4 < 200/mm(3).
   Conclusions: Our study may provide a part of the pathophysiological basis of the differences in coronary arteries between HIV-positive and HIV-negative patients, suggesting that the former present with peculiar morphological features at IVUS, even after adjustment for clinical variables. Furthermore, we confirmed that an advanced HIV infection is associated with a high risk of non-calcific plaques and with a worse prognosis, including cardiovascular events and ACS recurrence. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Peyracchia, Mattia; De Lio, Giulia; Montrucchio, Chiara; Omede, Pierluigi; GrossoMarra, Walter; Rinaldi, Mauro; D'Ascenzo, Fabrizio] Univ Turin, Div Cardiol, Citta Salute & Sci Molinette Hosp, Turin, Italy.
   [Manga, Pravin; Vachiat, Ahmed] Univ Witwatersrand, Charlotte Maxeke Johannesburg Acad Hosp, Div Cardiol, Johannesburg, South Africa.
   [Pennacchi, Mauro; Sardella, Gennaro; Fedele, Francesco; Mancone, Massimo] Sapienza Univ Rome, Policlin Umberto 1, Dept Cardiovasc Resp Nephrol Anesthesiol & Geriat, Latina, Italy.
   [Calcagno, Andrea; Moretti, Claudio; Bonora, Stefano] Univ Turin, Div Infect Dis, Turin, Italy.
   [d'Ettore, Gabriella; Vullo, Vincenzo] Sapienza Univ Rome, Policlin Umberto 1, Dept Infect Dis, Latina, Italy.
   [Cerrato, Enrico; Vullo, Francesco] Rivoli & San Luigi Gonzaga Univ Hosp, Infermi Hosp, Intervent Cardiol, Turin, Italy.
   [Biondi-Zoccai, Giuseppe] Sapienza Univ Rome, Dept Medicosurg Sci & Biotechnol, Latina, Italy.
   [Biondi-Zoccai, Giuseppe] IRCCS Neuromed, Dept AngioCardioNeurol, Pozzilli, Italy.
   [Vullo, Francesco] Sapienza Univ Rome, Dept Radiol Ontol & Anatomo Pathol Sci, Latina, Italy.
RP Mancone, M (reprint author), Sapienza Univ Rome, Policlin Umberto 1, Dept Cardiovasc Resp Nephrol Anesthesiol & Geriat, Latina, Italy.; D'Ascenzo, F (reprint author), Dept Internal Med, Div Cardiol, Turin, Italy.
EM massimo.mancone@uniroma1.it; fabrizio.dascenzo@gmail.com
RI bonora, stefano/AAC-2993-2019; Biondi-Zoccai, Giuseppe/C-9670-2012
OI bonora, stefano/0000-0002-7537-3341; Biondi-Zoccai,
   Giuseppe/0000-0001-6103-8510
NR 70
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 218
EP 226
DI 10.1016/j.atherosclerosis.2018.05.001
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600030
PM 29803160
DA 2019-10-28
ER

PT J
AU Sakamoto, A
   Torii, S
   Jinnouchi, H
   Finn, AV
   Virmani, R
   Kolodgie, FD
AF Sakamoto, Atsushi
   Torii, Sho
   Jinnouchi, Hiroyuki
   Finn, Aloke V.
   Virmani, Renu
   Kolodgie, Frank D.
TI Pathologic intimal thickening: Are we any closer to understand early
   transitional plaques that lead to symptomatic disease?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Coronary atherosclerosis; Diffuse intimal thickening; Lipid pool;
   Macrophage; Pathologic intimal thickening; Smooth muscle cell
ID ATHEROSCLEROSIS; PROTEOGLYCANS; PROGRESSION; ARTERIES; LESIONS
C1 [Sakamoto, Atsushi; Torii, Sho; Jinnouchi, Hiroyuki; Finn, Aloke V.; Virmani, Renu; Kolodgie, Frank D.] CVPath Inst Inc, 19 Firstfield Rd, Gaithersburg, MD 20878 USA.
   [Finn, Aloke V.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
RP Virmani, R (reprint author), CVPath Inst Inc, 19 Firstfield Rd, Gaithersburg, MD 20878 USA.
EM rvirmani@cvpath.org
FU SUNRISE lab; Boston ScientificBoston Scientific; Medtronic
   CardioVascular
FX CVPath Institute has received institutional research support from 480
   Biomedical, Abbott Vascular, ART, BioSensors International, Biotronik,
   Boston Scientific, Celonova, Claret Medical, Cook Medical, Cordis,
   Edwards Lifescience, Medtronic, MicroPort, MicroVention, Celonova,
   OrbusNeich, ReCore, SINO Medical Technology, Spectranetics, Surmodics,
   Terumo Corporation, W.L. Gore and Xeltis. S.T. receives honoraria from
   Abbott Vascular Japan and Terumo Corporation, and research grants from
   SUNRISE lab. R.V. has received honoraria from 480 Biomedical, Abbott
   Vascular, Boston Scientific, Cook Medical, Lutonix, Medtronic, Terumo
   Corporation and W.L. Gore; and is a consultant for 480 Biomedical,
   Abbott Vascular, Medtronic, and W.L. Gore. A.V. Finn has sponsored
   research agreements with Boston Scientific and Medtronic CardioVascular
   and is an advisory board member to Medtronic CardioVascular. Other
   authors report no conflicts of interest.
NR 15
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 227
EP 229
DI 10.1016/j.atherosclerosis.2018.04.033
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600031
PM 29801687
DA 2019-10-28
ER

PT J
AU Enkhmaa, B
   Prakash, N
   Berglund, L
AF Enkhmaa, Byambaa
   Prakash, Nishant
   Berglund, Lars
TI Non-HDL-C levels and residual cardiovascular risk: Do
   population-specific precision approaches offer any advantages?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Cardiovascular risk; Lipids; Atherosclerosis; HDL cholesterol;
   Populations
ID DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-ARTERY-DISEASE
C1 [Enkhmaa, Byambaa; Prakash, Nishant; Berglund, Lars] Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA.
RP Berglund, L (reprint author), Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA.
EM lberglund@ucdavis.edu
FU UC Davis Clinical and Translational Science Center [UL1 TR001860]; NIH
   Building Interdisciplinary Research Careers in Women's Health/K12
   Program [2K12HD051958]
FX We gratefully acknowledge partial support from the UC Davis Clinical and
   Translational Science Center (UL1 TR001860) and the NIH Building
   Interdisciplinary Research Careers in Women's Health/K12 Program
   (2K12HD051958).
NR 18
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 230
EP 231
DI 10.1016/j.atherosclerosis.2018.05.010
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600032
PM 29764695
DA 2019-10-28
ER

PT J
AU Korosoglou, G
   Giusca, S
   Katus, HA
AF Korosoglou, Grigorios
   Giusca, Sorin
   Katus, Hugo A.
TI The coronary calcium paradox: Yet another step towards the
   differentiation between stable and rupture-prone coronary plaques?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Cardiac computed tomography; Acute coronary syndromes; Coronary
   calcification; Culprit lesions; Rupture-prone plaque
ID CHEST-PAIN; VULNERABLE PATIENT; TROPONIN-T; CALCIFICATION; ANGIOGRAPHY;
   OUTCOMES
C1 [Korosoglou, Grigorios; Giusca, Sorin] GRN Hosp Weinheim, Cardiol & Vasc Med, Weinheim, Germany.
   [Katus, Hugo A.] Heidelberg Univ, Dept Med Cardiol Angiol & Pneumol, Heidelberg, Germany.
RP Korosoglou, G (reprint author), GRN Acad Teaching Hosp Weinheim, Dept Cardiol & Vasc Med, Roentgenstr 1, D-69469 Weinheim, Germany.
EM gkorosoglou@hotmail.com
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 232
EP 234
DI 10.1016/j.atherosclerosis.2018.05.012
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600033
PM 29759509
DA 2019-10-28
ER

PT J
AU Brito, FA
   Pedrosa, W
   Maluf, CB
   dos Reis, RCP
   Fedeli, LMG
   Castilhos, C
   Barreto, SM
   Vidigal, PG
AF Brito, Fabiano A.
   Pedrosa, William
   Maluf, Chams B.
   dos Reis, Rodrigo C. P.
   Fedeli, Ligia M. G.
   Castilhos, Cristina
   Barreto, Sandhi M.
   Vidigal, Pedro G.
TI Non-HDL-C goals based on the distribution of population percentiles in
   ELSA-Brasil: Is it time to change?
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiovascular disease; LDL cholesterol; Non-HDL cholesterol; Population
   percentiles; Treatment goals
ID DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE;
   APOLIPOPROTEIN-B; LDL-CHOLESTEROL; RISK; MANAGEMENT; DYSLIPIDEMIA;
   ADULT; METAANALYSIS; ASSOCIATION
AB Background and aims: Nonehigh-density lipoprotein cholesterol (non-HDL-C) goals are defined as 30 mg/dL (0.78mmol/L) higher than the respective low-density lipoprotein cholesterol (LDL-C) goals. This definition, however, do not consider the population distribution of non-HDL-C, which could represent a more appropriate individual goal when both markers are discordant. The aim of this study is to establish non-HDL-C goals at the same population percentiles of LDL-C.
   Methods: Non-HDL-C values were assigned at the same percentiles correspondent to the LDL-C treatment goals for 14,837 participants from the Longitudinal Study of Adult Health (ELSA-Brasil) with tri-glycerides levels <= 400 mg/dL (4.52 mmol/L). We also assessed the frequency of reclassification, defined as the number of subjects with LDL-C levels in the recommended therapeutic category, but with non-HDL-C levels above or below the category.
   Results: The non-HDL-C values, based on correspondent LDL-C population percentiles, were 92 (2.38), 122 (3.16), 156 (4.04), 191 (4.95), and 223 mg/dL (5.78 mmol/L). Among participants with LDL-C <70 mg/dL (1.81 mmol/L), 22.8% were reclassified in a higher category according to the guidelines-based non-HDL-C cut-off and 30.1% according to the population percentile-based cut-off; 25.6% and 64.1%, respectively, if triglycerides concurrently 150-199 mg/dL (1.69-2.25 mmol/L).
   Conclusions: Our results demonstrated that non-HDL-C percentiles-based goals were up to 8 mg/dL (0.21 mmol/L) lower than the guidelines recommended goal and had a profound impact on the reclassification of participants, notably when LDL-C was <100 mg/dL (2.56 mmol/L), the treatment goal for high risk patients. Therefore, non-HDL-C goals should be changed for reduction of residual risk. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Brito, Fabiano A.; Maluf, Chams B.; Vidigal, Pedro G.] Univ Fed Minas Gerais, Sch Med, Dept Clin Pathol, Belo Horizonte, MG, Brazil.
   [Brito, Fabiano A.; Pedrosa, William] Hermes Pardini Lab, Vespasiano, MG, Brazil.
   [Barreto, Sandhi M.] Univ Fed Minas Gerais, Sch Med, Dept Social & Prevent Med, Belo Horizonte, MG, Brazil.
   [dos Reis, Rodrigo C. P.] Univ Fed Rio Grande do Sul, Dept Stat, Porto Alegre, RS, Brazil.
   [Fedeli, Ligia M. G.] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Castilhos, Cristina] Univ Fed Rio Grande do Sul, Clin Hosp, Porto Alegre, RS, Brazil.
RP Vidigal, PG (reprint author), Univ Fed Minas Gerais, Dept Clin Pathol, Av Prof Alfredo Balena 190,Sala 403, BR-30130100 Belo Horizonte, MG, Brazil.
EM pedrovidigal@ufmg.br
RI Barreto, Sandhi M/D-2855-2014; Vidigal, Pedro/K-4834-2016
OI Barreto, Sandhi M/0000-0001-7383-7811; Vidigal,
   Pedro/0000-0001-8035-1350
FU Brazilian Ministry of Health (Science and Technology Department);
   Brazilian Ministry of Science and Technology (CNPq, National Research
   Council) [01 06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06
   0278.00 MG, 01 06 0115.00SP, 01 06 0071.00 RJ]; Brazilian Ministry of
   Science and Technology (FINEP, Financiadora de Estudos e Projetos) [01
   06 0010.00 RS, 01 06 0212.00 BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01
   06 0115.00SP, 01 06 0071.00 RJ]
FX ELSA-Brasil baseline study was supported by the Brazilian Ministry of
   Health (Science and Technology Department) and the Brazilian Ministry of
   Science and Technology (FINEP, Financiadora de Estudos e Projetos and
   CNPq, National Research Council), grants 01 06 0010.00 RS, 01 06 0212.00
   BA, 01 06 0300.00 ES, 01 06 0278.00 MG, 01 06 0115.00SP, 01 06 0071.00
   RJ.
NR 28
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 243
EP 250
DI 10.1016/j.atherosclerosis.2018.04.007
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600035
PM 29729963
DA 2019-10-28
ER

PT J
AU Puchner, SB
   Mayrhofer, T
   Park, J
   Lu, MT
   Liu, T
   Maurovich-Horvat, P
   Ghemigian, K
   Bittner, DO
   Fleg, JL
   Udelson, JE
   Truong, QA
   Hoffmann, U
   Ferencik, M
AF Puchner, Stefan B.
   Mayrhofer, Thomas
   Park, Jakob
   Lu, Michael T.
   Liu, Ting
   Maurovich-Horvat, Pal
   Ghemigian, Khristine
   Bittner, Daniel O.
   Fleg, Jerome L.
   Udelson, James E.
   Truong, Quynh A.
   Hoffmann, Udo
   Ferencik, Maros
TI Differences in the association of total versus local coronary artery
   calcium with acute coronary syndrome and culprit lesions in patients
   with acute chest pain: The coronary calcium paradox
SO ATHEROSCLEROSIS
LA English
DT Article
DE Coronary artery calcium; Acute coronary syndrome; Coronary artery
   calcium score; Coronary artery calcium density; Cardiac computed
   tomography; Culprit lesions; High-risk coronary plaque
ID ROMICAT-II TRIAL; LIPID-LOWERING THERAPY; NAPKIN-RING SIGN; CT
   ANGIOGRAPHY; COMPUTED-TOMOGRAPHY; ATHEROSCLEROTIC PLAQUE; INTRAVASCULAR
   ULTRASOUND; MYOCARDIAL-INFARCTION; VIRTUAL HISTOLOGY; VULNERABLE PLAQUE
AB Background and aims: Total coronary artery calcium (CAC) burden is associated with an increased cardiovascular risk, while local CAC may represent stable plaques. We determined differences in relationship of total CAC with acute coronary syndrome (ACS) and local CAC with culprit lesions in patients with suspected ACS.
   Methods: We performed computed tomography (CT) for CAC and CT angiography to assess the presence of significant stenosis and high-risk plaque (positive remodeling, low CT attenuation, napkin-ring sign, spotty calcium) in 37 patients with ACS and 223 controls. Total and segmental Agatston scores were measured. Culprit lesions were assessed in subjects with ACS.
   Results: Patients (n = 260) with vs. without ACS had higher total CAC score (median 229, 25th-75th percentile 75-517 vs. 27, 25th-75th percentile 0-99, p< 0.001), higher prevalence of significant stenosis (78% vs. 7%, p< 0.001) and high-risk plaque (95% vs. 59%, p< 0.001). In those with ACS, culprit (n = 41) vs. non-culprit (n = 200) lesions, had similar segmental CAC score (median 22, 25th-75th percentile 4-71 vs. 14, 25th-75th percentile 0-51; p = 0.37), but higher prevalence of significant stenosis (81% vs. 11%, p< 0.001) and high-risk plaque (76% vs. 51%, p = 0.005). Significant stenosis (odds ratio 40.2, 95% CI 15.6-103.9, p< 0.001) and high-risk plaque (odds ratio 3.4, 95% CI 1.3-9.1, p = 0.02), but not segmental CAC score (odds ratio 1.0, 95% CI 1.0-1.0, p = 0.47), were associated with culprit lesions of ACS.
   Conclusions: Total CAC burden was associated with ACS but segmental CAC was not associated with culprit lesions. Our findings suggest that total but not local CAC is a marker of ACS risk and support the hypothesis that extensive local CAC is a marker of plaque stability. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Puchner, Stefan B.; Mayrhofer, Thomas; Park, Jakob; Lu, Michael T.; Liu, Ting; Ghemigian, Khristine; Bittner, Daniel O.; Hoffmann, Udo; Ferencik, Maros] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
   [Puchner, Stefan B.; Mayrhofer, Thomas; Park, Jakob; Lu, Michael T.; Liu, Ting; Ghemigian, Khristine; Bittner, Daniel O.; Hoffmann, Udo; Ferencik, Maros] Harvard Med Sch, Boston, MA USA.
   [Puchner, Stefan B.; Mayrhofer, Thomas; Park, Jakob; Lu, Michael T.; Liu, Ting; Ghemigian, Khristine; Bittner, Daniel O.; Hoffmann, Udo; Ferencik, Maros] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
   [Puchner, Stefan B.] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Vienna, Austria.
   [Mayrhofer, Thomas] Stralsund Univ Appl Sci, Sch Business Studies, Stralsund, Germany.
   [Liu, Ting] China Med Univ, Affiliated Hosp 1, Dept Radiol, Shenyang, Liaoning, Peoples R China.
   [Maurovich-Horvat, Pal] Semmelweis Univ, Heart & Vasc Ctr, MTA SE Cardiovasc Imaging Res Grp, Budapest, Hungary.
   [Bittner, Daniel O.] Univ Hosp Erlangen, Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Cardiol, Erlangen, Germany.
   [Fleg, Jerome L.] NHLBI, Div Cardiovasc Sci, Bldg 10, Bethesda, MD 20892 USA.
   [Udelson, James E.] Tufts Med Ctr, Div Cardiol, Boston, MA USA.
   [Udelson, James E.] Tufts Med Ctr, Cardiovasc Ctr, Boston, MA USA.
   [Truong, Quynh A.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA.
   [Truong, Quynh A.] Weill Cornell Med Coll, Div Cardiol, New York, NY USA.
   [Ferencik, Maros] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, 3180 Sam Jackson Pk Rd,Mail Code UHN62, Portland, OR 97239 USA.
RP Ferencik, M (reprint author), Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, 3180 Sam Jackson Pk Rd,Mail Code UHN62, Portland, OR 97239 USA.
EM ferencik@ohsu.edu
FU NIH, American College of Radiology Imaging Network [U01HL092040,
   U01HL092022]
FX ROMICAT II Support NIH U01HL092040 and U01HL092022, American College of
   Radiology Imaging Network.
NR 46
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUL
PY 2018
VL 274
BP 251
EP 257
DI 10.1016/j.atherosclerosis.2018.04.017
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GJ0PF
UT WOS:000434955600036
PM 29703635
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Cheon, EJ
   Cha, DH
   Cho, SK
   Noh, HM
   Park, S
   Kang, SM
   Gee, HY
   Lee, SH
AF Cheon, Eun Jeong
   Cha, Do Hyeon
   Cho, Sung Kweon
   Noh, Hye-Min
   Park, Sungha
   Kang, Seok-Min
   Gee, Heon Yung
   Lee, Sang-Hak
TI Novel association between CDKAL1 and cholesterol efflux capacity:
   Replication after GWAS-based discovery
SO ATHEROSCLEROSIS
LA English
DT Article
DE Lipoproteins; Genomics; Cholesterol; Atherosclerosis; Polymorphism;
   Single nucleotide
ID GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; PHOSPHOLIPID TRANSFER
   PROTEIN; TYPE-2 DIABETES-MELLITUS; HDL CHOLESTEROL; GENOTYPE IMPUTATION;
   SUSCEPTIBILITY LOCI; ATHEROSCLEROSIS; VISUALIZATION; FUNCTIONALITY
AB Background and aims: Although the importance of the functional properties of high-density lipoprotein (HDL) has been increasingly emphasized, studies on the genetic factors associated with HDL function are highly limited. The aim of this study was to identify genetic variants associated with an individual's cholesterol efflux capacity (CEC) using a genome-wide association study approach.
   Methods: This study included a discovery group of 607 subjects with coronary artery disease and an independent replication group of 158 subjects. CEC was assessed using a radioisotope and ApoB-depleted serum. Genome-wide associations between the adjusted CEC and genotyped and imputed variants were examined with linear regression, assuming an additive genetic model. Finally, adjustments were made for confounding parameters to assess the independence of associations and to determine R-2 of overall model on CEC.
   Results: In the discovery group, 631 variants showed significant association with CEC, and five of them were found to correlate with CEC in the replication group. One of them was located near LOC541471 in 2q13, whereas the other four (rs117835232, rs117252933, rs118064592, and rs150434350) were located in CDKAL1 in 6p22.3. The association between the presence of any CDKAL1 variant and CEC was significant after adjustment for clinical and laboratory variables. High-density lipoprotein-cholesterol levels also showed a very significant association with CEC. Body mass index, current alcohol use, triglycerides levels, low-density lipoprotein-cholesterol levels and statin use showed borderline associations with CEC.
   Conclusions: We identified and replicated genetic variants associated with CEC using a genome-wide association study-based approach. CDKAL1 variants showed correlations with CEC independent of HDL-cholesterol levels and other clinical characteristics. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Cheon, Eun Jeong; Noh, Hye-Min; Park, Sungha; Kang, Seok-Min; Lee, Sang-Hak] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea.
   [Cheon, Eun Jeong] Yonsei Univ, Coll Med, Seoul, South Korea.
   [Cho, Sung Kweon] Sungkyunkwan Univ, SAIHST, Dept Clin Res Design & Evaluat, Seoul, South Korea.
   [Park, Sungha; Kang, Seok-Min; Lee, Sang-Hak] Yonsei Univ, Severance Hosp, Coll Med, Dept Internal Med,Div Cardiol, Seoul, South Korea.
   [Gee, Heon Yung] Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Dept Pharmacol, Seoul, South Korea.
RP Lee, SH (reprint author), Yonsei Univ, Severance Hosp, Coll Med, Div Cardiol,Dept Internal Med, 134 Shinchon Dong, Seoul 120752, South Korea.; Gee, HY (reprint author), Yonsei Univ, Coll Med, Dept Pharmacol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hygee@yuhs.ac; shl1106@yuhs.ac
RI Gee, Heon Yung/K-7781-2019
OI Gee, Heon Yung/0000-0002-8741-6177; Park, Sungha/0000-0001-5362-478X;
   Kang, Seok-Min/0000-0001-9856-9227; Cha, Do Hyeon/0000-0003-1005-7783
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Science, and Technology
   [2012R1A1A1029061, 2017R1D1A1B03029399, 2015R1D1A1A01056685]; Yonsei
   University College of Medicine, Seoul, Korea
FX This research was financially supported by the Basic Science Research
   Program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education, Science, and Technology (2012R1A1A1029061
   and 2017R1D1A1B03029399 to SH Lee and 2015R1D1A1A01056685 to HY Gee);
   and the student research grant program of Yonsei University College of
   Medicine, Seoul, Korea (DH Cha).
NR 42
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 21
EP 27
DI 10.1016/j.atherosclerosis.2018.04.011
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300004
PM 29674289
DA 2019-10-28
ER

PT J
AU Stolberg, CR
   Mundbjerg, LH
   Funch-Jensen, P
   Gram, B
   Bladbjerg, EM
   Juhl, CB
AF Stolberg, Charlotte Ron
   Mundbjerg, Lene Hymoller
   Funch-Jensen, Peter
   Gram, Bibi
   Bladbjerg, Else-Marie
   Juhl, Claus Bogh
TI Effects of gastric bypass surgery followed by supervised physical
   training on inflammation and endothelial function: A randomized
   controlled trial
SO ATHEROSCLEROSIS
LA English
DT Article
DE C-reactive protein (CRP); Exercise; Intercellular adhesion molecule 1
   (ICAM-1); Interleukin 6 (IL-6); Tissue-type plasminogen activator
   antigen (t-PA:Ag); Von willebrand factor (vWF)
ID TISSUE-PLASMINOGEN ACTIVATOR; CARDIOVASCULAR RISK-FACTORS; C-REACTIVE
   PROTEIN; BARIATRIC SURGERY; WEIGHT-LOSS; INSULIN-RESISTANCE;
   ADIPOSE-TISSUE; OBESE WOMEN; EXERCISE; OVERWEIGHT
AB Background and aims: Obesity and physical inactivity are both associated with low-grade inflammation and endothelial dysfunction. Bariatric surgery improves markers of inflammation and endothelial function, but it is unknown if physical training after bariatric surgery can improve these markers even further. Therefore, we aimed to investigate the effects of Roux-en-Y gastric bypass (RYGB) followed by physical training on markers of low-grade inflammation and endothelial function.
   Methods: Sixty patients approved for RYGB underwent examinations pre-surgery, 6, 12, and 24 months post-surgery. Six months post-surgery, they were randomized 1:1 to an intervention group or a control group. The interventions consisted of two weekly sessions of supervised moderate intensity physical training for a period of 26 weeks. Fasting blood samples were analyzed for concentrations of interleukin 6 (IL-6), C-reactive protein (CRP), intercellular adhesion molecule 1 (ICAM-1), tissue-type plasminogen activator antigen (t-PA:Ag) and von Willebrand factor (vWF).
   Results: RYGB markedly improved markers of inflammation (IL-6, CRP) (p < 0.001) and endothelial function (ICAM-1, t-PA:Ag, vWF) (p < 0.05), and the improvements were sustained 24 months postsurgery (p < 0.01), except for the effects on vWF. We found no correlations between the changes in weight or BMI and the changes in markers of inflammation and endothelial function, except that the change in vWF was found to be inversely correlated with the changes in weight and BMI. We observed no effects of supervised physical training on markers on inflammation or endothelial function (p> 0.1 for all).
   Conclusions: RYGB causes substantial and sustained favorable effects on markers of inflammation and endothelial function. Supervised physical training after RYGB did not cause additional improvements. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Stolberg, Charlotte Ron; Mundbjerg, Lene Hymoller; Juhl, Claus Bogh] Hosp Southwest Jutland, Dept Med, Sect Endocrinol, Egtved, Denmark.
   [Stolberg, Charlotte Ron; Mundbjerg, Lene Hymoller; Gram, Bibi; Bladbjerg, Else-Marie; Juhl, Claus Bogh] Univ Southern, Dept Reg Hlth Res, Odense, Denmark.
   [Stolberg, Charlotte Ron; Mundbjerg, Lene Hymoller] Odense Univ Hosp, Odense Patient Data Explorat Network, OPEN, Odense, Denmark.
   [Funch-Jensen, Peter] Aarhus Univ Hosp, Dept Clin Med, Aarhus, Denmark.
   [Bladbjerg, Else-Marie] Hosp Southwest Jutland, Dept Clin Biochem, Unit Thrombosis Res, Egtved, Denmark.
RP Stolberg, CR (reprint author), Sydvestjysk Sygehus, Endokrinologisk Ambulatorium, Finsensgade 35, DK-6700 Esbjerg, Denmark.
EM Charlotte.roen.stolberg@rsyd.dk
OI Bladbjerg, Else Marie/0000-0003-0912-2437
FU Department of Regional Health Research, University of Southern Denmark;
   Hospital of Southwest Jutland, Denmark; Department of
   Medicine/Endocrinology, Hospital of Southwest Jutland, Denmark; Region
   of Southern Denmark; Karola Jorgensen Research Foundation; Edith and
   Vagn Hedegaard Jensens Foundation; Family Hede Nielsens Foundation
FX The research was supported by the Department of Regional Health
   Research, University of Southern Denmark and Hospital of Southwest
   Jutland, Denmark; the Department of Medicine/Endocrinology, Hospital of
   Southwest Jutland, Denmark; The Region of Southern Denmark; The Karola
   Jorgensen Research Foundation; The Edith and Vagn Hedegaard Jensens
   Foundation and The Family Hede Nielsens Foundation.
NR 54
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 37
EP 44
DI 10.1016/j.atherosclerosis.2018.04.002
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300006
PM 29677629
DA 2019-10-28
ER

PT J
AU Amoakwa, K
   Fashanu, OE
   Tibuakuu, M
   Zhao, D
   Guallar, E
   Whelton, SP
   O'Neal, WT
   Post, WS
   Budoff, MJ
   Michos, ED
AF Amoakwa, Kojo
   Fashanu, Oluwaseun E.
   Tibuakuu, Martin
   Zhao, Di
   Guallar, Eliseo
   Whelton, Seamus P.
   O'Neal, Wesley T.
   Post, Wendy S.
   Budoff, Matthew J.
   Michos, Erin D.
TI Resting heart rate and the incidence and progression of valvular
   calcium: The Multi-Ethnic Study of Atherosclerosis (MESA)
SO ATHEROSCLEROSIS
LA English
DT Article
DE Resting heart rate; Aortic valve calcium; Mitral annular calcium;
   Progression; Cardiovascular; Computed tomography
ID AORTIC-VALVE CALCIFICATION; MITRAL ANNULUS CALCIFICATION;
   CARDIOVASCULAR-DISEASE; COMPUTED-TOMOGRAPHY; RISK-FACTORS; STENOSIS;
   ASSOCIATION; CORONARY; POPULATION; REPRODUCIBILITY
AB Background and aims: Left-sided valvular calcification is associated with cardiovascular disease (CVD) morbidity and mortality. Resting heart rate (RHR) may influence valvular calcium progression through shear stress. Whether RHR, an established CVD risk factor, is associated with valvular calcium progression is unknown. We assessed whether RHR predicts incidence and progression of mitral annular calcium (MAC) and aortic valve calcium (AVC) in a community-based cohort free of CVD at baseline. Methods: RHR was obtained from baseline electrocardiograms of 5498 MESA participants. MAC and AVC were quantified using Agatston scoring from cardiac computed tomography scans obtained at baseline and at a second examination during follow-up. We examined associations of RHR with incident MAC/AVC and annual change in MAC/AVC scores, after adjusting for demographics, CVD risk factors, physical activity, and atrioventricular nodal blocker use.
   Results: At baseline, participants had mean age of 62 +/- 10 years and mean RHR of 63 10 bpm; 12.3% and 8.9% had prevalent AVC and MAC, respectively. Over a median of 2.3 years, 4.1% and 4.5% developed incident AVC and MAC, respectively. Each 10 bpm higher RHR was significantly associated with incident MAC [Risk Ratio 1.17 (95% CI 1.03-1.34)], but not incident AVC. However, RHR was associated with AVC progression [(beta=1.62 (0.45-2.80) Agatston units/year for every 10 bpm increment], but not MAC progression.
   Conclusions: Higher RHR was associated with MAC incidence and AVC progression, independent of traditional CVD risk factors. Future studies are needed to determine whether modification of RHR through lifestyle or pharmacologic interventions can reduce valvular calcium incidence or progression. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Amoakwa, Kojo] St Agnes Healthcare, Baltimore, MD USA.
   [Fashanu, Oluwaseun E.; Tibuakuu, Martin; Zhao, Di; Guallar, Eliseo; Whelton, Seamus P.; Post, Wendy S.; Michos, Erin D.] Johns Hopkins Sch Med, Ciccarone Ctr Prevent Cardiovasc Dis, Baltimore, MD USA.
   [Tibuakuu, Martin] St Lukes Hosp, Dept Med, Chesterfield, MO USA.
   [Zhao, Di; Guallar, Eliseo; Post, Wendy S.; Michos, Erin D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [O'Neal, Wesley T.] Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA USA.
   [Budoff, Matthew J.] Univ Calif Los Angeles, Med Ctr, Los Angeles Biomed Res Inst Harbor, Los Angeles, CA 90024 USA.
RP Michos, ED (reprint author), Johns Hopkins Univ, Sch Med, Ciccarone Ctr Prevent Heart Dis, Div Cardiol, Baltimore, MD 21287 USA.
EM edonnell@jhmi.edu
OI Michos, Erin/0000-0002-5547-5084; Budoff, Matthew/0000-0002-9616-1946
FU Blumenthal Scholars Fund for Preventive Cardiology Research at Johns
   Hopkins School of Medicine; Pollin Preventive Cardiology Research Fund
   at Johns Hopkins School of Medicine; National Heart, Lung, And Blood
   Institute (NHLBI) of the National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [F32-HL134290];
   NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL071739, HHSN268201500003I, N01-HC-95159,
   N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164,
   N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169];
   NCATSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1-TR-000040, UL1-TR-001079,
   UL1-TR-001420]
FX Drs. Michos and Zhao were supported by the Blumenthal Scholars Fund for
   Preventive Cardiology Research at Johns Hopkins School of Medicine. Dr.
   Fashanu is supported by the Pollin Preventive Cardiology Research Fund
   at Johns Hopkins School of Medicine. Dr. O'Neal is supported by the
   National Heart, Lung, And Blood Institute (NHLBI) of the National
   Institutes of Health under award number F32-HL134290. This research was
   supported by grant R01 HL071739 from the NHLBI. MESA was supported by
   contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161,
   N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166,
   N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the NHLBI, and by
   grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from NCATS.
NR 34
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 45
EP 52
DI 10.1016/j.atherosclerosis.2018.04.004
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300007
PM 29677630
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Harteveld, AA
   Denswil, NP
   Van Hecke, W
   Kuijf, HJ
   Vink, A
   Spliet, WGM
   Daemen, MJ
   Luijten, PR
   Zwanenburg, JJM
   Hendrikse, J
   van der Kolk, AG
AF Harteveld, Anita A.
   Denswil, Nerissa P.
   Van Hecke, Wim
   Kuijf, Hugo J.
   Vink, Aryan
   Spliet, Wim G. M.
   Daemen, Mat J.
   Luijten, Peter R.
   Zwanenburg, Jaco J. M.
   Hendrikse, Jeroen
   van der Kolk, Anja G.
TI Ex vivo vessel wall thickness measurements of the human circle of Willis
   using 7T MRI
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Brain; Cerebral circulation; Magnetic resonance
   imaging; Vessel wall; Wall thickness
ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK-ASSESSMENT; MIDDLE
   CEREBRAL-ARTERIES; HIGH-RESOLUTION MRI; INTRACRANIAL ATHEROSCLEROSIS;
   CEREBROVASCULAR-DISEASE; POPULATION; VISUALIZATION; METAANALYSIS;
   PLAQUES
AB Background and aims: MRI can detect intracranial vessel wall thickening before any luminal stenosis is present. Apart from representing a vessel wall lesion, wall thickening could also reflect normal (age-related) variations in vessel wall thickness present throughout the intracranial arterial vasculature. The aim of this study was to perform vessel wall thickness measurements of the major intracranial arteries in ex vivo circle of Willis (CoW) specimens using 7T MRI, to obtain more detailed information about wall thickness variations of the intracranial arteries.
   Methods: Fifteen human CoW specimens were scanned at 7T MRI with an ultrahigh-resolution T-1-weighted sequence. Five specimens were used for validation of MRI measurements with histology and evaluation of inter-rater reliability and agreement. The other 10 specimens from patients with (n = 5) and without (n = 5) cerebrovascular disease were used for vessel wall thickness measurements over the entire length of the major arterial segments of the CoW using MRI only.
   Results: MRI measurements showed excellent agreement with histology. Mean wall thickness varied from 0.45 to 0.66 mm, minimum wall thickness from 0.31 to 0.42 mm, maximum wall thickness from 0.52 to 0.86 mm, and normalized wall index from 0.64 to 0.75. On average, vessel walls were thicker for symptomatic patients compared to asymptomatic patients.
   Conclusions: High-resolution MRI enables accurate measurement of vessel wall thickness in ex vivo CoW specimens. Vessel wall thickness measurements over the entire length of segments showed considerable variation both within and between arterial segments of patients. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Harteveld, Anita A.; Luijten, Peter R.; Zwanenburg, Jaco J. M.; Hendrikse, Jeroen; van der Kolk, Anja G.] Univ Med Ctr Utrecht, Dept Radiol, Postbox 85500, NL-3508 GA Utrecht, Netherlands.
   [Denswil, Nerissa P.; Daemen, Mat J.] Acad Med Ctr, Dept Pathol, Postbox 22660, NL-1100 DD Amsterdam, Netherlands.
   [Van Hecke, Wim; Vink, Aryan; Spliet, Wim G. M.] Univ Med Ctr Utrecht, Dept Pathol, Postbox 85500, NL-3508 GA Utrecht, Netherlands.
   [Kuijf, Hugo J.] Univ Med Ctr Utrecht, Image Sci Inst, Postbox 85500, NL-3508 GA Utrecht, Netherlands.
RP Harteveld, AA (reprint author), Univ Med Ctr Utrecht, Dept Radiol, Postbox 85500, NL-3508 GA Utrecht, Netherlands.
EM a.a.harteveld-2@umcutrecht.nl
RI Zwanenburg, Jaco J.M./N-2724-2019
OI Zwanenburg, Jaco J.M./0000-0002-4282-5719; Daemen,
   Mat/0000-0003-1076-199X; Denswil, Nerissa/0000-0002-5420-3909; van der
   Kolk, Anja/0000-0002-8267-8848; Harteveld, Anita/0000-0002-3379-0710
FU Netherlands Organisation for Scientific ResearchNetherlands Organization
   for Scientific Research (NWO) [91712322]; European Research Council
   under European Union/ERCEuropean Research Council (ERC) [637024];
   ERCEuropean Research Council (ERC) [337333]
FX This work was funded by the Netherlands Organisation for Scientific
   Research under grant no91712322 (JH) and the European Research Council
   under the European Union's Horizon 2020 Programme (H2020)/ERC grant
   agreement no637024 (JH) and ERC grant agreement no337333 (JZ).
NR 35
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 106
EP 114
DI 10.1016/j.atherosclerosis.2018.04.023
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300015
PM 29715587
OA Other Gold
DA 2019-10-28
ER

PT J
AU Fernandes, RA
   Ritti-Dias, RM
   Balagopal, PB
   Conceicao, RDO
   Santos, RD
   Cucato, GG
   Bittencourt, MS
AF Fernandes, Romulo Araujo
   Ritti-Dias, Raphael Mendes
   Balagopal, P. Babu
   Conceicao, Raquel D. O.
   Santos, Raul D.
   Cucato, Gabriel Grizzo
   Bittencourt, Marcio Sommer
TI Self-initiated physical activity is associated with high sensitivity
   C-reactive protein: A longitudinal study in 5,030 adults
SO ATHEROSCLEROSIS
LA English
DT Article
DE Exercise; Body mass index; Cardiovascular risk; C reactive protein;
   Inflammation
ID CARDIOVASCULAR RISK-FACTORS; MORTALITY; PROFILES; MEN
AB Background and aims: Structured regular exercise programs decrease high-sensitivity C-reactive protein (hsCRP), a marker of low-grade inflammation in adults. Longitudinal effects of self-initiated physical activity levels (PAL) on hsCRP are less clear. This study evaluated the association of longitudinal changes in hsCRP in relation to modifications in PAL, over time, in a large sample of adults.
   Methods: Participants included 5030 adults, 4045 (80%) males, undergoing routine health screening examinations. Elevated level of hsCRP was defined as >= 3 mg/L. Self-reported PAL, height, weight, blood pressure and blood samples were collected at baseline and after a median of 2.9 years (P25th 1.97 and P75th 4.37 yrs). Participants were stratified according to their PAL at baseline and follow-up as: i) persistently physically inactive; ii) became physically inactive; iii) became physically active; iv) persistently physically active (active both at baseline and follow-up).
   Results: Persistently physically active participants had lower odds of having higher hsCRP (OR = 0.35 [95% CI: 0.25 to 0.48]). The maintenance of high PAL was associated with lower hsCRP in both sexes (men: OR = 0.44 [0.30 to 0.65] and women: OR = 0.35 [0.16 to 0.76]). Participants with overweight/obesity (OR = 0.43 [95% CI: 0.29 to 0.63]) and smokers (OR = 0.123 [95% CI: 0.03 to 0.60]) who were persistently active had lower odds of having higher hsCRP compared to physically inactive peers.
   Conclusions: Self-initiated PAL was longitudinally associated with hsCRP in adults. The data suggest that the initiation or maintenance of PA attenuates the low-grade inflammatory state, independent of sex, body weight and smoking status. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Fernandes, Romulo Araujo] Sao Paulo State Univ UNESP, Presidente Prudente, Brazil.
   [Ritti-Dias, Raphael Mendes] Univ Nove Julho, Sao Paulo, Brazil.
   [Balagopal, P. Babu] Nemours Childrens Specialty Care, Jacksonville, FL USA.
   [Balagopal, P. Babu] Mayo Clin, Coll Med, Jacksonville, FL 32224 USA.
   [Conceicao, Raquel D. O.; Santos, Raul D.; Cucato, Gabriel Grizzo; Bittencourt, Marcio Sommer] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Santos, Raul D.] Univ Sao Paulo, Lipid Clin Heart Inst InCor, Sao Paulo, Brazil.
   [Bittencourt, Marcio Sommer] Fac Israelita Ciencias Saude Albert Einstein, Sao Paulo, Brazil.
RP Ritti-Dias, RM (reprint author), Rua Vergueiro,325 Morumbi, Sao Paulo, Brazil.
EM raphaelritti@gmail.com
RI Bittencourt, Marcio/C-1444-2011; Dias, Raphael Ritti/G-4200-2013;
   Ritti-Dias, Raphael/J-5780-2019; Santos, Raul D./A-1170-2010; Cucato,
   Gabriel/A-6860-2015; Fernandes, Romulo A/G-3114-2012
OI Bittencourt, Marcio/0000-0002-3711-1754; Dias, Raphael
   Ritti/0000-0001-7883-6746; Ritti-Dias, Raphael/0000-0001-7883-6746;
   Santos, Raul D./0000-0002-9860-6582; Cucato,
   Gabriel/0000-0002-2060-8852; Fernandes, Romulo A/0000-0003-1576-8090
NR 20
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 131
EP 135
DI 10.1016/j.atherosclerosis.2018.02.011
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300020
PM 29544861
OA Green Published
DA 2019-10-28
ER

PT J
AU Chu, M
   von Birgelen, C
   Li, YG
   Westra, J
   Yang, JQ
   Holm, NR
   Reiber, JHC
   Wijns, W
   Tu, SX
AF Chu, Miao
   von Birgelen, Clemens
   Li, Yingguang
   Westra, Jelmer
   Yang, Junqing
   Holm, Niels R.
   Reiber, Johan H. C.
   Wijns, William
   Tu, Shengxian
TI Quantification of disturbed coronary flow by disturbed vorticity index
   and relation with fractional flow reserve
SO ATHEROSCLEROSIS
LA English
DT Article
DE Vascular hemodynamics; Flow patterns; Coronary angiography; Coronary
   artery disease; Fractional flow reserve
ID WALL SHEAR-STRESS; ATHEROSCLEROTIC PLAQUE; ARTERY-DISEASE; ANGIOGRAPHY;
   INTERVENTION; SEVERITY; STENOSES; ANATOMY; LESIONS; IMPACT
AB Background and aims: The relation between FFR and local coronary flow patterns is incompletely understood. We aimed at developing a novel hemodynamic index to quantify disturbed coronary flow, and to investigate its relationship with lesion-associated pressure-drop, and fractional flow reserve (FFR).
   Methods: Three-dimensional angiographic reconstruction and computational fluid dynamics were applied to simulate pulsatile coronary flow. Disturbed vorticity index (DVI) was derived to quantify the stenosis-induced flow disturbance. The relation between DVI and pressure-drop was assessed in 9 virtual obstruction models. Furthermore, we evaluated the correlation between DVI, FFR, hyperemic flow velocity, and anatomic parameters in 84 intermediate lesions from 73 patients.
   Results: In virtual models, DVI increased with increasing flow rate, stenosis severity, and lesion complexity. The correlation between DVI and pressure-drop across all models was excellent (determination coefficient R-2 = 0.85, p < 0.001). In vivo, DVI showed a correlation with FFR (rho (rho) = -0.74, p < 0.001) that was stronger than the relations of FFR with hyperemic flow velocity (rho = -0.27, p=0.015), lesion length (rho -0.36, p = 0.001) and percent diameter stenosis (rho = -0.40, p < 0.001).
   Conclusions: DVI, a novel index to quantify disturbed flow, was related to pressure-drop in virtual obstruction models and showed a strong inverse relation with FFR in intermediate lesions in vivo. It supports the prognostic value of FFR and may provide additional information about sources of energy loss when measuring FFR. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Chu, Miao; Tu, Shengxian] Shanghai Jiao Tong Univ, Biomed Instrument Inst, Sch Biomed Engn, Shanghai, Peoples R China.
   [Chu, Miao; Tu, Shengxian] Shanghai Jiao Tong Univ, Shanghai Med X Engn Res Ctr, Shanghai, Peoples R China.
   [von Birgelen, Clemens] MST, Thoraxctr Twente, Dept Cardiol, Enschede, Netherlands.
   [Li, Yingguang; Reiber, Johan H. C.] Leiden Univ, Med Ctr, Div Image Proc, Leiden, Netherlands.
   [Westra, Jelmer; Holm, Niels R.] Aarhus Univ Hosp, Dept Cardiol, Skejby, Denmark.
   [Yang, Junqing] Guangdong Gen Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China.
   [Wijns, William] Natl Univ Ireland, Lambe Inst Translat Med & Curam, Galway, Ireland.
   [Wijns, William] Saolta Univ Healthcare Grp, Galway, Ireland.
RP Tu, SX (reprint author), Shanghai Jiao Tong Univ, Med X Res Inst, Room 123,1954 Huashan Rd, Shanghai 200030, Peoples R China.
EM sxtu@sjtu.edu.cn
RI Li, Yingguang/F-4945-2018; Westra, Jelmer/O-7712-2018
OI Li, Yingguang/0000-0003-3907-4309; Westra, Jelmer/0000-0002-1926-0844;
   Reiber, Johan HC/0000-0002-0387-6417; Tu, Shengxian/0000-0001-9681-1067;
   Wijns, William/0000-0002-7267-4376
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [31500797]; National Key Research and Development Program of
   China [2016YFC0100500]
FX The study was supported by the Natural Science Foundation of China
   (Grant No. 31500797) and the National Key Research and Development
   Program of China (Grant No. 2016YFC0100500).
NR 26
TC 3
Z9 3
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 136
EP 144
DI 10.1016/j.atherosclerosis.2018.02.023
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300021
PM 29501225
DA 2019-10-28
ER

PT J
AU Ress, C
   Paulweber, M
   Goebel, G
   Willeit, K
   Rufinatscha, K
   Strobl, A
   Salzmann, K
   Kedenko, L
   Tschoner, A
   Staudacher, G
   Iglseder, B
   Tilg, H
   Paulweber, B
   Kaser, S
AF Ress, Claudia
   Paulweber, Mariya
   Goebel, Georg
   Willeit, Karin
   Rufinatscha, Kerstin
   Strobl, Anna
   Salzmann, Karin
   Kedenko, Ludmilla
   Tschoner, Alexander
   Staudacher, Gabriele
   Iglseder, Bernhard
   Tilg, Herbert
   Paulweber, Bernhard
   Kaser, Susanne
TI Circulating Wnt inhibitory factor 1 levels are associated with
   development of cardiovascular disease
SO ATHEROSCLEROSIS
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; CAROTID-ARTERY ATHEROSCLEROSIS; SIGNALING
   PATHWAY; DICKKOPF-1 PROMOTES; SCLEROSTIN; CALCIFICATION; ANTAGONIST;
   PROTEIN; ADIPOGENESIS; PATHOGENESIS
AB Background and aims: Wnt signaling is involved in atherosclerotic plaque formation directly and indirectly by modulating cardiovascular risk factors. We investigated whether circulating concentrations of Wnt inhibitors are associated with cardiovascular events in subjects with intermediate cardiovascular risk.
   Methods: 904 non-diabetic subjects participating in the SAPHIR study were assessed. In the SAPHIR study, middle-aged women without overt atherosclerotic disease at study entry were followed up for 10 years. 88 patients of our study cohort developed cardiovascular disease at follow-up (CVD group). Subjects of the CVD group were 1: 2 case-control matched for age, sex, BMI and smoking behavior with subjects without overt cardiovascular disease after a 10 year-follow-up (control group). 18 patients of the CVD group and 19 subjects of the control group were retrospectively excluded due to fulfilling exclusion criteria. Baseline circulating sclerostin, dickkopf (DKK)-1, secreted frizzled-related protein (SFRP)-1 and Wnt inhibitory factor (WIF)-1 levels were assessed by ELISA.
   Results: Baseline systemic SFRP-1 and WIF-1 levels were significantly higher in patients with cardiovascular events (n = 70) when compared to healthy controls (n = 157) while DKK-1 and sclerostin levels were similar in both groups. Logistic regression analysis revealed WIF-1 as a significant predictor of future cardiovascular events.
   Conclusions: Our data suggest that increased SFRP-1 and WIF-1 levels precede the development of symptomatic atherosclerotic disease. Assessment of systemic WIF-1 levels, which turned out to be independently associated with CVD, might help to early identify patients at intermediate cardiovascular risk. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Ress, Claudia; Rufinatscha, Kerstin; Strobl, Anna; Salzmann, Karin; Tschoner, Alexander; Staudacher, Gabriele; Tilg, Herbert; Kaser, Susanne] Med Univ Innsbruck, Dept Internal Med 1, Innsbruck, Austria.
   [Ress, Claudia; Rufinatscha, Kerstin; Salzmann, Karin; Kedenko, Ludmilla; Kaser, Susanne] Med Univ Innsbruck, Christian Doppler Lab Metab Crosstalk, Innsbruck, Austria.
   [Paulweber, Mariya; Willeit, Karin; Paulweber, Bernhard] Paracelsus Private Univ Salzburg, Dept Internal Med 1, Salzburg, Austria.
   [Goebel, Georg] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Econ, Innsbruck, Austria.
   [Iglseder, Bernhard] Paracelsus Private Univ Salzburg, Dept Geriatr, Salzburg, Austria.
   [Willeit, Karin] Inselspital Bern, Dept Neurol, Bern, Switzerland.
   [Rufinatscha, Kerstin] Heinrich Heine Univ, Univ Hosp, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany.
RP Kaser, S (reprint author), Med Univ Innsbruck, Dept Internal Med 1, Christian Doppler Lab Metab Crosstalk, Anichstr 35, A-6020 Innsbruck, Austria.
EM susanne.kaser@i-med.ac.at
RI Strobl, Anna/A-4218-2018
OI Strobl, Anna/0000-0002-7873-2469
FU Austrian National Bank [15889]
FX This project was supported by an anniversary grant of the Austrian
   National Bank (Jubilaumsfonds Nr 15889).
NR 40
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 1
EP 7
DI 10.1016/j.atherosclerosis.2018.03.045
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300001
PM 29649633
DA 2019-10-28
ER

PT J
AU Hara, T
   Tsukada, N
   Okano, M
   Ishida, T
   Hirata, K
   Shiomi, M
AF Hara, Tetsuya
   Tsukada, Norie
   Okano, Mitsumasa
   Ishida, Tatsuro
   Hirata, Ken-ichi
   Shiomi, Masashi
TI Progression of calcific aortic valve sclerosis in WHHLMI rabbits
SO ATHEROSCLEROSIS
LA English
DT Article
DE WHHLMI rabbits; Aortic valve stenosis; LDL-Cholesterol
ID HERITABLE HYPERLIPIDEMIC RABBITS; ATHEROSCLEROTIC CORONARY-ARTERIES;
   FAMILIAL HYPERCHOLESTEROLEMIA; ANIMAL-MODEL; IN-VIVO; NATURAL-HISTORY;
   STENOSIS; DISEASE; LIPOPROTEINS; CHOLESTEROL
AB Background and aims: Aortic valve stenosis (AS) is the most common valvular heart disease and can be life-threatening. The pathogenesis of aortic valve calcification remains largely unknown, primarily due to the lack of an adequate animal model. The high-cholesterol diet-induced AS model in rabbits is one of the established models, but it has the significant limitation of liver dysfunction leading to low survival rates. We hypothesized that a myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbit, an animal model of familial hypercholesterolemia and atherosclerosis, is a useful animal model of AS.
   Methods: WHHLMI rabbits, aged 20 months and 30 months (n = 19), and control Japanese White rabbits (n = 4), aged 30 months, were used and evaluated by echocardiography under anesthesia. Pathological evaluation and quantitative analyses by polymerase chain reaction (PCR) were also performed.
   Results: The lipid profile was similar between 20 months and 30 months. Two rabbits died due to spontaneous myocardial infarction during the study. Thirty-month-old WHHLMI rabbits exhibited significantly smaller aortic valve area (0.22 +/- 0.006 cm(2) vs. 0.12 +/- 0.01 cm(2), p < 0.05) and higher maximal transvalvular pressure gradient (7.0 +/- 0.32 vs. 9.9 +/- 0.95 mmHg, p < 0.05) than 20 month-old rabbits. Macroscopic examination of excised aortic valves demonstrated thickened and degenerated valve leaflets at 30 months. Histological evaluation confirmed thickened leaflets with calcified nodules at 30 months. Real-time PCR of resected aortic valve also showed increased expression level of calcification-related molecules including osteopontin, Sox9, Bmp2, RANKL, osteoprotegerin, and Runx2 (p < 0.05 each) in 30-month-old rabbits.
   Conclusions: WHHLMI rabbits may be useful models of early-stage AS in vivo. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hara, Tetsuya; Okano, Mitsumasa; Ishida, Tatsuro; Hirata, Ken-ichi] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo, Japan.
   [Tsukada, Norie; Shiomi, Masashi] Kobe Univ, Grad Sch Med, Inst Expt Anim, Kobe, Hyogo, Japan.
   [Tsukada, Norie; Shiomi, Masashi] Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Div Comparat Pathophysiol, Kobe, Hyogo, Japan.
RP Hara, T (reprint author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.; Shiomi, M (reprint author), Kobe Univ, Grad Sch Med, Inst Expt Anim, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.; Shiomi, M (reprint author), Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Div Comparat Pathophysiol,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM thara@med.kobe-u.ac.jp; ieakusm@med.kobe-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [23300157]
FX This work was supported by Grants-In-Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology of
   Japan (#23300157).
NR 51
TC 0
Z9 0
U1 2
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 8
EP 14
DI 10.1016/j.atherosclerosis.2018.03.044
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300002
PM 29654986
DA 2019-10-28
ER

PT J
AU Imahori, Y
   Mathiesen, EB
   Leon, DA
   Hopstock, LA
   Hughes, AD
   Johnsen, SH
   Jorgensen, L
   Emaus, N
   Morgan, KE
AF Imahori, Yume
   Mathiesen, Ellisiv B.
   Leon, David A.
   Hopstock, Laila A.
   Hughes, Alun D.
   Johnsen, Stein Harald
   Jorgensen, Lone
   Emaus, Nina
   Morgan, Katy E.
TI The contribution of obesity to carotid atherosclerotic plaque burden in
   a general population sample in Norway: The Tromso Study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Carotid plaque; Adiposity; Anthropometric measures;
   Waist-to-hip ratio (WHR)
ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK-FACTORS;
   CORONARY-HEART-DISEASE; FOLLOW-UP; SUBCLINICAL ATHEROSCLEROSIS;
   WEIGHT-LOSS; CIRCUMFERENCE; PROGRESSION; ASSOCIATION; ARTERIES
AB Background and aims: Few studies have investigated the association of different measures of adiposity with carotid plaque. We aimed to investigate and compare the associations of four measures of adiposity: body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) with the presence of carotid plaque and total plaque area (TPA) in the right carotid artery.
   Methods: We included 4906 individuals aged 31-88 years who participated in a population-based study with ultrasonography of the right carotid artery. Adiposity measures were converted to sex-specific SD units to allow comparison of effect sizes. TPA was log transformed due to its skewed distribution. Logistic and linear regression models were used respectively to investigate the association of each adiposity measure with the presence of plaque and with log-transformed TPA. Estimates were adjusted for potential confounders and mediators such as blood pressure and lipids.
   Results: After adjustment for age, sex, smoking, and education level, there was strong evidence of an association between all adiposity measures and log-transformed TPA, whereas only WHR was weakly associated with presence of plaque. WHR showed the largest adjusted effect size for both log-transformed TPA (beta 0.055, 95% CI 0.028-0.081) and the presence of plaque (OR 1.07, 95% CI 1.01-1.15). Adjustment for mediators led to appreciable attenuation of observed effects.
   Conclusions: Adiposity is more consistently associated with extent of plaque burden than with whether an individual does or does not have any plaque. There was evidence that established biomarkers mediate much of this association. Abdominal adiposity appears to show the strongest effect. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Imahori, Yume; Leon, David A.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Noncommunicable Dis Epidemiol, London, England.
   [Mathiesen, Ellisiv B.; Johnsen, Stein Harald] UiT Arctic Univ Norway, Univ Hosp North Norway, Dept Clin Med, Dept Neurol, Tromso, Norway.
   [Leon, David A.] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Community Med, Tromso, Norway.
   [Hopstock, Laila A.; Jorgensen, Lone; Emaus, Nina] UiT Arctic Univ Norway, Fac Hlth Sci, Dept Hlth & Care Sci, Tromso, Norway.
   [Jorgensen, Lone] UiT Arctic Univ Norway, Univ Hosp North Norway, Dept Clin Therapeut Serv, Tromso, Norway.
   [Hughes, Alun D.] UCL, UCL Inst Cardiovasc Sci, Fac Populat Hlth Sci, Dept Populat Sci & Expt Med, London, England.
   [Morgan, Katy E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat, Dept Med Stat, London, England.
RP Imahori, Y (reprint author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
EM yume.imahori@lshtm.ac.uk
RI Hughes, Alun/N-3781-2013; Leon, David A/G-2195-2010
OI Hughes, Alun/0000-0001-5432-5271; Leon, David A/0000-0001-9747-1762;
   Hopstock, Laila/0000-0003-0072-7421
NR 42
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 15
EP 20
DI 10.1016/j.atherosclerosis.2018.04.014
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300003
PM 29665456
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Rodriguez-Gallego, E
   Gomez, J
   Domingo, P
   Ferrando-Martinez, S
   Peraire, J
   Vilades, C
   Veloso, S
   Lopez-Dupla, M
   Beltran-Debon, R
   Alba, V
   Vargas, M
   Castellano, AJ
   Leal, M
   Pacheco, YM
   Ruiz-Mateos, E
   Gutierrez, F
   Vidal, F
   Rull, A
AF Rodriguez-Gallego, Esther
   Gomez, Josep
   Domingo, Pere
   Ferrando-Martinez, Sara
   Peraire, Joaquim
   Vilades, Consuelo
   Veloso, Sergi
   Lopez-Dupla, Miguel
   Beltran-Debon, Raul
   Alba, Veronica
   Vargas, Montserrat
   Castellano, Alfonso J.
   Leal, Manuel
   Maria Pacheco, Yolanda
   Ruiz-Mateos, Ezequiel
   Gutierrez, Felix
   Vidal, Francesc
   Rull, Anna
CA CORIS-NADES Events Study Grp
TI Circulating metabolomic profile can predict dyslipidemia in HIV patients
   undergoing antiretroviral therapy
SO ATHEROSCLEROSIS
LA English
DT Article
DE ART therapy; Dyslipidemia; HIV; Lipids; Lipoproteins; Metabolomics; NMR
ID IMMUNODEFICIENCY-VIRUS-INFECTION; DENSITY LIPOPROTEIN CHOLESTEROL;
   CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; PARTICLE NUMBER; PLASMA
   LACTATE; LIPID PROFILE; RISK-FACTORS; HAART; ATHEROSCLEROSIS
AB Background and aims: Dyslipidemia in HIV-infected patients is unique and pathophysiologically associated with host factors, HIV itself and the use of antiretroviral therapy (ART). The use of nuclear magnetic resonance spectroscopy (NMR) provides additional data to conventional lipid measurements concerning the number of lipoprotein subclasses and particle sizes.
   Methods: To investigate the ability of lipoprotein profile, we used a circulating metabolomic approach in a cohort of 103 ART-naive HIV-infected patients, who were initiating non-nucleoside analogue transcriptase inhibitor (NNRTI)-based ART, and we subsequently followed up these patients for 36 months. Univariate and multivariate analyses were performed to evaluate the predictive power of NMR spectroscopy.
   Results: VLDL-metabolism (including VLDL lipid concentrations, sizes, and particle numbers), total triglycerides and lactate levels resulted in good classifiers of dyslipidemia (AUC 0.903). Total particles/HDLP ratio was significantly higher in ART-associated dyslipidemia compared to ART-normolipidemia (p = 0.001). Large VLDL-Ps were positively associated with both LDL-triglycerides (rho 0.682, p < 0.001) and lactate concentrations (rho 0.416, p < 0.001), the last one a marker of mitochondrial low oxidative capacity.
   Conclusions: Our data suggest that circulating metabolites have better predictive values for HIV/ART-related dyslipidemia onset than do the biochemical markers associated with conventional lipid measurements. NMR identifies changes in VLDL-P, lactate and LDL-TG as potential clinical markers of baseline HIV-dyslipidemia predisposition. Differences in circulating metabolomics, especially differences in particle size, are indicators of important derangements of mitochondrial function that are linked to ART related dyslipidemia. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Rodriguez-Gallego, Esther; Gomez, Josep; Peraire, Joaquim; Vilades, Consuelo; Veloso, Sergi; Lopez-Dupla, Miguel; Beltran-Debon, Raul; Alba, Veronica; Vargas, Montserrat; Castellano, Alfonso J.; Vidal, Francesc; Rull, Anna] Univ Rovira & Virgili, Hosp Univ Joan 23, IISPV, Tarragona, Spain.
   [Gomez, Josep] Univ Rovira & Virgili, Dept Elect Engn, IISPV, Metabol Platform, Tarragona, Spain.
   [Domingo, Pere] Hosp Santa Creu & Sant Pau, Infect Dis Unit, Barcelona, Spain.
   [Ferrando-Martinez, Sara] NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Leal, Manuel; Maria Pacheco, Yolanda; Ruiz-Mateos, Ezequiel] Univ Seville, Virgen Rocio Univ Hosp, CSIC, Inst Biomed Seville,Lab Immunovirol,IBiS, Seville, Spain.
   [Gutierrez, Felix] Hosp Gen Elche, Infect Dis Unit, Alicante, Spain.
   [Gutierrez, Felix] Univ Miguel Hernandez, Alicante, Spain.
RP Vidal, F; Rull, A (reprint author), Univ Rovira & Virgili, Hosp Univ Joan 23, IISPV, Tarragona, Spain.
EM fvidalmarsal.hj23.ics@gencat.cat; anna.rull@iispv.cat
RI Rodero, Felix Gutierrez/Q-7880-2018; Rull, Anna/A-9438-2017;
   Rodriguez-Gallego, Esther/B-6581-2016; Ruiz-Mateos,
   Ezequiel/P-9741-2019; Beltran-Debon, Raul/A-9287-2014; Pacheco, Yolanda
   M./C-8457-2015; Gomez, Josep/H-2617-2018
OI Rodero, Felix Gutierrez/0000-0002-9485-6867; Rull,
   Anna/0000-0002-8907-7754; Rodriguez-Gallego, Esther/0000-0002-6363-2510;
   Ruiz-Mateos, Ezequiel/0000-0001-6747-7813; Beltran-Debon,
   Raul/0000-0001-9691-1906; Pacheco, Yolanda M./0000-0002-9451-8083;
   Gomez, Josep/0000-0002-0573-7621; Vilades, Consuelo/0000-0002-2991-9593;
   PERAIRE, JOAQUIM/0000-0001-7808-5479; Vidal,
   Francesc/0000-0002-6692-6186
FU Fondo de Investigacion Sanitaria-ISCIII-FEDEREuropean Union (EU)
   [PI08/893, PI10/02635, PI11/02512, PI11/00376, PI12/02283, PI13/0796,
   PI13/02256, PI14/0700, PI14/0063, PI16/00684, PI16/00503, PI16/01740];
   Ministerio de Sanidad-Politica Social e IgualdadMinistry of Health,
   Spain [EC11-293]; Programa de Suport als Grups de Recerca AGAURAgencia
   de Gestio D'Ajuts Universitaris de Recerca Agaur (AGUAR) [2014SGR250];
   Gilead Fellowship ProgramGilead Sciences [GLD14/293]; FISABIO
   [UGP-14-197, UGP-15-232]; SPANISH AIDS Research Network-ISCIII-FEDER
   (Spain) [RD12/0017/0005, RD12/0017/0014, RD12/0017/0023, RD16/0025/0006,
   RD16/0025/0020, RD16/0025/0038]; Programa de Intensificacion de
   Investigadores-ISCIII [INT11/240, INT12/282, INT12/383, INT13/232,
   INT15/226]; Programa Miguel Servet-ISCIII [CPII13/00037, CPII014/00025];
   Consejeria de Salud y Bienestar Social of Junta de Andalucia through
   Programa Nicolas Monardes [C-0010/13]; Accio Instrumental d'incorporacio
   de cientifics i tecnolegs from Departament de Salut-Generalitat de
   Catalunya (PERIS) [SLT002/16/00101]
FX This work was supported by the Fondo de Investigacion Sanitaria
   [PI08/893, PI10/02635, PI11/02512, PI11/00376, PI12/02283, PI13/0796,
   PI13/02256, PI14/0700, PI14/0063, PI16/00684, PI16/00503,
   PI16/01740]-ISCIII-FEDER; Ministerio de Sanidad-Politica Social e
   Igualdad (EC11-293); Programa de Suport als Grups de Recerca AGAUR
   (2014SGR250); Gilead Fellowship Program GLD14/293; FISABIO (UGP-14-197,
   UGP-15-232); The SPANISH AIDS Research Network [RD12/0017/0005,
   RD12/0017/0014, RD12/0017/0023, RD16/0025/0006, RD16/0025/0020,
   RD16/0025/0038]-ISCIII-FEDER (Spain). PD and FV are supported by a
   grants from the Programa de Intensificacion de Investigadores
   [INT11/240, INT12/282, INT12/383, INT13/232, INT15/226]-ISCIII. YMP and
   ER-M are supported by the Programa Miguel Servet [CPII13/00037,
   CPII014/00025]-ISCIII. YMP is also supported by the Consejeria de Salud
   y Bienestar Social of Junta de Andalucia through Programa Nicolas
   Monardes (C-0010/13). AR is supported by a grant from the Accio
   Instrumental d'incorporacio de cientifics i tecnolegs from Departament
   de Salut-Generalitat de Catalunya (PERIS SLT002/16/00101).
NR 32
TC 4
Z9 4
U1 2
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 28
EP 36
DI 10.1016/j.atherosclerosis.2018.04.008
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300005
PM 29677628
DA 2019-10-28
ER

PT J
AU Macedoni, M
   Hovnik, T
   Plesnik, E
   Kotnik, P
   Bratina, N
   Battelino, T
   Groselj, U
AF Macedoni, Maddalena
   Hovnik, Tinka
   Plesnik, Emil
   Kotnik, Primoz
   Bratina, Natasa
   Battelino, Tadej
   Groselj, Urh
TI Metabolic control, ApoE genotypes, and dyslipidemia in children,
   adolescents and young adults with type 1 diabetes
SO ATHEROSCLEROSIS
LA English
DT Article
DE Dyslipidemia; Type 1 diabetes; APOE genotype; Metabolic control; Lipid
   profiles; Children
ID APOLIPOPROTEIN-E POLYMORPHISM; CARDIOVASCULAR RISK-FACTORS;
   PEDIATRIC-PATIENTS; GLYCEMIC CONTROL; HEART-DISEASE; LIPID-LEVELS;
   ASSOCIATION; ATHEROSCLEROSIS; PREVALENCE; MORTALITY
AB Background and aims: Limited data is available on the factors influencing the lipid profiles and the prevalence of dyslipidemia in children, adolescents and young adults with type 1 diabetes. We aimed at assessing the influences of metabolic control and ApoE genotypes on lipid profiles and the prevalence of dyslipidemia in children, adolescents and young adults with type 1 diabetes.
   Methods: Children, adolescents and young adults with type 1 diabetes from our nationwide cohort attending the annual check-up were prospectively included. Data on metabolic control and expanded lipid profiles were collected, and ApoE genotyping performed. Test for homoscedasticity of continuous variables was followed by ANOVA and Welch's ANOVA tests, and Chi-square test was used for categorical variables with Kruskal-Wallis test as a control.
   Results: 467 patients were included in the data analysis: 226 female (48.4%), mean age 14.71 5.09 years and diabetes duration 6.74 + 4.54 years. Mean HbAlc was 61 + 5 mmoL/mol (7.71 + 1.22%), with no gender-related differences. Females had higher mean total cholesterol (p < 0.001), LDL-C (p = 0.005), HDL-C (p < 0.001), non-HDL-C (p = 0.003), and ApoB levels (p < 0.001). 26.3% of participants had LDL-C levels above the type 1 diabetes LDL-C-goal of 2.6 mmoL/L, and 19.5% had elevated/borderlineelevated lipoprotein(a) (Lp(a)). HbAlc levels were positively related to higher levels of LDL-C (p = 0.0070) and Lp(a) (p = 0.0020). Participants with ApoE4(e3/e4) allele had higher levels of LDL-C (p = 0.010), independently of HbAlc.
   Conclusions: Females and subjects with suboptimal metabolic control had more adverse lipid profiles. ApoE4(e3/e4) alleles were associated with significantly higher LDL-C levels, independently of HbAlc. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Macedoni, Maddalena] Univ Milan, V Buzzi Childrens Hosp, Dept Pediat, Sect Diabet & Metab, Milan, Italy.
   [Hovnik, Tinka; Kotnik, Primoz; Bratina, Natasa; Battelino, Tadej; Groselj, Urh] UMC Ljubljana, Univ Childrens Hosp, Ljubljana, Slovenia.
   [Plesnik, Emil] Marand Doo, Ljubljana, Slovenia.
   [Kotnik, Primoz; Battelino, Tadej] Univ Ljubljana, Fac Med, Ljubljana, Slovenia.
RP Groselj, U (reprint author), Univ Med Ctr Ljubljana, Univ Childrens Hosp, Dept Pediat Endocrinol Diabet & Metab Dis, Bohoriceva 20, SI-1000 Ljubljana, Slovenia.
EM urh.groselj@kclj.si
OI Groselj, Urh/0000-0002-5246-9869; Battelino, Tadej/0000-0002-0273-4732
FU ISPAD Fellowship Grant; Slovene National Research Agency [P3-0343,
   J3-6798]; UMC Ljubljana RD grant [20150138]
FX Maddalena Macedoni received funding from 2015 ISPAD Fellowship Grant.
   The study was supported in part by the Slovene National Research Agency
   Grants P3-0343, J3-6798 and the UMC Ljubljana R&D grant No. 20150138.
NR 41
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 53
EP 58
DI 10.1016/j.atherosclerosis.2018.04.013
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300008
PM 29679801
DA 2019-10-28
ER

PT J
AU Wu, ZQ
   Camargo, CA
   Khaw, KT
   Waayer, D
   Lawes, CMM
   Toop, L
   Scragg, R
AF Wu, Zhenqiang
   Camargo, Carlos A., Jr.
   Khaw, Kay-Tee
   Waayer, Debbie
   Lawes, Carlene M. M.
   Toop, Les
   Scragg, Robert
TI Effects of vitamin D supplementation on adherence to and persistence
   with long-term statin therapy: Secondary analysis from the randomized,
   double-blind, placebo-controlled ViDA study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Vitamin D; Statin; Adherence; Persistence
ID DRUG-THERAPY; CHOLESTEROL; IMPACT; RISK; INTERVENTION; METAANALYSIS;
   INTOLERANCE; MORTALITY; EFFICACY; MYALGIA
AB Background and aims: Long-term statin use increases survival. However, the adherence to and persistence with statin use are challenging and this influences the success of statin treatment. Our aim was to explore if monthly vitamin D supplementation (100,0004U) improves the adherence to and persistence with long-term statin use in older adults.
   Methods: We conducted a secondary analysis of a trial comparing data on dispensed statin prescriptions, between participants allocated to vitamin D supplementation or placebo, for those taking statin therapy. Primary outcomes were defined as adherence to (proportion of days covered by prescriptions >80%) and persistence (non-discontinuation of the statin therapy following an allowed 30 days gap between refills) with all statins over a 24-month measurement period of statin therapy. Secondary outcomes were defined as adherence and persistence at other measurement periods for all types of statins and for individual statins.
   Results: Overall, 2494 participants were on long-term statins at follow-up (vitamin D =1243, placebo = 1251). Compared with placebo, monthly vitamin D supplementation did not improve the proportion with adherence (risk ratio: 1.01, p=0.62), but improved the persistence probability of taking all statins after 24 months (hazard ratio: 1.15, p=0.02). In further analyses, significant differences were observed in the adherence to simvastatin, the first-line statin therapy.
   Conclusions: Monthly vitamin D supplementation improved persistence with statins use over a 24 month measurement period in older adults on long-term statin therapy, especially for participants on simvastatin. The role of vitamin D supplementation as an adjunct therapy for patients on long-term statins merits further investigation. (C) 2018 Published by Elsevier B.V.
C1 [Wu, Zhenqiang; Waayer, Debbie; Lawes, Carlene M. M.; Scragg, Robert] Univ Auckland, Sch Populat Hlth, Private Bag 92019, Auckland 1142, New Zealand.
   [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
   [Khaw, Kay-Tee] Univ Cambridge, Dept Publ Hlth, Cambridge, England.
   [Toop, Les] Univ Otago, Dept Publ Hlth & Gen Practice, Christchurch, New Zealand.
RP Scragg, R (reprint author), Univ Auckland, Sch Populat Hlth, Private Bag 92019, Auckland 1142, New Zealand.
EM r.scragg@auckland.ac.nz
RI Camargo, Carlos A./C-2145-2008
OI Camargo, Carlos A./0000-0002-5071-7654; Waayer,
   Debbie/0000-0003-4627-8342; Wu, Zhenqiang/0000-0002-6712-8602
FU Health Research Council of New ZealandHealth Research Council of New
   Zealand [10/400]; Accident Compensation Corporation of New Zealand
FX This work was supported by the Health Research Council of New Zealand
   (grant 10/400), the main government funder of research, and by the
   Accident Compensation Corporation of New Zealand, the main government
   insurer for accidents.
NR 32
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 59
EP 66
DI 10.1016/j.atherosclerosis.2018.04.009
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300009
PM 29684661
DA 2019-10-28
ER

PT J
AU Chen, X
   Duong, MN
   Nicholls, SJ
   Bursill, C
AF Chen, Xing
   My-Ngan Duong
   Nicholls, Stephen J.
   Bursill, Christina
TI Myeloperoxidase modification of high-density lipoprotein suppresses
   human endothelial cell proliferation and migration via inhibition of
   ERK1/2 and Akt activation
SO ATHEROSCLEROSIS
LA English
DT Article
DE Endothelial cells; High-density lipoproteins; Myeloperoxidase;
   Proliferation; Migration
ID APOLIPOPROTEIN-A-I; NITRIC-OXIDE SYNTHASE; INCIDENT CARDIOVASCULAR
   EVENTS; LIPID-PEROXIDATION; CHOLESTEROL TRANSPORT; HDL; OXIDATION;
   KINASE; DISEASE; IMPAIRS
AB Background and aims: Preclinical studies show high-density lipoproteins (HDL) have a protective and reparative effect on the endothelium. HDL is, however, susceptible to oxidation, which affects function. Myeloperoxidase (MPO)-induced modification of HDL results in loss of anti-apoptotic and anti-inflammatory functions, however, its effect on endothelial proliferation and migration has not been characterized.
   Methods: HUVECs were co-incubated with MPO-oxidised-or native-HDL (nHDL) in proliferation and migration assays. Signalling proteins were assessed in Western blots.
   Results: nHDL caused dose-dependent increases of endothelial proliferation and migration. Consistent with an increase in cellular proliferation, HDL also stimulated proliferative cellular nuclear antigen (PCNA) expression and ERK phosphorylation in a concentration-dependent manner, which did not occur with MPO-oxidised HDL. HDL increased Akt phosphorylation, a driver of cellular migration. Contrastingly, MPO-oxidised HDL was unable to increase Akt phosphorylation and extensively-oxidised HDL inhibited Akt phosphorylation.
   Conclusions: HDL promotes endothelial proliferation and migration, mediated in part via activation of ERK and Akt signalling. MPO-induced oxidative modification of HDL attenuates the endothelial-protective effects of HDL. These findings suggest that in an oxidative milieu, present in ageing and disease, HDL is likely to become ineffective. This has implications for HDL-raising therapies and emphasizes the need for strategies that prevent oxidation-related HDL dysfunction. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Chen, Xing; My-Ngan Duong; Nicholls, Stephen J.] Cleveland Clin, Dept Cell Biol & Cardiovasc Med, Cleveland, OH 44195 USA.
   [My-Ngan Duong; Nicholls, Stephen J.; Bursill, Christina] South Australian Hlth & Med Res Inst, Heart Hlth, Adelaide, SA 5000, Australia.
   [My-Ngan Duong; Nicholls, Stephen J.; Bursill, Christina] Univ Adelaide, Dept Hlth & Med Sci, Adelaide, SA 5000, Australia.
RP Duong, MN (reprint author), South Australian Hlth & Med Res Inst, Heart Hlth, POB 11060, Adelaide, SA 5001, Australia.
EM myngan.duong@sahmri.com
OI Nicholls, Stephen/0000-0002-9668-4368; Bursill,
   Christina/0000-0002-0682-8760
FU departmental funds at Cleveland Clinic Foundation
FX Funding was provided by departmental funds at Cleveland Clinic
   Foundation.
NR 48
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 75
EP 83
DI 10.1016/j.atherosclerosis.2018.04.006
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300011
PM 29702428
DA 2019-10-28
ER

PT J
AU Furuta, Y
   Hata, J
   Mukai, N
   Hirakawa, Y
   Ago, T
   Kitazono, T
   Kiyohara, Y
   Ninomiya, T
AF Furuta, Yoshihiko
   Hata, Jun
   Mukai, Naoko
   Hirakawa, Yoichiro
   Ago, Tetsuro
   Kitazono, Takanari
   Kiyohara, Yutaka
   Ninomiya, Toshiharu
TI Secular trends in the incidence, risk factors, and prognosis of
   transient ischemic attack in Japan: The Hisayama Study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Transient ischemic attack; Incidence; Epidemiology; Cohort study; Risk
   factors
ID POPULATION; STROKE; ATHEROSCLEROSIS; COMMUNITY; DISEASE
AB Background and aims: We aimed to investigate secular trends in the incidence, risk factors, and prognosis of transient ischemic attack (TIA) in a general Japanese population.
   Methods: Two cohorts consisting of stroke-free Japanese individuals aged >= 40 years in 1961 (n = 1621) and 1988 (n = 2646) were followed up for 24 years. The associations of potential risk factors with the development of TIA were estimated by a Cox proportional hazards model. The influence of TIA on the risk of total stroke over the subsequent 10 years was compared between the sub-cohorts of subjects with TIA and age-and sex-matched control subjects from each cohort.
   Results: During follow-up, 28 subjects in the 1961 cohort and 34 in the 1988 cohort experienced TIA. The age-standardized incidence of TIA was significantly lower in the 1988 cohort than the 1961 cohort (0.66 vs. 1.01 per 1000 person-years, p = 0.02). While elevated systolic blood pressure was significantly associated with the risk of TIA in both cohorts, glucose intolerance and higher serum cholesterol levels were associated with TIA risk only in the 1988 cohort. The subjects experiencing TIA had approximately 7-8-fold higher risks for the 10-year incidence of total and ischemic strokes compared with the corresponding control subjects without TIA both in the 1961 and 1988 sub-cohorts, and the relative risks were not significantly different between sub-cohorts.
   Conclusions: Our results suggest that the incidence of TIA decreased during the past half century, probably due to the spread of antihypertensive treatments in the general Japanese population. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Furuta, Yoshihiko; Hata, Jun; Mukai, Naoko; Hirakawa, Yoichiro; Ninomiya, Toshiharu] Kyushu Univ, Grad Sch Med Sci, Dept Epidemiol & Publ Hlth, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Furuta, Yoshihiko; Hata, Jun; Mukai, Naoko; Hirakawa, Yoichiro; Ago, Tetsuro; Kitazono, Takanari] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Hata, Jun; Mukai, Naoko; Kitazono, Takanari; Ninomiya, Toshiharu] Kyushu Univ, Grad Sch Med Sci, Ctr Cohort Studies, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Kiyohara, Yutaka] Hisayama Res Inst Lifestyle Dis, 1822-1 Kubara, Hisayama, Fukuoka 8112501, Japan.
RP Hata, J (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Epidemiol & Publ Hlth, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
EM junhata@eph.med.kyushu-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [JP16H02644, JP16H02692, JP16H05850, JP16H05557,
   JP17H04126, JP15K09267, JP15K08738, JP15K09835, JP16K09244, JP17K09114,
   JP17K09113, JP17K01853]; Health and Labour Sciences Research Grants of
   the Ministry of Health, Labour and Welfare of JapanMinistry of Health,
   Labour and Welfare, Japan [H25-Junkankitou [Seishuu]-Sitei-022,
   H29-Junkankitou-Ippan-003, H27-Shokuhin-[Sitei]-017]; Japan Agency for
   Medical Research and DevelopmentJapan Agency for Medical Research and
   Development (AMED) [dk0207025, ek0210082, gm0610007, ek0210083,
   km0405202, ek0210080]
FX This study was supported in part by Grants-in-Aid for Scientific
   Research (A) (JP16H02644, and JP16H02692) and (B) (JP16H05850,
   JP16H05557, and JP17H04126) and (C) (JP15K09267, JP15K08738, JP15K09835,
   JP16K09244, JP17K09114, JP17K09113, and JP17K01853) from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan; by Health
   and Labour Sciences Research Grants of the Ministry of Health, Labour
   and Welfare of Japan (H25-Junkankitou [Seishuu]-Sitei-022,
   H29-Junkankitou-Ippan-003, and H27-Shokuhin-[Sitei]-017); and by the
   Japan Agency for Medical Research and Development (dk0207025, ek0210082,
   gm0610007, ek0210083, km0405202, ek0210080).
NR 26
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 84
EP 90
DI 10.1016/j.atherosclerosis.2018.04.010
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300012
PM 29702429
DA 2019-10-28
ER

PT J
AU Bogiatzi, C
   Gloor, G
   Allen-Vercoe, E
   Reid, G
   Wong, RG
   Urquhart, BL
   Dinculescu, V
   Ruetz, KN
   Velenosi, TJ
   Pignanelli, M
   Spence, JD
AF Bogiatzi, Chrysi
   Gloor, Gregory
   Allen-Vercoe, Emma
   Reid, Gregor
   Wong, Ruth G.
   Urquhart, Bradley L.
   Dinculescu, Vincent
   Ruetz, Kelsey N.
   Velenosi, Thomas J.
   Pignanelli, Michael
   Spence, J. David
TI Metabolic products of the intestinal microbiome and extremes of
   atherosclerosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Intestinal microbiome; Renal impairment; TMAO;
   Resistant atherosclerosis
ID TRIMETHYLAMINE-N-OXIDE; CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE;
   P-CRESOL; HEMODIALYSIS-PATIENTS; GUT MICROBIOTA; L-CARNITINE; RED MEAT;
   RISK; MORTALITY
AB Background and aims: There is increasing awareness that the intestinal microbiome plays an important role in human health. We investigated its role in the burden of carotid atherosclerosis, measured by ultrasound as total plaque area.
   Methods: Multiple regression with traditional risk factors was used to identify three phenotypes among 316/3056 patients attending vascular prevention clinics. Residual score (RES; i.e. the distance off the regression line, similar to standard deviation) was used to identify the 5% of patients with much less plaque than predicted by their risk factors (Protected, RES < -2), the 90% with about as much plaque as predicted (Explained, RES -2 to 2), and the 5% with much more plaque than predicted (Unexplained RES >2). Metabolic products of the intestinal microbiome that accumulate in renal failure - gut-derived uremic toxins (GDUT) - were assayed in plasma by ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry.
   Results: Plasma levels of trimethylamine n-oxide (TMAO), p-cresyl sulfate, p-cresyl glucuronide, and phenylacetylglutamine were significantly lower among patients with the Protected phenotype, and higher in those with the Unexplained phenotype, despite no significant differences in renal function or in dietary intake of nutrient precursors of GDUT. In linear multiple regression with a broad panel of risk factors, TMAO (p = 0.011) and p-cresyl sulfate (p = 0.011) were significant independent predictors of carotid plaque burden.
   Conclusions: The intestinal microbiome appears to play an important role in atherosclerosis. These findings raise the possibility of novel approaches to treatment of atherosclerosis such as fecal transplantation and probiotics. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Bogiatzi, Chrysi; Spence, J. David] Western Univ, Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, 1400 Western Rd, London, ON N6G 2V4, Canada.
   [Bogiatzi, Chrysi] McMaster Univ, Dept Neurol, Hamilton, ON, Canada.
   [Gloor, Gregory; Wong, Ruth G.] Western Univ, Schulich Sch Med & Dent, Dept Biochem, London, ON, Canada.
   [Allen-Vercoe, Emma] Univ Guelph, Dept Mol & Cell Biol, Guelph, ON, Canada.
   [Reid, Gregor] Western Univ, Schulich Sch Med & Dent, Dept Urol, London, ON, Canada.
   [Reid, Gregor] Western Univ, Schulich Sch Med & Dent, Dept Microbiol, London, ON, Canada.
   [Urquhart, Bradley L.; Ruetz, Kelsey N.; Velenosi, Thomas J.] Western Univ, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada.
   [Dinculescu, Vincent] Univ Calgary, Dept Radiol, Calgary, AB, Canada.
   [Pignanelli, Michael] Schulich Sch Med & Dent MD Candidate, CIHR Summer Res Training Program, Calgary, AB, Canada.
   [Spence, J. David] Western Univ, Div Neurol, London, ON, Canada.
   [Spence, J. David] Western Univ, Div Clin Pharmacol, London, ON, Canada.
RP Spence, JD (reprint author), Western Univ, Robarts Res Inst, Stroke Prevent & Atherosclerosis Res Ctr, 1400 Western Rd, London, ON N6G 2V4, Canada.
EM dspence@robarts.ca
RI ; Spence, J. David/K-6396-2013
OI Gloor, Gregory/0000-0001-5803-3380; Spence, J. David/0000-0001-7478-1098
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [133416]
FX The study was funded by the Canadian Institutes of Health Research,
   Grant number 133416.
NR 38
TC 16
Z9 16
U1 2
U2 27
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 91
EP 97
DI 10.1016/j.atherosclerosis.2018.04.015
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300013
PM 29702430
DA 2019-10-28
ER

PT J
AU Mofrad, MD
   Djafarian, K
   Mozaffari, H
   Shab-Bidar, S
AF Mofrad, Manije Darooghegi
   Djafarian, Kurosh
   Mozaffari, Hadis
   Shab-Bidar, Sakineh
TI Effect of magnesium supplementation on endothelial function: A
   systematic review and meta-analysis of randomized controlled trials
SO ATHEROSCLEROSIS
LA English
DT Review
DE Magnesium; Endothelial function; meta-Analysis
ID INTIMA-MEDIA THICKNESS; CORONARY RISK-FACTORS; HEMODIALYSIS-PATIENTS;
   DIETARY MAGNESIUM; BRACHIAL-ARTERY; MORTALITY RISK; DOUBLE-BLIND;
   ATHEROSCLEROSIS; DYSFUNCTION; SERUM
AB Background and aims: Findings of past studies are inconsistent regarding the effects of magnesium (Mg) supplementation on endothelial function (EF). We performed this meta-analysis to examine the effects of magnesium supplementation on flow-mediated dilation (FMD) and carotid intima media thickness (CIMT) as markers of EF.
   Methods: Literature searches of English publications in MEDLINE and EMBASE databases were conducted up to November 2017. Results are reported as weighted mean difference (MD) with 95% confidence intervals (CI) using random effects model (DerSimoniane-Laird method). Cochrane's Q test and I-squared (I-2) were used to determine heterogeneity among included studies. To determine potential sources of heterogeneity, subgroup analysis was conducted for pre-defined criteria. Funnel plot and Egger's regression test were used to assess publication bias.
   Results: Seven RCTs with 306 participants were included. Mg supplementation significantly increased FMD (MD: 2.97; 95% CI: 0.23 to 5.70%, p = 0.033). Between studies heterogeneity was high and subgroup analysis could not identify the sources of heterogeneity. Magnesium supplementation had no significant effect on CIMT (MD: -0.13 mm; 95% CI: 0.27, 0.01; p = 0.077) with high heterogeneity. Mg dose, duration of treatment, healthy status, baseline CIMT and sample size were the potential sources of heterogeneity. Mg supplementation could decrease CIMT to a greater extent in hemodialysis (HD) patients; lower doses of Mg, higher sample size and follow up duration and subjects with higher baseline CIMT also reduced the heterogeneity to some degree (p < 0.001).
   Conclusions: Magnesium supplementation may improve endothelial function without affecting carotid intima media thickness. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Mofrad, Manije Darooghegi; Mozaffari, Hadis; Shab-Bidar, Sakineh] Tehran Univ Med Sci, Sch Nutr Sci & Dietet, Dept Community Nutr, POB 14155-6117, Tehran, Iran.
   [Mofrad, Manije Darooghegi] Univ Tehran Med Sci, Students Sci Res Ctr, Tehran, Iran.
   [Djafarian, Kurosh] Tehran Univ Med Sci, Sch Nutr Sci & Dietet, Dept Clin Nutr, Tehran, Iran.
RP Shab-Bidar, S (reprint author), Tehran Univ Med Sci, Sch Nutr Sci & Dietet, Dept Community Nutr, POB 14155-6117, Tehran, Iran.
EM s_shabbidar@tums.ac.ir
RI djafarian, kurosh/D-5563-2018
OI djafarian, kurosh/0000-0002-9134-7178
NR 52
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 98
EP 105
DI 10.1016/j.atherosclerosis.2018.04.020
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300014
PM 29709832
DA 2019-10-28
ER

PT J
AU Gutierrez-Chico, JL
   Zhao, SJ
   Chatzizisis, YS
AF Luis Gutierrez-Chico, Juan
   Zhao, Shijia
   Chatzizisis, Yiannis S.
TI Vorticity: At the crossroads of coronary biomechanics and physiology
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Coronary artery disease; Vorticity; Coronary physiology; Biomechanics
ID FRACTIONAL FLOW RESERVE; WAVE-FREE RATIO
C1 [Luis Gutierrez-Chico, Juan] DRK Klinikum Westend, Berlin, Germany.
   [Luis Gutierrez-Chico, Juan] Punta de Europa Univ Hosp, Cadiz, Spain.
   [Zhao, Shijia; Chatzizisis, Yiannis S.] Univ Nebraska, Cardiovasc Div, Cardiovasc Biol & Biomech Lab, Med Ctr, Omaha, NE USA.
   [Luis Gutierrez-Chico, Juan] Punta de Europa Univ Hosp, Cardiol Dept, Crtra Getares S-N, Cadiz 11207, Spain.
RP Gutierrez-Chico, JL (reprint author), DRK Klinikum Westend, Berlin, Germany.; Gutierrez-Chico, JL (reprint author), Punta de Europa Univ Hosp, Cadiz, Spain.; Gutierrez-Chico, JL (reprint author), Punta de Europa Univ Hosp, Cardiol Dept, Crtra Getares S-N, Cadiz 11207, Spain.
EM juanluis.gutierrezchico@ictra.es
OI Gutierrez-Chico, Juan Luis/0000-0002-0812-7925
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 115
EP 116
DI 10.1016/j.atherosclerosis.2018.04.001
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300016
PM 29665968
DA 2019-10-28
ER

PT J
AU Westerterp, M
AF Westerterp, Marit
TI AIBP decreases atherogenesis by augmenting cholesterol efflux
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Cholesterol efflux; Atherosclerosis; Inflammation
ID HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTERS; ACCELERATES
   ATHEROSCLEROSIS; GENE-EXPRESSION; INFLAMMATION; DEFICIENCY; CAPACITY;
   PROTEIN; CLONING; ABCA1
C1 [Westerterp, Marit] Univ Groningen, Univ Med Ctr Groningen, Sect Mol Genet, Dept Pediat, Groningen, Netherlands.
RP Westerterp, M (reprint author), Univ Med Ctr Groningen, Sect Mol Genet, Dept Pediat, ERIBA Bldg 3226 Room 04-14,Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.
EM m.westerterp@umcg.nl
FU Netherlands Organization of Scientific Research VIDI-grant [917.15.350];
   Rosalind Franklin Fellowship from University Medical Center Groningen
FX M. Westerterp is supported by the Netherlands Organization of Scientific
   Research VIDI-grant 917.15.350, and a Rosalind Franklin Fellowship from
   the University Medical Center Groningen.
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 117
EP 118
DI 10.1016/j.atherosclerosis.2018.04.018
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300017
PM 29699701
DA 2019-10-28
ER

PT J
AU Bellasi, A
   Di Lullo, L
   Raggi, P
AF Bellasi, Antonio
   Di Lullo, Luca
   Raggi, Paolo
TI Cardiovascular calcification: The emerging role of micronutrients
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Phosphate; Magnesium; Aortic valve calcification
ID AORTIC-VALVE DISEASE; VALVULAR CALCIFICATION; ATHEROSCLEROSIS MESA;
   KIDNEY-DISEASE; PHOSPHORUS; HEMODIALYSIS; ASSOCIATION; MORTALITY;
   PHOSPHATE; BINDERS
C1 [Bellasi, Antonio] ASST Lariana, St Anna Hosp, Dept Nephrol & Dialysis, Como, Italy.
   [Di Lullo, Luca] Parodi Delfino Hosp, Dept Nephrol & Dialysis, Colleferro, Italy.
   [Raggi, Paolo] Univ Alberta, Dept Med, Mazankowski Alberta Heart Hosp, Edmonton, AB, Canada.
RP Raggi, P (reprint author), 8440 112 St 4A7-050, Edmonton, AB T6G 2B7, Canada.
EM raggi@ualberta.ca
RI bellasi, antonio/M-3744-2013
OI bellasi, antonio/0000-0001-7830-1645
NR 20
TC 3
Z9 3
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 119
EP 121
DI 10.1016/j.atherosclerosis.2018.04.019
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300018
PM 29705018
DA 2019-10-28
ER

PT J
AU Zhang, M
   Zhao, GJ
   Yao, F
   Xia, XD
   Gong, D
   Zhao, ZW
   Chen, LY
   Zheng, XL
   Tang, XE
   Tang, CK
AF Zhang, Min
   Zhao, Guo-Jun
   Yao, Feng
   Xia, Xiao-Dan
   Gong, Duo
   Zhao, Zhen-Wang
   Chen, Ling-Yan
   Zheng, Xi-Long
   Tang, Xiao-Er
   Tang, Chao-Ke
TI AIBP reduces atherosclerosis by promoting reverse cholesterol transport
   and ameliorating inflammation in apoE(-/-) mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE AIBP; HDL; RCT; NF-kappa B; Atherosclerosis; Inflammation
ID HIGH-DENSITY-LIPOPROTEIN; EFFLUX CAPACITY; HDL CHOLESTEROL;
   BINDING-PROTEIN; APOA-I; ABCA1; ANGIOGENESIS; MACROPHAGES; POLARIZATION;
   DEGRADATION
AB Background and aims: ApoA-1 binding protein (AIBP) is a secreted protein that interacts with apoA-1 and accelerates cholesterol efflux from cells. We have recently reported that AIBP promotes apoA-1 binding to ABCA1 in the macrophage cell membrane, partially through 115-123 amino acids. However, the effects of AIBP on the development of atherosclerosis in vivo remain unknown.
   Methods: ApoE(-/-) mice with established atherosclerotic plaques were infected with rAAV-AIBP or rAAV-AIBP(Delta 115- 123), respectively.
   Results: AIBP-treated mice showed reduction of atherosclerotic lesion formation, increase in circulating HDL levels and enhancement of reverse cholesterol transport to the plasma, liver, and feces. AIBP increased ABCA1 protein levels in aorta and peritoneal macrophages. Furthermore, AIBP could diminish atherosclerotic plaque macrophage content and the expression of chemotaxis-related factors. In addition, AIBP prevented macrophage inflammation by inactivating NF-kappa B and promoted the expression of M2 markers like Mrc-1 and Arg-1. However, lack of 115-123 amino acids of AIBP(Delta 115-123) had no such preventive effects on the progression of atherosclerosis.
   Conclusions: Our observations demonstrate that AIBP inhibits atherosclerosis progression and suggest that it may be an effective target for prevention of atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zhang, Min; Yao, Feng; Xia, Xiao-Dan; Gong, Duo; Zhao, Zhen-Wang; Chen, Ling-Yan; Tang, Chao-Ke] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Med Res Ctr, Inst Cardiovasc Res,Key Lab Atherosclerol Hunan P, Hengyang 421001, Hunan, Peoples R China.
   [Zhao, Guo-Jun] Guilin Med Univ, Dept Histol & Embryol, 1 Zhiyuan Rd, Guilin 541100, Guangxi, Peoples R China.
   [Tang, Xiao-Er] Shaoyang Univ, Dept Pathophysiol, Shaoyang 422000, Hunan, Peoples R China.
   [Zheng, Xi-Long] Univ Calgary, Hlth Sci Ctr, Libin Cardiovasc Inst Alberta, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
RP Tang, CK (reprint author), Univ South China, Inst Cardiovasc Res, Hengyang 421001, Hunan, Peoples R China.; Tang, XE (reprint author), Shaoyang Univ, Dept Pathophysiol, Med Coll, Shaoyang 422000, Hunan, Peoples R China.
EM tangxiaoer19800505@tom.com; tangchaoke@qq.com
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China [81570408, 81370377, 81470569]; construct program of
   the key discipline in Hunan Province, China (Basic Medicine Sciences in
   University of South China) [[2011]76]; University of South China
   Innovation Foundation for Postgraduate [2016XCX04]
FX The authors gratefully acknowledge the financial support from the
   National Natural Sciences Foundation of China (81570408, 81370377, and
   81470569), the construct program of the key discipline in Hunan
   Province, China (Basic Medicine Sciences in University of South China,
   Xiangjiaofa NO. [2011]76), and University of South China Innovation
   Foundation for Postgraduate (2016XCX04).
NR 38
TC 6
Z9 7
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 122
EP 130
DI 10.1016/j.atherosclerosis.2018.03.010
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300019
PM 29555084
DA 2019-10-28
ER

PT J
AU Hisamatsu, T
   Miura, K
   Fujiyoshi, A
   Kadota, A
   Miyagawa, N
   Satoh, A
   Zaid, M
   Yamamoto, T
   Horie, M
   Ueshima, H
AF Hisamatsu, Takashi
   Miura, Katsuyuki
   Fujiyoshi, Akira
   Kadota, Aya
   Miyagawa, Naoko
   Satoh, Atsushi
   Zaid, Maryam
   Yamamoto, Takashi
   Horie, Minoru
   Ueshima, Hirotsugu
CA SESSA Res Grp
TI Serum magnesium, phosphorus, and calcium levels and subclinical calcific
   aortic valve disease: A population-based study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Aortic valve disease; Calcification; Magnesium; Phosphorus; Prospective
   study; Epidemiology
ID CARDIOVASCULAR-DISEASE; ATHEROSCLEROSIS MESA; METABOLIC SYNDROME;
   CORONARY ATHEROSCLEROSIS; COMPUTED-TOMOGRAPHY; DIETARY MAGNESIUM;
   PHOSPHATE LEVELS; STENOSIS; PROGRESSION; SCLEROSIS
AB Background and aims: Calcific aortic valve disease (CAVD) is the most common valve disease. Although micronutrients are known to contribute to cardiovascular disease, the relationship with CAVD remains poorly evaluated. We examined the association of serum levels of magnesium, phosphorus, and calcium with prevalence, incidence, and progression of aortic valve calcification (AVC).
   Methods: We conducted a prospective study in a population-based sample of Japanese men aged 40-79 years without known cardiovascular disease and chronic kidney disease at baseline, and quantified AVC from serial computed tomographic images with the Agatston method.
   Results: Of 938 participants at baseline (mean age, 63.7 +/- 9.9 years), AVC prevalence was observed in 173 (18.4%). Of 596 participants without baseline AVC at follow-up (median duration, 5.1 years), AVC incidence was observed in 138 (23.2%). After adjustment for demographics, behaviors and cardiovascular risk factors, relative risks (95% confidence intervals) in the highest versus lowest categories of serum magnesium, phosphorus, and calcium were 0.62 (0.44-0.86), 1.45 (1.02-2.04), and 1.43 (0.95-2.15), respectively, for AVC prevalence and 0.62 (0.42-0.92), 1.93 (1.28-2.91), and 1.09 (0.77-1.55), respectively, for AVC incidence. Their linear trends of serum magnesium and phosphorus were also all statistically significant. Of 131 participants with baseline AVC, there was no association of any serum micronutrients with AVC progression.
   Conclusions: Serum magnesium was inversely associated, while serum phosphorus was positively associated with AVC prevalence and incidence, suggesting that these serum micronutrients may be potential candidates for risk prediction or prevention of CAVD, and warranting further studies. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hisamatsu, Takashi] Shimane Univ, Dept Environm Med & Publ Hlth, Fac Med, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.
   [Hisamatsu, Takashi; Miura, Katsuyuki; Fujiyoshi, Akira; Kadota, Aya; Miyagawa, Naoko; Ueshima, Hirotsugu] Shiga Univ Med Sci, Dept Publ Hlth, Otsu, Shiga, Japan.
   [Miura, Katsuyuki; Kadota, Aya; Zaid, Maryam; Ueshima, Hirotsugu] Shiga Univ Med Sci, Ctr Epidemiol Res Asia, Otsu, Shiga, Japan.
   [Hisamatsu, Takashi; Yamamoto, Takashi; Horie, Minoru] Shiga Univ Med Sci, Dept Cardiovasc & Resp Med, Otsu, Shiga, Japan.
   [Satoh, Atsushi] Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fac Med, Fukuoka, Japan.
RP Hisamatsu, T (reprint author), Shimane Univ, Dept Environm Med & Publ Hlth, Fac Med, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.
EM hisataka@med.shimane-u.ac.jp
OI Fujiyoshi, Akira/0000-0002-5790-7119
FU Uehara Memorial FoundationUehara Memorial Foundation; Young Investigator
   Grant of the Shimane University; Ministry of Education, Culture, Sports,
   Science and Technology, JapanMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT) [13307016, 17209023, 21249043,
   23249036, 25253046]; Glaxo-Smith Klein; National Institutes of Health,
   USAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01HL068200]
FX This research was supported by the Uehara Memorial Foundation; by the
   Young Investigator Grant of the Shimane University; by the Grants-in-aid
   for Scientific Research (A) 13307016, (A) 17209023, (A) 21249043, (A)
   23249036, and (A) 25253046 from the Ministry of Education, Culture,
   Sports, Science and Technology, Japan; by Glaxo-Smith Klein; and by
   National Institutes of Health, USA [R01HL068200].
NR 46
TC 5
Z9 5
U1 1
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 145
EP 152
DI 10.1016/j.atherosclerosis.2018.03.035
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300022
PM 29655832
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Hoss, F
   Latz, E
AF Hoss, Florian
   Latz, Eicke
TI Inhibitory effects of colchicine on inflammasomes
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Pyrin; NLRP3; CVD; Inflammasome; Colchicine
ID INFLAMMATION
C1 [Hoss, Florian; Latz, Eicke] Univ Bonn, Univ Hosp, Inst Innate Immun, Bonn, Germany.
   [Latz, Eicke] Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA USA.
   [Latz, Eicke] German Ctr Neurodegenerat Dis, Bonn, Germany.
RP Hoss, F (reprint author), Univ Bonn, Univ Hosp, Inst Innate Immun, Bonn, Germany.
EM florian.hoss@uni-bonn.de
RI Latz, Eicke/H-3951-2014
OI Latz, Eicke/0000-0003-1488-5666; Hoss, Florian/0000-0002-9231-5848
NR 8
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 153
EP 154
DI 10.1016/j.atherosclerosis.2018.02.026
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300023
PM 29526464
DA 2019-10-28
ER

PT J
AU Martinez, GJ
   Celermajer, DS
   Patel, S
AF Martinez, Gonzalo J.
   Celermajer, David S.
   Patel, Sanjay
TI Reply to: "Inhibitory effects of colchicine on inflammasomes"
SO ATHEROSCLEROSIS
LA English
DT Letter
DE NLRP3 inflammasome; Colchicine; IL-1beta; Atherosclerosis
ID NLRP3 INFLAMMASOME; PYRIN
C1 [Martinez, Gonzalo J.] Pontificia Univ Catolica, Div Cardiovasc Dis, Santiago, Chile.
   [Celermajer, David S.; Patel, Sanjay] Univ Sydney, Sydney Med Sch, Dept Cardiol, Royal Prince Alfred Hosp, Sydney, NSW, Australia.
   [Celermajer, David S.; Patel, Sanjay] Heart Res Inst, Sydney, NSW, Australia.
RP Martinez, GJ (reprint author), Pontificia Univ Catolica, Div Cardiovasc Dis, Santiago, Chile.
EM gjmartin@uc.cl
OI Celermajer, David/0000-0001-7640-0439
NR 12
TC 0
Z9 0
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 155
EP 156
DI 10.1016/j.atherosclerosis.2018.03.042
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300024
PM 29628279
DA 2019-10-28
ER

PT J
AU Martinez, GJ
   Celermajer, DS
   Patel, S
AF Martinez, G. J.
   Celermajer, D. S.
   Patel, S.
TI The NLRP3 inflammasome and the emerging role of colchicine to inhibit
   atherosclerosis-associated inflammation (vol 269, pg 262, 2018)
SO ATHEROSCLEROSIS
LA English
DT Correction
EM Sanjay.Patel@hri.org.au
NR 1
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 157
EP 157
DI 10.1016/j.atherosclerosis.2018.03.043
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300025
PM 29655831
DA 2019-10-28
ER

PT J
AU Touboul, PJ
   Labreuche, J
   Bruckert, E
   Schargrodsky, H
   Prati, P
   Tosetto, A
   Hernandez-Hernandez, R
   Woo, KS
   Silva, H
   Vicaut, E
   Amarenco, P
AF Touboul, Pierre-Jean
   Labreuche, Julien
   Bruckert, Eric
   Schargrodsky, Herman
   Prati, Patrizio
   Tosetto, Alberto
   Hernandez-Hernandez, Rafael
   Woo, Kam-Sang
   Silva, Honorio
   Vicaut, Eric
   Amarenco, Pierre
TI HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients
   with automated edge detection IMT measurement (vol 232, pg 65, 2014)
SO ATHEROSCLEROSIS
LA English
DT Correction
C1 [Touboul, Pierre-Jean; Labreuche, Julien; Amarenco, Pierre] INSERM U 698, Paris, France.
   [Touboul, Pierre-Jean; Vicaut, Eric; Amarenco, Pierre] Paris Diderot & Sorbonne Paris City Univ, Paris, France.
   [Touboul, Pierre-Jean; Labreuche, Julien; Amarenco, Pierre] Hop Bichat Claude Bernard, AP HP, Dept Neurol, Paris, France.
   [Touboul, Pierre-Jean; Labreuche, Julien; Amarenco, Pierre] Hop Bichat Claude Bernard, AP HP, Stroke Ctr, Paris, France.
   [Schargrodsky, Herman; Silva, Honorio] Buenos Aires Italian Hosp, Dept Cardiol, Buenos Aires, DF, Argentina.
   [Prati, Patrizio] Gervasutta Hosp ASS 4, Dept Neurol, Udine, Italy.
   [Tosetto, Alberto] S Bortolo Hosp, Dept Hematol, Vicenza, Italy.
   [Hernandez-Hernandez, Rafael] Univ Centroccidental Lisandro Alvarado, Sch Med, Hypertens & Cardiovasc Risk Factors Clin, Clin Pharmacol Unit, Barquisimeto, Venezuela.
   [Woo, Kam-Sang] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Hong Kong, Peoples R China.
   [Silva, Honorio] InterAmer Fdn Clin Res, New York, NY USA.
   [Vicaut, Eric] Fernand Widal Hosp, Dept Biostat, Paris, France.
   [Bruckert, Eric] Pierre & Marie Curie Univ, Pitie Salpetriere Univ Hosp, Dept Endocrinol, Paris, France.
RP Amarenco, P (reprint author), Hop Xavier Bichat, Dept Neurol, 46 Rue Henri Huchard, F-75018 Paris, France.; Amarenco, P (reprint author), Hop Xavier Bichat, Stroke Ctr, 46 Rue Henri Huchard, F-75018 Paris, France.
EM pierre.amarenco@bch.aphp.fr
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 158
EP 158
DI 10.1016/j.atherosclerosis.2018.01.025
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300026
PM 29657021
DA 2019-10-28
ER

PT J
AU Sansone, R
   Baaken, M
   Horn, P
   Schuler, D
   Westenfeld, R
   Amabile, N
   Kelm, M
   Heiss, C
AF Sansone, Roberto
   Baaken, Maximilian
   Horn, Patrick
   Schuler, Dominik
   Westenfeld, Ralf
   Amabile, Nicolas
   Kelm, Malte
   Heiss, Christian
TI Release of endothelial microparticles in patients with arterial
   hypertension, hypertensive emergencies and catheter-related injury
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cell-derived microparticles; Endothelial function; Arterial
   hypertension; Endothelial function; Wall shear stress
ID CELLS; ATHEROSCLEROSIS; CORRELATE
AB Background and aims: Circulating endothelial microparticles (EMPs) are increased in arterial hypertension. The role of physicomechanical factors that may induce EMP release in vivo is still unknown. We studied the relationship of EMPs and physicomechanical factors in stable arterial hypertension and hypertensive emergencies, and investigated the pattern of EMP release after mechanical endothelial injury.
   Methods: In a pilot study, 41 subjects (50% hypertensives) were recruited. EMPs were discriminated by flow-cytometry (CD31(+)141(-), CD62e(+), CD144(+)). Besides blood pressure measurements, pulse-wave analysis was performed. Flow-mediated dilation (FMD), nitroglycerin-mediated dilation (NMD), and wall-shear-stress (WSS) were measured ultrasonographically in the brachial artery; microvascular perfusion by laser-Doppler (Clinicaltrials.gov: NCT02795377). We studied patients with hypertensive emergencies before and 4 h after BP lowering by urapidil (n =12) and studied the release of EMPs due to mechanical endothelial injury after coronary angiography (n =10).
   Results: Hypertensives exhibited increased EMPs (CD31(+)141(-), CD144, CD62e(+)) as compared to normotensives and EMPs univariately correlated with systolic BP (SBP), augmentation index, and pulse wave velocity and inversely with FMD. CD31(+)141--EMPs correlated with diameter and inversely with WSS and NMD. CD62e and CD144(+)-EMPs inversely correlated with microvascular function. During hypertensive emergency, only CD62e and CD144(+)-EMPs were further elevated and FMD was decreased compared to stable hypertensives. Blood pressure lowering decreased CD62e and CD144(+)-EMPs and increased FMD. CD31(+)141 EMPs, diameter, and WSS remained unaffected. Similar to hypertensive emergency, catheter related endothelial injury increased only CD144(+) and CD62e(+)-EMPs.
   Conclusions: EMP release in hypertension is complex and may involve both physicomechanical endothelial injury and activation (CD144, CD62e(+)) and decreased wall shear stress (CD31+141-). (C) 2018 Elsevier B.V. All rights reserved.
C1 [Sansone, Roberto; Baaken, Maximilian; Horn, Patrick; Schuler, Dominik; Westenfeld, Ralf; Kelm, Malte; Heiss, Christian] Univ Duesseldorf, Med Fac, Div Cardiol Pulmonol & Vasc Med, Dusseldorf, Germany.
   [Kelm, Malte] Univ Duesseldorf, Med Fac, CARID Cardiovasc Res Inst Duesseldorf, Dusseldorf, Germany.
   [Amabile, Nicolas] Inst Mutualiste Montsouris, Paris, France.
   [Heiss, Christian] Univ Surrey, Fac Hlth & Med Sci, Guildford, Surrey, England.
   [Heiss, Christian] Surrey & Sussex Healthcare NHS Trust, Redhill, Surrey, England.
RP Heiss, C (reprint author), Univ Surrey, Fac Hlth & Med Sci, Sect Clin Med & Ageing, Guildford GU2 7XH, Surrey, England.
EM c.heiss@surrey.ac.uk
OI Kelm, Malte/0000-0003-0060-1052; Heiss, Christian/0000-0002-3212-8995
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG)
   [KE405/5-1, GRK 1902 TP9, SFB1116 TP A07, B06]; Forschungskommission of
   the Medical Faculty of the Heinrich-Heine University Duesseldorf;
   Susanne Bunnenberg Stiftung at the Duesseldorf Heart Center
FX This study was funded by the Deutsche Forschungsgemeinschaft (KE405/5-1
   to MK; GRK 1902 TP9 and SFB1116 TP A07 and B06 to CH and MK) and the
   Forschungskommission of the Medical Faculty of the Heinrich-Heine
   University Duesseldorf to CH, DS, and RS. MK was supported by the
   Susanne Bunnenberg Stiftung at the Duesseldorf Heart Center.
NR 29
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2018
VL 273
BP 67
EP 74
DI 10.1016/j.atherosclerosis.2018.01.012
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GG5YZ
UT WOS:000432773300010
PM 29684662
DA 2019-10-28
ER

PT J
AU Wu, S
   Yang, YM
   Zhu, J
   Ren, JM
   Wang, J
   Zhang, H
   Shao, XH
AF Wu, Shuang
   Yang, Yan-min
   Zhu, Jun
   Ren, Jia-meng
   Wang, Juan
   Zhang, Han
   Shao, Xing-hui
TI The association between plasma big endothelin-1 levels at admission and
   long-term outcomes in patients with atrial fibrillation
SO ATHEROSCLEROSIS
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; PROGNOSIS
AB Background and aims: The prognostic role of big endothelin-1 (ET-1) in atrial fibrillation (AF) is unclear. We aimed to assess its predictive value in patients with AF.& para;& para;Methods: A total of 716 AF patients were enrolled and divided into two groups based on the optimal cutoff value of big ET-1 in predicting all-cause mortality. The primary outcomes were all-cause mortality and major adverse events (MAEs). Cox regression analysis and net reclassification improvement (NRI) analysis were performed to assess the predictive value of big ET-1 on outcomes.& para;& para;Results: With the optimal cutoff value of 0.55 pmol/L, 326 patients were classified into the high big ET-1 levels group. Cardiac dysfunction and left atrial dilation were factors related to high big ET-1 levels. During a median follow-up of 3 years, patients with big ET-1 >= 0.55 pmol/L had notably higher risk of all-cause death (44.8% vs. 11.5%, p < 0.001), MAEs (51.8% vs. 17.4%, p < 0.001), cardiovascular death, major bleeding, and tended to have higher thromboembolic risk. After adjusting for confounding factors, high big ET-1 level was an independent predictor of all-cause mortality (hazard ratio (HR) 2.11, 95% confidence interval (CI) 1.46-3.05; p < 0.001), MAEs (HR 2.05, 95% CI 1.50-2.80; p = 0.001), and cardiovascular death (HR 2.44, 95% CI 1.52-3.93; p < 0.001). NRI analysis showed that big ET-1 allowed a significant improvement of 0.32 in the accuracy of predicting the risk of both all-cause mortality and MAEs.& para;& para;Conclusions: Elevated big ET-1 levels is an independent predictor of long-term all-cause mortality, MAEs, and cardiovascular death in patients with AF. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Yang, Yan-min] Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Emergency & Intens Care Ctr,State Key Lab Cardiov, Beijing 100037, Peoples R China.
   Peking Union Med Coll, Beijing 100037, Peoples R China.
RP Yang, YM (reprint author), Chinese Acad Med Sci, Natl Ctr Cardiovasc Dis, Fuwai Hosp, Emergency & Intens Care Ctr,State Key Lab Cardiov, Beijing 100037, Peoples R China.
EM yymfuwai@163.com
NR 27
TC 3
Z9 3
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 1
EP 7
DI 10.1016/j.atherosclerosis.2018.02.034
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800001
PM 29529394
DA 2019-10-28
ER

PT J
AU Konigstein, K
   Infanger, D
   Klenk, C
   Hinrichs, T
   Rossmeissl, A
   Baumann, S
   Hafner, B
   Hanssen, H
   Schmidt-Trucksass, A
AF Koenigstein, Karsten
   Infanger, Denis
   Klenk, Christopher
   Hinrichs, Timo
   Rossmeissl, Anja
   Baumann, Sandra
   Hafner, Benjamin
   Hanssen, Henner
   Schmidt-Trucksaess, Arno
TI Does obesity attenuate the beneficial cardiovascular effects of
   cardiorespiratory fitness?
SO ATHEROSCLEROSIS
LA English
DT Article
DE Arterial stiffness; Obesity; Body composition; Cardiorespiratory
   fitness; VO(2)peak; Brachial-ankle pulse wave velocity
ID PULSE-WAVE VELOCITY; ALL-CAUSE MORTALITY; X-RAY ABSORPTIOMETRY;
   BODY-MASS INDEX; ARTERIAL STIFFNESS; BIOELECTRICAL-IMPEDANCE; ABDOMINAL
   OBESITY; WEIGHT-LOSS; LIFE-STYLE; FOLLOW-UP
AB Background and aims: Higher cardiorespiratory fitness is associated with lower pulse wave velocity and arterial stiffness in normal weight individuals, and this has not been examined in obese individuals. It is unclear whether an altered body composition acts as a modifier of the association between cardiorespiratory fitness and arterial stiffness. We examined the association between peak oxygen uptake and brachial-ankle pulse wave velocity and analysed whether body composition attenuates this association in obese middle-aged individuals.& para;& para;Methods: Bio-impedance analysis-derived body composition assessment in 212 healthy and sedentary either overweight or obese individuals was followed by measurement of brachial-ankle pulse wave velocity and spiroergometric peak oxygen uptake. Multivariate analysis was performed to analyse the association between peak oxygen uptake and brachial-ankle pulse wave velocity and to assess the moderating effect of several body composition-related interaction terms (BMI, total body mass, body fat mass, waist circumference, waist-to-height ratio) on this association.& para;& para;Results: Peak oxygen uptake was inversely associated with brachial-ankle pulse wave velocity (beta = -0.059, 95% CI = -0.099; -0.018, p = 0.005). Testing for the impact of different body composition-related interaction terms on this association showed no significance, 95% CI lateralized towards positivity.& para;& para;Conclusions: This study shows an inverse association between cardiorespiratory fitness and arterial stiffness in middle-aged obese individuals. We also found a tendency towards an attenuating impact of an obese body composition on this association. Physical fitness seems to be a stronger modulator of cardiovascular risk than body composition but the success of training efforts may be compromised by obesity. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Koenigstein, Karsten; Infanger, Denis; Klenk, Christopher; Hinrichs, Timo; Rossmeissl, Anja; Baumann, Sandra; Hafner, Benjamin; Hanssen, Henner; Schmidt-Trucksaess, Arno] Univ Basel, Div Sports & Exercise Med, Dept Sport Exercise & Hlth, Birsstr 320 B, CH-4052 Basel, Switzerland.
RP Konigstein, K; Schmidt-Trucksass, A (reprint author), Univ Basel, Div Sports & Exercise Med, Dept Sport Exercise & Hlth, Birsstr 320 B, CH-4052 Basel, Switzerland.
EM k.koenigstein@unibas.ch; arno.schmidt-trucksaess@unibas.ch
RI Schmidt-Trucksass, Arno/I-7673-2015
OI Schmidt-Trucksass, Arno/0000-0002-4662-3911; Infanger,
   Denis/0000-0001-9028-7110; Hinrichs, Timo/0000-0001-6200-307X;
   Konigstein, Karsten/0000-0002-2994-8570
NR 50
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 21
EP 26
DI 10.1016/j.atherosclerosis.2018.03.014
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800004
PM 29544085
DA 2019-10-28
ER

PT J
AU Olkkonen, VM
   Sinisalo, J
   Jauhiainen, M
AF Olkkonen, Vesa M.
   Sinisalo, Juha
   Jauhiainen, Matti
TI New medications targeting triglyceride-rich lipoproteins: Can inhibition
   of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
SO ATHEROSCLEROSIS
LA English
DT Review
DE ANGPTL3; Antibody therapy; apoC-III; ASO; CVD; TRL
ID APOLIPOPROTEIN-C-III; LOW-DENSITY LIPOPROTEINS; OF-FUNCTION MUTATIONS;
   FAMILIAL COMBINED HYPOLIPIDEMIA; ANGIOPOIETIN-LIKE PROTEINS; PLASMA
   TRIGLYCERIDES; ENDOTHELIAL-CELLS; CORONARY EVENTS; B GENE; METABOLISM
AB Remarkably good results have been achieved in the treatment of atherosclerotic cardiovascular diseases (CVD) by using statin, ezetimibe, antihypertensive, antithrombotic, and PCSK9 inhibitor therapies and their proper combinations. However, despite this success, the remaining CVD risk is still high. To target this residual risk and to treat patients who are statin-intolerant or have an exceptionally high CVD risk for instance due to familial hypercholesterolemia (FH), new therapies are intensively sought. One pathway of drug development is targeting the circulating triglyceride-rich lipoproteins (TRL) and their lipolytic remnants, which, according to the current view, confer a major CVD risk. Angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C-III (apoC-III) are at present the central molecular targets for therapies designed to reduce TRL, and there are new drugs emerging that suppress their expression or inhibit the function of these two key proteins. The medications targeting these components are biological, either human monoclonal antibodies or antisense oligonucleotides. In this article, we briefly review the mechanisms of action of ANGPTL3 and apoC-III, the reasons why they have been considered promising targets of novel therapies for CVD, as well as the current status and the most important results of their clinical trials. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Olkkonen, Vesa M.; Jauhiainen, Matti] Minerva Fdn, Biomedicum 2U, Tukholmankatu 8, FI-00290 Helsinki, Finland.
   [Olkkonen, Vesa M.] Univ Helsinki, Fac Med, Dept Anat, FI-00014 Helsinki, Finland.
   [Sinisalo, Juha] Helsinki Univ Hosp, Heart & Lung Ctr, FI-00029 Helsinki, Finland.
   [Sinisalo, Juha] Univ Helsinki, FI-00029 Helsinki, Finland.
RP Olkkonen, VM (reprint author), Minerva Fdn, Biomedicum 2U, Tukholmankatu 8, FI-00290 Helsinki, Finland.
EM vesa.olkkonen@helsinki.fi
OI Olkkonen, Vesa/0000-0001-5553-7997; Sinisalo, Juha/0000-0002-0169-5137
FU Academy of FinlandAcademy of Finland [285223]; Jane and Aatos Erkko
   Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation;
   Finnish Foundation for Cardiovascular Research; Finnish Diabetes
   Research Foundation; Liv och Halsa Foundation; Novo Nordisk
   FoundationNovo Nordisk [NNF17OC0027234]; Paavo Nurmi Foundation; Magnus
   Ehrnrooth Foundation
FX This work was supported by the Academy of Finland (grant 285223 to
   V.M.O.), the Jane and Aatos Erkko Foundation (M.J.), the Sigrid Juselius
   Foundation (V.M.O.), the Finnish Foundation for Cardiovascular Research
   (V.M.O., M.J.), the Finnish Diabetes Research Foundation (V.M.O.), the
   Liv och Halsa Foundation (V.M.O.), the Novo Nordisk Foundation (grant
   NNF17OC0027234 to V.M.O.), the Paavo Nurmi Foundation (V.M.O.) and the
   Magnus Ehrnrooth Foundation (V.M.O., M.J.).
NR 66
TC 10
Z9 10
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 27
EP 32
DI 10.1016/j.atherosclerosis.2018.03.019
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800005
PM 29544086
OA Green Published
DA 2019-10-28
ER

PT J
AU Lim, S
   Eckel, RH
   Koh, KK
AF Lim, Soo
   Eckel, Robert H.
   Koh, Kwang Kon
TI Clinical implications of current cardiovascular outcome trials with
   sodium glucose cotransporter-2 (SGLT2) inhibitors
SO ATHEROSCLEROSIS
LA English
DT Review
DE Antidiabetic medications; Cardiovascular diseases; Prevention; Metabolic
   syndrome
ID INADEQUATE GLYCEMIC CONTROL; TYPE-2 DIABETES-MELLITUS; RENIN-ANGIOTENSIN
   SYSTEM; CHRONIC KIDNEY-DISEASE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND;
   BLOOD-PRESSURE; URIC-ACID; BETA-HYDROXYBUTYRATE; OXIDATIVE STRESS
AB The final goal in the management of patients with type 2 diabetes (T2D) is reduction in cardiovascular (CV) complications and total mortality. Various factors including hyperglycemia contribute to these complications and mortality directly and indirectly. In recent years, large-scale CV outcome trials with new antidiabetic medications, such as dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists, and sodium glucose cotransporter-2 (SGLT2) inhibitors, have been completed. Most clinical trials with DPP4 inhibitors have shown no inferiority compared with placebo treatments in terms of CV safety. However, they did not show benefits in terms of adverse CV events or mortality. CV outcome trials with GLP1 receptor agonists showed inconsistent results: lixisenatide did not show benefits in preventing major adverse CV events. In contrast, liraglutide and semaglutide (longer acting GLP1 receptor agonists) proved to be superior in terms of alleviating CV morbidity and mortality. Two large-scale CV outcome trials with SGLT2 inhibitors showed significant results: empagliflozin proved to be superior in preventing CV and all-cause mortality, and canagliflozin proved to be superior in preventing CV mortality but not all-cause mortality. So far, controlling cardiometabolic risk factors such as hemodynamic changes and weight loss by SGLT2 inhibitors are suggested to be the main mechanisms for these results. However, the risk-benefit profile for these new drugs will need further elucidation, and more studies are warranted to reveal the possible mechanisms. It will also be important to confirm these results from other ongoing trials with SGLT2 inhibitors. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lim, Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seongnam, South Korea.
   [Lim, Soo] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
   [Eckel, Robert H.] Univ Colorado, Dept Med, Div Endocrinol Metab & Diabet, Anschutz Med Campus,12801 East 17th Ave,RC1 South, Aurora, CO 80045 USA.
   [Eckel, Robert H.] Univ Colorado, Dept Med, Div Cardiol, Anschutz Med Campus,12801 East 17th Ave,RC1 South, Aurora, CO 80045 USA.
   [Koh, Kwang Kon] Gachon Univ, Gil Med Ctr, Heart Ctr, Dept Cardiovasc Med, Incheon, South Korea.
   [Koh, Kwang Kon] Gachon Cardiovasc Res Inst, Incheon, South Korea.
RP Eckel, RH (reprint author), Univ Colorado, Dept Med, Div Endocrinol Metab & Diabet, Anschutz Med Campus,12801 East 17th Ave,RC1 South, Aurora, CO 80045 USA.; Eckel, RH (reprint author), Univ Colorado, Dept Med, Div Cardiol, Anschutz Med Campus,12801 East 17th Ave,RC1 South, Aurora, CO 80045 USA.; Koh, KK (reprint author), Gachon Univ, Gil Med Ctr, Dept Cardiovasc Med, Cardiometab Syndrome Unit, 774 Beongil 21, Incheon 21565, South Korea.
EM Robert.Eckel@ucdenver.edu; kwangk@gilhospital.com
OI Lim, Soo/0000-0002-4137-1671
FU Korea Health Industry Development Institute (KHIDI) - Ministry for
   Health and Welfare, Korea [HI15C0987, HI14C1135]; Korean Society of
   CardioMetabolic Syndrome
FX This work was supported by a grant of the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI)
   funded by the Ministry for Health and Welfare, Korea (HI15C0987 &
   HI14C1135) and the Korean Society of CardioMetabolic Syndrome.
NR 76
TC 10
Z9 10
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 33
EP 40
DI 10.1016/j.atherosclerosis.2018.03.013
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800006
PM 29547706
DA 2019-10-28
ER

PT J
AU Vojinovic, D
   van der Lee, SJ
   van Duijn, CM
   Vernooij, MW
   Kavousi, M
   Amin, N
   Demirkan, A
   Ikram, MA
   van der Lugt, A
   Bos, D
AF Vojinovic, Dina
   van der Lee, Sven J.
   van Duijn, Cornelia M.
   Vernooij, Meike W.
   Kavousi, Maryam
   Amin, Najaf
   Demirkan, Ayse
   Ikram, M. Arfan
   van der Lugt, Aad
   Bos, Daniel
TI Metabolic profiling of intra- and extracranial carotid artery
   atherosclerosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Metabolomics; Atherosclerosis; Carotid artery
ID INTRACRANIAL ATHEROSCLEROSIS; RISK-FACTORS; GENOME-WIDE; FINNISH MEN;
   ALL-CAUSE; ASSOCIATION; BIOMARKERS; CORONARY; DISEASE; CALCIFICATION
AB Background and aims: Increasing evidence shows that intracranial carotid artery atherosclerosis may develop under the influence of a differential metabolic risk factor profile than atherosclerosis in the extracranial part of the carotid artery. To further elucidate these differences, we investigated associations of a wide range of circulating metabolites with intracranial and extracranial carotid artery atherosclerosis.& para;& para;Methods: From the population-based Rotterdam Study, blood samples from 1111 participants were used to determine a wide range of metabolites by proton nuclear magnetic resonance (NMR). Moreover, these participants underwent non-contrast computed tomography of the neck and head to quantify the amount of extra-and intracranial carotid artery calcification (ECAC and ICAC), as a proxy of atherosclerosis. We assessed associations of the metabolites with ICAC and ECAC and compared the metabolic association patterns of the two.& para;& para;Results: We found that one standard deviation (SD) increase in concentration of 3-hydroxybutyrate, a ketone body, was significantly associated with a 0.11 SD increase in ICAC volume (p = 1.8 x 10(-4)). When we compared the metabolic association pattern of ICAC with that of ECAC, we observed differences in glycolysis-related metabolite measures, lipoprotein subfractions, and amino acids. Interestingly, glyco-protein acetyls were associated with calcification in both studied vessel beds. These associations were most prominent in men.& para;& para;Conclusions: We found that a higher circulating level of 3-hydroxybutyrate was associated with an increase in ICAC. Furthermore, we found differences in metabolic association patterns of ICAC and ECAC, providing further evidence for location-specific differences in the etiology of atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Vojinovic, Dina; van der Lee, Sven J.; van Duijn, Cornelia M.; Vernooij, Meike W.; Kavousi, Maryam; Amin, Najaf; Demirkan, Ayse; Ikram, M. Arfan; Bos, Daniel] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
   [Vernooij, Meike W.; Ikram, M. Arfan; van der Lugt, Aad; Bos, Daniel] Erasmus Univ, Med Ctr, Dept Radiol & Nucl Med, Rotterdam, Netherlands.
   [Demirkan, Ayse] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands.
   [Ikram, M. Arfan] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands.
   [Bos, Daniel] Wytemaweg 80,Room NA-2824K, NL-3015 CN Rotterdam, Netherlands.
RP Bos, D (reprint author), Erasmus Univ, Med Ctr, Dept Epidemiol, Dept Radiol & Nucl Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.; Bos, D (reprint author), Wytemaweg 80,Room NA-2824K, NL-3015 CN Rotterdam, Netherlands.
EM d.bos@erasmusmc.nl
OI Vojinovic, Dina/0000-0001-5744-0232; Demirkan, Ayse/0000-0002-7546-0867;
   van der Lee, Sven/0000-0003-1606-8643
FU Erasmus MC University Medical Center; Erasmus University Rotterdam;
   Netherlands Organisation for Scientific Research (NWO)Netherlands
   Organization for Scientific Research (NWO); Netherlands Organisation for
   Health Research and Development (ZonMw)Netherlands Organization for
   Health Research and Development; Research Institute for Diseases in the
   Elderly (RIDE); Netherlands Genomics Initiative (NGI); Ministry of
   Education, Culture and ScienceMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT); Ministry of Health, Welfare and
   Sports; European Commission (DG XII)European Commission Joint Research
   Centre; Municipality of Rotterdam; Biobanking and Biomolecular Resources
   Research Infrastructure (BBMRI)-NL [184.021.007]; JNPD under the project
   PERADES [733051021]; European UnionEuropean Union (EU) [667375];
   Personalized pREvention of Chronic DIseases consortium (PRECeDI); NWO
   VENI grant (VENI) [91616165, 91616079]
FX The Rotterdam Study is supported by the Erasmus MC University Medical
   Center and Erasmus University Rotterdam; The Netherlands Organisation
   for Scientific Research (NWO); The Netherlands Organisation for Health
   Research and Development (ZonMw); the Research Institute for Diseases in
   the Elderly (RIDE); The Netherlands Genomics Initiative (NGI); the
   Ministry of Education, Culture and Science; the Ministry of Health,
   Welfare and Sports; the European Commission (DG XII); and the
   Municipality of Rotterdam. Metabolomics measurements were funded by
   Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)-NL
   (184.021.007) and the JNPD under the project PERADES (grant number
   733051021, Defining Genetic, Polygenic and Environmental Risk for
   Alzheimer's Disease using multiple powerful cohorts, focused Epigenetics
   and Stem cell metabolomics). This work has been performed as part of the
   CoSTREAM project (www.costream.eu) and has received funding from the
   European Union's Horizon 2020 research and innovation programme under
   grant agreement No 667375. This work has been performed as part of the
   CardioVasculair Onderzoek Nederland (CVON 2012-03). Ayse Demirkan, Dina
   Vojinovic, and Cornelia van Duijn have used exchange grants from
   Personalized pREvention of Chronic DIseases consortium (PRECeDI)
   (H2020-MSCA-RISE-2014). Ayse Demirkan is supported by the NWO VENI grant
   (VENI, 91616165). Maryam Kavousi is supported by the NWO VENI grant
   (VENI, 91616079).
NR 47
TC 8
Z9 8
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 60
EP 65
DI 10.1016/j.atherosclerosis.2018.03.015
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800010
PM 29550646
DA 2019-10-28
ER

PT J
AU Williams, BA
   Chagin, KM
   Bash, LD
   Boden, WE
   Duval, S
   Fowkes, FGR
   Mahaffey, KW
   Patel, MD
   D'Agostino, RB
   Peterson, ED
   Kattan, MW
   Bhatt, DL
   Bonaca, MP
AF Williams, Brent A.
   Chagin, Kevin M.
   Bash, Lori D.
   Boden, William E.
   Duval, Sue
   Fowkes, F. Gerry R.
   Mahaffey, Kenneth W.
   Patel, Mehul D.
   D'Agostino, Ralph B.
   Peterson, Eric D.
   Kattan, Michael W.
   Bhatt, Deepak L.
   Bonaca, Marc P.
TI External validation of the TIMI risk score for secondary cardiovascular
   events among patients with recent myocardial infarction
SO ATHEROSCLEROSIS
LA English
DT Article
DE Myocardial infarction; Secondary prevention; Risk stratification;
   Electronic medical record
ID CORONARY-ARTERY-DISEASE; CLINICAL-TRIAL; HEART-DISEASE; PREDICTION;
   MORTALITY; MODELS; STRATIFICATION; THROMBOLYSIS; POPULATION; PREVENTION
AB Background and aims: Risk stratification of patients with recent myocardial infarction (MI) for subsequent cardiovascular (CV) events helps identify patients most likely to benefit from secondary prevention therapies. This study externally validated a new risk score (TRS2P) for secondary events derived from the TRA2 degrees P-TIMI 50 trial among post-MI patients from two large health care systems.& para;& para;Methods: This retrospective cohort study included 9618 patients treated for acute MI at either the Cleveland Clinic (CC) or Geisinger Health System (GHS) between 2008 and 2013. Patients with a clinic visit within 2-52 weeks of MI were included and followed for CV death, repeat MI, and ischemic stroke through electronic medical records (EMR). The TRS2P is based on nine factors determined through EMR documentation. Discrimination and calibration of the TRS2P were quantified in both patient populations.& para;& para;Results: MI patients at CC and GHS were older, had more comorbidities, received fewer medications, and had higher 3-year event rates compared to subjects in the TRA2 degrees P trial: 31% (CC), 33% (GHS), and 10% (TRA2 degrees P-TIMI 50). The proposed risk score had similar discrimination across the three cohorts with c-statistics of 0.66 (CC), 0.66 (GHS), and 0.67 (TRA2 degrees P-TIMI 50). A strong graded relationship between the risk score and event rates was observed in all cohorts, though 3-year event rates were consistently higher within TRS2 degrees P strata in the CC and GHS cohorts relative to TRA2P-TIMI 50.& para;& para;Conclusions: The TRS2P demonstrated consistent risk discrimination across trial and non-trial patients with recent MI, but event rates were consistently higher in the non-trial cohorts. (C) 2018 Published by Elsevier B.V.
C1 [Williams, Brent A.] Geisinger Hlth Syst, Danville, PA USA.
   [Chagin, Kevin M.; Kattan, Michael W.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Bash, Lori D.; Patel, Mehul D.] Merck & Co Inc, Kenilworth, NJ USA.
   [Boden, William E.] Boston Univ, Sch Med, Massachusetts Vet Epidemiol Res & Informat Ctr MA, VA New England Healthcare Syst, Boston, MA 02118 USA.
   [Duval, Sue] Univ Minnesota, Div Cardiovasc, Minneapolis, MN 55455 USA.
   [Fowkes, F. Gerry R.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
   [Mahaffey, Kenneth W.] Stanford Univ, Dept Med, Sch Med, Stanford Ctr Clin Res, Stanford, CA 94305 USA.
   [Patel, Mehul D.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA.
   [D'Agostino, Ralph B.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
   [Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
   [Bhatt, Deepak L.] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA.
   [Bhatt, Deepak L.] Harvard Med Sch, Boston, MA USA.
   [Bonaca, Marc P.] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.
RP Williams, BA (reprint author), Geisinger Hlth Syst, Dept Epidemiol & Hlth Serv Res, 100 North Acad Ave, Danville, PA 17822 USA.
EM bawilliams2@geisinger.edu
OI Duval, Sue/0000-0003-1025-8665; Kattan, Michael/0000-0002-3840-4161
FU Merck & Co., Inc., Kenilworth, NJ, USA; Geisinger Health System;
   Cleveland Clinic Foundation; Merck & Co. Inc., Kenilworth, NJ, USA
FX This work was supported by Merck & Co., Inc., Kenilworth, NJ, USA,
   through research agreements with the Geisinger Health System and the
   Cleveland Clinic Foundation. The Scientific Committee received
   consultation fees from Merck & Co. Inc., Kenilworth, NJ, USA.
NR 33
TC 7
Z9 7
U1 3
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 80
EP 86
DI 10.1016/j.atherosclerosis.2018.03.026
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800013
PM 29579671
DA 2019-10-28
ER

PT J
AU Hodges, GW
   Bang, CN
   Forman, JL
   Olsen, MH
   Boman, K
   Ray, S
   Kesaniemi, YA
   Eugen-Olsen, J
   Greve, AM
   Jeppesen, JL
   Wachtell, K
AF Hodges, Gethin W.
   Bang, Casper N.
   Forman, Julie L.
   Olsen, Michael H.
   Boman, Kurt
   Ray, Simon
   Kesaniemi, Y. Antero
   Eugen-Olsen, Jesper
   Greve, Anders M.
   Jeppesen, Jorgen L.
   Wachtell, Kristian
TI Effect of simvastatin and ezetimibe on suPAR levels and outcomes
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Biomarker; Cardiovascular disease; Cardiovascular risk;
   Inflammation; Statins; SuPAR
ID UROKINASE PLASMINOGEN-ACTIVATOR; CHRONIC KIDNEY-DISEASE;
   CARDIOVASCULAR-DISEASE; AORTIC-STENOSIS; RECEPTOR; POPULATION
AB Background and aims: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker associated with cardiovascular disease. Statins lower both low-density lipoprotein (LDL)-cholesterol and C-reactive protein (CRP), resulting in improved outcomes. However, whether lipid-lowering therapy also lowers suPAR levels is unknown.& para;& para;Methods: We investigated whether treatment with Simvastatin 40 mg and Ezetimibe 10 mg lowered plasma suPAR levels in 1838 patients with mild-moderate, asymptomatic aortic stenosis, included in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study, using a pattern mixture model. A 1-year Cox analysis, adjusted for established cardiovascular risk factors, allocation to study treatment, peak aortic valve velocity and baseline suPAR, was performed to evaluate relationships between change in suPAR with all-cause mortality and the composite endpoint of major cardiovascular events (MCE) composed of ischemic cardiovascular events (ICE) and aortic valve related events (AVE).& para;& para;Results: After 4.3 years of follow-up, suPAR levels had increased by 9.2% (95% confidence interval [CI]: 7.0%-11.5%) in the placebo group, but only by 4.1% (1.9%-6.2%) in the group with lipid-lowering treatment (p<0.001). In a multivariate 1-year analysis, 1-year suPAR was strongly associated with all-cause mortality, hazard ratio (HR) = 2.05 (1.17-3.61); MCE 1.40 (1.01-1.92); and AVE 1.42 (1.02-1.99) (all p<0.042) for each doubling of suPAR; but was not associated with ICE.& para;& para;Conclusions: Simvastatin and Ezetimibe treatment impeded the progression of the time-related increase in plasma suPAR levels. Year-1 suPAR was associated with all-cause mortality, MCE, and AVE irrespective of baseline levels (SEAS study: NCT00092677). (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hodges, Gethin W.; Jeppesen, Jorgen L.] Univ Copenhagen, Amager Hvidvore Hosp Glostrup, Dept Med Glostrup, Copenhagen, Denmark.
   [Bang, Casper N.] Danish Heart Fdn, Copenhagen, Denmark.
   [Bang, Casper N.] Zealand Univ Hosp, Dept Cardiol, Roskilde, Denmark.
   [Forman, Julie L.] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark.
   [Olsen, Michael H.] Holbaek Cent Hosp, Dept Internal Med, Holbaek, Denmark.
   [Olsen, Michael H.] Univ Southern Denmark, Odense Univ Hosp, Ctr Individualized Med Arterial Dis, Odense, Denmark.
   [Boman, Kurt] Umea Univ, Dept Publ Hlth & Clin Med, Res Unit, Umea, Sweden.
   [Ray, Simon] Univ Hosp South Manchester, Manchester Acad Hlth Sci Ctr, Dept Cardiol, Manchester, Lancs, England.
   [Kesaniemi, Y. Antero] Oulu Univ Hosp, Med Res Ctr Oulu, Res Inst Internal Med, Oulu, Finland.
   [Kesaniemi, Y. Antero] Univ Oulu, Oulu, Finland.
   [Eugen-Olsen, Jesper] Copenhagen Univ Hosp Hvidovre, Clin Res Ctr, Hvidovre, Denmark.
   [Greve, Anders M.] Rigshosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Wachtell, Kristian] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway.
RP Hodges, GW (reprint author), Glostrup Cty Hosp, Ndr Ringvej 57, DK-2600 Glostrup, Denmark.
EM gethin.william.hodges.02@regionh.dk
OI Forman, Julie/0000-0001-7368-0869; Bang, Casper/0000-0002-4618-6096
FU Novo Nordisk FoundationNovo Nordisk
FX The authors would like to thank the Novo Nordisk Foundation, whose
   research grant facilitated the writing of this article.
NR 23
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 129
EP 136
DI 10.1016/j.atherosclerosis.2018.03.030
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800019
PM 29602140
DA 2019-10-28
ER

PT J
AU Chung, GE
   Lee, JH
   Lee, H
   Kim, MK
   Yim, JY
   Choi, SY
   Kim, YJ
   Yoon, JH
   Kim, D
AF Chung, Goh Eun
   Lee, Jeong-Hoon
   Lee, Heesun
   Kim, Min Kyung
   Yim, Jeong Yoon
   Choi, Su-Yeon
   Kim, Yoon Jun
   Yoon, Jung-Hwan
   Kim, Donghee
TI Nonalcoholic fatty liver disease and advanced fibrosis are associated
   with left ventricular diastolic dysfunction
SO ATHEROSCLEROSIS
LA English
DT Article
DE Hepatic steatosis; Non-obese; Fibrosis; Heart failure
ID PRESERVED EJECTION FRACTION; HEART-FAILURE; INSULIN-RESISTANCE; HEPATIC
   STEATOSIS; EUROPEAN-SOCIETY; DIAGNOSIS; ECHOCARDIOGRAPHY; POPULATION;
   RISK; RECOMMENDATIONS
AB Background and aims: Nonalcoholic fatty liver disease (NAFLD) may be associated with a wide spectrum of cardiac abnormalities, which share many metabolic risk factors. This study aimed to evaluate whether NAFLD is associated with left ventricular (LV) diastolic dysfunction independent of other classical risk factors.& para;& para;Methods: A total of 3300 subjects (mean age, 54.1 years; 62.9% men), who underwent echocardiography and hepatic ultrasonography, were enrolled. LV diastolic dysfunction was diagnosed and graded using conventional and Doppler echocardiographic assessments. NAFLD was diagnosed by ultrasonographic findings without any evidence of significant alcohol consumption or viral hepatitis, other liver diseases, or medication provoking fatty liver. Advanced fibrosis was defined as having intermediate-high probability for advanced fibrosis using the NAFLD fibrosis score.& para;& para;Results: The prevalence of LV diastolic dysfunction was 35.1%. NAFLD had a higher prevalence and severity of LV diastolic dysfunction. The prevalence rates of LV diastolic dysfunction were significantly increased according to the NAFLD fibrosis grade (30.4% for no-NAFLD, 35.2% for NAFLD without advanced fibrosis and 57.4% for NAFLD with advanced fibrosis, p < 0.001). Multivariable analysis showed that NAFLD was associated with a 29% increase in the risk of diastolic dysfunction compared with controls (odds ratio [OR] 1.29; 95% confidence interval [CI] 1.07-1.60). There was significant interaction between obesity (BMI < 25 kg/m(2) vs. >= 25 kg/m(2)) and advanced fibrosis for LV diastolic dysfunction. A significant, incrementally increased risk of diastolic dysfunction according to the fibrosis grade was more pronounced in the non-obese population [adjusted OR (95% CI), 1.40 (1.06-1.84) for NAFLD without advanced fibrosis, 1.44 (0.95-2.17) for NAFLD with advanced fibrosis vs. no NAFLD, P for trend = 0.022] compared with the obese population (p for trend = 0.081), independent of other well-defined risk factors.& para;& para;Conclusions: NAFLD was associated with increased risk for LV diastolic dysfunction. In addition, an incrementally increased risk for LV diastolic dysfunction according to fibrosis grade was prominent in the non-obese population. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Chung, Goh Eun; Lee, Heesun; Yim, Jeong Yoon; Choi, Su-Yeon; Kim, Donghee] Seoul Natl Univ Hosp, Healthcare Syst Gangnam Ctr, Dept Internal Med, Seoul, South Korea.
   [Lee, Jeong-Hoon; Kim, Yoon Jun; Yoon, Jung-Hwan] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
   [Lee, Jeong-Hoon; Kim, Yoon Jun; Yoon, Jung-Hwan] Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea.
   [Kim, Min Kyung] Sheikh Khalifa Specialty Hosp, Dept Internal Med, Ras Alkhaimah, U Arab Emirates.
   [Kim, Donghee] Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, 300 Pasteur Dr, Stanford, CA 94304 USA.
RP Kim, D (reprint author), Stanford Univ, Sch Med, Div Gastroenterol & Hepatol, 300 Pasteur Dr, Stanford, CA 94304 USA.
EM messmd@chol.com
RI Lee, Jeong-Hoon/Q-1055-2018; Kim, Donghee/C-4288-2013
OI Lee, Jeong-Hoon/0000-0002-0315-2080; Kim, Donghee/0000-0003-1919-6800;
   Kim, Yoon Jun/0000-0001-9141-7773
NR 46
TC 3
Z9 4
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 137
EP 144
DI 10.1016/j.atherosclerosis.2018.03.027
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800020
PM 29604480
DA 2019-10-28
ER

PT J
AU Bell, EJ
   Decker, PA
   Tsai, MY
   Pankow, JS
   Hanson, NQ
   Wassel, CL
   Larson, NB
   Cohoon, KP
   Budoff, MJ
   Polak, JF
   Stein, JH
   Bielinski, SJ
AF Bell, Elizabeth J.
   Decker, Paul A.
   Tsai, Michael Y.
   Pankow, James S.
   Hanson, Naomi Q.
   Wassel, Christina L.
   Larson, Nicholas B.
   Cohoon, Kevin P.
   Budoff, Matthew J.
   Polak, Joseph F.
   Stein, James H.
   Bielinski, Suzette J.
TI Hepatocyte growth factor is associated with progression of
   atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)
SO ATHEROSCLEROSIS
LA English
DT Article
DE Hepatocyte growth factor; Atherosclerosis; Cardiovascular risk factors;
   Coronary artery calcium; Carotid plaque
ID CORONARY-ARTERY CALCIUM; INTIMA-MEDIA THICKNESS; COMPUTED-TOMOGRAPHY;
   ETHNIC-DIFFERENCES; HEART-DISEASE; CALCIFICATION; FIBROSIS; DYSFUNCTION;
   THERAPY
AB Background and aims: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque.& para;& para;Methods: Participants aged 45-84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables.& para;& para;Results: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6-4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01-1.08, p = 0.005).& para;& para;Conclusions: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Bell, Elizabeth J.; Cohoon, Kevin P.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN 55905 USA.
   [Decker, Paul A.; Larson, Nicholas B.] Mayo Clin, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN 55905 USA.
   [Tsai, Michael Y.; Hanson, Naomi Q.] Univ Minnesota, Lab Med & Pathol, Minneapolis, MN USA.
   [Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Wassel, Christina L.] Univ Vermont, Coll Med, Dept Pathol & Lab Med, Colchester, VT USA.
   [Budoff, Matthew J.] Los Angeles Biomed Res Inst, Torrance, CA USA.
   [Polak, Joseph F.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Stein, James H.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA.
   [Bielinski, Suzette J.] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, 200 First St Southwest, Rochester, MN 55905 USA.
   [Cohoon, Kevin P.] Univ Wisconsin, Sch Med & Publ Hlth, 750 Highland Ave, Madison, WI 53705 USA.
RP Bielinski, SJ (reprint author), Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, 200 First St Southwest, Rochester, MN 55905 USA.
EM bielinski.suzette@mayo.edu
OI Budoff, Matthew/0000-0002-9616-1946; Pankow, James/0000-0001-7076-483X;
   Stein, James/0000-0002-2770-8223
FU NIH T32 Training GrantUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HL07111-40]; National
   Institutes of Health (NIH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [N01 HC95159, N01
   HC95160, N01 HC95161, N01 HC95162, N01 HC95163, N01 HC95164, N01
   HC95165, N01 HC95166, N01 HC95167, N01 HC95168]; National Heart, Lung,
   and Blood Institute (NHLBI) at NIH [N01 HC95169]; National Center for
   Research Resources at NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [UL1 TR000040, UL1 TR001079]; NHLBI at NIH
   [R01 HL98077]
FX Dr. Bell is supported by the NIH T32 Training Grant HL07111-40. This
   study was supported by the National Institutes of Health (NIH; grant
   numbers N01 HC95159, N01 HC95160, N01 HC95161, N01 HC95162, N01 HC95163,
   N01 HC95164, N01 HC95165, N01 HC95166, N01 HC95167, and N01 HC95168);
   National Heart, Lung, and Blood Institute (NHLBI) at NIH (grant number
   N01 HC95169); and National Center for Research Resources at NIH (grant
   numbers UL1 TR000040 and UL1 TR001079). Funding for adhesion protein
   levels was provided by the NHLBI at NIH (grant number R01 HL98077).
NR 35
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 162
EP 167
DI 10.1016/j.atherosclerosis.2018.03.040
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800023
PM 29609131
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Herraiz-Adillo, A
   Cavero-Redondo, I
   Alvarez-Bueno, C
   Bidner, J
   Martinez-Vizcaino, V
   Notario-Pacheco, B
AF Herraiz-Adillo, Angel
   Cavero-Redondo, Ivan
   Alvarez-Bueno, Celia
   Bidner, Johana
   Martinez-Vizcaino, Vicente
   Notario-Pacheco, Blanca
TI Spectrum effect and spectrum bias in the oscillometric ankle brachial
   index to diagnose peripheral arterial disease: Clinical implications
SO ATHEROSCLEROSIS
LA English
DT Article
DE Ankle-brachial index; Peripheral artery disease; Oscillometry; Spectrum
   bias; Spectrum effect
ID LIKELIHOOD RATIOS; DIABETIC-PATIENTS; ACCURACY; TESTS; ASSOCIATION;
   SPECIFICITY; SENSITIVITY; ANGIOGRAPHY; PREVALENCE; GUIDELINES
AB Background and aims: The diagnostic performance of the oscillometric ankle brachial index (ABI) to detect peripheral arterial disease (PAD) varies among populations, suggesting a spectrum effect. When this heterogeneity modifies post-test probabilities, a spectrum bias arises. This study evaluates the presence and influence of spectrum effect and spectrum bias on test performance and clinical decisions.& para;& para;Methods: Oscillometric and Doppler ABI were compared in two settings: Primary-Care (333 legs) and Vascular-Service (41 legs). Spectrum effect was assessed using stratification and logistic regression, while spectrum bias was assessed through graphical and statistical tests based on predictive values and likelihood ratios, respectively.& para;& para;Results: Across subgroups, sensitivity ranged from 61.5% to 90.9%, and specificity from 81.8% to 99.1%. Logistic regression confirmed a spectrum effect in setting, diabetes, smoking status and age (univariate), and setting and diabetes (multivariate model). The positive likelihood ratio ranged from 5.0 to 89.1 in subgroups, leading to a spectrum bias in diabetic, smoking (both subgroups) and age (both subgroups). Therefore, a positive test ruled in differently the disease across subgroups, with a high rate of false positives in diabetic, smoking and >75-year-old patients.& para;& para;The negative likelihood ratio ranged from 0.09 to 0.39 in subgroups, with significant spectrum bias in Primary-Care patients, non-diabetics and smokers. Thus, in these subgroups, a negative test ruled out the disease with less certainty.& para;& para;Conclusions: Spectrum effect and spectrum bias were found in oscillometric ABI to detect PAD, potentially affecting clinical decisions, especially for positive tests. Information about spectrum variables and the application of specific subgroups indicators are necessary. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Herraiz-Adillo, Angel; Cavero-Redondo, Ivan; Alvarez-Bueno, Celia; Bidner, Johana; Martinez-Vizcaino, Vicente; Notario-Pacheco, Blanca] Univ Castilla La Mancha, Social & Hlth Care Res Ctr, Santa Teresa Jornet S-N, Cuenca 16071, Spain.
   [Herraiz-Adillo, Angel] Hlth Serv Castilla La Mancha SESCAM, Dept Primary Care, Tragacete, Cuenca, Spain.
   [Martinez-Vizcaino, Vicente] Univ Autonoma Chile, Fac Ciencias Salud, Talca, Chile.
RP Martinez-Vizcaino, V (reprint author), Univ Castilla La Mancha, Social & Hlth Care Res Ctr, Santa Teresa Jornet S-N, Cuenca 16071, Spain.
EM vicente.martinez@uclm.es
RI Alvarez-Bueno, Celia/R-4075-2019; Cavero-Redondo, Ivan/R-4818-2019
OI Alvarez-Bueno, Celia/0000-0002-6176-1618; Herraiz-Adillo,
   Angel/0000-0002-2691-0315
NR 30
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 8
EP 13
DI 10.1016/j.atherosclerosis.2018.03.003
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800002
PM 29529395
DA 2019-10-28
ER

PT J
AU Risko, P
   Platenik, J
   Buchal, R
   Potockova, J
   Kraml, PJ
AF Risko, Peter
   Platenik, Jan
   Buchal, Richard
   Potockova, Jana
   Kraml, Pavel J.
TI Long-term donors versus non-donor men: Iron metabolism and the
   atherosclerotic process
SO ATHEROSCLEROSIS
LA English
DT Article
DE Blood donation; Labile iron pool; Monocytes; Iron metabolism;
   Atherosclerosis
ID MYOCARDIAL-INFARCTION; BODY IRON; STORES; BLOOD; RISK; DEFICIENCY;
   EXPRESSION; FERRITIN; DISEASE; CERULOPLASMIN
AB Background and aims: The increased iron level and the labile iron pool (LIP) in circulating monocytes are connected to a higher frequency of cardiovascular events.& para;& para;Methods: The study investigates the relationship between LIP in circulating monocytes and markers of iron metabolism and atherosclerosis (inflammation, oxidative stress, endothelial dysfunction and arterial elasticity) in long-term blood donors and non-donor volunteers.& para;& para;Results: We found that donors had significantly higher LIP values than the control group (1.89 +/- 0.47 mu M vs. 1.50 -E 0.41 mu M, p = 0.007). Despite the observed tendency for the donor group to have higher blood pressure, cholesterol, glucose and HOMAR-IR (homeostasis model assessment of insulin resistance), the groups did not differ in inflammatory markers, markers of endothelial dysfunction and markers of impaired arterial elasticity. The donor group had significant changes in iron metabolism (higher serum Fe, ceruloplasmin, and TfR/Ft ratio (transferrin receptor/ferritin ratio) and lower hepcidin, ferritin, and CD163), indicating depletion of body iron stores and activation of iron turnover.& para;& para;Conclusions: LIP seems to be a good marker of iron turnover activity in these individuals despite the lack of a decrease in the hemoglobin concentration. We did not find a significant correlation between LIP levels and atherosclerosis progression in the two groups. However, further studies are needed to assess long-term donorship as a protective factor against atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Risko, Peter; Potockova, Jana; Kraml, Pavel J.] Charles Univ Prague, Fac Med 3, Univ Hosp Kralovske Vinohrady, Dept Internal Med 2, Prague, Czech Republic.
   [Platenik, Jan; Buchal, Richard] Charles Univ Prague, Fac Med 1, Inst Med Biochem & Lab Med, Prague, Czech Republic.
RP Risko, P (reprint author), FNKV, Dept Internal Med 2, Srobarova 1150-50, Prague 10034 10, Czech Republic.
EM riskopeter1985@gmail.com
FU Internal Grant Agency, Ministry of Health, Czech Republic
   [NT13671-4/2012]
FX The study was supported by the Internal Grant Agency, Ministry of
   Health, Czech Republic, grant No.: NT13671-4/2012.
NR 41
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 14
EP 20
DI 10.1016/j.atherosclerosis.2018.03.009
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800003
PM 29544084
DA 2019-10-28
ER

PT J
AU Carlsson, AC
   Jansson, JH
   Soderberg, S
   Ruge, T
   Larsson, A
   Arnlov, J
AF Carlsson, Axel C.
   Jansson, Jan-Hakan
   Soderberg, Stefan
   Ruge, Toralph
   Larsson, Anders
   Arnlov, Johan
TI Levels of soluble tumor necrosis factor receptor 1 and 2, gender, and
   risk of myocardial infarction in Northern Sweden
SO ATHEROSCLEROSIS
LA English
DT Article
DE Inflammation; Oxidative stress; All-cause mortality; CRP; Cytokines;
   Community based cohort; Tumor necrosis factor
ID CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK; TOTAL MORTALITY;
   ASSOCIATION; INFLAMMATION; POPULATION; MECHANISMS; ARTHRITIS; EVENTS;
   FOLLOW
AB Background and aims: Soluble receptors for tumor necrosis factor alpha (sTNFR1 and sTNFR2) have been associated with cardiovascular diseases, and some evidence points towards a difference in associated risk between men and women. We aimed to study the association between sTNFR1 and sTNFR2 and incident myocardial infarctions (MI) and to explore the influence of established cardiovascular risk factors in men and women.& para;& para;Methods: We conducted a nested case control study in three large Swedish cohorts, including 533 myocardial infarction cases, and 1003 age-, sex- and cohort-matched controls. Odds ratios (OR) with 95% confidence intervals (CI) were calculated.& para;& para;Results: An association between circulating sTNFR1 and sTNFR2 and an increased risk for MI was found when comparing cases and controls. The odds ratios were significant after adjustment for established cardiovascular risk factors and C-reactive protein in women (OR 1.44, 95% CI 1.08-1.93 for TNFR1, and 1.61, 95% CI 1.11-2.34 for TNFR2), but was abolished in men. Women with a combination of elevated CRP and values in the upper quartile of TNFR1 or TNFR2 had a 5-fold higher risk of myocardial infarction versus those with normal CRP and values in the lower three quartiles of TNFR1 or TNFR2.& para;& para;Conclusions: As the risk estimates for TNFR1 and TNFR2 were higher and remained significant after adjustments for established cardiovascular risk factors in women but not in men, a potential role for TNFR1 and TNFR2 in identifying women with a higher MI risk is possible. The future clinical role of TNFR1 and TNFR2 in combination with CRP to identify high risk patients for coronary heart disease has yet to be determined. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Carlsson, Axel C.; Arnlov, Johan] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Ctr Family Med, Huddinge, Sweden.
   [Carlsson, Axel C.] Uppsala Univ, Cardiovasc Epidemiol, Dept Med Sci, Uppsala, Sweden.
   [Jansson, Jan-Hakan] Umea Univ, Res Unit Skelleftea, Dept Publ Hlth & Clin Med, Umea, Sweden.
   [Soderberg, Stefan] Umea Univ, Heart Ctr, Dept Publ Hlth & Clin Med, Umea, Sweden.
   [Ruge, Toralph] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med Solna, Stockholm, Sweden.
   [Ruge, Toralph] Karolinska Univ Hosp Huddinge, Funct Emergency Med, Stockholm, Sweden.
   [Larsson, Anders] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
   [Arnlov, Johan] Dalarna Univ, Sch Hlth & Social Sci, Falun, Sweden.
RP Carlsson, AC (reprint author), Karolinska Inst, Div Family Med & Primary Care, Alfred Nobels Alle 12, S-14183 Huddinge, Sweden.
EM axelcefam@hotmail.com
OI Soderberg, Stefan/0000-0001-9225-1306
FU Swedish Research CouncilSwedish Research Council; Swedish Heart-Lung
   FoundationSwedish Heart-Lung Foundation; Thureus foundation; Marianne
   and Marcus Wallenberg Foundation; Dalarna University; Uppsala
   University; Umea University
FX This study was supported by The Swedish Research Council, Swedish
   Heart-Lung Foundation, Thureus foundation, the Marianne and Marcus
   Wallenberg Foundation, Dalarna, Uppsala and Umea Universities. The
   funding sources did not play any role in the design and conduct of the
   study; collection, management, analysis, and interpretation of the data;
   and preparation, review, or approval of the manuscript. Dr. Arnlov is
   the guarantor of this work. Dr. Soderberg had full access to all the
   data, and takes full responsibility for the integrity of data and the
   accuracy of data analysis.
NR 37
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 41
EP 46
DI 10.1016/j.atherosclerosis.2018.03.020
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800007
PM 29547707
DA 2019-10-28
ER

PT J
AU Sung, KC
   Lee, MY
   Lee, JY
   Lee, SH
   Kim, JY
   Wild, SH
   Byrne, CD
AF Sung, Ki-Chul
   Lee, Mi-Yeon
   Lee, Jong-Young
   Lee, Sung-Ho
   Kim, Jang-Young
   Wild, Sarah H.
   Byrne, Christopher D.
TI Resolution of fatty liver and weight loss: Independent associations with
   changes in serum lipids and apolipoproteins
SO ATHEROSCLEROSIS
LA English
DT Article
DE BMI; Obesity; Non-alcoholic fatty liver disease; Fatty liver; Lipid;
   Insulin resistance; Metabolic syndrome
ID INSULIN-RESISTANCE; HEPATIC STEATOSIS; TRIGLYCERIDE CONTENT; DISEASE;
   RISK; POPULATION; EXERCISE; OBESITY; METAANALYSIS; RELIABILITY
AB Background and aims: It is uncertain whether resolution of fatty liver can improve cardiovascular disease risk factors, independently of changes in body mass index (BMI). Our aim was to test whether resolution of fatty liver is associated with improvements in components of the lipid profile, independently of changes in BMI, and to quantify and compare the magnitude of benefit of resolution of liver fat, and decreases in BMI on the lipid profile.& para;& para;Methods: 36,195 subjects with fatty liver were studied. Persistence/resolution of fatty liver was determined by ultrasound at follow up (mean 4.93 years). Total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and apolipoproteins were measured at baseline and follow up. Regression modelling was undertaken to test the independence of associations between change in fatty liver status or change in BMI, with any change in lipid profile concentrations between baseline and follow up.& para;& para;Results: Mean (SD) age was 36.3 +/- 6.6 and 39.8 +/- 8.7 years (men and women, respectively). Resolution of fatty liver occurred in 7,086, and persisted in 29,109 subjects. Mean +/- SD weight change was -3.2 +/- 4.3 (similar to 1 kg/m(2) decrease in BMI) with resolution of, and +0.5 +/- 3.5 kg with persistence of fatty liver, respectively. Both resolution of fatty liver and decrease in BMI were independently associated with improvements in all components of the lipid profile and there was a similar magnitude of benefit associated with resolution of fatty liver, or 1 kg/m(2) decrease in BMI.& para;& para;Conclusions: Resolution of fatty liver improves the lipid profile, independently of weight loss. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Sung, Ki-Chul; Lee, Jong-Young; Lee, Sung-Ho] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Div Cardiol,Dept Internal Med, 29 Saemunan Ro, Seoul 03181, South Korea.
   [Lee, Mi-Yeon] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Div Biostat,Dept R&D Management, Seoul, South Korea.
   [Kim, Jang-Young] Yonsei Univ, Wonju Coll Med, Dept Cardiol, Wonju, South Korea.
   [Wild, Sarah H.] Univ Edinburgh, Ctr Populat Hlth Sci, Lothian Pl, Edinburgh, Midlothian, Scotland.
   [Byrne, Christopher D.] Univ Southampton, Southampton Gen Hosp, Endocrinol & Metab Unit, IDS Bldg, Southampton, Hants, England.
   [Byrne, Christopher D.] Univ Southampton, Southampton Gen Hosp, Biomed Res Ctr, Southampton Natl Inst Hlth Res, Southampton, Hants, England.
RP Sung, KC (reprint author), Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Div Cardiol,Dept Internal Med, 29 Saemunan Ro, Seoul 03181, South Korea.; Byrne, CD (reprint author), Univ Southampton, Southampton Gen Hosp, Nutr & Metab, IDS Bldg,MP 887,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM kcmd.sung@samsung.com; c.d.byrne@soton.ac.uk
RI ; Rhee, Eun-Jung/M-9294-2015
OI Byrne, Christopher D/0000-0001-6322-7753; Rhee,
   Eun-Jung/0000-0002-6108-7758
FU MRC-KHIDI UK-KOREA PARTNERING AWARD (Medical Research Council)
   [MC_PC_16016]
FX The authors are supported by the MRC-KHIDI UK-KOREA PARTNERING AWARD
   (Medical Research Council MC_PC_16016).
NR 31
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 47
EP 53
DI 10.1016/j.atherosclerosis.2018.03.018
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800008
PM 29547708
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Taivainen, SH
   Yli-Ollila, H
   Juonala, M
   Kahonen, M
   Raitakari, OT
   Laitinen, TM
   Laitinen, TP
AF Taivainen, S. Helena
   Yli-Ollila, Heikki
   Juonala, Markus
   Kahonen, Mika
   Raitakari, Olli T.
   Laitinen, Tiina M.
   Laitinen, Tomi P.
TI Influence of cardiovascular risk factors on longitudinal motion of the
   common carotid artery wall
SO ATHEROSCLEROSIS
LA English
DT Article
DE Arterial stiffness; Cardiovascular risk factors; Carotid artery
   distensibility; Intima-media thickness; Motion tracking; Ultrasound
   imaging; Arteriosclerosis
ID INTIMA-MEDIA THICKNESS; YOUNG-ADULTS; STIFFNESS; DISTENSIBILITY;
   ATHEROSCLEROSIS; DISPLACEMENT; CHILDHOOD; MOVEMENT; INDEXES
AB Background and aims: Carotid artery longitudinal wall motion (CALM) is a new biomarker, which can be measured together with carotid intima-media thickness and distensibility measurements in the same session. Our objective was to study the relationship between these indicators of vascular health and cardiovascular risk factors in a large and well-characterized study population.& para;& para;Methods: The study population consisted of 465 subjects aged 30-45 years. Successful measurements were performed in 287 participants.& para;& para;Results: The peak-to-peak and retrograde amplitudes of the longitudinal motion were inversely correlated with systolic blood pressure (SBP; r = -0.152, p<0.05 and r = -0.189, p<0.01), diastolic blood pressure (DBP; r = -0.170, p<0.01 and r = -0.256, p<0.001) and body mass index (BMI; r = -0.158, p<0.01 and r = -0.291, p<0.001). In addition, retrograde amplitude of longitudinal motion indirectly correlated with total cholesterol and triglycerides (r = -0.163, p<0.01 and r = -0.228, p<0.001, respectively). Amplitude of antegrade longitudinal motion was directly correlated with DBP, total cholesterol, LDL-cholesterol, triglycerides and BMI (r = 0.198-0.274, p<0.001 for all). Antegrade longitudinal motion increased and retrograde longitudinal motion decreased with the increasing number of cardiovascular risk factors.& para;& para;Conclusions: The magnitude of correlation coefficients between CALM parameters and risk factors was comparable with those for carotid intima-media thickness and distensibility. However, the correlation profile for various risk factors was different and CALM gives additional information regarding arteriosclerosis and risk factors. (C) 2018 Published by Elsevier B.V.
C1 [Taivainen, S. Helena; Yli-Ollila, Heikki; Laitinen, Tiina M.; Laitinen, Tomi P.] Kuopio Univ Hosp, Dept Clin Physiol & Nucl Med, Kuopio, Finland.
   [Taivainen, S. Helena; Laitinen, Tomi P.] Univ Eastern Finland, Dept Clin Physiol & Nucl Med, Kuopio, Finland.
   [Yli-Ollila, Heikki] Kanta Hame Cent Hosp, Dept Radiol, Hameenlinna, Finland.
   [Yli-Ollila, Heikki] Univ Eastern Finland, Dept Appl Phys, Kuopio, Finland.
   [Juonala, Markus] Univ Turku, Dept Med, Turku, Finland.
   [Juonala, Markus] Turku Univ Hosp, Div Med, Turku, Finland.
   [Juonala, Markus] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
   [Kahonen, Mika] Univ Tampere, Dept Clin Physiol, Tampere, Finland.
   [Kahonen, Mika] Tampere Univ Hosp, Tampere, Finland.
   [Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland.
   [Raitakari, Olli T.] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, Turku, Finland.
RP Taivainen, SH (reprint author), Kuopio Univ Hosp, Dept Clin Physiol & Nucl Med, POB 100, FI-70029 Kys, Finland.
EM helena.taivainen@kuh.fi
RI Tarvainen, Mika P/B-1290-2009
OI Tarvainen, Mika P/0000-0001-8686-5395; Juonala,
   Markus/0000-0001-9498-364X
FU Academy of FinlandAcademy of Finland [134309, 126925, 121584, 124282,
   129378, 117787, 41071]; Social Insurance Institution of Finland; Kuopio,
   Tampere and Turku University Hospital Medical Funds; Juho Vainio
   Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; Yrjo
   Jahnsson Foundation; Paavo Nurmi Foundation; Finnish Foundation for
   Cardiovascular Research; Finnish Cultural FoundationFinnish Cultural
   Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation
FX This study was financially supported by research funds from specified
   government transfers to Kuopio University Hospital, the Finnish Cultural
   Foundation of North Savo, Ida Montins Foundation and Kuopio University
   Foundation. The Young Finns Study has been financially supported by the
   Academy of Finland: grants 134309 (Eye), 126925, 121584, 124282, 129378
   (Salve), 117787 (Gendi), and 41071 (Skidi), the Social Insurance
   Institution of Finland, Kuopio, Tampere and Turku University Hospital
   Medical Funds, Juho Vainio Foundation, Sigrid Juselius Foundation, Yrjo
   Jahnsson Foundation, Paavo Nurmi Foundation, Finnish Foundation for
   Cardiovascular Research and Finnish Cultural Foundation, Tampere
   Tuberculosis Foundation and Emil Aaltonen Foundation.
NR 30
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 54
EP 59
DI 10.1016/j.atherosclerosis.2018.02.037
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800009
PM 29550645
DA 2019-10-28
ER

PT J
AU Soderstrom, LA
   Tarnawski, L
   Olofsson, PS
AF Soderstrom, Leif A.
   Tarnawski, Laura
   Olofsson, Peder S.
TI CD137: A checkpoint regulator involved in atherosclerosis
SO ATHEROSCLEROSIS
LA English
DT Review
DE Inflammation; Tumor necrosis factor receptor superfamily; 4-1BB;
   Vascular inflammation; Cardiovascular disease; Costimulation; Leukocytes
ID TUMOR-NECROSIS-FACTOR; ACUTE CORONARY SYNDROMES; T-CELL COSTIMULATION;
   EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NF-KAPPA-B; DENDRITIC CELLS;
   ENDOTHELIAL-CELLS; HYPERLIPIDEMIC MICE; MONOCLONAL-ANTIBODY; MONOCYTE
   ACTIVATION
AB Inflammation is associated with atherosclerotic plaque development and precipitation of myocardial infarction and stroke, and anti-inflammatory therapy may reduce disease severity. Costimulatory molecules are key regulators of immune cell activity and inflammation, and are associated with disease development in atherosclerosis. Accumulating evidence indicates that a costimulatory molecule of the Tumor Necrosis Factor Receptor superfamily, the checkpoint regulator CD137, promotes atherosclerosis and vascular inflammation in experimental models. In light of the burgeoning consideration of CD137-targeted therapy in the clinic, it will be important to better understand costimulator immunobiology in development of cardiovascular disease. Here, we review available data on the costimulator CD137 and its potential role in atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Soderstrom, Leif A.; Tarnawski, Laura; Olofsson, Peder S.] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Dept Med,Expt Cardiovasc Med, Stockholm, Sweden.
   [Soderstrom, Leif A.] Karolinska Univ Hosp, Perioperat Med & Intens Care Med, Stockholm, Sweden.
   [Olofsson, Peder S.] North Shore LIJ Hlth Syst, Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY USA.
RP Olofsson, PS (reprint author), Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Dept Med,Expt Cardiovasc Med, Stockholm, Sweden.; Olofsson, PS (reprint author), Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Expt Cardiovasc Med, L8 03, S-17176 Stockholm, Sweden.
EM Peder.Olofsson@ki.se
FU Knut och Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation;
   Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation; Stockholm
   City Council (ALF)
FX Funding was provided by Knut och Alice Wallenberg Foundation, the
   Swedish Heart-Lung Foundation, and the Stockholm City Council (ALF).
NR 104
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 66
EP 72
DI 10.1016/j.atherosclerosis.2018.03.007
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800011
PM 29571029
DA 2019-10-28
ER

PT J
AU Hsieh, CY
   Lee, CH
   Wu, DP
   Sung, SF
AF Hsieh, Cheng-Yang
   Lee, Cheng-Han
   Wu, Darren Philbert
   Sung, Sheng-Feng
TI Prediction of new-onset atrial fibrillation after first-ever ischemic
   stroke: A comparison of CHADS(2), CHA(2)DS(2)-VASc and HATCH scores and
   the added value of stroke severity
SO ATHEROSCLEROSIS
LA English
DT Article
ID CRYPTOGENIC STROKE; SCORING SYSTEM; UNDETERMINED SOURCE; NATIONWIDE
   COHORT; EMBOLIC STROKES; RISK-FACTORS; ATTACK; VALIDATION; DIAGNOSIS;
   DATABASE
AB Background and aims: Early detection of atrial fibrillation after stroke is important for secondary prevention in stroke patients without known atrial fibrillation (AF). We aimed to compare the performance of CHADS(2), CHA(2)DS(2)-VASc and HATCH scores in predicting AF detected after stroke (AFDAS) and to test whether adding stroke severity to the risk scores improves predictive performance.& para;& para;Methods: Adult patients with first ischemic stroke event but without a prior history of AF were retrieved from a nationwide population-based database. We compared C-statistics of CHADS(2), CHA(2)DS(2)-VASc and HATCH scores for predicting the occurrence of AFDAS during stroke admission (cohort I) and during follow-up after hospital discharge (cohort II). The added value of stroke severity to prediction models was evaluated using C-statistics, net reclassification improvement, and integrated discrimination improvement.& para;& para;Results: Cohort I comprised 13,878 patients and cohort II comprised 12,567 patients. Among them, 806 (5.8%) and 657 (5.2%) were diagnosed with AF, respectively. The CHADS(2) score had the lowest C-statistics (0.558 in cohort I and 0.597 in cohort II), whereas the CHA(2)DS(2)-VASc score had comparable C-statistics (0.603 and 0.644) to the HATCH score (0.612 and 0.653) in predicting AFDAS. Adding stroke severity to each of the three risk scores significantly increased the model performance.& para;& para;Conclusions: In stroke patients without known AF, all three risk scores predicted AFDAS during admission and follow-up, but with suboptimal discrimination. Adding stroke severity improved their predictive abilities. These risk scores, when combined with stroke severity, may help prioritize patients for continuous cardiac monitoring in daily practice. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hsieh, Cheng-Yang] Tainan Sin Lau Hosp, Dept Neurol, Tainan, Taiwan.
   [Lee, Cheng-Han] Natl Cheng Kung Univ Hosp & Coll Med, Dept Internal Med, Div Cardiol, Tainan, Taiwan.
   [Wu, Darren Philbert; Sung, Sheng-Feng] Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med, Div Neurol, Chiayi, Taiwan.
RP Sung, SF (reprint author), Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med, Div Neurol, 539 Zhongxiao Rd, Chiayi 60002, Taiwan.
EM sfsung@cych.org.tw
RI Hsieh, Cheng-Yang/W-4841-2019
OI Hsieh, Cheng-Yang/0000-0002-8772-4073
FU Ditmanson Medical Foundation Chia-Yi Christian Hospital Research Program
   [R106-021]; Tainan Sin Lau Hospital [SLH-106-07]
FX This research was supported in part by the Ditmanson Medical Foundation
   Chia-Yi Christian Hospital Research Program (R106-021) and the Tainan
   Sin Lau Hospital (grant number SLH-106-07).
NR 50
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 73
EP 79
DI 10.1016/j.atherosclerosis.2018.03.024
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800012
PM 29571030
DA 2019-10-28
ER

PT J
AU Buschmann, EE
   Lee, EJ
   Jacobi, D
   Woischnig, AK
   Ulusans, S
   Schumacher, M
   Smith, KH
   Pagonas, N
   Bramlage, P
   Klisch, J
   Hillmeister, P
   Buschmann, IR
AF Buschmann, Eva Elina
   Lee, Eun-Ji
   Jacobi, Dorit
   Woischnig, Anne-Katrin
   Ulusans, Susann
   Schumacher, Martin
   Smith, Katherine H.
   Pagonas, Nikolaos
   Bramlage, Peter
   Klisch, Joachim
   Hillmeister, Philipp
   Buschmann, Ivo R.
TI Induction of extracranial arteriogenesis by an arteriovenous fistula in
   a pig model
SO ATHEROSCLEROSIS
LA English
DT Article
DE Arteriogenesis; Collateral growth; Fluid shear stress; Shunt; Rete
   mirabile; Macrophage
ID COLLATERAL ARTERY GROWTH; COLONY-STIMULATING FACTOR;
   NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; CIRCULATION; OCCLUSION; BRAIN;
   MCP-1; MICE; FLOW
AB Background and aims: Arteriogenesis, the positive outward remodeling and growth of pre-existent collateral vessels, holds potential as a novel treatment for ischemic vascular disease. An extracranial arteriogenesis model in a pig will allow us to study molecular changes in a complex arteriolar network in a more clinically relevant large-animal model.& para;& para;To increase fluid shear stress in the brain, an experimental carotid arteriovenous fistula (AVF model) in minipigs was established, providing high flow through the extracranial rete mirabile. The aim of the study was to examine whether creation of a carotid AVF can induce extracranial arteriogenesis in the pig. Methods: Angiography was performed to demonstrate blood flow diversion. Animals were sacrificed after 0, 3 and 14 days post-surgery and both retia mirabilia were removed. Immunohistochemical analysis was performed to analyze cell proliferation and accumulation of mononuclear cells in the vessel wall.& para;& para;Results: After 3 days of high-flow conditions, increases in vascular cell proliferation (approximately 1.5-fold; p = 0.143) and monocyte invasion (approximately 6-fold; p = 0.057) were observed when compared to animals sacrificed immediately after AVF formation. Quantitative PCR (RT-qPCR) analysis from rete mirabile tissue samples 3 days post-surgery revealed that monocyte chemoattractant protein (MCP)-1 and tissue inhibitor of metalloproteinases (TIMP)-1 were highly upregulated. Expression of the proarteriogenic marker, CD44, reached maximum expression level 14 days post-surgery.& para;& para;Conclusions: In response to high levels of shear stress produced in the pig AVF model, the onset of the arteriogenic process can be induced. This was demonstrated by enhanced cell proliferation, monocyte invasion and vascular remodeling. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Buschmann, Eva Elina] Med Univ Graz, Ctr Internal Med, Dept Cardiol, Graz, Austria.
   [Buschmann, Eva Elina; Lee, Eun-Ji; Jacobi, Dorit; Woischnig, Anne-Katrin; Hillmeister, Philipp; Buschmann, Ivo R.] Charite Univ Med Berlin, CCR, Dept Internal Med Cardiol, Berlin, Germany.
   [Buschmann, Eva Elina; Pagonas, Nikolaos; Bramlage, Peter; Hillmeister, Philipp; Buschmann, Ivo R.] Brandenburg Med Sch, Dept Angiol, Brandenburg Havel, Germany.
   [Ulusans, Susann; Schumacher, Martin] Univ Klinikum Freiburg, Neuroradiol, Freiburg, Germany.
   [Smith, Katherine H.; Bramlage, Peter] Inst Pharmacol & Prevent Med, Cloppenburg, Germany.
   [Klisch, Joachim] Helios Klinikum Erfurt, Inst Radiol & Neuroradiol, Erfurt, Germany.
RP Buschmann, EE (reprint author), Landeskrankenhaus Univ, Klinikum Graz, Univ Klin Innere Med, Klin Abt Kardiol, Auenbruggerpl 15, A-8036 Graz, Austria.
EM eva.Buschmann@medunigraz.at
RI Pagonas, Nikolaos/V-2241-2019
OI Smith, Katherine/0000-0003-3304-5822
NR 28
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 87
EP 93
DI 10.1016/j.atherosclerosis.2018.03.008
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800014
PM 29579672
DA 2019-10-28
ER

PT J
AU Dekkers, IA
   de Mutsert, R
   Rabelink, TJ
   Jukema, JW
   de Roos, A
   Rosendaal, FR
   Lamb, HJ
   de Vries, APJ
AF Dekkers, Ilona A.
   de Mutsert, Renee
   Rabelink, Ton J.
   Jukema, Johan W.
   de Roos, Albert
   Rosendaal, Frits R.
   Lamb, Hildo J.
   de Vries, Aiko P. J.
TI Associations between normal range albuminuria, renal function and
   cardiovascular function in a population-based imaging study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Albuminuria; Glomerular filtration rate; Vascular stiffness;
   Cardiovascular system; Magnetic resonance imaging
ID PULSE-WAVE VELOCITY; HEPATIC TRIGLYCERIDE CONTENT; CAROTID-ARTERY
   BIFURCATION; GLOMERULAR-FILTRATION-RATE; NETHERLANDS EPIDEMIOLOGY;
   CYSTATIN-C; GENERAL-POPULATION; KIDNEY-DISEASE; HEART-FAILURE; OBESITY
AB Background and aims: In patients with impaired renal function and macroalbuminuria, cardiovascular risk factors are highly prevalent, however, whether this is also present in the general population is unclear. We investigated whether normal-range albuminuria and renal function are associated with cardiovascular function in the general population.& para;& para;Methods: In this cross-sectional analysis of the NEO study, urinary albumin-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and intima-media thickness were assessed in all participants (n = 6503), and a random subset underwent MRI for pulse wave velocity (n = 2451) and/or cardiac imaging (n = 1138).& para;& para;Results: Multiple linear regression analysis was performed while adjusting for sex, age, smoking, mean arterial blood pressure, total body fat, and fasting glucose. After adjustment, albuminuria and renal function were positively associated with left ventricle (LV) mass index (UACR, 0.941 g/m(2) [95% CI: 0.21,1.67] p = 0.012; eGFR, 0.748 g/m(2) [95% CI: 0.15,1.35] p = 0.015) and LV cardiac index (UACR, 0.056 L/min/m(2) [95% CI: 0.00,0.11] p = 0.038; eGFR, 0.080 L/min/m(2) [95% CI: 0.03,0.13] p = 0.001). Albuminuria showed a weak association with arterial thickness (UACR, 0.003 mm [95% CI: 0.00,0.01] p = 0.015) and arterial stiffness (UACR, 0.073 m/s [95% CI: 0.01,0.13] p = 0.036), but not with renal function. No associations were observed for LV ejection fraction and LV diastolic function.& para;& para;Conclusions: Normal-range albuminuria was positively associated with LV mass index, LV cardiac index, arterial thickness and arterial stiffness. Our findings support the hypothesis that even within normal range, albuminuria is a marker of cardiovascular health. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Dekkers, Ilona A.; de Roos, Albert; Lamb, Hildo J.] Leiden Univ, Med Ctr, Dept Radiol, C2-S,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
   [de Mutsert, Renee; Rosendaal, Frits R.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands.
   [Rabelink, Ton J.; de Vries, Aiko P. J.] Leiden Univ, Med Ctr, Dept Internal Med, Div Nephrol & Transplant Med Leiden, Leiden, Netherlands.
   [Jukema, Johan W.] Leiden Univ, Med Ctr, Dept Cardiol Leiden, Leiden, Netherlands.
RP Dekkers, IA (reprint author), Leiden Univ, Med Ctr, Dept Radiol, C2-S,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
EM i.a.dekkers@lumc.nl
RI Rabelink, Ton J./A-5316-2008; Dekkers, Ilona/J-2572-2019
OI Rabelink, Ton J./0000-0001-6780-5186; Dekkers, Ilona/0000-0002-3329-0660
FU Division and the Board of Directors of the Leiden University Medical
   Centre; Leiden University, Research Profile Area 'Vascular and
   Regenerative Medicine'
FX The NEO study is supported by the participating Departments, the
   Division and the Board of Directors of the Leiden University Medical
   Centre, and by the Leiden University, Research Profile Area 'Vascular
   and Regenerative Medicine'.
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 94
EP 100
DI 10.1016/j.atherosclerosis.2018.03.029
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800015
PM 29579673
OA Other Gold
DA 2019-10-28
ER

PT J
AU Pirro, M
   Bianconi, V
   Schiaroli, E
   Francisci, D
   Mannarino, MR
   Bagaglia, F
   Sahebkar, A
   Merriman, T
   Baldelli, F
AF Pirro, Matteo
   Bianconi, Vanessa
   Schiaroli, Elisabetta
   Francisci, Daniela
   Mannarino, Massimo R.
   Bagaglia, Francesco
   Sahebkar, Amirhossein
   Merriman, Tony
   Baldelli, Franco
TI Elevated serum uric acid levels are associated with endothelial
   dysfunction in HIV patients receiving highly-active antiretroviral
   therapy
SO ATHEROSCLEROSIS
LA English
DT Article
DE HIV; HAART; Uric acid; Metabolic syndrome; Endothelial function
ID HUMAN-IMMUNODEFICIENCY-VIRUS; METABOLIC SYNDROME; INFECTED PATIENTS;
   ASYMPTOMATIC HYPERURICEMIA; ALLOPURINOL; DISEASE; URATE; RISK;
   MORTALITY; PREVALENCE
AB Background and aims: Elevated serum uric acid (SUA) levels may be associated with endothelial dysfunction. Increased rates of metabolic syndrome (MS) and elevated SUA levels were described in human immunodeficiency virus (HIV) infected patients. We investigated whether SUA levels are associated with endothelial dysfunction in HIV positive patients receiving highly-active antiretroviral therapy (HAART) irrespective of MS.& para;& para;Methods: In this cross-sectional study of 250 HIV positive patients receiving stable HAART, we evaluated the relationship between MS, SUA levels and endothelial function. SUA levels and brachial artery flow-mediated dilation (bFMD) were measured. The relationship between logarithmic (LG)-transformed SUA levels and bFMD was evaluated after correction for MS.& para;& para;Results: MS was detected in 28.4% of patients and elevated SUA levels (>= 6 mg/dL) in 25.2%. MS was associated with higher LG-SUA levels (age-, gender-and glomerular filtration rate-adjusted beta = 0.204, p = 0.001). The crude linear association between LG-SUA levels and LG-bFMD (beta = -0.166, p = 0.008) was abolished after correction for MS (beta = -0.089, p = 0.172). When SUA levels were used as a categorical variable (>= 6 mg/dL or <6 mg/dL and SUA quartiles, respectively), the association between LG-SUA levels and LG-bFMD remained significant after adjustment for MS (beta = -0.142, p = 0.022 and beta = -0.163, p = 0.010, respectively).& para;& para;Conclusions: MS significantly affects SUA levels in HAART-treated HIV infected patients. The negative association between SUA and bFMD is independent of MS only for elevated SUA levels. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Pirro, Matteo; Bianconi, Vanessa; Mannarino, Massimo R.; Bagaglia, Francesco] Univ Perugia, Dept Med, Unit Internal Med, I-06129 Perugia, Italy.
   [Schiaroli, Elisabetta; Francisci, Daniela; Baldelli, Franco] Univ Perugia, Dept Med, Unit Infect Dis, I-06129 Perugia, Italy.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Biotechnol Res Ctr, Mashhad 9177948564, Iran.
   [Merriman, Tony] Univ Otago, Dept Biochem, Dunedin 9054, New Zealand.
RP Pirro, M (reprint author), Univ Perugia, Hosp Santa Maria Misericordia, Unit Internal Med, Piazzale Menghini 1, I-06129 Perugia, Italy.
EM matteo.pirro@unipg.it
RI Bianconi, Vanessa/AAC-2058-2019; schiaroli, elisabetta/N-9098-2015;
   Mannarino, Massimo Raffaele/J-4577-2012
OI Bianconi, Vanessa/0000-0001-6987-9349; schiaroli,
   elisabetta/0000-0002-3216-4144; Mannarino, Massimo
   Raffaele/0000-0003-4694-5504
NR 57
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 101
EP 107
DI 10.1016/j.atherosclerosis.2018.03.031
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800016
PM 29597116
DA 2019-10-28
ER

PT J
AU Dufour, D
   Khalil, A
   Nuyens, V
   Rousseau, A
   Delporte, C
   Noyon, C
   Cortese, M
   Reye, F
   Pireaux, V
   Neve, J
   Vanhamme, L
   Robaye, B
   Lelubre, C
   Desmet, JM
   Raes, M
   Boudjeltia, KZ
   Van Antwerpen, P
AF Dufour, Damien
   Khalil, Alia
   Nuyens, Vincent
   Rousseau, Alexandre
   Delporte, Cedric
   Noyon, Caroline
   Cortese, Melissa
   Reye, Florence
   Pireaux, Valerie
   Neve, Jean
   Vanhamme, Luc
   Robaye, Bernard
   Lelubre, Christophe
   Desmet, Jean-Marc
   Raes, Martine
   Boudjeltia, Karim Zouaoui
   Van Antwerpen, Pierre
TI Native and myeloperoxidase-oxidized low-density lipoproteins act in
   synergy to induce release of resolvin-D1 from endothelial cells
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Inflammation; Lipid mediators; Lipidomics; Low-density
   lipoproteins (LDLs); Myeloperoxidase; Omega-3 fatty acids; Tandem mass
   spectrometry
ID LIPID MEDIATORS; LC-MS/MS; INFLAMMATION; RESOLUTION; LDL;
   ATHEROSCLEROSIS; MECHANISMS; COPPER; BINDS; ACID
AB Background and aims: Oxidation of native low-density lipoproteins (LDLs-nat) plays an important role in the development of atherosclerosis. A major player in LDL-nat oxidation is myeloperoxidase (MPO), a heme enzyme present in azurophil granules of neutrophils and monocytes. MPO produces oxidized LDLs called Mox-LDLs, which cause a pro-inflammatory response in human microvascular endothelial cells (HMEC), monocyte/macrophage activation and formation of foam cells. Resolvin D1 (RvD1) is a compound derived from the metabolism of the polyunsaturated fatty acid DHA, which promotes resolution of inflammation at the ng/ml level.& para;& para;Methods: In the present study, we used liquid chromatography-mass spectrometry (LC-MS/MS) to investigate the synthesis of RvD1 and its precursors-17(S)-hydroxy docosahexaenoic acid (17S-HDHA) and docosahexaenoic acid (DHA) - by HMEC, in the presence of several concentrations of Mox-LDLs, copper-oxidized-LDLs (Ox-LDLs), and native LDLs or in mouse plasma. The LC-MS/MS method has been validated and applied to cell supernatants and plasma to measure production of RvD1 and its precursors in several conditions.& para;& para;Results: Mox-LDLs played a significant role in the synthesis of RvD1 and 17S-HDHA from DHA compared to Ox-LDLs. Moreover, Mox-LDLs and LDLs-nat acted in synergy to produce RvD1. In addition, different correlations were found between RvD1 and M1 macrophages, age of mice or Cl-Tyr/Tyr ratio.& para;& para;Conclusions: These results suggest that although Mox-LDLs are known to be pro-inflammatory and deleterious in the context of atherosclerosis, they are also able to induce a pro-resolution effect by induction of RvD1 from HMEC. Finally, our data also suggest that HMEC can produce RvD1 on their own. (C) 2018 Published by Elsevier B.V.
C1 [Dufour, Damien; Delporte, Cedric; Noyon, Caroline; Cortese, Melissa; Reye, Florence; Neve, Jean; Van Antwerpen, Pierre] Univ Libre Bruxelles, Fac Pharm, Lab Pharmaceut Chem & Analyt Platform, Brussels, Belgium.
   [Khalil, Alia; Nuyens, Vincent; Rousseau, Alexandre; Lelubre, Christophe; Boudjeltia, Karim Zouaoui] Univ Libre Bruxelles, A Vesale Hosp, CHU Charleroi, Lab Expt Med,ULB Unit 222, Montignies le Tilleul, Belgium.
   [Vanhamme, Luc] Univ Libre Bruxelles, Lab Neurovasc Signaling, Gosselies, Belgium.
   [Pireaux, Valerie; Raes, Martine] Univ Namur, URBC Narilis, B-5000 Namur, Belgium.
   [Desmet, Jean-Marc] Univ Libre Bruxelles, A Vesale Hosp, CHU Charleroi, Unit Dialysis, Montignies le Tilleul, Belgium.
   [Robaye, Bernard] Univ Libre Bruxelles, IRIBHM, Inst Interdisciplinary Res, Gosselies, Belgium.
RP Dufour, D (reprint author), Univ Libre Bruxelles, Fac Pharm, Lab Pharmaceut Chem & Analyt Platform, Brussels, Belgium.
EM damien.dufour@ulb.ac.be
RI Delporte, Cedric/C-2228-2013
OI Delporte, Cedric/0000-0001-7453-7028
FU Belgian Fund for Scientific Research (FRS-FNRS)Fonds de la Recherche
   Scientifique - FNRS [34553.08, 2.5018.12]; Universite Libre de
   Bruxelles; F.R.S. - FNRSFonds de la Recherche Scientifique - FNRS
   [T.0136.13 PDR]
FX This study was supported by grants from the Belgian Fund for Scientific
   Research (FRS-FNRS, Grant 34553.08 and 2.5018.12), from the Universite
   Libre de Bruxelles (FER 2007). C. Noyon and M. Cortese are research
   fellows of the FRS-FNRS, C. Delporte is a postdoctoral researcher funded
   by the F.R.S. - FNRS (T.0136.13 PDR) and L. Vanhamme is Research
   Director of the FRS-FNRS.
NR 40
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 108
EP 117
DI 10.1016/j.atherosclerosis.2018.03.012
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800017
PM 29597117
DA 2019-10-28
ER

PT J
AU Andrews, JPM
   Fayad, ZA
   Dweck, MR
AF Andrews, Jack P. M.
   Fayad, Zahi A.
   Dweck, Marc R.
TI New methods to image unstable atherosclerotic plaques
SO ATHEROSCLEROSIS
LA English
DT Review
DE Unstable plaque; Computed tomography; Positron emission tomography
ID POSITRON-EMISSION-TOMOGRAPHY; ACUTE CORONARY SYNDROME; IMPAIRED
   GLUCOSE-TOLERANCE; OPTICAL COHERENCE TOMOGRAPHY; ACUTE
   MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIAL; HIGH-INTENSITY
   SIGNALS; NAPKIN-RING SIGN; VASCULAR INFLAMMATION; FDG-PET/CT
AB Atherosclerotic plaque rupture is the primary mechanism responsible for myocardial infarction and stroke, the top two killers worldwide. Despite being potentially fatal, the ubiquitous prevalence of atherosclerosis amongst the middle aged and elderly renders individual events relatively rare. This makes the accurate prediction of MI and stroke challenging. Advances in imaging techniques now allow detailed assessments of plaque morphology and disease activity. Both CT and MR can identify certain unstable plaque characteristics thought to be associated with an increased risk of rupture and events. PET imaging allows the activity of distinct pathological processes associated with atherosclerosis to be measured, differentiating patients with inactive and active disease states. Hybrid integration of PET with CT or MR now allows for an accurate assessment of not only plaque burden and morphology but plaque biology too. In this review, we discuss how these advanced imaging techniques hold promise in redefining our understanding of stable and unstable coronary artery disease beyond symptomatic status, and how they may refine patient risk-prediction and the rationing of expensive novel therapies. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Andrews, Jack P. M.; Dweck, Marc R.] Univ Edinburgh, Royal Infirm Edinburgh, Ctr Cardiovasc Sci, Chancellors Bldg, Edinburgh EH16 4SB, Midlothian, Scotland.
   [Fayad, Zahi A.] Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA.
RP Fayad, ZA (reprint author), Icahn Sch Med Mt Sinai, Translat & Mol Imaging Inst, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM zahi.fayad@mssm.edu
RI Fayad, Zahi/Z-3272-2019
OI Fayad, Zahi/0000-0002-3439-7347; dweck, marc/0000-0001-9847-5917
FU BHF Clinical Research Training Fellowship [FS/17/51/33096]; Sir Jules
   Thorn Biomedical Research Award [15/JTA]; British Heart
   FoundationBritish Heart Foundation [FS/14/78/31020]; NIH NHLBIUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01
   HL131478]; NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01 HL071021, R01 HL128056, R01HL135878];
   NBIB [R01 EB009638]; AHAAmerican Heart Association [14SFRN20780005]
FX JPMA is supported by BHF Clinical Research Training Fellowship no.
   FS/17/51/33096. ZAF by NIH NHLBI P01 HL131478; NHLBI R01 HL071021; NHLBI
   R01 HL128056; R01HL135878; NBIB R01 EB009638; and AHA 14SFRN20780005.
   MRD is supported by the Sir Jules Thorn Biomedical Research Award 2015
   (15/JTA) and by the British Heart Foundation (FS/14/78/31020).
NR 113
TC 11
Z9 11
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 118
EP 128
DI 10.1016/j.atherosclerosis.2018.03.021
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800018
PM 29602139
OA Other Gold, Green Accepted
DA 2019-10-28
ER

PT J
AU Wake, M
   Onishi, Y
   Guelfucci, F
   Oh, A
   Hiroi, S
   Shimasaki, Y
   Teramoto, T
AF Wake, Mayumi
   Onishi, Yoshie
   Guelfucci, Florent
   Oh, Akinori
   Hiroi, Shinzo
   Shimasaki, Yukio
   Teramoto, Tamio
TI Treatment patterns in hyperlipidaemia patients based on administrative
   claim databases in Japan
SO ATHEROSCLEROSIS
LA English
DT Article
DE Hyperlipidaemia; Treatment patterns; Persistence; Adherence; Claims
   database
ID LIPID INTERVENTION TRIAL; LOW-DOSE SIMVASTATIN; ATHEROSCLEROTIC
   CARDIOVASCULAR-DISEASES; LARGE-SCALE COHORT; DENSITY-LIPOPROTEIN
   CHOLESTEROL; SOCIETY JAS GUIDELINES; CORONARY-HEART-DISEASE; PRIMARY
   PREVENTION; J-LIT; SERUM-CHOLESTEROL
AB Background and aims: Real-world evidence on treatment of hyperlipidaemia (HLD) in Japan is limited. We aimed to describe treatment patterns, persistence with, and adherence to treatment in Japanese patients with HLD.& para;& para;Methods: Retrospective analyses of adult HLD patients receiving drug therapy in 2014-2015 were conducted using the Japan Medical Data Center (JMDC) and Medical Data Vision (MDV) databases. Depending on their HLD treatment history, individuals were categorised as untreated (UT) or previously treated (PT), and were followed for at least 12 months. Outcomes of interest included prescribing patterns of HLD drug classes, persistence with treatment at 12 months, and adherence to treatment.& para;& para;Results: Data for 49,582 and 53,865 patients from the JMDC and MDV databases, respectively, were analysed. First-line HLD prescriptions for UT patients were predominantly for moderate statins (JMDC: 75.9%, MDV: 77.0%). PT patients most commonly received combination therapy (JMDC: 43.9%, MDV: 52.6%). Approximately half of the UT patients discontinued treatment during observation. Within each cohort, persistence rates were lower in UT patients than in PT patients (JMDC: 45.0% vs. 77.5%; MDV: 51.9% vs. 85.3%). Adherence was >= 80% across almost all HLD drug classes, and was slightly lower in the JMDC cohort than MDV cohort.& para;& para;Conclusions: Most common prescriptions were moderate statins in UT patients and combination therapy in PT patients. The high discontinuation rate of HLD therapy in UT patients warrants further investigation and identification of methods to encourage and support long-term persistence. (C) 2018 Published by Elsevier B.V.
C1 [Wake, Mayumi; Oh, Akinori; Hiroi, Shinzo; Shimasaki, Yukio] Takeda Pharmaceut Co Ltd, Japan Med Affairs, Tokyo, Japan.
   [Onishi, Yoshie] Creat Ceut KK, Tokyo, Japan.
   [Guelfucci, Florent] Creat Ceut KK, Paris, France.
   [Teramoto, Tamio] Teikyo Univ, Teikyo Acad Res Ctr, Tokyo, Japan.
RP Teramoto, T (reprint author), Teikyo Univ, Teikyo Acad Res Ctr, Itabashi Ku, 11-1,Kaga2 Chome, Tokyo 1738605, Japan.
EM ttera@med.teikyo-u.ac.jp
OI Oh, Akinori/0000-0003-4281-0338
FU Takeda Pharmaceutical Company Limited, Tokyo, Japan
FX Funding for this research was provided by Takeda Pharmaceutical Company
   Limited, Tokyo, Japan.
NR 32
TC 4
Z9 4
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 145
EP 152
DI 10.1016/j.atherosclerosis.2018.03.023
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800021
PM 29604481
OA Other Gold
DA 2019-10-28
ER

PT J
AU Liu, SY
   Yang, YY
   Jiang, SY
   Tang, NN
   Tian, JW
   Ponnusamy, M
   Tariq, MA
   Lian, ZX
   Xin, H
   Yu, T
AF Liu, Shaoyan
   Yang, Yanyan
   Jiang, Shaoyan
   Tang, Ningning
   Tian, Jiawei
   Ponnusamy, Murugavel
   Tariq, Muhammad Akram
   Lian, Zhexun
   Xin, Hui
   Yu, Tao
TI Understanding the role of non-coding RNA (ncRNA) in stent restenosis
SO ATHEROSCLEROSIS
LA English
DT Review
DE Non-coding RNA; Coronary artery disease; Restonosis; microRNA; Long
   non-coding RNA; Immune response; Inflammation
ID VASCULAR SMOOTH-MUSCLE; CELL PHENOTYPIC SWITCH; CORONARY STENT;
   NEOINTIMA FORMATION; MOLECULAR-MECHANISMS; DOWN-REGULATION;
   GROWTH-FACTOR; CIRCULAR RNA; IN-VITRO; PROLIFERATION
AB Coronary heart disease (CHD) is one of the leading disorders with the highest mortality rate. Percutaneous angioplasty and stent implantation are the currently available standard methods for the treatment of obstructive coronary artery disease. However, the stent being an exogenous substance causes several complications by promoting the proliferation of vascular smooth muscle cells, immune responses and neointima formation after implantation, leading to post-stent restenosis (ISR) and late thrombosis. The prevention of these adverse vascular events is important to achieve long-term proper functioning of the heart after stent implantation. Non-coding ribonucleic acids (ncRNAs) are RNA molecules not translated into proteins, theyhave a great potential in regulating endothelial cell and vascular smooth muscle function as well as inflammatory reactions. In this review, we outline the regulatory functions of different classes of ncRNA in cardiovascular disease and propose ncRNAs as new targets for stent restonosis treatment. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Liu, Shaoyan; Lian, Zhexun; Xin, Hui] Qingdao Univ, Affiliated Hosp, Dept Cardiol, 16 Jiangsu Rd, Qingdao 266000, Peoples R China.
   [Yang, Yanyan; Tang, Ningning; Ponnusamy, Murugavel; Yu, Tao] Qingdao Univ, Inst Translat Med, Qingdao 266021, Peoples R China.
   [Jiang, Shaoyan] Qingdao Univ, Affiliated Cardiovasc Hosp, Dept Cardiol, Qingdao 266000, Peoples R China.
   [Tian, Jiawei] Qingdao Univ, Affiliated Hosp, Dept Emergency, Qingdao 266000, Peoples R China.
   [Tariq, Muhammad Akram] Univ Calif Santa Cruz, Jack Baskin Sch Engn, Dept Biomol Engn, Santa Cruz, CA 95064 USA.
RP Xin, H (reprint author), Qingdao Univ, Affiliated Hosp, Dept Cardiol, 16 Jiangsu Rd, Qingdao 266000, Peoples R China.; Yu, T (reprint author), Qingdao Univ, Inst Translat Med, Ctr Vasc Biol, 38 Deng Zhou Rd, Qingdao 266021, Peoples R China.
EM xinhuiqy@163.com; yutao0112@qdu.edu.cn
RI Ponnusamy, Murugavel/X-5699-2018
OI Ponnusamy, Murugavel/0000-0001-5558-8719; Yu, tao/0000-0002-0925-2242
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31701208]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2016M590616,
   2017M612189]; Natural Science Foundation of Shandong ProvinceNatural
   Science Foundation of Shandong Province [ZR2017MC067]; Doctoral
   foundation of Shandong province [201601016]; People's livelihood science
   and technology project of Qingdao [16-6-2-18-nsh, 17-1-1-40-jch]
FX This work was supported by National Natural Science Foundation of China
   (31701208); China Postdoctoral Science Foundation (2016M590616,
   2017M612189), Natural Science Foundation of Shandong Province
   (ZR2017MC067), Doctoral foundation of Shandong province (201601016) and
   The People's livelihood science and technology project of Qingdao
   (16-6-2-18-nsh, 17-1-1-40-jch).
NR 85
TC 7
Z9 7
U1 3
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 153
EP 161
DI 10.1016/j.atherosclerosis.2018.03.036
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800022
PM 29609130
DA 2019-10-28
ER

PT J
AU Yu, B
   Khan, K
   Hamid, Q
   Mardini, A
   Siddique, A
   Aguilar-Gonzalez, LP
   Makhoul, G
   Alaws, H
   Genest, J
   Thanassoulis, G
   Cecere, R
   Schwertani, A
AF Yu, Bin
   Khan, Kashif
   Hamid, Qutayba
   Mardini, Ahmad
   Siddique, Ateeque
   Aguilar-Gonzalez, Louis Philippe
   Makhoul, Georges
   Alaws, Hossny
   Genest, Jacques
   Thanassoulis, George
   Cecere, Renzo
   Schwertani, Adel
TI Pathological significance of lipoprotein(a) in aortic valve stenosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Human; Aortic valve stenosis; Calcium; Oxidized phospholipids; Oxidant
   formation; ELISA; MS/MS
ID VALVULAR HEART-DISEASE; WNT SIGNALING PATHWAY; OXIDIZED PHOSPHOLIPIDS;
   RISK; CALCIFICATION; PROGRESSION; ATHEROSCLEROSIS; APOLIPOPROTEIN;
   INFLAMMATION; MANAGEMENT
AB Background and aims: Aortic valve stenosis (AVS) affects a significant percentage of our elderly population and younger subjects with familial hypercholesterolemia. Lipoprotein(a) [Lp(a)] has been associated with AVS in recent genetic studies. The purpose of this study was to determine the effects of Lp(a) on human aortic valve interstitial cells (HAVICs), and to identify apolipoproteins and phospholipids in diseased human aortic valves.& para;& para;Methods: We examined the effects of Lp(a) on HAVICs mineralization and oxidant formation. Proteomic analyses were used to determine the effects of Lp(a) on downstream intracellular markers. We also used mass spectroscopy to identify the different lipoproteins and oxidized phospholipids in calcified aortic valves.& para;& para;Results: HAVICs incubated with either LDL or Lp(a) had significantly higher calcium deposition, compared to control (p<0.001), with Lp(a) having the most significant effect (p<0.01) compared to LDL. Proteomic analysis after 10 days of treatment with Lp(a) resulted in enrichment of proteins involved in calcium deposition and vesicle biogenesis. Treatment of HAVICs with Lp(a) significantly increased ROS formation (p<0.05). Patients with calcific aortic stenosis had higher plasma Lp(a) concentrations compared to non-CAD individuals (p<0.001). LC-MS/MS revealed the presence of apolipoproteins and phospholipids in calcified human aortic valves.& para;& para;Conclusions: The present study outlines an association between Lp(a) and AVS, and suggests that Lp(a) may serve as a potential target for therapeutic purposes to manage the progression of AVS. (C) 2018 Published by Elsevier B.V.
C1 [Yu, Bin; Khan, Kashif; Mardini, Ahmad; Siddique, Ateeque; Aguilar-Gonzalez, Louis Philippe; Makhoul, Georges; Alaws, Hossny; Genest, Jacques; Thanassoulis, George; Cecere, Renzo; Schwertani, Adel] McGill Univ, Hlth Ctr, Div Cardiol, 1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada.
   [Yu, Bin; Khan, Kashif; Mardini, Ahmad; Siddique, Ateeque; Aguilar-Gonzalez, Louis Philippe; Makhoul, Georges; Alaws, Hossny; Genest, Jacques; Thanassoulis, George; Cecere, Renzo; Schwertani, Adel] McGill Univ, Hlth Ctr, Div Cardiac Surg, 1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada.
   [Hamid, Qutayba] McGill Univ, Montreal, PQ, Canada.
   [Hamid, Qutayba] Univ Sharjah, Sharjah, U Arab Emirates.
RP Schwertani, A (reprint author), McGill Univ, Hlth Ctr, Glen EM1-2224,1001 Blvd Decarie, Montreal, PQ H4A 3J1, Canada.
EM adel.schwertani@mcgill.ca
FU Canadian Institute of Health ResearchCanadian Institutes of Health
   Research (CIHR) [PJT-148983]; NSERCNatural Sciences and Engineering
   Research Council of Canada [RGPIN-2017-05328]
FX This work was supported by the Canadian Institute of Health Research
   (PJT-148983) and NSERC (RGPIN-2017-05328).
NR 39
TC 2
Z9 3
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 168
EP 174
DI 10.1016/j.atherosclerosis.2018.03.025
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800024
PM 29614432
DA 2019-10-28
ER

PT J
AU Dhar, I
   Lysne, V
   Seifert, R
   Svingen, GFT
   Ueland, PM
   Nygard, OK
AF Dhar, Indu
   Lysne, Vegard
   Seifert, Reinhard
   Svingen, Gard F. T.
   Ueland, Per M.
   Nygard, Ottar K.
TI Plasma methionine and risk of acute myocardial infarction: Effect
   modification by established risk factors
SO ATHEROSCLEROSIS
LA English
DT Article
DE Acute myocardial infarction; Methionine; Lipids; Amino acids; Angina
   pectoris
ID GLYCINE N-METHYLTRANSFERASE; FATTY LIVER-DISEASE; ONE-CARBON METABOLISM;
   NITRIC-OXIDE; VITAMIN STATUS; HOMOCYSTEINE; ATHEROSCLEROSIS; DEFICIENCY;
   STABILITY; EVENTS
AB Background and aims: Methionine (Met) is an essential amino acid involved in methylation reactions and lipid metabolism. A Met-deficient diet may cause hepatic lipid accumulation, which is considered an independent risk factor for atherosclerosis. However, the prospective relationship between circulating Met and incident acute myocardial infarction (AMI) is unknown.& para;& para;Methods: We studied the associations of plasma Met and incident AMI in 4156 patients (77% men; median age 62 years) with stable angina pectoris, among whom the majority received lipid lowering therapy with statins. Risk associations were estimated using Cox-regression analyses.& para;& para;Results: Plasma Met was negatively related to age, serum levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and apolipoprotein (apo) B at baseline (all p <= 0.05). During a median follow-up of 7.5 years, 534 (12.8%) patients experienced an AMI. There was no overall association between plasma Met and incident AMI; however, plasma Met was inversely associated with risk among patients with high as compared to low levels of serum LDL-C or apo B 100 (multivariate adjusted HRs per SD [95% CI] 0.84 [0.73-0.96] and 0.83[0.73-0.95], respectively; p-interaction <= 0.02). Trends towards an inverse risk relationship were also observed among those younger than 62 years and patients without diabetes or hypertension.& para;& para;Conclusions: Low plasma Met was associated with increased risk of AMI in patients with high circulating levels of atherogenic lipids, but also in subgroups with presumably lower cardiovascular risk. The determinants of Met status and their relation with residual cardiovascular risk in patients with coronary heart disease should be further investigated. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Dhar, Indu; Lysne, Vegard; Ueland, Per M.; Nygard, Ottar K.] Univ Bergen, Dept Clin Sci, N-5021 Bergen, Norway.
   [Dhar, Indu; Nygard, Ottar K.] Univ Bergen, KG Jebsen Ctr Diabet Res, N-5009 Bergen, Norway.
   [Seifert, Reinhard; Svingen, Gard F. T.; Nygard, Ottar K.] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway.
   [Ueland, Per M.] Bevital AS, N-5021 Bergen, Norway.
RP Dhar, I (reprint author), Univ Bergen, Haukeland Univ Hosp, Dept Clin Sci, Lab Bldg,9th Floor,Jonas Lies Vei 87, N-5021 Bergen, Norway.
EM Indu.Dhar@uib.no
RI Ueland, Per M/C-7340-2013
FU KG Jebsen Center for Diabetes Research, University of Bergen; Department
   of Heart Disease at Haukeland University Hospital; Western Norway
   Regional Health Authority; Foundation to Promote Research into
   Functional Vitamin B12 Deficiency, Bergen, Norway
FX Funding of this project was provided by the KG Jebsen Center for
   Diabetes Research, University of Bergen, the Department of Heart Disease
   at Haukeland University Hospital, the Western Norway Regional Health
   Authority, and the Foundation to Promote Research into Functional
   Vitamin B12 Deficiency, Bergen, Norway.
NR 35
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 175
EP 181
DI 10.1016/j.atherosclerosis.2018.03.038
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800025
PM 29621698
DA 2019-10-28
ER

PT J
AU Masuda, Y
   Kurikawa, N
   Nishizawa, T
AF Masuda, Yusuke
   Kurikawa, Nobuya
   Nishizawa, Tomohiro
TI Overexpressing human GPR109A leads to pronounced reduction in plasma
   triglyceride levels in BAC transgenic rats
SO ATHEROSCLEROSIS
LA English
DT Article
ID RECEPTOR PARTIAL AGONIST; NICOTINIC-ACID RECEPTOR; ESTER TRANSFER
   PROTEIN; INSULIN-RESISTANCE; ADIPOCYTE LIPOLYSIS; ADIPOSE-TISSUE;
   MOLECULAR-IDENTIFICATION; PUMA-G; NIACIN; MICE
AB Background and aims: Nicotinic acid administration causes plasma non-esterifled fatty acid (NEFA) reduction and plasma lipid changes, including reduced triglyceride levels. GPR109A, which is expressed mainly in adipose tissue and has anti-lipolytic activity, was reported to be a molecular target for nicotinic acid. However, recent clinical reports have shown that most GPR109A agonists failed to induce clinically meaningful plasma lipid changes. In addition, a recent study has shown that the TG lowering effect of nicotinic acid was not diminished in Gpr109a deficient mice, which is different from the original finding. Therefore, whether GPR109A activation can lead to plasma lipid changes is unclear.& para;& para;Methods: We created a bacterial artificial chromosome (BAC) transgenic rat expressing human GPR109A (Tg rat) and examined the in vivo role of GPR109A.& para;& para;Results: Under fasted conditions, plasma NEFA and triglyceride levels in Tg rats were lower than those in non-Tg rats. In this condition, a positive correlation between plasma NEFA and triglyceride or beta-hydroxybutyrate levels was observed. Furthermore, insulin levels in Tg rats were lower than those in non-Tg rats only when a reduction in NEFAs was observed, which is a phenomenon also reported for nicotinic acid. Interestingly, body weight gain in Tg rats was significantly lower than in non-Tg rats.& para;& para;Conclusions: These results suggest that GPR109A signaling leads to a reduction in triglyceride and insulin levels, and that the triglyceride-lowering effect of nicotinic acid is at least partially mediated by GPR109A signaling. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Masuda, Yusuke; Nishizawa, Tomohiro] Daiichi Sankyo Co Ltd, End Organ Dis Labs, Shinagawa Ku, 1-2-58 Hiromachi, Tokyo, Japan.
   [Kurikawa, Nobuya] Daiichi Sankyo Co Ltd, Venture Sci Labs, Shinagawa Ku, 1-2-58 Hiromachi, Tokyo, Japan.
RP Masuda, Y (reprint author), Daiichi Sankyo Co Ltd, End Organ Dis Labs, Shinagawa Ku, 1-2-58 Hiromachi, Tokyo, Japan.
EM masuda.yusuke.z8@daiichisankyo.co.jp
NR 45
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 182
EP 192
DI 10.1016/j.atherosclerosis.2018.03.041
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800026
PM 29625294
DA 2019-10-28
ER

PT J
AU Suarez-Ortegon, MF
   McLachlan, S
   Price, AH
   Fernandez-Balsells, M
   Franch-Nadal, J
   Mata-Cases, M
   Barrot-de la Puente, J
   Mundet-Tuduri, X
   Mauricio, D
   Ricart, W
   Wild, SH
   Strachan, MWJ
   Price, JF
   Fernandez-Real, JM
AF Fabian Suarez-Ortegon, Milton
   McLachlan, Stela
   Price, Anna H.
   Fernandez-Balsells, Merce
   Franch-Nadal, Josep
   Mata-Cases, Manel
   Barrot-de la Puente, Joan
   Mundet-Tuduri, Xavier
   Mauricio, Didac
   Ricart, Wifredo
   Wild, Sarah H.
   Strachan, Mark W. J.
   Price, Jackie F.
   Fernandez-Real, Jose-Manuel
TI Decreased iron stores are associated with cardiovascular disease in
   patients with type 2 diabetes both cross-sectionally and longitudinally
SO ATHEROSCLEROSIS
LA English
DT Article
DE Ferritin; Cardiovascular disease; Type 2 diabetes
ID CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; RISK-FACTORS; SERUM
   FERRITIN; PRIMARY-CARE
AB Background and aims: The possible contribution of iron to cardiovascular complications of type 2 diabetes (T2D) has been scarcely investigated. We aimed to study whether serum ferritin is linked to prevalent/incident cardiovascular disease (CVD) in T2D.& para;& para;Methods: The prevalence of coronary heart disease (CHD), cerebrovascular disease (CEVD) and CVD was evaluated in the SIDIAP study (n = 38,617) and prevalence and 7-year incidence were analysed in the Edinburgh Type 2 Diabetes Study (ET2DS) (n = 821). Logistic and Cox regressions were used to describe associations between serum ferritin and CVD adjusting for confounding variables.& para;& para;Results: Increase of 1 SD unit in log-ferritin was associated with lower CVD prevalence in fully-adjusted models (ET2DS odds ratio (OR) 95% confidence interval (CI): 0.81 (0.68-0.96), p = 0.018; SIDIAP study: 0.91 (0.88-0.94), p < 0.001). In ET2DS, ferritin in the highest (vs. the lowest) quintile was associated with lower incidence of CVD (fully adjusted HR 95% CI: 0.46 (0.26-0.83), p = 0.010). This association persisted after removing subjects with CVD at baseline (n = 536) (HR 95% CI: 0.34 (0.14-0.81), p = 0.016).& para;& para;Conclusions: Low iron status was associated with CVD risk in T2D. This pattern was consistent in populations at different cardiovascular risk. Low iron status seems to be harmful for cardiovascular health in T2D and it may be a target for intervention. (C) 2018 Published by Elsevier B.V.
C1 [Fabian Suarez-Ortegon, Milton; McLachlan, Stela; Price, Anna H.; Wild, Sarah H.; Price, Jackie F.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.
   [Fabian Suarez-Ortegon, Milton] Univ Valle, Nutr Grp, Cali, Colombia.
   [Fernandez-Balsells, Merce; Ricart, Wifredo; Fernandez-Real, Jose-Manuel] CIBEROBN CB06 03 010, Inst Invest Biomed Girona IdIBGi, Dept Diabet Endocrinol & Nutr, Girona, Spain.
   [Fernandez-Balsells, Merce; Ricart, Wifredo; Fernandez-Real, Jose-Manuel] ISCIII, Girona, Spain.
   [Franch-Nadal, Josep; Mata-Cases, Manel; Barrot-de la Puente, Joan; Mundet-Tuduri, Xavier] Inst Univ Invest AtencioPrimaria Jordi Gol IDIAP, Unitat Suport Recerca Barcelona Ciutat, DAP Catgrp, Barcelona, Spain.
   [Franch-Nadal, Josep] Inst Catal Salut, Primary Hlth Care Ctr Raval Sud, Gerencia Ambit Atencio Primaria Barcelona Ciutat, Barcelona, Spain.
   [Franch-Nadal, Josep; Mata-Cases, Manel; Mauricio, Didac] Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain.
   [Mata-Cases, Manel] Inst Catal Salut, Primary Hlth Care La Mina St Adria de Beso, Gerencia Ambit Atencio Primaria Barcelona Ciutat, Barcelona, Spain.
   [Strachan, Mark W. J.] Western Gen Hosp, Metab Unit, Edinburgh, Midlothian, Scotland.
RP Suarez-Ortegon, MF (reprint author), Univ Edinburgh, Coll Med & Vet Med, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.; Fernandez-Real, JM (reprint author), Hosp Girona Dr JosepTrueta, Dept Diabet Endocrinol & Nutr, Carretera Franca S-N, Girona 17007, Spain.
EM Milton.Suarez@ed.ac.uk; jmfreal@idibgi.org
RI Mauricio, Didac/B-7951-2009; mata-cases, manel/W-9485-2019;
   Franch-Nadal, Josep/AAC-1945-2019
OI Mauricio, Didac/0000-0002-2868-0250; mata-cases,
   manel/0000-0003-3693-3622; Franch-Nadal, Josep/0000-0002-5175-1555;
   FERNANDEZ-BALSELLS, MERCE/0000-0001-8221-4237
FU UK Medical Research CouncilMedical Research Council UK (MRC); Pfizer
   (ET2DS); Colombian Administrative Department of Science, Technology and
   innovation (COLCIENCIAS)Departamento Administrativo de Ciencia,
   Tecnologia e Innovacion Colciencias [529]
FX UK Medical Research Council and a grant from Pfizer (ET2DS). M.F.S.O
   received a scholarship (2011 #529) for doctoral studies from the
   Colombian Administrative Department of Science, Technology and
   innovation (COLCIENCIAS).
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 193
EP 199
DI 10.1016/j.atherosclerosis.2018.03.028
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800027
PM 29625295
DA 2019-10-28
ER

PT J
AU Martinez-Amezcua, P
   Matsushita, K
   Simonsick, EM
   Ferrucci, L
   Schrack, JA
AF Martinez-Amezcua, Pablo
   Matsushita, Kunihiro
   Simonsick, Eleanor M.
   Ferrucci, Luigi
   Schrack, Jennifer A.
TI Fatigability and functional performance among older adults with
   low-normal ankle-brachial index: Cross-sectional findings from the
   Baltimore Longitudinal Study of Aging
SO ATHEROSCLEROSIS
LA English
DT Article
DE Fatigability; Peripheral artery disease; Functional performance
ID PERIPHERAL ARTERIAL-DISEASE; PHYSICAL-ACTIVITY; LEG SYMPTOMS; HEALTH
   ABC; MOBILITY; DECLINE; ASSOCIATIONS; METAANALYSIS; PREVALENCE;
   DISABILITY
AB Background and aims: Peripheral artery disease (PAD) is associated with poor mobility and fatigue, but the relationship between preclinical ankle-brachial index (ABI) and early markers of fatigue and functional decline has not been defined.& para;& para;Methods: 570 adults, 50 and older, from the Baltimore Longitudinal Study of Aging (N=570), with normal values of ABI (1-1.39), were classified into ABI tertiles. Perceived fatigability was assessed after a 5-min, treadmill walk (1.5 mph) using the Borg rating of perceived exertion (RPE, range 6-20). Functional evaluation included the Health, Aging and Body Composition Physical Performance Battery (HABC PPB), time to complete a 400-m corridor walk (LDCW), and VO2 peak (ml/kg/min). High RPE and poor walking endurance (PWE) were defined as RPE >= 10 and taking >5 min for the LDCW, respectively. Differences between tertiles in fatigability and functional measures were tested adjusting for demographics, behavioral characteristics, self-reported fatigue, and medical history.& para;& para;Results: Mean LDCW time and RPE were greater for participants in the lowest tertile compared to those in the highest; mean VO2 peak and HABC PPB scores were lower, suggesting hierarchical associations between fatigability, functional performance, and ABI (p < 0.05 for all). Odds of PWE were greater for those in the lowest ABI tertile compared to the highest; odds of reporting high RPE were greater for those in the middle tertile.& para;& para;Conclusions: Lower ABI is associated with poorer physical function and increased fatigability, suggesting that early changes in ABI may infer greater risk of functional decline, even among those who may not progress to PAD. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Martinez-Amezcua, Pablo; Matsushita, Kunihiro; Schrack, Jennifer A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Martinez-Amezcua, Pablo; Schrack, Jennifer A.] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD USA.
   [Simonsick, Eleanor M.; Ferrucci, Luigi] NIA, Intramural Res Program, Baltimore, MD 21224 USA.
RP Martinez-Amezcua, P (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.
EM pablov489@jhu.edu
RI Simonsick, Eleanor/W-6864-2019
OI Martinez-Amezcua, Pablo/0000-0002-3076-0946
FU Intramural Research Program of the National Institute on AgingUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Aging (NIA); NIH/NCIUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R21AG053198];
   NIH/NIAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [P30AG021334]
FX This work was supported in part by the Intramural Research Program of
   the National Institute on Aging. Extramural funding provided by NIH/NCI
   R21AG053198 and NIH/NIA P30AG021334.
NR 33
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 200
EP 206
DI 10.1016/j.atherosclerosis.2018.03.037
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800028
PM 29627740
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Delacroix, S
   Chokka, RG
   Nelson, AJ
   Wong, DT
   Pederson, S
   Nimmo, J
   Rajwani, A
   Williams, K
   Teo, KS
   Worthley, SG
AF Delacroix, Sinny
   Chokka, Ramesh G.
   Nelson, Adam J.
   Wong, Dennis T.
   Pederson, Stephen
   Nimmo, Joanne
   Rajwani, Adil
   Williams, Kerry
   Teo, Karen S.
   Worthley, Stephen G.
TI Effects of renal sympathetic denervation on myocardial structure,
   function and perfusion: A serial CMR study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Renal denervation; Resistant hypertension; Magnetic resonance imaging;
   Myocardial perfusion reserve index; T1 mapping; Circumferential strain
ID CARDIOVASCULAR MAGNETIC-RESONANCE; CORONARY-HEART-DISEASE;
   PROOF-OF-CONCEPT; RESISTANT HYPERTENSION; ARTERIAL STIFFNESS; CENTRAL
   HEMODYNAMICS; BLOOD-PRESSURE; VALIDATION; STROKE; PREVALENCE
AB Background and aims: Echocardiographic studies have shown improvements in cardiac indices associated with renal sympathetic denervation (RDN), however, the benefits on myocardial perfusion have never been assessed. This trial was designed to study the effects of RDN on myocardial perfusion using cardiac magnetic resonance (CMR) imaging.& para;& para;Methods: A total of 14 patients with resistant hypertension were recruited for RDN and myocardial perfusion, alongside other CMR indices, was assessed at baseline and at 6 months.& para;& para;Results: RDN showed significant reduction of mean office blood pressures from 181/100 +/- 19/16 mmHg to 147/85 +/- 19/17 mmHg, 6 months after the procedure (p < 0.0001). This was combined with significant improvement in regional aortic distensibility (p < 0.02) and associated with trends of improved myocardial perfusion reserve index (baseline = 2.2 +/- 1; 6 months = 2.9 +/- 1 units) (p = 0.08). Left ventricular end systolic volume index decreased from baseline to 6 months post procedure, 27 +/- 13 ml/m(2) vs. 22 +/- 10 ml/m(2) (p = 0.03), but there was no significant change in left ventricular end diastolic volume index (p = 0.09). There was significant improvement in mean left ventricular ejection fraction from 68 +/- 10% to 72 + 9%, 6 months post procedure (p = 0.04). T1 mapping failed to detect fibrosis in these patients at baseline and therefore no change was noted, however, extracellular volume percent improved from 46 +/- 4% at baseline to 41 +/- 8% at 6 months (p = 0.002).& para;& para;Conclusions: This study demonstrates that renal sympathetic denervation increased myocardial perfusion by 32% as assessed by CMR, and, this was associated with improvements in cardiac volumes and function. Larger well controlled and randomized studies are required to assess the clinical significance of these findings. Crown Copyright (C) 2018 Published by Elsevier B.V. All rights reserved.
C1 [Delacroix, Sinny; Chokka, Ramesh G.; Nelson, Adam J.; Nimmo, Joanne; Rajwani, Adil; Williams, Kerry; Teo, Karen S.; Worthley, Stephen G.] Royal Adelaide Hosp, Cardiovasc Res Ctr, Adelaide, SA, Australia.
   [Delacroix, Sinny; Chokka, Ramesh G.; Nelson, Adam J.; Nimmo, Joanne; Rajwani, Adil; Williams, Kerry; Teo, Karen S.; Worthley, Stephen G.] Univ Adelaide, Discipline Med, Fac Hlth Sci, Adelaide, SA, Australia.
   [Wong, Dennis T.] Monash Med Ctr, 246 Clayton Rd, Clayton, Vic, Australia.
   [Delacroix, Sinny; Chokka, Ramesh G.; Nelson, Adam J.; Wong, Dennis T.; Nimmo, Joanne; Rajwani, Adil; Williams, Kerry; Teo, Karen S.; Worthley, Stephen G.] South Australian Hlth & Med Res Inst, North Terrace, Adelaide, SA, Australia.
   [Pederson, Stephen] Univ Adelaide, Sch Biol Sci, Bioinformat Hub, Adelaide, SA, Australia.
RP Delacroix, S (reprint author), Univ Adelaide, Dept Med, Adelaide, SA 5000, Australia.
EM sinny.delacroix@adelaide.edu.au
OI Rajwani, Adil/0000-0002-4196-7205
FU St. Jude MedicalSt. Jude Medical
FX The study was completed with grant support from St. Jude Medical.
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 207
EP 215
DI 10.1016/j.atherosclerosis.2018.03.022
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800029
PM 29627741
DA 2019-10-28
ER

PT J
AU Harris, WS
AF Harris, William S.
TI Redefining target omega-3 index levels: The Japan Public Health Center
   Study
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Omega-3 fatty acids; Eicosapentaenoic acid; Docosahexaenoic acid;
   Docosapentaenoic acid; Smoking; Epidemiology; Prospective cohort study;
   Cardiovascular disease
ID CORONARY-HEART-DISEASE; FATTY-ACIDS; RISK; BIOMARKERS; MORTALITY;
   STROKE; COHORT; DEATH; MEN
C1 [Harris, William S.] Univ South Dakota, Sanford Sch Med, Dept Internal Med, 5009 W 12th St,Suite 8, Sioux Falls, SD 57106 USA.
   [Harris, William S.] OmegaQuant Analyt LLC, 5009 W 12th St,Suite 8, Sioux Falls, SD 57106 USA.
RP Harris, WS (reprint author), Univ South Dakota, Sanford Sch Med, Dept Internal Med, 5009 W 12th St,Suite 8, Sioux Falls, SD 57106 USA.; Harris, WS (reprint author), OmegaQuant Analyt LLC, 5009 W 12th St,Suite 8, Sioux Falls, SD 57106 USA.
EM bill@omegaquant.com
RI Harris, William Stephen/T-1674-2019
OI Harris, William Stephen/0000-0003-3042-9353
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 216
EP 218
DI 10.1016/j.atherosclerosis.2018.01.030
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800030
PM 29525224
DA 2019-10-28
ER

PT J
AU Bellasi, A
   Raggi, P
AF Bellasi, Antonio
   Raggi, Paolo
TI Among markers of risk, uric acid remains a two-faced Janus awaiting
   definitive framing
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Uric acid; Atherosclerosis; Cardiovascular events
ID CHRONIC KIDNEY-DISEASE; OUTCOMES; URATE; CKD
C1 [Bellasi, Antonio] St Anna Hosp, Dept Nephrol & Dialysis, ASST Lariana, Como, Italy.
   [Raggi, Paolo] Univ Alberta, Mazankowski Alberta Heart Hosp, Dept Med, Edmonton, AB, Canada.
RP Raggi, P (reprint author), MD 8440-112 St,4A7-050, Edmonton, AB T6G 2B7, Canada.
EM raggi@ualberta.ca
RI bellasi, antonio/M-3744-2013
OI bellasi, antonio/0000-0001-7830-1645
NR 16
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 219
EP 221
DI 10.1016/j.atherosclerosis.2018.03.017
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800031
PM 29551186
DA 2019-10-28
ER

PT J
AU Stock, J
AF Stock, Jane
TI The highs and lows of cardiovascular disease prevention
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE PCSK9; FOURIER; GLAGOV; CANTOS
ID PCSK9 INHIBITOR EVOLOCUMAB; RANDOMIZED CLINICAL-TRIAL; LDL-CHOLESTEROL
   LEVELS; HIGH-RISK PATIENTS; SUBCLINICAL ATHEROSCLEROSIS; SECONDARY
   ANALYSIS; SAFETY; EFFICACY; BOCOCIZUMAB; PROGRESSION
C1 [Stock, Jane] World Trade Ctr Goteborg, European Atherosclerosis Soc, Massans Gata 10, SE-41251 Gothenburg, Sweden.
RP Stock, J (reprint author), World Trade Ctr Goteborg, European Atherosclerosis Soc, Massans Gata 10, SE-41251 Gothenburg, Sweden.
EM office@eas-society.org
NR 25
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 222
EP 224
DI 10.1016/j.atherosclerosis.2018.03.005
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800032
PM 29602514
DA 2019-10-28
ER

PT J
AU Lunegova, OS
   Mirrakhimov, EM
AF Lunegova, Olga S.
   Mirrakhimov, Erkin M.
TI The scientific and educational activity of the European Atherosclerosis
   Society (EAS) in Kyrgyzstan
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE International symposium; Educational activity; European Atherosclerosis
   Society (EAS)
C1 [Lunegova, Olga S.; Mirrakhimov, Erkin M.] Togolok Moldo 3, Bishkek, Kyrgyzstan.
RP Lunegova, OS (reprint author), Togolok Moldo 3, Bishkek, Kyrgyzstan.
EM olga.lunegova@gmail.com
RI Mirrakhimov, Erkin/E-6900-2017
OI Mirrakhimov, Erkin/0000-0003-2982-6108
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 225
EP 225
DI 10.1016/j.atherosclerosis.2018.03.002
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800033
PM 29548511
DA 2019-10-28
ER

PT J
AU Hamazaki, K
   Iso, H
   Eshak, ES
   Ikehara, S
   Ikeda, A
   Iwasaki, M
   Hamazaki, T
   Tsugane, S
AF Hamazaki, Kei
   Iso, Hiroyasu
   Eshak, Ehab S.
   Ikehara, Satoyo
   Ikeda, Ai
   Iwasaki, Motoki
   Hamazaki, Tomohito
   Tsugane, Shoichiro
CA JPHC Study Grp
TI Plasma levels of n-3 fatty acids and risk of coronary heart disease
   among Japanese: The Japan Public Health Center-based (JPHC) study
SO ATHEROSCLEROSIS
LA English
DT Article
DE n-3 polyunsaturated fatty acids; Coronary heart disease; Nested
   case-control study
ID CARDIOVASCULAR-DISEASE; EICOSAPENTAENOIC ACID; NIPPON DATA80; FISH;
   METAANALYSIS; ASSOCIATION; EVENTS; COHORT; OMEGA-3-FATTY-ACIDS;
   MORTALITY
AB Background and aims: Higher intake of fish or n-3 polyunsaturated fatty acids (PUFAs) has been associated with reduced risk of coronary heart disease (CHD). However, it is unclear whether increased blood levels of n-3 PUFAs are associated with reduced risk of CHD in the Japanese population.& para;& para;Methods: The relationship between circulating levels of n-3 PUFAs (eicosapentaenoic acid + docosapentaenoic acid + docosahexaenoic acid) and risk of CHD was examined in a nested case-control study among participants in the Japan Public Health Center (JPHC)-based Study Cohort. Plasma n-3 PUFA phospholipid levels were measured at baseline by gas chromatography in 209 cases with CHD and 418 controls matched for sex, age, date of blood draw, time elapsed since last meal before blood collection, and study location. The CHD cases (n = 209) comprised 168 cases of myocardial infarction and 41 of sudden cardiac death, otherwise classified as 157 non-fatal and 52 fatal coronary events, respectively. Mean duration of follow-up was 13.5 years.& para;& para;Results: Multivariate conditional logistic analysis showed no significant association between n-3 PUFAs and risk of total CHD. The odds ratio (OR) for the highest versus lowest quartiles of plasma n-3 PUFAs was 0.79 (95% confidence interval [95% CI]: 0.41-1.51, p for trend = 0.51). Subtype analysis of CHD revealed that the multivariate ORs for the highest versus lowest quartiles for n-3 PUFAs were 0.91 (95% CI: 0.43 -1.89, p for trend = 0.90) for myocardial infarction, 0.08 (95% CI: 0.01-0.88, p for trend = 0.04) for sudden cardiac death, 0.89 (95% CI: 0.42-1.89, p for trend = 0.97) for nonfatal coronary events, and 0.12 (95% CI: 0.02-0.75, p for trend = 0.03) for fatal coronary events.& para;& para;Conclusions: Plasma n-3 PUFA levels were not associated with risk of total CHD but were inversely associated with risks of sudden cardiac death and fatal coronary events among middle-aged Japanese individuals. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Hamazaki, Kei] Univ Toyama, Fac Med, Dept Publ Hlth, 2630 Sugitani, Toyama, Toyama 9300194, Japan.
   [Iso, Hiroyasu; Eshak, Ehab S.; Ikehara, Satoyo; Ikeda, Ai] Osaka Univ, Grad Sch Med, Dept Social Med, Publ Hlth, Osaka, Japan.
   [Eshak, Ehab S.] Menia Univ, Fac Med, Dept Publ Hlth & Prevent Med, Al Minya, Egypt.
   [Ikehara, Satoyo] Osaka Med Coll, Dept Hyg & Publ Hlth, Osaka, Japan.
   [Ikeda, Ai] Juntendo Univ, Dept Publ Hlth, Tokyo, Japan.
   [Iwasaki, Motoki; Tsugane, Shoichiro] Natl Canc Ctr, Ctr Publ Hlth Sci, Epidemiol & Prevent Grp, Tokyo, Japan.
   [Hamazaki, Tomohito] Univ Toyama, Inst Nat Med, Dept Clin Sci, Toyama, Japan.
   [Hamazaki, Tomohito] Toyama Jonan Onsen Daini Hosp, Toyama, Japan.
RP Hamazaki, K (reprint author), Univ Toyama, Fac Med, Dept Publ Hlth, 2630 Sugitani, Toyama, Toyama 9300194, Japan.
EM keihama@med.u-toyama.ac.jp
RI Tsugane, Shoichiro/A-2424-2015
OI Tsugane, Shoichiro/0000-0003-4105-2774; Ishihara,
   Junko/0000-0002-9516-5646; Eshak, Ehab/0000-0002-3564-1938
FU Ministry of Health, Labour and Welfare of JapanMinistry of Health,
   Labour and Welfare, Japan; National Cancer Center Research and
   Development FundNational Cancer Center - Japan;  [20590638]
FX This work was supported by a Grant-in-Aid for Scientific Research (C)
   (20590638), the National Cancer Center Research and Development Fund
   (since 2011, principal investigator is ST), and a Grant-in-Aid for
   Cancer Research from the Ministry of Health, Labour and Welfare of Japan
   (from 1989 to 2010, principal investigator from 1997 to 2010 is ST). The
   funding source had no role in the study design; the collection,
   analysis, and interpretation of data; writing the report; or the
   decision to submit the paper for publication.
NR 27
TC 5
Z9 5
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 226
EP 232
DI 10.1016/j.atherosclerosis.2017.12.004
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800034
PM 29277442
DA 2019-10-28
ER

PT J
AU Jun, JE
   Lee, YB
   Lee, SE
   Ahn, JY
   Kim, G
   Jin, SM
   Hur, KY
   Lee, MK
   Kang, MR
   Kim, JH
AF Jun, Ji Eun
   Lee, You-Bin
   Lee, Seung-Eun
   Ahn, Ji Yeon
   Kim, Gyuri
   Jin, Sang-Man
   Hur, Kyu Yeon
   Lee, Moon-Kyu
   Kang, Mi Ra
   Kim, Jae Hyeon
TI Elevated serum uric acid predicts the development of moderate coronary
   artery calcification independent of conventional cardiovascular risk
   factors
SO ATHEROSCLEROSIS
LA English
DT Article
DE Uric acid; Coronary artery calcification; Cardiovascular disease
ID METABOLIC SYNDROME; DISEASE EVENTS; BLOOD-PRESSURE; YOUNG-ADULTS;
   CALCIUM; ASSOCIATION; PROGRESSION; PLASMA; URATE; ATHEROSCLEROSIS
AB Background and aims: Hyperuricemia was frequently noted in subjects with a high risk of cardiovascular disease (CVD). This study aimed to elucidate whether serum uric acid (SUA) is associated with development of moderate coronary artery calcification in generally healthy adults.& para;& para;Methods: A total of 9297 subjects underwent multidetector CT for the evaluation of CAC at least two times during their annual health examinations. Among them, 4461 participants without CVD history and who had no (scores 0) or minimal CAC (scores 1-10) in their first examination were enrolled. The association between SUA as a continuous and categorical variable and development of moderate coronary artery calcification (CAC score > 100) was assessed by Cox regression analysis. Receiver-operating characteristic (ROC) curves were constructed to investigate the diagnostic efficacy of SUA.& para;& para;Results: During a median follow-up of 4.1 years, 131 incident cases of moderate calcification developed. Baseline SUA concentration was significantly higher in subjects with progression to moderate coronary artery calcification (6.6 +/- 1.3 vs. 5.8 +/- 1.3 mg/dL, p < 0.001). SUA as a continuous variable (per 1 mg/dL) and divided into quartiles was positively associated with a higher risk of development of moderate calcification after adjustment for conventional CVD risk factors. The addition of SUA to the conventional CVD risk factors improved the predictive power for development of moderate coronary artery calcification.& para;& para;Conclusions: SUA was an independent predictor for development of moderate coronary artery calcification in subjects with no or minimal calcification. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Jun, Ji Eun; Lee, You-Bin; Lee, Seung-Eun; Ahn, Ji Yeon; Kim, Gyuri; Jin, Sang-Man; Hur, Kyu Yeon; Lee, Moon-Kyu; Kim, Jae Hyeon] Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Endocrinol & Metab,Sch Med, 81 Irwon Ro, Seoul 135710, South Korea.
   [Kang, Mi Ra] Sungkyunkwan Univ, Samsung Med Ctr, Dept Hlth Promot Ctr, Sch Med, 81 Irwon Ro, Seoul 135710, South Korea.
   [Kim, Jae Hyeon] Sungkyunkwan Univ, Dept Clin Res Design & Evaluat, SAIHST, Sch Med, 81 Irwon Ro, Seoul 135710, South Korea.
RP Kim, JH (reprint author), Samsung Med Ctr, Div Endocrinol & Metab, Seoul 135710, South Korea.
EM jaehyeon@skku.edu
OI Kim, Gyuri/0000-0002-2242-2816
NR 44
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 233
EP 239
DI 10.1016/j.atherosclerosis.2018.02.014
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800035
PM 29482886
DA 2019-10-28
ER

PT J
AU Tanriverdi, Z
   Besli, F
   Gungoren, F
   Altiparmak, IH
   Yesilay, AB
AF Tanriverdi, Zulkif
   Besli, Feyzullah
   Gungoren, Fatih
   Altiparmak, Ibrahim Halil
   Yesilay, Asuman Bicer
TI Determination of the optimal cut-off value of serum uric acid
   concentration in patients with acute coronary syndrome
SO ATHEROSCLEROSIS
LA English
DT Letter
ID MORTALITY
C1 [Tanriverdi, Zulkif; Besli, Feyzullah; Gungoren, Fatih; Altiparmak, Ibrahim Halil; Yesilay, Asuman Bicer] Harran Univ, Dept Cardiol, Fac Med, TR-63300 Sanliurfa, Turkey.
RP Tanriverdi, Z (reprint author), Harran Univ, Dept Cardiol, Fac Med, TR-63300 Sanliurfa, Turkey.
EM ztverdi@gmail.com
OI Besli, Feyzullah/0000-0002-6206-8700
NR 4
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 240
EP 240
DI 10.1016/j.atherosclerosis.2018.02.002
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800036
PM 29448980
DA 2019-10-28
ER

PT J
AU Cordero, A
   Lopez-Pineda, A
   Bertomeu-Martinez, V
AF Cordero, Alberto
   Lopez-Pineda, Adriana
   Bertomeu-Martinez, Vicente
TI Reply to: "Determination of the optimal cut-off value of serum uric acid
   concentration in patients with acute coronary syndrome"
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Cardiology; Risk factors; Uric acid; Hyperuricemia; Acute coronary
   syndrome
ID PREDICTION; SCORE
C1 [Cordero, Alberto; Lopez-Pineda, Adriana; Bertomeu-Martinez, Vicente] Hosp Univ San Juan, Cardiol Dept, Carretera Valencia Alicante S-N, Alicante 03550, Spain.
   [Cordero, Alberto] Ctr Invest Biomed Red Enfermedade Cardiovasc, Madrid, Spain.
   [Lopez-Pineda, Adriana] Miguel Hernandez Univ, Clin Med Dept, Catedra Med Familia, Alacant, Spain.
RP Cordero, A (reprint author), Hosp Univ San Juan, Cardiol Dept, Carretera Valencia Alicante S-N, Alicante 03550, Spain.
EM acorderofort@gmail.com
OI Lopez-Pineda, Adriana/0000-0002-2117-0178; Cordero,
   Alberto/0000-0003-0000-7109
NR 7
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 241
EP 242
DI 10.1016/j.atherosclerosis.2018.03.011
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800037
PM 29551187
DA 2019-10-28
ER

PT J
AU Abraham, P
   Lesourd, L
   Guilleron, C
   Durand, S
   Ammi, M
   Henni, S
AF Abraham, Pierre
   Lesourd, Laura
   Guilleron, Celine
   Durand, Sylvain
   Ammi, Myriam
   Henni, Samir
TI Exercise oximetry in patients with arterial claudication
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Transcutaneous partial tissue oxygen pressure; Exercise test; Diagnosis;
   Peripheral artery disease; Claudication
ID OXYGEN-PRESSURE MEASUREMENTS; TCPO(2)
C1 [Abraham, Pierre; Lesourd, Laura; Guilleron, Celine] Univ Hosp Angers, Lab Exercise Investigat & Sports Med, Angers, France.
   [Abraham, Pierre; Henni, Samir] Fac Med, CNRS, INSERM 771,UMR 6015, MitoVasc Inst,Fac Med, Angers, France.
   [Lesourd, Laura; Guilleron, Celine; Durand, Sylvain] Le Mans Univ, MIP, EA 4334, Motricite,Interact Performance, Ave Olivier Messiaen, F-72085 Le Mans 9, France.
   [Ammi, Myriam] Univ Hosp Angers, Dept Vasc & Thorac Surg, Angers, France.
   [Henni, Samir] Univ Hosp Angers, Vasc Med, Angers, France.
RP Abraham, P (reprint author), Univ Angers, Univ Hosp, INSERM 1083, Fac Med,Mitovasc,CNRS 6015, Angers, France.
EM piabraham@chu-angers.fr
NR 8
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 243
EP 244
DI 10.1016/j.atherosclerosis.2018.02.032
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800038
PM 29523341
DA 2019-10-28
ER

PT J
AU Kovacs, D
   Biro, K
   Koltai, K
   Endrei, D
   Toth, K
   Kesmarky, G
AF Kovacs, David
   Biro, Katalin
   Koltai, Katalin
   Endrei, Dora
   Toth, Kalman
   Kesmarky, Gabor
TI Reply to: "Exercise oximetry in patients with arterial claudication"
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Peripheral artery disease; Transcutaneous partial tissue oxygen
   pressure; Exercise test; 6-min walk test; Intermittent claudication
C1 [Kovacs, David; Biro, Katalin; Koltai, Katalin; Endrei, Dora; Toth, Kalman; Kesmarky, Gabor] Univ Pecs, Med Sch, Dept Med 1, Ifjusag Utja 13, H-7624 Pecs, Hungary.
RP Kesmarky, G (reprint author), Univ Pecs, Med Sch, Dept Med 1, Ifjusag Utja 13, H-7624 Pecs, Hungary.
EM kesmarky.gabor@pte.hu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 245
EP 246
DI 10.1016/j.atherosclerosis.2018.03.032
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800039
PM 29576226
DA 2019-10-28
ER

PT J
AU Della Schiava, N
   Lermusiaux, P
AF Della Schiava, Nellie
   Lermusiaux, Patrick
TI Comments and question on "Selective inhibition of endothelial NF-kappa B
   signaling attenuates chronic intermittent hypoxia-induced
   atherosclerosis in mice"
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Hypoxia; Atherosclerosis; Cytokines; Growth factor
C1 [Della Schiava, Nellie; Lermusiaux, Patrick] Univ Hosp Lyon, Vasc & Endovasc Surg Dept, Lyon, France.
   [Lermusiaux, Patrick] Claude Bernard Lyon 1 Univ, Lyon, France.
RP Della Schiava, N (reprint author), Hop Edouard Herriot, Vasc & Endovascular Surg Dept, 5 Pl Arsonval, F-69003 Lyon, France.
EM dellaschiava.nellie@neuf.fr
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 247
EP 247
DI 10.1016/j.atherosclerosis.2018.03.033
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800040
PM 29598966
DA 2019-10-28
ER

PT J
AU Song, D
   Fang, G
   Mao, SZ
   Ye, X
   Liu, G
   Miller, EJ
   Greenberg, H
   Liu, SF
AF Song, Dongmei
   Fang, Guoqiang
   Mao, Sun-zhong
   Ye, Xiaobing
   Liu, Gang
   Miller, Edmund J.
   Greenberg, Harly
   Liu, Shu Fang
TI Reply to: "Comments and question on "Selective inhibition of endothelial
   NF-kappa B signaling attenuates chronic intermittent hypoxia-induced
   atherosclerosis in mice""
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Intermittent hypoxia; Atherosclerosis; Nuclear factor kappa B; Hypoxia
   inducible factor
C1 [Song, Dongmei; Liu, Shu Fang] Hebei Med Univ, Affiliated Hosp 1, Shijiazhuang 050031, Hebei, Peoples R China.
   [Fang, Guoqiang; Mao, Sun-zhong; Ye, Xiaobing; Liu, Gang; Miller, Edmund J.; Greenberg, Harly; Liu, Shu Fang] Donald & Barbara Zucker Sch Med Hofstra Northwell, Feinstein Inst Med Res, Ctr Pulm Crit Care & Sleep Med, Manhasset, NY 11030 USA.
RP Liu, SF (reprint author), Feinstein Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.
EM Sliu@northwell.edu
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 248
EP 248
DI 10.1016/j.atherosclerosis.2018.03.034
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800041
PM 29587962
DA 2019-10-28
ER

PT J
AU Krauskopf, E
AF Krauskopf, Erwin
TI New metrics to meet new challenges
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Bibliometric; Impact factor; Quartiles; Editorial management
C1 [Krauskopf, Erwin] Univ Andres Bello, Fac Ciencias Biol, Republ 239, Santiago 000001, Chile.
RP Krauskopf, E (reprint author), Univ Andres Bello, Fac Ciencias Biol, Republ 239, Santiago 000001, Chile.
EM erwin.krauskopf@unab.cl
RI Krauskopf, Erwin/J-3971-2019
OI Krauskopf, Erwin/0000-0002-4082-5758
NR 3
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAY
PY 2018
VL 272
BP 249
EP 250
DI 10.1016/j.atherosclerosis.2018.03.006
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GD3DT
UT WOS:000430383800042
PM 29551188
DA 2019-10-28
ER

PT J
AU Eltoft, A
   Arntzen, KA
   Wilsgaard, T
   Mathiesen, EB
   Johnsen, SH
AF Eltoft, Agnethe
   Arntzen, Kjell Arne
   Wilsgaard, Tom
   Mathiesen, Ellisiv B.
   Johnsen, Stein Harald
TI Interleukin-6 is an independent predictor of progressive atherosclerosis
   in the carotid artery: The Tromso Study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Population study; Carotid ultrasound; Atherosclerosis; Plaque
   progression; Biomarkers; Inflammation
ID C-REACTIVE PROTEIN; CARDIOVASCULAR EVENTS; MULTIPLE BIOMARKERS; PLAQUE
   INFLAMMATION; COGNITIVE DECLINE; DAL-PLAQUE; DISEASE; STENOSIS; RISK;
   MYELOPEROXIDASE
AB Background and aims: Novel biomarkers are linked to cardiovascular disease (CVD). The aim of the present study was to investigate the association between 28 blood biomarkers and the formation and progression of carotid plaque.
   Methods: In a nested case control study with 703 participants from the population based Tromso Study, a large biomarker panel was measured in blood obtained at baseline. Carotid ultrasound was assessed both at baseline and at 6 years of follow-up. Four groups were defined: Group 1: no plaque at baseline or at follow-up (reference group); Group 2: novel plaque at follow-up; Group 3: stable plaque at follow-up; Group 4: progression of plaque at follow-up. By multinomial logistic regression analyses, we assessed the risk of being in the different plaque groups with regard to traditional cardiovascular risk factors and levels of biomarkers at baseline.
   Results: Adjusted for traditional risk factors, interleukin-6 (IL-6) was an independent predictor of plaque progression (OR 1.44, 95% CI 1.12-1.85 per SD increase in IL-6 level). This result remained significant after inclusion of other novel biomarkers to the model, and when subjects with former CVD were excluded. Neopterin was protective of novel plaque formation (OR 0.73, 95% CI 0.57-0.93). Myeloperoxidase and Caspase-1 were independent predictors of plaque progression, but this effect disappeared when excluding subjects with former CVD.
   Conclusions: IL-6 is an independent predictor of plaque progression, suggesting that it may be a marker of progressive atherosclerosis in the general population and that its central role in CVD may be related to promotion of plaque growth. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Eltoft, Agnethe; Arntzen, Kjell Arne; Mathiesen, Ellisiv B.; Johnsen, Stein Harald] Arctic Univ Norway, Dept Clin Med, Tromso, Norway.
   [Eltoft, Agnethe; Arntzen, Kjell Arne; Mathiesen, Ellisiv B.; Johnsen, Stein Harald] Univ Hosp North Norway, Dept Neurol, N-9038 Tromso, Norway.
   [Wilsgaard, Tom] Arctic Univ Norway, Dept Community Med, Tromso, Norway.
RP Eltoft, A (reprint author), Univ Hosp North Norway, Dept Neurol, N-9038 Tromso, Norway.
EM agnethe.eltoft@unn.no
FU Research Council of NorwayResearch Council of Norway; Norwegian Council
   on Cardiovascular Disease; Northern Norway Regional Health Authority;
   University of Tromso; Norwegian Foundation for Health and
   Rehabilitation; Odd Berg Research Foundation; Simon Fougner Hartmann's
   Family Fund
FX The Tromso Study has been supported by the Research Council of Norway;
   the Norwegian Council on Cardiovascular Disease; the Northern Norway
   Regional Health Authority; the University of Tromso; the Norwegian
   Foundation for Health and Rehabilitation; the Odd Berg Research
   Foundation and the Simon Fougner Hartmann's Family Fund.
NR 48
TC 10
Z9 10
U1 1
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 1
EP 8
DI 10.1016/j.atherosclerosis.2018.02.005
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400001
PM 29453087
DA 2019-10-28
ER

PT J
AU Zhao, YL
   Yang, YQ
   Xing, RM
   Cui, XQ
   Xiao, YF
   Xie, L
   You, PP
   Wang, TT
   Zeng, L
   Peng, WH
   Li, DL
   Chen, HQ
   Liu, MY
AF Zhao, Yongliang
   Yang, Yiqing
   Xing, Roumei
   Cui, Xueqin
   Xiao, Yufang
   Xie, Ling
   You, Panpan
   Wang, Tongtong
   Zeng, Li
   Peng, Wenhui
   Li, Dali
   Chen, Huaqing
   Liu, Mingyao
TI Hyperlipidemia induces typical atherosclerosis development in Ldlr and
   Apoe deficient rats
SO ATHEROSCLEROSIS
LA English
DT Article
DE Apoe; Ldl receptor; Atherosclerosis; Rat; Gene knockout
ID DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-E; BRACHIOCEPHALIC ARTERY;
   KNOCKOUT MICE; INFLAMMATION; DIET; HYPERCHOLESTEROLEMIA; CHOLESTEROL;
   DELIVERY; GLUCOSE
AB Background and aims: Low-density lipoprotein receptor (Ldlr) and apolipoprotein E (Apoe) knockout (KO) mice have been widely used as animal models of atherosclerosis. However, data suggested that it is difficult to develop typical atherosclerosis in rats. To this end, Ldlr and Apoe KO rats were generated and the potential to develop novel atherosclerosis models was evaluated.
   Methods: We established Apoe/Ldlr single and double KO (DKO) rats via the CRISPR/Cas9 system in the same background. Phenotypes of dyslipidemia and atherosclerosis in these KO rats were systematically characterized.
   Results: Knockout of either gene led to severe dyslipidemia and liver steatosis. Significant atherosclerotic plaques were observed in the abdominal aorta of all mutant rats fed a normal diet for 48 weeks. Western diet greatly aggravated atherosclerosis and fatty liver. In addition, we found mononuclear cell infiltration in early lesions. Increased expression of inflammatory cytokines, as well as macrophage accumulation in lesions of mutants, was observed, indicating that mononuclear cell trafficking and endothelial inflammation affected atherogenesis. Moreover, mutant rats displayed a sex difference profile more similar to humans in which males had heavier plaque burdens than females.
   Conclusions: Deficiency of either Ldlr or Apoe genes induced hyperlipidemia, which promoted endothelial inflammation and led to typical atherosclerosis in rats on normal or Western diets. These models display certain advantages, which will benefit future investigations of atherosclerotic pathology and antiatherosclerotic therapeutics. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zhao, Yongliang; Yang, Yiqing; Xing, Roumei; Cui, Xueqin; Xiao, Yufang; Xie, Ling; You, Panpan; Wang, Tongtong; Li, Dali; Chen, Huaqing; Liu, Mingyao] East China Normal Univ, Sch Life Sci, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China.
   [Zeng, Li] Bioray Labs Inc, Shanghai, Peoples R China.
   [Peng, Wenhui] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Cardiol, Shanghai, Peoples R China.
   [Liu, Mingyao] Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Dept Mol & Cellular Med, Houston, TX USA.
RP Li, DL; Chen, HQ; Liu, MY (reprint author), East China Normal Univ, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
EM dlli@bio.ecnu.edu.cn; hqchen@bio.ecnu.edu.cn; myliu@bio.ecnu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31271468]
FX This work was supported by a grant from the National Natural Science
   Foundation of China [31271468] to HC.
NR 37
TC 5
Z9 5
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 26
EP 35
DI 10.1016/j.atherosclerosis.2018.02.015
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400004
PM 29459263
DA 2019-10-28
ER

PT J
AU Bundy, JD
   Chen, J
   Yang, W
   Budoff, M
   Go, AS
   Grunwald, JE
   Kallem, RR
   Post, WS
   Reilly, MP
   Ricardo, AC
   Rosas, SE
   Zhang, XM
   He, J
AF Bundy, Joshua D.
   Chen, Jing
   Yang, Wei
   Budoff, Matthew
   Go, Alan S.
   Grunwald, Juan E.
   Kallem, Radhakrishna R.
   Post, Wendy S.
   Reilly, Muredach P.
   Ricardo, Ana C.
   Rosas, Sylvia E.
   Zhang, Xiaoming
   He, Jiang
CA CRIC Study Investigators
TI Risk factors for progression of coronary artery calcification in
   patients with chronic kidney disease: The CRIC study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Coronary artery disease; Chronic kidney disease; Risk factors;
   Epidemiology
ID RENAL-INSUFFICIENCY COHORT; CARDIOVASCULAR EVENTS; CALCIUM PROGRESSION;
   SERUM PHOSPHATE; MORTALITY RISK; ALL-CAUSE; ATHEROSCLEROSIS;
   ASSOCIATION; DIALYSIS; ADULTS
AB Background and aims: Coronary artery calcification (CAC) is common among patients with chronic kidney disease (CKD) and predicts the risk for cardiovascular disease (CVD). We examined the associations of novel risk factors with CAC progression among patients with CKD.
   Methods: Among 1123 CKD patients in the Chronic Renal Insufficiency Cohort (CRIC) Study, CAC was measured in Agatston units at baseline and a follow-up visit using electron beam computed tomography or multidetector computed tomography.
   Results: Over an average 3.3-year follow-up, 109 (25.1%) participants without CAC at baseline had incident CAC and 124 (18.0%) participants with CAC at baseline had CAC progression, defined as an annual increase of >= 100 Agatston units. After adjustment for established atherosclerotic risk factors, several novel risk factors were associated with changes in CAC over follow-up. Changes in square root transformed CAC score associated with 1 SD greater level of risk factors were -0.20 (95% confidence interval, -0.31 to -0.10; p < 0.001) for estimated glomerular filtration rate, 0.14 (0.02-0.25; p = 0.02) for 24-h urine albumin, 0.25 (0.15-0.34; p < 0.001) for cystatin C, -0.17 (-0.27 to -0.07; p < 0.001) for serum calcium, 0.14 (0.03-0.24; p = 0.009) for serum phosphate, 0.24 (0.14-0.33; p < 0.001) for fibroblast growth factor-23, 0.13 (0.04-0.23; p = 0.007) for total parathyroid hormone, 0.17 (0.07-0.27; p < 0.001) for interleukin-6, and 0.12 (0.02-0.22; p = 0.02) for tumor necrosis factor-alpha.
   Conclusions: Reduced kidney function, calcium and phosphate metabolism disorders, and inflammation, independent of established CVD risk factors, may progress CAC among CKD patients. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Bundy, Joshua D.; Chen, Jing; He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,Suite 2000, New Orleans, LA 70118 USA.
   [Yang, Wei; Zhang, Xiaoming] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
   [Budoff, Matthew] Los Angeles Cty Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA USA.
   [Go, Alan S.] Kaiser Permanente, Div Res, Oakland, CA USA.
   [Grunwald, Juan E.; Kallem, Radhakrishna R.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Post, Wendy S.] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
   [Reilly, Muredach P.] Columbia Univ, Dept Med, Med Ctr, New York, NY USA.
   [Ricardo, Ana C.] Univ Illinois, Dept Med, Chicago, IL USA.
   [Rosas, Sylvia E.] Harvard Univ, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP He, J (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1440 Canal St,Suite 2000, New Orleans, LA 70118 USA.
EM jhe@tulane.edu
OI Reilly, Muredach/0000-0002-3035-9386; Budoff,
   Matthew/0000-0002-9616-1946; Bundy, Joshua/0000-0002-6054-2624
FU National Institute of Diabetes and Digestive and Kidney DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Diabetes & Digestive &
   Kidney Diseases (NIDDK) [U01DK060990, U01DK060984, U01DK061022,
   U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902];
   Perelman School of Medicine at the University of Pennsylvania Clinical
   and Translational Science Award NIH/NCATS [UL1TR000003]; Johns Hopkins
   Institute for Clinical and Translational Research (ICTR) [UL1
   TR-000424]; University of Maryland GCRC [M01 RR-16500]; Clinical and
   Translational Science Collaborative of ClevelandUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Advancing Translational Sciences (NCATS)
   [UL1TR000439]; Michigan Institute for Clinical and Health Research
   [UL1TR000433]; University of Illinois at Chicago [CTSA UL1RR029879];
   Tulane COBRE for Clinical and Translational Research in Cardiometabolic
   Diseases [P20 GM109036]; Kaiser Permanente NIH/NCRR UCSF-CTSI [UL1
   RR-024131]
FX Funding for the CRIC Study was obtained under a cooperative agreement
   from the National Institute of Diabetes and Digestive and Kidney
   Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021,
   U01DK061028, U01DK060980, U01DK060963, and U01DK060902). In addition,
   this study was supported in part by the Perelman School of Medicine at
   the University of Pennsylvania Clinical and Translational Science Award
   NIH/NCATS UL1TR000003, the Johns Hopkins Institute for Clinical and
   Translational Research (ICTR) UL1 TR-000424, University of Maryland GCRC
   M01 RR-16500, Clinical and Translational Science Collaborative of
   Cleveland, UL1TR000439, Michigan Institute for Clinical and Health
   Research UL1TR000433, University of Illinois at Chicago CTSA
   UL1RR029879, Tulane COBRE for Clinical and Translational Research in
   Cardiometabolic Diseases P20 GM109036, and Kaiser Permanente NIH/NCRR
   UCSF-CTSI UL1 RR-024131.
NR 32
TC 13
Z9 13
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 53
EP 60
DI 10.1016/j.atherosclerosis.2018.02.009
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400007
PM 29459266
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Tarraf, W
   Criqui, MH
   Allison, MA
   Wright, CB
   Fornage, M
   Daviglus, M
   Kaplan, RC
   Davis, S
   Conceicao, AS
   Gonzalez, HM
AF Tarraf, Wassim
   Criqui, Michael H.
   Allison, Matthew A.
   Wright, Clinton B.
   Fornage, Myriam
   Daviglus, Martha
   Kaplan, Robert C.
   Davis, Sonia
   Conceicao, Alan S.
   Gonzalez, Hector M.
TI Ankle brachial index and cognitive function among Hispanics/Latinos:
   Results from the Hispanic Community Health Study/Study of Latinos
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cognition; Ankle-brachial index; Atherosclerosis; ABI; Peripheral
   arterial disease; Cardiovascular health; Hispanics; Latinos;
   Epidemiology
ID AMERICAN-HEART-ASSOCIATION; NEUROCOGNITIVE FUNCTION;
   CARDIOVASCULAR-DISEASE; ARTERIAL STIFFNESS; UNITED-STATES; RISK-FACTORS;
   IMPAIRMENT; POPULATION; STROKE; DEMENTIA
AB Background and aims: The Ankle-Brachial index (ABI) is a well-accepted measure of peripheral artery disease (arterial stenosis and stiffness) and has been shown to be associated with cognitive function and disorders; however, these associations have not been examined in Hispanics/Latinos. Therefore, we sought to examine relationships between ABI and cognitive function among diverse middle-age and older Hispanics/Latinos.
   Methods: We used cross-sectional data on n = 7991 participants aged 45-74 years, without stroke or coronary heart disease, from the Hispanic Community Health Study/Study of Latinos. Our primary outcome, global cognition (GC), was a continuous composite score of four cognitive domains (verbal learning and memory, verbal fluency, executive function, and mental status). Secondary outcomes were the individual tests representing these domains. The ABI was analyzed continuously and categorically with standard clinical cut-points. We tested associations using generalized survey regression models incrementally adjusting for confounding factors. Age, sex, hypertension, diabetes, and dyslipidemia moderations were examined through interactions with the primary exposure.
   Results: In age, sex, and education adjusted models, continuous ABI had an inverse u-shape association with worse GC. We found similar associations with measures of verbal learning and memory, verbal fluency, executive function, but not with low mental status. The associations were attenuated, but not completely explained, by accounting for the confounders and not modified by age, sex, education, and vascular disease risks.
   Conclusions: In addition to being a robust indicator of arterial compromise, our study suggests that abnormal ABI readings may also be useful for early signaling of subtle cognitive deficits. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Tarraf, Wassim] Wayne State Univ, Inst Gerontol, 87 East Ferry St,240 Knapp Bldg, Detroit, MI 48202 USA.
   [Tarraf, Wassim] Wayne State Univ, Dept Hlth Care Sci, 87 East Ferry St,240 Knapp Bldg, Detroit, MI 48202 USA.
   [Criqui, Michael H.] Univ Calif San Diego, Family & Preventat Med, 9500 Gilman Dr,MC 0607,SCRB 352, La Jolla, CA 92093 USA.
   [Allison, Matthew A.] Univ Calif San Diego, Family & Preventat Med, 9500 Gilman Dr,MC 0965, La Jolla, CA 92093 USA.
   [Wright, Clinton B.] NINDS, Div Clin Res, NIH, 6001 Execut Blvd,Suite 3309, Bethesda, MD 20892 USA.
   [Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, 1825 Pressler St,Bldg SRB 530G, Houston, TX 77030 USA.
   [Daviglus, Martha] Univ Illinois, Feinberg Sch Med, Dept Preventat Med, 1819 W Polk St,MC 764,Suite 246, Chicago, IL 60612 USA.
   [Kaplan, Robert C.] Albert Einstein Coll Med, Epidemiol & Populat Hlth, 1300 Morris Pk Ave,Belfer Bldg,Room 1306C, Bronx, NY 10461 USA.
   [Davis, Sonia] Univ N Carolina, Dept Biostat, 137 East Franklin St,Suite 203, Chapel Hill, NC 27514 USA.
   [Conceicao, Alan S.] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
   [Gonzalez, Hector M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
   [Gonzalez, Hector M.] Univ Calif San Diego, Shiley Marcos Alzheimers Dis Res Ctr, La Jolla, CA 92093 USA.
RP Gonzalez, HM (reprint author), Univ Calif San Diego, Dept Neurosci, Shiley Marcos Alzheimers Dis Res Ctr, 9500 Gilman Dr 0949, La Jolla, CA 92093 USA.
EM hectorgonzalez@ucsd.edu
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HC-65233]; Michigan Alzheimer Disease Center
   [P30-AG53760]; Shiley-Marcos Alzheimer's Disease Research Center
   [AG05131]; National Heart, Lung, and Blood Institute (NHLBI)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)
   [N01-HC65233, N01-HC65234, N01-HC65235, N01-HC65236, N01-HC65237];
   NHLBI: National Institute on Minority Health and Health Disparities;
   NHLBI: National Institute on Deafness and Other Communication Disorders;
   NHLBI: National Institute of Dental and Craniofacial Research; NHLBI:
   National Institute of Diabetes and Digestive and Kidney Diseases; NHLBI:
   National Institute of Neurological Disorders and Stroke; NHLBI: NIH
   Institution-Office of Dietary Supplements;  [R01-AG48642]
FX Dr. Tarraf, Dr. Gonzalez, and Mr. Conceicao receive support for this
   work from R01-AG48642. Drs. Tarraf and Gonzalez previously received
   support from NHLBI HC-65233. Dr. Tarraf receives support from the
   Michigan Alzheimer Disease Center (P30-AG53760). Dr. Gonzalez receives
   support from the Shiley-Marcos Alzheimer's Disease Research Center
   (AG05131). The Hispanic Community Health Study/Study of Hispanic/Latinos
   was carried out as a collaborative study supported by contracts from the
   National Heart, Lung, and Blood Institute (NHLBI) to the University of
   North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert
   Einstein College of Medicine (N01-HC65235), Northwestern University
   (N01-HC65236), and San Diego State University (N01-HC65237). The
   following Institutes/Centers/Offices contribute to the HCHS/SOL through
   a transfer of funds to the NHLBI: National Institute on Minority Health
   and Health Disparities, National Institute on Deafness and Other
   Communication Disorders, National Institute of Dental and Craniofacial
   Research, National Institute of Diabetes and Digestive and Kidney
   Diseases, National Institute of Neurological Disorders and Stroke, NIH
   Institution-Office of Dietary Supplements.
NR 41
TC 2
Z9 3
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 61
EP 69
DI 10.1016/j.atherosclerosis.2018.02.016
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400008
PM 29459267
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Fang, Q
   Wang, ZC
   Zhan, Y
   Li, D
   Zhang, K
   Zhou, T
   Yang, HD
   Zhang, C
   Li, XL
   Min, XW
   Chen, WH
   Guo, H
   He, MA
   Kong, WJ
   Wu, TC
   Zhang, XM
AF Fang, Qin
   Wang, Zhichao
   Zhan, Yue
   Li, Dan
   Zhang, Kun
   Zhou, Tao
   Yang, Handong
   Zhang, Ce
   Li, Xiulou
   Min, Xinwen
   Chen, Weihong
   Guo, Huan
   He, Mei-an
   Kong, Weijia
   Wu, Tangchun
   Zhang, Xiaomin
TI Hearing loss is associated with increased CHD risk and unfavorable
   CHD-related biomarkers in the Dongfeng-Tongji cohort
SO ATHEROSCLEROSIS
LA English
DT Article
DE Hearing loss; Prevalent CHD; CHD-related biomarkers
ID IMPAIRMENT; DISEASE; ADULTS
AB Background and aims: The association between hearing loss and coronary heart disease (CHD) is inconsistent. We aimed to investigate the association of hearing loss with prevalent CHD and CHD-related biomarkers among a middle aged and elderly Chinese population.
   Methods: We included 14,755 Chinese aged 64.6 years from the Dongfeng-Tongji Cohort in 2013. Hearing loss was classified into normal, mild, moderate or greater levels by the pure tone average (PTA) at low frequency and high frequency, respectively. Logistic regression models were used to estimate the odds ratios (ORs) of CHD risk in relation to hearing loss. Linear regression models were used to evaluate the effect of hearing loss on CHD-related biomarkers.
   Results: The adjusted ORs for prevalent CHD increased gradually with the increasing hearing loss levels. Compared with normal hearing, individuals having mild-and moderate or greater-hearing loss had a higher CHD risk of 19% and 20% at low frequency, and 33% and 41% at high frequency, respectively (all p for trend < 0.05). The associations were more evident among subjects who were females, overweight, exposed to occupational noise and with hyperglycemia, hypertension or dyslipidemia at low frequency, and those with hyperglycemia at high frequency. Meanwhile, moderate or greater hearing loss combined with overweight, hyperglycemia, hypertension or dyslipidemia had joint effects on CHD. In addition, the majority of CHD-related biomarkers worsened with increasing hearing loss levels.
   Conclusions: There may be a dose-response relationship between hearing loss and CHD prevalence, and the association could partially be explained by intermediate CHD-related biomarkers. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Fang, Qin; Chen, Weihong; Guo, Huan; He, Mei-an; Wu, Tangchun; Zhang, Xiaomin] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan, Hubei, Peoples R China.
   [Fang, Qin; Chen, Weihong; Guo, Huan; He, Mei-an; Wu, Tangchun; Zhang, Xiaomin] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.
   [Wang, Zhichao; Zhan, Yue; Li, Dan; Zhang, Kun; Zhou, Tao; Kong, Weijia] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan 430022, Hubei, Peoples R China.
   [Yang, Handong; Zhang, Ce; Li, Xiulou; Min, Xinwen] Dongfeng Motor Corp, Dongfeng Cent Hosp, Shiyan, Peoples R China.
   [Yang, Handong; Zhang, Ce; Li, Xiulou; Min, Xinwen] Hubei Univ Med, Shiyan, Peoples R China.
RP Zhang, XM (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.; Zhang, XM (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Environm Protect, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.; Zhang, XM (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, State Key Lab Environm Hlth Incubating, 13 Hangkong Rd, Wuhan 430030, Hubei, Peoples R China.
EM mingxz117@hust.edu.cn
RI Zhang, Xiaomin/F-3206-2018
OI Min, Xinwen/0000-0002-8429-6560; Kong, Wei-Jia/0000-0001-5410-2297
FU Natural National Scientific Foundation of ChinaNational Natural Science
   Foundation of China [81373093, 81673139, 81230069, 81390542, 81230021];
   111 ProjectMinistry of Education, China - 111 Project [B12004]; Program
   for Changjiang ScholarsProgram for Changjiang Scholars & Innovative
   Research Team in University (PCSIRT); Innovative Research Team in
   University of Ministry of Education of ChinaMinistry of Education, China
   [IRT1246]
FX This work was supported by the Natural National Scientific Foundation of
   China (81373093, 81673139, 81230069, 81390542, and 81230021), 111
   Project (No. B12004); and the Program for Changjiang Scholars;
   Innovative Research Team in University of Ministry of Education of China
   (No. IRT1246).
NR 32
TC 2
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 70
EP 76
DI 10.1016/j.atherosclerosis.2018.01.048
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400009
PM 29477559
DA 2019-10-28
ER

PT J
AU Blunder, S
   Messner, B
   Scharinger, B
   Doppler, C
   Zeller, I
   Zierer, A
   Laufer, G
   Bernhard, D
AF Blunder, Stefan
   Messner, Barbara
   Scharinger, Bernhard
   Doppler, Christian
   Zeller, Iris
   Zierer, Andreas
   Laufer, Guenther
   Bernhard, David
TI Targeted gene expression analyses and immunohistology suggest a
   pro-proliferative state in tricuspid aortic valve-, and senescence and
   viral infections in bicuspid aortic valve-associated thoracic aortic
   aneurysms
SO ATHEROSCLEROSIS
LA English
DT Article
DE Aneurysm; DNA damage; Senescence; Aging; Proliferation; Infection;
   Phenotype switching; TOLL-Like receptor 3
ID SMOOTH-MUSCLE-CELLS; TOLL-LIKE RECEPTOR-3; DAMAGE; ATM; MECHANISMS;
   PHENOTYPE; APOPTOSIS; BIOLOGY; PROTEIN; MEDIA
AB Background and aims: Despite the potential life-threatening consequences of thoracic aortic aneurysms (TAAs), the pathogenesis of these diseases is still poorly understood. While some aspects of TAA formation have been elucidated, the role of vascular smooth muscle cells (SMCs) in both bicuspid aortic valve (BAV)-associated and degenerative tricuspid aortic valve (TAV)-associated TAAs has not yet been fully unravelled. Thus, this work was aimed at uncovering processes in SMC biology that may contribute to TAA formation.
   Methods: Using isolated SMCs and tissue samples from TAAs linked to BAV syndrome, TAV-associated degenerative TAAs and control aortas, we performed targeted mRNA expression profile analyses and conducted immunohistological analyses on aortic wall tissue sections.
   Results: While SMC expression profiles and tissue analyses in TAV-TAAs clearly point toward a pro-proliferative state of the aortic media SMCs, BAV-TAA SMCs and tissue provide evidence for DNA damage, DNA damage response signalling as well as profound TLR-3 signalling.
   Conclusions: The data presented in this study emphasizes the importance of SMCs in TAA development. Furthermore, our results provide evidence that the state of SMCs in the BAV-TAA (senescent) and TAV-TAA (pro-proliferative) differs significantly. For the first time, we also present findings that may argue for the occurrence of a viral infection in BAV-TAA SMCs. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Blunder, Stefan] Innsbruck Med Univ, Dept Dermatol & Venereol, Innsbruck, Austria.
   [Blunder, Stefan; Messner, Barbara; Scharinger, Bernhard; Laufer, Guenther] Med Univ Vienna, Dept Cardiac Surg, Cardiac Surg Res Lab, Vienna, Austria.
   [Doppler, Christian; Bernhard, David] Johannes Kepler Univ Linz, Med Fac, Ctr Med Res, Krankenhaus Str 7a,3 OG, A-4020 Linz, Austria.
   [Zeller, Iris] Med Univ Vienna, Dept Lab Med, Div Clin Microbiol, Vienna, Austria.
   [Zierer, Andreas] Johannes Kepler Univ Linz, Med Fac, Univ Clin Cardiac Vascular & Thorac Surg, Linz, Austria.
RP Bernhard, D (reprint author), Johannes Kepler Univ Linz, Med Fac, Ctr Med Res, Krankenhaus Str 7a,3 OG, A-4020 Linz, Austria.
EM david.bernhard@jku.at
RI ; Laufer, Guenther/Q-1933-2016
OI Scharinger, Bernhard/0000-0002-3753-8563; Bernhard,
   David/0000-0002-2383-6607; Laufer, Guenther/0000-0001-7257-110X;
   Messner, Barbara/0000-0001-8331-6497
NR 47
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 111
EP 119
DI 10.1016/j.atherosclerosis.2018.02.007
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400014
PM 29486395
OA Other Gold
DA 2019-10-28
ER

PT J
AU Siniarski, A
   Haberka, M
   Mostowik, M
   Golebiowska-Wiatrak, R
   Poreba, M
   Malinowski, KP
   Gasior, Z
   Konduracka, E
   Nessler, J
   Gajos, G
AF Siniarski, Aleksander
   Haberka, Maciej
   Mostowik, Magdalena
   Golebiowska-Wiatrak, Renata
   Poreba, Malgorzata
   Malinowski, Krzysztof Piotr
   Gasior, Zbigniew
   Konduracka, Ewa
   Nessler, Jadwiga
   Gajos, Grzegorz
TI Treatment with omega-3 polyunsaturated fatty acids does not improve
   endothelial function in patients with type 2 diabetes and very high
   cardiovascular risk: A randomized, double-blind, placebo-controlled
   study (Omega-FMD)
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiovascular disease; Atherosclerosis; Type 2 diabetes; Omega-3
   polyunsaturated fatty acids; Flow-mediated dilation
ID PERCUTANEOUS CORONARY INTERVENTION; DUAL ANTIPLATELET THERAPY;
   EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; DIETARY SUPPLEMENTATION;
   FISH CONSUMPTION; BRACHIAL-ARTERY; HEART-DISEASE; OMEGA-3-FATTY-ACIDS;
   METAANALYSIS
AB Background and aims: Numerous recent studies conducted in different clinical settings have focused on the benefits of omega-3 polyunsaturated fatty acids (n-3 PUFAs) in the prevention of cardiovascular diseases. There is limited evidence that patients with type 2 diabetes (T2D) and very high cardiovascular risk can also benefit from a high dose of n-3PUFAs, especially those on optimal medical therapy as recommended by the guidelines. The aim of the present study was to assess the impact of high-dose n-3 PUFA treatment on endothelial function in patients with T2D and established atherosclerotic cardiovascular disease (ASCVD).
   Methods: We conducted a prospective randomized double-blind, placebo-controlled, 2-center study, in which endothelial function was measured using flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD). Serum fatty acids composition was measured by gas chromatography. All measurements were done at baseline and after 3 months of treatment with PUFAs at a dose of 2 g/d (n = 36) or placebo (n = 38).
   Results: The majority of the study population was treated with optimal medical therapy. Despite significantly higher concentrations of eicosapentaenoic acid (EPA) and docosahexaenoic acid in the n-3 PUFA group after 3-month treatment, we did not observe significant changes in endothelial function indices (FMD and NMD). However, in regression analysis, only baseline FMD was associated with EPA concentration before 3 months of n-3 PUFA treatment.
   Conclusions: Three months of high-dose n-3 PUFA treatment in very high-risk patients with ASCVD and T2D did not improve the endothelial function indices. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Siniarski, Aleksander; Mostowik, Magdalena; Golebiowska-Wiatrak, Renata; Poreba, Malgorzata; Konduracka, Ewa; Nessler, Jadwiga; Gajos, Grzegorz] John Paul 2 Hosp, Krakow, Poland.
   [Haberka, Maciej; Gasior, Zbigniew] Med Univ Silesia, Sch Hlth Sci, Dept Cardiol, Katowice, Poland.
   [Siniarski, Aleksander; Golebiowska-Wiatrak, Renata; Konduracka, Ewa; Nessler, Jadwiga; Gajos, Grzegorz] Jagiellonian Univ, Med Coll, Fac Med, Dept Coronary Dis & Heart Failure, Krakow, Poland.
   [Mostowik, Magdalena] Jagiellonian Univ, Med Coll, Dept Med Educ, Krakow, Poland.
   [Malinowski, Krzysztof Piotr] Jagiellonian Univ, Med Coll, Fac Hlth Sci, Inst Publ Hlth, Krakow, Poland.
RP Gajos, G (reprint author), Jagiellonian Univ, Med Coll, Fac Med, John Paul Hosp 2,Dept Coronary Dis & Heart Failur, Ul Pradnicka 80, PL-31202 Krakow, Poland.
EM grzegorz.gajos@uj.edu.pl
RI Siniarski, Aleksander/W-6108-2019; Konduracka, Ewa/R-7948-2019; Gajos,
   Grzegorz/None
OI Siniarski, Aleksander/0000-0002-7493-3626; Gasior,
   Zbigniew/0000-0003-3616-8932; Gajos, Grzegorz/0000-0002-7361-3559;
   Konduracka, Ewa/0000-0002-0993-3953; Malinowski,
   Krzysztof/0000-0003-2189-0498
FU National Science Centre Poland [2011/03/B/NZ5/0576]; Jagiellonian
   University Medical College [K/ZDS/005642]
FX The publication was supported by the following grants: National Science
   Centre Poland (2011/03/B/NZ5/0576; to GG) and Jagiellonian University
   Medical College (K/ZDS/005642; to GG).
NR 49
TC 7
Z9 7
U1 2
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 148
EP 155
DI 10.1016/j.atherosclerosis.2018.02.030
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400019
PM 29518747
DA 2019-10-28
ER

PT J
AU Becattini, C
   Dentali, F
   Camporese, G
   Sembolini, A
   Rancan, E
   Tonello, C
   Manina, G
   Padayattil, S
   Agnelli, G
AF Becattini, Cecilia
   Dentali, Francesco
   Camporese, Giuseppe
   Sembolini, Agnese
   Rancan, Elena
   Tonello, Chiara
   Manina, Giorgia
   Padayattil, Seena
   Agnelli, Giancarlo
TI Carotid atherosclerosis and risk for ischemic stroke in patients with
   atrial fibrillation on oral anticoagulant treatment
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atrial fibrillation; Carotid atherosclerosis; Carotid stenosis; Stroke;
   Anticoagulants
ID ARTERY STENOSIS; THROMBOEMBOLISM; STRATIFICATION; GUIDELINES;
   MANAGEMENT; MORTALITY; IMPROVES; DISEASE; EVENTS
AB Background and aims: Whether carotid atherosclerosis is associated with an increased risk for ischemic stroke in patients with atrial fibrillation (AF) on anticoagulant treatment is undefined. To explore this association, patients with AF on treatment with vitamin K antagonists were included in a multicenter, prospective study.
   Methods: At inclusion in the study, patients underwent Doppler-ultrasonography for the assessment of carotid atherosclerosis and then were prospectively followed. Ischemic stroke or transient ischemic attack (TIA) were the primary study outcomes; death and its causes were reported.
   Results: Overall, 587 patients were included in the study. At ultrasonography, 380 patients had carotid atherosclerosis (64.7%) and 45 internal carotid (ICA) stenosis >50% (7.7%). During a mean follow-up of 41 +/- 15 months, 30 patients had an ischemic stroke or TIA (1.49% per patient-year, 95% CI 0.96-2.03) and 81 patients died (4.01% per patient-year, 95% CI 3.16-4.86). Carotid atherosclerosis was associated with a significant increase in the risk for the composite of ischemic stroke or TIA or death after adjusting for CHA2DS2VASc (6.0% vs. 3.1% patient-year; HR 1.60, 95% CI 0.99-2.59; p = 0.05). ICA >= 50% was associated with a not significant increase in the risk of ischemic stroke or TIA (2.05% vs. 1.45% patient-year; HR 1.39, 95% CI 0.42-4.58) or all-cause death (6.1% vs. 3.8% patient-year; HR 1.66, 95% CI 0.83-3.32).
   Conclusions: In patients with AF, carotid atherosclerosis is a predictor for the composite of cerebrovascular events or death while on anticoagulant therapy. In patients with AF and carotid atherosclerosis, the clinical benefit of a more intense antithrombotic treatment should be evaluated. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Becattini, Cecilia; Sembolini, Agnese; Manina, Giorgia; Agnelli, Giancarlo] Univ Perugia, Internal & Cardiovasc Med Stroke Unit, Perugia, Italy.
   [Dentali, Francesco; Rancan, Elena] Univ Insubria, Internal Med, Varese, Italy.
   [Camporese, Giuseppe; Tonello, Chiara] Univ Hosp Padua, Unit Angiol, Padua, Italy.
   [Padayattil, Seena] Univ Hosp Padua, Cardiol Unit, Padua, Italy.
RP Becattini, C (reprint author), Univ Perugia, Internal & Cardiovasc Med Stroke Unit, Perugia, Italy.
EM cecilia.becattini@unipg.it
FU Societa Italiana di Medicina Interna
FX Dr Giorgia Manina received a Research Grant for this study by the
   Societa Italiana di Medicina Interna on October 2012.
NR 24
TC 3
Z9 3
U1 3
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 177
EP 181
DI 10.1016/j.atherosclerosis.2018.02.004
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400022
PM 29524860
DA 2019-10-28
ER

PT J
AU Zaccardi, F
   Kunutsor, SK
   Seidu, S
   Davies, MJ
   Khunti, K
AF Zaccardi, Francesco
   Kunutsor, Setor K.
   Seidu, Samuel
   Davies, Melanie J.
   Khunti, Kamlesh
TI Is the lower risk of venous thromboembolism with statins related to
   low-density-lipoprotein reduction? A network meta-analysis and
   meta-regression of randomised controlled trials
SO ATHEROSCLEROSIS
LA English
DT Article
DE Venous thromboembolism; Statin; Meta-analysis; LDL-cholesterol; Clinical
   trials
ID SYSTEMATIC REVIEWS; 000 PARTICIPANTS; PREVENTION; EFFICACY; SAFETY;
   INCONSISTENCY; CHOLESTEROL; THERAPY; CANCER; WOMEN
AB Background and aims: Meta-analyses of randomised controlled trials (RCTs) have suggested a possible benefit of statin treatment on the risk of venous thromboembolism (VTE), with potential differences by type and dose of statins. We aimed to assess differences among statins and to investigate the relationship between risk of VTE and reduction of LDL-cholesterol (LDL-c) levels.
   Methods: We electronically searched, through November 29, 2017, RCTs comparing a statin with either placebo or another statin treatment, including 100 or more adult participants, and lasting at least 24 weeks. Data on first VTE events and LDL-c was analysed with a network meta-analysis and a meta-regression.
   Results: Thirty RCTs (159,058 participants; 1431 events) were included, with 28 reporting LDL-c data. Network meta-analysis indicated a larger benefit for rosuvastatin compared to placebo and other statins; 50% of the effect of statins on VTE risk reduction, however, was explained by their different potencies in lowering LDL-c. The risk reduction in VTE was proportional to LDL-c decrease (37% relative lower risk per each 1 mmol/L reduction in LDL-c), without an apparent threshold. A reduction of 1 mmol/L in LDL-c would translate in 37 less VTE events per year in 100,000 people in UK, corresponding to 3162 prevented episodes per year in people between 50 and 59 years.
   Conclusions: In RCTs with statin treatment, the reduction of VTE risk was only partially related to LDL-c reduction and the benefit was larger than that observed for atherothrombotic risk. Further RCTs are warranted to clarify the relationship between statin, lipid modifications, and VTE risk. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zaccardi, Francesco; Seidu, Samuel; Davies, Melanie J.; Khunti, Kamlesh] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England.
   [Kunutsor, Setor K.] Univ Bristol, Sch Clin Sci, Level 1 Learning & Res Bldg, Bristol BS10 5NB, Avon, England.
RP Zaccardi, F (reprint author), Leicester Gen Hosp, Leicester Diabet Ctr, Leicester LE5 4PW, Leics, England.
EM frazac@fastwebnet.it
RI Kunutsor, Setor K/H-9807-2019
OI Kunutsor, Setor K/0000-0002-2625-0273; Davies,
   Melanie/0000-0002-9987-9371
FU Sanofi-AventisSanofi-Aventis; National Institute for Health Research
   Collaboration for Leadership in Applied Health Research and Care - East
   Midlands (NIHR CLAHRC - EM)
FX FZ is a Clinical Research Fellow funded with an unrestricted Educational
   Grant from Sanofi-Aventis to the University of Leicester and supported
   by the National Institute for Health Research Collaboration for
   Leadership in Applied Health Research and Care - East Midlands (NIHR
   CLAHRC - EM). The funding sources had no involvement in this study.
NR 46
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 223
EP 231
DI 10.1016/j.atherosclerosis.2018.02.035
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400027
PM 29524865
DA 2019-10-28
ER

PT J
AU Yin, H
   Pickering, JG
AF Yin, Hao
   Pickering, J. Geoffrey
TI Aortic smooth muscle cells and myocardial infarction: Does the ascending
   aorta feel a heart attack?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
ID ACUTE CORONARY SYNDROMES; VASA VASORUM; MECHANISMS
C1 [Yin, Hao; Pickering, J. Geoffrey] Univ Western Ontario, Robarts Res Inst, London, ON, Canada.
   [Pickering, J. Geoffrey] London Hlth Sci Ctr, 339 Windermere Rd, London, ON N6A 5A5, Canada.
   [Pickering, J. Geoffrey] Univ Western Ontario, Dept Med Cardiol, London, ON, Canada.
   [Pickering, J. Geoffrey] Univ Western Ontario, Dept Biochem, London, ON, Canada.
   [Pickering, J. Geoffrey] Univ Western Ontario, Dept Med Biophys, London, ON, Canada.
RP Pickering, JG (reprint author), London Hlth Sci Ctr, 339 Windermere Rd, London, ON N6A 5A5, Canada.
EM gpickering@robarts.ca
RI Pickering, J. Geoffrey/G-3341-2011
OI Pickering, J. Geoffrey/0000-0001-6474-3274
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [FDN-143326]
FX This work was supported by a grant from the Canadian Institutes of
   Health Research (FDN-143326). JGP holds the Heart and Stroke Foundation
   of Ontario - Barnett/Ivey Chair.
NR 12
TC 0
Z9 0
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 232
EP 234
DI 10.1016/j.atherosclerosis.2018.02.017
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400028
PM 29459027
DA 2019-10-28
ER

PT J
AU Wongsurawat, T
   Woo, CC
   Giannakakis, A
   Lin, XY
   Cheow, ESH
   Lee, CN
   Richards, M
   Sze, SK
   Nookaew, I
   Kuznetsov, VA
   Sorokin, V
AF Wongsurawat, Thidathip
   Woo, Chin Cheng
   Giannakakis, Antonis
   Lin, Xiao Yun
   Cheow, Esther Sok Hwee
   Lee, Chuen Neng
   Richards, Mark
   Sze, Siu Kwan
   Nookaew, Intawat
   Kuznetsov, Vladimir A.
   Sorokin, Vitaly
TI Distinctive molecular signature and activated signaling pathways in
   aortic smooth muscle cells of patients with myocardial infarction
SO ATHEROSCLEROSIS
LA English
DT Article
DE Myocardial infarction; Vascular smooth muscle cells; Superoxide radical
   degradation pathway analysis; SOD1
ID GENE-EXPRESSION; ARTERIAL; DISEASE; RISK
AB Background and aims: We aim to identify significant transcriptome alterations of vascular smooth muscle cells (VSMCs) in the aortic wall of myocardial infarction (MI) patients. Providing a robust transcriptomic signature, we aim to highlight the most likely aberrant pathway(s) in MI VSMCs.
   Methods and results: Laser-captured microdissection (LCM) was used to obtain VSMCs from aortic wall tissues harvested during coronary artery bypass surgery. Microarray gene analysis was applied to analyse VSMCs from 17 MI and 19 non-MI patients. Prediction Analysis of Microarray (PAM) identified 370 genes that significantly discriminated MI and non-MI samples and were enriched in genes responsible for muscle development, differentiation and phenotype regulation. Incorporation of gene ontology (GO) led to the identification of a 21-gene VSMCs-associated classifier that discriminated between MI and non-MI patients with 92% accuracy. The mass spectrometry-based iTRAQ analysis of the MI and non-MI samples revealed 94 proteins significantly differentiating these tissues. Ingenuity Pathway Analysis (IPA) of 370 genes revealed top pathways associated with hypoxia signaling in the cardiovascular system. Enrichment analysis of these proteins suggested an activation of the superoxide radical degradation pathway. An integrated transcriptome-proteome pathway analysis revealed that superoxide radical degradation pathway remained the most implicated pathway. The intersection of the top candidate molecules from the transcriptome and proteome highlighted superoxide dismutase (SOD1) overexpression.
   Conclusions: We provided a novel 21-gene VSMCs-associated MI classifier in reference to significant VSMCs transcriptome alterations that, in combination with proteomics data, suggests the activation of superoxide radical degradation pathway in VSMCs of MI patients. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Wongsurawat, Thidathip; Giannakakis, Antonis; Kuznetsov, Vladimir A.] ASTAR, Bioinformat Inst, Dept Genome & Gene Express Data Anal, Singapore 138671, Singapore.
   [Wongsurawat, Thidathip; Nookaew, Intawat] Univ Arkansas Med Sci, Coll Med, Dept Biomed Informat, Little Rock, AR 72205 USA.
   [Woo, Chin Cheng; Lee, Chuen Neng; Sorokin, Vitaly] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 119228, Singapore.
   [Lin, Xiao Yun; Lee, Chuen Neng; Sorokin, Vitaly] Natl Univ Hlth Syst, Natl Univ Heart Ctr, Dept Cardiac Thorac & Vasc Surg, Singapore 119228, Singapore.
   [Cheow, Esther Sok Hwee; Sze, Siu Kwan] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore.
   [Richards, Mark] Natl Univ Heart Ctr, Cardiovasc Res Inst, Singapore 119228, Singapore.
   [Richards, Mark] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 119228, Singapore.
   [Kuznetsov, Vladimir A.] Nanyang Technol Univ, Sch Comp Sci & Engn, Singapore 639798, Singapore.
RP Sorokin, V (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 119228, Singapore.; Kuznetsov, VA (reprint author), Nanyang Technol Univ, Sch Comp Sci & Engn, Singapore 639798, Singapore.
EM vladimirk@bii.a-star.edu.sg; vitaly_sorokin@nuhs.edu.sg
RI Sorokin, Vitaly/A-2773-2014; Wongsurawat, Thidathip/K-5590-2019; Lee,
   Chuen Neng/B-4516-2011
OI Lee, Chuen Neng/0000-0001-9748-4424
FU National University Health System Clinician Scientist Program,
   Singapore; Biomedical Institutes of A*STAR, Singapore
FX This work was supported by the National University Health System
   Clinician Scientist Program, Singapore and Biomedical Institutes of
   A*STAR, Singapore.
NR 32
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 237
EP 244
DI 10.1016/j.atherosclerosis.2018.01.024
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400030
PM 29395098
OA Other Gold
DA 2019-10-28
ER

PT J
AU Diederichsen, MZ
   Diederichsen, SZ
   Mickley, H
   Steffensen, FH
   Lambrechtsen, J
   Sand, NPR
   Christensen, KL
   Olsen, MH
   Diederichsen, A
   Gronhoj, MH
AF Diederichsen, Marie Zoga
   Diederichsen, Soren Zoga
   Mickley, Hans
   Steffensen, Flemming Hald
   Lambrechtsen, Jess
   Sand, Niels Peter Ronnow
   Christensen, Kent Lodberg
   Olsen, Michael Hecht
   Diederichsen, Axel
   Gronhoj, Mette Hjortdal
TI Prognostic value of suPAR and hs-CRP on cardiovascular disease
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiovascular disease; Atherosclerosis; Cardiovascular risk factors;
   Coronary artery calcification; Inflammatory markers; Soluble urokinase
   plasminogen activator receptor; High-sensitive C-reactive-protein
ID C-REACTIVE-PROTEIN; PLASMINOGEN-ACTIVATOR RECEPTOR; CORONARY-ARTERY
   CALCIFICATION; TRADITIONAL RISK-FACTORS; HEART-DISEASE; CALCIUM SCORES;
   ATHEROSCLEROSIS; EVENTS; MARKERS; QUANTIFICATION
AB Background and aims: Studies have shown that soluble urokinase Plasminogen Activator Receptor (suPAR) and CRP (both inflammatory markers) and coronary artery calcification (CAC) are independent risk predictors for cardiovascular (CV) disease. The aim of this study is to assess whether suPAR and CRP have an increased predictive prognostic value beyond the traditional CV risk factors and the CAC score.
   Methods: A population sample of 1179 subjects, free of CV disease was included. The subjects underwent traditional CV risk evaluation, CAC assessment and blood sampling for suPAR and CRP. CV events were extracted from The Danish National Patient Register after 6.5 years. The additive values of suPAR and CRP were evaluated by unadjusted Kaplan Meier analysis, adjusted hazard ratio and ROCAUC models.
   Results: 1179 participants (47.6% males, mean age 55 years) were included. 73 events occurred. In Kaplan Meier analyses, suPAR and CRP were significantly associated with CV events (p = 0.03 and p = 0.002). Adjusted for the CV risk factors and the CAC score, the hazard ratios for suPAR and CRP were 1.17 (95% confidence interval [CI] 1.01-1.34) and 1.04 (95% CI 1.01-1.06), respectively. suPAR was associated with a substantial risk among women (2.03; 95% CI 1.45-2.84) and 60-year-old subjects (1.44; 95% CI 1.09-1.90). By ROCAUC, neither suPAR nor CRP provided significant estimates (0.7100 and 0.7054) compared to the traditionally CV risk factors (0.6952, p = 0.24 and p = 0.16) and CAC score (0.7481, p = 0.33 and p = 0.32).
   Conclusions: Adjusted for traditional CV risk factors and CAC score, suPAR and CRP were of minor importance in risk prediction. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Diederichsen, Marie Zoga; Mickley, Hans; Diederichsen, Axel; Gronhoj, Mette Hjortdal] Odense Univ Hosp, Dept Cardiol, JB Winslows Vej 4, DK-5000 Odense C, Denmark.
   [Diederichsen, Soren Zoga] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, DK-2100 Copenhagen, Denmark.
   [Steffensen, Flemming Hald] Sygehus Lillebaelt Vejle, Dept Cardiol, Kabbeltoft 25, DK-7100 Vejle, Denmark.
   [Lambrechtsen, Jess] Svendborg Hosp, Dept Cardiol, Valdemarsgade 53, DK-5700 Svendborg, Denmark.
   [Sand, Niels Peter Ronnow] Hosp South West Denmark, Dept Cardiol, Finsensgade 35, DK-6700 Esbjerg, Denmark.
   [Sand, Niels Peter Ronnow] Univ Southern Denmark, Inst Reg Hlth Serv Res, Winslowpk 19,C, DK-5000 Odense C, Denmark.
   [Christensen, Kent Lodberg] Aarhus Univ Hosp, Dept Cardiol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
   [Olsen, Michael Hecht] Holbaek Cent Hosp, Dept Internal Med, Cardiol Sect, Smedelundsgade 60, DK-4300 Holbaek, Denmark.
   [Olsen, Michael Hecht; Diederichsen, Axel] Odense Univ Hosp, Ctr Individualized Med Arterial Dis CIMA, JB Winslows Vej 4, DK-5000 Odense C, Denmark.
   [Olsen, Michael Hecht; Diederichsen, Axel] Univ Southern Denmark, Cardiovasc Ctr Excellence CAVAC, Odense, Denmark.
RP Diederichsen, MZ (reprint author), Odense Univ Hosp, Dept Cardiol, JB Winslows Vej 4, DK-5000 Odense C, Denmark.
EM mzdiederichsen@gmail.com
RI Diederichsen, Axel Cosmus Pyndt/C-3355-2013
OI Diederichsen, Axel Cosmus Pyndt/0000-0002-1285-4826; Steffensen,
   Flemming Hald/0000-0003-0252-6631
FU Danish Heart Foundation; Region of Southern Denmark; Odense University
   Hospital; Odense Patient data Explorative Network; University of
   Southern Denmark; Bonnelykke Foundation; A.P. Moller and Chastine
   Mc-Kinney Moller Foundation; Aase and Ejnar Danielsens Foundation; Herta
   Christensens Foundation
FX The Danish Heart Foundation, Region of Southern Denmark, Odense
   University Hospital, Odense Patient data Explorative Network, University
   of Southern Denmark, the Bonnelykke Foundation, the A.P. Moller and
   Chastine Mc-Kinney Moller Foundation for general purposes, the Aase and
   Ejnar Danielsens Foundation and the Herta Christensens Foundation. The
   funders had no role in the study design, data collection, data analysis
   and interpretation, writing of the report, or the decision to submit the
   article for publication.
NR 31
TC 2
Z9 3
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 245
EP 251
DI 10.1016/j.atherosclerosis.2018.01.029
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400031
PM 29402404
DA 2019-10-28
ER

PT J
AU Palm, F
   Pussinen, PJ
   Safer, A
   Tervahartiala, T
   Sorsa, T
   Urbanek, C
   Becher, H
   Grau, AJ
AF Palm, Frederick
   Pussinen, Pirkko J.
   Safer, Anton
   Tervahartiala, Taina
   Sorsa, Timo
   Urbanek, Christian
   Becher, Heiko
   Grau, Armin J.
TI Serum matrix metalloproteinase-8, tissue inhibitor of metalloproteinase
   and myeloperoxidase in ischemic stroke
SO ATHEROSCLEROSIS
LA English
DT Article
DE Ischemic stroke; Inflammation; MMP-8; MPO
ID CARDIOVASCULAR-DISEASE EVENTS; ALL-CAUSE MORTALITY; LUDWIGSHAFEN STROKE;
   BIOMARKERS; SCALE; INFLAMMATION; ASSOCIATION; COLLAGENASE; ACTIVATION;
   PROTEIN
AB Background and aims: Matrix metalloproteinase (MMP)-8 and myeloperoxidase (MPO) may contribute to cerebral damage in acute ischemic stroke. We tested the hypothesis that levels of MPO, MMP-8 and the ratio between MMP-8 and its regulator, tissue inhibitor of metalloproteinase (TIMP-1), are increased in acute ischemic stroke and its etiologic subgroups and they correlate with stroke severity.
   Methods: In a cross-sectional case-control study, serum concentrations of MMP-8, MPO and TIMP-1 were assessed within 24 h after admission in 470 first-ever ischemic stroke patients and 809 age-and sex-matched controls, randomly selected from the population. Odds ratios (OR) per decade of log transformed dependent variables were calculated and adjusted for age, sex and vascular risk factors.
   Results: Levels of MMP-8 (OR 4.9; 95% CI 3.4-7.2), MMP-8/TIMP-1 ratio (3.0; 2.2-4.1) and MPO (6.6; 4.0-11.0) were independently associated with ischemic stroke. MMP-8 levels differed between etiologic stroke subgroups (p = 0.019, ANOVA), with higher levels in cardioembolic stroke and stroke due to large vessel disease, and lower levels in microangiopathic stroke. MMP-8, MMP-8/TIMP-1 ratio and MPO (p < 0.001) concentrations showed positive associations with stroke severity independent of stroke etiology.
   Conclusions: Concentrations of serum neutrophil markers are increased after ischemic stroke and associate with stroke severity and etiology. The value of these biomarkers in diagnostics and prognostics is worth being evaluated. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Palm, Frederick; Urbanek, Christian; Grau, Armin J.] Klinikum Ludwigshafen, Dept Neurol, Ludwigshafen, Germany.
   [Pussinen, Pirkko J.; Tervahartiala, Taina; Sorsa, Timo] Univ Helsinki, Oral & Maxillofacial Dis, Helsinki, Finland.
   [Safer, Anton; Becher, Heiko] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany.
   [Sorsa, Timo] Karolinska Inst, Dept Dent Med, Huddinge, Sweden.
   [Becher, Heiko] Univ Med Ctr Hamburg Eppendorf, Inst Med Biometry & Epidemiol, Hamburg, Germany.
RP Palm, F (reprint author), Stadt Klinikum Ludwigshafen, Dept Neurol, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM frederickpalm@gmx.de
FU German Research Foundation (DFG)German Research Foundation (DFG) [BE
   2056/5-1, GR 1102/5-1, GR 1687/2-1]; Academy of FinlandAcademy of
   Finland [1266053]; Sigrid Juselius FoundationSigrid Juselius Foundation;
   Finnish Dental Association Apollonia
FX This work was supported by the German Research Foundation (DFG), [BE
   2056/5-1, GR 1102/5-1, GR 1687/2-1], the Academy of Finland (grant
   number 1266053), the Sigrid Juselius Foundation, and the Finnish Dental
   Association Apollonia.
NR 37
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 9
EP 14
DI 10.1016/j.atherosclerosis.2018.02.012
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400002
PM 29453088
OA Green Published
DA 2019-10-28
ER

PT J
AU Vitverova, B
   Blazickova, K
   Najmanova, I
   Vicen, M
   Hyspler, R
   Dolezelova, E
   Nemeckova, I
   Tebbens, JD
   Bernabeu, C
   Pericacho, M
   Nachtigal, P
AF Vitverova, Barbora
   Blazickova, Katerina
   Najmanova, Iveta
   Vicen, Matej
   Hyspler, Radek
   Dolezelova, Eva
   Nemeckova, Ivana
   Tebbens, Jurjen Duintjer
   Bernabeu, Carmelo
   Pericacho, Miguel
   Nachtigal, Petr
TI Soluble endoglin and hypercholesterolemia aggravate endothelial and
   vessel wall dysfunction in mouse aorta
SO ATHEROSCLEROSIS
LA English
DT Article
DE Soluble endoglin; Endothelial dysfunction; eNOS; Vascular reactivity;
   Mice
ID BETA RECEPTOR; EXPRESSION; PROTEIN; DILATION; ADHESION; RELEASE; KINASE;
   NO
AB Background and aims: Increased plasma levels of soluble endoglin (sEng) were detected in patients with endothelial dysfunction-related disorders and hypercholesterolemia. In this study, we hypothesized that high levels of sEng accompanied by mild hypercholesterolemia could aggravate endothelial and vessel wall dysfunction and affect endoglin/eNOS signaling in mouse aorta.
   Methods: Three-month-old female transgenic mice on CBAxC57BL/6J background, with high levels of sEng (Sol-Eng(+) high HFD), and their littermates with low levels of sEng (Sol-Eng(+) low HFD), were fed a high fat diet for six months. Plasma samples were used for biochemical, ELISA and Luminex analyses of total cholesterol, sEng and inflammatory markers. Functional parameters of aorta were assessed with wire myograph 620M. Western blot analyses of membrane endoglin/eNOS signaling and endothelial dysfunction/inflammation markers in aorta were performed.
   Results: Functional analysis of aorta showed impaired KCl induced vasoconstriction, endothelial-dependent relaxation after the administration of acetylcholine as well as endothelial-independent relaxation induced by sodium nitroprusside in the Sol-Eng(+) high HFD group compared to the Sol-Eng(+) low HFD group. Ach-induced vasodilation after administration of L-NAME was significantly higher in the Sol-Eng(+) high HFD group compared to the Sol-Eng(+) low HFD group. The expression of endoglin, p-eNOS/eNOS, pSmad2/3/Smad2/3 signaling pathway was significantly lower in the Sol-Eng(+) high HFD group compared to the Sol-Eng(+) low HFD group.
   Conclusions: The results indicate that long-term hypercholesterolemia combined with high levels of sEng leads to the aggravation of endothelial and vessel wall dysfunction in aorta, with possible alterations of the membrane endoglin/eNOS signaling, suggesting that high levels of soluble endoglin might be considered as a risk factor of cardiovascular diseases. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Vitverova, Barbora; Blazickova, Katerina; Najmanova, Iveta; Vicen, Matej; Dolezelova, Eva; Nemeckova, Ivana; Nachtigal, Petr] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Biol & Med Sci, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic.
   [Hyspler, Radek] Univ Hosp, Ctr Res & Dev, Hradec Kralove, Czech Republic.
   [Tebbens, Jurjen Duintjer] Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Biophys & Phys Chem, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic.
   [Bernabeu, Carmelo] CSIC, Spanish Natl Res Council, Ctr Biol Res, Plaza Murillo 2, E-28040 Madrid, Spain.
   [Bernabeu, Carmelo] Biomed Res Networking Ctr Rare Dis CIBERER, Madrid 28040, Spain.
   [Pericacho, Miguel] Univ Salamanca, Biomed Res Inst Salamanca IBSAL, Salamanca 37007, Spain.
   [Pericacho, Miguel] Univ Salamanca, Dept Physiol & Pharmacol, Renal & Cardiovasc Physiopathol Unit, Salamanca 37007, Spain.
RP Nachtigal, P (reprint author), Charles Univ Prague, Fac Pharm Hradec Kralove, Dept Biol & Med Sci, Heyrovskeho 1203, Hradec Kralove 50005, Czech Republic.
EM petr.nachtigal@faf.cuni.cz
RI Bernabeu, Carmelo/L-3226-2014; Vicen, Matej/S-8443-2017; Vitverova,
   Barbora/T-4468-2017; Najmanova, Iveta/T-5295-2017; Bernabeu,
   Carmelo/P-4662-2019; Tebbens, Jurjen Duintjer/H-5488-2012; Pericacho,
   Miguel/H-1786-2016
OI Bernabeu, Carmelo/0000-0002-1563-6162; Vicen, Matej/0000-0002-7568-6989;
   Vitverova, Barbora/0000-0002-4446-2712; Najmanova,
   Iveta/0000-0002-8443-0512; Bernabeu, Carmelo/0000-0002-1563-6162;
   Tebbens, Jurjen Duintjer/0000-0003-0553-854X; Pericacho,
   Miguel/0000-0003-0226-482X
FU Czech Science foundation (GACR)Grant Agency of the Czech Republic
   [GA15-24015S]; Czech Health Research Council (AZV CR) [17-31754A]; Grant
   Agency of Charles University in Prague [1284214/C, 1158413C,
   SVV/2016/260293]; Ministerio de Economia y Competitividad of Spain
   [SAF2013-43421-R]; Instituto de Salud Carlos IIIInstituto de Salud
   Carlos III [PI16/00460, Retic RD16/0009/0025]; FEDER funds from the
   European Commission
FX The work was supported by grants from Czech Science foundation (GACR
   number GA15-24015S), Czech Health Research Council (AZV CR number
   17-31754A), the Grant Agency of Charles University in Prague (number
   1284214/C, 1158413C and grant SVV/2016/260293), Ministerio de Economia y
   Competitividad of Spain (SAF2013-43421-R to CB Centro de Investigacion
   Biomedica en Red de Enfermedades Raras (CIBERER; to CB), and Instituto
   de Salud Carlos III (PI16/00460 and Retic RD16/0009/0025,
   REDINREN-FEDER). CIBERER and REDINREN are initiatives of the Instituto
   de Salud Carlos III (ISCIII) of Spain supported by FEDER funds from the
   European Commission.
NR 36
TC 6
Z9 7
U1 2
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 15
EP 25
DI 10.1016/j.atherosclerosis.2018.02.008
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400003
PM 29459262
DA 2019-10-28
ER

PT J
AU Lee, DY
   Yang, TL
   Huang, YH
   Lee, CI
   Chen, LJ
   Shih, YT
   Wei, SY
   Wang, WL
   Wu, CC
   Chiu, JJ
AF Lee, Ding-Yu
   Yang, Tung-Lin
   Huang, Yi-Hsuan
   Lee, Chih-I.
   Chen, Li-Jing
   Shih, Yu-Tsung
   Wei, Shu-Yi
   Wang, Wei-Li
   Wu, Chih-Cheng
   Chiu, Jeng-Jiann
TI Induction of microRNA-10a using retinoic acid receptor-alpha and
   retinoid x receptor-alpha agonists inhibits atherosclerotic lesion
   formation
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Endothelial cell; MicroRNA; Retinoic acid receptor;
   Shear stress
ID NUCLEAR HORMONE-RECEPTORS; HISTONE DEACETYLASES; DISTURBED FLOW;
   ACTIVATION; CELLS; MICE
AB Background and aims: MicroRNA (miR)-10a is a shear-regulated miR with the lowest expression in vascular endothelial cells (ECs) in athero-susceptible regions with oscillatory shear stress (OS). The aim of this study is to elucidate the relationship between EC miR-10a and atherosclerosis and develop a hemodynamics-based strategy for atherosclerosis treatment.
   Methods: A combination of in vitro flow system and in vivo experimental animals was used to examine the functional roles of EC miR-10a and its clinical applications in atherosclerosis.
   Results: En face staining showed that EC miR-10a is down-regulated in the inner curvature (OS region) of aortic arch in rats. Co-administration with retinoic acid receptor-alpha (RAR alpha)-and retinoid X receptor-alpha (RXR alpha)-specific agonists rescued EC miR-10a expression in this OS region. These effects of OS and RAR alpha/RXR alpha-specific agonists on EC miR-10a expression were confirmed by the in vitro flow system, and were modulated by the RAR alpha-histone deacetylases complex, with the consequent modulation in the downstream GATA6/vascular cell adhesion molecule (VCAM)-1 signaling cascade. Animal studies showed that miR-10a levels are decreased in both aortic endothelium of atherosclerotic lesions and blood plasma from apolipoprotein E-deficient (ApoE(-/-)) mice. In vivo induction of EC miR-10a by administration of RAR alpha/RXR alpha-specific agonists protects ApoE(-/-) mice from atherosclerosis through inhibition of GATA6/VCAM-1 signaling and inflammatory cell infiltration.
   Conclusions: Our findings indicate that down-regulation of miR-10a in aortic endothelium and blood serum is associated with atherosclerosis, and miR-10a has potential to be developed as diagnostic molecule for atherosclerosis. Moreover, EC miR-10a induction by RAR alpha/RXR alpha-specific agonists is a potential hemodynamics-based strategy for atherosclerosis treatment. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lee, Ding-Yu] China Univ Sci & Technol, Dept Food Sci, Taipei, Taiwan.
   [Lee, Ding-Yu] China Univ Sci & Technol, Dept Biol Sci & Technol, Taipei, Taiwan.
   [Lee, Ding-Yu; Yang, Tung-Lin; Huang, Yi-Hsuan; Lee, Chih-I.; Chen, Li-Jing; Shih, Yu-Tsung; Wei, Shu-Yi; Wang, Wei-Li; Chiu, Jeng-Jiann] Natl Hlth Res Inst, Inst Cellular & Syst Med, Miaoli 350, Taiwan.
   [Yang, Tung-Lin] Natl Cent Univ, Dept Life Sci, Jhongli, Taiwan.
   [Wu, Chih-Cheng] Natl Taiwan Univ Hosp, Hsinchu Branch, Dept Cardiol, Internal Med, Hsinchu, Taiwan.
   [Wu, Chih-Cheng; Chiu, Jeng-Jiann] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu, Taiwan.
   [Chiu, Jeng-Jiann] Natl Cheng Kung Univ, Inst Biomed Engn, Tainan, Taiwan.
   [Chiu, Jeng-Jiann] Taipei Med Univ, Coll Pharm, Taipei, Taiwan.
   [Chiu, Jeng-Jiann] Natl Taiwan Univ, Inst Polymer Sci & Engn, Taipei, Taiwan.
RP Chiu, JJ (reprint author), Natl Hlth Res Inst, Inst Cellular & Syst Med, Miaoli 350, Taiwan.
EM jjchiu@nhri.org.tw
OI WU, CHIH-CHENG/0000-0002-9690-6573
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan
   [MOST-106-2633-B-009-001/105-2321-B-400-007/106-3114-Y-043-021,
   MOST-103-2321-B-400-011]; National Health Research Institutes Central
   Government S T grant [106-1901-01-10-02/106-0324-01-10-07]
FX This work was supported by the Ministry of Science and Technology,
   Taiwan [grant numbers
   MOST-106-2633-B-009-001/105-2321-B-400-007/106-3114-Y-043-021 (to
   J.-J.C.) and MOST-103-2321-B-400-011 (to D.-Y.L.)] and National Health
   Research Institutes Central Government S & T grant [grant numbers
   106-1901-01-10-02/106-0324-01-10-07 (to J.-J.C.)].
NR 21
TC 4
Z9 4
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 36
EP 44
DI 10.1016/j.atherosclerosis.2018.02.010
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400005
PM 29459264
DA 2019-10-28
ER

PT J
AU Kowall, B
   Lehmann, N
   Mahabadi, AA
   Lehnich, AT
   Moebus, S
   Budde, T
   Seibel, R
   Gronemeyer, D
   Erbel, R
   Jockel, KH
   Stang, A
AF Kowall, Bernd
   Lehmann, Nils
   Mahabadi, Amir-Abbas
   Lehnich, Anna-Therese
   Moebus, Susanne
   Budde, Thomas
   Seibel, Rainer
   Groenemeyer, Dietrich
   Erbel, Raimund
   Joeckel, Karl-Heinz
   Stang, Andreas
TI Sleep characteristics and progression of coronary artery calcification:
   Results from the Heinz Nixdorf Recall cohort study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Sleep duration; Sleep disorders; Napping; Atherosclerosis; Coronary
   artery calcification
ID ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK
   STRATIFICATION; GENERAL-POPULATION; CAUSAL-DIAGRAMS; DURATION;
   METAANALYSIS; ATHEROSCLEROSIS; CALCIUM
AB Background and aims: Sleep characteristics are associated with incident cardiovascular diseases (CVD), but there is a lack of studies on the association between sleep characteristics and incidence/progression of coronary artery calcification (CAC).
   Methods: In the Heinz Nixdorf Recall Study, a population-based cohort study in Germany, CAC was assessed by electron-beam tomography at baseline and at 5-year follow-up. In an analysis set of 3043 subjects (age at baseline 45-74 years; 47% men), we fitted logistic and linear regression models to assess associations between self-rated sleep characteristics (nocturnal and total sleep duration; napping; various sleep disorders) and CAC incidence/CAC progression. Progression was measured as 5-year progression factor, as categories of absolute CAC change, and additionally characterized as rapid or slow compared to an extrapolation of baseline CAC values.
   Results: We observed barely any association between sleep characteristics and CAC progression regardless of the chosen statistical approach; associations between sleep and CAC incidence were slightly larger, e.g., the geometric mean of the 5-year CAC progression factor was 6.8% (95% confidence interval: -9.5; 25.9) larger for <= 5 h, 2.9% (-7.3; 14.3) larger for 5.1-6.9 h and 7.1% (-2.4; 15.7) smaller for -7.5 h total sleep compared to 7- <7.5 h total sleep. For subjects with any regular sleep disorder, the geometric mean of the 5-year CAC progression was 3.5% (-4.7; 11.2) smaller compared to subjects without any regular sleep disorder.
   Conclusions: In this German cohort study, sleep characteristics were barely associated with CAC progression. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Kowall, Bernd; Lehnich, Anna-Therese; Stang, Andreas] Univ Duisburg Essen, Med Fac, Inst Med Informat Biometry & Epidemiol, Ctr Clin Epidemiol, Essen, Germany.
   [Lehmann, Nils; Erbel, Raimund; Joeckel, Karl-Heinz] Univ Duisburg Essen, Univ Clin Essen, Inst Med Informat Biometry & Epidemiol, Essen, Germany.
   [Mahabadi, Amir-Abbas] Univ Clin Essen, Dept Cardiol, West German Heart & Vasc Ctr Essen, Essen, Germany.
   [Moebus, Susanne] Univ Clin Essen, Inst Med Informat Biometry & Epidemiol, Ctr Urban Epidemiol, Essen, Germany.
   [Budde, Thomas] Alfred Krupp Hosp, Essen, Germany.
   [Seibel, Rainer] Diagnosticum, Mulheim, Germany.
   [Groenemeyer, Dietrich] Univ Witten Herdecke, Dept Radiol & Microtherapy, Bochum, Germany.
   [Stang, Andreas] Boston Univ, Sch Publ Hlth, Dept Epidemiol, 715 Albany St,Talbot Bldg, Boston, MA 02118 USA.
RP Kowall, B (reprint author), IMIBE, Ctr Clin Epidemiol, Hufelandstr 55, D-45147 Essen, Germany.
EM bernd.kowall@uk-essen.de
FU German Ministry of Education and Science (BMBF)Federal Ministry of
   Education & Research (BMBF); Deutsche Forschungsgemeinschaft (DFG)German
   Research Foundation (DFG) [ER 155/6-1, ER 155/6-2, SI 236/8-1, SI
   236/9-1]; German Federal Ministry of Education and Science (BMBF)Federal
   Ministry of Education & Research (BMBF) [01ER1305]
FX We thank the Heinz Nixdorf Foundation [Chairman: Martin Nixdorf; Past
   Chairman: Dr Jur Gerhard Schmidt (deceased)], for their generous support
   of this study. This study is also supported by the German Ministry of
   Education and Science (BMBF) that transferred the monitoring of the
   study to the German Aero-space Center [Deutsches Zentrum fur Luft-und
   Raumfahrt (DLR)], Bonn, Germany. An international advisory board and
   quality control as well as event committee were established, but had no
   role concerning the study design, data collection, analysis,
   interpretation, or writing the report. The Deutsche
   Forschungsgemeinschaft (DFG) supported the study (DFG project: ER
   155/6-1, ER 155/6-2, SI 236/8-1, and SI 236/9-1).; Prof. Stang receives
   a grant from the German Federal Ministry of Education and Science
   (BMBF), grant number 01ER1305.
NR 36
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 45
EP 52
DI 10.1016/j.atherosclerosis.2018.02.013
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400006
PM 29459265
DA 2019-10-28
ER

PT J
AU Raggi, P
AF Raggi, Paolo
TI Atherosclerosis imaging to refine cardiovascular risk assessment in
   diabetic patients: Computed tomography and positron emission tomography
   applications
SO ATHEROSCLEROSIS
LA English
DT Review
DE Atherosclerosis; Cardiovascular imaging; Risk assessment; Diabetes
   mellitus; Computer tomography; Positron emission tomography
ID CORONARY-ARTERY CALCIUM; IMPAIRED GLUCOSE-TOLERANCE; INTERNATIONAL
   MULTICENTER REGISTRY; ULTRASONIC TISSUE CHARACTERIZATION; CT ANGIOGRAPHY
   EVALUATION; PLAQUE INFLAMMATION; VASCULAR INFLAMMATION; PROGNOSTIC
   VALUE; CAROTID PLAQUE; SUBCLINICAL ATHEROSCLEROSIS
AB The lifetime cardiovascular risk of a diabetic patient is approximately 4-5 times higher than that of an age and sex matched individual without diabetes mellitus. Despite the well-publicized cardiovascular risk equivalence of diabetes mellitus, it has become apparent that not all diabetic patients are equally at high-risk and many patients may have a level of risk similar to that of the general population. Cardiovascular imaging has been employed to address the dilemma of a more accurate risk stratification of diabetic patients. Two randomized clinical trials aiming at uncovering the presence of unknown obstructive coronary artery disease (CAD) gave disappointing results. In fact, the number of patients with inducible myocardial ischemia and/or severe obstructive disease was lower than expected and the overall outcome was not improved after having brought the existence of CAD to light. Other techniques that may help identify a diabetic patient susceptible to suffer future events have therefore being explored. In this review we discuss two imaging tools that provide anatomical and functional information on pre-clinical coronary atherosclerosis: computed tomography for calcium scoring, and plaque characterization and myocardial ischemia detection and positron emission tomography using tracers to identify functionally unstable plaques. Despite the availability of several imaging techniques there remain numerous questions as to the utility of imaging to define risk in diabetes mellitus and an optimal approach has yet to be found. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Raggi, Paolo] Mazankowski Alberta Heart Inst, Edmonton, AB, Canada.
   [Raggi, Paolo] Univ Alberta, Edmonton, AB, Canada.
RP Raggi, P (reprint author), 8440-112 St,4A7-050, Edmonton, AB T6G 2B7, Canada.
EM raggi@ualberta.ca
NR 62
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 77
EP 83
DI 10.1016/j.atherosclerosis.2018.02.021
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400010
PM 29477560
DA 2019-10-28
ER

PT J
AU Burggraaf, B
   van Breukelen-van der Stoep, DF
   de Vries, MA
   Klop, B
   van Zeben, J
   van de Geijn, GJM
   van der Meulen, N
   Birnie, E
   Prinzen, L
   Cabezas, MC
AF Burggraaf, Benjamin
   van Breukelen-van der Stoep, Deborah F.
   de Vries, Marijke A.
   Klop, Boudewijn
   van Zeben, Jende
   van de Geijn, Gert-Jan M.
   van der Meulen, Noelle
   Birnie, Erwin
   Prinzen, Lenneke
   Cabezas, Manuel Castro
TI Progression of subclinical atherosclerosis in subjects with rheumatoid
   arthritis and the metabolic syndrome
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Cardiovascular risk; Carotid artery; Intervention;
   Intima media thickness
ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS;
   DISEASE; MORTALITY; METAANALYSIS; EVENTS; PLAQUE; DEATH
AB Background and aims: Rheumatoid arthritis (RA) has been associated with an increased risk of atherosclerosis. We aimed to evaluate the progression of carotid intima media thickness (cIMT) in RA patients subject to a cardiovascular treat-to-target intervention. In addition, the presence of the metabolic syndrome (MetS) on cIMT outcomes was evaluated.
   Methods: We performed a cohort analysis of FRANCIS, in which RA patients <= 70 years without CVD or diabetes mellitus were randomized for either a treat-to-target intervention or usual care concerning CVD risk factors. MetS was scored at baseline.
   Results: Three-year data was available in 212 well-controlled RA patients. The treat-to-target intervention resulted in a lower cIMT progression over three years compared to the usual care. However, there was no difference in cIMT at three years between groups. MetS was present in 40.1% of RA patients. Baseline cIMT was significantly higher in RA patients with MetS compared to those without (0.619 (0.112) versus 0.557 (0.104) mm; p < 0.001). After three years, cIMT progression was comparable (0.043 (0.071) versus 0.043 (0.072) mm; p = 0.96). In RA patients with MetS, the presence of plaques increased over three years from 12.9% to 23.5% (p = 0.01). The type of intervention had no effect on cIMT progression in RA patients with MetS. However, in subjects without MetS, treat-to-target resulted in a lower progression.
   Conclusions: RA patients with MetS showed an increased CVD risk profile based on both a higher prevalence of CVD risk factors and structural vascular changes. A treat-to-target approach of CVD risk factors reduced cIMT progression only in RA patients without MetS. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Burggraaf, Benjamin; de Vries, Marijke A.; Klop, Boudewijn; van der Meulen, Noelle; Cabezas, Manuel Castro] Franciscus Gasthuis & Vlietland, Dept Internal Med, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands.
   [van Breukelen-van der Stoep, Deborah F.; van Zeben, Jende] Franciscus Gasthuis & Vlietland, Dept Rheumatol, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands.
   [van de Geijn, Gert-Jan M.; Prinzen, Lenneke] Franciscus Gasthuis & Vlietland, Dept Clin Chem, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands.
   [Birnie, Erwin] Franciscus Gasthuis & Vlietland, Dept Stat & Educ, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands.
   [van Breukelen-van der Stoep, Deborah F.] Ziekenhuis Gelderse Vallei, Dept Rheumatol, Willy Brandtlaan 10, NL-6716 RP Ede, Netherlands.
RP Burggraaf, B (reprint author), Franciscus Gasthuis & Vlietland, Dept Internal Med, Kleiweg 500, NL-3045 PM Rotterdam, Netherlands.
EM b.burggraaf@franciscus.nl
FU Research Foundation Internal Medicine Franciscus Gasthuis; Coolsingel
   Foundation
FX Funded by the Research Foundation Internal Medicine Franciscus Gasthuis
   and the Coolsingel Foundation. The latter is a public research fund with
   no involvement in the study or in the submitted manuscript.
NR 29
TC 3
Z9 4
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 84
EP 91
DI 10.1016/j.atherosclerosis.2018.02.019
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400011
PM 29482038
DA 2019-10-28
ER

PT J
AU Arya, R
   Escalante, A
   Farook, VS
   Restrepo, JF
   Battafarano, DF
   Almeida, M
   Kos, MZ
   Fourcaudot, MJ
   Mummidi, S
   Kumar, S
   Curran, JE
   Jenkinson, CP
   Blangero, J
   Duggirala, R
   del Rincon, I
AF Arya, Rector
   Escalante, Agustin
   Farook, Vidya S.
   Restrepo, Jose F.
   Battafarano, Daniel F.
   Almeida, Marcio
   Kos, Mark Z.
   Fourcaudot, Marcel J.
   Mummidi, Srinivas
   Kumar, Satish
   Curran, Joanne E.
   Jenkinson, Christopher P.
   Blangero, John
   Duggirala, Ravindranath
   del Rincon, Inmaculada
TI A genetic association study of carotid intima-media thickness (CIMT) and
   plaque in Mexican Americans and European Americans with rheumatoid
   arthritis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Carotid plaque; Subclinical atherosclerosis; Genetic association; Genes;
   Single nucleotide polymorphisms
ID GENOME-WIDE ASSOCIATION; CORONARY-HEART-DISEASE; CARDIOVASCULAR EVENTS;
   ARTERY-DISEASE; SUBCLINICAL ATHEROSCLEROSIS; RISK-FACTORS; LOCI;
   HERITABILITY; METAANALYSIS; POPULATIONS
AB Background and aims: Little is known about specific genetic determinants of carotid-intima-media thickness (CIMT) and carotid plaque in subjects with rheumatoid arthritis (RA). We have used the Metabochip array to fine map and replicate loci that influence variation in these phenotypes in Mexican Americans (MAs) and European Americans (EAs).
   Methods: CIMT and plaque were measured using ultrasound from 700 MA and 415 EA patients with RA and we conducted association analyses with the Metabochip single nucleotide polymorphism (SNP) data using PLINK.
   Results: In MAs, 12 SNPs from 11 chromosomes and 6 SNPs from 6 chromosomes showed suggestive associations (p < 1 x 10(-4)) with CIMT and plaque, respectively. The strongest association was observed between CIMT and rs17526722 (SLC17A2 gene) (beta +/- SE = -0.84 +/- 0.18, p = 3.80 x 10(-6)). In EAs, 9 SNPs from 7 chromosomes and 7 SNPs from 7 chromosomes showed suggestive associations with CIMT and plaque, respectively. The top association for CIMT was observed with rs1867148 (PPCDC gene, beta +/- SE = 0.28 +/- 0.06, p = 5.11 x 10(-6)). We also observed strong association between plaque and two novel loci: rs496916 from COL4A1 gene (OR = 0.51, p = 3.15 x 10(-6)) in MAs and rs515291 from SLCA13 gene (OR = 0.50, p = 3.09 x 10(-5)) in EAs.
   Conclusions: We identified novel associations between CIMT and variants in SLC17A2 and PPCDC genes, and between plaque and variants from COL4A1 and SLCA13 that may pinpoint new candidate risk loci for subclinical atherosclerosis associated with RA. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Arya, Rector; Farook, Vidya S.; Almeida, Marcio; Kos, Mark Z.; Mummidi, Srinivas; Kumar, Satish; Curran, Joanne E.; Jenkinson, Christopher P.; Blangero, John; Duggirala, Ravindranath] Univ Texas Rio Grande Valley, Sch Med, Dept Human Genet, 1214 W Schunior St, Edinburg, TX 78541 USA.
   [Arya, Rector; Farook, Vidya S.; Almeida, Marcio; Kos, Mark Z.; Mummidi, Srinivas; Kumar, Satish; Curran, Joanne E.; Jenkinson, Christopher P.; Blangero, John; Duggirala, Ravindranath] Univ Texas Rio Grande Valley, Sch Med, South Texas Diabet & Obes Inst, 1214 W Schunior St, Edinburg, TX 78541 USA.
   [Escalante, Agustin; Restrepo, Jose F.; del Rincon, Inmaculada] Univ Texas Hlth, Div Rheumatol & Clin Immunol, Dept Med, San Antonio, TX USA.
   [Battafarano, Daniel F.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA.
   [Fourcaudot, Marcel J.] Univ Texas Hlth, Dept Med, Div Diabet, San Antonio, TX USA.
RP Arya, R (reprint author), Univ Texas Rio Grande Valley, Sch Med, Dept Human Genet, 1214 W Schunior St, Edinburg, TX 78541 USA.; Arya, R (reprint author), Univ Texas Rio Grande Valley, Sch Med, South Texas Diabet & Obes Inst, 1214 W Schunior St, Edinburg, TX 78541 USA.
EM rector.arya@utrgv.edu
RI Mummidi, Srinivas/H-3335-2017
OI Mummidi, Srinivas/0000-0002-4068-6380
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01-HL-085742,
   R01-HD-037151, UL1-RR-25767]
FX This work was supported by grants from the US National Institutes of
   Health (R01-HL-085742, R01-HD-037151, and UL1-RR-25767).
NR 54
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 92
EP 101
DI 10.1016/j.atherosclerosis.2017.11.024
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400012
PM 29482039
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Ivanov, S
   Merlin, J
   Lee, MKS
   Murphy, AJ
   Guinamard, RR
AF Ivanov, Stoyan
   Merlin, Johanna
   Lee, Man Kit Sam
   Murphy, Andrew J.
   Guinamard, Rodolphe R.
TI Biology and function of adipose tissue macrophages, dendritic cells and
   B cells
SO ATHEROSCLEROSIS
LA English
DT Review
DE Macrophage; Dendritic cell; B cell; Adipose tissue; Obesity
ID PERIPHERAL LYMPHOID ORGANS; ALTERNATIVELY ACTIVATED MACROPHAGES; PROMOTE
   INSULIN-RESISTANCE; COLONY-STIMULATING FACTOR; ATHEROSCLEROTIC LESIONS;
   RECEPTOR DEFICIENCY; LOCAL PROLIFERATION; ADAPTIVE THERMOGENESIS;
   RESIDENT MACROPHAGES; CHRONIC INFLAMMATION
AB The increasing incidence of obesity and its socio-economical impact is a global health issue due to its associated co-morbidities, namely diabetes and cardiovascular disease [1-5]. Obesity is characterized by an increase in adipose tissue, which promotes the recruitment of immune cells resulting in low-grade inflammation and dysfunctional metabolism. Macrophages are the most abundant immune cells in the adipose tissue of mice and humans. The adipose tissue also contains other myeloid cells (dendritic cells (DC) and neutrophils) and to a lesser extent lymphocyte populations, including T cells, B cells, Natural Killer (NK) and Natural Killer T (NKT) cells. While the majority of studies have linked adipose tissue macrophages (ATM) to the development of low-grade inflammation and co-morbidities associated with obesity, emerging evidence suggests for a role of other immune cells within the adipose tissue that may act in part by supporting macrophage homeostasis. In this review, we summarize the current knowledge of the functions ATMs, DCs and B cells possess during steady-state and obesity. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Ivanov, Stoyan; Merlin, Johanna; Guinamard, Rodolphe R.] Univ Nice Sophia Antipolis, Fac Med, Mediterranean Ctr Mol Med, INSERM U1065, Nice, France.
   [Lee, Man Kit Sam; Murphy, Andrew J.] Baker Heart & Diabet Inst, Haematopoiesis & Leukocyte Biol, Melbourne, Vic, Australia.
RP Guinamard, RR (reprint author), Univ Nice Sophia Antipolis, Fac Med, Mediterranean Ctr Mol Med, INSERM U1065, Nice, France.
EM Stoyan.ivanov@unice.fr; rguinamard@unice.fr
RI Guinamard, Rodolphe/P-9804-2016
OI Guinamard, Rodolphe/0000-0002-7400-582X; Ivanov,
   Stoyan/0000-0002-0527-2297
FU NHMRCNational Health and Medical Research Council of Australia
   [APP1085752]; National Heart FoundationNational Heart Foundation of
   Australia [100440]; Centre National de la Recherche Scientifique
   (CNRS)Centre National de la Recherche Scientifique (CNRS); Institut
   National de la Sante et de la Recherche Medicale (INSERM)Institut
   National de la Sante et de la Recherche Medicale (Inserm); Agence
   Nationale de la RechercheFrench National Research Agency (ANR)
   [ANR-17-CE14-0017-01]
FX AJM is supported by a career development fellowship from the NHMRC
   (APP1085752), a future leader fellowship from the National Heart
   Foundation (100440). RRG is supported by Centre National de la Recherche
   Scientifique (CNRS). SI is supported by Institut National de la Sante et
   de la Recherche Medicale (INSERM) and Agence Nationale de la Recherche
   (ANR-17-CE14-0017-01).
NR 131
TC 14
Z9 14
U1 1
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 102
EP 110
DI 10.1016/j.atherosclerosis.2018.01.018
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400013
PM 29482037
DA 2019-10-28
ER

PT J
AU Arca, M
   Ansell, D
   Averna, M
   Fanelli, F
   Gorcyca, K
   Iorga, SR
   Maggioni, AP
   Paizis, G
   Tomic, R
   Catapano, AL
AF Arca, Marcello
   Ansell, David
   Averna, Maurizio
   Fanelli, Francesca
   Gorcyca, Katherine
   Iorga, Serban R.
   Maggioni, Aldo P.
   Paizis, Georges
   Tomic, Radovan
   Catapano, Alberico L.
TI Statin utilization and lipid goal attainment in high or very-high
   cardiovascular risk patients: Insights from Italian general practice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiovascular disease; Low-density lipoprotein cholesterol;
   Non-high-density lipoprotein cholesterol; Prevention; Statin
ID ACUTE CORONARY SYNDROMES; CHOLESTEROL-LOWERING TREATMENT; PRIMARY-CARE
   PRACTICE; LDL-CHOLESTEROL; FAMILIAL HYPERCHOLESTEROLEMIA;
   RANDOMIZED-TRIALS; HEART-DISEASE; MYOCARDIAL-INFARCTION; THERAPY;
   METAANALYSIS
AB Background and aims: Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk.
   Methods: Patients aged >= 18 years with a valid low-density lipoprotein cholesterol (LDL-C) measurement in 2015 were selected from the IMS Health Real World Data database; non-high-density lipoprotein cholesterol (non-HDL-C) was assessed in those with available total cholesterol measurements. Index dates were defined as the last valid lipid measurement in 2015. Patients were hierarchically classified into mutually exclusive risk categories: heterozygous familial hypercholesterolemia (primary and secondary prevention), atherosclerotic CV disease (including recent acute coronary syndrome [ACS], chronic coronary heart disease, stroke, and peripheral arterial disease), and diabetes mellitus (DM) alone. Statin and non-statin lipid-modifying therapy (LMT) use, and European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guideline-recommended goal attainment, were assessed.
   Results: Among 66,158 patients meeting selection criteria, the overall rate of LMT prescriptions was 53.3%, including 7.7% on high-intensity statin therapy. Statin use was highest for recent ACS and lowest for DM alone. LDL-C goal attainment was 16.0% for <1.8 mmol/l and 45.0% for <2.5 mmol/l; 24.3% reached non-HDL-C <2.6 mmol/l and 52.2% were at <3.3 mmol/l. Goal achievement was greatest with high-intensity statin use.
   Conclusions: Statin use in this cohort was consistent with previous reports in Italian patients at high/very-high CV risk, and low relative to statin use in other European countries. The low rate of ESC/EAS lipid goal attainment observed was consistent with outcomes of other European studies. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Arca, Marcello] Sapienza Univ Rome, Dept Internal Med & Med Specialties, Azienda Policlin Umberto 1 Viale Policlin 155, I-00161 Rome, Italy.
   [Ansell, David] IMS Hlth, London, England.
   [Averna, Maurizio] Univ Palermo, Sch Med, Dept Internal Med & Med Specialties, Palermo, Italy.
   [Fanelli, Francesca; Paizis, Georges; Tomic, Radovan] Sanofi, Milan, Italy.
   [Gorcyca, Katherine] Sanofi, Bridgewater, NJ USA.
   [Iorga, Serban R.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
   [Maggioni, Aldo P.] ANMCO, Res Ctr, Florence, Italy.
   [Catapano, Alberico L.] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy.
   [Catapano, Alberico L.] IRCCS Multimed, Milan, Italy.
RP Arca, M (reprint author), Sapienza Univ Rome, Dept Internal Med & Med Specialties, Azienda Policlin Umberto 1 Viale Policlin 155, I-00161 Rome, Italy.
EM marcello.arca@uniroma1.it
RI Catapano, alberico/AAC-2827-2019
OI Maggioni, Aldo Pietro/0000-0003-2764-6779; Catapano, Alberico
   Luigi/0000-0002-7593-2094; Averna, Maurizio/0000-0003-3558-9209
FU SanofiSanofi-Aventis; Regeneron Pharmaceuticals, Inc.
FX This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc.
NR 49
TC 3
Z9 3
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 120
EP 127
DI 10.1016/j.atherosclerosis.2018.02.024
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400015
PM 29499359
OA Green Published
DA 2019-10-28
ER

PT J
AU Zhai, MC
   Guo, JY
   Ma, HY
   Shi, W
   Jou, D
   Yan, D
   Liu, TS
   Tao, JW
   Duan, JL
   Wang, YN
   Li, S
   Lv, JG
   Li, CL
   Lin, JY
   Zhang, CT
   Lin, L
AF Zhai, Maocai
   Guo, Junyi
   Ma, Haiyan
   Shi, Wei
   Jou, David
   Yan, Dan
   Liu, Tianshu
   Tao, Jingwen
   Duan, Jialin
   Wang, Yina
   Li, Sheng
   Lv, Jiagao
   Li, Chenglong
   Lin, Jiayuh
   Zhang, Cuntai
   Lin, Li
TI Ursolic acid prevents angiotensin II-induced abdominal aortic aneurysm
   in apolipoprotein E-knockout mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Abdominal aortic aneurysm; Inflammation; Ursolic acid; ADAM17; STAT3;
   MMPs
ID SMOOTH-MUSCLE-CELLS; INFLAMMATION; INHIBITION; METALLOPROTEINASES;
   MIGRATION; GROWTH
AB Background and aims: Abdominal aortic aneurysms (AAA) is a chronic inflammatory disease in which signal transducer and activator of transcription 3 (STAT3), and disintegrin and metalloproteinase 17 (ADAM17) play important roles. However, it remains unclear whether ursolic acid (UA), a natural pentacyclic triterpenoid carboxylic acid, can have an impact on STAT3 and ADAM17 and hence influence the formation of AAA. The objective of this study was to characterize the potential effect of UA on the pathogenesis of AAA and on STAT3 and ADAM17.
   Methods: Male ApoE(-/-) mice were infused with angiotensin II (AngII) (1000 ng/kg/min) for 4 weeks to induce AAAs. Daily intragastric gavage with 100mg/kg UA or tap water containing Tween 80 as controls was provided. Immunohistochemistry, cell viability assay, colony formation, wound healing assay, and Western blot were used to explore the potential effect of UA on AAA.
   Results: UA decreased the incidence of AngII-induced AAA in mice. UA alleviated the degradation of elastin fibers and inflammation and decreased the expression of MMP2, MMP9, ADAM17 and phospho-STAT3 (pSTAT3) in aorta of mice induced with AngII. UA inhibited the constitutive and stimuli-induced (AngII and tumor necrosis factor-alpha) expression of MMP2, MMP9, ADAM17 and pSTAT3 in vascular smooth muscle cells (VSMCs). Furthermore, UA decreased cell viability, and suppressed colony formation and wound healing in vitro.
   Conclusions: We demonstrated that UA ameliorated the severity of AAA and exhibited an inhibitory effect on the expression of pSTAT3 and ADAM17. UA might emerge as a promising agent contributing to the prevention or treatment of AAA. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zhai, Maocai; Guo, Junyi; Shi, Wei; Yan, Dan; Liu, Tianshu; Tao, Jingwen; Duan, Jialin; Wang, Yina; Li, Sheng; Lv, Jiagao; Lin, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med,Div Cardiol, Wuhan 430030, Hubei, Peoples R China.
   [Ma, Haiyan] First Peoples Hosp Shangqiu, Div Cardiol, Dept Internal Med, Shangqiu, Peoples R China.
   [Jou, David] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Dept Pediat,Res Inst,Ctr Childhood Canc, Columbus, OH 43210 USA.
   [Li, Chenglong] Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL USA.
   [Lin, Jiayuh] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.
   [Zhang, Cuntai] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Geriatr, Wuhan 430030, Hubei, Peoples R China.
RP Lin, L (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med,Div Cardiol, Wuhan 430030, Hubei, Peoples R China.; Zhang, CT (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Geriatr, Wuhan 430030, Hubei, Peoples R China.
EM zhangcuntaiwh@163.com; linlee271227@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81570416, 81372402, 81001005, 81571377, 81570337];
   Outstanding Young Investigator Foundation of Tongji Hospital [YXQN009];
   Fundamental Research Fund for the Central Universities (HUST)
   [0118540019, 2017KFYXJJ099]; Science and Technology Project Foundation
   of Wuhan [2017060201010175]
FX This research was supported by National Natural Science Foundation of
   China to Li Lin (81570416, 81372402 and 81001005), Cuntai Zhang
   (81571377) and Sheng Li (81570337), the Outstanding Young Investigator
   Foundation of Tongji Hospital to Li Lin (YXQN009), the Fundamental
   Research Fund for the Central Universities (HUST) to Li Lin (0118540019)
   and Jiagao Lv (2017KFYXJJ099), and the Science and Technology Project
   Foundation of Wuhan to Jiagao Lv (2017060201010175).
NR 31
TC 2
Z9 2
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 128
EP 135
DI 10.1016/j.atherosclerosis.2018.02.022
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400016
PM 29499360
DA 2019-10-28
ER

PT J
AU Lin, SY
   Chen, DC
   Lin, CL
   Lee, HC
   Lin, TC
   Wang, IK
   Hsu, CY
   Kao, CH
AF Lin, Shih-Yi
   Chen, Der-Cherng
   Lin, Cheng-Li
   Lee, Han-Chung
   Lin, Tsung-Chih
   Wang, I-Kuan
   Hsu, Chung-Y.
   Kao, Chia-Hung
TI Risk of acute coronary syndrome in patients with cervical spondylosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cervical spondylosis; Cardiovascular; Acute coronary syndrome; Cohort
   study
ID CARDIOVASCULAR EVENTS; PROPENSITY-SCORE; DISEASE; COHORT; PLAQUE
AB Background and aims: Cervical spondylosis (CS) is reported to be associated with increased sympathetic activity and hypertension. However, the cardiovascular (CV) outcomes of patients with CS are largely unknown.
   Methods: A national insurance claims dataset of 22 million enrollees in Taiwan during 1999-2010 was used as the research database. We identified 27,948 patients with CS and age-, sex-, and comorbiditymatched controls. By using multivariate logistic regression analysis after adjustment for potential cardiovascular (CV) confounders, we calculated odds ratios (ORs) with 95% confidence intervals (CIs) to quantify the association between CS and acute coronary syndrome (ACS).
   Results: A total of 744 ACS events were identified among the 27,948 patients with CS. The overall incidence of ACS was 4.27 per 1000 person-years in the CS cohort and 3.90 per 1000 person-years in the non-CS cohort, with an adjusted hazard ratio (aHR) of 1.13 (95% CI = 1.08-1.18). The aHRs of ACS were 1.08 (95% CI = 1.03-1.15) in the CS cohort without myelopathy and 1.20 (95% CI = 1.13-1.28) in the CS cohort with myelopathy, compared with the non-CS cohort. Compared with patients with CS without neurological signs, patients with CS receiving rehabilitation exhibited a 0.67 aHRs of ACS (95% CI = 0.59 -0.76), whereas those with neurological signs receiving spinal decompression exhibited 0.73 aHRs of ACS (95% CI = 0.63-0.84).
   Conclusions: CS is associated with an increased risk of ACS. Receiving treatment for CS, either rehabilitation or spinal decompression, is associated with less risk of ACS. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lin, Shih-Yi; Chen, Der-Cherng; Lee, Han-Chung; Wang, I-Kuan; Hsu, Chung-Y.; Kao, Chia-Hung] China Med Univ, Coll Med, Grad Inst Clin Med Sci, 2 Yuh Der Rd, Taichung 40447, Taiwan.
   [Lin, Shih-Yi; Chen, Der-Cherng; Lee, Han-Chung; Wang, I-Kuan; Hsu, Chung-Y.; Kao, Chia-Hung] China Med Univ, Coll Med, Sch Med, Taichung, Taiwan.
   [Lin, Shih-Yi; Wang, I-Kuan] China Med Univ Hosp, Div Nephrol, Taichung, Taiwan.
   [Lin, Shih-Yi; Wang, I-Kuan] China Med Univ Hosp, Kidney Inst, Taichung, Taiwan.
   [Chen, Der-Cherng; Lee, Han-Chung] China Med Univ Hosp, Div Neurosurg, Taichung, Taiwan.
   [Chen, Der-Cherng; Lee, Han-Chung] China Med Univ, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ, Coll Med, Taichung, Taiwan.
   [Lin, Tsung-Chih] St Martin De Porres Hosp, Dept Orthoped, Chiayi, Taiwan.
   [Kao, Chia-Hung] China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan.
   [Kao, Chia-Hung] China Med Univ Hosp, PET Ctr, Taichung, Taiwan.
   [Kao, Chia-Hung] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan.
RP Kao, CH (reprint author), China Med Univ, Coll Med, Grad Inst Clin Med Sci, 2 Yuh Der Rd, Taichung 40447, Taiwan.
EM d10040@mail.cmuh.org.tw
FU Ministry of Health and Welfare, Taiwan [MOHW107-TDU-B-212-123004]; China
   Medical University Hospital; Academia Sinica Stroke Biosignature Project
   [BM10701010021]; MOST Clinical Trial Consortium for Stroke [MOST
   106-2321-B-039-005-]; Tseng-Lien Lin Foundation, Taichung, Taiwan;
   Katsuzo and Kiyo Aoshima Memorial Funds, Japan
FX This work was supported by grants from the Ministry of Health and
   Welfare, Taiwan (MOHW107-TDU-B-212-123004), China Medical University
   Hospital; Academia Sinica Stroke Biosignature Project (BM10701010021);
   MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005-);
   Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo
   Aoshima Memorial Funds, Japan. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript. No additional external funding received for this study.
NR 30
TC 3
Z9 4
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 136
EP 141
DI 10.1016/j.atherosclerosis.2018.02.029
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400017
PM 29518745
DA 2019-10-28
ER

PT J
AU Ricalde, A
   Allison, M
   Rifkin, D
   Shaw, R
AF Ricalde, Aldrich
   Allison, Matthew
   Rifkin, Dena
   Shaw, Richard
TI Anthropometric measures of obesity and renal artery calcification:
   Results from the Multi-Ethnic Study of Atherosclerosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Obesity; Waist circumference; Waist-hip ratio; Renal artery; Vascular
   calcification
ID CARDIOVASCULAR-DISEASE; WAIST CIRCUMFERENCE; CALCIFIED ATHEROSCLEROSIS;
   VISCERAL ADIPOSITY; RISK-FACTORS; CALCIUM; ASSOCIATIONS; HYPERTENSION;
   PREVALENCE; ADULTS
AB Background and aims: Renal artery calcium (RAC) has been linked to several cardiovascular disease (CVD) risk factors, including age, male gender, and hypertension. The purpose of this study was to determine whether anthropometric measures of obesity are associated with presence of RAC.
   Methods: We studied 1287 community-dwelling adults enrolled in the Multi-Ethnic Study of Atherosclerosis. Logistic regression models adjusted for CVD risk factors were used to examine body mass index (BMI), waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR) as primary predictors of RAC.
   Results: Study participants had a mean age of 67.7 years, 55.7% were female, and 36.8% were non-Hispanic White. Prevalence of RAC was 33.3%. WC and WHR as continuous variables were not significant with adjustment. Subjects with high WC, as defined by World Health Organization cut-offs, had significantly higher odds for RAC in the fully adjusted model. BMI and HC were not significantly associated with RAC in any models.
   Conclusions: In this community-based sample of older adults, higher levels of WC are significantly associated with RAC independently of CVD risk factors. Adults who meet World Health Organization criteria for high WC may be at higher risk for complications of calcified atherosclerosis in the renal arteries. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Ricalde, Aldrich] Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, Honolulu, HI 96822 USA.
   [Allison, Matthew] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
   [Rifkin, Dena] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Shaw, Richard] Calif Pacific Med Ctr, Div Cardiol, San Francisco, CA USA.
RP Ricalde, A (reprint author), 2351 Clay St,Ste 380, San Francisco, CA 94115 USA.
EM aldrichr@hawaii.edu
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [HHSN268201500003I,
   N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163,
   N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168,
   N01-HC-95169]; NCRRUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [UL1-TR-000040, UL1-TR-001079]; American
   Federation for Aging Research; Medical Student Training in Aging
   Research Program at the University of California, San Diego (NIH)
   [5T35AG026757-13]
FX This research was supported by contracts HHSN268201500003I,
   N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163,
   N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and
   N01-HC-95169 from the National Heart, Lung, and Blood Institute and by
   grants UL1-TR-000040 and UL1-TR-001079 from NCRR. Additional support
   from the American Federation for Aging Research and the Medical Student
   Training in Aging Research Program at the University of California, San
   Diego (NIH Project number 5T35AG026757-13).
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 142
EP 147
DI 10.1016/j.atherosclerosis.2018.02.031
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400018
PM 29518746
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Busnelli, M
   Manzini, S
   Parolini, C
   Escalante-Alcalde, D
   Chiesa, G
AF Busnelli, Marco
   Manzini, Stefano
   Parolini, Cinzia
   Escalante-Alcalde, Diana
   Chiesa, Giulia
TI Lipid phosphate phosphatase 3 in vascular pathophysiology
SO ATHEROSCLEROSIS
LA English
DT Review
DE Lipid phosphate phosphatase 3; Lysophosphatidic acid;
   Sphingosine-1-phosphate; Genome-wide association studies; Coronary
   artery disease; Embryonic cardiovascular development; Atherosclerosis
ID CORONARY-ARTERY-DISEASE; CONTAINING ENZYME CHLOROPEROXIDASE; FUNGUS
   CURVULARIA-INAEQUALIS; ENDOTHELIAL BARRIER FUNCTION; PROTEIN-COUPLED
   RECEPTOR; GENOME-WIDE ASSOCIATION; SPHINGOSINE 1-PHOSPHATE;
   LYSOPHOSPHATIDIC ACID; CELL-MIGRATION; SPHINGOSINE-1-PHOSPHATE RECEPTOR
AB LPP3 is an integral membrane protein belonging to a family of enzymes (LPPs) that display broad substrate specificity and catalyse dephosphorylation of several lipid substrates, including lysophosphatidic acid and sphingosine-1-phosphate.
   In mammals, the LPP family consists of three enzymes named LPP1, LPP2 and LPP3, which are encoded by three independent genes, PLPP1, PLPP2 and PLPP3, respectively (formerly known as PPAP2A, PPAP2C, PPAP2B). These three enzymes, in vitro, do not seem to differ for catalytic activities and substrate preferences. However, in vivo targeted inactivation of the individual genes has indicated that the enzymes do not have overlapping functions and that LPP3, specifically, plays a crucial role in vascular development.
   In 2011, two genome-wide association studies have identified PLPP3 as a novel locus associated with coronary artery disease susceptibility. Shortly after these reports, tissue specific inactivation of PLPP3 in mice highlighted a specific role for LPP3 in vascular pathophysiology and, more recently, in atherosclerosis development.
   This review is aimed at providing an updated overview on the function of LPP3 in embryonic cardiovascular development and on the experimental and clinical evidences relating this enzyme to vascular cell functions and cardiovascular disease. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Busnelli, Marco; Manzini, Stefano; Parolini, Cinzia; Chiesa, Giulia] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy.
   [Escalante-Alcalde, Diana] Univ Nacl Autonoma Mexico, Div Neurociencias, Inst Fisiol Celular, Cdmx 04510, DF, Mexico.
RP Chiesa, G (reprint author), Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy.; Busnelli, M (reprint author), Dept Pharmacol & Biomol Sci, Via Balzaretti 9, I-20133 Milan, Italy.
EM marco.busnelli@unimi.it; giulia.chiesa@unimi.it
FU European CommunityEuropean Community (EC) [201668, 305739]; Fondazione
   CariploFondazione Cariplo [2011-0645]
FX This work was funded by the European Community's Seventh Framework
   Programme (FP7/2007-2013) AtheroRemo, grant no. 201668, the European
   Community's Seventh Framework Programme (FP7/2012-2017) RiskyCAD, grant
   no. 305739 and by Fondazione Cariplo (2011-0645).
NR 132
TC 1
Z9 1
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 156
EP 165
DI 10.1016/j.atherosclerosis.2018.02.025
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400020
PM 29518748
DA 2019-10-28
ER

PT J
AU Al-Sharea, A
   Murphy, AJ
   Huggins, LA
   Hu, Y
   Goldberg, IJ
   Nagareddy, PR
AF Al-Sharea, Annas
   Murphy, Andrew J.
   Huggins, L. A.
   Hu, Y.
   Goldberg, Ira J.
   Nagareddy, Prabhakara R.
TI SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein
   clearance in Ldlr(-/-) type 1 diabetic mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Hyperglycemia; Atherosclerosis; Myelopoiesis; Dyslipidemia;
   Strepzotocin; Lipoproteins
ID HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-DEFICIENT MICE; E-NULL MICE;
   CARDIOVASCULAR-DISEASE; TRANSGENIC MICE; KNOCKOUT MICE; CHOLESTEROL;
   LIVER; ACID; OVEREXPRESSION
AB Background and aims: Leukocytosis, particularly monocytosis, has been shown to promote atherosclerosis in both diabetic and non-diabetic mouse models. We previously showed that hyperglycemia independently promotes monocytosis and impairs the resolution of atherosclerosis. Since patients with chronic diabetes often develop dyslipidemia and also have increased risk for atherosclerosis, we sought to examine how controlling blood glucose affects atherosclerosis development in the presence of severe hyperlipidemia.
   Methods: Diabetes was induced using streptozotocin (STZ) in low density lipoprotein receptor (Ldlr) knockout (Ldlr(-/-)) mice after which they were fed a high-cholesterol diet for 4 weeks. Control and diabetic mice were treated with vehicle or sodium glucose cotransporter inhibitor (SGLT2i, Phlorizin or Dapagliflozin) for the duration of the diet.
   Results: Induction of diabetes resulted in a dramatic increase in plasma cholesterol (TC) and triglyceride (TG) levels. These mice also exhibited an increased number of circulating monocytes and neutrophils. Monocytosis was driven by increased proliferation of progenitor cells in the bone marrow. Tighter glycemic control by SGLT2i treatment not only reduced monocytosis and atherosclerosis but also improved plasma lipoprotein profile. Interestingly, improved lipoprotein profile was not due to decreased TG synthesis or clearance via low density lipoprotein receptor-related protein (Lrp) 1 or scavenger receptor class B member (Scarb1) pathways, but likely mediated by heparin sulfate proteoglycans (HSPG)dependent clearance mechanisms in the liver. Further examination of the liver revealed an important role for bile acid transporters (Abcg5, Abcg8) and cytochrome P450 enzymes in the clearance of hepatic cholesterol.
   Conclusions: These data suggest that tighter glycemic control in diabetes can improve lipoprotein clearance exclusive of Ldlr, likely via HSPG and bile acid pathways, and has an overall net positive effect on atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Murphy, Andrew J.; Huggins, L. A.; Hu, Y.; Goldberg, Ira J.; Nagareddy, Prabhakara R.] Columbia Univ, Dept Med, Div Prevent Med & Nutr, New York, NY USA.
   [Al-Sharea, Annas; Murphy, Andrew J.] Baker Heart & Diabet Inst, Melbourne, Vic, Australia.
   [Huggins, L. A.; Hu, Y.; Goldberg, Ira J.] NYU, Dept Med, 550 1St Ave, New York, NY 10016 USA.
   [Nagareddy, Prabhakara R.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
RP Nagareddy, PR (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
EM pnreddy@uab.edu
RI Nagareddy, Prabhakara R/J-3225-2019
OI Nagareddy, Prabhakara R/0000-0002-0294-641X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HL122505, HL137799, DK095684];
   NHMRCNational Health and Medical Research Council of Australia
   [APP1106154, APP1085752]; National Heart FoundationNational Heart
   Foundation of Australia [100440]
FX PRN is supported by grants from the NIH (HL122505, HL137799) and IJG
   (DK095684). A.J.M is supported by a NHMRC grant (APP1106154), a Career
   Development Fellowship from the NHMRC (APP1085752) and a Future Leader
   Fellowship from the National Heart Foundation (100440).
NR 45
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 166
EP 176
DI 10.1016/j.atherosclerosis.2018.02.028
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400021
PM 29518749
DA 2019-10-28
ER

PT J
AU Jiang, H
   Xin, SJ
   Yan, YM
   Lun, Y
   Yang, X
   Zhang, J
AF Jiang, Han
   Xin, Shijie
   Yan, Yumeng
   Lun, Yu
   Yang, Xiao
   Zhang, Jian
TI Abnormal acetylation of FOXP3 regulated by SIRT-1 induces Treg
   functional deficiency in patients with abdominal aortic aneurysms
SO ATHEROSCLEROSIS
LA English
DT Article
DE Abdominal aortic aneurysm; Treg; FOXP3 acetylation; SITT1
ID T-CELLS; HISTONE DEACETYLASES; PROTEIN; MICE; AUTOIMMUNITY;
   PATHOGENESIS; INFLAMMATION; RESPONSES; SIRTUINS; SURVIVAL
AB Background and aims: Acetylation levels of FOXP3 could influence its expression level and SIRT1 is a deacetylase, which could regulate the acetylation level of FOXP3. We aimed to investigate the mechanism of Treg dysfunction, which might be caused by abnormal acetylation of FOXP3 regulated by SIRT1 in abdominal aortic aneurysm (AAA) patients.
   Methods: Peripheral CD4(+) T cells from AAA patients, abdominal aortic atherosclerotic occlusive disease (AOD) patients, and healthy donors (HC) were analyzed by flow cytometry to determine the percentage of CD4(+)CD25(+) Tregs and CD4(+)CD25(+)FOXP3(+) T cells in CD4(+) T cells. Expression of FOXP3 and SIRT1 was analyzed byWestern Blot. Cultured CD4(+) T cells were treated with SIRT1 specific inhibitor EX-527 or left untreated. Acetylation expression of FOXP3 in CD4(+) T cells was analyzed by immunoprecipitation and Western Blot. The suppressive function of Treg was analyzed by CFSE-assay.
   Results: AAA patients had significantly lower CD4(+)CD25(+)FOXP3(+) T cells. Western blot results showed that AAA CD4(+) T cells had significantly less FOXP3 expression but significantly higher SIRT1 expression. After EX-527 treatment, CD4(+)CD25(+)FOXP3(+) T cells and FOXP3 expression in the AAA group were significantly increased. FOXP3 acetylation level in the AAA group was lower than in control groups. After EX-527 treatment, it was significantly increased. AAA Tregs exhibited less suppressive activity, EX-527 treatment significantly increased the suppressive activity of AAA Tregs.
   Conclusions: Our data demonstrate that reduced FOXP3 expression and Treg function in AAA patients are regulated by SIRT1-induced FOXP3 deacetylation. EX-527 could up-regulate FOXP3 acetylation and increase number and suppressive function of Treg in AAA patients. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Jiang, Han; Xin, Shijie; Lun, Yu; Yang, Xiao; Zhang, Jian] China Med Univ, Hosp 1, Dept Vasc Surg, Nanjing Bei Str 155, Shenyang 110001, Liaoning, Peoples R China.
   [Yan, Yumeng] China Med Univ, Shengjing Hosp, Dept Clin Nutr, Sanhao Str 36, Shenyang 110004, Liaoning, Peoples R China.
RP Zhang, J (reprint author), China Med Univ, Hosp 1, Dept Vasc Surg, Nanjing Bei Str 155, Shenyang 110001, Liaoning, Peoples R China.
EM jianzhang@cmu.edu.cn
OI Xin, Shijie/0000-0001-6278-8794
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [304717076]; Ministry of Education of ChinaMinistry
   of Education, China [208028]; Natural Science Foundation of Liaoning
   Province, ChinaNatural Science Foundation of Liaoning Province
   [2014021028]
FX This work was supported by the National Nature Science Foundation of
   China (grant 304717076) and the Ministry of Education of China (Key
   Research Project of Science and Technology; grant 208028) and Natural
   Science Foundation of Liaoning Province, China (grant 2014021028).
NR 40
TC 1
Z9 1
U1 1
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 182
EP 192
DI 10.1016/j.atherosclerosis.2018.02.001
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400023
PM 29524861
DA 2019-10-28
ER

PT J
AU Damen, MSMA
   dos Santos, JC
   Hermsen, R
   van der Vliet, JA
   Netea, MG
   Riksen, NP
   Dinarello, CA
   Joosten, LAB
   Heinhuis, B
AF Damen, Michelle S. M. A.
   dos Santos, Jessica Cristina
   Hermsen, Rob
   van der Vliet, J. Adam
   Netea, Mihai G.
   Riksen, Niels P.
   Dinarello, Charles A.
   Joosten, Leo A. B.
   Heinhuis, Bas
TI Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting
   in reduced intracellular lipid concentrations in primary human
   hepatocytes
SO ATHEROSCLEROSIS
LA English
DT Article
DE Interleukin-(IL-) 32; Cardiovascular disease (CVD); HDL cholesterol;
   Liver; Atherosclerosis; Receptors/lipoprotein
ID HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; CARDIOVASCULAR-DISEASE;
   CHOLESTEROL EFFLUX; HDL-CHOLESTEROL; HEART-DISEASE; TRANSPORTER;
   RECEPTOR; INFLAMMATION; IL-32
AB Background and aims: The role of interleukin (IL-) 32 in inflammatory conditions is well-established, however, the mechanism behind its role in atherosclerosis remains unexplained. Our group reported a promoter single nucleotide polymorphism in IL-32 associated with higher high-density lipoprotein (HDL) concentrations. We hypothesize that endogenous IL-32 in liver cells, a human monocytic cell line and carotid plaque tissue, can affect atherosclerosis by regulating (HDL) cholesterol homeostasis via expression of cholesterol transporters/mediators.
   Methods: Human primary liver cells were stimulated with recombinant human (rh) TNF alpha and poly I:C to study the expression of IL-32 and mediators in cholesterol pathways. Additionally, IL-32 was overexpressed in HepG2 cells and overexpressed and silenced in THP-1 cells to study the direct effect of IL-32 on cholesterol transporters expression and function.
   Results: Stimulation of human primary liver cells resulted in induction of IL-32 alpha, IL-32 beta and IL-32 gamma mRNA expression (p < 0.01). A strong correlation between the expression of IL-32 gamma and ABCA1, ABCG1, LXR alpha and apoA1 was observed (p < 0.01), and intracellular lipid concentrations were reduced in the presence of endogenous IL-32 (p < 0.05). Finally, IL32 gamma and ABCA1 mRNA expression was upregulated in carotid plaque tissue and when IL-32 was silenced in THP-1 cells, mRNA expression of ABCA1 was strongly reduced.
   Conclusions: Regulation of IL-32 in human primary liver cells, HepG2 and THP-1 cells strongly influences the mRNA expression of ABCA1, ABCG1, LXR alpha and apoA1 and affects intracellular lipid concentrations in the presence of endogenous IL-32. These data, for the first time, show an important role for IL32 in cholesterol homeostasis. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Damen, Michelle S. M. A.; dos Santos, Jessica Cristina; Netea, Mihai G.; Riksen, Niels P.; Dinarello, Charles A.; Joosten, Leo A. B.; Heinhuis, Bas] Dept Internal Med, Nijmegen, Netherlands.
   [Damen, Michelle S. M. A.; dos Santos, Jessica Cristina; Netea, Mihai G.; Riksen, Niels P.; Dinarello, Charles A.; Joosten, Leo A. B.; Heinhuis, Bas] Radboud Ctr Infect Dis RCI, Nijmegen, Netherlands.
   [dos Santos, Jessica Cristina] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Hermsen, Rob] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands.
   [van der Vliet, J. Adam] Radboud Univ Nijmegen, Med Ctr, Dept Surg, Div Vasc & Transplant Surg, Nijmegen, Netherlands.
   [Dinarello, Charles A.] Univ Colorado Denver, Div Infect Dis, Sch Med, Aurora, CO 80045 USA.
RP Joosten, LAB (reprint author), Univ Nijmegen, Med Ctr, Dept Internal Med 463, Geert Grootepl 8, NL-6525 GA Nijmegen, Netherlands.
EM leo.joosten@radboudumc.nl
RI Riksen, Niels P/G-8260-2015; Dinarello, Charles/C-8524-2013; Damen,
   Michelle/D-9686-2016
OI Riksen, Niels P/0000-0001-9197-8124; dos Santos, Jessica
   Cristina/0000-0001-9191-7356
FU Dutch Foundation for Rheumatism [13-03-302]; Nijmegen Institute for
   Infection, Inflammation and Immunity (N4i), the Netherlands
FX This research was supported by grants from the Dutch Foundation for
   Rheumatism (Nr.13-03-302) and the Nijmegen Institute for Infection,
   Inflammation and Immunity (N4i), the Netherlands.
NR 51
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 193
EP 202
DI 10.1016/j.atherosclerosis.2018.02.027
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400024
PM 29524862
OA Green Published, Other Gold
DA 2019-10-28
ER

PT J
AU Kasselman, LJ
   Vernice, NA
   DeLeon, J
   Reiss, AB
AF Kasselman, Lora J.
   Vernice, Nicholas A.
   DeLeon, Joshua
   Reiss, Allison B.
TI The gut microbiome and elevated cardiovascular risk in obesity and
   autoimmunity
SO ATHEROSCLEROSIS
LA English
DT Review
DE Microbiota; Atherosclerosis; Inflammation; Short-chain fatty acids;
   Obesity; Type 1 diabetes mellitus; Rheumatoid arthritis; Systemic lupus
   erythematosus
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; AMERICAN-HEART-ASSOCIATION; C-REACTIVE
   PROTEIN; RHEUMATOID-ARTHRITIS; WEIGHT-LOSS; INTESTINAL MICROBIOTA;
   INFLAMMATORY ARTHRITIS; SCIENTIFIC STATEMENT; HELICOBACTER-PYLORI;
   INSULIN SENSITIVITY
AB Cardiovascular disease associated with obesity and autoimmunity is the leading cause of death in these populations and significant residual risk remains despite current treatment approaches. Obesity, type 1 diabetes mellitus (T1DM), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) are linked to chronic inflammation, and subjects with these disorders have characteristic shifts in their gut microbiome composition. Recent data suggest that alterations in gut microbial and metabolic composition may be responsible, in part, for induction of chronic inflammation, thus promoting cardiovascular disease. Common microbiome changes observed in obesity, T1DM, RA, and SLE include a decrease in the ratio of bacteria, such as Gram-positive Firmicutes to Gram-negative Bacteroidetes, as well as an overabundance or depletion of certain species, including Prevotella copri. The consequent effects of these shifts include alterations in the metabolic composition of the gut, hyper-activation of toll-like receptor 4 (TLR-4), upregulation of inflammatory pathways, e.g. c-Jun N-terminal kinase and nuclear factor-kappa B (NF kappa B), increased intestinal permeability, increased C-reactive protein, and increased levels of trimethylamine N-oxide (TMAO). Differential microbiome compositions may also explain sex differences observed in autoimmunity, where a male gut microbiome promotes anti-inflammatory processes as compared to a female pro-inflammatory gut microbiome. Intervention at the level of the microbiota appears to attenuate symptoms in these inflammatory syndromes with probiotic treatment, such as Lactobacilli, playing a uniquely beneficial role in restoring intestinal health, decreasing inflammation, and reducing cardiovascular disease. This review will discuss obesity, T1DM, RA, and SLE in the context of how each unique microbiome profile contributes to elevated cardiovascular risk. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Kasselman, Lora J.] NYU, Winthrop Hosp, Winthrop Res Inst, 101 Mineola Blvd, Mineola, NY 11501 USA.
   NYU, Winthrop Hosp, Dept Med, Mineola, NY USA.
RP Kasselman, LJ (reprint author), NYU, Winthrop Hosp, Winthrop Res Inst, 101 Mineola Blvd, Mineola, NY 11501 USA.
EM lkasselman@nyuwinthrop.org
FU American Heart AssociationAmerican Heart Association [16GRNT26430041];
   Elizabeth Daniell Research Fund
FX This work was supported by the American Heart Association under grant
   number 16GRNT26430041 and by The Elizabeth Daniell Research Fund. We
   thank Janet and Robert Buescher for their generous support.
NR 119
TC 25
Z9 28
U1 11
U2 64
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 203
EP 213
DI 10.1016/j.atherosclerosis.2018.02.036
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400025
PM 29524863
HC Y
HP N
DA 2019-10-28
ER

PT J
AU Lo Gullo, A
   Rodriguez-Carrio, J
   Aragona, CO
   Dattilo, G
   Zito, C
   Suarez, A
   Loddo, S
   Atteritano, M
   Saitta, A
   Mandraffino, G
AF Lo Gullo, Alberto
   Rodriguez-Carrio, Javier
   Aragona, Caterina Oriana
   Dattilo, Giuseppe
   Zito, Concetta
   Suarez, Ana
   Loddo, Saverio
   Atteritano, Marco
   Saitta, Antonino
   Mandraffino, Giuseppe
TI Subclinical impairment of myocardial and endothelial functionality in
   very early psoriatic and rheumatoid arthritis patients: Association with
   vitamin D and inflammation
SO ATHEROSCLEROSIS
LA English
DT Article
DE Rheumatoid arthritis; Inflammatory joint diseases; Speckle-tracking
   echocardiography; Vitamin D
ID CORONARY-ARTERY-DISEASE; GLOBAL LONGITUDINAL STRAIN; LEFT-VENTRICULAR
   FUNCTION; CARDIOVASCULAR RISK; CLASSIFICATION CRITERIA; SYSTOLIC
   FUNCTION; PROGENITOR CELLS; DEFORMATION; INTERLEUKIN-1; IMPROVES
AB Background and aims: Cardiovascular (CV) morbidity is increased in inflammatory joint diseases (IJD), as rheumatoid (RA) and psoriatic arthritis (PsA). Whereas increased prevalence of subclinical atherosclerosis has been reported in these conditions, whether an early myocardial functionality is also impaired remains unknown. The aim of this study was to evaluate the myocardial functionality by speckle-tracking echocardiography (STE) in recent onset RA and PsA patients and its potential associations with the levels of circulating CD34(+) cells, vitamin D, and with disease activity.
   Methods: STE was used to assess the myocardial functionality in patients with very early RA (n = 41) and PsA (n = 35) without traditional CV risk factors, and 58 matched healthy controls (HC). Global longitudinal and circumferential strain (GLS and GCS) was estimated. Pulse wave velocity (PWV) and carotid intima-media thickness (cIMT) were measured as surrogate markers of atherosclerosis. Circulating CD34(+) counts were evaluated by flow cytometry and vitamin D levels were quantified by HPLC. Disease activity was assessed by Disease Activity Score-28 (DAS28).
   Results: RA patients exhibited impaired GLS and GCS (both p < 0.001) as compared to HC, GLS being also altered in PsA (p = 0.020 vs. HC). DAS28 was correlated to GLS (r = 0.908, p < 0.001) and GCS (r = 0.868, p < 0.001) in RA, these findings being confirmed by multivariate regression analyses adjusted for confounders and Principal Component Analyses. GLS and GCS were impaired in PsA patients with high disease activity as compared to HC, and GLS was found to be a predictor of cIMT in this condition. On the other hand, vitamin D was negatively associated with cIMT in HC (r = -0.308, p = 0.026) but not in PsA or RA, although decreased levels were observed (both p < 0.001). Vitamin D was an independent predictor of decreased CD34(+) levels in PsA and RA. CD34(+) counts negatively correlated DAS28, GLS and GCS in RA.
   Conclusions: Subclinical myocardial dysfunction is observed in IJD patients with preserved left-ventricular function and without traditional CV risk factors. Subclinical myocardial dysfunction was found to be a very early event in IJD. Disease activity was the main predictor of myocardial strain impairment. Interestingly, myocardial function was altered and associated with cIMT also in PsA patients with high disease activity. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lo Gullo, Alberto; Aragona, Caterina Oriana; Dattilo, Giuseppe; Zito, Concetta; Loddo, Saverio; Atteritano, Marco; Saitta, Antonino; Mandraffino, Giuseppe] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
   [Rodriguez-Carrio, Javier; Suarez, Ana] Univ Oviedo, Fac Med, Dept Funct Biol, Area Immunol, Campus El Cristo,C Julian Claveria S-N,L-19, E-33006 Oviedo, Spain.
   [Rodriguez-Carrio, Javier; Suarez, Ana] Inst Invest Sanitaria Principado Asturias ISPA, Oviedo, Spain.
   [Rodriguez-Carrio, Javier] Hosp Univ Cent Asturias, REDinREN ISCIII, Inst Reina Sofia Invest Nefrol, Bone & Mineral Res Unit, Oviedo, Spain.
RP Rodriguez-Carrio, J (reprint author), Univ Oviedo, Fac Med, Dept Funct Biol, Area Immunol, Campus El Cristo,C Julian Claveria S-N,L-19, E-33006 Oviedo, Spain.
EM rodriguezcjavier@uniovi.es
RI Suarez, Ana/F-4492-2015; Mandraffino, Giuseppe/J-1242-2019; Mandraffino,
   Giuseppe/K-4346-2018; Gullo, Alberto Lo/AAC-2766-2019; Loddo,
   Saverio/I-7397-2012
OI Suarez, Ana/0000-0002-4452-7539; Mandraffino,
   Giuseppe/0000-0003-0272-2237; Mandraffino, Giuseppe/0000-0003-0272-2237;
   Loddo, Saverio/0000-0002-3338-9599; Rodriguez-Carrio,
   Javier/0000-0002-0011-5102; Lo Gullo, Alberto/0000-0003-4383-0314
FU "Instituto de Salud Carlos III" (ISCIII, Spain)Instituto de Salud Carlos
   III [PI16/00113]; MINECO, Spain [FJCI-2015-23849]
FX J.R.-C. and A.S. are supported by the "Instituto de Salud Carlos III"
   (grant PI16/00113; ISCIII, Spain), and J.R.-C. is recipient of a
   fellowship from the "Juan de la Cierva" program (FJCI-2015-23849;
   MINECO, Spain).
NR 56
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 214
EP 222
DI 10.1016/j.atherosclerosis.2018.03.004
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400026
PM 29524864
DA 2019-10-28
ER

PT J
AU Bellasi, A
   Di Lullo, L
   Di Iorio, B
AF Bellasi, Antonio
   Di Lullo, Luca
   Di Iorio, Biagio
TI Vascular inflammation: A call for a specific and sensitive biomarker?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE suPAR; Inflammation; Outcome; CV risk; CRP
ID RANDOMIZED CLINICAL-TRIAL; CORONARY-ARTERY CALCIUM;
   MYOCARDIAL-INFARCTION; GENERAL-POPULATION; DISEASE; PREDICTION;
   MORTALITY; EVENTS; SUPAR; RISK
C1 [Bellasi, Antonio] ASST Lariana, St Anna Hosp, Dept Nephrol & Dialysis, Como, Italy.
   [Di Lullo, Luca] Osped Parodi, Dept Nephrol & Dialysis, Rome, Italy.
   [Di Iorio, Biagio] PO A Landolfi, Dept Nephrol & Dialysis, Solofra, AV, Italy.
RP Bellasi, A (reprint author), St Anna Hosp, ASST Lariana, Via Ravona 20, I-22020 San Fermo Della Battagli, CO, Italy.
EM antoniobellasi@gmail.com
RI bellasi, antonio/M-3744-2013
OI bellasi, antonio/0000-0001-7830-1645
NR 18
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD APR
PY 2018
VL 271
BP 235
EP 236
DI 10.1016/j.atherosclerosis.2018.02.018
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA GA1PX
UT WOS:000428090400029
PM 29463388
DA 2019-10-28
ER

PT J
AU Nam, P
   Choi, BG
   Choi, SY
   Byun, JK
   Mashaly, A
   Park, Y
   Jang, WY
   Kim, W
   Choi, JY
   Park, EJ
   Na, JO
   Choi, CU
   Lim, HE
   Kim, EJ
   Park, CG
   Seo, HS
   Oh, DJ
   Rha, SW
AF Nam, Purumeh
   Choi, Byoung Geol
   Choi, Se Yeon
   Byun, Jae Kyeong
   Mashaly, Ahmed
   Park, Yoonjee
   Jang, Won Young
   Kim, Woohyeun
   Choi, Jah Yeon
   Park, Eun Jin
   Na, Jin Oh
   Choi, Cheol Ung
   Lim, Hong Euy
   Kim, Eung Ju
   Park, Chang Gyu
   Seo, Hong Seog
   Oh, Dong Joo
   Rha, Seung-Woon
TI The impact of myocardial bridge on coronary artery spasm and long-term
   clinical outcomes in patients without significant atherosclerotic
   stenosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Myocardial bridge; Coronary artery spasm; Acetylcholine
ID 3-YEAR FOLLOW-UP; ENDOTHELIAL DYSFUNCTION; INFARCTION; ANGINA
AB Background and aims: Myocardial bridge (MB) and coronary artery spasm (CAS) can induce a sustained chest pain, acute coronary syndrome (ACS) and even sudden cardiac death. The aim of this study is to evaluate the relationship between MB and CAS and its impact on long-term clinical outcomes.
   Methods: A total of 812 patients with MB without significant coronary artery disease (CAD), who underwent acetylcholine (ACH) provocation test, were enrolled. Significant CAS was defined as >= 70% temporary narrowing by ACH test, and MB was defined as the characteristic phasic systolic compression of the coronary artery with a decrease of more than 30% in diameter on the angiogram after intracoronary nitroglycerin infusion. To adjust baseline confounders, logistic regression analysis was performed. The primary endpoint was incidence of CAS, and secondary endpoints were major adverse cardiac events (MACE) and recurrent angina requiring repeat coronary angiography (CAG) at 5 years.
   Results: MB is closely implicated in a high incidence of CAS, spontaneous spasm, ischemic ECG change and chest pain during ACH provocation test. In addition, MB of various severity and reference vessel size was substantially implicated in CAS incidence, and severe MB was a strong risk factor of CAS. MB patients with CAS were shown to have a higher rate of recurrent angina compared with MB patients without CAS, up to a 5-year follow-up. However, there were no differences regarding the incidence of MACE.
   Conclusions: Severe MB was associated with high incidence of CAS, and MB patients with CAS were likely to have a higher incidence of recurrent angina. Intensive medical therapy and close clinical follow-up are needed for better clinical outcomes in MB patients with CAS. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Nam, Purumeh] Korea Univ, Coll Med, Dept Med, Seoul, South Korea.
   [Choi, Byoung Geol; Choi, Se Yeon; Byun, Jae Kyeong] Korea Univ, Grad Sch, Dept Med, Seoul, South Korea.
   [Mashaly, Ahmed; Park, Yoonjee; Jang, Won Young; Kim, Woohyeun; Choi, Jah Yeon; Park, Eun Jin; Na, Jin Oh; Choi, Cheol Ung; Lim, Hong Euy; Kim, Eung Ju; Park, Chang Gyu; Seo, Hong Seog; Oh, Dong Joo; Rha, Seung-Woon] Korea Univ, Guro Hosp, Cardiovasc Ctr, 148 Gurodong Ro, Seoul 08308, South Korea.
RP Rha, SW (reprint author), Korea Univ, Guro Hosp, Cardiovasc Ctr, 148 Gurodong Ro, Seoul 08308, South Korea.
EM swrha617@korea.ac.kr
OI Choi, Byoung Geol/0000-0002-6090-869X
NR 25
TC 5
Z9 5
U1 2
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 8
EP 12
DI 10.1016/j.atherosclerosis.2018.01.026
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800002
PM 29407892
DA 2019-10-28
ER

PT J
AU Bozic, M
   Mendez-Barbero, N
   Gutierrez-Munoz, C
   Betriu, A
   Egido, J
   Fernandez, E
   Martin-Ventura, JL
   Valdivielso, JM
   Blanco-Colio, LM
AF Bozic, Milica
   Mendez-Barbero, Nerea
   Gutierrez-Munoz, Carmen
   Betriu, Angels
   Egido, Jesus
   Fernandez, Elvira
   Martin-Ventura, Jose L.
   Valdivielso, Jose M.
   Blanco-Colio, Luis M.
CA Investigators NEFRONA study
TI Combination of biomarkers of vascular calcification and sTWEAK to
   predict cardiovascular events in chronic kidney disease
SO ATHEROSCLEROSIS
LA English
DT Article
DE CKD; Cardiovascular outcomes; Osteoprotegerin; Osteopontin; TWEAK
ID ELEVATED OSTEOPROTEGERIN; OSTEOPONTIN; ATHEROSCLEROSIS; DIFFERENTIATION;
   DEFICIENT; TWEAK; MORTALITY; MARKER; CELLS; RISK
AB Background and aims: Vascular calcification (VC) and atherosclerosis are associated with an increased cardiovascular morbimortality in chronic kidney disease (CKD). Osteoprotegerin (OPG) and osteopontin (OPN) are involved in both VC and CKD. Soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) has been related to cardiovascular disease. We hypothesized that OPG, OPN and sTWEAK levels may be associated with a higher prevalence of cardiovascular outcomes in patients with CKD.
   Methods: The presence of calcified or non-calcified atherosclerotic plaques was assessed in 1043 stage 3 to 5D CKD patients from The NEFRONA Study. Biochemical measurements and OPG, OPN and sTWEAK serum levels were analyzed. Patients were followed for cardiovascular outcomes (41 +/- 16 months).
   Results: At recruitment, 26% of CKD patients had VC. The adjusted odds ratios for having VC were 2.22 (1.32-3.75); p =.003 for OPG, and 0.45 (0.24-0.84); p =.01 for sTWEAK concentrations. After follow-up, 95 CV events occurred. In a Cox model, patients with OPG or OPN above and sTWEAK below their optimal cut-off points had an adjusted higher risk of cardiovascular events [HR: 2.10 (1.49-3.90); p =.02; 1.65 (1.02-2.65); p =.04; 2.05 (1.28-3.29), p =.003; respectively]. When CKD patients were grouped according to the number of biomarkers above (OPG and OPN) or below (sTWEAK) their cut-off points, the combination of these biomarkers showed the highest risk for cardiovascular events [HR: 9.46 (3.80 -23.5) p <.001]. A composite score of these three biomarkers increased the C-statistic and net reclassification index beyond conventional risk factors and VC.
   Conclusions: The combination of OPG, OPN and sTWEAK increased the predictability of cardiovascular outcomes. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Bozic, Milica; Betriu, Angels; Fernandez, Elvira; Valdivielso, Jose M.] IRBLLEIDA, Vasc & Renal Translat Res Grp, Unit Detect & Treatment Atherothrombot Dis UDETMA, Lleida, Spain.
   [Bozic, Milica; Betriu, Angels; Fernandez, Elvira; Valdivielso, Jose M.] Spanish Network Renal Res RedInRen, Barcelona, Spain.
   [Mendez-Barbero, Nerea; Gutierrez-Munoz, Carmen; Egido, Jesus; Martin-Ventura, Jose L.; Blanco-Colio, Luis M.] Univ Autonoma Madrid, FIIS Fdn Jimenez Diaz, Vasc Res Lab, Madrid, Spain.
   [Egido, Jesus] Spanish Biomed Res Ctr Diabet & Associated Metab, Barcelona, Spain.
   [Martin-Ventura, Jose L.; Blanco-Colio, Luis M.] Spanish Biomed Res Ctr Cardiovasc Dis CIBERCV, Barcelona, Spain.
RP Valdivielso, JM (reprint author), IRBLLEIDA, Vasc & Renal Translat Res Grp, Unit Detect & Treatment Atherothrombot Dis UDETMA, Lleida, Spain.; Blanco-Colio, LM (reprint author), FIIS Fdn Jimenez Diaz, Vasc Res Lab, Madrid, Spain.
EM valdivielso@medicina.udl.cat; lblanco@fjd.es
RI MARTIN-VENTURA, JOSE LUIS/Z-2386-2019; Valdivielso, Jose M/B-5673-2009;
   Blanco-Colio, Luis M./Z-2390-2019; Bozic, Milica/B-7425-2009
OI Valdivielso, Jose M/0000-0003-1343-0184; Bozic,
   Milica/0000-0002-6064-1446; MARTIN-VENTURA, JOSE
   LUIS/0000-0003-2090-8641; Blanco-Colio, Luis Miguel/0000-0002-1560-6609
FU Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos
   IIIInstituto de Salud Carlos III [PI13/00395, PI14/00386, PI14/00384,
   PI16/ 01419, PI16/01354, RD12/0042/0038, RD16/0009/0011]; Spanish
   Biomedical Research Centre in Cardiovascular Disease (CIBERCV);
   Fundacion Renal Inigo Alvarez de Toledo (FRIAT); AbbVieAbbott
   Laboratories
FX This work was supported by Fondo de Investigaciones Sanitarias,
   Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias
   ISCiii/FEDER PI13/00395, PI14/00386, PI14/00384, PI16/ 01419, PI16/01354
   and RETICS RD12/0042/0038, RD16/0009/0011), Spanish Biomedical Research
   Centre in Cardiovascular Disease (CIBERCV) and Fundacion Renal Inigo
   Alvarez de Toledo (FRIAT). The NEFRONA study was partially funded by a
   research grant from AbbVie.
NR 45
TC 4
Z9 4
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 13
EP 20
DI 10.1016/j.atherosclerosis.2018.01.011
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800003
PM 29407881
DA 2019-10-28
ER

PT J
AU Maracle, CX
   Agca, R
   Helder, B
   Meeuwsen, JAL
   Niessen, HWM
   Biessen, EAL
   de Winther, MPJ
   de Jager, SCA
   Nurmohamed, MT
   Tas, SW
AF Maracle, Chrissta X.
   Agca, Rabia
   Helder, Boy
   Meeuwsen, John A. L.
   Niessen, Hans W. M.
   Biessen, Erik A. L.
   de Winther, Menno P. J.
   de Jager, Saskia C. A.
   Nurmohamed, Mike T.
   Tas, Sander W.
TI Noncanonical NF-kappa B signaling in microvessels of atherosclerotic
   lesions is associated with inflammation, atheromatous plaque morphology
   and myocardial infarction
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Angiogenesis; Inflammation; Nuclear factor kappaB; Cell
   signaling
ID CORONARY-HEART-DISEASE; RHEUMATOID-ARTHRITIS; ENDOTHELIAL-CELLS;
   BOWEL-DISEASE; ANGIOGENESIS; NEOVASCULARIZATION; LIGHT; RISK; MICE; CD40
AB Background and aims: Neovascularization is associated with atherosclerotic plaque instability and increased chance of myocardial infarction (MI). Patients with chronic inflammatory diseases (CID) have increased risk of atherosclerosis, and evidence demonstrates that NF-kappa B inducing kinase (NIK)-mediated noncanonical NF-kappa B signaling in endothelial cells (EC) is linked to inflammation and angiogenesis. Here, we hypothesized NIK may also be activated in EC of atherosclerotic lesion microvessels.
   Methods: Using cohorts of atherosclerotic lesions from coronary and carotid arteries, we quantified NIK expression in plaque microvessels and compared it to pathological markers, including inflammatory cell content, plaque characteristics and MI. Differences in gene transcripts were evaluated between stable and ruptured lesions.
   Results: NIK+C were present in both coronary and carotid lesions. In CID patients, plaques with stenosis > 40% had an increased number of NIK+EC and higher content of immune cells (p < .05) as compared to controls. Immune cells per NIK+EC were also greater in CID patients (p < .05), with pronounced differences as stenosis increased. In unstable lesions, NIK+EC were elevated as were EC expressing CXCL12 (p < .05). NIK+EC were increased in lesions with lipid content > 40% (p < .05) and more abundant in coronary artery lesions implicated in MI (p < .05). These vessels also associated with atheromatous rather than fibrous plaque morphology (p < .05). Transcriptomic profiling demonstrated components of noncanonical NF-kappa B pathway were also upregulated in ruptured plaques (p < .05).
   Conclusions: NIK+EC associate with chronic inflammation in advanced lesions and are linked to markers of local inflammation, lipid content, unstable plaque phenotype and development of MI. Therefore, targeting noncanonical NF-kappa B signaling may hold therapeutic potential for patients with atherosclerosis and cardiovascular disease. (c) 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
C1 [Maracle, Chrissta X.; Helder, Boy; Tas, Sander W.] Univ Amsterdam, Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Maracle, Chrissta X.; Helder, Boy; Tas, Sander W.] Univ Amsterdam, Acad Med Ctr, Lab Expt Immunol, Amsterdam, Netherlands.
   [Agca, Rabia; Niessen, Hans W. M.; Nurmohamed, Mike T.] READE, Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands.
   [Agca, Rabia; Niessen, Hans W. M.; Nurmohamed, Mike T.] Vrije Univ Amsterdam, Amsterdam Rheumatol & Immunol Ctr, Med Ctr, Amsterdam, Netherlands.
   [Meeuwsen, John A. L.; de Jager, Saskia C. A.] Univ Utrecht, Med Ctr, Lab Expt Cardiol, Utrecht, Netherlands.
   [Biessen, Erik A. L.] Maastricht Univ, Med Ctr, Dept Expt Vasc Pathol, Maastricht, Netherlands.
   [de Winther, Menno P. J.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Amsterdam, Netherlands.
RP Tas, SW (reprint author), Univ Amsterdam, Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM s.w.tas@amc.uva.nl
RI Tas, Sander/I-7402-2016
OI Tas, Sander/0000-0002-8940-1788; Maracle, Chrissta/0000-0002-3142-184X
FU Clinical Fellowship (ZonMw) [90700359]; Dutch Arthritis Foundation
   [12-2-304]; Academic Medical Center/University of Amsterdam
FX This work was supported by a Clinical Fellowship (ZonMw; grant 90700359)
   and a Dutch Arthritis Foundation grant (12-2-304) to S.W. Tas. C.X.M.
   was supported by a research grant from the Academic Medical
   Center/University of Amsterdam.
NR 46
TC 9
Z9 9
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 33
EP 41
DI 10.1016/j.atherosclerosis.2018.01.032
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800006
PM 29407886
OA Other Gold
DA 2019-10-28
ER

PT J
AU Yao, L
   Folsom, AR
   Alonso, A
   Lutsey, PL
   Pankow, JS
   Guan, WH
   Cheng, S
   Lederle, FA
   Tang, WH
AF Yao, Lu
   Folsom, Aaron R.
   Alonso, Alvaro
   Lutsey, Pamela L.
   Pankow, James S.
   Guan, Weihua
   Cheng, Susan
   Lederle, Frank A.
   Tang, Weihong
TI Association of carotid atherosclerosis and stiffness with abdominal
   aortic aneurysm: The atherosclerosis risk in communities (ARIC) study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Abdominal aortic aneurysm; Carotid distensibility;
   Carotid plaque; Carotid intima-media thickness
ID ARTERIAL STIFFNESS; WALL THICKNESS; TASK-FORCE; BODY-SIZE; DIAMETER;
   DISEASE; MANIFESTATIONS; TROMSO; AGE
AB Background and aims: Individuals with atherosclerosis and stiffness often have increased abdominal aortic diameters, but prospective evidence linking them to the risk of abdominal aortic aneurysm (AAA) is limited.
   Methods: We prospectively examined the relationship of carotid atherosclerosis and stiffness with future risk of AAA in ARIC. At Visits 1 (1987-89) or 2 (1990-1992), we assessed carotid atherosclerosis (represented by greater carotid intima-media thickness [cIMT] or presence of atherosclerotic plaque) and lower carotid distensibility (reflected by a higher carotid Beta Index). We identified incident, clinical AAAs during follow-up through 2011 using hospital discharge codes, Medicare outpatient diagnoses, or death certificates.
   Results: Participants' mean age at baseline was 54.2 years (SD 5.8), 45% were male and 73% white. During a median of 22.5 years of follow-up, 542 clinical AAAs were ascertained. After multivariable adjustment, the presence of carotid atherosclerotic plaque at baseline was associated with 1.31 (95% CI: 1.10-1.57; p = 0.003) times higher risk of clinical AAA. Greater cIMT and Beta Index were also associated with clinical AAA with a dose-response across quartiles (p trend for both: 0.006; hazard ratios [95% CI] for the highest vs. lowest quartiles: 1.55 [1.13-2.11] and 1.68 [1.16-2.43], respectively). The associations of cIMT and Beta Index with AAA were independent of each other.
   Conclusions: This prospective population-based study found that indices of greater carotid atherosclerosis and lower carotid distensibility are markers of increased AAA risk. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Yao, Lu; Folsom, Aaron R.; Lutsey, Pamela L.; Pankow, James S.; Tang, Weihong] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
   [Alonso, Alvaro] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Guan, Weihua] Univ Minnesota, Div Biostat, Minneapolis, MN 55454 USA.
   [Cheng, Susan] Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.
   [Lederle, Frank A.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
RP Tang, WH (reprint author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.
EM tang0097@umn.edu
RI Alonso, Alvaro/A-4917-2010
OI Alonso, Alvaro/0000-0002-2225-8323; Pankow, James/0000-0001-7076-483X
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL103695];
   ARIC [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, HHSN268201100012C]
FX This research is financially supported by the National Heart, Lung, and
   Blood Institute (NHLBI) through grant R01 HL103695 and ARIC contracts
   HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, and HHSN268201100012C.
NR 42
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 110
EP 116
DI 10.1016/j.atherosclerosis.2018.01.044
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800015
PM 29407878
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Kim, EN
   Kim, MY
   Lim, JH
   Kim, Y
   Shin, SJ
   Park, CW
   Kim, YS
   Chang, YS
   Yoon, HE
   Choi, BS
AF Kim, Eun Nim
   Kim, Min Young
   Lim, Ji Hee
   Kim, Yaeni
   Shin, Seok Joon
   Park, Cheol Whee
   Kim, Yong-Soo
   Chang, Yoon Sik
   Yoon, Hye Eun
   Choi, Bum Soon
TI The protective effect of resveratrol on vascular aging by modulation of
   the renine-angiotensin system
SO ATHEROSCLEROSIS
LA English
DT Article
DE Aorta; Arterial aging; Inflammation; Oxidative stress;
   Renine-angiotensin system; Resveratrol
ID CARDIOVASCULAR-DISEASE ENTERPRISES; PREVENTS RENAL LIPOTOXICITY;
   PPAR-ALPHA; SUPEROXIDE-DISMUTASE; MAJOR SHAREHOLDERS; MOUSE MODEL;
   RECEPTOR; SIRT1; ACTIVATION; EXPRESSION
AB Background and aims: This study evaluated the effects of resveratrol on arterial aging and the renin-angiotensin system (RAS) in mice and vascular smooth muscle cells (VSMCs).
   Methods: Aging mice were divided into control and resveratrol groups. Histological changes, inflammation, oxidative stress, RAS components, and the expression of AMP-activated protein kinase (AMPK), silent information regulator T1 (SIRT1), peroxisome proliferator-activated receptor-gamma co-activator 1 alpha (PGC-1 alpha), and anti-oxidative enzymes was measured in thoracic aortas of 24-month-old mice. The effect of resveratrol on fibrosis, cell senescence, and RAS components was also investigated in VSMCs stimulated by angiotensin (Ang) II.
   Results: Aorta media thickness, inflammation, fibrosis, and oxidative stress were significantly lower in the resveratrol group than in the control group. Resveratrol treatment decreased serum Ang II level and the aortic expression of prorenin receptor (PRR) and angiotensin converting enzyme (ACE), and increased serum Ang-(1-7) level and the expression of ACE2, Ang II type 2 receptor (AT2R), and Mas receptor (MasR). Resveratrol increased the expression of phosphorylated AMPK, SIRT1, PGC-1 alpha, phosphorylated endothelial nitric oxide synthase and superoxide dismutase 1 and 2, and decreased that of NADPH oxidase 2 and 4. In Ang II-stimulated VSMCs, resveratrol treatment markedly decreased the number of senescence associated beta-galactosidase stained cells and pro-fibrotic protein expression and increased the expression of AT2R and MasR.
   Conclusions: Resveratrol protects against arterial aging and this effect is associated with reduced activity of the PRReACEeAng II axis and stimulation of the ACE2-Ang-(1-7)-ATR2-MasR axis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Kim, Eun Nim; Kim, Min Young; Lim, Ji Hee; Kim, Yaeni; Shin, Seok Joon; Park, Cheol Whee; Kim, Yong-Soo; Chang, Yoon Sik; Yoon, Hye Eun; Choi, Bum Soon] Catholic Univ Korea, Coll Med, Dept Internal Med, Div Nephrol, 222 Banpo Daero, Seoul 137701, South Korea.
   [Kim, Yaeni; Shin, Seok Joon; Yoon, Hye Eun] Incheon St Marys Hosp, Dept Internal Med, Incheon, South Korea.
   [Park, Cheol Whee; Kim, Yong-Soo; Choi, Bum Soon] Seoul St Marys Hosp, Dept Internal Med, Seoul, South Korea.
   [Chang, Yoon Sik] Yeouido St Marys Hosp, Dept Internal Med, Seoul, South Korea.
RP Choi, BS (reprint author), Catholic Univ Korea, Coll Med, Dept Internal Med, Div Nephrol, 222 Banpo Daero, Seoul 137701, South Korea.; Yoon, HE (reprint author), Catholic Univ Korea, Coll Med, Incheon St Marys Hosp, Div Nephrol,Dept Internal Med, 56 Dongsu Ro, Incheon 21431, South Korea.
EM berrynana@catholic.ac.kr; sooncb@catholic.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT and future Planning
   [2014R1A1A3A04050919]; Basic Science Research Program through the NRF;
   Ministry of Education, Science and TechnologyMinistry of Education,
   Science and Technology, Republic of Korea [NRF-2016R1D1A1A09919985]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT and future Planning (2014R1A1A3A04050919), and by the
   Basic Science Research Program through the NRF, funded by the Ministry
   of Education, Science and Technology (NRF-2016R1D1A1A09919985).
NR 52
TC 18
Z9 20
U1 2
U2 19
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 123
EP 131
DI 10.1016/j.atherosclerosis.2018.01.043
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800017
PM 29407880
DA 2019-10-28
ER

PT J
AU Pelczarska, A
   Jakubczyk, M
   Jakubiak-Lasocka, J
   Banach, M
   Mysliwiec, M
   Gruchala, M
   Niewada, M
AF Pelczarska, Aleksandra
   Jakubczyk, Michal
   Jakubiak-Lasocka, Joanna
   Banach, Maciej
   Mysliwiec, Malgorzata
   Gruchala, Marcin
   Niewada, Maciej
TI The cost-effectiveness of screening strategies for familial
   hypercholesterolaemia in Poland
SO ATHEROSCLEROSIS
LA English
DT Article
DE Familial hypercholesterolemia; Cost-effectiveness; Cost-utility;
   Screening; Genetic test; Cascade screening
ID CORONARY-HEART-DISEASE; STATIN-TREATED PATIENTS; CARDIOVASCULAR-DISEASE;
   MYOCARDIAL-INFARCTION; LIPID-LEVELS; MANAGEMENT; PREVALENCE; PROGRAM;
   DIAGNOSIS; CARE
AB Background and aims: Familial hypercholesterolaemia (FH) elevates the cholesterol level and increases the risk of coronary events and death. Early detection and treatment reduce this risk. We aimed to determine the cost-effectiveness of FH screening in Poland in children, first job takers, and after an acute coronary syndrome (ACS) event, each followed by a cascade screening in the relatives of the positivelydiagnosed subjects.
   Methods: A decision tree was constructed to model the diagnosis process. We considered scenarios with and without genetic testing. A life-time Markov was built to investigate the effectiveness (life years gained, LYG; and quality-adjusted life years, QALY) and cost (public payer perspective) of treatment in FH-affected subjects. The clinical benefits result from early treatment reducing the risk of coronary heart disease (and death, in result). Model parameters were based on published data and experts' opinions. The costs (patients visits, tests, drugs) were estimated from the National Health Fund data and other publicly-available sources.
   Results: Screening ACS patients below 55/65 years of age in men/women is the most cost-effective strategy: the cost of one LYG (QALY) amounts to 100 EUR (110 EUR). Removing the age limit or using genetic tests reduced cost-effectiveness; nonetheless, all strategies remained cost effective: the cost of one LYG or QALY was < 5040 EUR, much lower than the official threshold of ca. 29,800 EUR/QALY.
   Conclusions: Screening for FH is highly cost-effective in Poland. The strategies are complementary, and using a combination thereof is recommended. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Pelczarska, Aleksandra; Jakubiak-Lasocka, Joanna] HealthQuest, Warsaw, Poland.
   [Jakubczyk, Michal] SGH Warsaw Sch Econ, Decis Anal & Support Unit, Warsaw, Poland.
   [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Lodz, Poland.
   [Mysliwiec, Malgorzata] Med Univ Gdansk, Chair & Clin Paediat Diabetol & Endocrinol, Gdansk, Poland.
   [Gruchala, Marcin] Med Univ Gdansk, Dept Cardiol 1, Gdansk, Poland.
   [Niewada, Maciej] Med Univ Warsaw, Dept Clin & Expt Pharmacol, Warsaw, Poland.
RP Niewada, M (reprint author), Med Univ Warsaw, Dept Clin & Expt Pharmacol, Warsaw, Poland.
EM maciej.niewada@wum.edu.pl
RI Banach, Maciej/A-1271-2009; Gruchala, Marcin/S-8407-2018
OI Banach, Maciej/0000-0001-6690-6874; NIEWADA, MACIEJ/0000-0002-3730-1996;
   Gruchala, Marcin/0000-0003-4901-2291
NR 56
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 132
EP 138
DI 10.1016/j.atherosclerosis.2018.01.036
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800018
PM 29407882
DA 2019-10-28
ER

PT J
AU Tscharre, M
   Herman, R
   Rohla, M
   Hauser, C
   Farhan, S
   Freynhofer, MK
   Huber, K
   Weiss, TW
AF Tscharre, Maximilian
   Herman, Robert
   Rohla, Miklos
   Hauser, Christina
   Farhan, Serdar
   Freynhofer, Matthias K.
   Huber, Kurt
   Weiss, Thomas W.
TI Uric acid is associated with long-term adverse cardiovascular outcomes
   in patients with acute coronary syndrome undergoing percutaneous
   coronary intervention
SO ATHEROSCLEROSIS
LA English
DT Article
DE Uric acid; Hyperuricemia; Acute coronary syndrome; Percutaneous coronary
   intervention; Long-term adverse outcomes
ID LEFT-VENTRICULAR MASS; OXIDATIVE STRESS; ENDOTHELIAL DYSFUNCTION;
   NITRIC-OXIDE; CELL-PROLIFERATION; ALLOPURINOL; DISEASE; GOUT;
   PATHOGENESIS; PROGRESSION
AB Background and aims: Evidence links uric acid (UA) with the promotion of cardiovascular disease. We assessed the prognostic value of UA on long-term major adverse outcomes (MACE) in patients with acute coronary syndrome (ACS), undergoing percutaneous coronary intervention (PCI).
   Methods: As primary endpoint, we assessed the association of UA (continuous and dichotomized) with MACE, including cardiovascular death, myocardial infarction (MI) and stroke, using Cox regression and propensity matching. As secondary endpoints, the influence of hyperuricemia (defined as UA levels > 6.0 mg/dl in women, and >7.0 mg/dl in men) was analysed separately for cardiovascular death, MI, and stroke. The incremental prognostic value of UA was tested using the net reclassification improvement (NRI), and the integrated discrimination improvement (IDI).
   Results: We included 1215 patients. Hyperuricemia was present in 356 (29.3%) patients. Mean follow-up was 5.5 years. UA (HR 1.091 [1.035-1.150]; p = 0.001) and hyperuricemia (HR 1.750 [1.388-2.207]; p < 0.001) were significantly associated with MACE. Results were consistent between Cox regression and propensity matched analysis. Patients with hyperuricemia had a 1.6-fold increased relative risk for cardiovascular death (p = 0.005) and a 1.5-fold increased risk for MI (p = 0.032). For stroke, hyperuricemia only constituted a confounder (HR 1.104; p = 0.970). The prognostic accuracy of an established risk prediction model was significantly increased by adding UA (continuous NRI p = 0.004; categorical NRI p = 0.029; IDI p = 0.002).
   Conclusions: Our data suggest an independent association of elevated UA with long-term MACE in ACS patients undergoing PCI. Whether lowering UA might be beneficial remains to be elucidated in large clinical trials. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Tscharre, Maximilian; Herman, Robert; Rohla, Miklos; Hauser, Christina; Farhan, Serdar; Freynhofer, Matthias K.; Huber, Kurt; Weiss, Thomas W.] Wilhelminen Hosp, Med Dept 3, Cardiol & Intens Care Med, Montleartstr 37, A-1160 Vienna, Austria.
   [Huber, Kurt; Weiss, Thomas W.] Sigmund Freud Univ, Fac Med, Vienna, Austria.
RP Tscharre, M (reprint author), Wilhelminen Hosp, Med Dept 3, Cardiol & Intens Care Med, Montleartstr 37, A-1160 Vienna, Austria.
EM maximilian.tscharre@meduniwien.ac.at
OI Herman, Robert/0000-0002-8773-1732
FU Association for the Promotion of Research in Atherosclerosis; Thrombosis
   and Vascular Biology (ATVB); Ludwig Boltzmann Foundation for
   Cardiovascular Research, Vienna, Austria
FX This work was supported by the Association for the Promotion of Research
   in Atherosclerosis, Thrombosis and Vascular Biology (ATVB), and by the
   Ludwig Boltzmann Foundation for Cardiovascular Research, Vienna,
   Austria.
NR 49
TC 5
Z9 5
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 173
EP 179
DI 10.1016/j.atherosclerosis.2018.02.003
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800024
PM 29432935
DA 2019-10-28
ER

PT J
AU Mazidi, M
   Katsiki, N
   Mikhailidis, DP
   Banach, M
AF Mazidi, Mohsen
   Katsiki, Niki
   Mikhailidis, Dimitri P.
   Banach, Maciej
TI The link between insulin resistance parameters and serum uric acid is
   mediated by adiposity
SO ATHEROSCLEROSIS
LA English
DT Article
DE Inflammation; Glucose homeostasis; Insulin resistance; Adiposity; Serum
   uric acid
ID C-REACTIVE PROTEIN; IMPAIRED FASTING GLUCOSE; CORONARY-HEART-DISEASE;
   BONE-MINERAL DENSITY; METABOLIC SYNDROME; PLASMA-GLUCOSE; FOLLOW-UP; US
   ADULTS; RISK; HYPERURICEMIA
AB Background and aims: Conflicting results suggest a link between serum uric acid (SUA), inflammation and glucose/insulin homeostasis; however, the role of adiposity in this relationship is not clear. Therefore, we evaluated the role of different adiposity factors, including central body mass index (BMI), peripheral waist circumference (WC), and visceral adiposity [visceral adipose tissue (apVAT)], on the association between SUA, inflammation and glucose/insulin homeostasis among US adults.
   Methods: Data were extracted from the 2005-2010 US National Health and Nutrition Examination Surveys. Overall, 16,502 participants were included in the analysis (mean age = 47.1 years, 48.2% men). Analysis of co-variance and "conceptus causal mediation" models were applied, while accounting for survey design.
   Results: Corrected models showed that subjects with higher SUA levels have a less favorable profile of inflammation and glucose/insulin homeostasis parameters (all p < 0.001). We found that all our potential mediators (BMI, WC and apVAT) had an impact (to various extents) on the link between variables, including serum C-reactive protein (CRP), apolipoprotein-B (apoB), insulin resistance markers, 2-h blood glucose (2hG) and triglyceride, and fasting blood glucose (FBG) (TyG) index (all p < .001), while none of the potential mediators (BMI, apVAT, WC) had an impact on the link between FBG and glycated hemoglobin with SUA (all p > 0.05). We have found that all of our mediators partially mediated the link between inflammation and glucose/insulin homeostasis parameters and SUA. Of note, apVAT fully mediated the association between SUA and 2hG.
   Conclusions: By applying advanced statistical techniques, we shed light on the complex link of SUA with inflammation and glucose/insulin homeostasis and quantify the role of adiposity factors in that link. (c) 2017 Published by Elsevier Ireland Ltd.
C1 [Mazidi, Mohsen] Chinese Acad Sci, Inst Genet & Dev Biol, Key State Lab Mol Dev Biol, Beijing, Peoples R China.
   [Mazidi, Mohsen] Univ Chinese Acad Sci IC UCAS, Int Coll, Inst Genet & Dev Biol, West Beichen Rd, Chaoyang, Peoples R China.
   [Katsiki, Niki] Aristotle Univ Thessaloniki, Hippokrat Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece.
   [Mikhailidis, Dimitri P.] Univ Coll London UCL, Dept Clin Biochem, Univ Coll London Med Sch, Royal Free Campus, London, England.
   [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Chair Nephrol & Hypertens, Lodz, Poland.
   [Banach, Maciej] Polish Mothers Mem Hosp Res Inst PMMHRI, Lodz, Poland.
   [Banach, Maciej] Univ Zielona Gora, Cardiovasc Res Ctr, Zielona Gora, Poland.
RP Mazidi, M (reprint author), Chinese Acad Sci, Inst Genet & Dev Biol, Key State Lab Mol Dev Biol, Beijing, Peoples R China.
EM moshen@genetics.ac.cn
RI Banach, Maciej/A-1271-2009
OI Banach, Maciej/0000-0001-6690-6874
FU world academy of sciences studentship of the Chinese Academy of Sciences
FX MM was supported by the world academy of sciences studentship of the
   Chinese Academy of Sciences.
NR 60
TC 11
Z9 12
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 180
EP 186
DI 10.1016/j.atherosclerosis.2017.12.033
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800025
PM 29459295
DA 2019-10-28
ER

PT J
AU Stock, JK
AF Stock, Jane K.
TI The challenge of peripheral arterial disease: How do we improve outcome?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Peripheral arterial disease (PAD); Atherosclerotic cardiovascular
   disease (ASCVD); Multiple vascular beds; Antiplatelet agents; Statin;
   Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker;
   Cardiovascular; FOURIER; CHD; Hypertension; MI, stroke or cardiovascular
   death; MACE; Kaplan-Meier rate; LDL-C reduction; Stroke; Kaplan-Meier
   period; PCSK9 inhibitor
ID CARDIOVASCULAR EVENTS; RISK; PREVALENCE; MORTALITY
C1 [Stock, Jane K.] European Atherosclerosis Soc, World Trade Ctr Goteborg, Massans Gata 10, SE-40224 Gothenburg, Sweden.
RP Stock, JK (reprint author), European Atherosclerosis Soc, World Trade Ctr Goteborg, Massans Gata 10, SE-40224 Gothenburg, Sweden.
EM office@eas-society.org
NR 16
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 196
EP 198
DI 10.1016/j.atherosclerosis.2017.12.031
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800030
PM 29395100
DA 2019-10-28
ER

PT J
AU Wigren, M
   Svenugnsson, E
   Mattisson, IY
   Gustafsson, JT
   Gunnarsson, I
   Zickert, A
   Elvin, K
   Jensen-Urstad, K
   Bengtsson, A
   Gullstrand, B
   Fredrikson, GN
   Nilsson, J
AF Wigren, Maria
   Svenugnsson, Elisabet
   Mattisson, Ingrid Yao
   Gustafsson, Johanna T.
   Gunnarsson, Iva
   Zickert, Agneta
   Elvin, Kerstin
   Jensen-Urstad, Kerstin
   Bengtsson, Anders
   Gullstrand, Birgitta
   Fredrikson, Gunilla Nordin
   Nilsson, Jan
TI Cardiovascular disease in systemic lupus erythematosus is associated
   with increased levels of biomarkers reflecting receptor-activated
   apoptosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Systemic lupus erythematosus; Cardiovascular disease; Apoptosis; Matrix
   metalloproteinases
ID AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CORONARY-ARTERY-DISEASE;
   ACCELERATED ATHEROSCLEROSIS; DENSITY-LIPOPROTEIN; RHEUMATOID-ARTHRITIS;
   MACROPHAGE APOPTOSIS; PLAQUE VULNERABILITY; PEPTIDE SEQUENCES;
   RISK-FACTORS; MICE
AB Background and aims: There is convincing evidence that adaptive immune responses affect the development of atherosclerosis and thrombosis and several autoimmune diseases are associated with increased cardiovascular risk. However, our understanding of the underlying mechanisms remains limited. We investigated how biomarkers reflecting four aspects of autoimmunity: apoptosis, inflammation, tissue degradation and repair, associate with cardiovascular disease (CVD) in subjects with systemic lupus erythematosus (SLE).
   Methods: We investigated 484 well-characterized SLE patients, 69 of whom had CVD (coronary artery disease, cerebrovascular disease or peripheral artery disease), and 253 controls. Occurrence of carotid plaques was investigated with ultrasound. Plasma levels of biomarkers reflecting apoptosis (Fas, TNF receptor 1, TRAIL receptor 2), inflammation (IL-6, IL-8, monocyte chemotactic protein-1), tissue degradation (matrix metalloproteinase (MMP)-1, MMP-3, MMP-7), and tissue repair (platelet-derived growth factor, epidermal growth factor and stem cell factor) were analyzed by Proximity Extension Assay.
   Results: Subjects with SLE had markedly elevated plasma levels of biomarkers reflecting apoptosis, inflammation and tissue degradation as compared to controls. SLE patients with CVD had higher levels of Fas, TNF receptor 1, TRAIL receptor 2, MMP-1 and -7 than those without CVD. The same associations were found for the presence of a carotid plaque. When controlling for the factors included in the Framingham risk score, all biomarkers except MMP-1 remained associated with the presence of a carotid plaque, while only TRAIL receptor 2 levels remained significantly associated with CVD.
   Conclusions: Our findings argue that the cardiovascular risk in SLE is associated with increased cell death by apoptosis and tissue degradation. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Wigren, Maria; Mattisson, Ingrid Yao; Fredrikson, Gunilla Nordin; Nilsson, Jan] Lund Univ, Dept Clin Sci Malmo, Lund, Sweden.
   [Svenugnsson, Elisabet; Gustafsson, Johanna T.; Gunnarsson, Iva; Zickert, Agneta; Elvin, Kerstin] Dept Med, Rheumatol Unit, Solna, Sweden.
   [Jensen-Urstad, Kerstin] Karolinska Univ Hosp, Karolinska Inst, Sodersjukhuset, Dept Clin Physiol, Stockholm, Sweden.
   [Bengtsson, Anders; Gullstrand, Birgitta] Lund Univ, Dept Clin Sci Lund, Lund, Sweden.
RP Nilsson, J (reprint author), Skane Univ Hosp, CRC 91 12,Jan Waldenstroms Gata 35, S-20502 Malmo, Sweden.
EM jan.nilsson@med.lu.se
FU Swedish Research CouncilSwedish Research Council [2015-02811]; Swedish
   Heart-Lung foundationSwedish Heart-Lung Foundation [20170520]; European
   Union's Seventh Framework Program (FP7) under VIA [603131]; Albert
   Pahlsson Foundation; Swedish Rheumatism Association; King Gustaf V 80th
   Birthday Fund; Swedish Society of Medicine; Ake Wiberg Foundation; Clas
   Groschinsky Foundation; Karolinska Institutet FoundationsKarolinska
   Institutet; Skane Council; Stockholm Council; Karolinska
   InstitutetKarolinska Institutet
FX This work was supported by grants from the Swedish Research Council
   (2015-02811); Swedish Heart-Lung foundation (20170520), the European
   Union's Seventh Framework Program (FP7/2007-2013) under grant agreement
   VIA no 603131, Albert Pahlsson Foundation, Swedish Rheumatism
   Association, King Gustaf V 80th Birthday Fund, Swedish Society of
   Medicine, Ake Wiberg Foundation, Clas Groschinsky Foundation, Karolinska
   Institutet Foundations, and ALF funding from the Skane and Stockholm
   County Councils and Karolinska Institutet.
NR 47
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 1
EP 7
DI 10.1016/j.atherosclerosis.2018.01.022
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800001
PM 29407876
DA 2019-10-28
ER

PT J
AU Wang, AX
   Cui, Y
   Meng, X
   Su, ZP
   Cao, YB
   Yang, YL
   Liu, CC
   Dai, LY
   Wang, YX
   Wang, YL
AF Wang, Anxin
   Cui, Ying
   Meng, Xia
   Su, Zhaoping
   Cao, Yibin
   Yang, Yuling
   Liu, Changcheng
   Dai, Liye
   Wang, Youxin
   Wang, Yilong
TI The relationship between oxidized low-density lipoprotein and the NIHSS
   score among patients with acute ischemic stroke: The SOS-Stroke Study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Oxidized low-density lipoprotein; NIHSS score; Acute ischemic stroke;
   Oxidative stress; Atherosclerosis
ID SMALL-VESSEL DISEASE; OXIDATIVE STRESS; ATHEROSCLEROSIS; LDL;
   INFLAMMATION; BIOMARKERS; SEVERITY; LESIONS
AB Background and aims: Oxidized low-density lipoprotein (oxLDL) has a defined role in the genesis and development of atherosclerosis, however, whether it is related to severity of neurological deficits is rarely reported. The aim of our study was to investigate the potential association between oxLDL and the National Institutes of Health Stroke Scale (NIHSS) score among patients with acute ischemic stroke.
   Methods: Between January 2014 and October 2014, we recruited 4111 patients with acute ischemic stroke (AIS), who were admitted within 7 days-43 hospitals in China, and participated in the SOS-Stroke Study. We collected detailed clinical data and then tested the relationship between oxLDL and the NIHSS score using a multivariate linear regression analysis.
   Results: After adjusting for age, gender, ethnicity, marriage and other confounding variables, the elevated NIHSS score was significantly associated with increased oxLDL levels, and each 1-mg/dL elevation in oxLDL concentration resulted in an increase of 0.027 in the NIHSS score.
   Conclusions: A positive correlation was found between plasma levels of oxLDL and the NIHSS score in patients with acute ischemic stroke. Higher plasma levels of oxLDL potentially suggest a worse prognosis in AIS patients. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Wang, Anxin; Meng, Xia; Su, Zhaoping; Dai, Liye; Wang, Yilong] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, 6 Tiantanxili, Beijing 100050, Peoples R China.
   [Wang, Anxin; Meng, Xia; Su, Zhaoping; Dai, Liye; Wang, Yilong] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Wang, Anxin; Meng, Xia; Su, Zhaoping; Dai, Liye; Wang, Yilong] Beijing Inst Brain Disorders, Ctr Stroke, Beijing, Peoples R China.
   [Wang, Anxin; Meng, Xia; Su, Zhaoping; Dai, Liye; Wang, Yilong] Beijing Key Lab Translat Med Cerebrovasc Dis, Beijing, Peoples R China.
   [Wang, Anxin; Wang, Youxin] Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China.
   [Cui, Ying; Cao, Yibin; Yang, Yuling] North China Univ Sci & Technol, Tangshan Gongren Hosp, Dept Neurol, Tangshan, Peoples R China.
   [Liu, Changcheng] Capital Med Univ, Beijing Inst Heart Long & Blood Vessel Dis, Beijing Anzhen Hosp, Dept Cardiovasc Surg, Beijing, Peoples R China.
RP Wang, AX (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, 6 Tiantanxili, Beijing 100050, Peoples R China.
EM wangyilong@ccmu.edu.cn
FU China Stroke Prevention Project of the National Health and Family
   Planning Commission; National natural science foundation of
   ChinaNational Natural Science Foundation of China [81600999, 81673247]
FX This study was supported by the China Stroke Prevention Project of the
   National Health and Family Planning Commission, National natural science
   foundation of China (81600999 and 81673247).
NR 29
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 21
EP 25
DI 10.1016/j.atherosclerosis.2018.01.028
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800004
PM 29407884
DA 2019-10-28
ER

PT J
AU Drouin-Chartier, JP
   Tremblay, AJ
   Bergeron, J
   Lamarche, B
   Couture, P
AF Drouin-Chartier, Jean-Philippe
   Tremblay, Andre J.
   Bergeron, Jean
   Lamarche, Benoit
   Couture, Patrick
TI High serum triglyceride concentrations in patients with homozygous
   familial hypercholesterolemia attenuate the efficacy of lipoprotein
   apheresis by dextran sulfate adsorption
SO ATHEROSCLEROSIS
LA English
DT Article
DE Homozygous familial hypercholesterolemia; Lipoprotein apheresis; Dextran
   sulfate adsorption; Triglyceride; LDL-Cholesterol
ID CORONARY-HEART-DISEASE; LDL RECEPTOR GENE; CARDIOVASCULAR-DISEASE;
   FRIEDEWALD FORMULA; CHOLESTEROL; PLASMA; MUTATION; HYPERLIPOPROTEINEMIA;
   APOLIPOPROTEIN(A); POPULATION
AB Background and aims: Maximizing the acute reduction of LDL-cholesterol (C) and lipoprotein (a) (Lp(a)) concentrations in patients with homozygous familial hypercholesterolemia (HoFH) is the main goal of lipoprotein apheresis (LA). The objective of this study was to examine how the pre-LA serum TG concentrations influence the efficacy of LA to acutely reduce LDL-C and Lp(a) concentrations in HoFH patients.
   Methods: Data from 1761 LA treatments of HoFH patients (n = 10) and compound heterozygous patients (n = 5) collected between 2008 and 2016 were analyzed. These data included the pre-and post-LA concentrations of LDL-C, TGs and Lp(a); volume of filtered plasma; type of LA system used (dextran sulfate adsorption (DSA) or heparin-induced extracorporeal LDL precipitation (HELP)); and interval between treatments.
   Results: A significant association between the pre-LA TG concentrations and acute LA-induced reduction in LDL-C, modified by the type of LA system used, was observed (p pre-LA TG quartile*LA system =.04). Using the DSA system, the acute reduction of the LDL-C concentrations was attenuated by 3.9% when the preLA TG concentrations were > 2.09 mmol/L vs. <= 0.93 mmol/L (highest vs. lowest quartiles: =59.4% vs. =63.3%, p =.007). Using the HELP system, no significant difference was observed in the reduction of LDL-C between the highest and the lowest quartiles of serum TGs (=65.8% vs. =66.4%, p =.9). No association was observed between pre-LA TG concentrations and acute LA-induced decrease in Lp(a) (p =.2).
   Conclusions: The efficacy of LA is inversely associated with pre-LA TG concentrations in HoFH patients who used the DSA system instead of the HELP system. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Drouin-Chartier, Jean-Philippe; Tremblay, Andre J.; Couture, Patrick] Laval Univ, Dept Med, Inst Nutr & Funct Foods, Quebec City, PQ, Canada.
   [Drouin-Chartier, Jean-Philippe; Bergeron, Jean; Couture, Patrick] Laval Univ, CHU Quebec, Dept Med, Lipid Clin, Quebec City, PQ, Canada.
   [Drouin-Chartier, Jean-Philippe; Bergeron, Jean; Couture, Patrick] Laval Univ, CHU Quebec, Dept Med, Lipid Res Ctr, Quebec City, PQ, Canada.
   [Lamarche, Benoit] Laval Univ, Sch Nutr, Inst Nutr & Funct Foods, Quebec City, PQ, Canada.
RP Couture, P (reprint author), Laval Univ, Inst Nutr & Funct Foods INAF, 2440 Hochelaga Blvd, Quebec City, PQ G1V 0A6, Canada.
EM patrick.couture@crchul.ulaval.ca
OI Lamarche, Benoit/0000-0002-4443-5378; Couture,
   Patrick/0000-0002-8414-3847
FU Canadian Institutes of Health Research, Agriculture and Agri-Food
   Canada; MerckMerck & Company; PfizerPfizer; Atrium Innovations; Kaneka
   Corporation; Canadian Institutes of Health ResearchCanadian Institutes
   of Health Research (CIHR); Natural Sciences and Engineering Research
   Council of CanadaNatural Sciences and Engineering Research Council of
   Canada; Agriculture and Agri-Food CanadaAgriculture & Agri Food Canada;
   Fonds de Recherche du Quebec e Sante
FX PC has received funding in the last 5 years from the Canadian Institutes
   of Health Research, Agriculture and Agri-Food Canada, Merck, Pfizer,
   Atrium Innovations and the Kaneka Corporation. BL has received funding
   in the last 5 years from the Canadian Institutes of Health Research, the
   Natural Sciences and Engineering Research Council of Canada, Agriculture
   and Agri-Food Canada, Pfizer, Atrium Innovations and Merck. JPDC is the
   recipient of doctoral scholarships from the Canadian Institutes of
   Health Research and the Fonds de Recherche du Quebec e Sante. The other
   authors report no conflicts of interest.
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 26
EP 32
DI 10.1016/j.atherosclerosis.2018.01.005
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800005
PM 29407885
DA 2019-10-28
ER

PT J
AU Kayikcioglu, M
   Tokgozoglu, L
   Yilmaz, M
   Kaynar, L
   Aktan, M
   Durmus, RB
   Gokce, C
   Temizhan, A
   Ozcebe, OI
   Akyol, TK
   Okutan, H
   Sag, S
   Gul, OO
   Salcioglu, Z
   Yenercag, M
   Altunkeser, BB
   Kuku, I
   Yasar, HY
   Kurtoglu, E
   Kose, MD
   Demircioglu, S
   Pekkolay, Z
   Ilhan, O
AF Kayikcioglu, Meral
   Tokgozoglu, Lale
   Yilmaz, Mehmet
   Kaynar, Leylagul
   Aktan, Melih
   Durmus, Rana Berru
   Gokce, Cumali
   Temizhan, Ahmet
   Ozcebe, Osman Ilhami
   Akyol, Tulay Karaagac
   Okutan, Harika
   Sag, Saim
   Gul, Ozen Oz
   Salcioglu, Zafer
   Yenercag, Mustafa
   Altunkeser, Bulent B.
   Kuku, Irfan
   Yasar, Hamiyet Yilmaz
   Kurtoglu, Erdal
   Kose, Melis Demir
   Demircioglu, Sinan
   Pekkolay, Zafer
   Ilhan, Osman
TI A nation-wide survey of patients with homozygous familial
   hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT
   1 registry)
SO ATHEROSCLEROSIS
LA English
DT Article
DE Lipoprotein apheresis; Homozygous familial hypercholesterolemia; Turkey;
   Registry
ID LIPOPROTEIN APHERESIS; FOLLOW-UP; DIAGNOSIS; INSIGHTS; THERAPY
AB Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive intervention to prevent death due to coronary heart disease and/or atherosclerosis. Where available, lipoprotein apheresis (LA) is the mainstay of treatment to promote survival.
   Methods: A-HIT1 registry was conducted with the aim of providing insight to the real-life management of HoFH patients undergoing LA in Turkey, where LA procedures are fully reimbursed and widely available. Participating centers provided patient information, including family history, treatment patterns and relevant laboratory values, via a standard questionnaire.
   Results: The study evaluated 88 patients (mean age: 27 +/- 11 years, 41 women) in 19 centers. All patients were receiving regular LA with a clinical diagnosis of HoFH. Mean age at first symptom disease was 10 +/- 10 years, and at diagnosis it was 12 +/- 11 years; 74.7% were diagnosed before age 15 years; and only 31% before the age of 7. First referral of most patients was to pediatricians. Early onset coronary artery disease was present in 57.8% of patients. Mean age at first LA was 21 +/- 12 years. Only 11 (12.5%) patients were undergoing LA weekly. Mean frequency of apheresis sessions was 19 +/- 13 days. For the last four LA sessions, LDL-C levels reached the target in only in 5.7% of patients.
   Conclusions: Diagnosis of HoFH is delayed, and LDL targets are not reached. LA frequencies are not optimal. Urgent attention is needed to support the survival of patients with HoFH. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Kayikcioglu, Meral] Ege Univ, Med Fac, Dept Cardiol, Izmir, Turkey.
   [Tokgozoglu, Lale] Hacettepe Univ, Med Fac, Dept Cardiol, Ankara, Turkey.
   [Yilmaz, Mehmet] Gaziantep Univ, Med Fac, Dept Hematol, Gaziantep, Turkey.
   [Kaynar, Leylagul] Erciyes Univ, Med Fac, Dept Hematol, Kayseri, Turkey.
   [Aktan, Melih; Durmus, Rana Berru] Istanbul Univ, Istanbul Fac Med, Dept Hematol, Istanbul, Turkey.
   [Gokce, Cumali] Mustafa Kemal Univ, Med Fac, Dept Endocrinol, Antakya, Turkey.
   [Temizhan, Ahmet] Yuksek Ihtisas Training & Res Hosp, Dept Cardiol, Ankara, Turkey.
   [Ozcebe, Osman Ilhami; Akyol, Tulay Karaagac] Hacettepe Univ, Med Fac, Dept Hematol, Ankara, Turkey.
   [Okutan, Harika; Sag, Saim] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Hematol, Ankara, Turkey.
   [Sag, Saim] Uludag Univ, Med Fac, Dept Cardiol, Bursa, Turkey.
   [Gul, Ozen Oz] Uludag Univ, Med Fac, Dept Endocrinol & Metab, Bursa, Turkey.
   [Salcioglu, Zafer] Kanuni Sultan Suleyman Training & Res Hosp, Dept Pediat Hematol, Istanbul, Turkey.
   [Yenercag, Mustafa] 19 Mayis Univ, Med Fac, Dept Cardiol, Samsun, Turkey.
   [Altunkeser, Bulent B.] Selcuk Univ, Med Fac, Dept Cardiol, Konya, Turkey.
   [Kuku, Irfan] Inonu Univ, Med Fac, Dept Hematol, Malatya, Turkey.
   [Yasar, Hamiyet Yilmaz] Tepecik Training & Res Hosp, Dept Endocrinol & Metab, Izmir, Turkey.
   [Kurtoglu, Erdal] Antalya Training & Res Hosp, Dept Hematol, Antalya, Turkey.
   [Kose, Melis Demir] Behcet Uz Children Training & Res Hosp, Dept Pediat Metab, Izmir, Turkey.
   [Demircioglu, Sinan] Necmettin Erbakan Univ, Meram Med Fac, Dept Hematol, Konya, Turkey.
   [Pekkolay, Zafer] Dicle Univ, Med Fac, Dept Endocrinol, Diyarbakir, Turkey.
   [Ilhan, Osman] Ankara Univ, Med Fac, Ibn I Sina Hosp, Dept Hematol, Ankara, Turkey.
RP Kayikcioglu, M (reprint author), Ege Univ, Sch Med, Dept Cardiol, Izmir, Turkey.
EM meral.kayikcioglu@gmail.com
RI YILMAZ, MEHMET BIRHAN/Y-1372-2019; pekkolay, zafer/Q-4492-2019; Kaynar,
   Leylagul/F-6991-2013
OI YILMAZ, MEHMET BIRHAN/0000-0002-8169-8628; pekkolay,
   zafer/0000-0002-5323-2257; Kaynar, Leylagul/0000-0002-2035-9462;
   yenercag, mustafa/0000-0002-0933-7852; Demircioglu,
   Sinan/0000-0003-1277-5105
FU Aegerion pharmaceuticals; Amryt Pharmaceuticals
FX This investigator initiated study was funded by Aegerion
   pharmaceuticals, and authors wish to thank Nigel Eastmond of Eastmond
   Medicomm Ltd for assistance in editing the final manuscript, which was
   funded by Amryt Pharmaceuticals.
NR 25
TC 7
Z9 7
U1 1
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 42
EP 48
DI 10.1016/j.atherosclerosis.2018.01.034
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800007
PM 29407887
DA 2019-10-28
ER

PT J
AU Mehta, A
   Patel, J
   Al Rifai, M
   Ayers, CR
   Neeland, IJ
   Kanaya, AM
   Kandula, N
   Blaha, MJ
   Nasir, K
   Blumenthal, RS
   Joshi, PH
AF Mehta, Anurag
   Patel, Jaideep
   Al Rifai, Mahmoud
   Ayers, Colby R.
   Neeland, Ian J.
   Kanaya, Alka M.
   Kandula, Namratha
   Blaha, Michael J.
   Nasir, Khurram
   Blumenthal, Roger S.
   Joshi, Parag H.
TI Inflammation and coronary artery calcification in South Asians: The
   Mediators of Atherosclerosis in South Asians Living in America (MASALA)
   study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Inflammation; Coronary artery calcium; Prevention; Biomarker; South
   Asian
ID C-REACTIVE-PROTEIN; PLASMA ADIPONECTIN LEVELS; DENSITY-LIPOPROTEIN
   CHOLESTEROL; NECROSIS-FACTOR-ALPHA; HEART-DISEASE;
   CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; LEPTIN LEVELS;
   SUBCLINICAL ATHEROSCLEROSIS; GENDER-DIFFERENCES
AB Background and aims: Inflammatory biomarkers and adipocytokines (IBA) may contribute to atherosclerosis by promoting vascular inflammation. The association between IBA and coronary artery calcium (CAC), a marker of subclinical atherosclerosis, is not well defined in South Asians (SA). We hypothesized that IBA (high sensitivity C-reactive protein [hsCRP], tumor necrosis factor alpha [TNF-alpha], adiponectin, and leptin) were independently associated with and improved discrimination of CAC among SA.
   Methods: We analyzed IBA and CAC among participants in the prospective Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. We used logistic regression models to examine crosssectional associations of IBA with CAC presence (CAC > 0) and severity (CAC > 100), and C-statistics to assess the incremental contribution of each IBA to traditional risk factors (TRF) from the AHA/ACC Pooled Cohort Equations (PCE) for discrimination of CAC.
   Results: Among 906 participants in the MASALA study, women (n = 420) had significantly higher levels of hsCRP, adiponectin, and leptin but lower levels of TNF-alpha than men (p <.01 for all). There was no significant association between any of the four IBA and either CAC category in multivariable-adjusted models, respectively. Lastly, none of the four IBA improved discrimination of CAC presence or severity when added to elements of the PCE.
   Conclusions: IBA were not associated with CAC presence or severity in the MASALA population. IBA did not help identify SA at risk of subclinical atherosclerosis, although associations with ASCVD events remain unclear. In SA, CAC may have a distinct pathophysiology independent of inflammation as measured by IBA. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Mehta, Anurag] UT Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA.
   [Patel, Jaideep; Al Rifai, Mahmoud; Blaha, Michael J.; Nasir, Khurram; Blumenthal, Roger S.; Joshi, Parag H.] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Baltimore, MD USA.
   [Patel, Jaideep] Virginia Commonwealth Univ, Med Ctr, Dept Internal Med, Richmond, VA USA.
   [Al Rifai, Mahmoud] Univ Kansas, Sch Med, Dept Med, Wichita, KS 67214 USA.
   [Ayers, Colby R.] UT Southwestern Med Ctr, Dept Clin Sci, Dallas, TX 75390 USA.
   [Neeland, Ian J.; Joshi, Parag H.] UT Southwestern Med Ctr, Dept Internal Med, Div Cardiol, 5323 Harry Hines Blvd,E5-730F, Dallas, TX 75390 USA.
   [Kanaya, Alka M.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   [Kandula, Namratha] Northwestern Univ, Dept Med, Chicago, IL 60611 USA.
   [Nasir, Khurram] Baptist Hlth Med Grp, Ctr Prevent & Wellness Res, Miami Beach, FL USA.
   [Nasir, Khurram] Florida Int Univ, Dept Med, Herbert Wertheim Coll Med, Miami, FL 33199 USA.
RP Joshi, PH (reprint author), UT Southwestern Med Ctr, Dept Internal Med, Div Cardiol, 5323 Harry Hines Blvd,E5-730F, Dallas, TX 75390 USA.
EM Parag.Joshi@utsouthwestern.edu
FU National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI); National Center for
   Research ResourcesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [R01-HL093009]; Cliff Lede Family Foundation;
   National Institutes of Health and National Center for Research Resources
   through UCSF-CTSI [UL1 RR024131];  [K24HL112827]
FX The MASALA study was supported by the National Heart, Lung, and Blood
   Institute and the National Center for Research Resources grant
   R01-HL093009, adipocytokine measurements were supported by K24HL112827,
   and Lp(a) measurements were supported by the Cliff Lede Family
   Foundation. Data collection at UCSF was supported by National Institutes
   of Health and National Center for Research Resources through UCSF-CTSI
   Grant Number UL1 RR024131.
NR 52
TC 3
Z9 3
U1 2
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 49
EP 56
DI 10.1016/j.atherosclerosis.2018.01.033
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800008
PM 29407888
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Ren, K
   Zhu, X
   Zheng, Z
   Mo, ZC
   Peng, XS
   Zeng, YZ
   Ou, HX
   Zhang, QH
   Qi, HZ
   Zhao, GJ
   Yi, GH
AF Ren, Kun
   Zhu, Xiao
   Zheng, Zhi
   Mo, Zhong-Cheng
   Peng, Xiao-Shan
   Zeng, Yong-Zhi
   Ou, Han-Xiao
   Zhang, Qing-Hai
   Qi, Hui-Zhou
   Zhao, Guo-Jun
   Yi, Guang-Hui
TI MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid
   uptake from HDL cholesterol via the post- transcriptional repression of
   scavenger receptor class Btype I
SO ATHEROSCLEROSIS
LA English
DT Article
DE miR-24; SR-BI; HDL-Cholesterol; Selective lipid uptake; Atherosclerosis
ID HIGH-DENSITY-LIPOPROTEIN; B TYPE-I; CASSETTE TRANSPORTER A1; SR-BI;
   THP-1 MACROPHAGES; CARDIOVASCULAR-DISEASE; LESION DEVELOPMENT;
   ENDOTHELIAL-CELLS; SIGNALING PATHWAY; DEFICIENT MICE
AB Background and aims: Liver scavenger receptor class B type I (SR-BI) exerts atheroprotective effects through selective lipid uptake (SLU) from high-density lipoprotein cholesterol (HDL-C). Low hepatic SRBI expression leads to high HDL-C levels in the circulation and an increased risk of atherosclerosis. Furthermore, macrophage SR-BI mediates bidirectional cholesterol flux and may protect against atherogenesis. Previous studies have revealed that miR-24 is closely related to cardiovascular disease (CVD) progression. We aimed to investigate the molecular mechanisms by which miR-24 participates in SR-BI-mediated selective HDL cholesteryl ester (HDL-CE) uptake and further atherogenesis in apoE(-/-) mice.
   Methods: Bioinformatic predictions and luciferase reporter assays were utilized to detect the association between miR-24 and the SR-BI 30 untranslated region (30 UTR), and RT-PCR and western blotting were used to evaluate SR-BI mRNA and protein expression, respectively. The effects of miR-24 on Dil-HDL uptake were determined by flow cytometry assay. Double-radiolabeled HDL (I-125-TC-/[H-3] CEt-HDL) was utilized to measure the effects of miR-24 on HDL and CE binding and SLU in HepG2 and PMAtreated THP-1 cells. In addition, total cholesterol (TC) levels in HepG2 cells were analyzed using enzymatic methods, and macrophage lipid content was evaluated by high-performance liquid chromatography (HPLC) assay. Small interfering RNA (siRNA) and pcDNA3.1(-)-hSR-BI plasmid transfection procedures were utilized to confirm the role of SR-BI in the effects of miR-24 on Dil-HDL uptake, SLU and cholesterol levels in both cell types. Hepatic SR-BI level in apoE(-/-) mice was measured by western blotting. Liver TC, FC and CE levels and plasma triglycerides (TG), TC and HDL-C levels were evaluated enzymatically using commercial test kits. Atherosclerotic lesion sizes were measured using Oil Red O and hematoxylin-eosin staining.
   Results: miR-24 directly repressed SR-BI expression by targeting its 30UTR. In addition, miR-24 decreased Dil-HDL uptake and SLU in HepG2 and THP-1 macrophages. In the presence of HDL, miR-24 decreased TC levels in HepG2 cells and TC, free cholesterol (FC) and CE levels in macrophages. Overexpression and down-regulation assays showed that SR-BI mediated the effects of miR-24 on Dil-HDL uptake, SLU and cholesterol levels. Lastly, miR-24 administration decreased hepatic SR-BI expression and promoted atheromatous plaque formation in apoE(-/-) mice, findings in line with those of our in vitro studies.
   Conclusions: These findings indicate that miR-24 accelerates atherogenesis by repressing SR-BI-mediated SLU from HDL-C. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Ren, Kun; Zhu, Xiao; Zheng, Zhi; Peng, Xiao-Shan; Zeng, Yong-Zhi; Qi, Hui-Zhou; Yi, Guang-Hui] Univ South China, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, 28 W Changsheng Rd, Hengyang City 421001, Hunan, Peoples R China.
   [Mo, Zhong-Cheng; Ou, Han-Xiao] Univ South China, Dept Histol & Embryol, Hengyang 421001, Hunan, Peoples R China.
   [Zhang, Qing-Hai] Univ South China, Affiliated Hosp 1, Clin Res Inst, Hengyang 421001, Hunan, Peoples R China.
   [Zhao, Guo-Jun] Guilin Med Univ, Dept Histol & Embryol, Guilin 541004, Guangxi, Peoples R China.
RP Yi, GH (reprint author), Univ South China, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, 28 W Changsheng Rd, Hengyang City 421001, Hunan, Peoples R China.
EM ghyi6108@163.com
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China [81770490, 81670401]; Hunan Provincial Innovation
   Foundation For Postgraduates [CX2017B503]; Aid Program for Science and
   Technology Innovative Research Team in Higher Educational Institutions
   of Hunan Province [2008-244]; Construct Program of the Key Discipline in
   Hunan Province (Basic Medicine Sciences in University of South China)
FX The study was fiscally supported by the National Natural Sciences
   Foundation of China (No. 81770490 and 81670401), the Hunan Provincial
   Innovation Foundation For Postgraduates (CX2017B503), the Aid Program
   for Science and Technology Innovative Research Team in Higher
   Educational Institutions (2008-244) of Hunan Province, and the Construct
   Program of the Key Discipline in Hunan Province (Basic Medicine Sciences
   in University of South China).
NR 41
TC 5
Z9 5
U1 1
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 57
EP 67
DI 10.1016/j.atherosclerosis.2018.01.045
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800009
PM 29407889
DA 2019-10-28
ER

PT J
AU Song, DM
   Fang, GQ
   Mao, SZ
   Ye, XB
   Liu, G
   Miller, EJ
   Greenberg, H
   Liu, SF
AF Song, Dongmei
   Fang, Guoqiang
   Mao, Sun-zhong
   Ye, Xiaobing
   Liu, Gang
   Miller, Edmund J.
   Greenberg, Harly
   Liu, Shu Fang
TI Selective inhibition of endothelial NF-kappa B signaling attenuates
   chronic intermittent hypoxia-induced atherosclerosis in mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Intermittent hypoxia; Atherosclerosis; Cardiovascular risk factor;
   Nuclear factor kappa B; Obstructive sleep apnea; Endothelial
ID OBSTRUCTIVE SLEEP-APNEA; VASCULAR-LESIONS; MOUSE MODELS; EARLY SIGNS;
   CONTRIBUTES; EXPRESSION; COMMITTEE; COUNCIL; ARTERIOSCLEROSIS;
   INFLAMMATION
AB Background and aims: Chronic intermittent hypoxia (CIH) exposure causes atherosclerosis, although the underlying mechanisms are poorly understood. This study defines the role of endothelial intrinsic NF-kappa B signaling in the atherogenic response to CIH.
   Methods: We created ApoE-ECI-kappa Bmt mice that are deficient in the apolipoprotein E gene (ApoE(-/-)) and overexpress an I-kappa B alpha mutant (I-kappa Bmt) selectively in endothelial cells. ApoE(-/-) and ApoE-ECI-kappa Bmt mice were fed a normal chow diet (NCD) or high cholesterol diet (HCD) and exposed to sham or CIH, and atherosclerotic lesions were quantified.
   Results: CIH exposure activated NF-kappa B in aortas, and induced the expression of endothelial-specific and NF-kappa B-dependent genes, E-selectin and vascular cell adhesion molecule (VCAM)-1, in the aortas and hearts. Endothelial I-kappa Bmt overexpression in ApoE-ECI-kappa Bmt mice significantly inhibited CIH-induced NF-kappa B activity, and suppressed E-selectin and VCAM-1 expressions, confirming endothelial NF-kappa B inhibition in ApoE-ECI-(kappa Bmt) mice. ApoE(-/-) mice, on NCD, developed mild atherosclerotic lesions spontaneously, and developed advanced and larger areas of atherosclerotic plaques when exposed to CIH. ApoE(-/-) mice also developed advanced atherosclerotic lesions when fed an HCD alone. The HCD-induced atherosclerotic plaques became more advanced, and plaque areawas doubled in mice exposed to HCD thorn CIH. Endothelial I-kappa Bmt overexpression in ApoE-ECI-(kappa Bmt) mice attenuated spontaneously developed atherosclerotic lesions, abrogated CIH-induced atherosclerosis and mitigated CIH-mediated facilitation of HCD-induced atherosclerosis.
   Conclusions: These results suggest that endothelial intrinsic NF-kappa B signaling may play a pivotal role in CIH-induced atherosclerosis. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Song, Dongmei; Liu, Shu Fang] Hebei Med Univ, Affiliated Hosp 1, 89 Dong Gang Rd, Shijiazhuang 050031, Hebei, Peoples R China.
   [Song, Dongmei; Fang, Guoqiang; Mao, Sun-zhong; Ye, Xiaobing; Liu, Gang; Miller, Edmund J.; Greenberg, Harly; Liu, Shu Fang] Donald & Barbara Zucker Sch Med Hofstra Northwell, Feinstein Inst Med Res, Ctr Pulm Crit Care & Sleep Med, Manhasset, NY USA.
RP Song, DM (reprint author), Hebei Med Univ, Affiliated Hosp 1, 89 Dong Gang Rd, Shijiazhuang 050031, Hebei, Peoples R China.; Liu, SF (reprint author), Feinstein Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA.
EM dongmeisong2016@126.com; SLiu@northwell.edu
FU Hebei province international collaboration special grant, China
   [17397771D]
FX This work was supported partially by Hebei province international
   collaboration special grant, China (Grant #, 17397771D).
NR 46
TC 9
Z9 9
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 68
EP 75
DI 10.1016/j.atherosclerosis.2018.01.027
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800010
PM 29407890
DA 2019-10-28
ER

PT J
AU Lee, JY
   Chung, J
   Kim, KH
   An, SH
   Kim, M
   Park, J
   Kwon, K
AF Lee, Ji Yoon
   Chung, Jihwa
   Kim, Kyoung Hwa
   An, Shung Hyun
   Kim, Minsuk
   Park, Junbeom
   Kwon, Kihwan
TI Fluid shear stress regulates the expression of Lectin-like oxidized low
   density lipoprotein receptor-1 via KLF2-AP-1 pathway depending on its
   intensity and pattern in endothelial cells
SO ATHEROSCLEROSIS
LA English
DT Article
DE Fluid shear stress; Vascular endothelial cells; LOX-1; Mechanosensory
   complex; Kruppel-like factor 2; Activator protein-1
ID TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTORS; DISTURBED FLOW;
   MECHANOSENSORY COMPLEX; VASCULAR ENDOTHELIUM; MESSENGER-RNA;
   UP-REGULATION; C-JUN; ATHEROSCLEROSIS; LOX-1
AB Background and aims: Vascular endothelial cells (ECs) are exposed to fluid shear stress (FSS), which modulates vascular pathophysiology. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is crucial in endothelial dysfunction and atherosclerosis. We elucidated the mechanism regulating LOX-1 expression in ECs by FSS.
   Methods: Human umbilical vein endothelial cells were exposed to laminar shear stress (LSS) of indicated intensities using a unidirectional steady flow, or to oscillatory shear stress (OSS) using a bidirectional disturbed flow. In vivo studies were performed in a mouse model of partial carotid ligation and human pulmonary artery sections.
   Results: Within ECs, OSS upregulated LOX-1 expression, while LSS (20 dyne/cm(2)) downregulated it. We confirmed that OSS-induced LOX-1 expression was suppressed when the mechanotransduction was inhibited by knockdown of the mechanosensory complex. In addition, we demonstrated that Kruppellike factor 2 (KLF2) has an inhibitory role on OSS-induced LOX-1 expression. Next, we determined that activator protein-1 (AP-1) was the key transcription factor inducing LOX-1 expression by OSS, which was inhibited by KLF2 overexpression. To explore whether the intensity of LSS affects LOX-1 expression, we tested three different intensities (20, 60, and 120 dyne/cm(2)) of LSS. We observed higher LOX-1 expression with high shear stresses of 120 dyne/cm(2) compared to 20 and 60 dyne/cm(2), with OSS-like KLF2-AP-1 signaling patterns. Furthermore, ECs within disturbed flow regions showed upregulated LOX-1 expression in vivo.
   Conclusions: We concluded that LOX-1 expression on ECs is regulated via FSS depending on its intensity as well as pattern. Furthermore, this is mediated through the KLF2-AP1 pathway of mechanotransduction. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lee, Ji Yoon; Chung, Jihwa; Kim, Kyoung Hwa; An, Shung Hyun; Kwon, Kihwan] Ewha Womans Univ, Sch Med, Med Res Inst, Seoul 158710, South Korea.
   [Kim, Minsuk] Ewha Womans Univ, Sch Med, Dept Pharmacol, Seoul 158710, South Korea.
   [Park, Junbeom; Kwon, Kihwan] Ewha Womans Univ, Sch Med, Div Cardiol, Dept Internal Med, Seoul 158710, South Korea.
RP Kwon, K (reprint author), Ewha Womans Univ, Sch Med, Div Cardiol, Dept Internal Med, Seoul 158710, South Korea.
EM kankadin@ewha.ac.kr
FU Bio & Medical Technology Development Program [2011-0019695]
FX This work was supported by the Bio & Medical Technology Development
   Program (No. 2011-0019695).
NR 53
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 76
EP 88
DI 10.1016/j.atherosclerosis.2018.01.038
PG 13
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800011
PM 29407891
DA 2019-10-28
ER

PT J
AU Gocmen, R
   Arsava, EM
   Oguz, KK
   Topcuoglu, MA
AF Gocmen, Rahsan
   Arsava, Ethem Murat
   Oguz, Kader Karli
   Topcuoglu, Mehmet Akif
TI Atherosclerotic intracranial internal carotid artery calcification and
   intravenous thrombolytic therapy for acute ischemic stroke
SO ATHEROSCLEROSIS
LA English
DT Article
DE Acute stroke; Tissue plasminogen activator; Intracranial carotid artery;
   Siphon; Distensibility; Disability
ID VON-WILLEBRAND-FACTOR; HEMORRHAGIC TRANSFORMATION; REVASCULARIZATION
AB Background and aims: Intracranial internal carotid artery calcification (IICAC) is a frequent and readily available finding in acute stroke patients treated with intravenous (IV) tissue plasminogen activator (tPA). We aimed to investigate the effects of IICAC subtype (medial and intimal) on the response to IV tPA.
   Methods: In this retrospective study, 91 (57% female, age 69 +/- 13 years) consecutive acute anterior circulation stroke patients treated with IV tPA were included. IICAC were diagnosed and classified according to Kockelkoren's methods.
   Results: IV tPAwas effective at 24 h in 48% of patients with no IICAC (n=27), 60% of intimal IICAC (n=50) and 43% of medial IICAC (n=14) (p=0.408). Presence of medial IICAC tended to be linked negatively to early dramatic response to IV tPA (p=0.052). IICAC status had no significant effect on the third month good (mRS <= 2; 48% in no IICAC, 36% in intimal IICAC and 29% in medial IICAC; p=0.189) and favorable outcome (mRS <= 1; 56% in no IICAC, 48% in intimal IICAC, 43% in medial IICAC, p=0.411). Frequency of symptomatic post-tPA cerebral hemorrhage was marginally higher in patients with non-intimal IICAC (21% vs. 4% in no-IICAC, 4% in intimal-IICAC, p-0.052). Exploratory multivariate analysis documented that this effect was stable (p=0.004) after adjustment for age, admission NIHSS and door-to-needle time.
   Conclusions: Medial type IICAC has been associated with numerical increase of symptomatic intracerebral hemorrhage and decrease of early dramatic response in stroke patients receiving IV tPA. Acknowledging that these preliminary observations should be replicated in larger cohorts, it is currently reasonable to say that "the treatment" is still useful in these patients and the presence of medial IICAC does not justify withholding IV tPA. (C) 2018 Elsevier B. V. All rights reserved.
C1 [Gocmen, Rahsan; Oguz, Kader Karli] Hacettepe Univ Hosp, Neuroradiol Sect, Dept Radiol, Ankara, Turkey.
   [Arsava, Ethem Murat; Topcuoglu, Mehmet Akif] Hacettepe Univ Hosp, Dept Neurol, Ankara, Turkey.
   [Arsava, Ethem Murat; Topcuoglu, Mehmet Akif] Hacettepe Univ Hosp, Neurol Intens Care Unit, Ankara, Turkey.
RP Topcuoglu, MA (reprint author), Hacettepe Univ Hosp, Neurol Intens Care Unit, Dept Neurol, TR-06100 Ankara, Turkey.
EM mat@hacettepe.edu.tr
NR 24
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 89
EP 94
DI 10.1016/j.atherosclerosis.2018.01.035
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800012
PM 29407893
DA 2019-10-28
ER

PT J
AU Kadoya, M
   Kurajoh, M
   Kakutani-Hatayama, M
   Morimoto, A
   Miyoshi, A
   Kosaka-Hamamoto, K
   Shoji, T
   Moriwaki, Y
   Inaba, M
   Koyama, H
AF Kadoya, Manabu
   Kurajoh, Masafumi
   Kakutani-Hatayama, Miki
   Morimoto, Akiko
   Miyoshi, Akio
   Kosaka-Hamamoto, Kae
   Shoji, Takuhito
   Moriwaki, Yuji
   Inaba, Masaaki
   Koyama, Hidenori
TI Low sleep quality is associated with progression of arterial stiffness
   in patients with cardiovascular risk factors: HSCAA study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cohort study; Objectively sleep quality; Actigraph; Arterial stiffness;
   Pulse wave velocity
ID PULSE-WAVE VELOCITY; TYPE-2 DIABETES-MELLITUS; ISCHEMIC-STROKE PATIENTS;
   HEART-RATE-VARIABILITY; ALL-CAUSE MORTALITY; AORTIC STIFFNESS;
   BLOOD-PRESSURE; DURATION; PREDICTOR; DISEASE
AB Background and aims: Improvement in sleep quality is considered to be a viable target for prevention and treatment of cardiovascular diseases. To gain insight into its underlying mechanisms, we evaluated the significance of objectively measured sleep quality in patients with regard to progression of arterial stiffness over a 3-year follow-up period.
   Methods: This prospective cohort study included 306 serial patients registered in the Hyogo Sleep Cardio-Autonomic Atherosclerosis (HSCAA) study. In addition to classical cardiovascular risk factors (body mass index, current smoking, past history of cardiovascular disease, dyslipidemia, diabetes mellitus), the participants were examined for ambulatory blood pressure (BP), apnea-hypopnea index (AHI), standard deviation of the NN (RR) interval (SDNN) for heart rate variability (HRV), and objective sleep quality using actigraphy findings. Brachial-ankle pulse wave velocity (baPWV) was measured at both baseline and follow-up (36.6 +/- 6.8 months) as a parameter of arterial stiffness.
   Results: Increases in PWV (%) were greater (p=0.03) in the low sleep quality (LSQ) group (5.75 +/- 1.15%) as compared to the normal sleep quality group (2.69 +/- 0.85%). Patients with the greatest increase (>= 20%) from baseline exhibited a significantly (p < 0.05) larger percentage of LSQ (75% vs. 49.6%) as compared to those without PWV progression (<0%), with the association still significant (odds ratio 3.62, 95% confidence interval 1.04-12.55, p=0.04) even after adjustment for other clinical risk factors. For all subjects, univariate logistic regression analyses showed that diabetes and LSQ were significantly associated with the greatest increase of PWV. Comparisons of characteristics among specific subgroups showed more prominent associations of LSQ with the greatest increase of PWV in patients with greater age, dyslipidemia, and higher AHI.
   Conclusions: LSQ was associated with progression of arterial stiffness over a 3-year period, independent of cardiovascular risk factors such as BP, AHI, and HRV. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Kadoya, Manabu; Kakutani-Hatayama, Miki; Morimoto, Akiko; Miyoshi, Akio; Kosaka-Hamamoto, Kae; Shoji, Takuhito; Moriwaki, Yuji; Koyama, Hidenori] Hyogo Coll Med, Dept Internal Med, Div Diabet Endocrinol & Metab, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
   [Kurajoh, Masafumi; Inaba, Masaaki] Osaka City Univ, Grad Sch Med, Dept Endocrinol Metab & Mol Med, Osaka, Japan.
RP Koyama, H (reprint author), Hyogo Coll Med, Dept Internal Med, Div Diabet Endocrinol & Metab, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.
EM hkoyama@hyo-med.ac.jp
FU JSPS KAKENHI grantMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP16K19562,
   23591329]
FX This study was supported by a JSPS KAKENHI grant (JP16K19562 to M.
   Kadoya and 23591329 to H. Koyama).
NR 39
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 95
EP 101
DI 10.1016/j.atherosclerosis.2018.01.039
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800013
PM 29407894
DA 2019-10-28
ER

PT J
AU Maeba, R
   Kojima, K
   Nagura, M
   Komori, A
   Nishimukai, M
   Okazaki, T
   Uchida, S
AF Maeba, Ryouta
   Kojima, Ken-ichiro
   Nagura, Michito
   Komori, Aya
   Nishimukai, Megumi
   Okazaki, Tomoki
   Uchida, Shunya
TI Association of cholesterol efflux capacity with plasmalogen levels of
   high-density lipoprotein: A cross-sectional study in chronic kidney
   disease patients
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cholesterol efflux capacity; Chronic kidney disease; High-density
   lipoprotein; Plasmalogen
ID CORONARY-ARTERY-DISEASE; SERUM CHOLINE PLASMALOGENS; STAGE
   RENAL-DISEASE; ANTIINFLAMMATORY PROPERTIES; ETHANOLAMINE PLASMALOGENS;
   CARDIOVASCULAR MORTALITY; PHOSPHOLIPID-COMPOSITION; EICOSAPENTAENOIC
   ACID; LIQUID-CHROMATOGRAPHY; CLINICAL-SIGNIFICANCE
AB Background and aim: Current research suggests that dysfunctional high-density lipoprotein (HDL) with low cholesterol efflux capacity may accelerate atherosclerosis, particularly in chronic kidney disease (CKD). We previously reported that serum levels of plasmalogens closely correlated with HDL concentration, and could serve as a novel biomarker for atherosclerosis. In the present study, we analyzed the association of cholesterol efflux capacity of HDL with clinical and biochemical parameters, including plasmalogens, in CKD patients.
   Methods: We enrolled 24 mild-to-moderate CKD patients (CKD-3-4) and 33 end-stage renal disease (ESRD) patients nearing hemodialysis (CKD-5), and assessed physiological atherosclerotic scores, cholesterol efflux capacity, and plasmalogens levels in HDL. Furthermore, the effect of plasmalogen on cholesterol efflux capacity of HDL was examined by in vitro studies with re-constituted HDL (rHDL) and HDL prepared from CKD-5 patient (ESRD-HDL) with additional phospholipids.
   Results: There were significant differences in many parameters between the two groups. In particular, plasmalogens levels and cholesterol efflux capacity of HDL were significantly reduced in the CKD-5 group compared to those in the CKD-3-4 group (-35.1%, p<0.001, -36.8%, p<0.001, respectively). Multivariate linear regression analyses revealed that ethanolamine plasmalogen levels of HDL were independently associated with cholesterol efflux capacity (p=0.045) and plaque scores (p=0.035). In vitro studies also indicated that additional plasmalogens augmented cholesterol efflux ability of HDL.
   Conclusions: High plasmalogens concentrations in HDL may correlate with acceleration of cholesterol efflux and their decreased levels may promote atherosclerosis in advanced CKD patients. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Maeba, Ryouta; Komori, Aya; Okazaki, Tomoki] Teikyo Univ, Sch Med, Dept Biochem, Tokyo, Japan.
   [Kojima, Ken-ichiro; Nagura, Michito; Uchida, Shunya] Teikyo Univ, Sch Med, Dept Internal Med, Tokyo, Japan.
   [Nishimukai, Megumi] Iwate Univ, Fac Agr, Dept Anim Sci, Morioka, Iwate, Japan.
RP Maeba, R (reprint author), Teikyo Univ, Sch Med, Dept Biochem, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.
EM maeba@med.teikyo-u.ac.jp
FU "Knowledge Cluster Initiative" (2nd stage, "Sapporo Biocluster Bio-S")
   of the Ministry of Education, Science, Sports and Culture of Japan
FX This study was in part supported by the "Knowledge Cluster Initiative"
   (2nd stage, "Sapporo Biocluster Bio-S '') of the Ministry of Education,
   Science, Sports and Culture of Japan.
NR 48
TC 7
Z9 7
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 102
EP 109
DI 10.1016/j.atherosclerosis.2018.01.037
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800014
PM 29407877
DA 2019-10-28
ER

PT J
AU Rodriguez-Borjabad, C
   Ibarretxe, D
   Girona, J
   Ferre, R
   Feliu, A
   Amigo, N
   Guijarro, E
   Masana, L
   Plana, N
AF Rodriguez-Borjabad, Celia
   Ibarretxe, Daiana
   Girona, Josefa
   Ferre, Raimon
   Feliu, Albert
   Amigo, Nuria
   Guijarro, Eugenio
   Masana, Luis
   Plana, Nuria
CA DECOPIN Grp
TI Lipoprotein profile assessed by 2D-1H-NMR and subclinical
   atherosclerosis in children with familial hypercholesterolaemia
SO ATHEROSCLEROSIS
LA English
DT Article
DE Lipoprotein profile; 2D-1H-NMR; Heterozygous familial;
   hypercholesterolaemia; Polygenic hypercholesterolaemia; Children
ID LOW-DENSITY-LIPOPROTEIN; INTIMA-MEDIA THICKNESS; CARDIOVASCULAR-DISEASE;
   CAROTID ULTRASOUND; PARTICLE-SIZE; SUSCEPTIBILITY; SUBFRACTIONS;
   SPECTROSCOPY; CHOLESTEROL; DISCORDANCE
AB Background and aims: Familial hypercholesterolaemia (FH) is underdiagnosed in children. In addition to lipid concentrations, lipoprotein particle quantity and quality could influence cardiovascular risk. We aimed to perform a comprehensive plasma lipid study, including lipoprotein particle number and size assessment by two-dimensional nuclear magnetic resonance (2D-1H-NMR), in children with FH compared to non-affected children and to evaluate the clinical value of these factors as subclinical atherosclerosis biomarkers.
   Methods: One hundred eighty-three children participating in the broad "Hypercholesterolemia Early Detection Programme" (Decopin Project) were recruited. They were categorized as FH, if they had either a positive genetic test or clinical certainty, or as control children (CCh). Medical history, anthropometry and clinical variables were recorded. Standard biochemical measurements were performed. The lipoprotein profile was studied by 2D-1H-NMR. Carotid intima-media thickness (cIMT) was assessed by sonography in 177 children.
   Results: FH children had a significant 36% increase in LDL particles. The small LDL fraction was increased by 33% compared to CCh. The relative relationship between large, medium and small LDL and the mean LDL particle size was similar between FH children and CCh. The total and small LDL particle numbers were directly associated with and contributed to the determination of the mean cIMT according to bivariate and multivariate analyses in FH children.
   Conclusions: The higher cholesterol levels of FH children are due to an overall increased number of all LDL particle subclasses, including a notable 33% increase in small LDL. Total and small LDL particle number shows a good correlation with cIMT in FH children. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Rodriguez-Borjabad, Celia; Ibarretxe, Daiana; Girona, Josefa; Ferre, Raimon; Masana, Luis; Plana, Nuria] Univ Rovira & Virgili, Vasc Med & Metab Unit, Res Unit Lipids & Atherosclerosis, St Joan Univ Hosp,IISPV, Reus, Spain.
   [Rodriguez-Borjabad, Celia; Ibarretxe, Daiana; Girona, Josefa; Ferre, Raimon; Masana, Luis; Plana, Nuria] Spanish Biomed Res Ctr Diabet & Associated Metab, Madrid, Spain.
   [Feliu, Albert] Univ Rovira & Virgili, Pediat Res Unit, IISPV, Reus, Spain.
   [Amigo, Nuria] Univ Rovira & Virgili, IISPV, Dept Elect Engn & Automat, Tarragona, Spain.
   [Guijarro, Eugenio] Bonavista Primary Hlth Care, Tarragona, Spain.
RP Plana, N (reprint author), Univ Rovira & Virgili, St Joan Univ Hosp, Res Unit Lipids & Atherosclerosis, Vasc Med & Metab Unit, C St Llorenc 21, E-43201 Reus, Spain.
EM luis.masana@urv.cat
RI MASANA, LUIS/M-7002-2019; Girona, Josefa/U-3489-2018
OI MASANA, LUIS/0000-0002-0789-4954; Girona, Josefa/0000-0002-6267-8779;
   Plana, Nuria/0000-0002-4231-7618
FU "Marato de TV3" (project: Preventing Premature Coronary Heart Disease in
   Catalonia by Expanding Familial Hypercholesterolemia Diagnosis)
   [20152430]
FX This study was funded by the "Marato de TV3" (tittle of the project:
   Preventing Premature Coronary Heart Disease in Catalonia by Expanding
   Familial Hypercholesterolemia Diagnosis); grant number 20152430.
NR 23
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 117
EP 122
DI 10.1016/j.atherosclerosis.2018.01.040
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800016
PM 29407879
DA 2019-10-28
ER

PT J
AU Florczak, AS
   Henni, S
   Signolet, I
   Hamel, JF
   Humeau-Heurtier, A
   Rousseau, P
   Abraham, P
AF Florczak, Anne-Sophie
   Henni, Samir
   Signolet, Isabelle
   Hamel, Jean-Francois
   Humeau-Heurtier, Anne
   Rousseau, Pascal
   Abraham, Pierre
TI Vasodilator response to galvanic current stimulation of the skin
   accurately detects acetylsalicylic acid intake: A study in 400 vascular
   patients
SO ATHEROSCLEROSIS
LA English
DT Article
DE Laser speckle contrast imaging; Microcirculation; Peripheral vascular
   disease
ID MICROVASCULAR ENDOTHELIAL FUNCTION; ANODAL CURRENT APPLICATION; ASPIRIN
   RESISTANCE; DOSE ASPIRIN; INHIBITION; MECHANISMS; DISEASE; HUMANS;
   REFLEX
AB Background and aims: The first cause of low-dose acetylsalicylic-acid (ASA) inefficacy is poor adherence to treatment. No non-invasive technique is available to assess ASA intake. Current-induced vasodilation (CIV) was found abolished in healthy volunteers after low-dose ASA intake. We tested clinical characteristics, treatments, and comorbid conditions influencing CIV amplitude in vascular patients.
   Methods: CIV was tested in 400 patients (277 males and 123 females, aged 65.4 +/- 13.4 years). We focused on clinical characteristics, treatments, and comorbid conditions as covariates of CIV amplitude. We studied the CIV amplitude to covariate relationships with multivariate linear regression and receiver operating characteristics (ROC).
   Results: The multivariate linear model determined that ASA intake within the last 48 h and the interaction between ASA intake and body mass index (BMI) were the sole covariates associated with CIV amplitude. For the whole population, the area under the ROC curve (AUC) for CIV to predict ASA intake was 0.853 [95% confidence interval (CI): 0.814-0.892]. Considering separately the areas observed for non-obese (BMI <= 30, n = 303) and obese (BMI>30, n = 93) patients, the AUC [95% CI] was 0.873 [0.832 -0.915] and 0.776 [0.675-0.878], respectively (p = 0.083).
   Conclusions: ASA is the only drug that affects the amplitude of CIV response observed after galvanic current application to the skin of vascular patients. CIV depends on BMI but not age or gender. As such, CIV appears to be a potential objective marker of ASA intake and could facilitate future non-invasive assessments of adherence to ASA treatment. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Florczak, Anne-Sophie; Henni, Samir; Signolet, Isabelle; Abraham, Pierre] Univ Hosp Angers, Lab Vasc Invest, Angers, France.
   [Florczak, Anne-Sophie; Rousseau, Pascal] Univ Hosp Angers, Dept Plast Surg, Angers, France.
   [Henni, Samir; Signolet, Isabelle; Abraham, Pierre] CNRS, MitoVasc Inst, Fac Med, UMR 6015,INSERM 1083, Angers, France.
   [Hamel, Jean-Francois] Univ Hosp Angers, Dept Biostat, Maison Rech, Angers, France.
   [Humeau-Heurtier, Anne] Univ Angers, LARIS, Angers, France.
RP Abraham, P (reprint author), Univ Hosp, Lab Vasc Invest, 4 Rue Larrey, F-49933 Angers 9, France.
EM piabraham@chu-angers.fr
FU Pfizer FrancePfizer
FX The study was promoted by the University Hospital in Angers and
   supported, in part, by a non-conditional grant from Pfizer France.
NR 27
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 139
EP 145
DI 10.1016/j.atherosclerosis.2018.01.041
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800019
PM 29407883
DA 2019-10-28
ER

PT J
AU Pereira, SC
   Parente, JM
   Belo, VA
   Mendes, AS
   Gonzaga, NA
   do Vale, GT
   Ceron, CS
   Tanus-Santos, JE
   Tirapelli, CR
   Castro, MM
AF Pereira, Sherliane C.
   Parente, Juliana M.
   Belo, Vanessa A.
   Mendes, Atlante S.
   Gonzaga, Natalia A.
   do Vale, Gabriel T.
   Ceron, Carla S.
   Tanus-Santos, Jose Eduardo
   Tirapelli, Carlos R.
   Castro, Michele M.
TI Quercetin decreases the activity of matrix metalloproteinase-2 and
   ameliorates vascular remodeling in renovascular hypertension
SO ATHEROSCLEROSIS
LA English
DT Article
DE Antioxidant; Matrix metalloproteinase; Vascular remodeling;
   Hypertension; Oxidative stress
ID SMOOTH-MUSCLE-CELLS; FOCAL ADHESION KINASE; ANGIOTENSIN-II; ENDOTHELIAL
   DYSFUNCTION; CARDIOVASCULAR-DISEASES; RESISTANCE ARTERIES; OXIDATIVE
   STRESS; TGF-BETA; IN-VITRO; RATS
AB Background and aims: Increased activity of matrix metalloproteinase (MMP)-2 is observed in aortas of different models of hypertension, and its activation is directly mediated by oxidative stress. As quercetin is an important flavonoid with significant antioxidant effects, the hypothesis here is that quercetin will reduce increased MMP-2 activity by decreasing oxidative stress in aortas of hypertensive rats and then ameliorate hypertension-induced vascular remodeling.
   Methods: Male two-kidney one-clip (2K1C) hypertensive Wistar rats and controls were treated with quercetin (10 mg/kg/day) or its vehicle for three weeks by gavage. Rats were then analyzed at five weeks of hypertension. Systolic blood pressure (SBP) was determined by tail-cuff plethysmography. Aortas were used to determine MMP activity by in situ zymography and reactive oxygen species (ROS) levels by dihydroethidium. Western blot was performed to detect focal adhesion kinase (FAK) and phosphorylated-FAK levels.
   Results: SBP was increased in 2K1C rats and only a borderline reduction in SBP was observed after treating 2K1C rats with quercetin. Cross-sectional area and the number of vascular smooth muscle cells were significantly increased in aortas of hypertensive rats, and quercetin reduced them. Quercetin reduced ROS levels in aortas of 2K1C rats and the increased activity of gelatinases in situ. However, quercetin did not affect the levels of tissue inhibitor of MMP (TIMP)-2 and did not interfere with FAK and p-FAK levels in aortas of hypertensive rats. Furthermore, different concentrations of quercetin did not directly reduce the activity of human recombinant MMP-2 in vitro.
   Conclusions: Quercetin reduces hypertension-induced vascular remodeling, oxidative stress and MMP-2 activity in aortas. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Pereira, Sherliane C.; Parente, Juliana M.; Belo, Vanessa A.; Mendes, Atlante S.; Gonzaga, Natalia A.; do Vale, Gabriel T.; Ceron, Carla S.; Tanus-Santos, Jose Eduardo; Tirapelli, Carlos R.; Castro, Michele M.] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
   [Gonzaga, Natalia A.; do Vale, Gabriel T.; Tirapelli, Carlos R.] Univ Sao Paulo, Coll Nursing Ribeirao Preto, DEPCH, Pharmacol Lab, Av Bandeirantes 3900, BR-14040902 Ribeirao Preto, Brazil.
   [Ceron, Carla S.] Univ Fed Alfenas, Fac Pharmaceut Sci, Gabriel Monteiro da Silva 700, BR-37130001 Alfenas, MG, Brazil.
RP Castro, MM (reprint author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pharmacol, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP, Brazil.
EM castro@fmrp.usp.br
RI Gonzaga, Natalia/D-6517-2017; Vale, Gabriel/O-2695-2017; Mazzaron de
   Castro, Michele/C-7412-2013; Ceron, Carla S/F-1160-2015
OI Gonzaga, Natalia/0000-0003-1511-3318; Vale, Gabriel/0000-0002-8626-9240;
   Mazzaron de Castro, Michele/0000-0002-3424-6573; Ceron, Carla
   S/0000-0001-8882-5792
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo BrazilFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/11412-0];
   Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES; Fundacao de Apoio ao Ensino, Pesquisa e Assistencia,
   Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto,
   Universidade de Sao Paulo
FX Our study was funded by Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo Brazil (2014/11412-0), Conselho Nacional de Pesquisa e
   Desenvolvimento Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior and Fundacao de Apoio ao Ensino, Pesquisa e
   Assistencia, Hospital das Clinicas da Faculdade de Medicina de Ribeirao
   Preto, Universidade de Sao Paulo.
NR 45
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 146
EP 153
DI 10.1016/j.atherosclerosis.2018.01.031
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800020
PM 29425960
OA Bronze
DA 2019-10-28
ER

PT J
AU Lin, SY
   Lin, CL
   Lin, CC
   Wang, IK
   Hsu, WH
   Kao, CH
AF Lin, Shih-Yi
   Lin, Cheng-Li
   Lin, Cheng-Chieh
   Wang, I-Kuan
   Hsu, Wu-Huei
   Kao, Chia-Hung
TI Risk of acute coronary syndrome and peripheral arterial disease in
   chronic liver disease and cirrhosis: A nationwide population-based study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Acute coronary syndrome; Liver cirrhosis; Peripheral arterial disease;
   Cohort study
ID FATTY LIVER; NITRIC-OXIDE; ENDOTHELIAL FUNCTION; METABOLIC SYNDROME;
   COHORT; ATHEROSCLEROSIS; DYSFUNCTION; TAIWAN; COMPLICATIONS;
   EPIDEMIOLOGY
AB Background & aims: Until now, no study has investigated the risks of acute coronary syndrome (ACS) and peripheral arterial disease (PAD) in cirrhosis.
   Methods: In this study, 57,214 patients diagnosed with cirrhosis between 2000 and 2010 were identified from the Taiwan National Health Insurance claims data. Each patient was randomly selected and frequency-matched with an individual without cirrhosis by age, sex, and index year.
   Results: The overall incidence rates of ACS and PAD were 2.81 and 2.97 per 1000 person-years, respectively, in the cirrhosis cohort. The cirrhosis cohort had a higher risk of ACS [adjusted subhazard ratio (aSHR) = 1.12, 95% confidence interval (CI) = 1.03-1.22] and PAD (aSHR = 1.11, 95% CI = 1.02-1.21). The risk of ACS was highest among members of the cirrhosis cohort with ascites (aSHR = 1.09, 95% CI = 1.11-1.19).
   Conclusions: Patients with chronic liver disease and cirrhosis have higher risks of ACS and PAD than those without chronic liver disease and cirrhosis. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Lin, Shih-Yi; Lin, Cheng-Chieh; Wang, I-Kuan; Hsu, Wu-Huei; Kao, Chia-Hung] China Med Univ, Grad Inst Clin Med Sci, 2 Yuh Der Rd, Taichung 404, Taiwan.
   [Lin, Shih-Yi; Lin, Cheng-Chieh; Wang, I-Kuan; Hsu, Wu-Huei; Kao, Chia-Hung] China Med Univ, Sch Med, Coll Med, 2 Yuh Der Rd, Taichung 404, Taiwan.
   [Lin, Shih-Yi; Wang, I-Kuan] China Med Univ Hosp, Div Nephrol, Taichung, Taiwan.
   [Lin, Shih-Yi; Wang, I-Kuan] China Med Univ Hosp, Kidney Inst, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ, Coll Med, Taichung, Taiwan.
   [Lin, Cheng-Chieh] China Med Univ Hosp, Dept Family Med, Taichung, Taiwan.
   [Hsu, Wu-Huei] China Med Univ Hosp, Div Pulm & Crit Care Med, Taichung, Taiwan.
   [Hsu, Wu-Huei] China Med Univ, Taichung, Taiwan.
   [Kao, Chia-Hung] China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan.
   [Kao, Chia-Hung] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan.
RP Kao, CH (reprint author), China Med Univ, Grad Inst Clin Med Sci, 2 Yuh Der Rd, Taichung 404, Taiwan.; Kao, CH (reprint author), China Med Univ, Sch Med, Coll Med, 2 Yuh Der Rd, Taichung 404, Taiwan.
EM d10040@mail.cmuh.org.tw
FU Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence [MOHW106-TDU-B-212-113004]; China Medical University
   Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project
   [BM10601010036]; NRPB Stroke Clinical Trial Consortium [MOST
   106-2321-B-039-005]; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan
   Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima
   Memorial Funds, Japan
FX This study is supported in part by the Taiwan Ministry of Health and
   Welfare Clinical Trial and Research Center of Excellence
   (MOHW106-TDU-B-212-113004); China Medical University Hospital, Academia
   Sinica Taiwan Biobank Stroke Biosignature Project (BM10601010036); NRPB
   Stroke Clinical Trial Consortium (MOST 106-2321-B-039-005); Tseng-Lien
   Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation,
   Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The
   funders had no role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. No additional
   external funding was received for this study.
NR 39
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 154
EP 159
DI 10.1016/j.atherosclerosis.2018.01.047
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800021
PM 29425961
DA 2019-10-28
ER

PT J
AU Kranenburg, G
   Visseren, FLJ
   de Borst, GJ
   de Jong, PA
   Spiering, W
AF Kranenburg, Guido
   Visseren, Frank L. J.
   de Borst, Gert Jan
   de Jong, Pim A.
   Spiering, Wilko
CA SMART Studygrp
TI Arterial stiffening and thickening in patients with pseudoxanthoma
   elasticum
SO ATHEROSCLEROSIS
LA English
DT Article
DE PXE; Arteriosclerosis; Arterial stiffening-medial arterial wall disease
ID ISOLATED SYSTOLIC HYPERTENSION; INTIMA-MEDIA THICKNESS; PULSE-WAVE
   VELOCITY; CARDIOVASCULAR RISK; VASCULAR CALCIFICATION; ABC TRANSPORTER;
   MUTATIONS; STIFFNESS; DISEASE; MANIFESTATIONS
AB Background and aims: Patients with pseudoxanthoma elasticum (PXE), a monogenetic calcification disease, are at high vascular risk. Although the precise arterial phenotype remains unestablished, it is hypothesized that PXE predominantly affects the medial arterial layer leading to arterial stiffening. We aimed to test this hypothesis by measuring arterial wall characteristics in PXE and comparisons with the general population and diabetes mellitus type 2 (DM2), a condition typically associated with mixed intimal and medial arterial disease.
   Methods: Extensive arterial wall characterization was performed in 203 PXE patients involving intimamedia thickness (IMT), pulse wave velocity (PWV) and pulse pressure (PP) measurements. IMT and PWV in PXE were compared with the general population using age, sex and mean arterial pressure corrected values for each PXE patient. IMT and PP were compared between PXE and DM2 independently of sex, age and systolic blood pressure, using data of DM2 patients (n = 1033) from the Second Manifestations of ARTerial disease (SMART) cohort.
   Results: PXE patients had significantly higher IMT (mean difference 0.09 mm; 95% CI 0.07-0.12 mm) and PWV (mean difference 2.5 m/s; 95% CI 1.9-3.0 m/s) compared to the general population. IMT in PXE was lower compared to DM2 (0.72 mm; 95% CI 0.68-0.75 mm vs. 0.85 mm; 95% CI 0.83-0.87 mm, p-value<0.01), whereas PP in PXE was higher compared to DM2 (60 mmHg; 95% CI 59-62 vs. 57 mmHg; 95% CI 57-58mmHg, p-value<0.01).
   Conclusions: PXE patients have thicker arterial walls than the general population, but thinner arterial walls than DM2 patients at similar age. Arterial stiffening is more pronounced in PXE patients compared to DM2 patients. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Kranenburg, Guido; Visseren, Frank L. J.; Spiering, Wilko] Univ Utrecht, Dept Vasc Med, Univ Med Ctr Utrecht, POB 85500, NL-3508 GA Utrecht, Netherlands.
   [de Borst, Gert Jan] Univ Utrecht, Dept Vasc Surg, Univ Med Ctr Utrecht, Utrecht, Netherlands.
   [de Jong, Pim A.] Univ Utrecht, Dept Radiol, Univ Med Ctr Utrecht, Utrecht, Netherlands.
RP Spiering, W (reprint author), Univ Utrecht, Dept Vasc Med, Univ Med Ctr Utrecht, POB 85500, NL-3508 GA Utrecht, Netherlands.
EM W.Spiering@umcutrecht.nl
OI Visseren, Frank/0000-0003-3951-5223
NR 37
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 160
EP 165
DI 10.1016/j.atherosclerosis.2018.02.006
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800022
PM 29432933
DA 2019-10-28
ER

PT J
AU Curjuric, I
   Imboden, M
   Bettschart, R
   Caviezel, S
   Dratva, J
   Pons, M
   Rothe, T
   Schmidt-Trucksass, A
   Stolz, D
   Thun, GA
   von Eckardstein, A
   Kronenberg, F
   Ferrarotti, I
   Probst-Hensch, NM
AF Curjuric, Ivan
   Imboden, Medea
   Bettschart, Robert
   Caviezel, Seraina
   Dratva, Julia
   Pons, Marco
   Rothe, Thomas
   Schmidt-Trucksass, Arno
   Stolz, Daiana
   Thun, Gian Andri
   von Eckardstein, Arnold
   Kronenberg, Florian
   Ferrarotti, Ilaria
   Probst-Hensch, Nicole M.
TI Alpha-1 antitrypsin deficiency: From the lung to the heart?
SO ATHEROSCLEROSIS
LA English
DT Article
DE MESH): carotid intima-media thickness; Cardiovascular diseases; Alpha-1
   antitrypsin deficiency; Mendelian randomization analysis; Cohort study
ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR-DISEASE; SAPALDIA COHORT;
   ALPHA(1)-ANTITRYPSIN; ATHEROSCLEROSIS; INHIBITOR; RISK; INFLAMMATION;
   METAANALYSIS; POPULATION
AB Background and aims: Alpha-1 antitrypsin (A1AT) is the most abundant serine protease inhibitor in human blood and exerts important anti-inflammatory and immune-modulatory effects. In combination with smoking or other long-term noxious exposures such as occupational dust and fumes, genetic A1AT deficiency can cause chronic obstructive pulmonary disease, a condition with elevated cardiovascular risk. The effects of A1AT deficiency on cardiovascular risk have hardly been studied today.
   Methods: Using data from 2614 adults from the population-based SAPALDIA cohort, we tested associations of serum A1AT and SERPINA1 mutations with carotid intima-media thickness (CIMT, measured by B-mode ultrasonography) or self-reported arterial hypertension or cardiovascular disease in multiple regression models using a Mendelian Randomization like analysis design. Mutations Pi-S and Pi-Z were coded as ordinal genotype score (MM, MS, MZ/SS, SZ and ZZ), according to their progressive biological impact.
   Results: Serum A1AT concentration presented a u-shaped association with CIMT. At the lower end of the A1AT distribution, an analogous, linear association between SERPINA1 score and higher CIMT was observed, resulting in an estimated 1.2% (95%-confidence interval -0.1-2.5) increase in CIMT per unit (p = 0.060). Genotype score was significantly associated with arterial hypertension with an odds ratio (OR) of 1.2 (1.0-1.5) per unit (p = 0.028). The association with cardiovascular disease was not significant (OR 1.3 (0.9-1.9)).
   Conclusions: Our results support a possible causal relationship between genetic A1AT deficiency and increased cardiovascular risk, which needs to be better taken into account for the management of affected patients and first-degree relatives. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Curjuric, Ivan; Imboden, Medea; Caviezel, Seraina; Dratva, Julia; Thun, Gian Andri; Probst-Hensch, Nicole M.] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland.
   [Curjuric, Ivan; Imboden, Medea; Caviezel, Seraina; Dratva, Julia; Thun, Gian Andri; Probst-Hensch, Nicole M.] Univ Basel, Basel, Switzerland.
   [Bettschart, Robert] Lungenpraxis Hirslanden Klin Aarau, Aarau, Switzerland.
   [Pons, Marco] Reg Hosp Lugano, Div Pulm Med, Lugano, Switzerland.
   [Rothe, Thomas] Zurcher Hohenklin Davos, Davos, Switzerland.
   [Schmidt-Trucksass, Arno] Univ Basel, Div Sports & Exercise Med, Dept Sport Exercise & Hlth, Basel, Switzerland.
   [Stolz, Daiana] Univ Hosp Basel, Clin Resp Med & Pulm Cell Res, Basel, Switzerland.
   [Thun, Gian Andri] Barcelona Inst Sci & Technol, CNAG CRG, Barcelona, Spain.
   [Thun, Gian Andri] Univ Pompeu Fabra, Barcelona, Spain.
   [von Eckardstein, Arnold] Univ Hosp Zurich, Inst Clin Chem, Zurich, Switzerland.
   [Kronenberg, Florian] Med Univ Innsbruck, Div Genet Epidemiol, Dept Med Genet Mol & Clin Pharmacol, Innsbruck, Austria.
   [Ferrarotti, Ilaria] Univ Pavia, Pneumol Unit Fdn IRCCS Policlin San Matteo, Dept Internal Med & Therapeut, Ctr Diag Inherited Alpha Antitrypsin Deficiency 1, Pavia, Italy.
   [Curjuric, Ivan] Krebsregister Aargau, POB 4037, CH-5001 Aarau, Switzerland.
RP Curjuric, I (reprint author), Swiss Trop & Publ Hlth Inst SwissTPH, Socinstr 57,POB, CH-4002 Basel, Switzerland.
EM ivan.curjuric@swisstph.ch
RI Schmidt-Trucksass, Arno/I-7673-2015; Kronenberg, Florian/B-1736-2008
OI Kronenberg, Florian/0000-0003-2229-1120; Schmidt-Trucksass,
   Arno/0000-0002-4662-3911
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [33CS30-148470/12, 33CSCO-134276/1, 33CSCO-108796, 324730_135673,
   3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302,
   3200-052720, 3200-042532, 4026-028099, PMPDP3_129021/1,
   PMPDP3_141671/1]; Federal Office for the Environment; Federal Office of
   Public Health; Federal Office of Roads and Transport; canton's
   government of Aargau; canton's government of Basel-Stadt; canton's
   government of Basel-Land; canton's government of Geneva; canton's
   government of Luzern; canton's government of Ticino; canton's government
   of Valais; canton's government of Zurich; Swiss Lung League; canton's
   Lung League of Basel Stadt/Basel Landschaft; canton's Lung League of
   Graubunden; Stiftung ehemals Bundner Heilstatten; SUVA; Freiwillige
   Akademische Gesellschaft; UBS Wealth Foundation; Talecris
   Biotherapeutics GmbH; Abbott DiagnosticsAbbott Laboratories; European
   CommissionEuropean Commission Joint Research Centre [018996]; Wellcome
   TrustWellcome Trust [WT 084703MA]
FX The Swiss National Science Foundation (grants no 33CS30-148470/1&2,
   33CSCO-134276/1, 33CSCO-108796, 324730_135673, 3247BO-104283,
   3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720,
   3200-042532, 4026-028099, PMPDP3_129021/1, PMPDP3_141671/1), the Federal
   Office for the Environment, the Federal Office of Public Health, the
   Federal Office of Roads and Transport, the canton's government of
   Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and
   Zurich, the Swiss Lung League, the canton's Lung League of Basel
   Stadt/Basel Landschaft, Geneva, Ticino, Valais, Graubunden and Zurich,
   Stiftung ehemals Bundner Heilstatten, SUVA, Freiwillige Akademische
   Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH,
   Abbott Diagnostics, European Commission 018996 (GABRIEL), Wellcome Trust
   WT 084703MA. None of the funding bodies had a role in the concept,
   design, data collection, analysis and interpretation of the study.
NR 43
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 166
EP 172
DI 10.1016/j.atherosclerosis.2018.01.042
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800023
PM 29432934
DA 2019-10-28
ER

PT J
AU Reiner, Z
AF Reiner, Zeljko
TI PCSK9 inhibitors in clinical practice: Expectations and reality
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE PCSK9 inhibitors; LDL-cholesterol; Familial hypercholesterolaemia;
   Statin intolerance; Evolocumab; Alirocumab
ID FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR-DISEASE; PREVENTION;
   MANAGEMENT; THERAPY
C1 [Reiner, Zeljko] Univ Zagreb, Univ Hosp Ctr Zagreb, Sch Med, Dept Internal Med, Kispaticeva 12, Zagreb 10000, Croatia.
RP Reiner, Z (reprint author), Univ Zagreb, Univ Hosp Ctr Zagreb, Sch Med, Dept Internal Med, Kispaticeva 12, Zagreb 10000, Croatia.
EM zreiner@kbc-zagreb.hr
NR 15
TC 13
Z9 13
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 187
EP 188
DI 10.1016/j.atherosclerosis.2018.01.001
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800026
PM 29366497
DA 2019-10-28
ER

PT J
AU Jansen, JFA
AF Jansen, Jacobus F. A.
TI Assessment of extracranial and intracranial atherosclerosis: Don't
   dismiss old school autopsy
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Atherosclerosis; Carotid arteries; Cerebral arteries; Risk factors;
   Imaging
ID RISK-FACTORS; POPULATION; STENOSIS; PREVALENCE; STROKE
C1 [Jansen, Jacobus F. A.] Maastricht Univ, Med Ctr, Dept Radiol, Maastricht, Netherlands.
RP Jansen, JFA (reprint author), Maastricht Univ, Med Ctr, Dept Radiol, Maastricht, Netherlands.
EM jacobus.jansen@mumc.nl
RI Jansen, Jacobus F.A./C-4098-2009
OI Jansen, Jacobus F.A./0000-0002-5271-8060
NR 9
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 189
EP 190
DI 10.1016/j.atherosclerosis.2018.01.002
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800027
PM 29370885
DA 2019-10-28
ER

PT J
AU de Carvalho, LSF
AF de Carvalho, Luiz Sergio F.
TI Total cholesterol and the risk of stroke: A double-edged sword or a
   blunt knife?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Total cholesterol; Stroke; Ischemic stroke; Hemorrhagic stroke;
   Intracerebral hemorrhage
ID HEMORRHAGIC STROKE; METAANALYSIS; TRIALS
C1 [de Carvalho, Luiz Sergio F.] State Univ Campinas UNICAMP, Lab Atherosclerosis & Vasc Biol, Campinas, SP, Brazil.
   [de Carvalho, Luiz Sergio F.] Escola Super Ciencias Saude, Brasilia, DF, Brazil.
RP de Carvalho, LSF (reprint author), State Univ Campinas Unicamp, Lab Atherosclerosis & Vasc Biol AteroLab, BR-13084971 Campinas, SP, Brazil.
EM luizsergiofc@gmail.com
RI Carvalho, Luiz Sergio/A-8917-2019; Carvalho, Luiz Sergio F/I-5536-2019
OI Carvalho, Luiz Sergio/0000-0001-6465-356X; Carvalho, Luiz Sergio
   F/0000-0001-6465-356X
NR 12
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 191
EP 192
DI 10.1016/j.atherosclerosis.2018.01.016
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800028
PM 29395097
DA 2019-10-28
ER

PT J
AU Rattazzi, M
   Rosenfeld, ME
AF Rattazzi, Marcello
   Rosenfeld, Michael E.
TI The multifaceted role of macrophages in cardiovascular calcification
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Macrophages; Calcification
ID ENDOPLASMIC-RETICULUM STRESS; VASCULAR CALCIFICATION; MOUSE-MODEL;
   PLAQUES; BURDEN; CELLS
C1 [Rattazzi, Marcello] Univ Padua, Dept Med DIMED, Padua, Italy.
   [Rosenfeld, Michael E.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
RP Rattazzi, M (reprint author), Univ Padua, Dept Med DIMED, Med Interna 1, Ca Foncello Univ Hosp, Via Osped 1, I-31100 Treviso, Italy.
EM marcello.rattazzi@unipd.it
NR 20
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 193
EP 195
DI 10.1016/j.atherosclerosis.2018.01.046
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800029
PM 29395099
DA 2019-10-28
ER

PT J
AU Dube, PR
   Chikkamenahalli, LL
   Birnbaumer, L
   Vazquez, G
AF Dube, Prabhatchandra R.
   Chikkamenahalli, Lakshmikanth L.
   Birnbaumer, Lutz
   Vazquez, Guillermo
TI Reduced calcification and osteogenic features in advanced
   atherosclerotic plaques of mice with macrophage-specific loss of TRPC3
SO ATHEROSCLEROSIS
LA English
DT Article
DE TRPC3; Macrophage; Vascular calcification
ID BONE MORPHOGENETIC PROTEIN-2; APOE-DEFICIENT MICE; M1 MACROPHAGES;
   VASCULAR CALCIFICATION; MOUSE-MODEL; CELLS; ROLES; RANKL
AB Background and aims: Recent in vitro studies have showed that in macrophages, deletion of the nonselective Ca2+-permeable channel TRPC3 impairs expression of the osteogenic protein BMP-2. The pathophysiological relevance of this effect in atherosclerotic plaque calcification remains to be determined.
   Methods: We used Ldlr(-/-) mice with macrophage-specific loss of TRPC3 (MacTrpc3(-/-)/Ldlr(-/-)) to examine the effect of macrophage Trpc3 on plaque calcification and osteogenic features in advanced atherosclerosis.
   Results: After 25 weeks on high fat diet, aortic root plaques in MacTrpc3(-/-)/Ldlr(-/-) mice showed reduced size, lipid and macrophage content compared to controls. Plaque calcification was decreased in MacTrpc3(-/-)/Ldlr(-/-) mice, and this was accompanied by marked reduction in BMP-2, Runx-2 and phospho-SMAD1/5 contents within macrophage-rich areas. Expression of Bmp-2 and Runx-2 was also reduced in bone marrow-derived macrophages from MacTrpc3(-/-)/Ldlr(-/-) mice.
   Conclusions: These findings show that, in advanced atherosclerosis, selective deletion of TRPC3 in macrophages favors plaque regression and impairs the activity of a novel macrophage-associated, BMP-2-dependent mechanism of calcification. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Dube, Prabhatchandra R.; Chikkamenahalli, Lakshmikanth L.; Vazquez, Guillermo] Univ Toledo, Coll Med & Life Sci, Ctr Hypertens & Personalized Med, Dept Physiol & Pharmacol, Hlth Sci Campus,3000 Transverse Dr, Toledo, OH 43614 USA.
   [Birnbaumer, Lutz] NIEHS, Neurobiol Lab, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.
   [Birnbaumer, Lutz] Inst Biomed Res BIOMED UCA CONICET, Fac Med Sci, Ave Alicia Moreau de Justo 1600,C1107AFF, Buenos Aires, DF, Argentina.
RP Vazquez, G (reprint author), 3000 Transverse Dr,UTHSC Mail Stop 1008, Toledo, OH 43614 USA.
EM Guillermo.Vazquez@utoledo.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R56HL125619]; Intramural Research
   Program (NIH Project) [Z01-ES-101864]
FX Work was supported by NIH grant R56HL125619 (to G.V.) and the Intramural
   Research Program (NIH Project Z01-ES-101864 to L.B.).
NR 17
TC 2
Z9 2
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 199
EP 204
DI 10.1016/j.atherosclerosis.2017.12.025
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800031
PM 29290366
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Stoekenbroek, RM
   Hartgers, ML
   Rutte, R
   de Wijer, DD
   Stroes, ESG
   Hovingh, GK
AF Stoekenbroek, Robert M.
   Hartgers, Merel L.
   Rutte, Roger
   de Wijer, Douwe D.
   Stroes, Erik S. G.
   Hovingh, G. Kees
TI PCSK9 inhibitors in clinical practice: Delivering on the promise?
SO ATHEROSCLEROSIS
LA English
DT Article
DE PCSK9 inhibitors; Familial hypercholesterolemia; Statin intolerance;
   Hypercholesterolemia; Lipid-lowering drugs
ID ACUTE CORONARY SYNDROMES; STATIN THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA;
   CARDIOVASCULAR EVENTS; METAANALYSIS; EFFICACY; SAFETY; ALIROCUMAB;
   EZETIMIBE; ADHERENCE
AB Background and aims: In clinical trials, protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors robustly lowered LDL-cholesterol (LDL-c) and had a favorable tolerability and safety profile. Based on these findings, PCSK9 inhibitors are incorporated in updates of clinical treatment guidelines. However, trial results do not necessarily predict the effectiveness under real-world conditions. The aim of the current study is to determine the efficacy and tolerability of PCSK9 inhibitors in routine outpatient care.
   Methods: The cohort comprised all patients who were prescribed evolocumab or alirocumab at the outpatient clinic of a large university hospital in the Netherlands. Eligible patients required additional lipid-lowering despite maximally tolerated statin therapy and ezetimibe, or were statin intolerant. Data were systematically collected during routine outpatient visits.
   Results: The study included 238 patients of whom 67.2% had familial hypercholesterolemia (FH) and 42.9% were statin intolerant. The mean LDL-c reduction was 55.0% from a baseline of 4.4 mmol/L. LDL-c goals were attained by 62.3% of patients. Side effects were reported by 15.5% of patients and 2.5% discontinued treatment. No meaningful differences in efficacy or tolerability were observed between patients with FH or statin intolerance, or across treatment regimens.
   Conclusions: The observed lipid reductions and side effects profile of PCSK9 inhibitors in a routine care setting were comparable to observations in clinical trials. (c) 2018 The Authors. Published by Elsevier B.V.
C1 [Stoekenbroek, Robert M.; Hartgers, Merel L.; Rutte, Roger; de Wijer, Douwe D.; Stroes, Erik S. G.; Hovingh, G. Kees] Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands.
RP Hovingh, GK (reprint author), Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands.
EM g.k.hovingh@amc.uva.nl
OI Rutte, Roger/0000-0002-4499-5092
FU AmgenAmgen; SanofiSanofi-Aventis; Chiesi; Regeneron; MerckMerck &
   Company; Uniqure; Akcea; PfizerPfizer; Amgen Inc.Amgen; Eli LillyEli
   Lilly
FX ESGS reports that reimbursement has been paid to his institution for
   lecturing fees/advisory boards by Amgen, Sanofi, Chiesi, Regeneron,
   Merck, Uniqure, Akcea.; GKH reports that reimbursement has been paid to
   his institution for lecturing fees/advisory boards by Amgen, Sanofi and
   Pfizer related to PCSK9 inhibitors and institutional research funding
   related to PCSK9 inhibitor clinical trials from Amgen Inc., Sanofi, Eli
   Lilly and Pfizer.
NR 34
TC 10
Z9 10
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 205
EP 210
DI 10.1016/j.atherosclerosis.2017.11.027
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800032
PM 29254691
OA Other Gold
DA 2019-10-28
ER

PT J
AU Yi, SW
   Shin, DH
   Kim, H
   Yi, JJ
   Ohrr, H
AF Yi, Sang-Wook
   Shin, Dae-Hee
   Kim, Hyeyun
   Yi, Jee-Jeon
   Ohrr, Heechoul
TI Total cholesterol and stroke mortality in middle-aged and elderly
   adults: A prospective cohort study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Blood cholesterol; Intracerebral hemorrhage; Ischemic stroke; Cohort
   studies; Subarachnoid hemorrhage
ID SERUM TOTAL CHOLESTEROL; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN
   CHOLESTEROL; RANDOMIZED CONTROLLED-TRIALS; HEMORRHAGIC STROKE;
   ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; CARDIOVASCULAR-DISEASE; BLOOD
   CHOLESTEROL; STATIN THERAPY
AB Background and aims: The association between cholesterol and stroke has been inconsistent. This study aimed to examine the association between total cholesterol (TC) and mortality from total stroke and stroke subtypes.
   Methods: 503,340 Korean adults aged 40-80 years without a history of heart disease or stroke participated in routine health examinations in 2002 and 2003, and were followed up until 2013. Adjusted hazard ratios (HRs) for stroke (I60-I69) mortality were calculated.
   Results: Nonlinear associations for total stroke (U-curve) and hemorrhagic stroke (L-curve), especially intracerebral hemorrhage (ICH), but a linear association for ischemic stroke, were found. In the range <200 mg/dL, TC was inversely associated with stroke mortality (HR per 39 mg/dL [1 mmol/L] increase = 0.88 [95% CI = 0.80-0.95]), mainly due to hemorrhagic stroke (HR = 0.78 [0.68-0.90]), especially ICH (HR = 0.72 [0.62-0.85]). In the upper range (200-349 mg/dL), TC was positively associated with stroke mortality (HR = 1.09 [1.01-1.16]); ICH and subarachnoid hemorrhage mortality showed no inverse association. The associations were generally similar in middle-aged (40-64 years) and elderly (>= 65 years) adults and, in the upper range, each 1 mmol/L (39 mg/dL) higher TC was associated with 11% higher mortality from stroke (95% CI = 2%-21%) in the elderly. Both middle-aged (39%) and elderly (23%) adults had higher ischemic stroke mortality associated with TC >= 240 mg/dL, compare to <200 mg/dL.
   Conclusions: TC level around 200 mg/dL was associated with the lowest risk of overall stroke in the elderly and middle-aged adults. No stroke subtype including ICH, was inversely associated with TC in the range >= 200 mg/dL. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Yi, Sang-Wook] Catholic Kwandong Univ, Coll Med, Dept Prevent Med & Publ Hlth, Bumil Ro 579, Kangnung 25601, Gangwon Do, South Korea.
   [Yi, Sang-Wook] Catholic Kwandong Univ, Int St Marys Hosp, Inst Clin & Translat Res, Incheon 22711, South Korea.
   [Shin, Dae-Hee] Catholic Kwandong Univ, Int St Marys Hosp, Coll Med, Cardiovasc Ctr, Incheon 22711, South Korea.
   [Kim, Hyeyun] Catholic Kwandong Univ, Int St Marys Hosp, Coll Med, Dept Neurol, Incheon 22711, South Korea.
   [Yi, Jee-Jeon] Catholic Kwandong Univ, Inst Occupat & Environm Hlth, Kangnung 25601, South Korea.
   [Ohrr, Heechoul] Yonsei Univ, Dept Prevent Med, Coll Med, Seoul 03722, South Korea.
RP Yi, SW (reprint author), Catholic Kwandong Univ, Coll Med, Dept Prevent Med & Publ Hlth, Bumil Ro 579, Kangnung 25601, Gangwon Do, South Korea.
EM flyhigh@cku.ac.kr
OI Yi, Jee-Jeon/0000-0003-4602-297X; Yi, Sang-Wook/0000-0002-6656-6205;
   /0000-0002-8008-5539
FU NHIS of Korea; Catholic Kwandong University [201705850001]
FX Health examinations were funded and managed by the NHIS of Korea. This
   work was supported by research funds from Catholic Kwandong University
   (201705850001). Catholic Kwandong University had no role in study
   design, data collection, the writing of the manuscript, or the decision
   to submit it for publication.
NR 42
TC 8
Z9 8
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 211
EP 217
DI 10.1016/j.atherosclerosis.2017.12.003
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800033
PM 29241770
DA 2019-10-28
ER

PT J
AU Suemoto, CK
   Grinberg, LT
   Leite, REP
   Ferretti-Rebustini, REL
   Jacob, W
   Yaffe, K
   Nitrini, R
   Pasqualucci, CA
AF Suemoto, Claudia K.
   Grinberg, Lea T.
   Leite, Renata E. P.
   Ferretti-Rebustini, Renata E. L.
   Jacob-Filho, Wilson
   Yaffe, Kristine
   Nitrini, Ricardo
   Pasqualucci, Carlos A.
TI Morphometric measurements of extracranial and intracranial
   atherosclerotic disease: A population-based autopsy study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Carotid arteries; Cerebral arteries; Risk factors;
   Epidemiology
ID RISK-FACTORS; CEREBRAL-ARTERIES; CT-ANGIOGRAPHY; GLOBAL BURDEN;
   STENOSIS; STROKE
AB Background and aims: Intracranial (IAD) and extracranial atherosclerotic diseases (EAD) have been mostly investigated using imaging methods. Autopsy studies allow for a direct and complete evaluation of the atherosclerotic disease. We aimed to investigate the frequency of IAD and EAD, their association, and related risk profiles in a large cross-sectional autopsy study.
   Methods: We measured the intima-media thickness and stenosis of the common (CCA) and internal carotid arteries (ICA), using morphometric measurements. The main outcome was stenosis (>= 50%) in the artery with the largest obstruction among the 12 cerebral arteries. We used multivariable logistic regression models to investigate the association between EAD and IAD.
   Results: In 661 participants (mean age = 71.3 +/- 11.7 y, 51% male), stenosis was more common in IAD than in EAD (59% vs. 51%). EAD was associated with Caucasian race, hypertension, and smoking, while IAD was associated with older age, less years of education, hypertension, diabetes, and a previous history of stroke. Stenosis in CCA and ICA was associated with more than two times the odds of having stenosis in the intracranial arteries (CCA: OR = 2.32, 95% CI = 1.64; 3.28; ICA: OR = 2.51, 95% CI = 1.76; 3.57).
   Conclusions: In this population-based autopsy study, IAD was common, even more common than EAD, but correlated with EAD. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Suemoto, Claudia K.; Leite, Renata E. P.; Jacob-Filho, Wilson] Univ Sao Paulo, Sch Med, Div Geriatr, Sao Paulo, Brazil.
   [Grinberg, Lea T.] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA.
   [Ferretti-Rebustini, Renata E. L.] Univ Sao Paulo, Sch Nursing, Dept Med Surg Nursing, Sao Paulo, Brazil.
   [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94143 USA.
   [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Psychiat, San Francisco, CA 94143 USA.
   [Yaffe, Kristine] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
   [Nitrini, Ricardo] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil.
   [Pasqualucci, Carlos A.] Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
RP Suemoto, CK (reprint author), Ave Dr Arnaldo 455,Room 1355, BR-01246903 Sao Paulo, SP, Brazil.
EM cksuemoto@usp.br
RI Suemoto, Claudia/C-7218-2012
OI Suemoto, Claudia/0000-0002-5942-4778
FU University of Sao Paulo Medical School [LIM-22]; Coordination for the
   Improvement of Higher Education Personnel (CAPES)CAPES
FX LIM-22 University of Sao Paulo Medical School; CKS received scholarships
   from Coordination for the Improvement of Higher Education Personnel
   (CAPES).
NR 29
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD MAR
PY 2018
VL 270
BP 218
EP 223
DI 10.1016/j.atherosclerosis.2017.12.015
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FZ5NC
UT WOS:000427639800034
PM 29254693
OA Green Accepted, Bronze
DA 2019-10-28
ER

PT J
AU Chang, JJ
   Katsanos, AH
   Khorchid, Y
   Dillard, K
   Kerro, A
   Burgess, LG
   Goyal, N
   Alexandrov, AW
   Alexandrov, AV
   Tsivgoulis, G
AF Chang, Jason J.
   Katsanos, Aristeidis H.
   Khorchid, Yasser
   Dillard, Kira
   Kerro, Ali
   Burgess, Lucia Goodwin
   Goyal, Nitin
   Alexandrov, Anne W.
   Alexandrov, Andrei V.
   Tsivgoulis, Georgios
TI Higher low-density lipoprotein cholesterol levels are associated with
   decreased mortality in patients with intracerebral hemorrhage
SO ATHEROSCLEROSIS
LA English
DT Article
DE Intracerebral hemorrhage; Low-density lipoprotein; LDL; Mortality;
   Stroke; Statin; Cholesterol
ID HEMATOMA GROWTH; STATIN USE; ISCHEMIC-STROKE; METAANALYSIS; RISK;
   MICROBLEEDS; ATORVASTATIN; OUTCOMES; THERAPY; TRIALS
AB Background and aims: The relationship between lipoprotein levels, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and clinical outcome after intracerebral hemorrhage (ICH) remains controversial. We sought to evaluate the association of lipoprotein cholesterol levels and statin dosage with clinical and neuroimaging outcomes in patients with ICH.
   Methods: Data on consecutive patients hospitalized with spontaneous acute ICH was prospectively collected over a 5-year period and retrospectively analyzed. Demographic characteristics, clinical severity documented by NIHSS-score and ICH-score, neuroimaging parameters, pre-hospital statin use and doses, and LDL-C and HDL-C levels were recorded. Outcome events characterized were hematoma volume, hematoma expansion, in-hospital functional outcome, and in-hospital mortality.
   Results: A total of 672 patients with acute ICH [(mean age 61.6 +/- 14.0 years, 43.6% women, median ICH score 1 (IQR: 0-2)] were evaluated. Statin pretreatment was not associated with neuroimaging or clinical outcomes. Higher LDL-C levels were associated with several markers of poor clinical outcome and in-hospital mortality. LDL-C levels were independently and negatively associated with the cubed root of hematoma volume (linear regression coefficient -0.021, 95% CI: -0.042 - -0.001; p = 0.049) on multiple linear regression models. Higher admission LDL-C (OR 0.88, 95% CI 0.77-0.99; p = 0.048) was also an independent predictor for decreased hematoma expansion. Higher admission LDL-C levels were independently (p < 0.001) associated with lower likelihood of in-hospital mortality (OR per 10 mg/dL increase 0.68, 95% CI: 0.57-0.80) in multivariable logistic regression models.
   Conclusions: Higher LDL-C levels at hospital admission were an independent predictor for lower likelihood of hematoma expansion and decreased in-hospital mortality in patients with acute spontaneous ICH. This association requires independent confirmation. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Chang, Jason J.] MedStar Washington Hosp Ctr, Dept Crit Care Med, Washington, DC USA.
   [Katsanos, Aristeidis H.; Tsivgoulis, Georgios] Univ Athens, Attikon Univ Hosp, Sch Med, Dept Neurol 2, Athens, Greece.
   [Khorchid, Yasser; Dillard, Kira; Kerro, Ali; Burgess, Lucia Goodwin; Goyal, Nitin; Alexandrov, Anne W.; Alexandrov, Andrei V.; Tsivgoulis, Georgios] Univ Tennessee, Ctr Hlth Sci, Dept Neurol, Memphis, TN 38163 USA.
   [Alexandrov, Anne W.] Australian Catholic Univ, Sydney, BC, Australia.
RP Chang, JJ (reprint author), MedStar Washington Hosp, Med Ctr, Dept Crit Care Med, 110 Irving St,NW,Rm 4B42, Washington, DC 20010 USA.
EM jjwchang@hotmail.com
NR 30
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 14
EP 20
DI 10.1016/j.atherosclerosis.2017.12.008
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800003
PM 29253643
DA 2019-10-28
ER

PT J
AU Jung, S
   Song, SW
   Lee, S
   Kim, SH
   Ann, SJ
   Cheon, EJ
   Yi, G
   Choi, EY
   Lee, SH
   Joo, HC
   Ryu, DH
   Lee, SH
   Hwang, GS
AF Jung, Sunhee
   Song, Suk-Won
   Lee, Sak
   Kim, Se Hoon
   Ann, Soo-jin
   Cheon, Eun Jeong
   Yi, Gijong
   Choi, Eui-Young
   Lee, Seung Hyun
   Joo, Hyun-Chel
   Ryu, Do Hyun
   Lee, Sang-Hak
   Hwang, Geum-Sook
TI Metabolic phenotyping of human atherosclerotic plaques: Metabolic
   alterations and their biological relevance in plaque-containing aorta
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Metabolomics; Lipidomics; Quinic acid
ID CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS; QUINIC ACID; URIC-ACID; SERUM;
   GLUTATHIONE; RISK; SPHINGOLIPIDS; ATHEROGENESIS; ACCUMULATION
AB Background and aims: Atherosclerosis is a chronic inflammatory disease characterized by thickening of the arterial wall. However, a limited number of studies have been conducted on metabolic profiling of human aortic tissue.
   Methods: We applied liquid chromatography/mass spectrometry to perform global and targeted profiling of plaque-containing aortic tissue. The aorta samples included plaque-containing (n = 18) and control plaque-free (n = 24) aortic tissue from patients undergoing aortic surgery.
   Results: The metabolic patterns of atherosclerotic and control vessels were significantly different. Meta-bolites in the purine and glutathione pathways showed dysregulation of oxidative stress in plaques, and levels of glucosylceramide, tryptophan, and kynurenine, which are related to inflammation, were also altered. Interestingly, an increased level of quinic acid was observed in plaques (p < 0.000), and we demonstrated an inhibitory effect of quinic acid on inflammatory activation and oxidative stress in macrophages.
   Conclusions: Our study provides insight into the disease mechanism and potential markers of atherosclerosis through comprehensive metabolic profiling of human aortic tissue samples containing plaque. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Jung, Sunhee; Hwang, Geum-Sook] Korea Basic Sci Inst, Integrated Metabol Res Grp, Western Seoul Ctr, Seoul 120140, South Korea.
   [Jung, Sunhee; Ryu, Do Hyun] Sungkyunkwan Univ, Dept Chem, Suwon 440746, South Korea.
   [Song, Suk-Won; Yi, Gijong] Yonsei Univ, Coll Med, Dept Thorac & Cardiovasc Surg, Gangnam Severance Hosp, Seoul, South Korea.
   [Lee, Sak; Lee, Seung Hyun; Joo, Hyun-Chel] Yonsei Univ, Coll Med, Severance Hosp, Div Cardiovasc Surg, Seoul, South Korea.
   [Kim, Se Hoon] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea.
   [Ann, Soo-jin; Cheon, Eun Jeong; Lee, Sang-Hak] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea.
   [Cheon, Eun Jeong] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Div Cardiol,Heart Ctr, Seoul, South Korea.
   [Lee, Sang-Hak] Yonsei Univ, Coll Med, Severance Hosp, Div Cardiol,Dept Internal Med, 50-1,Yonsei Ro, Seoul 03722, South Korea.
   [Hwang, Geum-Sook] Ewha Womans Univ, Dept Life Sci, Seoul, South Korea.
RP Lee, SH (reprint author), Yonsei Univ, Coll Med, Severance Hosp, Div Cardiol,Dept Internal Med, 50-1,Yonsei Ro, Seoul 03722, South Korea.; Hwang, GS (reprint author), Korea Basic Sci Inst, 150,Bugahyeon Ro, Seoul 03759, South Korea.
EM shl1106@yuhs.ac; gshwang@kbsi.re.kr
OI Song, Suk-Won/0000-0002-9850-9707; Kim, Se Hoon/0000-0001-7516-7372;
   lee, seung hyun/0000-0002-0311-6565; Lee, Sak/0000-0001-6130-2342; Choi,
   Eui-Young/0000-0003-3732-0190; Joo, hyunchel/0000-0002-6842-2942
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [2013M3A9B6046418, 2015M3A6A4076702]; National Research Council of
   Science and Technology (CAP-2-KBSI); Korea Basic Science Institute
   [T37415]
FX This study was supported by the National Research Foundation of Korea
   (2013M3A9B6046418 and 2015M3A6A4076702), the National Research Council
   of Science and Technology (CAP-2-KBSI) and the Korea Basic Science
   Institute (T37415). We are grateful to Jiyeong Jeong, RN, for her
   excellent assistance with clinical data collection and patient care.
NR 40
TC 4
Z9 4
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 21
EP 28
DI 10.1016/j.atherosclerosis.2017.11.034
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800004
PM 29253644
DA 2019-10-28
ER

PT J
AU Rallidis, LS
   Pavlakis, G
   Foscolou, A
   Kotakos, C
   Katsimardos, A
   Drosatos, A
   Zolindaki, M
   Panagiotakos, DB
AF Rallidis, Loukianos S.
   Pavlakis, George
   Foscolou, Alexandra
   Kotakos, Christos
   Katsimardos, Andreas
   Drosatos, Alexandros
   Zolindaki, Maria
   Panagiotakos, Demosthenes B.
TI High levels of lipoprotein (a) and premature acute coronary syndrome
SO ATHEROSCLEROSIS
LA English
DT Article
DE Premature myocardial infarction; Lipoprotein(a); Acute coronary syndrome
ID ELEVATION MYOCARDIAL-INFARCTION; INDEPENDENT RISK-FACTOR; LONG-TERM
   PROGNOSIS; ARTERY-DISEASE; HEART-DISEASE; PLASMA LIPOPROTEIN(A);
   YOUNG-PATIENTS; AGE; STATINS; PEOPLE
AB Background and aims: High levels of lipoprotein(a) [Lp(a)] are associated with increased risk of acute coronary syndrome (ACS). We explored whether Lp(a) exhibits a stronger association with premature ACS.
   Methods: A case-control study was conducted; 1457 patients with a history of ACS (54.8 +/- 13 years, 86% males) and 2090 age-sex matched adults free of cardiovascular disease were enrolled. Bio-clinical characteristics [risk factors, low-density lipoprotein-cholesterol, Lp(a)] were derived through standard procedures.
   Results: A 10 mg/dL increase in Lp(a) was associated with 4% (95% CI, 1.01 to 1.02) higher likelihood of having ACS in younger (<45 years) and 2% (95% CI, 1.01 to 1.02) higher likelihood in middle-aged (45-60 years) individuals. Adjusting for common risk factors, elevated Lp(a), i.e. >50 mg/dL, was still associated with increased likelihood of ACS in younger adults (<45 years) (OR = 2.88, 95% CI, 1.7 to 4.6) and in middle aged ones (45 and 60 years) (OR = 2.06, 95% CI, 1.4 to 3.2), but not in older participants (>60 years) (OR = 1.31, 95% CI, 0.8 to 2.4).
   Conclusions: Lp(a) seems to be an independent risk factor for ACS in individuals <45 years, and high Lp(a) levels increase by similar to 3folds the risk for ACS. The association is preserved but is less in middle-aged individuals (45-60 years) and is abolished >60 years. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Rallidis, Loukianos S.; Katsimardos, Andreas; Drosatos, Alexandros] Univ Gen Hosp Attikon, Dept Cardiol 2, Athens, Greece.
   [Pavlakis, George] KAT Gen Hosp Attica, Athens, Greece.
   [Foscolou, Alexandra; Panagiotakos, Demosthenes B.] Harokopio Univ, Dept Nutr & Dietet, Sch Hlth Sci & Educ, Athens, Greece.
   [Kotakos, Christos] 251 Air Force Gen Hosp, Athens, Greece.
   [Zolindaki, Maria] Gen Hosp Nikea, Biochem Lab, Piraeus, Greece.
   [Panagiotakos, Demosthenes B.] Univ Canberra, Fac Hlth, Canberra, ACT, Australia.
   [Panagiotakos, Demosthenes B.] LA TROBE Univ, Sch Allied Hlth, Coll Sci Hlth & Engn, Melbourne, Vic, Australia.
RP Rallidis, LS (reprint author), 74 Thermopylon St, Argiroupolis 16451, Greece.
EM lrallidis@gmail.com
RI Panagiotakos, Demosthenes/C-9776-2013; Panagiotakos,
   Demosthenes/M-9167-2019; Panagiotakos, Demosthenes/K-8294-2019
OI Panagiotakos, Demosthenes/0000-0001-8583-153X; Panagiotakos,
   Demosthenes/0000-0001-8583-153X; 
NR 33
TC 12
Z9 12
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 29
EP 34
DI 10.1016/j.atherosclerosis.2017.12.011
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800005
PM 29258004
DA 2019-10-28
ER

PT J
AU Li, SM
   He, WB
   Chen, J
   Cai, QQ
   Huang, FF
   Zhang, K
   Wang, JF
   Liu, X
   Huang, H
AF Li, Shao-Min
   He, Wan-Bing
   Chen, Jie
   Cai, Qing-Qing
   Huang, Fei-Fei
   Zhang, Kun
   Wang, Jing-Feng
   Liu, Xun
   Huang, Hui
TI Combined blockade of renin-angiotensin-aldosterone system reduced
   all-cause but not cardiovascular mortality in dialysis patients: A
   mediation analysis and systematic review
SO ATHEROSCLEROSIS
LA English
DT Review
DE Dialysis; Renin-angiotensin-aldosterone system; Combined blockade;
   Efficacy; Safety; Mortality
ID CHRONIC KIDNEY-DISEASE; CHRONIC-HEMODIALYSIS PATIENTS; CONVERTING
   ENZYME-INHIBITORS; HEART-FAILURE PATIENTS; BLOOD-PRESSURE; DOUBLE-BLIND;
   RISK; SPIRONOLACTONE; HYPOTENSION; MORBIDITY
AB Background and aims: Full blockade of renin-angiotensin-aldosterone system (RAAS) is believed to decrease morbidity and mortality of patients with chronic kidney disease. In non-dialysis patients, combined RAAS blockade with two different RAAS blockers causes more adverse events without improving survival, but its role in maintenance dialysis patients is still unclear. We conducted a systematic review and mediation analysis to investigate the efficacy and safety of combined RAAS blockade in dialysis patients.
   Methods: Comprehensive search was conducted in PubMed, EMBASE, Web of Science and Cochrane Library database to June 2017 to identify relevant studies. Studies comparing combined with single RAAS blockade and reporting all-cause death, cardiovascular death, hypotension or hyperkalemia in dialysis patients were included. Effect sizes were calculated with randomized effects model and summarized as odd ratios (OR).
   Results: A total of 9 studies with 13,050 dialysis patients were included. Compared with single blockade, combined blockade significantly reduced all-cause mortality (OR 0.71, 95% confidence interval 0.54-0.93, p = 0.01), while cardiovascular mortality remained unchanged (0.85, 0.45-1.59, p = 0.61). Combined blockade tended to increase odd of hypotension but not odd of hyperkalemia (1.54, 1.00-2.38, p = 0.05; 0.89, 0.76-1.05, p = 0.17). Further mediation analysis indicated that hypotension might exert a suppression effect on the survival benefit of angiotensin-converting enzyme inhibitor plus angiotensin receptor blocker treatment on cardiovascular mortality.
   Conclusions: Combined RAAS blockade might be a promising treatment in dialysis patients to further reduce mortality if blood pressure was well controlled. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Li, Shao-Min; He, Wan-Bing; Chen, Jie; Huang, Fei-Fei; Zhang, Kun; Wang, Jing-Feng; Huang, Hui] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Dept Cardiol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.
   [Li, Shao-Min; Liu, Xun] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Internal Med, Div Nephrol, Guangzhou 510630, Guangdong, Peoples R China.
   [Li, Shao-Min; He, Wan-Bing; Huang, Fei-Fei; Zhang, Kun; Wang, Jing-Feng; Huang, Hui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Lab RNA & Major Dis Brain & Heart, Guangzhou 510120, Guangdong, Peoples R China.
   [Chen, Jie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Radiotherapy Dept, Guangzhou 510120, Guangdong, Peoples R China.
   [Cai, Qing-Qing] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou 510060, Guangdong, Peoples R China.
RP Liu, X (reprint author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Internal Med, Div Nephrol, Guangzhou 510630, Guangdong, Peoples R China.; Huang, H (reprint author), Sun Yat Sen Univ, Dept Cardiol, Sun Yat Sen Mem Hosp, 107 West Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.
EM naturestyle@163.com; huangh8@mail.sysu.edu.cn
FU NSFCNational Natural Science Foundation of China [81670676, 81422011,
   81370837, 81500563, 81370866, 81070612]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [2014A030313035]; Key Laboratory of Malignant Tumor Molecular
   Mechanism and Translational Medicine of Guangzhou Bureau of Science and
   Information Technology [[2013]163]; Key Laboratory of Malignant Tumor
   Gene Regulation and Target Therapy of Guangdong Higher Education
   Institutes [KLB09001]; National Project of Scientific and Technical
   Supporting Programs, Ministry of Science & Technology of ChinaMinistry
   of Science and Technology, China [2011BAI10B00]
FX This work was supported in part by NSFC [grant numbers 81670676,
   81422011, 81370837, 81500563, 81370866, 81070612]; Natural Science
   Foundation of Guangdong Province [grant numbers 2014A030313035]; Key
   Laboratory of Malignant Tumor Molecular Mechanism and Translational
   Medicine of Guangzhou Bureau of Science and Information Technology
   [grant number [2013]163]; Key Laboratory of Malignant Tumor Gene
   Regulation and Target Therapy of Guangdong Higher Education Institutes
   [grant number KLB09001]; the National Project of Scientific and
   Technical Supporting Programs, Ministry of Science & Technology of China
   [grant number 2011BAI10B00]. The funding resources did not involve in
   study design, data collection, analysis and interpretation, writing of
   the report or decision to submit the article for publication.
NR 47
TC 1
Z9 1
U1 3
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 35
EP 41
DI 10.1016/j.atherosclerosis.2017.12.009
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800006
PM 29258005
DA 2019-10-28
ER

PT J
AU Lightell, DJ
   Moss, SC
   Woods, TC
AF Lightell, Daniel J., Jr.
   Moss, Stephanie C.
   Woods, T. Cooper
TI Upregulation of miR-221 and-222 in response to increased extracellular
   signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia
   in diabetes mellitus
SO ATHEROSCLEROSIS
LA English
DT Article
DE Diabetes mellitus; Intimal thickening; miR-221; miR-222; p27(Kip1)
ID MUSCLE-CELL PROLIFERATION; CAROTID-ARTERY; MOUSE MODEL; RAPAMYCIN
   RESISTANCE; DEFECTIVE REGULATION; NONDIABETIC SUBJECTS; RELATIVE
   RESISTANCE; INSULIN-RESISTANCE; CORONARY-ARTERIES; PROTEIN-KINASES
AB Background and aims: Diabetes is associated with accelerated arterial intimal thickening that contributes to the increased cardiovascular disease seen in this population. In healthy arteries, intimal thickening is inhibited by elevated levels of the cyclin-dependent kinase inhibitor, p27(Kip1), and intimal thickening is promoted by activation of the mammalian Target of Rapamycin to promote degradation of p27(Kip1) protein. Recently, we reported that two microRNAs, miR-221 and -222, which promote intimal thickening via down-regulation of mRNA encoding p27(Kip1), are elevated in the arteries of diabetic patients. To determine if these miRNAs are critical to the increased intimal thickening under diabetic conditions, we examined the regulation of p27(Kip1) in a mouse model of diabetes.
   Methods: Comparisons of p27(Kip1) signaling in NONcNZO10 mice fed a diabetogenic versus control diet were performed using immunochemistry and real-time PCR.
   Results: Vascular smooth muscle cells and arteries of diabetic mice exhibited decreased levels of p27(Kip1) that derived from destabilization of p27(Kip1) mRNA in an extracellular signal response kinase-1/2 (ERK-1/2) dependent manner. The activity of ERK-1/2 is increased in the arteries of diabetic mice and promotes an increase in miR-221 and -222. Inhibition of miR-221 and -222 restores normal levels of p27(Kip1) mRNA and protein in the arteries of diabetic mice and reduces intimal thickening following wire injury.
   Conclusions: These data suggest diabetes is accompanied by increases in arterial miR-221 and -222 expression that promotes intimal thickening. Inhibition of the increased miR-221 and -222 may be efficacious in the prevention of the cardiovascular complications of diabetes. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Lightell, Daniel J., Jr.; Woods, T. Cooper] Tulane Univ, Sch Med, Dept Physiol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Lightell, Daniel J., Jr.; Woods, T. Cooper] Tulane Univ, Sch Med, Dept Med, Sect Cardiol, New Orleans, LA 70112 USA.
   [Lightell, Daniel J., Jr.; Moss, Stephanie C.; Woods, T. Cooper] Ochsner Clin Fdn, Lab Mol Cardiol, New Orleans, LA USA.
RP Woods, TC (reprint author), Tulane Univ, Sch Med, Dept Physiol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM twoods3@tulane.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01HL127092,
   P30GM103337, U54GM104940]; American Diabetes AssociationAmerican
   Diabetes Association [1-13-BS-210]
FX Research reported in this publication was supported by National
   Institutes of Health (R01HL127092, P30GM103337 and U54GM104940) and the
   American Diabetes Association (1-13-BS-210).
NR 46
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 71
EP 78
DI 10.1016/j.atherosclerosis.2017.12.016
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800011
PM 29276985
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Mitchelmore, A
   Stoner, L
   Lambrick, D
   Jobson, S
   Faulkner, J
AF Mitchelmore, Andrew
   Stoner, Lee
   Lambrick, Danielle
   Jobson, Simon
   Faulkner, James
TI Reliability of oscillometric central blood pressure and central systolic
   loading in individuals over 50 years: Effects of posture and fasting
SO ATHEROSCLEROSIS
LA English
DT Article
DE Arterial stiffness; Augmentation index; Posture; Fasting state;
   Reliability; Pulse wave analysis; SphygmoCor XCEL
ID ARTERIAL STIFFNESS; AUGMENTATION INDEX; BODY POSITION; SPHYGMOCOR XCEL;
   IMPACT; DEVICE; SUPINE; WOMEN; ARM
AB Background and aims: The between-day reliability of oscillometric pulse wave analysis has been demonstrated in a young, healthy population but not in an older sample. This study examined the between-day reliability of the SphygmoCor XCEL in individuals over 50 years. As blood pressure is measured in a range of postures and fasting states (supine/seated, fasted/non-fasted), this study also investigated the effect of these variables on central blood pressure and central systolic loading.
   Methods: Fifty-one adults (m = 21; age 57 +/- 6.4 y) were tested on three mornings in supine and seated conditions and in fasted and non-fasted states. Data was analysed as a whole and for normotensive (n = 25) and hypertensive participants (n = 26).
   Results: SphygmoCor XCEL demonstrated strong reliability in the whole sample for central systolic and diastolic blood pressures, augmentation index (AIx) and AIx75 (ICC = 0.77-0.95). Significant interaction effects were observed in central diastolic blood pressure, central pulse pressure, augmentation index (AIx) and AIx75 (p < 0.05; h(p)(2) = 0.10-0.23). Fasting state had a greater influence on central pressures in a seated than supine posture, but a greater effect on central systolic loading measures in a supine posture.
   Conclusions: The SphygmoCor XCEL is a reliable tool to assess central haemodynamic variables in an older population. It would be pertinent for clinicians and researchers to record central measures in a supine posture to minimise the effects of food consumption. Conversely, the assessment of central systolic loading should occur in a seated condition to minimise the influence of varying fasting states. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Mitchelmore, Andrew; Jobson, Simon; Faulkner, James] Univ Winchester, Dept Sport & Exercise, Winchester SO22 4NR, Hants, England.
   [Stoner, Lee] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA.
   [Lambrick, Danielle] Univ Southampton, Fac Hlth Sci, Southampton, Hants, England.
RP Mitchelmore, A (reprint author), Univ Winchester, Dept Sport & Exercise, Winchester SO22 4NR, Hants, England.
EM Andrew.Mitchelmore@winchester.ac.uk
OI Lambrick, Danielle/0000-0002-0325-6015; Mitchelmore,
   Andrew/0000-0002-1493-9735; Jobson, Simon/0000-0002-1377-2128
NR 30
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 79
EP 85
DI 10.1016/j.atherosclerosis.2017.12.030
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800012
PM 29339276
DA 2019-10-28
ER

PT J
AU Hui, TH
   McClelland, RL
   Allison, MA
   Rodriguez, CJ
   Kronmal, RA
   Heckbert, SR
   Michos, ED
   Barter, PJ
   Rye, KA
   Ong, KL
AF Hui, Tsz Him
   McClelland, Robyn L.
   Allison, Matthew A.
   Rodriguez, Carlos J.
   Kronmal, Richard A.
   Heckbert, Susan R.
   Michos, Erin D.
   Barter, Philip J.
   Rye, Kerry-Anne
   Ong, Kwok Leung
TI The relationship of circulating fibroblast growth factor 21 levels with
   incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atrial fibrillation; Cardiovascular disease; Fibroblast growth factor
   21; Multi-ethnic study of atherosclerosis
ID NATRIURETIC PEPTIDE; SUBCLINICAL ATHEROSCLEROSIS; OXIDATIVE STRESS;
   RISK-FACTORS; PPAR-ALPHA; HEART; ASSOCIATION; MESA;
   FIBROBLAST-GROWTH-FACTOR-21; PREDICTOR
AB Background and aims: Elevated circulating levels of fibroblast growth factor 21 (FGF21) are associated with multiple cardiovascular disease (CVD) risk factors and incident events. Previous small cross-sectional studies, mainly in Chinese populations, have suggested FGF21 may play a role in the development of atrial fibrillation (AF). We therefore investigated the relationship of FGF21 levels with incident AF in participants free of clinically apparent CVD at baseline in a large, multi-ethnic cohort.
   Methods: A total of 5729 participants of four major ethnic groups (Caucasian, African American, Hispanic American, and Chinese American) from the Multi-Ethnic Study of Atherosclerosis (MESA), who were free of AF and had plasma FGF21 levels measured by ELISA at the baseline exam, were included in the analysis. Participants were followed up for incident AF over a median period of 12.9 years. Cox proportional hazards regression analysis was used.
   Results: Among the 5729 participants, 778 participants developed incident AF. Participants with incident AF had significantly higher baseline FGF21 levels than those without incident AF (median = 166.0 and 142.8 pg/mL, p < 0.001). After adjusting for possible confounders, including demographic, socioeconomic and lifestyle factors, traditional CVD risk factors and circulating inflammatory markers, higher baseline FGF21 levels did not predict incident AF over the follow up period. There was no effect modification by sex or ethnicity.
   Conclusions: Baseline FGF21 levels were not associated with the development of AF in an ethnically diverse population followed long-term. Our findings do not support an important role of FGF21 in AF development. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Hui, Tsz Him; Barter, Philip J.; Rye, Kerry-Anne; Ong, Kwok Leung] Univ New South Wales, Sch Med Sci, Lipid Res Grp, Sydney, NSW, Australia.
   [McClelland, Robyn L.; Kronmal, Richard A.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
   [Allison, Matthew A.] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA.
   [Rodriguez, Carlos J.] Wake Forest Univ, Dept Epidemiol & Prevent, Sch Med, Winston Salem, NC 27109 USA.
   [Rodriguez, Carlos J.] Wake Forest Univ, Dept Med, Sch Med, Winston Salem, NC 27109 USA.
   [Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
   [Michos, Erin D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Michos, Erin D.] Johns Hopkins Sch Med, Div Cardiol, Baltimore, MD USA.
RP Ong, KL (reprint author), Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia.
EM oklws@yahoo.com.hk
RI Ong, Kwok Leung/B-9018-2009
OI Ong, Kwok Leung/0000-0001-7229-7614; Michos, Erin/0000-0002-5547-5084
FU NSW CVRN Research Development Project Grant from the National Heart
   Foundation of Australia [100715]; University of New South Wales
   [RG134592]; Australian National Health and Medical Research Council
   Career Development FellowshipNational Health and Medical Research
   Council of Australia [1122854]; National Heart, Lung, and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HHSN268201500003I, N01-HC-95159, N01-HC-95160,
   N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165,
   N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, R01-HL-127659];
   National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1-TR-000040, UL1-TR001079, UL1-TR-001420]
FX The FGF21 level measurement was supported by the NSW CVRN Research
   Development Project Grant (100715) from the National Heart Foundation of
   Australia to Dr. Kwok Leung Ong. Kwok Leung Ong was supported by the
   Vice-Chancellor's Postdoctoral Fellowship from the University of New
   South Wales (RG134592) and the Australian National Health and Medical
   Research Council Career Development Fellowship (1122854). The MESA study
   was supported by contracts HHSN268201500003I, N01-HC-95159,
   N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164,
   N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and
   R01-HL-127659 from the National Heart, Lung, and Blood Institute, by
   grants UL1-TR-000040, UL1-TR001079, and UL1-TR-001420 from National
   Center for Advancing Translational Sciences.
NR 40
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 86
EP 91
DI 10.1016/j.atherosclerosis.2017.12.026
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800013
PM 29351855
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Nam, KW
   Kwon, HM
   Jeong, HY
   Park, JH
   Kim, SH
   Jeong, SM
AF Nam, Ki-Woong
   Kwon, Hyung-Min
   Jeong, Han-Yeong
   Park, Jin-Ho
   Kim, Sang Hyuck
   Jeong, Su-Min
TI High neutrophil to lymphocyte ratios predict intracranial
   atherosclerosis in a healthy population
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Inflammation; Magnetic resonance imaging; Magnetic
   resonance angiography; Leukocyte; Neutrophil; Lymphocyte
ID CAROTID-ARTERY STENOSIS; ACUTE ISCHEMIC-STROKE; METABOLIC SYNDROME;
   NEUTROPHIL/LYMPHOCYTE RATIO; DISEASE; SEVERITY; DYSLIPIDEMIA;
   HYPERTENSION; ASSOCIATION; MECHANISMS
AB Background and aims: Although atherosclerosis has been shown to be an inflammatory disease, intracranial atherosclerosis (ICAS) has not been well addressed. The purpose of this study was to evaluate the relationship between the neutrophil to lymphocyte ratio (NLR) and the presence of ICAS lesions in a generally healthy population.
   Methods: A consecutive series of subjects, who voluntarily visited for health check-ups between January 2006 and December 2013, were selected. Brain magnetic resonance imaging, brain magnetic angiography (MRA), and blood cell count data were assessed. ICAS was defined as an occlusion or more than 50% stenosis of intracranial vessels, as observed on brain MRA images. NLR was calculated based on absolute neutrophil and lymphocyte counts.
   Results: A total of 2842 subjects were evaluated, and 76 ICAS cases were found. The median NLR was 1.52 [1.17-2.01]. In multivariate analysis, NLR remained an independent predictor of ICAS [adjusted OR (aOR) = 1.72, 95% confidence interval (CI) = 1.01-2.95, p = 0.048]. Age (aOR = 1.08, 95% CI = 1.05-1.11, p < 0.001) and hypertension (aOR = 1.81, 95% CI = 1.11-2.94, p = 0.017) were also significant factors for ICAS independent of NLR. Regarding ICAS burdens, NLR was significantly higher when the number of ICAS lesions (p = 0.017) or occlusive ICAS lesions (p = 0.005) was increased in a dose-response manner.
   Conclusions: A high NLR was associated with both prevalence and burdens of ICAS in a healthy population. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Nam, Ki-Woong; Jeong, Han-Yeong] Seoul Natl Univ, Dept Neurol, Coll Med, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
   [Nam, Ki-Woong; Jeong, Han-Yeong; Park, Jin-Ho; Kim, Sang Hyuck; Jeong, Su-Min] Seoul Natl Univ Hosp, 101 Daehakno, Seoul 03080, South Korea.
   [Park, Jin-Ho; Kim, Sang Hyuck; Jeong, Su-Min] Seoul Natl Univ, Dept Family Med, Coll Med, 101 Daehakno, Seoul 03080, South Korea.
   [Kwon, Hyung-Min] Seoul Natl Univ, Dept Neurol, Coll Med, Seoul, South Korea.
   [Kwon, Hyung-Min] Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
RP Kwon, HM (reprint author), Seoul Natl Univ, Dept Neurol, Coll Med, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.; Park, JH (reprint author), Seoul Natl Univ Hosp, 101 Daehakno, Seoul 03080, South Korea.; Park, JH (reprint author), Seoul Natl Univ, Dept Family Med, Coll Med, 101 Daehakno, Seoul 03080, South Korea.; Kwon, HM (reprint author), Seoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
EM hmkwon@snu.ac.kr; kkolzzi0@gmail.com
OI Kwon, Hyung-Min/0000-0002-6101-7127
NR 39
TC 6
Z9 6
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 117
EP 121
DI 10.1016/j.atherosclerosis.2017.12.035
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800017
PM 29353226
DA 2019-10-28
ER

PT J
AU Tedesco, CC
   Veglia, F
   de Faire, U
   Kurl, S
   Smit, AJ
   Rauramaa, R
   Giral, P
   Amato, M
   Bonomi, A
   Ravani, A
   Frigerio, B
   Castelnuovo, S
   Sansaro, D
   Mannarino, E
   Humphries, SE
   Hamsten, A
   Tremoli, E
   Baldassarre, D
AF Tedesco, Calogero C.
   Veglia, Fabrizio
   de Faire, Ulf
   Kurl, Sudhir
   Smit, Andries J.
   Rauramaa, Rainer
   Giral, Philippe
   Amato, Mauro
   Bonomi, Alice
   Ravani, Alessio
   Frigerio, Beatrice
   Castelnuovo, Samuela
   Sansaro, Daniela
   Mannarino, Elmo
   Humphries, Steve E.
   Hamsten, Anders
   Tremoli, Elena
   Baldassarre, Damiano
CA IMPROVE Study Grp
TI Association of lifelong occupation and educational level with
   subclinical atherosclerosis in different European regions. Results from
   the IMPROVE study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Socioeconomic status; European countries; Geographical
   variations; Vascular risk factors
ID INTIMA-MEDIA THICKNESS; CORONARY-HEART-DISEASE; SOCIOECONOMIC-STATUS;
   CARDIOVASCULAR-DISEASE; CAROTID ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION;
   OLDER-ADULTS; RISK; INEQUALITIES; POPULATION
AB Background and aims: We aimed to examine the association between socioeconomic status (SES) and subclinical atherosclerosis, as assessed by carotid intima-media-thickness (C-IMT) and to investigate whether the effect of social inequality on C-IMT is mediated by cardiovascular (CV) risk factors and whether it is dissimilar in men and women, and in different European countries.
   Methods: We assessed the association of lifelong occupation and educational level with C-IMT in the IMPROVE study cohort including 3703 subjects (median age 64.4 years; 48% men) from Southern (Italy), Western (France and the Netherlands) and Northern Europe (Finland and Sweden). Three summary measures of C-IMT (IMTmean, IMTmax, IMTmean-max), obtained from four segments of both carotids, were considered.
   Results: After adjusting for conventional CV risk factors, current employment status and diet, C-IMT was higher in manual workers than in white collars (+7.7%, +5.3%, +4.6% for IMTmax, IMTmean-max and IMTmean, respectively; all p<.0001). Similar results were obtained by stratification for educational level. The effect of occupation on C-IMT was comparable in men and women and in different age groups, and was only partially mediated by differences in CV risk factors. Of note, the association of C-IMT with occupation was significant in Western and Northern Europe but not in Italy, with a significant statistical interaction (p = .0005).
   Conclusions: Low SES was associated with subclinical atherosclerosis in subjects with at least three CV risk factors. Such association was stronger in Northern and Western Europe than in Italy. This difference was not completely explained by inequalities in CV risk factors and behavioural variables. (C) 2017 Published by Elsevier Ireland Ltd.
C1 [Tedesco, Calogero C.; Veglia, Fabrizio; Amato, Mauro; Bonomi, Alice; Ravani, Alessio; Frigerio, Beatrice; Sansaro, Daniela; Tremoli, Elena; Baldassarre, Damiano] IRCCS, Ctr Cardiol Monzino, Via Parea 4, Milan, Italy.
   [de Faire, Ulf] Karolinska Inst, Inst Environm Med, Karolinska Univ Hosp, Div Cardiovasc Epidemiol,Dept Cardiol, Solna, Sweden.
   [de Faire, Ulf] Karolinska Inst, Stockholm, Sweden.
   [Kurl, Sudhir] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio Campus, Kuopio, Finland.
   [Smit, Andries J.] Univ Groningen, Univ Med Ctr Groningen, Dept Med, Groningen, Netherlands.
   [Rauramaa, Rainer] Kuopio Res Inst Exercise Med, Fdn Res Hlth Exercise & Nutr, Kuopio, Finland.
   [Giral, Philippe] Grp Hop Pitie Salpetriere, AP HP, Serv Endocrinol Metab, Unites Prevent Cardiovasc, Paris, France.
   [Castelnuovo, Samuela] Osped Ca Granda Milano, Ctr Dislipidemie E Grossi Paoletti, Milan, Italy.
   [Mannarino, Elmo] Univ Perugia, Dept Clin & Expt Med, Internal Med Angiol & Arteriosclerosis Dis, Perugia, Italy.
   [Humphries, Steve E.] UCL, Inst Cardiovasc Sci, British Heart Fdn Labs, Cardiovasc Genet, Rayne Bldg, London, England.
   [Hamsten, Anders] Karolinska Inst, Dept Med Solna, Cardiovasc Med Unit, Stockholm, Sweden.
   [Tremoli, Elena] Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy.
   [Baldassarre, Damiano] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy.
RP Veglia, F (reprint author), IRCCS, Ctr Cardiol Monzino, Via Parea 4, Milan, Italy.
EM fabrizio.veglia@ccfm.it
RI AMATO, Mauro/N-2058-2019; TREMOLI, ELENA/I-8126-2018; Baldassarre,
   Damiano/J-3295-2016
OI AMATO, Mauro/0000-0002-0118-5719; TREMOLI, ELENA/0000-0002-0929-6106;
   Baldassarre, Damiano/0000-0002-2766-8882; Bonomi,
   Alice/0000-0001-5409-0791
FU European CommissionEuropean Commission Joint Research Centre
   [QLG1-CT-2002-00896]; Ministero della Salute Ricerca Corrente,
   ItalyMinistry of Health, Italy [2622841 BIO23]; Swedish Heart-Lung
   FoundationSwedish Heart-Lung Foundation [20140433]; Swedish Research
   CouncilSwedish Research Council [8691, 0593]; Foundation for Strategic
   Research; Stockholm County CouncilStockholm County Council [562183];
   Academy of FinlandAcademy of Finland [110413]; British Heart
   FoundationBritish Heart Foundation [RG2008/008]
FX This study was supported by the European Commission (Contract number:
   QLG1-CT-2002-00896) (to ET, DB, AH, SEH, RR, UdF, AJS, PG, SK, EM),
   Ministero della Salute Ricerca Corrente, Italy (2622841 BIO23 to ET,
   DB), the Swedish Heart-Lung Foundation (20140433), the Swedish Research
   Council - project 8691(to AH) and 0593, (to UdF), the Foundation for
   Strategic Research, the Stockholm County Council - project 562183, (to
   AH), the Foundation for Strategic Research, the Academy of Finland -
   Grant #110413, (to SK) and the British Heart Foundation - RG2008/008,
   (to SEH). None of the aforementioned funding organizations or sponsors
   has had a specific role in design or conduct of the study, collection,
   management, analysis, or interpretation of the data, or preparation,
   review, or approval of the manuscript.
NR 31
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 129
EP 137
DI 10.1016/j.atherosclerosis.2017.12.023
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800019
PM 29353228
DA 2019-10-28
ER

PT J
AU Hilvo, M
   Simolin, H
   Metso, J
   Ruuth, M
   Oorni, K
   Jauhiainen, M
   Laaksonen, R
   Baruch, A
AF Hilvo, Mika
   Simolin, Helena
   Metso, Jari
   Ruuth, Maija
   Oorni, Katariina
   Jauhiainen, Matti
   Laaksonen, Reijo
   Baruch, Amos
TI PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
SO ATHEROSCLEROSIS
LA English
DT Article
DE PCSK9; Lipidomics; Lipoproteins; Atherosclerosis; Sphingolipids; Drug
   therapy
ID CORONARY-ARTERY-DISEASE; HEART-DISEASE; LDL-C; HYPERCHOLESTEROLEMIA;
   INFLAMMATION; DEFICIENCY; RISK
AB Background and aims: While inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is known to result in dramatic lowering of LDL-cholesterol (LDL-C), it is poorly understood how it affects other lipid species and their metabolism. The aim of this study was to characterize the alterations in the lipidome of plasma and lipoprotein particles after administration of PCSK9 inhibiting antibody to patients with established coronary heart disease.
   Methods: Plasma samples were obtained from patients undergoing a randomized placebo-controlled phase II trial (EQUATOR) for the safe and effective use of RG7652, a fully human monoclonal antibody inhibiting PCSK9 function. Lipoprotein fractions were isolated by sequential density ultracentrifugation, and both plasma and major lipoprotein classes (VLDL-IDL, LDL, HDL) were subjected to mass spectrometric lipidomic profiling.
   Results: PCSK9 inhibition significantly decreased plasma levels of several lipid classes, including sphingolipids (dihydroceramides, glucosylceramides, sphingomyelins, ceramides), cholesteryl esters and free cholesterol. Previously established ceramide ratios predicting cardiovascular mortality, or inflammation related eicosanoid lipids, were not altered. RG7652 treatment also affected the overall and relative distribution of lipids in lipoprotein classes. An overall decrease of total lipid species was observed in LDL and VLDL thorn IDL particles, while HDL-associated phospholipids increased. Following the treatment, LDL displayed reduced lipid cargo, whereas relative lipid proportions of the VLDL thorn IDL particles were mostly unchanged, and there were relatively more lipids carried in the HDL particles.
   Conclusions: Administration of PCSK9 antibody significantly alters the lipid composition of plasma and lipoprotein particles. These changes further shed light on the link between anti-PCSK9 therapies and cardiovascular risk. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hilvo, Mika; Simolin, Helena; Laaksonen, Reijo] Zora Biosci Oy, Biol 1, Espoo 02150, Finland.
   [Metso, Jari; Jauhiainen, Matti] Minerva Fdn, Biomed, FI-00290 Helsinki, Finland.
   [Metso, Jari; Jauhiainen, Matti] Natl Inst Hlth & Welf, Genom & Biomarkers Unit, Biomed, FI-00290 Helsinki, Finland.
   [Ruuth, Maija; Oorni, Katariina] Wihuri Res Inst, Haartmaninkatu 8, FI-00290 Helsinki, Finland.
   [Ruuth, Maija] Univ Helsinki, Res Programs Unit, FI-00014 Helsinki, Finland.
   [Laaksonen, Reijo] Univ Tampere, Finnish Cardiovasc Res Ctr, Tampere, Finland.
   [Laaksonen, Reijo] Tampere Univ Hosp, Finnish Clin Biobank Tampere, Tampere, Finland.
   [Baruch, Amos] Genentech Inc, Dev Sci, 1 DNA Way MS 46-1A, San Francisco, CA 94080 USA.
RP Laaksonen, R (reprint author), Zora Biosci Oy, Biol 1, Espoo 02150, Finland.; Baruch, A (reprint author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM reijo.laaksonen@zora.fi; baruch.amos@gene.com
RI Oorni, Katariina/G-2484-2011; Ruuth, Maija/P-6767-2019
OI Oorni, Katariina/0000-0002-9525-0250; Ruuth, Maija/0000-0001-8903-0617
FU Finnish Foundation for Cardiovascular Research; Academy of
   FinlandAcademy of Finland [265940]; Jane and Aatos Erkko Foundation
   [01062016]
FX M.R. and K.O. were supported by Finnish Foundation for Cardiovascular
   Research and K.O. by Academy of Finland (grant number 265940). M.J. and
   J.M. were supported by Jane and Aatos Erkko Foundation (#01062016).
NR 24
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 159
EP 165
DI 10.1016/j.atherosclerosis.2018.01.004
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800023
PM 29366988
OA Green Published
DA 2019-10-28
ER

PT J
AU Stojkovic, S
   Jurisic, M
   Kopp, CW
   Koppensteiner, R
   Huber, K
   Wojta, J
   Gremmel, T
AF Stojkovic, Stefan
   Jurisic, Magdalena
   Kopp, Christoph W.
   Koppensteiner, Renate
   Huber, Kurt
   Wojta, Johann
   Gremmel, Thomas
TI Circulating microRNAs identify patients at increased risk of in-stent
   restenosis after peripheral angioplasty with stent implantation
SO ATHEROSCLEROSIS
LA English
DT Article
DE miR-195; Peripheral artery disease; In-stent restenosis;
   Revascularization
ID ANKLE-BRACHIAL INDEX; MUSCLE-CELL PHENOTYPE; MYOCARDIAL-INFARCTION;
   DISEASE; ASSOCIATION; EXPRESSION; BIOMARKERS; ATHEROSCLEROSIS;
   LIMITATIONS; MODULATION
AB Background and aims: Target lesion restenosis is the most frequent complication after angioplasty and stenting for peripheral artery disease (PAD). MicroRNAs (miRs) regulate crucial pathophysiological processes leading to in-stent restenosis and thrombosis. The aim of this study was to investigate the predictive value of 11 miRs for the composite endpoint of target lesion restenosis and atherothrombotic events (primary endpoint), and target vessel revascularization (TVR, secondary endpoint) in 62 consecutive PAD patients after infrainguinal angioplasty with stent implantation.
   Methods: Circulating miRs were assessed using quantitative real-time polymerase chain reactions.
   Results: Within the 2 years of follow-up, the primary endpoint occurred in 26 patients (41.9%), and 21 patients (33.9%) underwent TVR. miR-92a and miR-195 were identified as independent predictors of the primary endpoint after adjustment for age, sex and clinical risk factors with respective HR per 1 increase of standard deviation (1-SD) of 0.55 (95% CI: 0.34-0.88, p = 0.013) and HR per 1-SD of 0.40 (95% CI: 0.23-0.68, p = 0.001). MiR-195 independently predicted TVR with HR per 1-SD of 0.40 (95% CI: 0.22-0.75, p = 0.005). Adding miR-195 to clinical risk factors improved Harrell's C-index to 0.75 (95% CI: 0.66-0.85, p = 0.03) and was superior to a model with miR-92a (C-index: 0.70, 95% CI: 0.60-0.80, p for comparison = 0.012). Assessment of both miR-92a and miR-195 had no incremental value when compared to miR-195 alone (C-index: 0.79, 95% CI: 0.69-0.88, p = 0.313).
   Conclusions: Circulating miR-195 predicts adverse ischemic events and TVR after infrainguinal angioplasty with stent implantation. MiR-195 could improve risk stratification after peripheral endovascular revascularizations. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Stojkovic, Stefan; Jurisic, Magdalena; Kopp, Christoph W.; Koppensteiner, Renate; Wojta, Johann; Gremmel, Thomas] Med Univ Vienna, Dept Internal Med 2, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Huber, Kurt] Wilhelminen Hosp, Med Dept Cardiol & Emergency Med 3, Vienna, Austria.
   [Huber, Kurt] Sigmund Freud Private Univ, Med Sch, Vienna, Austria.
   [Wojta, Johann] Med Univ Vienna, Core Facil, Vienna, Austria.
   [Wojta, Johann] Ludwig Boltzmann Cluster Cardiovasc Res, Vienna, Austria.
RP Gremmel, T (reprint author), Med Univ Vienna, Dept Internal Med 2, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM thomas.gremmel@meduniwien.ac.at
OI Wojta, Johann/0000-0002-1282-9276; Gremmel, Thomas/0000-0001-9554-7292
FU Medizinisch-Wissenschaftliche Fonds des Burgermeisters der
   Bundeshauptstadt Wien [14016]; Anniversary Fund of Austrian National
   Bank [AP15688ONB]; Association for the Promotion of Research in
   Arteriosclerosis, Thrombosis and Vascular Biology
FX The research was funded by the "Medizinisch-Wissenschaftliche Fonds des
   Burgermeisters der Bundeshauptstadt Wien" to Thomas Gremmel, grant
   number 14016; by the Anniversary Fund of Austrian National Bank grant to
   Johann Wojta, OeNB grant number: AP15688ONB. Furthermore, the work was
   supported by the Association for the Promotion of Research in
   Arteriosclerosis, Thrombosis and Vascular Biology.
NR 61
TC 6
Z9 6
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 197
EP 203
DI 10.1016/j.atherosclerosis.2018.01.020
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800029
PM 29366993
DA 2019-10-28
ER

PT J
AU Gragnano, F
   Calabro, P
AF Gragnano, Felice
   Calabro, Paolo
TI Role of dual lipid-lowering therapy in coronary atherosclerosis
   regression: Evidence from recent studies
SO ATHEROSCLEROSIS
LA English
DT Review
DE Ezetimibe; PCSK9 inhibitors; Lipid-lowering therapy; Atherosclerosis;
   Plaque regression
ID RANDOMIZED CONTROLLED-TRIAL; DENSITY-LIPOPROTEIN CHOLESTEROL; C-REACTIVE
   PROTEIN; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA;
   CARDIOVASCULAR-DISEASE PREVENTION; INTENSIVE STATIN THERAPY;
   NON-HDL-CHOLESTEROL; PRECISE-IVUS TRIAL; INTRAVASCULAR ULTRASOUND;
   ENDOTHELIAL DYSFUNCTION
AB Despite recent therapeutic advances, there is an unmet need in cardiovascular disease prevention. Clinical trials and meta-analyses have established that LDL-C lowering, particularly by statin therapy, reduces the progression of coronary atherosclerosis and the risk of coronary events. Insufficient LDL-C reduction and high residual risk in a significant proportion of statin-treated patients signify that additional therapies are required to deliver more effective coronary care. Pharmacological inhibition of cholesterol absorption (with ezetimibe) and PCSK9 activity (with evolocumab or alirocumab) provides potentially useful approaches for the therapeutic modulation of LDL-C metabolism in statin-treated patients. In recent trials, combination strategies involving a statin and non-statin agent (ezetimibe or evolocumab) have been shown to promote coronary atherosclerosis regression and improve cardiovascular outcomes in patients with moderate-to-high cardiovascular risk. This review summarizes recent evidence on the effects of dual lipid-lowering therapy on coronary atherosclerosis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Gragnano, Felice; Calabro, Paolo] AORN St Anna & San Sebastiano, Div Clin Cardiol, Caserta, Italy.
   [Gragnano, Felice; Calabro, Paolo] Univ Campania Luigi Vanvitelli, Dept Cardiothorac & Resp Sci, Naples, Italy.
RP Calabro, P (reprint author), AORN St Anna & San Sebastiano, Div Clin Cardiol, Caserta, Italy.; Calabro, P (reprint author), Univ Campania Luigi Vanvitelli, Dept Cardiothorac & Resp Sci, Naples, Italy.
EM paolo.calabro@unicampania.it
OI Gragnano, Felice/0000-0002-6943-278X; calabro, paolo/0000-0002-5018-830X
FU Italian Ministry of Education, University and ResearchMinistero dell'
   Istruzione, dell' Universita e della Ricerca (MIUR) [FIRB RBFR12W5V5]
FX Work supported by a grant from the Italian Ministry of Education,
   University and Research (FIRB RBFR12W5V5) to the corresponding author.
NR 92
TC 10
Z9 10
U1 1
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 219
EP 228
DI 10.1016/j.atherosclerosis.2018.01.012
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800032
PM 29407597
DA 2019-10-28
ER

PT J
AU Haruhara, K
   Wakui, H
   Azushima, K
   Kurotaki, D
   Kawase, W
   Uneda, K
   Haku, S
   Kobayashi, R
   Ohki, K
   Kinguchi, S
   Ohsawa, M
   Minegishi, S
   Ishigami, T
   Matsuda, M
   Yamashita, A
   Nakajima, H
   Tamura, T
   Tsuboi, N
   Yokoo, T
   Tamura, K
AF Haruhara, Kotaro
   Wakui, Hiromichi
   Azushima, Kengo
   Kurotaki, Daisuke
   Kawase, Wataru
   Uneda, Kazushi
   Haku, Sona
   Kobayashi, Ryu
   Ohki, Kohji
   Kinguchi, Sho
   Ohsawa, Masato
   Minegishi, Shintaro
   Ishigami, Tomoaki
   Matsuda, Miyuki
   Yamashita, Akio
   Nakajima, Hideaki
   Tamura, Tomohiko
   Tsuboi, Nobuo
   Yokoo, Takashi
   Tamura, Kouichi
TI Angiotensin receptor-binding molecule in leukocytes in association with
   the systemic and leukocyte inflammatory profile
SO ATHEROSCLEROSIS
LA English
DT Article
DE Inflammation; Leukocyte; Non-communicable diseases; Receptor;
   Renin-angiotensin system
ID II TYPE-1 RECEPTOR; C-REACTIVE PROTEIN; CHRONIC KIDNEY-DISEASE;
   LOW-GRADE INFLAMMATION; DROPLET DIGITAL PCR; CARDIOVASCULAR-DISEASE;
   HYPERTENSION; ACTIVATION; HYPERTROPHY; RISK
AB Background and aims: The components of the renin-angiotensin system in leukocytes is involved in the pathophysiology of non-communicable diseases (NCDs), including hypertension, atherosclerosis and chronic kidney disease. Angiotensin II type 1 receptor (AT1R)-associated protein (ATRAP) is an AT1R-specific binding protein, and is able to inhibit the pathological activation of AT1R signaling in certain animal models of NCDs. The aim of the present study was to investigate the expression and regulation of ATRAP in leukocytes.
   Methods: Human leukocyte ATRAP mRNA was measured with droplet digital polymerase chain reaction system, and analyzed in relation to the clinical variables. We also examined the leukocyte cytokines mRNA in bone-marrow ATRAP-deficient and wild-type chimeric mice after injection of low-dose lipopolysaccharide.
   Results: The ATRAP mRNA was abundantly expressed in leukocytes, predominantly granulocytes and monocytes, of healthy subjects. In 86 outpatients with NCDs, leukocyte ATRAP mRNA levels correlated positively with granulocyte and monocyte counts and serum C-reactive protein levels. These positive relationships remained significant even after adjustment. Furthermore, the leukocyte ATRAP mRNA was significantly associated with the interleukin-1 beta, tumor necrosis factor-a and monocyte chemotactic protein-1 mRNA levels in leukocytes of NCDs patients. In addition, the leukocyte interleukin-1 beta mRNA level was significantly upregulated in bone marrow ATRAP-deficient chimeric mice in comparison to wild-type chimeric mice after injection of lipopolysaccharide.
   Conclusions: These results suggest that leukocyte ATRAP is an emerging marker capable of reflecting the systemic and leukocyte inflammatory profile, and plays a role as an anti-inflammatory factor in the pathophysiology of NCDs. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Haruhara, Kotaro; Wakui, Hiromichi; Azushima, Kengo; Uneda, Kazushi; Haku, Sona; Kobayashi, Ryu; Ohki, Kohji; Kinguchi, Sho; Ohsawa, Masato; Minegishi, Shintaro; Ishigami, Tomoaki; Matsuda, Miyuki; Tamura, Kouichi] Yokohama City Univ, Grad Sch Med, Dept Med Sci & Cardiorenal Med, Yokohama, Kanagawa, Japan.
   [Azushima, Kengo] Duke NUS Med Sch, Cardiovasc & Metab Disorders Program, Singapore, Singapore.
   [Kurotaki, Daisuke; Kawase, Wataru; Tamura, Tomohiko] Yokohama City Univ, Grad Sch Med, Dept Immunol, Yokohama, Kanagawa, Japan.
   [Yamashita, Akio] Yokohama City Univ, Grad Sch Med, Dept Mol Biol, Yokohama, Kanagawa, Japan.
   [Nakajima, Hideaki] Yokohama City Univ, Grad Sch Med, Dept Hematol & Clin Immunol, Yokohama, Kanagawa, Japan.
   [Haruhara, Kotaro; Tsuboi, Nobuo; Yokoo, Takashi] Jikei Univ, Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Tokyo, Japan.
RP Wakui, H; Azushima, K; Tamura, T (reprint author), Yokohama City Univ, Grad Sch Med, Dept Med Sci & Cardiorenal Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM hiro1234@yokohama-cu.ac.jp; azushima@yokohama-cu.ac.jp;
   tamukou@med.yokohama-cu.ac.jp
OI Haruhara, Kotaro/0000-0003-1918-0390; Azushima,
   Kengo/0000-0002-5136-0730
FU Jikei University Graduate Research Fund; Yokohama Foundation for
   advancement of Medical Science; Uehara Memorial FoundationUehara
   Memorial Foundation; Japan Society for the Promotion of ScienceMinistry
   of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan
   Society for the Promotion of Science; SENSHIN Medical ResearchSENSHIN
   Medical Research FoundationKayamori FoundationKayamori Foundation of
   Informational Science AdvancementMukai Science and Technology
   FoundationFukuda Foundation for Medical TechnologyInoue Foundation for
   ScienceInoue Research Award for Young ScientistsKissei Pharmaceutical
   Co., Ltd.; Banyu Life Science Foundation InternationalBanyu Life Science
   Foundation International; Salt Science Research Foundation [1733]; Kanae
   Foundation for the Promotion of Medical Science; Cardiovascular Research
   Fund, Tokyo, Japan
FX This research was supported by The Jikei University Graduate Research
   Fund. This work was also supported by grants from the Yokohama
   Foundation for advancement of Medical Science, by a Uehara Memorial
   Foundation grant, Grants-in-Aid for Scientific Research from the Japan
   Society for the Promotion of Science, grants from SENSHIN Medical
   Research, the Banyu Life Science Foundation International, the Salt
   Science Research Foundation (1733), the Kanae Foundation for the
   Promotion of Medical Science and a grant-in-aid from The Cardiovascular
   Research Fund, Tokyo, Japan.
NR 56
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 236
EP 244
DI 10.1016/j.atherosclerosis.2018.01.013
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800034
PM 29407599
DA 2019-10-28
ER

PT J
AU Roy, J
AF Roy, Joy
TI Stroke outcome is associated with baseline renal function: A risk factor
   that matters!
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Renal function; Chronic kidney disease; Ischemic stroke
ID CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS; MORTALITY; INDIVIDUALS;
   DYSFUNCTION; MORBIDITY
C1 [Roy, Joy] Karolinska Univ Hosp, Dept Vasc Surg, S-17176 Stockholm, Sweden.
   [Roy, Joy] Karolinska Univ Hosp, Dept Mol Med & Surg, CMM L8 03, S-17176 Stockholm, Sweden.
RP Roy, J (reprint author), Karolinska Univ Hosp, Dept Vasc Surg, S-17176 Stockholm, Sweden.; Roy, J (reprint author), Karolinska Univ Hosp, Dept Mol Med & Surg, CMM L8 03, S-17176 Stockholm, Sweden.
EM joy.roy@ki.se
NR 20
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 258
EP 259
DI 10.1016/j.atherosclerosis.2018.01.003
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800039
PM 29366498
DA 2019-10-28
ER

PT J
AU Elhakeem, A
   Murray, ET
   Cooper, R
   Kuh, D
   Whincup, P
   Hardy, R
AF Elhakeem, Ahmed
   Murray, Emily T.
   Cooper, Rachel
   Kuh, Diana
   Whincup, Peter
   Hardy, Rebecca
TI Leisure-time physical activity across adulthood and biomarkers of
   cardiovascular disease at age 60-64: A prospective cohort study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Biomarkers; Cardiovascular disease; Exercise; Physical
   activity
ID CORONARY-HEART-DISEASE; BIRTH COHORT; OLDER MEN; FOLLOW-UP; LONGITUDINAL
   ASSOCIATIONS; INFLAMMATORY MARKERS; ARTERIAL STIFFNESS; NATIONAL-SURVEY;
   SEDENTARY-TIME; BODY-MASS
AB Background and aims: This study examined associations between leisure-time physical activity (LTPA) across adulthood (from age 36) and cardiovascular disease (CVD) biomarkers at age 60-64.
   Methods: LTPA was reported by study participants from the MRC National Survey of Health and Development at ages 36, 43, 53 and 60-64 (n = 1754) and categorised as inactive, moderately active (1-4/month) or most active (5+/month) at each age. Linear regression was used to examine associations between a cumulative adulthood LTPA score (range = 0-8), and change in LTPA between ages 36 and 60-64 (i.e. always inactive, became inactive, became active, always active) and inflammatory [C-reactive protein (CRP), interleukin-6 (IL-6)], endothelial [tissue-Plasminogen Activator (t-PA), E-selectin] and adipokine [leptin, adiponectin] measures extracted from overnight fasting blood samples at age 60-64.
   Results: The more active a participant was over adulthood, the better their biomarker profile, e.g. fully-adjusted difference in t-PA (both sexes) and adiponectin (women) per unit increase in the LTPA score (95% confidence interval) = -2.2% (-3.6; -0.8) and 2.0% (0.2; 3.8). Those that became active at age 60-64 showed slightly healthier biomarker profiles than those that became inactive [e.g. fully-adjusted difference in IL-6 = -9.9% (-23.9; 4.1) vs. -3.8% (-12.4; 4.8)], although the best profiles were seen for those always active [IL-6: -15.0% (-24.2; -5.7)], when compared with the always inactive group.
   Conclusions: Greater accumulation of LTPA across adulthood was associated with a more favourable CVD biomarker profile in early old age. Earlier uptake and long-term maintenance of LTPA may provide the greatest benefits for CVD prevention. (C) 2017 The Authors. Published by Elsevier Ireland Ltd.
C1 [Elhakeem, Ahmed; Cooper, Rachel; Kuh, Diana; Hardy, Rebecca] UCL, MRC Unit Lifelong Hlth & Ageing, London, England.
   [Elhakeem, Ahmed] Univ Bristol, Bristol Med Sch, Musculoskeletal Res Unit, Translat Hlth Sci, Bristol, Avon, England.
   [Murray, Emily T.] UCL, Dept Epidemiol & Publ Hlth, London, England.
   [Whincup, Peter] St Georges Univ London, Populat Hlth Res Inst, London, England.
RP Elhakeem, A (reprint author), Univ Bristol, Bristol Med Sch, Southmead Hosp, Musculoskeletal Res Unit,Translat Hlth Sci, Level 1,Learning & Res Bldg, Bristol BS10 5NB, Avon, England.
EM a.elhakeem@bristol.ac.uk
OI Cooper, Rachel/0000-0003-3370-5720; Elhakeem, Ahmed/0000-0001-7637-6360
FU UK Medical Research CouncilMedical Research Council UK (MRC)
   [MC_UU_12019/1, G1001143]
FX This work was supported by the UK Medical Research Council
   [MC_UU_12019/1 and G1001143]. The funder had no role in the writing of
   the manuscript and played no part in the decision to submit it for
   publication.
NR 47
TC 4
Z9 4
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 279
EP 287
DI 10.1016/j.atherosclerosis.2017.11.019
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800043
PM 29180005
OA Green Published, Green Accepted, Other Gold
DA 2019-10-28
ER

PT J
AU Wang, IK
   Liu, CH
   Yen, TH
   Jeng, JS
   Sung, SF
   Huang, PH
   Li, JY
   Sun, Y
   Wei, CY
   Lien, LM
   Tsai, IJ
   Sung, FC
   Hsu, CY
AF Wang, I-Kuan
   Liu, Chung-Hsiang
   Yen, Tzung-Hai
   Jeng, Jiann-Shing
   Sung, Sheng-Feng
   Huang, Pai-Hao
   Li, Jie-Yuan
   Sun, Yu
   Wei, Cheng-Yu
   Lien, Li-Ming
   Tsai, I-Ju
   Sung, Fung-Chang
   Hsu, Chung Y.
CA Taiwan Stroke Registry Investigato
TI Renal function is associated with 1-month and 1-year mortality in
   patients with ischemic stroke
SO ATHEROSCLEROSIS
LA English
DT Article
DE Estimated glomerular filtration rate; Ischemic stroke; Mortality; Renal
   function
ID CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; ALL-CAUSE MORTALITY;
   CARDIOVASCULAR-DISEASE; CLINICAL-OUTCOMES; NATIONAL-HEALTH; DYSFUNCTION;
   RISK; PREVALENCE; IMPACT
AB Background and aims: Renal dysfunction is a potent risk factor for cardiovascular diseases, including stroke. This study aimed to evaluate the impact of admission estimated glomerular filtration rate (eGFR) levels on short-term (1-month) and long-term (1-year) mortality in patients with acute ischemic stroke.
   Methods: From the Taiwan Stroke Registry data, we classified ischemic stroke patients, identified from April 2006 to December 2015, into 5 groups by eGFR at admission: >= 90, 60-89, 30-59, 15-29, and <15 mL/min/1.73 m(2) or on dialysis. Risks of 1-month mortality and 1-year mortality after ischemic stroke were investigated by the eGFR level.
   Results: Among 52,732 ischemic stroke patients, 1480 died within one month. The 1-month mortality rate was over 5-fold greater in patients with eGFR <15 mL/min/1.73 m(2) or dialysis than in patients with eGFR >= 90 mL/min/1.73 m(2) (2.88 versus 0.56 per 1000 person-days). The adjusted hazard ratio (HR) of 1-month mortality increased from 1.31 (95% CI = 1.08-1.59) for patients with eGFR 60-89 mL/min/1.73 m(2) to 2.33 (95% CI = 1.80-3.02) for patients with eGFR <15 mL/min/1.73 m(2) or on dialysis. 3226 patients died within one year. The adjusted HR of mortality increased from 1.38 (95% CI = 1.21-1.59) for patients with eGFR 60-89 mL/min/1.73 m(2) to 2.60 (95% CI 2.18-3.10) for patients with eGFR <15 mL/min/1.73 m(2) or on dialysis, compared to patients with eGFR >= 90 mL/min/1.73 m(2).
   Conclusions: After acute ischemic stroke, patients with reduced eGFR are at elevated risks of short-term and long-term deaths in a graded relationship. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Wang, I-Kuan] China Med Univ, Coll Med, Dept Internal Med, Taichung, Taiwan.
   [Wang, I-Kuan] China Med Univ Hosp, Div Nephrol, Taichung, Taiwan.
   [Liu, Chung-Hsiang; Hsu, Chung Y.] China Med Univ Hosp, Dept Neurol, Taichung, Taiwan.
   [Yen, Tzung-Hai] Chang Gung Mem Hosp, Div Nephrol, Taipei, Taiwan.
   [Yen, Tzung-Hai] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Jeng, Jiann-Shing; Huang, Pai-Hao] Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan.
   [Sung, Sheng-Feng] Chiayi Christian Hosp, Ditmanson Med Fdn, Dept Internal Med, Div Neurol, Chiayi, Taiwan.
   [Huang, Pai-Hao] Cathay Gen Hosp, Dept Neurol, Taipei, Taiwan.
   [Huang, Pai-Hao] Fu Jen Catholic Univ, Dept Neurol, New Taipei, Taiwan.
   [Li, Jie-Yuan] E Da Hosp, Dept Neurol, Kaohsiung, Taiwan.
   [Li, Jie-Yuan] I Shou Univ, Sch Med, Kaohsiung, Taiwan.
   [Sun, Yu] En Chu Kong Hosp, Dept Neurol, New Taipei, Taiwan.
   [Wei, Cheng-Yu] Chang Bing Show Chwan Mem Hosp, Dept Neurol, Lukang, Changhua, Taiwan.
   [Wei, Cheng-Yu] Chinese Culture Univ, Coll Educ, Dept Exercise & Hlth Promot, Taipei, Taiwan.
   [Lien, Li-Ming] Shin Kong Wu Ho Su Mem Hosp, Dept Neurol, Taipei, Taiwan.
   [Lien, Li-Ming] Taipei Med Univ, Coll Med, Taipei, Taiwan.
   [Tsai, I-Ju; Sung, Fung-Chang] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Sung, Fung-Chang] China Med Univ, Coll Publ Hlth, Dept Hlth Serv Adm, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
RP Sung, FC (reprint author), China Med Univ, Coll Publ Hlth, Dept Hlth Serv Adm, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
EM fcsung1008@yahoo.com
OI Cheng, Chun-An/0000-0002-0380-7286; Huang,
   Chih-Shan/0000-0001-8232-1657; Lee, Yi-Chung/0000-0003-0102-164X; JENG,
   JIANN-SHING/0000-0002-1456-3686
FU research laboratory of pediatrics, Children's Hospital of China Medical
   University [DMR-105-041]; China Medical University Hospital
   [DMR-106-025, DMR-107-026]; Taiwan Ministry of Health and Welfare
   Clinical Trial and Research Center of Excellence
   [MOHW106-TDU-B-212-113004]; Academia Sinica Taiwan Biobank, Stroke
   Biosignature Project [BM10601010036]; Taiwan Clinical Trial Consortium
   for Stroke [MOST 106-2321-B-039-005]; Tseng-Lien Lin Foundation,
   Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan;
   Katsuzo and Kiyo Aoshima Memorial Funds, Japan
FX The present study was supported by the research laboratory of
   pediatrics, Children's Hospital of China Medical University
   (DMR-105-041), China Medical University Hospital (DMR-106-025 and
   DMR-107-026), Taiwan Ministry of Health and Welfare Clinical Trial and
   Research Center of Excellence (MOHW106-TDU-B-212-113004), Academia
   Sinica Taiwan Biobank, Stroke Biosignature Project (BM10601010036);
   Taiwan Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005);
   Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease
   Foundation, Taipei, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds,
   Japan.
NR 29
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 288
EP 293
DI 10.1016/j.atherosclerosis.2017.11.029
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800044
PM 29254692
DA 2019-10-28
ER

PT J
AU Sanchez-Hernandez, RM
   Prieto-Matos, P
   Civeira, F
   Lafuente, EE
   Vargas, MF
   Real, JT
   Goicoechea, FG
   Fuentes, FJ
   Pocovi, M
   Boronat, M
   Wagner, AM
   Masana, L
AF Maria Sanchez-Hernandez, Rosa
   Prieto-Matos, Pablo
   Civeira, Fernando
   Esteve Lafuente, Eduardo
   Frias Vargas, Manuel
   Real, Jose T.
   Goni Goicoechea, Fernando
   Fuentes, Francisco J.
   Pocovi, Miguel
   Boronat, Mauro
   Maria Wagner, Ana
   Masana, Luis
TI Autosomal recessive hypercholesterolemia in Spain
SO ATHEROSCLEROSIS
LA English
DT Article
DE Familial hypercholesterolemia; Autosomal recessive hypercholesterolemia;
   LDLRAP1
ID HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC-ANALYSIS; ARH;
   MUTATIONS; PHENOTYPE; PROTEIN
AB Background and aims: Autosomal recessive hypercholesterolemia (ARH) is a very rare disease, caused by mutations in LDL protein receptor adaptor 1 (LDLRAP1). It is characterized by high levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of premature cardiovascular disease. We aimed to characterize ARH in Spain.
   Methods: Data were collected from the Dyslipidemia Registry of the Spanish Atherosclerosis Society. A literature search was performed up to June 2017, and all diagnostic genetic studies for familial hypercholesterolemia of Spain were reviewed.
   Results: Seven patients with ARH were identified, 6 true homozygous and one compound heterozygous with a novel mutation: c.[863C>T]; p.[Ser288Leu]. High genetic heterogeneity was found in this cohort. True homozygous subjects for LDLRAP1 have more severe phenotypes than the compound heterozygous patient, but similar to patients with homozygous familial hypercholesterolemia (HoFH). Cardiovascular disease was present in 14% of the ARH patients. LDL-C under treatment was above 185 mg/dl and the response to PCSK9 inhibitors was heterogeneous. Finally, the estimated prevalence in Spain is very low, with just 1 case per 6.5 million people.
   Conclusions: ARH is a very rare disease in Spain, showing high genetic heterogeneity, similarly high LDLC concentrations, but lower incidence of ASCVD than HoFH. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Maria Sanchez-Hernandez, Rosa; Boronat, Mauro; Maria Wagner, Ana] Univ Las Palmas Gran Canaria, Secc Endocrinol & Nutr, Complejo Hosp Univ Insular Materno Infantil Gran, IUIBS, Las Palmas Gran Canaria, Spain.
   [Prieto-Matos, Pablo] Hosp Univ Salamanca, Inst Invest Biomed Salamanca, Unidad Endocrinol Pediat, Salamanca, Spain.
   [Civeira, Fernando] Univ Zaragoza, Unidad Clin & Invest Lipidos & Arterioesclerosis, Hosp Univ Miguel Servet, IIS Aragon,Ctr Invest Biomed Red Enfermedades Car, Zaragoza, Spain.
   [Esteve Lafuente, Eduardo] Hosp Univ Girona Dr Josep Trueta, Serv Endocrinol & Nutr, Girona, Spain.
   [Frias Vargas, Manuel] Ctr Salud San Andres, Madrid, Spain.
   [Real, Jose T.] Univ Valencia, Serv Endocrinol & Nutr, Hosp Clin Valencia, Dept Med,INCLIVA,Ctr Invest Biomed Diabet & Enfer, Valencia, Spain.
   [Goni Goicoechea, Fernando] Hosp Univ Basurto, Serv Endocrinol & Nutr, Bilbao, Spain.
   [Fuentes, Francisco J.] Univ Cordoba, Hosp Univ Reina Sofia, Ctr Invest Biomed Red Fisiopatolgia Obesidad & Nu, ISCIII,Inst Maimonedes Invest Biomed Cordoba IMIB, Madrid, Spain.
   [Pocovi, Miguel] Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, Fac Ciencias, IIS Aragon,CIBERCV, Zaragoza, Spain.
   [Masana, Luis] Univ Rovira & Virgili, Unidad Med Vasc & Metabol, Unidad Invest Lipidos & Arterioesclerosis, Hosp Univ Sant Joan,IISPV,CIBERDEM, Madrid, Spain.
RP Sanchez-Hernandez, RM (reprint author), Univ Las Palmas Gran Canaria, Secc Endocrinol & Nutr, Complejo Hosp Univ Insular Materno Infantil Gran, IUIBS, Las Palmas Gran Canaria, Spain.; Sanchez-Hernandez, RM (reprint author), Hosp Univ Insular Gran Canaria, Ave Maritima Sin Numero, Las Palmas Gran Canaria 35016, Las Palmas, Spain.
EM rosamariasanher@gmail.com
RI MASANA, LUIS/M-7002-2019; Boronat, Mauro/I-2851-2017; FUENTES JIMENEZ,
   FRANCISCO/G-4311-2016
OI MASANA, LUIS/0000-0002-0789-4954; Boronat, Mauro/0000-0001-8535-8543;
   FUENTES JIMENEZ, FRANCISCO/0000-0002-4584-7366
NR 26
TC 5
Z9 6
U1 1
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 1
EP 5
DI 10.1016/j.atherosclerosis.2017.12.006
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800001
PM 29245109
DA 2019-10-28
ER

PT J
AU Zeng, YP
   Cavalcante, R
   Collet, C
   Tenekecioglu, E
   Sotomi, Y
   Miyazaki, Y
   Katagiri, Y
   Asano, T
   Abdelghani, M
   Nie, SP
   Bourantas, CV
   Bruining, N
   Onuma, Y
   Serruys, PW
AF Zeng, Yaping
   Cavalcante, Rafael
   Collet, Carlos
   Tenekecioglu, Erhan
   Sotomi, Yohei
   Miyazaki, Yosuke
   Katagiri, Yuki
   Asano, Taku
   Abdelghani, Mohammad
   Nie, Shaoping
   Bourantas, Christos V.
   Bruining, Nico
   Onuma, Yoshinobu
   Serruys, Patrick W.
TI Coronary calcification as a mechanism of plaque/media shrinkage in
   vessels treated with bioresorbable vascular scaffold: A multimodality
   intracoronary imaging study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Bioresorbable vascular scaffold; Calcification; Plaque/media shrinkage;
   Echogenicity
ID LIPID-LOWERING THERAPY; OPTICAL COHERENCE TOMOGRAPHY; INTRAVASCULAR
   ULTRASOUND; VIRTUAL HISTOLOGY; CT ANGIOGRAPHY; FOLLOW-UP; PROGRESSION;
   ATHEROSCLEROSIS; ECHOGENICITY; ACQUISITION
AB Background and aims: Whether coronary calcification is correlated with plaque/media shrinkage (PS) remains unclear. The aim of this study was to assess the relationship between the calcification process and PS, combining serial optical coherence tomography (OCT) and intravascular ultrasound (IVUS) in vessels treated with bioresorbable vascular scaffolds (BVS).
   Methods: In 15 patients (16 vessels), OCT and IVUS images were matched using anatomic landmarks at post-procedure and five years. PS was defined as relative decrease in plaque/media area >5%. The association between the calcification process and PS was investigated. Mixed effect models were used to assess correlations and changes over time.
   Results: Seventy-two OCT and IVUS paired cross sections in-and out-scaffolded segments were matched at baseline and follow-up (432 images). In total, 35 out of the 72 cross sections showed PS, and 37 cross sections showed no PS (non-PS) at 5-year follow-up. Delta (Delta) plaque/media area showed negative correlation with Delta OCT calcium area (r = -0.29, p = 0.004), Delta OCT calcium arc (r = -0.42, p < 0.001), Delta OCT calcium length (r = -0.5, p < 0.001), and Delta IVUS calcium arc (r = -0.31, p = 0.024), respectively. On echogenicity analysis, Delta plaque/media area was positively associated with Delta hypoechogenic area (r = 0.47, p = 0.002). An increase in calcium area was negatively correlated to Delta hypoechogenicity (r = -0.29, p < 0.016). The increase in calcium area was positively correlated with Delta lumen area (r = 0.24, p = 0.044).
   Conclusions: In segments treated with BVS, the calcification process was associated with PS, decrease in the hypoechogenic tissue and late luminal enlargement. Combining IVUS and OCT provides a unique method to assess the correlation between the calcification process and plaque/media shrinkage. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Zeng, Yaping; Cavalcante, Rafael; Tenekecioglu, Erhan; Miyazaki, Yosuke; Bruining, Nico; Onuma, Yoshinobu] Erasmus MC, ThoraxCtr, Rotterdam, Netherlands.
   [Zeng, Yaping; Nie, Shaoping] Capital Med Univ, Emergency & Crit Care Ctr, Beijing Anzhen Hosp, Beijing, Peoples R China.
   [Collet, Carlos; Sotomi, Yohei; Katagiri, Yuki; Asano, Taku; Abdelghani, Mohammad] Acad Med Ctr, Dept Cardiol, Amsterdam, Netherlands.
   [Bourantas, Christos V.] UCL, Dept Cardiovasc Sci, London, England.
   [Onuma, Yoshinobu] Cardialysis BV, Rotterdam, Netherlands.
   [Serruys, Patrick W.] Imperial Coll, Int Ctr Circulatory Hlth, London, England.
   [Collet, Carlos] Univ Ziekenhuis Brussel, Dept Cardiol, Brussels, Belgium.
RP Serruys, PW (reprint author), Westblaak 98, NL-3012 KM Rotterdam, Netherlands.
EM patrick.w.j.c.serruys@gmail.com
RI TENEKECIOGLU, ERHAN/M-2810-2019; Abdelghani, Mohammad/T-2319-2019
OI TENEKECIOGLU, ERHAN/0000-0003-4376-2833; Abdelghani,
   Mohammad/0000-0001-6949-8749
NR 32
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 6
EP 13
DI 10.1016/j.atherosclerosis.2017.11.002
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800002
PM 29247976
DA 2019-10-28
ER

PT J
AU McCarthy, NS
   Vangjeli, C
   Surendran, P
   Treumann, A
   Rooney, C
   Ho, E
   Sever, P
   Thom, S
   Hughes, AD
   Munroe, PB
   Howard, P
   Johnson, T
   Caulfield, M
   Shields, DC
   O'Brien, E
   Fitzgerald, DJ
   Stanton, AV
AF McCarthy, Nina S.
   Vangjeli, Ciara
   Surendran, Praveen
   Treumann, Achim
   Rooney, Cathy
   Ho, Emily
   Sever, Peter
   Thom, Simon
   Hughes, Alun D.
   Munroe, Patricia B.
   Howard, Philip
   Johnson, Toby
   Caulfield, Mark
   Shields, Denis C.
   O'Brien, Eoin
   Fitzgerald, Desmond J.
   Stanton, Alice V.
TI Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane
   A(2) formation and with cardiovascular event free survival in the
   Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
SO ATHEROSCLEROSIS
LA English
DT Article
DE Genome wide association study; Thromboxane; Thrombosis
ID URIC-ACID; GAMMA; DISEASE; CYCLOOXYGENASE-2; ASPIRIN; RISK;
   11-DEHYDROTHROMBOXANE-B2; BIOSYNTHESIS; DETERMINANTS; ACTIVATION
AB Background and aims: Elevated urinary 11-dehydro thromboxane B-2 (TxB(2)), a measure of thromboxane A(2) formation in vivo, predicts future atherothrombotic events. To further understand this relationship, the genetic determinants of 11-dehydro TxB(2) and their associations with cardiovascular morbidity were investigated in this study.
   Methods: Genome-wide and targeted genetic association studies of urinary 11-dehydro TxB2 were conducted in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) participants.
   Results: The strongest associations were in PPARGC1B (rs4235745, rs32582, rs10515638) and CNTN4 (rs10510230, rs4684343), these 5 single nucleotide polymorphisms (SNPs) were independently associated with 11-dehydro TxB(2) formation. Haplotypes of 11-dehydro TxB(2) increasing alleles for both PPARGC1B and CNTN4 were significantly associated with 11-dehydro TxB(2), explaining 5.2% and 4.5% of the variation in the whole cohort, and 8.8% and 7.9% in participants not taking aspirin, respectively. In a second ASCOT population (n = 6199), addition of these 5 SNPs significantly improved the covariate-only Cox proportional hazards model for cardiovascular events (chisq = 14.7, p = 0.01). Two of the risk alleles associated with increased urinary 11-dehydro TxB(2) were individually associated with greater incidences of cardiovascular events -rs10515638 (HR = 1.31, p = 0.01) and rs10510230 (HR = 1.25, p = 0.007); effect sizes were larger in those not taking aspirin.
   Conclusions: PPARGC1B and CNTN4 genotypes are associated with elevated thromboxane A2 formation and with an excess of cardiovascular events. Aspirin appears to blunt these associations. If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making regarding the use of aspirin in primary prevention. (c) 2017 Elsevier B.V. All rights reserved.
C1 [McCarthy, Nina S.; Vangjeli, Ciara; Surendran, Praveen; Rooney, Cathy; Ho, Emily; Stanton, Alice V.] RCSI, Mol & Cellular Therapeut, Dublin, Ireland.
   [McCarthy, Nina S.] Univ Western Australia, Ctr Genet Origins Hlth & Dis, Perth, WA, Australia.
   [Surendran, Praveen; Shields, Denis C.; O'Brien, Eoin; Fitzgerald, Desmond J.] Univ Coll Dublin, UCD Conway Inst, Sch Med, Dublin, Ireland.
   [Treumann, Achim] Univ Newcastle, NUPPA, Newcastle Upon Tyne, Tyne & Wear, England.
   [Sever, Peter; Thom, Simon; Hughes, Alun D.] Imperial Coll London, Int Ctr Circulatory Hlth, London, England.
   [Munroe, Patricia B.; Howard, Philip; Johnson, Toby; Caulfield, Mark] Queen Mary Univ London, Clin Pharmacol, William Harvey Res Inst, Barts & London Med Sch, London, England.
   [Munroe, Patricia B.; Howard, Philip; Johnson, Toby; Caulfield, Mark] NIHR Barts Cardiovasc Biomed Res Unit, London, England.
   [Johnson, Toby] GlaxoSmithKline, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.
RP McCarthy, NS (reprint author), Ctr Genet Origins Hlth & Dis, Level 5,MRF Bldg,50 Murray St, Perth, WA 6000, Australia.
EM nina.mccarthy@uwa.edu
RI Hughes, Alun/N-3781-2013; Stanton, Alice V/F-4697-2012
OI Hughes, Alun/0000-0001-5432-5271; Treumann, Achim/0000-0002-9417-3505;
   Caulfield, Mark/0000-0001-9295-3594; Shields, Denis/0000-0003-4015-2474
FU Pfizer International, New York, NY, USA; Pfizer, New York, NY,
   USAPfizer; Servier Research Group, Paris, France; Leo Laboratories,
   Copenhagen, Denmark; Barts; London School of Medicine and Dentistry;
   Centre Nationale de Genotypage Paris; Health Research Board in Ireland
   [PHD/2007/11]
FX The HACVD sub-study was supported by an investigational grant by Pfizer
   International, New York, NY, USA. The principal funding source for ASCOT
   was Pfizer, New York, NY, USA.; Additional funding for ASCOT was
   provided by Servier Research Group, Paris, France, and Leo Laboratories,
   Copenhagen, Denmark. Genotyping was funded by Barts, the London School
   of Medicine and Dentistry, and by the Centre Nationale de Genotypage
   Paris. NMcC was funded by the Health Research Board in Ireland under
   grant number PHD/2007/11.
NR 26
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 42
EP 49
DI 10.1016/j.atherosclerosis.2017.12.013
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800007
PM 29258006
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Torres-Pena, JD
   Garcia-Rios, A
   Delgado-Casado, N
   Gomez-Luna, P
   Alcala-Diaz, JF
   Yubero-Serrano, EM
   Gomez-Delgado, F
   Leon-Acuna, A
   Lopez-Moreno, J
   Camargo, A
   Tinahones, FJ
   Delgado-Lista, J
   Ordovas, JM
   Perez-Martinez, P
   Lopez-Miranda, J
AF Torres-Pena, Jose D.
   Garcia-Rios, Antonio
   Delgado-Casado, Nieves
   Gomez-Luna, Purificacion
   Alcala-Diaz, Juan F.
   Yubero-Serrano, Elena M.
   Gomez-Delgado, Francisco
   Leon-Acuna, Ana
   Lopez-Moreno, Javier
   Camargo, Antonio
   Tinahones, Francisco J.
   Delgado-Lista, Javier
   Ordovas, Jose M.
   Perez-Martinez, Pablo
   Lopez-Miranda, Jose
TI Mediterranean diet improves endothelial function in patients with
   diabetes and prediabetes: A report from the CORDIOPREV study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Endothelial function; Diabetes; Prediabetes; CORDIOPREV study;
   Mediterranean diet; Secondary prevention
ID CORONARY-ARTERY-DISEASE; VIRGIN OLIVE OIL; LOW-FAT DIET; CARDIOVASCULAR
   RISK; BRACHIAL-ARTERY; MEDIATED VASODILATION; METABOLIC SYNDROME;
   PREDICTIVE-VALUE; WEIGHT-LOSS; DYSFUNCTION
AB Background and aims: Endothelial dysfunction (ED) plays a key role in the development of atherosclerotic cardiovascular disease (ASCVD). Likewise, type 2 diabetes (T2D) is a major CVD risk factor. Therefore, our objective was to explore whether long-term consumption of a Mediterranean diet (MedDiet) rich in olive oil or a low-fat diet (LF diet) was associated with an improvement in ED and whether the potential benefits were similar in patients with or without T2D in the CORDICOPREV clinical trial (NCT00924937).
   Methods: Endothelial function was measured in 805 participants who had completed follow-up ultrasound image studies, using ultrasonography of brachial artery to calculate flow mediated vasodilatation (FMD) before and after 1.5 years of intervention with a MedDiet [35% of calories from fat (22% monounsaturated) and 50% from carbohydrates] and LF diet [28% fat (12% monounsaturated) and 55% of calories from carbohydrates]. We categorized participants as patients with T2D, prediabetes, and without T2D according to the American Diabetes Association (ADA) criteria.
   Results: MedDiet increased FMD in patients with T2D [5.2 +/- 0.4 at 1.5 years vs. 3.8 +/- 0.4 at baseline; p = 0.04] and prediabetes [4.9 +/- 0.4 vs. 3.8 +/- 0.4; p = 0.04] and induced an improvement in FMD compared to LF diet in patients with diabetes [5.2 +/- 0.4 (MedDiet) vs. 3.7 +/- 0.4 (LF diet); p = 0.01]; whereas both diets maintained FMD stable in patients without diabetes.
   Conclusions: Habitual consumption of a MedDiet rich in extra virgin olive oil improves endothelial function in patients with prediabetes and diabetes. This takes great importance given that diet must be the cornerstone of treatment of patients with diabetes at high cardiovascular risk. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Torres-Pena, Jose D.; Garcia-Rios, Antonio; Delgado-Casado, Nieves; Gomez-Luna, Purificacion; Alcala-Diaz, Juan F.; Yubero-Serrano, Elena M.; Gomez-Delgado, Francisco; Leon-Acuna, Ana; Lopez-Moreno, Javier; Camargo, Antonio; Delgado-Lista, Javier; Perez-Martinez, Pablo; Lopez-Miranda, Jose] Univ Cordoba, Lipid & Atherosclerosis Unit, Dept Internal Med, IMIBIC,Reina Sofia Univ Hosp, Cordoba, Spain.
   [Torres-Pena, Jose D.; Garcia-Rios, Antonio; Delgado-Casado, Nieves; Gomez-Luna, Purificacion; Alcala-Diaz, Juan F.; Yubero-Serrano, Elena M.; Gomez-Delgado, Francisco; Leon-Acuna, Ana; Lopez-Moreno, Javier; Camargo, Antonio; Tinahones, Francisco J.; Delgado-Lista, Javier; Perez-Martinez, Pablo; Lopez-Miranda, Jose] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain.
   [Tinahones, Francisco J.] Univ Malaga, Biomed Res Inst Malaga IBIMA, Virgen Victoria Hosp, Malaga, Spain.
   [Ordovas, Jose M.] Tufts Univ, Sch Med, Jean Mayer US Dept Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Ordovas, Jose M.] Madrid Inst Adv Studiese Food, Madrid, Spain.
   [Ordovas, Jose M.] Natl Ctr Cardiovasc Res CNIC, Madrid, Spain.
RP Perez-Martinez, P (reprint author), Reina Sofia Univ Hosp, Lipid & Atherosclerosis Res Unit, Avda Menendez Pidal,S-N, Cordoba 14004, Spain.
EM pablopermar@yahoo.es
RI Alcala-Diaz, Juan F./Q-4455-2019; Camargo, Antonio/G-9720-2015;
   Lopez-Miranda, Jose/Y-8306-2019; Gomez Delgado, Francisco/H-4552-2015
OI Alcala-Diaz, Juan F./0000-0002-4572-3611; Camargo,
   Antonio/0000-0002-0415-4184; Lopez-Miranda, Jose/0000-0002-8844-0718;
   Gomez Delgado, Francisco/0000-0002-0216-2084; Tinahones, Francisco
   Jose/0000-0001-6871-4403; Delgado Lista, Francisco
   Javier/0000-0002-2982-2716
FU Fundacion Patrimonio Comunal Olivarero; CITOLIVA; Junta de Andalucia
   (Consejeria de Salud)Junta de Andalucia; Junta de Andalucia (Consejeria
   de Agricultura y Pesca); Junta de Andalucia (Consejeria de Innovacion,
   Ciencia y Empresa)Junta de Andalucia; Diputaciones de Jaen y Cordoba;
   Centro de Excelencia en Investigacion sobre Aceite de Oliva y Salud;
   Ministerio de Medio Ambiente, Medio Rural y Marino, Spain; Ministerio de
   Ciencia e Innovacion, SpainMinistry of Science and Innovation, Spain
   (MICINN) [AGL2009-122270, FIS PI13/00185, FIS PI13/00023]; Ministerio de
   Economia, Industria y Competitividad, Spain [AGL2015-67896-P,
   AGL2012/39615]; Instituto de Salud Carlos IIIInstituto de Salud Carlos
   III [PIE14/00005, PIE14/00031]; Proyecto de Excelencia, Consejeria de
   Economia, Innovacion, Ciencia y Empleo [CVI-7450]; European Community
   (JPI ERA-HDHL)European Community (EC) [PCIN-2016-084]; European
   Community (NUTRI-TECH European Integrated Project) [289511]; U.S.
   Department of Agriculture-Agricultural Research Service (ARS)United
   States Department of Agriculture (USDA) [58-1950-4-003]
FX The CORDIOPREV study is supported by the Fundacion Patrimonio Comunal
   Olivarero. We also received additional funding from CITOLIVA, Junta de
   Andalucia (Consejeria de Salud, Consejeria de Agricultura y Pesca,
   Consejeria de Innovacion, Ciencia y Empresa), Diputaciones de Jaen y
   Cordoba, Centro de Excelencia en Investigacion sobre Aceite de Oliva y
   Salud and Ministerio de Medio Ambiente, Medio Rural y Marino, Spain. It
   was also partly supported by research grants from the Ministerio de
   Ciencia e Innovacion, Spain (AGL2009-122270 to JLM, FIS PI13/00185 to
   PPM, FIS PI13/00023 to J DL); Ministerio de Economia, Industria y
   Competitividad, Spain (AGL2015-67896-P to JLM, AGL2012/39615 to JLM);
   Instituto de Salud Carlos III (PIE14/00005, PIE14/00031); Proyecto de
   Excelencia, Consejeria de Economia, Innovacion, Ciencia y Empleo
   (CVI-7450 to JLM); and by a Research Grant from the European Community
   (JPI ERA-HDHL PCIN-2016-084, NUTRI-TECH European Integrated
   Project-289511). The CIBEROBN is an initiative of the Instituto de Salud
   Carlos III, Madrid, Spain. The sponsors had no role in the study design,
   data collection and analysis, decision to publish or preparation of the
   manuscript. This material is based upon work supported by the U.S.
   Department of Agriculture-Agricultural Research Service (ARS), under
   Agreement No. 58-1950-4-003.
NR 43
TC 11
Z9 11
U1 1
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 50
EP 56
DI 10.1016/j.atherosclerosis.2017.12.012
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800008
PM 29274507
DA 2019-10-28
ER

PT J
AU Sturlaugsdottir, R
   Aspelund, T
   Bjornsdottir, G
   Sigurdsson, S
   Thorsson, B
   Eiriksdottir, G
   Gudnason, V
AF Sturlaugsdottir, Ran
   Aspelund, Thor
   Bjornsdottir, Gudlaug
   Sigurdsson, Sigurdur
   Thorsson, Bolli
   Eiriksdottir, Gudny
   Gudnason, Vilmundur
TI Predictors of carotid plaque progression over a 4-year follow-up in the
   Reykjavik REFINE-study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Carotid ultrasound; Risk factors; Plaque progression
ID DENSITY-LIPOPROTEIN CHOLESTEROL; INTIMA-MEDIA THICKNESS; RISK-FACTORS;
   CARDIOVASCULAR-DISEASE; OLDER PERSONS; ARTERY; ATHEROSCLEROSIS; TROMSO
AB Background and aims: Carotid plaque is an arterial marker suggested as a surrogate end point for cardiovascular disease. The aim of this study was to examine the association of risk factors at visit 1 with plaque formation and progression of total plaque area (TPA) during follow-up.
   Methods: We examined 1894 participants (50-69 years of age) in the population-based REFINE (Risk Evaluation For INfarct Estimates)-Reykjavik study.
   Results: Among those with no plaque at baseline, plaque formation was associated with low density lipoprotein, sex, waist, former smoker and physical activity. Furthermore, both the Icelandic Heart Association (IHA) coronary heart disease (CHD) risk score and the atherosclerotic cardiovascular disease (ASCVD) risk score were highly associated with plaque formation in these individuals (p < 0.001) and a better cardiovascular health score was protective. In those with plaque present at baseline, metabolic syndrome was associated with increased risk, while older age and statin use were associated with reduced risk of new plaque formation. Statin use was the only factor associated with the relative TPA progression, where participants not on treatment had 5.7% (p = 0.029) greater rate of progression compared with statin users.
   Conclusions: A number of conventional risk factors at visit 1 were individually associated with plaque formation, also when combined into CHD and ASCVD risk scores, but not with the relative progression in TPA. Medical intervention with statins can reduce the relative progression rate of TPA in the general population with low grade of atherosclerosis, supporting statin use to slow progression of atherosclerosis. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Sturlaugsdottir, Ran; Aspelund, Thor; Bjornsdottir, Gudlaug; Sigurdsson, Sigurdur; Thorsson, Bolli; Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
   [Sturlaugsdottir, Ran; Aspelund, Thor; Bjornsdottir, Gudlaug; Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland.
RP Gudnason, V (reprint author), Iceland Heart Assoc, Res Inst, Holtasmari 1, IS-201 Kopavogur, Iceland.
EM v.gudnason@hjarta.is
RI Aspelund, Thor/K-7022-2019; Gudnason, Vilmundur/K-6885-2015
OI Aspelund, Thor/0000-0002-7998-5433; Gudnason,
   Vilmundur/0000-0001-5696-0084
FU RANNIS (The Icelandic Research Fund) [090452]; Hjartavernd (Icelandic
   Heart Association)
FX This work was supported by grants from RANNIS (The Icelandic Research
   Fund 090452) and Hjartavernd (Icelandic Heart Association).
NR 31
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 57
EP 62
DI 10.1016/j.atherosclerosis.2017.12.005
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800009
PM 29274849
DA 2019-10-28
ER

PT J
AU Borghini, A
   Andreassi, MG
AF Borghini, Andrea
   Andreassi, Maria Grazia
TI Genetic polymorphisms offer insight into the causal role of microRNA in
   coronary artery disease
SO ATHEROSCLEROSIS
LA English
DT Review
DE Coronary artery disease microRNAs; Single nucleotide polymorphisms
ID SINGLE NUCLEOTIDE POLYMORPHISMS; LIPOPROTEIN-LIPASE; CIRCULATING
   MICRORNAS; HEART-DISEASE; MYOCARDIAL-INFARCTION; MEDIATED REGULATION;
   RISK; ASSOCIATION; MIR-146A; BINDING
AB There is growing interest in the potential of circulating microRNAs (miRNAs), a class of small and noncoding RNA molecules, as diagnostic and/or prognostic biomarkers in coronary artery disease (CAD). Despite this promising role, there are still widespread inconsistencies among studies, and important obstacles must be overcome before miRNAs can enter clinical practice.
   The study of single nucleotide polymorphisms (SNPs) in the miRNA regulatory network could help shed light on the causality of associations as well as validate the value of cardiovascular miRNAs. SNPs in miRNA biogenesis or miRNA targetome genes may affect miRNA expression and circulating levels or the fidelity of the miRNA-mRNA interaction, influencing susceptibility to atherosclerotic vascular disease.
   This review aims to provide a general overview of the available studies that have investigated the association of miRNA gene polymorphisms with the susceptibility to CAD development and progression, and to highlight potential future research perspectives. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Borghini, Andrea; Andreassi, Maria Grazia] CNR, Inst Clin Physiol, Via Moruzzi 1, I-56124 Pisa, Italy.
RP Borghini, A (reprint author), CNR, Inst Clin Physiol, Via Moruzzi 1, I-56124 Pisa, Italy.
EM aborghini@ifc.cnr.it
OI Andreassi, Maria Grazia/0000-0002-2163-0816; Borghini,
   Andrea/0000-0003-1061-8309
NR 96
TC 7
Z9 9
U1 1
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 63
EP 70
DI 10.1016/j.atherosclerosis.2017.12.022
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800010
PM 29276984
DA 2019-10-28
ER

PT J
AU Yamamoto, R
   Sacks, FM
   Hu, FB
   Rosner, B
   Furtado, JD
   Aroner, SA
   Ferrannini, E
   Baldi, S
   Kozakova, M
   Balkau, B
   Natali, A
   Jensen, MK
AF Yamamoto, Rain
   Sacks, Frank M.
   Hu, Frank B.
   Rosner, Bernard
   Furtado, Jeremy D.
   Aroner, Sarah A.
   Ferrannini, Ele
   Baldi, Simona
   Kozakova, Michaela
   Balkau, Beverley
   Natali, Andrea
   Jensen, Majken K.
CA RISC Investigators
TI High density lipoprotein with apolipoprotein C-III is associated with
   carotid intima-media thickness among generally healthy individuals
SO ATHEROSCLEROSIS
LA English
DT Article
DE High density lipoprotein (HDL); HDL subspecies; Apolipoprotein A-I;
   Apolipoprotein C-III; Atherosclerosis; Carotid intima-media thickness
   (cIMT)
ID CORONARY-HEART-DISEASE; TRIGLYCERIDE-RICH LIPOPROTEINS; TRADITIONAL
   RISK-FACTORS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CHOLESTEROL
   LEVELS; HDL CHOLESTEROL; ARTERY INTIMA; ATHEROSCLEROSIS; LIPIDS
AB Background and aims: About 6-7% of high density lipoprotein (HDL) has a protein called apolipoprotein (apo) C-III that regulates lipoprotein metabolism and can provoke an inflammatory response. HDL without apoC-III is inversely associated with coronary heart disease (CHD), whereas HDL with apoC-III is directly associated with CHD. We investigated how the presence of apoC-III affects the association between HDL and early stages of atherosclerosis measured as carotid intima-media thickness (cIMT).
   Methods: We examined the cross-sectional associations between the apoA-I concentrations of HDL subspecies with and without apoC-III and cIMT measured by high resolution B-mode carotid ultrasonography among 847 participants from the European multi-center Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study.
   Results: HDL with and without apoC-III demonstrated significantly opposite associations with both cIMT indexes (p-heterogeneity of associations comparing the two subspecies was 0.002 for cIMT at common carotid artery (cIMT at CCA) and 0.006 for the maximum cIMT in any carotid segment (cIMT max)). Compared to the lowest quintile, the highest quintile of apoA-I in HDL without apoC-III was associated with 3.7% lower cIMT at CCA (p-trend = 0.01) or 7.3% lower cIMT max (p-trend = 0.003), while the highest quintile of apoA-I in HDL with apoC-III was associated with 4.4% higher cIMT at CCA (p-trend = 0.001) or 7.9% higher cIMT max (p-trend = 0.002). Total apoA-I as well as total HDL cholesterol was not associated with cIMT whereas higher levels of total apoC-III and apoC-III contained in HDL were significantly associated with higher cIMT (p-trend < 0.01).
   Conclusions: HDL apoC-III is a promising target for atherosclerosis prevention and treatment. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Yamamoto, Rain; Sacks, Frank M.; Hu, Frank B.; Furtado, Jeremy D.; Aroner, Sarah A.; Jensen, Majken K.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
   [Rosner, Bernard] Harvard TH Chan Sch Publ Hlth, Dept Biostat, 665 Huntington Ave, Boston, MA 02115 USA.
   [Sacks, Frank M.; Hu, Frank B.; Rosner, Bernard; Jensen, Majken K.] Brigham & Womens Hosp, Channing Div Network Med, Dept Med, 180 Longwood Ave, Boston, MA 02115 USA.
   [Sacks, Frank M.; Hu, Frank B.; Rosner, Bernard; Jensen, Majken K.] Harvard Med Sch, 180 Longwood Ave, Boston, MA 02115 USA.
   [Ferrannini, Ele] CNR, Inst Clin Physiol, Pisa, Italy.
   [Baldi, Simona; Kozakova, Michaela; Natali, Andrea] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
   [Balkau, Beverley] UVSQ UPS, INSERM, U1018, CESP Team5, Villejuif, France.
RP Jensen, MK (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM mkjensen@hsph.harvard.edu
RI Natali, Andrea/N-5535-2015
OI Natali, Andrea/0000-0002-8465-7717; Furtado, Jeremy/0000-0002-5258-1869
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01HL095964];
   American Diabetes AssociationAmerican Diabetes Association [1-15-JF-30];
   EU grantEuropean Union (EU) [QLG1-CT-2001-01252]; AstraZeneca
   (Sweden)AstraZeneca
FX This work was supported by grants from National Institutes of Health
   (#R01HL095964) and American Diabetes Association (#1-15-JF-30). The RISC
   Study was supported by EU grant (# QLG1-CT-2001-01252) and AstraZeneca
   (Sweden).
NR 43
TC 1
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 92
EP 99
DI 10.1016/j.atherosclerosis.2017.12.029
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800014
PM 29351856
DA 2019-10-28
ER

PT J
AU Tellatin, S
   Maffei, P
   Osto, E
   Dassie, F
   Famoso, G
   Montisci, R
   Martini, C
   Fallo, F
   Marra, MP
   Mioni, R
   Iliceto, S
   Vettor, R
   Tona, F
AF Tellatin, Sara
   Maffei, Pietro
   Osto, Elena
   Dassie, Francesca
   Famoso, Giulia
   Montisci, Roberta
   Martini, Chiara
   Fallo, Francesco
   Marra, Martina Perazzolo
   Mioni, Roberto
   Iliceto, Sabino
   Vettor, Roberto
   Tona, Francesco
TI Coronary microvascular dysfunction may be related to IGF-1 in
   acromegalic patients and can be restored by therapy
SO ATHEROSCLEROSIS
LA English
DT Article
DE IGF-1; Microvascular dysfunction; Coronary flow reserve; Acromegaly; GH
ID GROWTH-FACTOR-I; NITRIC-OXIDE PRODUCTION; SMOOTH-MUSCLE-CELLS;
   ENDOTHELIAL-CELLS; CARDIOVASCULAR FUNCTION; RISK-FACTORS; ALL-CAUSE;
   INSULIN; DISEASE; POPULATION
AB Background and aims: Acromegaly increases the risk of cardiovascular mortality. Data on the cardiovascular risk in asymptomatic acromegaly are limited. In particular, data on coronary microvascular abnormalities are lacking. We assessed coronary flow reserve (CFR) as a marker of coronary microvascular function in asymptomatic acromegaly.
   Methods: We studied 40 acromegalic patients (23 male, age 52 +/- 11 years) without clinical evidence of cardiovascular disease, and 40 control subjects matched for age and sex. Coronary flow velocity in the left anterior descending coronary artery was detected by transthoracic Doppler echocardiography, at rest, and during adenosine infusion. CFR was the ratio of hyperaemic to resting diastolic flow velocity.
   Results: CFR was lower in patients than in controls (2.9 +/- 0.8 vs. 3.7 +/- 0.6, p < 0.0001) and was abnormal (<2.5) in 13 patients (32.5%) compared with any control subjects (0%) (p < 0.0001). CFR was inversely related to insulin-like growth factor 1 (IGF-1) levels (r = -0.5, p < 0.004). In patients with CFR -2.5, IGF-1 was higher (756 [ 381-898] mg/l versus 246 [186-484] mg/l, p < 0.007) whereas growth hormone (GH) levels were similar (6.3 [2.8-13.7] mg/l versus 5 [2.8-8.9] mg/l, p = 0.8). In multivariable linear regression analysis, IGF-1 was independently associated with CFR (p < 0.0001). In multiple logistic regression analysis, IGF-1 independently increased the probability of CFR -2.5 (p = 0.009). In four patients with active disease (all with CFR<2.5), treatment with somatostatin analogues normalized CFR. However the other four patients with active disease were not responder.
   Conclusions: Acromegalic patients have coronary microvascular dysfunction that may be restored by therapy with somatostatin analogues. IGF-1 independently correlates with the coronary microvascular impairment, suggesting the pivotal role of this hormone in explaining the increased cardiovascular risk in acromegaly. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Tellatin, Sara; Famoso, Giulia; Marra, Martina Perazzolo; Iliceto, Sabino; Tona, Francesco] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
   [Maffei, Pietro; Dassie, Francesca; Martini, Chiara; Fallo, Francesco; Mioni, Roberto; Vettor, Roberto] Univ Padua, Dept Med, Padua, Italy.
   [Osto, Elena] Univ Zurich, Fed Inst Technol Zurich ETHZ, Lab Translat Nutr Biol, Zurich, Switzerland.
   [Osto, Elena] Univ Zurich, Ctr Mol Cardiol, Zurich, Switzerland.
   [Osto, Elena] Univ Zurich, Univ Hosp, Zurich, Switzerland.
   [Montisci, Roberta] Univ Cagliari, Dept Med Sci M Aresu, Clin Cardiol, Osped San Giovanni Dio,AOU Cagliari, Cagliari, Italy.
RP Tona, F (reprint author), Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy.
EM francesco.tona@unipd.it
OI FALLO, FRANCESCO/0000-0002-7511-0226
NR 36
TC 1
Z9 1
U1 1
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 100
EP 105
DI 10.1016/j.atherosclerosis.2017.12.019
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800015
PM 29353224
DA 2019-10-28
ER

PT J
AU Pek, SLT
   Dissanayake, S
   Fong, JC
   Lin, MX
   Chan, EZL
   Tang, JIS
   Lee, CW
   Ong, HY
   Sum, CF
   Lim, SC
   Tavintharan, S
AF Pek, Sharon Li Ting
   Dissanayake, Sanjaya
   Fong, Jessie ChoiWan
   Lin, Michelle Xueqin
   Chan, Eric Zit Liang
   Tang, Justin I-Shing
   Lee, Chee Wan
   Ong, Hean Yee
   Sum, Chee Fang
   Lim, Su Chi
   Tavintharan, Subramaniam
TI Spectrum of mutations in index patients with familial
   hypercholesterolemia in Singapore: Single center study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Familial hypercholesterolemia; Low density lipoprotein cholesterol; LDL
   receptor; LDLR mutation; APOB mutation; Next generation sequencing
ID LIPOPROTEIN RECEPTOR GENE; DEFECTIVE APOLIPOPROTEIN B-100;
   CORONARY-ARTERY-DISEASE; DIETARY-CHOLESTEROL; IDENTIFICATION; VARIANTS;
   POPULATION; DIAGNOSIS; CRITERIA; BINDING
AB Background and aims: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease characterized by the presence of high plasma low density lipoproteins cholesterol (LDL-c). Patients with FH, with mutation detected, are at increased risk of premature cardiovascular disease compared to those without mutations. The aim of the study was to assess the type of mutations in patients, clinically diagnosed with FH in Singapore.
   Methods: Patients (probands) with untreated/highest on-treatment LDL-c>4.9 mmol/l were recruited (June 2015 to April 2017). Anthropometric, biochemical indices, blood and family history were collected. DNA was extracted and Next Generation Sequencing (NGS) was performed in 26 lipid-related genes, including LDLR, APOB and PCSK9, and validated using Sanger. Multiplex-ligation probe analyses for LDLR were performed to identify large mutation derangements. Based on HGVS nomenclature, LDLR mutations were classified as "Null"(nonsense, frameshift, large rearrangements) and "Defective"(point mutations which are pathogenic).
   Results: Ninety-six probands were recruited: mean age: (33.5 +/- 13.6) years. 52.1% (n = 50) of patients had LDLR mutations, with 15 novel mutations, and 4.2% (n = 4) had APOB mutations. Total cholesterol (TC) and LDL-c were significantly higher in those with LDLR mutations compared to APOB and no mutations [(8.53 +/- 1.52) vs. (6.93 +/- 0.47) vs. (7.80 +/- 1.32)] mmol/l, p = 0.012 and [(6.74 +/- 0.35) vs. (5.29 +/- 0.76) vs. (5.98 +/- 1.23)] mmol/l, p = 0.005, respectively. Patients with "null LDLR" mutations (n 1/4 13) had higher TC and LDL-c than "defective LDLR" mutations (n 1/4 35): [(9.21 +/- 1.60) vs. (8.33 +/- 1.41)] mmol/l, p = 0.034 and [(7.43 +/- 1.47) vs. (6.53 +/- 1.21)] mmol/l, p = 0.017, respectively.
   Conclusions: To our knowledge, this is the first report of mutation detection in patients with clinically suspected FH by NGS in Singapore. While percentage of mutations is similar to other countries, the spectrum locally differs. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Pek, Sharon Li Ting; Fong, Jessie ChoiWan; Lin, Michelle Xueqin; Chan, Eric Zit Liang; Lim, Su Chi; Tavintharan, Subramaniam] Khoo Teck Puat Hosp, Clin Res Unit, Singapore 768828, Singapore.
   [Sum, Chee Fang; Lim, Su Chi; Tavintharan, Subramaniam] Admiralty Med Ctr, Diabet Ctr, Singapore 730676, Singapore.
   [Dissanayake, Sanjaya; Sum, Chee Fang; Lim, Su Chi; Tavintharan, Subramaniam] Khoo Teck Puat Hosp, Div Endocrinol, Singapore 768828, Singapore.
   [Tang, Justin I-Shing; Lee, Chee Wan; Ong, Hean Yee] Khoo Teck Puat Hosp, Cardiol, Singapore 768828, Singapore.
   [Lim, Su Chi] Natl Univ Singapore Hosp, Saw Swee Hock Sch Publ Hlth, Singapore 117549, Singapore.
RP Tavintharan, S (reprint author), Khoo Teck Puat Hosp, Dept Med, Admiralty Med Ctr, Diabet Ctr, Singapore, Singapore.
EM subramaniam.tavintharan@ktph.com.sg
OI Ong, Hean Yee/0000-0003-0566-5901
FU Alexandra Health Pte Ltd [AHEG1503, STAR16104]
FX This study was supported by grants from Alexandra Health Pte Ltd
   (AHEG1503 and STAR16104).
NR 58
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 106
EP 116
DI 10.1016/j.atherosclerosis.2017.12.028
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800016
PM 29353225
DA 2019-10-28
ER

PT J
AU Mymin, D
   Salen, G
   Triggs-Raine, B
   Waggoner, DJ
   Dembinski, T
   Hatch, GM
AF Mymin, David
   Salen, Gerald
   Triggs-Raine, Barbara
   Waggoner, Darrel J.
   Dembinski, Thomas
   Hatch, Grant M.
TI The natural history of phytosterolemia: Observations on its homeostasis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Rare disease; Sterol; Homeostasis; Sterol regulatory element binding
   protein-2
ID A REDUCTASE-ACTIVITY; CHOLESTEROL-BIOSYNTHESIS; PLANT STEROLS;
   SITOSTEROLEMIA; XANTHOMATOSIS; DISEASE
AB Background and aims: Phytosterolemia is a rare genetic disease caused by mutation of the ABCG5/8 gene. Our aim was to elucidate the natural history and homeostasis of phytosterolemia.
   Methods: We analyzed a Hutterite kindred consisting of 21 homozygotes with phytosterolemia assembled over a period of two decades, all of whom carried the ABCG8 S107X mutation and were treated with ezetimibe.
   Results: Most of these subjects were asymptomatic and devoid of clinical stigmata, and this, since they were ascertained primarily by a process of cascade testing, suggests that, relative to its true prevalence, phytosterolemia is a condition of low morbidity. All subjects have responded well to treatment with ezetimibe. Initial (pre-treatment) and post-ezetimibe levels of cholesterol and sitosterol were measured and percentage changes on ezetimibe were calculated. We found initial levels to be inversely related to subjects' ages as were percentage responses to ezetimibe therapy. There was also a direct correlation between initial levels and percentage responses to ezetimibe. Hence on-treatment levels were very uniform.
   Conclusions: This evidence of a link with age leads us to propose that an age-related change in cholesterol and sterol homeostasis occurs at puberty in phytosterolemia and that the change is due to high sterol and/or stanol levels causing feedback inhibition of sterol regulatory element-binding protein (SREBP-2) processing. This would explain the well-documented phenomenon of depressed cholesterol synthesis in phytosterolemia. It is also well-known that LDL-receptor activity is increased, and this feasibly explains reduced LDL levels and consequent reduction of plasma cholesterol and sitosterol levels. Downregulated SREBP-2 processing would be expected to also lower proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and this would explain high LDL-receptor activity. The above state could be termed disrupted homeostasis and the alternative, seen mostly in children and characterized by hypercholesterolemia and hypersterolemia, simple homeostasis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Mymin, David] Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E3P4, Canada.
   [Mymin, David; Hatch, Grant M.] Univ Manitoba, Ctr Res & Treatment Atherosclerosis, Winnipeg, MB R3E3P4, Canada.
   [Salen, Gerald] Rutgers New Jersey Med Sch, Newark, NJ USA.
   [Triggs-Raine, Barbara] Univ Manitoba, Dept Biochem & Med Genet, Chicago, IL USA.
   [Waggoner, Darrel J.] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA.
   [Dembinski, Thomas] Univ Manitoba, Dept Clin Biochem, Winnipeg, MB R3E3P4, Canada.
   [Hatch, Grant M.] Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB R3E3P4, Canada.
RP Mymin, D (reprint author), Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E3P4, Canada.
EM david.mymin@umanitoba.ca
OI Triggs-Raine, Barbara/0000-0003-4719-6779
FU Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada
FX Supported by grants from the Heart and Stroke Foundation of Canada
   (G.M.H.). G.M.H. is the Canada Research Chair in Molecular Cardiolipin
   Metabolism.
NR 20
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 122
EP 128
DI 10.1016/j.atherosclerosis.2017.12.024
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800018
PM 29353227
DA 2019-10-28
ER

PT J
AU Klimiec, E
   Pasinska, P
   Kowalska, K
   Pera, J
   Slowik, A
   Dziedzic, T
AF Klimiec, Elzbieta
   Pasinska, Paulina
   Kowalska, Katarzyna
   Pera, Joanna
   Slowik, Agnieszka
   Dziedzic, Tomasz
TI The association between plasma endotoxin, endotoxin pathway proteins and
   outcome after ischemic stroke
SO ATHEROSCLEROSIS
LA English
DT Article
DE Stroke; Endotoxin; Inflammation; Outcome; Delirium; sCD14; LBP
ID LIPOPOLYSACCHARIDE-BINDING PROTEIN; CONFUSION ASSESSMENT METHOD;
   SYSTEMIC IMMUNE ACTIVATION; SOLUBLE CD14; ACUTE-PHASE; HUMAN MONOCYTES;
   HIV-INFECTION; HUMAN BLOOD; MORTALITY; DELIRIUM
AB Background and aims: In animals, peripheral lipopolysaccharide (LPS) injection before cerebral ischemia exacerbates neurological deficit, impairs survival and augments sickness behaviour. The goal of our study was to determine a relationship between plasma LPS, LPS pathway proteins (LPS binding protein (LBP) and sCD14) and outcome in stroke patients.
   Methods: We included 335 patients with ischemic stroke. Plasma LPS activity and levels of LBP and sCD14 were measured within 24 h after stroke onset. The endpoints of this study were (1) 3-month poor functional outcome defined as a modified Rankin Scale score >2; (2) 3-month and 12-month case fatality; (3) delirium during the first 7 days after admission.
   Results: Plasma LPS activity did not correlate with either functional outcome or mortality. The higher levels of LBP and sCD14 predicted 3-month and 12-month case fatality. The adjusted hazard ratio for 12-month case fatality was 1.84 (95% CI: 1.32-2.58, p < 0.01) for LBP and 1.62 (95% CI: 1.15-2.29, p < 0.01) for sCD14. On multivariate analysis, higher LPS activity (OR: 1.63, 95% CI: 1.15-2.31, p = 0.01) and higher LBP (OR: 1.44, 95% CI: 1.04-2.00, p = 0.03) and sCD14 levels (OR: 1.54, 95% CI: 1.12-2.13, p = 0.01) were associated with increased risk of delirium.
   Conclusions: In ischemic stroke patients, higher levels of plasma sCD14 and LBP are associated with increased risk of death, whereas, elevated LPS activity and higher levels of LBP and CD14 are associated with post-stroke delirium. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Klimiec, Elzbieta; Pasinska, Paulina; Kowalska, Katarzyna; Pera, Joanna; Slowik, Agnieszka; Dziedzic, Tomasz] Jagiellonian Univ, Dept Neurol, Med Coll, Ul Bot 3, PL-31503 Krakow, Poland.
RP Dziedzic, T (reprint author), Jagiellonian Univ, Dept Neurol, Med Coll, Ul Bot 3, PL-31503 Krakow, Poland.
EM dziedzic@cm-uj.krakow.pl
RI Julian, Esther/E-9216-2013; Pera, Joanna/U-5552-2018
OI Julian, Esther/0000-0002-6558-3978; Pera, Joanna/0000-0001-6142-2969;
   Dziedzic, Tomasz/0000-0003-4086-0729; Klimiec-Moskal,
   Elzbieta/0000-0002-1219-0062
FU National Science Center [DEC-2013/09/B/NZ4/01572]
FX This study was supported by the grant from National Science Center
   (DEC-2013/09/B/NZ4/01572).
NR 43
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 138
EP 143
DI 10.1016/j.atherosclerosis.2017.12.034
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800020
PM 29353229
DA 2019-10-28
ER

PT J
AU Croles, FN
   Van Loon, JE
   Dippel, DWJ
   De Maat, MPM
   Leebeek, FWG
AF Croles, F. Nanne
   Van Loon, Janine E.
   Dippel, Diederik W. J.
   De Maat, Moniek P. M.
   Leebeek, Frank W. G.
TI Antithrombin levels are associated with the risk of first and recurrent
   arterial thromboembolism at a young age
SO ATHEROSCLEROSIS
LA English
DT Article
ID CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; ISCHEMIC-STROKE;
   ITALIAN PROJECT; THROMBOSIS; ADULTS; THROMBOPHILIA; DEFICIENCY;
   PROGNOSIS; ATHEROSCLEROSIS
AB Background and aims: It is as yet unknown whether antithrombin levels are associated with arterial thromboembolism (ATE) at a young age. To investigate the association between antithrombin levels and premature and recurrent ATE, we performed a case-control study and a subsequent nested cohort study of premature coronary heart disease (CHD) patients.
   Methods: In the case-control study, we included 571 patients who had a recent premature ATE, including CHD and ischemic stroke (IS), and 461 healthy controls. The association between antithrombin levels (dichotomized: <= median vs. > median) and ATE was investigated. Subsequently we studied the association between antithrombin levels and recurrent cardiac events, ATE or death in a nested cohort of 323 CHD patients.
   Results: Low antithrombin levels (<= median, 1.04 IU/mL) are associated with an increased risk of ATE (OR 1.46; 95% CI: 1.09-1.96), after adjustment for classical cardiovascular risk factors. This was observed in the subgroups of CHD patients (1.43; 1.01-2.02) and IS patients (1.48; 1.01-2.19). CHD patients with low antithrombin levels had a higher risk of recurrent cardiac events (HR 2.16, 95% CI: 1.07-4.38). Especially in women with low antithrombin levels, the risk of recurrent cardiac events was high (HR 5.97, 95% CI 1.31-27.13) as was the risk of recurrent ATE or death (HR 4.22, 95% CI 1.19-15.00).
   Conclusions: Individuals with relatively low antithrombin levels have an increased risk for ATE at a younger age. CHD patients with low antithrombin levels, especially women, have a higher risk of recurrent cardiac events. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Croles, F. Nanne; De Maat, Moniek P. M.; Leebeek, Frank W. G.] Erasmus Univ, Med Ctr, Dept Hematol, Room Na823,POB 2040, NL-3000CA Rotterdam, Netherlands.
   [Van Loon, Janine E.] Erasmus Univ, Med Ctr, Dept Cardiol, Rotterdam, Netherlands.
   [Dippel, Diederik W. J.] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands.
RP Croles, FN (reprint author), Erasmus Univ, Med Ctr, Dept Hematol, Room Na823,POB 2040, NL-3000CA Rotterdam, Netherlands.
EM f.croles@erasmusmc.nl
FU MRACE grant of the Erasmus MC, Rotterdam, the Netherlands
FX This work was supported by a MRACE grant (2006) of the Erasmus MC,
   Rotterdam, the Netherlands (F.W.G. Leebeek).
NR 26
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 144
EP 150
DI 10.1016/j.atherosclerosis.2018.01.014
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800021
PM 29366986
OA Green Published, Other Gold
DA 2019-10-28
ER

PT J
AU Kovacs, D
   Csiszar, B
   Biro, K
   Koltai, K
   Endrei, D
   Juricskay, I
   Sandor, B
   Praksch, D
   Toth, K
   Kesmarky, G
AF Kovacs, David
   Csiszar, Beata
   Biro, Katalin
   Koltai, Katalin
   Endrei, Dora
   Juricskay, Istvan
   Sandor, Barbara
   Praksch, Dora
   Toth, Kalman
   Kesmarky, Gabor
TI Toe-brachial index and exercise test can improve the exploration of
   peripheral artery disease
SO ATHEROSCLEROSIS
LA English
DT Article
DE Toe pressure; Toe-brachial index; Ankle-brachial index; Transcutaneous
   partial tissue oxygen pressure; Exercise test; 6-Min walk test
ID TRANSCUTANEOUS OXYGEN-PRESSURE; DIAGNOSTIC-VALUE; BLOOD-PRESSURE; ANKLE;
   TENSION; GUIDELINES; MANAGEMENT; CONSENSUS; THERAPY; PULSE
AB Background and aims: We assumed that hand-held Doppler ultrasound (DUS) at rest was insufficient to assess the severity of peripheral artery disease (PAD). Toe pressure and transcutaneous tissue oxygen pressure were studied to prove whether these could identify more patients with severe lower limb ischemia; exercise was applied to provoke ischemia.
   Methods: 120 patients with PAD and 30 volunteers without PAD were recruited. DUS, transcutaneous tissue oxygen pressure (tcpO2) and toe pressure measurements were performed at rest and after exercise. The differential power of these examinations for severe limb ischemia (SLI) was determined by receiver-operating curves (ROCs) and pattern recognition by independent multicategory analysis (PRIMA).
   Results: There was an obvious significant difference between the patient and control groups at rest; after exercise; the ratio of severely impaired values (ankle-brachial index e ABI, toe-brachial index e TBI, tcpO(2) measured on index forefoot) increased significantly in the patient group (p < 0.05). TBI, tcpO(2), ABI measured after exercise could differentiate SLI better than the values of these tests at rest (p < 0.001). In ROC analysis, the largest area under the curve (AUC) was covered by post-(AUC: 0.860) and pre-exercise TBI (AUC: 0.785), and post-exercise tcpO(2) (AUC: 0.720) (p < 0.001). Post-exercise TBI gained the best discriminant score in PRIMA.
   Conclusions: Pre-and post-exercise non-invasive vascular tests could reveal severe limb ischemia. Toe pressure measurement and TBI should become a basic part of the vascular workup. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Kovacs, David; Csiszar, Beata; Biro, Katalin; Koltai, Katalin; Endrei, Dora; Juricskay, Istvan; Sandor, Barbara; Praksch, Dora; Toth, Kalman; Kesmarky, Gabor] Univ Pecs, Med Sch, Dept Med 1, Ifjusag Utja 13, H-7624 Pecs, Hungary.
RP Kesmarky, G (reprint author), Univ Pecs, Med Sch, Dept Med 1, Ifjusag Utja 13, H-7624 Pecs, Hungary.
EM kesmarky.gabor@pte.hu
NR 39
TC 5
Z9 4
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 151
EP 158
DI 10.1016/j.atherosclerosis.2018.01.023
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800022
PM 29366987
DA 2019-10-28
ER

PT J
AU Lin, CY
   Ho, CS
   Tsai, WC
   Chen, JY
AF Lin, Cheng-Yu
   Ho, Chin-Shan
   Tsai, Wei-Chuan
   Chen, Ju-Yi
TI Different effects of apnea during rapid eye movement period on
   peripheral arterial stiffness in obstructive sleep apnea
SO ATHEROSCLEROSIS
LA English
DT Article
DE Obstructive sleep apnea; Apnea-hypopnea index; Rapid eye movement;
   Arterial stiffness; Compliance index
ID CARDIOVASCULAR RISK-FACTORS; SCIENTIFIC STATEMENT; ENDOTHELIAL FUNCTION;
   METABOLIC SYNDROME; COMPLIANCE INDEX; REM-SLEEP; ASSOCIATION;
   HYPERTENSION; INFLAMMATION; MORTALITY
AB Bakground and aims: Obstructive sleep apnea (OSA) contributes to cardiovascular diseases, including arterial stiffness. The association between OSA and peripheral arterial stiffness indices remains controversial.
   Methods: This study recruited 275 patients who were referred for sleep apnea study. Arterial stiffness was assessed by peripheral compliance index (CI) and central pulse wave velocity derived from digital volume pulse (PWVDVP) by photoplethysmography. Overnight polysomnography and autonomic nerve system function tests were also conducted.
   Results: A total of 275 patients (170 men) were recruited. Most were middle-aged and overweight. Most patients (112/275, 40.7%) had rapid eye movement (REM)-predominant OSA. The CI was significantly correlated with the apneaehypopnea index (AHI) (R = -0.132, p = 0.029) and AHI-REM (R = -0.170, p = 0.005) and AHI non-REM (R = -0.122, p = 0.043). Among models and variable used to predict CI, only male sex (B = -0.708, p = 0.007) and AHI-REM (B = -0.010, p = 0.033) were independent predictors of CI. An increase in the interquartile range of AHI-REM was associated with a 9.6% decrease in CI.
   Conclusions: AHI-REM was independently correlated with a peripheral arterial stiffness index, CI. AHIREM may be a suitable surrogate marker for predicting peripheral arterial stiffness in OSA patients. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lin, Cheng-Yu] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Otolaryngol, Tainan, Taiwan.
   [Lin, Cheng-Yu] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Sleep Med Ctr, Tainan, Taiwan.
   [Ho, Chin-Shan] Natl Taiwan Sport Univ, Dept Adapted Phys Educ, Taoyuan, Taiwan.
   [Tsai, Wei-Chuan; Chen, Ju-Yi] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Div Cardiol,Dept Internal Med, 138 Sheng Li Rd, Tainan 704, Taiwan.
RP Chen, JY (reprint author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Div Cardiol,Dept Internal Med, 138 Sheng Li Rd, Tainan 704, Taiwan.
EM juyi@mail.ncku.edu.tw
NR 46
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 166
EP 171
DI 10.1016/j.atherosclerosis.2018.01.008
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800024
PM 29366989
DA 2019-10-28
ER

PT J
AU Zhuang, XD
   Ni, A
   Liao, LZ
   Guo, Y
   Dai, W
   Jiang, YX
   Zhou, HM
   Hu, X
   Du, ZM
   Wang, XQ
   Liao, XX
AF Zhuang, Xiaodong
   Ni, Ao
   Liao, Lizhen
   Guo, Yue
   Dai, Wei
   Jiang, Yunxi
   Zhou, Huimin
   Hu, Xun
   Du, Zhimin
   Wang, Xueqin
   Liao, Xinxue
TI Environment-wide association study to identify novel factors associated
   with peripheral arterial disease: Evidence from the National Health and
   Nutrition Examination Survey (1999-2004)
SO ATHEROSCLEROSIS
LA English
DT Article
DE Peripheral arterial disease; Environment-wide association study;
   Ankle-brachial index; Cross-sectional
ID SUDDEN CARDIAC DEATH; RISK-FACTORS; ALL-CAUSE; MORTALITY; POPULATION;
   CADMIUM; BIOMARKERS; CAROTENE; FRUIT; EWAS
AB Background and aims: An environment-wide association study (EWAS) may be useful to comprehensively test and validate associations between environmental factors and peripheral arterial disease (PAD) in an unbiased manner.
   Methods: Data from cross-sectional cohorts from the US National Health and Nutrition Examination Survey (1999-2004) were randomly 50: 50 split into training set and testing set. A value of ankle-brachial index (ABI) < 1.0 or > 1.4 defined PAD. We performed multiple linear regression analyses associating each of the 417 environmental and self-reported factors with PAD in the training set (false discovery rate < 5%). Significant findings were validated in the testing set (p < 0.05) and entered into a logistic regression model with penalized likelihood based on the Akaike Information Criterion (AIC).
   Results: Overall, 6819 participants > 40 years old were included. The validated factors comprised positive associations with smoking-associated factors (cigarette smoker, family smoker and smoked > 100 cigarettes, urinary cotinine), cadmium, urinary albumin, C-reactive protein, blood o-xylene and thyroxine 4, and inverse associations with alpha-carotene and trans-/cis-beta-carotene for PAD. Finally, only 4 of these factors were nominally significant in the AIC-selected model: cadmium (OR 1.27, 95% CI 1.12-1.45), cis-bcarotene (OR 0.81, 95% CI 0.72-0.91), CRP (OR 1.19, 95% CI 1.03-1.38) and urinary albumin (OR 1.20, 95% CI 1.04-1.38).
   Conclusions: Our systematic evaluation provides new knowledge on the complex array of environmental correlates of PAD. These identified correlates need to be probed in further observational and interventional studies. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Zhuang, Xiaodong; Guo, Yue; Zhou, Huimin; Hu, Xun; Du, Zhimin; Liao, Xinxue] Sun Yat Sen Univ, Affiliated Hosp 1, Cardiol Dept, Guangzhou, Guangdong, Peoples R China.
   [Zhuang, Xiaodong; Guo, Yue; Zhou, Huimin; Hu, Xun; Du, Zhimin; Liao, Xinxue] Minist Hlth, Key Lab Assisted Circulat, Beijing, Peoples R China.
   [Ni, Ao; Dai, Wei; Jiang, Yunxi; Wang, Xueqin] Sun Yat Sen Univ, Sch Math & Computat Sci, Dept Stat Sci, Guangzhou, Guangdong, Peoples R China.
   [Liao, Lizhen] Guangdong Pharmaceut Univ, Guangzhou Higher Educ Mega Ctr, Dept Hlth, Guangzhou, Guangdong, Peoples R China.
   [Wang, Xueqin] Carnegie Mellon Univ, Sun Yat Sen Univ, Joint Inst Engn, Guangzhou, Guangdong, Peoples R China.
RP Wang, XQ (reprint author), Sun Yat Sen Univ, Sch Math & Computat Sci, Dept Stat Sci, Guangzhou, Guangdong, Peoples R China.; Liao, XX (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
EM wangxq@mail.sysu.edu.cn; liaoxinx@mail.sysu.edu.cn
OI Zhuang, Xiao-Dong/0000-0001-6508-8507
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81600206]; Guangdong national nature science
   foundation [2016A030310140/0160903]
FX This study was supported by the National Natural Science Foundation of
   China (grants: 81600206), and Guangdong national nature science
   foundation (2016A030310140/0160903). The corresponding author had full
   access to all the data and had final responsibility for the decision to
   submit for publication.
NR 28
TC 8
Z9 8
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 172
EP 177
DI 10.1016/j.atherosclerosis.2018.01.006
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800025
PM 29366990
DA 2019-10-28
ER

PT J
AU Wu, VCC
   Chen, TH
   Wu, M
   Cheng, CW
   Chen, SW
   Chang, CW
   Chen, CC
   Chang, SH
   Hung, KC
   Chern, MS
   Lin, FC
   Chu, PH
   Wu, CS
AF Wu, Victor Chien-Chia
   Chen, Tien-Hsing
   Wu, Michael
   Cheng, Chun-Wen
   Chen, Shao-Wei
   Chang, Chun-Wei
   Chen, Ching-Chang
   Chang, Shang-Hung
   Hung, Kuo-Chun
   Chern, Ming-Shyan
   Lin, Fen-Chiung
   Chu, Pao-Hsien
   Wu, Cheng-Shyong
TI Comparison of cardiovascular outcomes and all-cause mortality in
   patients with chronic hepatitis B and C: A 13-year nationwide
   population-based study in Asia
SO ATHEROSCLEROSIS
LA English
DT Article
DE Viral hepatitis; Atherosclerosis; Cardiovascular outcomes
ID SMOOTH-MUSCLE-CELLS; ATHEROSCLEROTIC LESIONS; VIRUS SEROPOSITIVITY;
   INFECTIOUS-DISEASES; ENDOTHELIAL-CELLS; VASCULAR INJURY; RISK;
   CYTOMEGALOVIRUS; STROKE; ARTERIOSCLEROSIS
AB Background and aims: Viral hepatitis infection has been linked to increased atherosclerosis. We therefore investigated cardiovascular outcomes in patients with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection.
   Methods: Electronic medical records during 2000-2012 were retrieved from the Taiwan National Health Insurance Research Database. Exclusion criteria were age < 18, history of coexisting HBV and HCV infection, acute coronary syndrome, coronary intervention, venous thromboembolism, peripheral artery disease, stroke, major or gastrointestinal bleeding, malignancy, and a follow-up period < 180 days. Patients with HBV and HCV infection were propensity-matched then compared for outcomes. Primary outcomes were cardiovascular events at the 1-year follow-up, 3-year follow-up, 5-year follow-up, and at the end of follow-up.
   Results: 41,554 patients with diagnosis of HBV or HCV were retrieved from 2000 to 2012. After exclusion criteria, 31,943 patients were eligible for analysis and propensity score matched. The study population consisted of 6030 patients with HBV infection and 6030 patients with HCV infection. Risk of composite arterial events (acute coronary syndrome, peripheral artery disease, and acute ischemic stroke) was significantly higher in patients with HCV infection compared with patients with HBV infection (p = 0.012 at 5-year follow-up and p = 0.003 at the end of follow-up). All-cause mortality was significantly higher in patients with HCV infection compared with patients with HBV infection (p < 0.001 at 3-year follow-up, 5-year follow-up, and at the end of follow-up).
   Conclusions: In patients with chronic viral hepatitis, subjects with HCV infection had a significantly higher risk of composite arterial events and all-cause mortality compared with those with HBV infection. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Wu, Victor Chien-Chia; Chang, Shang-Hung; Hung, Kuo-Chun; Chern, Ming-Shyan; Lin, Fen-Chiung; Chu, Pao-Hsien] Chang Gung Mem Hosp, Linkou Med Ctr, Div Cardiol, 5 Fuxing St, Taoyuan 33305, Taiwan.
   [Chen, Tien-Hsing] Chang Gung Mem Hosp, Dept Cardiol, Keelung, Taiwan.
   [Wu, Michael] Brown Univ, Miriam & Rhode Isl Hosp, Warren Alpert Sch Med, Div Cardiovasc Med, Providence, RI 02912 USA.
   [Cheng, Chun-Wen] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Infect Dis, Taoyuan, Taiwan.
   [Chen, Shao-Wei] Chang Gung Mem Hosp, Linkou Med Ctr, Cardiothorac & Vasc Surg, Taoyuan, Taiwan.
   [Chang, Chun-Wei] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurol, Taoyuan, Taiwan.
   [Chen, Ching-Chang] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan, Taiwan.
   [Wu, Cheng-Shyong] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Chiayi, Taiwan.
RP Wu, VCC (reprint author), Chang Gung Mem Hosp, Linkou Med Ctr, Div Cardiol, 5 Fuxing St, Taoyuan 33305, Taiwan.
EM victorcwu@hotmail.com
RI Chu, Pao-Hsien/P-5249-2019
OI Chu, Pao-Hsien/0000-0003-0361-6348; Chang,
   Shang-hung/0000-0003-0462-2344
NR 31
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 178
EP 184
DI 10.1016/j.atherosclerosis.2018.01.007
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800026
PM 29366991
DA 2019-10-28
ER

PT J
AU Sugiura, T
   Dohi, Y
   Takase, H
   Ito, A
   Fujii, S
   Ohte, N
AF Sugiura, Tomonori
   Dohi, Yasuaki
   Takase, Hiroyuki
   Ito, Atsushi
   Fujii, Satoshi
   Ohte, Nobuyuki
TI Differential effects of brachial and central blood pressures on
   circulating levels of high-sensitivity cardiac troponin I in the general
   population
SO ATHEROSCLEROSIS
LA English
DT Article
DE High-sensitivity cardiac troponin I; Oxidative stress; Arterial
   stiffness; Augmentation index; B-type natriuretic peptide
ID CENTRAL AORTIC PRESSURE; REACTIVE OXYGEN METABOLITES; ARTERIAL
   STIFFNESS; OXIDATIVE STRESS; MYOCARDIAL-INFARCTION; EARLY-DIAGNOSIS;
   HEART-FAILURE; PULSE-WAVE; ATHEROSCLEROSIS; PREVENTION
AB Background and aims: Severe cardiac load increases circulating concentrations of high-sensitivity cardiac troponin I (hs-cTnI) through non-ischemic mechanisms. The present study was designed to investigate the effect of central blood pressure (BP), which reflects cardiac load rather than peripheral BP, on serum concentrations of hs-cTnI in subjects with or without increased arterial stiffness.
   Methods: We enrolled 1210 participants taking part in a yearly health checkup program. Laboratory measurements included serum concentrations of hs-cTnI and derivative reactive oxygen metabolites (dROM), as well as plasma concentrations of B-type natriuretic peptide (BNP). Central BP and the radial augmentation index (rAI) were evaluated non-invasively using an automated device.
   Results: Univariate and multivariable regression analysis showed that both brachial and central BP were significantly associated with hs-cTnI. When subjects were divided into two groups according to the mean rAI value, those with higher rAI had higher hs-cTnI concentrations than those with lower rAI. In subgroup analyses, in those with lower rAI, brachial but not central systolic BP was independently associated with hs-cTnI, whereas in those with higher rAI, central but not brachial systolic BP was independently associated with hs-cTnI. These associations remained significant after further adjustment for BNP and/or d-ROM concentrations.
   Conclusions: Circulating levels of hs-cTnI increase with increasing brachial and central BP, but the effect of central BP was greater in subjects with higher rAI. This indicates that central BP may have a strong effect on silent myocardial damage, assessed as increased circulating hs-cTnI, particularly in subjects with increased arterial stiffness. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Sugiura, Tomonori; Ohte, Nobuyuki] Nagoya City Univ, Grad Sch Med Sci, Dept Cardiorenal Med & Hypertens, Nagoya, Aichi, Japan.
   [Dohi, Yasuaki] Nagoya Gakuin Univ, Fac Rehabil Sci, Dept Internal Med, Nagoya, Aichi, Japan.
   [Takase, Hiroyuki] Enshu Hosp, Dept Internal Med, Hamamatsu, Shizuoka, Japan.
   [Ito, Atsushi; Fujii, Satoshi] Asahikawa Med Univ, Dept Lab Med, Asahikawa, Hokkaido, Japan.
RP Sugiura, T (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Cardiorenal Med & Hypertens, Mizuho Ku, Kawasumi 1,Mizuho Cho, Nagoya, Aichi 4678601, Japan.
EM tomosugi@med.nagoya-cu.ac.jp
OI Sugiura, Tomonori/0000-0001-5806-8161
NR 35
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 185
EP 191
DI 10.1016/j.atherosclerosis.2018.01.015
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800027
PM 29366992
DA 2019-10-28
ER

PT J
AU Yamamoto, K
   Miyoshi, H
   Cho, KY
   Nakamura, A
   Greenberg, AS
   Atsumi, T
AF Yamamoto, Kohei
   Miyoshi, Hideaki
   Cho, Kyu Yong
   Nakamura, Akinobu
   Greenberg, Andrew S.
   Atsumi, Tatsuya
TI Overexpression of perilipin1 protects against atheroma progression in
   apolipoprotein E knockout mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Perilipin1; PLIN1; Macrophage; Atherosclerosis
ID HORMONE-SENSITIVE LIPASE; DIET-INDUCED OBESITY; LIPID DROPLETS;
   STIMULATED LIPOLYSIS; ADIPOCYTE LIPOLYSIS; THP-1 MACROPHAGES;
   PAT-FAMILY; ADIPOPHILIN; PROTEINS; STORAGE
AB Background and aims: Perilipin1 (PLIN1), a lipid droplet-associated protein, plays an important role in the regulation of lipolysis and lipid storage in adipocytes. PLIN1 has recently been reported to be expressed in macrophages within atheroma plaques, suggesting PLIN1 may play a role in the accumulation of lipids at the arterial wall and in the development of atherosclerosis. To clarify the role of PLIN1 in the pathophysiology of atherosclerosis, we assessed the progression of atherosclerosis in PLIN1 transgenic mice (Plin1Tg).
   Methods: Plin1Tg were crossed with apolipoprotein E knockout mice (ApoeKO). C57BL/6J mice, ApoeKO and Plin1Tg/ApoeKO received a normal chow diet for 20 weeks. Body weight, gonadal fat mass and plasma lipid concentrations were measured. Aortas were collected for quantification of atheroma lesions and histological analysis by Oil Red O staining.
   Results: Body weight, gonadal adipose mass and plasma triglyceride concentrations were not significantly different among the three groups. In contrast, the atherosclerotic lesion area was significantly increased in ApoeKO (14.2 +/- 3.2%; p<.01) compared with C57BL/6J mice (3.3 +/- 1.2%) and Plin1Tg/ApoeKO (5.6 +/- 1.9%).
   Conclusions: Overexpressed PLIN1 in macrophages had a protected role against atheroma progression in ApoeKO in the absence of changes in gonadal fat mass or plasma lipid levels, presumably due to modification of the stability and/or inflammatory profile of macrophages. (C) 2018 The Authors. Published by Elsevier B.V.
C1 [Yamamoto, Kohei; Miyoshi, Hideaki; Cho, Kyu Yong; Nakamura, Akinobu; Atsumi, Tatsuya] Hokkaido Univ, Kita Ku, Sapporo, Hokkaido 0608638, Japan.
   [Greenberg, Andrew S.] Tufts Univ, Medford, MA 02155 USA.
RP Miyoshi, H (reprint author), Hokkaido Univ, Kita Ku, Sapporo, Hokkaido 0608638, Japan.
EM hmiyoshi@med.hokudai.ac.jp
RI Cho, Kyu Yong/Y-8130-2019
NR 29
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 192
EP 196
DI 10.1016/j.atherosclerosis.2018.01.019
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800028
PM 29407594
OA Other Gold, Green Published
DA 2019-10-28
ER

PT J
AU de la Calle, GM
   Fernandez-Ruiz, M
   Lopez-Medrano, F
   Polanco, N
   Gonzalez, E
   San Juan, R
   Ruiz-Merlo, T
   Origuen, J
   Paz-Artal, E
   Andres, A
   Aguado, JM
AF Maestro de la Calle, Guillermo
   Fernandez-Ruiz, Mario
   Lopez-Medrano, Francisco
   Polanco, Natalia
   Gonzalez, Esther
   San Juan, Rafael
   Ruiz-Merlo, Tamara
   Origuen, Julia
   Paz-Artal, Estela
   Andres, Amado
   Maria Aguado, Jose
TI Post-transplant hypocomplementemia: A novel marker of cardiovascular
   risk in kidney transplant recipients?
SO ATHEROSCLEROSIS
LA English
DT Article
DE Kidney transplantation; C3 hypocomplementemia; Atherothrombotic event;
   Cardiovascular risk; Prediction
ID C-REACTIVE PROTEIN; ACUTE MYOCARDIAL-INFARCTION; RENAL-TRANSPLANTATION;
   COMPLEMENT-SYSTEM; HEART-DISEASE; ATHEROSCLEROSIS; STROKE; ASSOCIATION;
   ACTIVATION; COMPONENTS
AB Background and aims: Cardiovascular disease (CVD) is a leading cause of mortality after kidney transplantation (KT). The potential role of the complement system in the pathogenesis of post-transplant CVD remains unexplored.
   Methods: Serum complement (C3 and C4) levels were measured at baseline and post-transplant months 1 and 6 in 447 kT recipients. The study outcome was post-transplant atherothrombotic event (PAE), a composite of acute coronary syndrome, critical peripheral arterial disease, stroke and/or transient ischemic attack.
   Results: After a median follow-up of 4.2 years, 48 PAEs occurred in 43 patients (cumulative incidence: 9.6%; incidence rate: 2.6 events per 100 transplant-years). No differences were found in C3 and C4 levels at baseline or month 1 between patients with or without PAE. However, C3 levels at month 6 were significantly lower in patients developing PAE beyond that point (i.e., late PAE) (96.9 +/- 22.3 vs. 109.6 +/- 24.0 mg/dL; p = 0.013). The presence of C3 hypocomplementemia at month 6 was associated with a lower PAE-free survival (p = 0.002). After adjusting for conventional CVD risk factors and acute graft rejection, C3 hypocomplementemia at month 6 remained as an independent risk factor for late PAE in all the exploratory models (minimum hazard ratio: 3.24; p = 0.011). With respect to a model exclusively based on clinical variables, the inclusion of C3 levels at month 6 improved predictive capacity (areas under ROC curves: 0.788 and 0.812, respectively).
   Conclusions: Post-transplant monitoring of serum C3 levels might be useful to identify KT recipients at increased risk of CVD. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Maestro de la Calle, Guillermo; Fernandez-Ruiz, Mario; Lopez-Medrano, Francisco; San Juan, Rafael; Ruiz-Merlo, Tamara; Origuen, Julia; Maria Aguado, Jose] Univ Complutense, Hosp Univ 12 Octubre, Hosp 12 Octubre I 12, Inst Invest,Sch Med,Unit Infect Dis, Madrid, Spain.
   [Polanco, Natalia; Gonzalez, Esther; Andres, Amado] Univ Complutense, Hosp Univ 12 Octubre, Hosp 12 Octubre I 12, Inst Invest,Sch Med,Dept Nephrol, Madrid, Spain.
   [Paz-Artal, Estela] Univ Complutense, Hosp Univ 12 Octubre, Hosp 12 Octubre I 12, Inst Invest,Sch Med,Dept Immunol, Madrid, Spain.
RP Fernandez-Ruiz, M (reprint author), Hosp Univ 12 Octubre, Ctr Actividades Ambulatorias, Unit Infect Dis, 2A Planta,Bloque D,Avda Cordoba S-N, Madrid 28041, Spain.
EM mario_fdezruiz@yahoo.es
OI Origuen, Julia/0000-0002-6507-0363; Fernandez-Ruiz,
   Mario/0000-0002-0315-8001
FU Fundacion Mutua Madrilena de Investigacion Medica (FMM) [2011/0082];
   Spanish Ministry of Economy and Competitiveness, Instituto de Salud
   Carlos III (Fondo de Investigaciones Sanitarias [FIS]) [11/01538];
   Spanish Ministry of Economy and Competitiveness, Instituto de Salud
   Carlos III (Proyecto Integrado de Excelencia [PIE]) [13/00045]; Spanish
   Ministry of Economy and Competitiveness, Instituto de Salud Carlos III
   [JR14/00036]
FX This study was supported by the Fundacion Mutua Madrilena de
   Investigacion Medica (FMM Grant 2011/0082) and the Spanish Ministry of
   Economy and Competitiveness, Instituto de Salud Carlos III (Fondo de
   Investigaciones Sanitarias [FIS] 11/01538 and Proyecto Integrado de
   Excelencia [PIE] 13/00045). M.F.R. holds a clinical research contract
   "Juan Rodes" (JR14/00036) from the Spanish Ministry of Economy and
   Competitiveness, Instituto de Salud Carlos III.
NR 38
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 204
EP 210
DI 10.1016/j.atherosclerosis.2018.01.021
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800030
PM 29407595
DA 2019-10-28
ER

PT J
AU Germano-Soares, AH
   Andrade-Lima, A
   Meneses, AL
   Correia, MA
   Parmenter, BJ
   Tassitano, RM
   Cucato, GG
   Ritti-Dias, RM
AF Germano-Soares, Antonio H.
   Andrade-Lima, Aluisio
   Meneses, Annelise L.
   Correia, Marilia A.
   Parmenter, Belinda J.
   Tassitano, Rafael M.
   Cucato, Gabriel G.
   Ritti-Dias, Raphael M.
TI Association of time spent in physical activities and sedentary behaviors
   with carotid-femoral pulse wave velocity: A systematic review and
   meta-analysis
SO ATHEROSCLEROSIS
LA English
DT Review
DE Accelerometer; Physical activity; Sedentary time; Arterial stiffness;
   Cardiovascular risk
ID ALL-CAUSE MORTALITY; ARTERIAL STIFFNESS; CARDIOMETABOLIC RISK;
   CARDIOVASCULAR-DISEASE; INVERSE RELATIONSHIP; EXERCISE; HEALTH;
   MODERATE; FITNESS; GLUCOSE
AB Background and aims: Increased arterial stiffness is linked to increased risk of cardiovascular disease and mortality. Studies have reported conflicting results regarding the relationship between arterial stiffness and time spent in sedentary behavior (SB) and physical activity (PA). The objective of this systematic review and meta-analysis was to assess the relationship between objectively measured light PA (LPA), moderate to vigorous PA (MVPA), and SB with the gold standard measurement of arterial stiffness, carotid-femoral pulse wave velocity (cfPWV).
   Methods: PubMed, Scopus, and Web of Science were searched for relevant studies published until November 2016. Studies reporting the correlation of objectively measured PA and SB with cfPWV in human adults > 18 years old were included in this analysis. Correlation coefficients (CCs) were converted to Z scores via Fisher's z values for the analysis of summary effects, using a random-effects model.
   Results: Twelve studies were included in the systematic review. The meta-analysis showed a negative correlation between cfPWV and LPA (CC -0.16; 95% CI: -0.29 to -0.03; p = 0.02) and MVPA (CC -0.16; 95% CI: -0.26 to -0.06; p<0.01), and a positive relationship between cfPWV and SB (CC 0.23; 95% CI: 0.12 to 0.35; p<0.01).
   Conclusions: Time spent in light and moderate physical activities is associated with lower arterial stiffness, while time spent in SB is related to higher arterial stiffness. It suggests that PA at any intensity is favorable for arterial stiffness, whereas SB leads to increased arterial stiffness. Considering that cfPWV has an independent prognostic value, these associations may have important clinical implications. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Germano-Soares, Antonio H.; Correia, Marilia A.; Tassitano, Rafael M.] Univ Pernambuco, Grad Program Phys Educ, Recife, PE, Brazil.
   [Andrade-Lima, Aluisio] Univ Sao Paulo, Sch Phys Educ & Sports, Sao Paulo, SP, Brazil.
   [Meneses, Annelise L.] Univ Sunshine Coast, Fac Sci Hlth Educ & Engn, Sunshine Coast, Qld, Australia.
   [Parmenter, Belinda J.] UNSW Sydney, Dept Exercise Physiol, Fac Med, Kensington, NSW, Australia.
   [Tassitano, Rafael M.] Rural Fed Univ Pernambuco, Recife, PE, Brazil.
   [Cucato, Gabriel G.; Ritti-Dias, Raphael M.] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [Ritti-Dias, Raphael M.] Univ Nove Julho, Sao Paulo, SP, Brazil.
RP Ritti-Dias, RM (reprint author), Univ Nove Julho, Programa Ciencias Reabilitacao, Rua Vergueiro 325, BR-01504000 Sao Paulo, Brazil.
EM raphaelritti@gmail.com
RI Dias, Raphael Ritti/G-4200-2013; Ritti-Dias, Raphael/J-5780-2019;
   Germano-Soares, Antonio Henrique/N-6537-2019; Cucato,
   Gabriel/A-6860-2015; Correia, Marilia/R-9976-2017
OI Dias, Raphael Ritti/0000-0001-7883-6746; Ritti-Dias,
   Raphael/0000-0001-7883-6746; Cucato, Gabriel/0000-0002-2060-8852;
   Parmenter, Belinda/0000-0001-8013-5658; Correia,
   Marilia/0000-0002-8983-3433
NR 52
TC 6
Z9 6
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 211
EP 218
DI 10.1016/j.atherosclerosis.2018.01.009
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800031
PM 29407596
DA 2019-10-28
ER

PT J
AU Lopez-Pineda, A
   Cordero, A
   Carratala-Munuera, C
   Orozco-Beltran, D
   Quesada, JA
   Bertomeu-Gonzalez, V
   Gil-Guillen, VF
   Bertomeu-Martinez, V
AF Lopez-Pineda, Adriana
   Cordero, Alberto
   Carratala-Munuera, Concepcion
   Orozco-Beltran, Domingo
   Quesada, Jose A.
   Bertomeu-Gonzalez, Vicente
   Gil-Guillen, Vicente F.
   Bertomeu-Martinez, Vicente
TI Hyperuricemia as a prognostic factor after acute coronary syndrome
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiology; Risk factors; Uric acid; Hyperuricemia; Acute coronary
   syndrome
ID SERUM URIC-ACID; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE;
   INDEPENDENT PREDICTOR; HOSPITAL MORTALITY; RENAL IMPAIRMENT;
   HEART-DISEASE; RISK-FACTOR; ALL-CAUSE; LEVEL
AB Background and aims: Many studies have reported the independent association between uric acid and cardiovascular disease, its role as a risk predictor for outcomes in people with acute coronary syndrome remains controversial. This study aims to assess the association between hyperuricemia and medium/long-term clinical outcomes in people with acute coronary syndrome and determine whether adding hyperuricemia to the GRACE score improves its predictive capability.
   Methods: This cohort study included patients admitted for acute coronary syndrome between 2008 and 2013. Outcomes were cardiovascular and total mortality, and major cardiovascular events. We used a multivariate model to adjust for potential confounding covariates and presented event rates with Kaplan-Meier curves. After adding hyperuricemia to the GRACE score, we compared scores from the reclassification table and the net reclassification improvement.
   Results: 1119 participants were included and followed-up for a mean of 36 months. Multivariate models showed hyperuricemia was independently associated with higher cardiovascular mortality (HR: 1.91; 95% CI: 1.32-2.76; p < 0.01), higher all-cause mortality (HR: 1.59; 95% CI: 1.18-2.15; p < 0.01) and higher major cardiovascular event rates (HR: 1.36; 95% CI: 1.11-1.67; p < 0.01). The hyperuricemia addition to GRACE score led to reclassifying 26% of the participants, and net reclassification improvement was 34%. However, the area under the curve increase was 0.009 and not statistically significant (p > 0.05).
   Conclusions: Hyperuricemia is associated with higher medium/long-term mortality and major cardiovascular event rates in patients following acute coronary syndrome. The addition of hyperuricemia to the GRACE score seems to improve risk classification but the discrimination of the new predictive model did not change. Hyperuricemic patients had higher all-cause mortality in medium and high-risk score categories. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Lopez-Pineda, Adriana; Cordero, Alberto; Bertomeu-Gonzalez, Vicente; Bertomeu-Martinez, Vicente] Hosp San Juan De Alicante, Cardiol Dept, Ctra Nnal 332 S-N, Alacant 03550', Spain.
   [Lopez-Pineda, Adriana; Carratala-Munuera, Concepcion; Orozco-Beltran, Domingo; Quesada, Jose A.; Gil-Guillen, Vicente F.] Miguel Hernandez Univ, Clin Med Dept, Catedra Med Familia, Alacant, Spain.
   [Cordero, Alberto] Hosp Clin Univ Santiago De Compostela SERGAS, Ctr Invest Biome Red Enfermedades Cardiovasc CIBE, Inst Invest St Santiago De Compostela IDIS, Santiago De Compostela, Spain.
   [Bertomeu-Gonzalez, Vicente] Miguel Hernandez Univ, Clin Med Dept, Alacant, Spain.
   [Gil-Guillen, Vicente F.] Fdn Invest Hosp Clin Comunidad Valenciana, Fdn INCLIVA, Ctr Invest Biome Red Enfermedades Cardiovasc CIBE, Valencia, Spain.
RP Cordero, A (reprint author), Hosp San Juan De Alicante, Cardiol Dept, Ctra Nnal 332 S-N, Alacant 03550', Spain.
EM acorderofort@gmail.com
OI Lopez-Pineda, Adriana/0000-0002-2117-0178; Bertomeu-Gonzalez,
   Vicente/0000-0001-5309-0562; Cordero, Alberto/0000-0003-0000-7109
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III
   [RD12/0042/0068]; CIBER Cardiovascular: CIBER CV [CB16/11/00420 FEDER,
   CB16/11/00226]
FX This study was supported by grants from Instituto de Salud Carlos III
   RD12/0042/0068 and from CIBER Cardiovascular: CIBER CV CB16/11/00420
   FEDER and CB16/11/00226. These organizations had no involvement in the
   design of the study; the collection, analysis, and interpretation of the
   data; or the decision to approve publication of the finished manuscript.
NR 50
TC 9
Z9 9
U1 0
U2 7
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 229
EP 235
DI 10.1016/j.atherosclerosis.2018.01.017
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800033
PM 29407598
DA 2019-10-28
ER

PT J
AU Yamamoto, H
   Yoshida, N
   Shinke, T
   Otake, H
   Kuroda, M
   Sakaguchi, K
   Hirota, Y
   Toba, T
   Takahashi, H
   Terashita, D
   Uzu, K
   Tahara, N
   Shinkura, Y
   Kuroda, K
   Nagasawa, Y
   Nagano, Y
   Tsukiyama, Y
   Yanaka, K
   Emoto, T
   Sasaki, N
   Yamashita, T
   Ogawa, W
   Hirata, K
AF Yamamoto, Hiroyuki
   Yoshida, Naofumi
   Shinke, Toshiro
   Otake, Hiromasa
   Kuroda, Masaru
   Sakaguchi, Kazuhiko
   Hirota, Yushi
   Toba, Takayoshi
   Takahashi, Hachidai
   Terashita, Daisuke
   Uzu, Kenzo
   Tahara, Natsuko
   Shinkura, Yuto
   Kuroda, Kouji
   Nagasawa, Yoshinori
   Nagano, Yuichiro
   Tsukiyama, Yoshiro
   Yanaka, Ken-ichi
   Emoto, Takuo
   Sasaki, Naoto
   Yamashita, Tomoya
   Ogawa, Wataru
   Hirata, Ken-ichi
TI Impact of CD14(++)CD16(+) monocytes on coronary plaque vulnerability
   assessed by optical coherence tomography in coronary artery disease
   patients
SO ATHEROSCLEROSIS
LA English
DT Article
DE CD14(++)CD16(+) monocytes; Thin-cap fibroatheroma; Fibrous cap
   thickness; Coronary plaque vulnerability; Optical coherence tomography;
   Glucose fluctuation
ID ACUTE MYOCARDIAL-INFARCTION; DAILY GLUCOSE FLUCTUATION; LIPID-LOWERING
   THERAPY; PROGENITOR CELLS; HEART-DISEASE; SUBSETS; ATHEROSCLEROSIS;
   MYELOPEROXIDASE; ASSOCIATION; ACQUISITION
AB Background and aims: This study examined the impact of CD14(++)CD16(+) monocytes on coronary plaque vulnerability, as assessed by optical coherence tomography (OCT), and investigated their association with daily glucose fluctuation. Although increased CD14(++)CD16(+) monocyte levels have been reported to increase cardiovascular events, their impact on coronary plaque vulnerability in coronary artery disease (CAD) patients with or without diabetes mellitus (DM) remains unclear.
   Methods: This prospective observational study included 50 consecutive patients with CAD, receiving lipid-lowering therapy and undergoing coronary angiography and OCT. Patients were divided into 3 tertiles according to the CD14(++)CD16(+) monocyte percentages assessed by flow cytometry. Standard OCT parameters were assessed for 97 angiographically intermediate lesions (diameter stenosis: 30-70%). Daily glucose fluctuation was analyzed by measuring the mean amplitude of glycemic excursion (MAGE).
   Results: CD14(++)CD16(+) monocytes negatively correlated with fibrous cap thickness (r = -0.508, p < 0.01). The presence of thin-cap fibroatheroma (TCFA) was increased stepwise according to the tertile of CD14(++)CD16(+) monocytes (0 [tertile 1] vs. 5 [tertile 2] vs. 10 [tertile 3], p < 0.01). CD14(++)CD16(+) monocytes were a significant determinant of TCFA (OR 1.279, p = 0.001). In non-DM patients, a significant relationship was found between CD14(++)CD16(+) monocytes and MAGE (r = 0.477, p = 0.018).
   Conclusions: CD14(++)CD16(+) monocytes were associated with coronary plaque vulnerability in CAD patients with well-regulated lipid levels both in DM and non-DM patients. Cross-talk between glucose fluctuation and CD14(++)CD16(+) monocytes may enhance plaque vulnerability, particularly in non-DM patients. CD14(++)CD16(+) monocytes could be a possible therapeutic target for coronary plaque stabilization. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Yamamoto, Hiroyuki; Yoshida, Naofumi; Shinke, Toshiro; Otake, Hiromasa; Kuroda, Masaru; Toba, Takayoshi; Takahashi, Hachidai; Terashita, Daisuke; Uzu, Kenzo; Tahara, Natsuko; Shinkura, Yuto; Kuroda, Kouji; Nagasawa, Yoshinori; Nagano, Yuichiro; Tsukiyama, Yoshiro; Yanaka, Ken-ichi; Emoto, Takuo; Sasaki, Naoto; Yamashita, Tomoya; Hirata, Ken-ichi] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med, Kobe, Hyogo, Japan.
   [Sakaguchi, Kazuhiko; Hirota, Yushi; Ogawa, Wataru] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Diabet & Endocrinol, Kobe, Hyogo, Japan.
RP Shinke, T (reprint author), Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM shinke@med.kobe-u.ac.jp
OI Yamashita, Tomoya/0000-0003-0267-3842; YOSHIDA,
   NAOFUMI/0000-0003-3949-0089
NR 38
TC 7
Z9 7
U1 1
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 245
EP 251
DI 10.1016/j.atherosclerosis.2018.01.010
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800035
PM 29407600
DA 2019-10-28
ER

PT J
AU von Eckardstein, A
   Negrini, S
AF von Eckardstein, Arnold
   Negrini, Simona
TI Ongoing and new challenges of our journal
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Atherosclerosis; Editorial board; Impact factor; Open access
C1 [von Eckardstein, Arnold] Univ Hosp, Inst Clin Chem, Ramistr 100, CH-8091 Zurich, Switzerland.
   [von Eckardstein, Arnold] Univ Zurich, Ramistr 100, CH-8091 Zurich, Switzerland.
RP von Eckardstein, A (reprint author), Univ Hosp, Inst Clin Chem, Ramistr 100, CH-8091 Zurich, Switzerland.; von Eckardstein, A (reprint author), Univ Zurich, Ramistr 100, CH-8091 Zurich, Switzerland.
EM arnold.voneckardstein@usz.ch
FU European Atherosclerosis Society (EAS)
FX We would like to thank all Authors, Co-Editors, Associate Editors,
   Editorial Board Members, and Reviewers, who are making all this
   possible. We also thank the European Atherosclerosis Society (EAS), of
   which Atherosclerosis is the official journal, for its continuous trust
   and support.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 252
EP 253
DI 10.1016/j.atherosclerosis.2017.12.002
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800036
PM 29439804
DA 2019-10-28
ER

PT J
AU Fogacci, F
   Cicero, AFG
AF Fogacci, Federica
   Cicero, Arrigo F. G.
TI Gene targeting for chylomicronemia syndrome: The brave new world
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Hyperchylomicronemia; Familial chylomicronemia syndrome; Lipoprotein
   lipase deficiency; Gene therapy
ID ALIPOGENE TIPARVOVEC
C1 [Fogacci, Federica; Cicero, Arrigo F. G.] Univ Bologna, Med & Surg Sci Dept, Atherosclerosis & Metab Dis Res Unit, Bologna, Italy.
RP Fogacci, F (reprint author), Univ Bologna, Med & Surg Sci Dept, Atherosclerosis & Metab Dis Res Unit, Bologna, Italy.
EM federica.fogacci@studio.unibo.it
RI Fogacci, Federica/R-5931-2016
OI Fogacci, Federica/0000-0001-7853-0042
NR 14
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 254
EP 255
DI 10.1016/j.atherosclerosis.2017.12.017
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800037
PM 29277440
DA 2019-10-28
ER

PT J
AU Tasci, I
AF Tasci, Ilker
TI Persistent physical activities in leisure time over decades improve late
   life CVD markers
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Physical activity; Leisure time physical activity; Biomarkers;
   Cardiovascular disease
ID CARDIOVASCULAR-DISEASE; PLASMINOGEN-ACTIVATOR; STYLE INTERVENTION;
   METABOLIC SYNDROME; EXERCISE; ATHEROSCLEROSIS; BIOMARKERS; OVERWEIGHT;
   OBESITY; HEALTH
C1 [Tasci, Ilker] Hlth Sci Univ, Gulhane Training & Res Hosp, Gulhane Med Sch, Dept Internal Med, TR-06018 Ankara, Turkey.
RP Tasci, I (reprint author), Hlth Sci Univ, Gulhane Training & Res Hosp, Gulhane Med Sch, Dept Internal Med, TR-06018 Ankara, Turkey.
EM ilker.tasci@sbu.edu.tr
OI TASCI, ILKER/0000-0002-0936-2476
NR 20
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 256
EP 257
DI 10.1016/j.atherosclerosis.2017.12.020
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800038
PM 29275895
DA 2019-10-28
ER

PT J
AU Stock, JK
AF Stock, Jane K.
TI Update on SAMS: Statin-associated muscle symptoms
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Statin associated muscle symptoms (SAMS); Real or nocebo effect;
   Clinicians; Atorvastatin; ASCOT LLA group; Genetic; SLCO1B1;
   Anion-transporting polypeptide 1B1 (OATP1B1); Genetics of diabetes and
   audit research tayside study (GoDARTS); Cardiovascular risk factor; The
   statin associated muscle symptom clinical index (SAMS-CI)
ID CLINICAL INDEX; INTOLERANCE; MYOPATHY; THERAPY
C1 [Stock, Jane K.] World Trade Ctr Goteborg, European Atherosclerosis Soc, Massans Gata 10, SE-41251 Gothenburg, Sweden.
RP Stock, JK (reprint author), World Trade Ctr Goteborg, European Atherosclerosis Soc, Massans Gata 10, SE-41251 Gothenburg, Sweden.
EM office@eas-society.org
NR 14
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 260
EP +
DI 10.1016/j.atherosclerosis.2017.12.032
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800040
PM 29361270
DA 2019-10-28
ER

PT J
AU Martinez, GJ
   Celermajer, DS
   Patel, S
AF Martinez, Gonzalo J.
   Celermajer, David S.
   Patel, Sanjay
TI The NLRP3 inflammasome and the emerging role of colchicine to inhibit
   atherosclerosis-associated inflammation
SO ATHEROSCLEROSIS
LA English
DT Review
DE Atherosclerosis; Inflammation; Inflammasome; Colchicine; Acute coronary
   syndrome; Myocardial infarction
ID ACUTE CORONARY SYNDROME; ACUTE MYOCARDIAL-INFARCTION; C-REACTIVE
   PROTEIN; FAMILIAL MEDITERRANEAN FEVER; SMOOTH-MUSCLE-CELLS; SECONDARY
   PREVENTION; CLONAL HEMATOPOIESIS; NALP3 INFLAMMASOME; OXIDATIVE STRESS;
   INTERLEUKIN-1
AB Atherosclerosis is considered a chronic inflammatory disease of the arterial wall. Recently, compelling evidence has arisen for the role of monocytes and neutrophils and a particular protein complex that resides within these cells - the NLRP3 inflammasome - in atherosclerosis-associated inflammation. It is now also known that cholesterol crystals are present through all stages of atherosclerosis and can activate the NLRP3 inflammasome within these inflammatory cells to produce interleukin 1 beta and interleukin 18 - key mediators in the inflammatory cascade that drive plaque progression and instability.
   In this review, we describe the role of monocytes/macrophages and neutrophils in atherosclerosis, outline mechanisms of activation of the NLRP3 inflammasome in the setting of atherosclerosis-associated inflammation and discuss potential therapies that specifically target the NLRP3 inflammasome and/or its downstream mediators in atherosclerosis, with a particular focus on the emerging role of colchicine. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Martinez, Gonzalo J.] Pontificia Univ Catolica, Div Cardiovasc Dis, Santiago, Chile.
   [Celermajer, David S.; Patel, Sanjay] Univ Sydney, Heart Res Inst, Sydney Med Sch, Royal Prince Alfred Hosp,Dept Cardiol, Sydney, NSW, Australia.
RP Patel, S (reprint author), Royal Prince Alfred Hosp, Dept Cardiol, Missenden Rd, Sydney, NSW 2050, Australia.
EM Sanjay.Patel@sswahs.nsw.gov.au
OI Celermajer, David/0000-0001-7640-0439
NR 136
TC 24
Z9 26
U1 3
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 262
EP 271
DI 10.1016/j.atherosclerosis.2017.12.027
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800041
PM 29352570
HC Y
HP N
DA 2019-10-28
ER

PT J
AU Teramoto, R
   Tada, H
   Kawashiri, M
   Nohara, A
   Nakahashi, T
   Konno, T
   Inazu, A
   Mabuchi, H
   Yamagishi, M
   Hayashi, K
AF Teramoto, Ryota
   Tada, Hayato
   Kawashiri, Masa-aki
   Nohara, Atsushi
   Nakahashi, Takuya
   Konno, Tetsuo
   Inazu, Akihiro
   Mabuchi, Hiroshi
   Yamagishi, Masakazu
   Hayashi, Kenshi
TI Molecular and functional characterization of familial chylomicronemia
   syndrome
SO ATHEROSCLEROSIS
LA English
DT Article
DE Familial chylomicronemia syndrome; Lipoprotein; Triglyceride;
   Lipoprotein lipase deficiency
ID LIPOPROTEIN-LIPASE GENE; HYPERTROPHIC CARDIOMYOPATHY; ACCELERATED
   ATHEROSCLEROSIS; SEVERE HYPERTRIGLYCERIDEMIA; MISSENSE MUTATION;
   VARIANTS; DISEASE; HYPERLIPOPROTEINEMIA; DEFICIENCY; ZEBRAFISH
AB Background and aims: Familial chylomicronemia syndrome is a rare autosomal recessive disorder leading to severe hypertriglyceridemia (HTG) due to mutations in lipoprotein lipase (LPL)-associated genes. Few data exist on the clinical features of the disorder or on comprehensive genetic approaches to uncover the causative genes and mutations.
   Methods: Eight patients diagnosed with familial hyperchylomicronemia with recessive inheritance were included in this study (two males and six females; median age of onset 23.0 years; mean triglyceride level 3446 mg/dl). We evaluated their clinical features, including coronary artery disease using coronary computed tomography, and performed targeted next-generation sequencing on a panel comprising 4813 genes associated with known clinical phenotypes. After standard filtering for allele frequency <1% and in silico annotation prediction, we used three types of variant filtering to identify causative mutations: homozygous mutations in known familial hyperchylomicronemia-associated genes, homozygous mutations with high damaging scores in novel genes, and deleterious mutations within 37 genes known to be associated with HTG.
   Results: A total of 1810 variants out of the 73,389 identified with 94.3% mean coverage (x20) were rare and nonsynonymous. Among these, our schema detected four pathogenic or likely pathogenic mutations in the LPL gene (p.Ala248LeufsTer4, p.Arg270Cys, p.Ala361Thr, and p.Val227Gly), including one novel mutation and a variant of uncertain significance. Patients harboring LPL gene mutations showed no severe atherosclerotic changes in the coronary arteries, but recurrent pancreatitis with long-term exposure to HTG was observed.
   Conclusions: These results demonstrate that LPL gene plays a major role in extreme HTG associated with hyperchylomicronemia, although the condition may not cause severe atherosclerosis. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Teramoto, Ryota; Tada, Hayato; Kawashiri, Masa-aki; Nohara, Atsushi; Nakahashi, Takuya; Konno, Tetsuo; Mabuchi, Hiroshi; Yamagishi, Masakazu; Hayashi, Kenshi] Kanazawa Univ, Grad Sch Med, Dept Cardiovasc & Internal Med, Kanazawa, Ishikawa, Japan.
   [Inazu, Akihiro] Kanazawa Univ, Grad Sch Med Sci, Dept Lab Sci Mol Biochem & Mol Biol, Kanazawa, Ishikawa, Japan.
RP Tada, H (reprint author), Kanazawa Univ, Grad Sch Med, Div Cardiovasc Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.
EM ht240z@sa3.so-net.ne.jp
RI inazu, akihiro/P-1234-2019
OI inazu, akihiro/0000-0001-9857-5686
FU Takeda Science FoundationTakeda Science Foundation (TSF); Mochida
   Memorial Foundation; Japan Heart Foundation; AstellasAstellas
   Pharmaceuticals
FX This work was supported by scientific research grants from the Takeda
   Science Foundation, the Mochida Memorial Foundation, and a Japan Heart
   Foundation & Astellas Grant for Research on Atherosclerosis Update.
NR 29
TC 4
Z9 4
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 272
EP 278
DI 10.1016/j.atherosclerosis.2017.11.006
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800042
PM 29153744
DA 2019-10-28
ER

PT J
AU Kankaanpaa, J
   Sampi, M
   Bloigu, R
   Wang, CG
   Akhi, R
   Kesaniemi, YA
   Remes, AM
   Ukkola, O
   Horkko, S
AF Kankaanpaa, Jari
   Sampi, Maritta
   Bloigu, Risto
   Wang, Chunguang
   Akhi, Ramin
   Kesaniemi, Y. Antero
   Remes, Anne M.
   Ukkola, Olavi
   Horkko, Sohvi
TI IgA antibodies to phosphocholine associate with long-term cardiovascular
   disease risk
SO ATHEROSCLEROSIS
LA English
DT Article
DE Phosphocholine; Streptococcus pneumoniae; Antibody; Cardiovascular
   disease; Biomarker
ID LOW-DENSITY-LIPOPROTEIN; PNEUMOCOCCAL VACCINATION; SERUM IGA; B-CELLS;
   AUTOANTIBODIES; EPITOPES
AB Background and aims: Antibodies to phosphocholine and oxidized LDL (oxLDL) are proposed to modify progression of atherosclerosis. We investigated the prognostic value of antibodies to phosphocholine (PCho), Streptococcus pneumoniae cell wall polysaccharide (CWPS) and oxLDL in defining long-term CVD survival.
   Methods: CVD incidence was followed for 18 years and analyzed with baseline plasma IgM, IgG and IgA antibody levels to PCho, CWPS and oxLDL in 1044 subjects of Oulu Project Elucidating Risk of Atherosclerosis study (OPERA).
   Results: During the follow-up period, 195 subjects (18.7%) had a CVD event. Cox model with ACC/AHA CVD adjustments (ASCVD) showed that IgA levels to PCho and IgA to CWPS were statistically significant factors predicting CVD risk. IgM and IgG antibodies to PCho, CWPS and oxLDL had no effect on CVD risk after adjusting for other risk factors. Net reclassification improvement (categories: 17-year risk <15%, 15-30%, >30%), was 0.06 (-0.001-0.12, p < 0.054), and IDI was 0.0124 (0.0036-0.0211, p < 0.006) with IgA-PCho added to the ASCVD risk model. Seventeen (9.4%) study subjects with CVD events were correctly reclassified into higher risk category while 9 (5.0%) subjects were classified into lower risk category. Among the non-cases, 58 (8.7%) subjects were correctly reclassified into lower risk, and 46 (5.9%) were reclassified into higher risk category.
   Conclusions: Plasma IgA antibodies to PCho and Streptococcus pneumoniae CWPS are significant predictors of long-term CVD risk. Additional studies on the role of IgA antibodies in atherogenesis and CVD are warranted. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Kankaanpaa, Jari; Sampi, Maritta; Wang, Chunguang; Akhi, Ramin; Horkko, Sohvi] Univ Oulu, Res Unit Biomed, Med Microbiol & Immunol, POB 5000, FI-90014 Oulu, Finland.
   [Kankaanpaa, Jari; Wang, Chunguang; Akhi, Ramin; Remes, Anne M.; Horkko, Sohvi] Univ Oulu, Univ Hosp, Med Res Ctr & Nordlab Oulu, POB 5000, FI-90014 Oulu, Finland.
   [Bloigu, Risto] Univ Oulu, Med Informat & Stat Res Grp, POB 5000, FI-90014 Oulu, Finland.
   [Kesaniemi, Y. Antero; Ukkola, Olavi] Univ Oulu, Oulu Univ Hosp, Med Res Ctr Oulu, Res Unit Internal Med, POB 5000, FI-90014 Oulu, Finland.
   [Remes, Anne M.] Univ Eastern Finland, Inst Clin Med Neurol, POB 1627, FI-70211 Kuopio, Finland.
   [Remes, Anne M.] Kuopio Univ Hosp, Dept Neurol, POB 100, FI-70029 Kuopio, Finland.
   [Remes, Anne M.] Univ Oulu, Res Unit Clin Neurosci, POB 5000, FI-90014 Oulu, Finland.
RP Horkko, S (reprint author), Univ Oulu, POB 5000, Oulu 90014, Finland.
EM sohvi.horkko@nordlab.fi
FU Finnish Foundation of Cardiovascular Research; University of Oulu
   Graduate School; Finnish Alzheimer's disease research society; Finnish
   Alzheimer's disease foundation; Finnish Brain Foundation; Finnish
   Foundation for Cardiovascular Research; Kyllikki and Uolevi Lehikoinen
   Foundation
FX This work is supported by The Finnish Foundation of Cardiovascular
   Research; University of Oulu Graduate School [J.K.]; Finnish Alzheimer's
   disease research society [J.K.] Finnish Alzheimer's disease foundation
   [J.K]; The Finnish Brain Foundation [J.K]; Finnish Foundation for
   Cardiovascular Research [M.S] and Kyllikki and Uolevi Lehikoinen
   Foundation [M.S].
NR 37
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 294
EP 300
DI 10.1016/j.atherosclerosis.2017.12.010
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800045
PM 29277441
DA 2019-10-28
ER

PT J
AU Valero-Elizondo, J
   Hong, JC
   Spatz, ES
   Salami, JA
   Desai, NR
   Rana, JS
   Khera, R
   Virani, SS
   Blankstein, R
   Blaha, MJ
   Nasir, K
AF Valero-Elizondo, Javier
   Hong, Jonathan C.
   Spatz, Erica S.
   Salami, Joseph A.
   Desai, Nihar R.
   Rana, Jamal S.
   Khera, Rohan
   Virani, Salim S.
   Blankstein, Ron
   Blaha, Michael J.
   Nasir, Khurram
TI Persistent socioeconomic disparities in cardiovascular risk factors and
   health in the United States: Medical Expenditure Panel Survey 2002-2013
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiovascular disease; Epidemiology; Health disparities; Risk factors
ID ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; US ADULTS;
   INCOME; TRENDS; MORTALITY; DISEASE; BURDEN; WOMEN
AB Background and aims: Socioeconomic status (SES) has been linked to worse cardiovascular risk factor (CRF) profiles and higher rates of cardiovascular disease (CVD), with an especially high burden of disease for low-income groups. We aimed to describe the trends in prevalence of CRFs among US adults by SES from 2002 to 2013.
   Methods: Data from the Medical Expenditure Panel Survey was analyzed. CRFs (obesity, diabetes, hypertension, physical inactivity, smoking and hypercholesterolemia), were ascertained by ICD-9-CM and/or self-report.
   Results: The proportion of individuals with obesity, diabetes and hypertension increased overall, with low-income groups representing a higher prevalence for each CRF. Of note, physical inactivity had the highest prevalence increase, with the "lowest-income" group observing a relative percent increase of 71.1%.
   Conclusions: Disparities in CRF burden continue to increase, across SES groups. Strategies to potentially eliminate the persistent health disparities gap may include a shift to greater coverage for prevention, and efforts to engage in healthy lifestyle behaviors. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Valero-Elizondo, Javier] Tecnol Monterrey, Catedra Cardiol & Med Vasc, Monterrey, Nuevo Leon, Mexico.
   [Valero-Elizondo, Javier; Salami, Joseph A.; Nasir, Khurram] Baptist Hlth South Florida, Ctr Healthcare Adv & Outcomes, Miami, FL USA.
   [Hong, Jonathan C.] Univ British Columbia, Div Cardiac Surg, Vancouver, BC, Canada.
   [Spatz, Erica S.; Desai, Nihar R.] Yale Univ, Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
   [Rana, Jamal S.] Kaiser Permanente Northern Calif, Div Cardiol, Oakland, CA USA.
   [Rana, Jamal S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA.
   [Khera, Rohan] UT Southwestern Med Ctr, Div Cardiol, Dallas, TX USA.
   [Virani, Salim S.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
   [Virani, Salim S.] Baylor Coll Med, Sect Cardiovasc Res, Houston, TX 77030 USA.
   [Blankstein, Ron] Brigham & Womens Hosp, Dept Med, Cardiovasc Div, Cardiovasc Imaging Program, Boston, MA 02115 USA.
   [Blankstein, Ron] Brigham & Womens Hosp, Radiol, 75 Francis St, Boston, MA 02115 USA.
   [Blaha, Michael J.; Nasir, Khurram] Johns Hopkins Ciccarone Ctr Prevent Cardiovasc Di, Baltimore, MD USA.
   [Nasir, Khurram] Florida Int Univ, Dept Epidemiol, Robert Stempel Coll Publ Hlth, Miami, FL 33199 USA.
   [Nasir, Khurram] Florida Int Univ, Dept Med, Herbert Wertheim Coll Med, Miami, FL 33199 USA.
   [Nasir, Khurram] Baptist Hlth South Florida, Miami Cardiac & Vasc Inst, Miami, FL USA.
RP Nasir, K (reprint author), Baptist Hlth South Florida, Ctr Healthcare Adv & Outcomes Res, 1500 San Remo Ave,Suite 340, Coral Gables, FL 33146 USA.
EM KhurramN@baptisthealth.net
RI Khera, Rohan/H-9029-2012; Khera, Rohan/P-2378-2019
OI Khera, Rohan/0000-0001-9467-6199; 
FU Agency for Healthcare Research and QualityUnited States Department of
   Health & Human ServicesAgency for Healthcare Research & Quality [K12
   HS023000-01]; National Heart, Lung, and Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI)
   [5T32HL125247-02]; National Center for Advancing Translational Sciences
   of the National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR001105]
FX Dr. Desai and Dr. Spatz are supported by grant K12 HS023000-01 from the
   Agency for Healthcare Research and Quality.; Dr. Khera is supported by
   the National Heart, Lung, and Blood Institute (5T32HL125247-02) and the
   National Center for Advancing Translational Sciences (UL1TR001105) of
   the National Institutes of Health.
NR 15
TC 5
Z9 5
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 301
EP 305
DI 10.1016/j.atherosclerosis.2017.12.014
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800046
PM 29254694
DA 2019-10-28
ER

PT J
AU Khoei, NS
   Grindel, A
   Wallner, M
   Molzer, C
   Doberer, D
   Marculescu, R
   Bulmer, A
   Wagner, KH
AF Khoei, Nazlisadat Seyed
   Grindel, Annemarie
   Wallner, Marlies
   Moelzer, Christine
   Doberer, Daniel
   Marculescu, Rodrig
   Bulmer, Andrew
   Wagner, Karl-Heinz
TI Mild hyperbilirubinaemia as an endogenous mitigator of overweight and
   obesity: Implications for improved metabolic health
SO ATHEROSCLEROSIS
LA English
DT Article
DE Bilirubin; Unconjugated bilirubin (UCB); Cardiovascular disease (CVD)
   risk factors; Anthropometric data; Overweight/obesity; Lipid profile
ID GILBERTS-SYNDROME; CARDIOVASCULAR-DISEASE; SERUM BILIRUBIN; MENDELIAN
   RANDOMIZATION; INVERSE RELATIONSHIP; HEART-DISEASE; RISK; METAANALYSIS;
   ASSOCIATION; ADULTS
AB Background and aims: Mild endogenous elevation of unconjugated bilirubin (UCB) as seen in Gilbert's syndrome (GS), might mitigate cardiovascular disease (CVD) risk factors including overweight/obesity. This study aimed to determine whether hyperbilirubinaemia is linked to improved anthropometric data and lipid profile.
   Methods: Our study considered GS and age-/gender-matched healthy controls (n = 248). Additionally, obese female type 2 diabetic patients (DM2) (n = 26) were included as a "disease control group".
   Results: BMI, hip circumference (HC), and lipid profile were significantly lower in GS. UCB was inversely correlated with BMI (p < 0.001), HC as well as with fat mass (FM) and lipid variables (p < 0.05). Moreover, DM2 patients had significantly lower UCB compared to GS and healthy controls. Older GS subjects (>= 35 years) had significantly reduced anthropometric data and improved lipid profile.
   Conclusions: Our results propose that the health promoting potential of mild hyperbilirubinaemia may extend to protection from age-related weight gain and dyslipidaemia. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Khoei, Nazlisadat Seyed; Grindel, Annemarie; Wagner, Karl-Heinz] Univ Vienna, Fac Life Sci, Dept Nutr Sci, Althanstr 14 UZA2, A-1090 Vienna, Austria.
   [Wallner, Marlies] Univ Appl Sci, FH JOANNEUM, Inst Dietet & Nutr, Alte Poststr 149, A-8020 Graz, Austria.
   [Moelzer, Christine] Univ Aberdeen, Sch Med Med Sci & Nutr, Inst Med Sci, Foresterhill,Ashgrove Rd West, Aberdeen AB25 2ZD, Scotland.
   [Doberer, Daniel] Med Univ Vienna, Vienna Gen Hosp, Dept Clin Pharmacol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
   [Marculescu, Rodrig] Med Univ Vienna, Clin Inst Lab Med, Vienna Gen Hosp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
   [Bulmer, Andrew] Griffith Univ, Sch Med Sci, Gold Coast 4222, Australia.
   [Bulmer, Andrew] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast 4222, Australia.
   [Wagner, Karl-Heinz] Univ Vienna, Fac Life Sci, Res Platform Act Ageing, Althanstr 14 UZA2, A-1090 Vienna, Austria.
RP Wagner, KH (reprint author), Univ Vienna, Fac Life Sci, Dept Nutr Sci, Althanstr 14 UZA2, A-1090 Vienna, Austria.
EM karl-heinz.wagner@univie.ac.at
RI Wagner, Karl-Heinz/B-9098-2013
OI Wagner, Karl-Heinz/0000-0002-1683-7265
FU University of Vienna;  [EU-IRSES-318962-BIOAGE]
FX The statistical evaluation was supported by internal grants of the
   University of Vienna and the EU-IRSES-318962-BIOAGE project.
NR 25
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 306
EP 311
DI 10.1016/j.atherosclerosis.2017.12.021
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800047
PM 29279144
DA 2019-10-28
ER

PT J
AU Mattioli, AV
   Farinetti, A
AF Mattioli, Anna Vittoria
   Farinetti, Alberto
TI Chocolate intake in pre-menopausal women
SO ATHEROSCLEROSIS
LA English
DT Letter
DE Chocolate; Women; Stroke
ID MEDITERRANEAN DIET; POPULATION; IMPACT
C1 [Mattioli, Anna Vittoria; Farinetti, Alberto] Univ Modena & Reggio Emilia, Surg Med & Dent Dept Morphol Sci Related Transpla, Oncol & Regenerat Med, Modena, Italy.
RP Mattioli, AV (reprint author), Univ Modena & Reggio Emilia, Surg Med & Dent Dept Morphol Sci Related Transpla, Oncol & Regenerat Med, Modena, Italy.
EM annavittoria.mattioli@unimore.it
RI Farinetti, Alberto/A-3591-2016; Mattioli, Anna Vittoria/G-6001-2012
OI Farinetti, Alberto/0000-0003-2133-3595; Mattioli, Anna
   Vittoria/0000-0003-1487-9530
NR 6
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 312
EP 312
DI 10.1016/j.atherosclerosis.2017.11.015
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800048
PM 29173999
DA 2019-10-28
ER

PT J
AU Dong, JY
   Iso, H
AF Dong, Jia-Yi
   Iso, Hiroyasu
TI Reply to: "Chocolate intake in pre-menopausal women"
SO ATHEROSCLEROSIS
LA English
DT Letter
ID CONSUMPTION; COHORT; STROKE; RISK; POPULATION; MEN
C1 [Dong, Jia-Yi; Iso, Hiroyasu] Osaka Univ, Grad Sch Med, Dept Social Med, Publ Hlth, Osaka, Japan.
RP Iso, H (reprint author), Osaka Univ, Grad Sch Med, Dept Social Med, Publ Hlth, Osaka, Japan.
EM iso@pbhel.med.osaka-u.ac.jp
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD FEB
PY 2018
VL 269
BP 313
EP 313
DI 10.1016/j.atherosclerosis.2017.12.018
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FV8PM
UT WOS:000424848800049
PM 29279143
DA 2019-10-28
ER

PT J
AU Garg, PK
   Norby, FL
   Polfus, LM
   Boerwinkle, E
   Gibbs, RA
   Grove, ML
   Folsom, AR
   Garimella, PS
   Matsushita, K
   Hoogeveen, RC
   Ballantyne, CM
AF Garg, Parveen K.
   Norby, Faye L.
   Polfus, Linda M.
   Boerwinkle, Eric
   Gibbs, Richard A.
   Grove, Megan L.
   Folsom, Aaron R.
   Garimella, Pranav S.
   Matsushita, Kunihiro
   Hoogeveen, Ron C.
   Ballantyne, Christie M.
TI Lipoprotein-associated phospholipase A(2) and risk of incident
   peripheral arterial disease: Findings from The Atherosclerosis Risk in
   Communities study (ARIC)
SO ATHEROSCLEROSIS
LA English
DT Article
DE Inflammation; Epidemiology; Peripheral artery disease;
   Lipoprotein-associated phospholipase A(2)
ID CORONARY-HEART-DISEASE; ACTIVATING-FACTOR ACETYLHYDROLASE; C-REACTIVE
   PROTEIN; LOW-DENSITY-LIPOPROTEIN; MIDDLE-AGED MEN; CARDIOVASCULAR RISK;
   ENZYMATIC DETERMINATION; MULTIETHNIC COHORT; ISCHEMIC-STROKE; FOLLOW-UP
AB Background and aims: Results from prospective studies evaluating the relationship between elevated lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity and incident peripheral arterial disease (PAD) have been mixed. We investigated whether higher Lp-PLA(2) levels are associated with increased risk of incident PAD and whether PLA2G7 gene variants, which result in lower Lp-PLA2 levels, are associated with reduced risk of incident PAD.
   Methods: Our analysis included 9922 participants (56% female; 21% African-American; mean age 63 years) without baseline PAD at ARIC Visit 4 (1996-1998), who had Lp-PLA2 activity measured and were subsequently followed for the development of PAD, defined by occurrence of a PAD-related hospitalization, through 2012. Cox proportional hazard models were performed to determine the association of Lp-PLA2 levels and PLA2G7 gene variants with incident PAD.
   Results: During a median follow-up of 14.9 years, we identified 756 incident cases of PAD. In analyses adjusting for age, race, and sex, each standard deviation increment in Lp-PLA(2) activity (62 nmol/ml/min) was associated with a higher risk of developing PAD (hazard ratio (HR) 1.17; 95% confidence interval (CI) 1.09, 1.26). This association remained significant after additional adjustment for risk factors, other cardiovascular disease, and medication use, but was strongly attenuated (HR: 1.09; 95% CI 1.00, 1.20). PLA2G7 variants were not associated with a lower risk of PAD in both white carriers (HR: 1.21; 95% CI: 0.17-8.56) and African-American carriers (HR: 0.83; 95% CI: 0.41-1.67), although statistical power was quite limited for this analysis, particularly in whites.
   Conclusions: While higher Lp-PLA2 activity was associated with an increased risk for incident PAD, it is likely a risk marker largely represented by traditional risk factors. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Garg, Parveen K.] Univ Southern Calif, Div Cardiol, Keck Sch Med, Los Angeles, CA USA.
   [Norby, Faye L.; Folsom, Aaron R.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
   [Polfus, Linda M.; Boerwinkle, Eric; Grove, Megan L.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA.
   [Gibbs, Richard A.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Garimella, Pranav S.] Univ Calif San Diego, Div Nephrol Hypertens, La Jolla, CA 92093 USA.
   [Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Dept Epidemiol, Baltimore, MD USA.
   [Hoogeveen, Ron C.; Ballantyne, Christie M.] Baylor Coll Med, Sect Atherosclerosis & Vasc Med, Houston, TX 77030 USA.
   [Hoogeveen, Ron C.; Ballantyne, Christie M.] Methodist DeBakey Heart Ctr, Ctr Cardiovasc Dis Prevent, Houston, TX USA.
RP Garg, PK (reprint author), 1510 San Pablo St Suite 322, Los Angeles, CA 90033 USA.
EM parveeng@med.usc.edu
RI Norby, Faye/S-3729-2017
OI Norby, Faye/0000-0002-1975-0405; Hoogeveen, Ron/0000-0003-2399-4653;
   Garg, Parveen/0000-0002-6482-2711
FU National Heart, Lung, and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [RC2HL102419,
   HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, HHSN268201100012C]; NHLBIUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI); National Human Genome
   Research InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Human
   Genome Research Institute (NHGRI) [U54 HG003273]
FX This work was supported by a sponsored project (RC2HL102419) from the
   National Heart, Lung, and Blood Institute (NHLBI), contracts
   (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, and HHSN268201100012C) with the NHLBI, and a grant
   (U54 HG003273) from the National Human Genome Research Institute.
NR 47
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 12
EP 18
DI 10.1016/j.atherosclerosis.2017.11.007
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500002
PM 29169030
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Jiang, ZY
   Lin, BJ
   Liu, TW
   Qin, SY
   Huang, S
   Shao, S
   Li, S
   Huang, RJ
   Huang, JN
AF Jiang, Zhiyuan
   Lin, Baojing
   Liu, Tangwei
   Qin, Shiyun
   Huang, Shan
   Shao, Shuang
   Li, Shuo
   Huang, Rongjie
   Huang, Jiangnan
TI Visceral fat index/percentage body fat ratio is independently associated
   with proximal aortic dilatation in a middle-aged and aged Chinese
   population in Liujiang of Guangxi
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cross-sectional study; Visceral fat index; Percentage body fat; Proximal
   aortic size; Proximal aortic dilatation
ID SUBCUTANEOUS ADIPOSE-TISSUE; X-RAY ABSORPTIOMETRY; DISEASE RISK-FACTORS;
   BIOELECTRICAL-IMPEDANCE; CARDIOVASCULAR-DISEASE; ROOT DILATATION;
   INSULIN SENSITIVITY; METABOLIC SYNDROME; REFERENCE VALUES; CUTOFF VALUES
AB Background and aims: Increased volume of visceral adipose tissue is associated with worsening of cardiovascular disease risk factors that contribute to aortic dilatation. We investigated the effects of visceral fat index (VFI) and VFI/percentage body fat (PBF) ratio on proximal aortic size and proximal aortic dilatation (PAD), to assess whether excess visceral fat deposition is an independent risk factor for PAD.
   Methods: 738 participants aged 35 years or more were included in this cross-sectional survey. The sizes of aortic valve annulus (AVA), sinuses of Valsalva (SV), sinotubular junction (STJ), and ascending aorta (AscAo) were measured by transthoracic ultrasound. Multivariate linear regression, binary logistic regression, Bayesian linear regression, and receiver operating characteristic curves were performed to clarify the effects of VFI and VFI/PBF ratio on PAD.
   Results: There were 78 participants (10.6%) with PAD. VFI and VFI/PBF ratio in the population with PAD was significantly increased, compared to the population without PAD (p < 0.001). However, PBF was not significantly different between the two populations. VFI/PBF ratio was positively associated with sizes of AVA, SV, STJ, and AscAo (p < 0.05), and was independently related to PAD (p < 0.05). A 1-SD increment in VFI/PBF ratio was associated with 13.35-fold increased risk of PAD (odds ratio: 13.35, p < 0.05).
   Conclusions: VFI/PBF ratio is independently associated with PAD. An increased proportion of visceral fat may contribute to PAD. VFI/PBF ratio calculation may be used for the preliminary identification of individuals at high risk of PAD in the Chinese population. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Jiang, Zhiyuan; Lin, Baojing; Liu, Tangwei; Huang, Shan; Shao, Shuang; Huang, Rongjie; Huang, Jiangnan] Guangxi Med Univ, Affiliated Hosp 1, Hypertens Div, 6 Shuangyong Rd, Nanning 530021, Peoples R China.
   [Qin, Shiyun] Guangxi Med Univ, Affiliated Hosp 1, Ultrasound Dept, Nanning, Peoples R China.
   [Li, Shuo] Guangxi Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanning, Peoples R China.
RP Huang, RJ; Huang, JN (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Hypertens Div, 6 Shuangyong Rd, Nanning 530021, Peoples R China.
EM Dr_Rongjie_Huang@yeah.ne; huangjn1998@163.com
FU China's National Key R&D Program in the Twelfth Five-year Plan
   [2011BAI11B01]
FX This study is supported by the China's National Key R&D Program in the
   Twelfth Five-year Plan (No. 2011BAI11B01).
NR 53
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 19
EP 26
DI 10.1016/j.atherosclerosis.2017.11.008
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500003
PM 29169031
DA 2019-10-28
ER

PT J
AU Bliden, KP
   Chaudhary, R
   Navarese, EP
   Sharma, T
   Kaza, H
   Tantry, US
   Gurbel, PA
AF Bliden, Kevin P.
   Chaudhary, Rahul
   Navarese, Eliano P.
   Sharma, Tushar
   Kaza, Himabindu
   Tantry, Udaya S.
   Gurbel, Paul A.
TI Thrombogenicity and central pulse pressure to enhance prediction of
   ischemic event occurrence in patients with established coronary artery
   disease: The MAGMA-ischemia score
SO ATHEROSCLEROSIS
LA English
DT Article
DE Risk assessment; Thrombogenicity; Central pulse pressure; Adverse
   cardiovascular outcomes; CAD
ID CARDIOVASCULAR RISK; HEART-DISEASE; MYOCARDIAL-INFARCTION;
   DIABETES-MELLITUS; PLATELET-FUNCTION; STENT RESTENOSIS; STABLE PATIENTS;
   VALIDATION; HYPERTENSION; ACTIVATION
AB Background and aims: Conventional cardiovascular risk estimators based on clinical demographics have limited prediction of coronary events. Markers for thrombogenicity and vascular function have not been explored in risk estimation of high-risk patients with coronary artery disease. We aimed to develop a clinical and biomarker score to predict 3-year adverse cardiovascular events.
   Methods: Four hundred eleven patients, with ejection fraction >= 40% undergoing coronary angiography, and found to have a luminal diameter stenosis >= 50%, were included in the analysis. Thrombelastography indices and central pulse pressure (CPP) were determined at the time of catheterization.
   Results: We identified predictors of death, myocardial infarction (MI) or stroke and developed a numerical ischemia risk score. The primary endpoint of cardiovascular death, MI or stroke occurred in 22 patients (5.4%). The factors associated with events were age, prior PCI or CABG, diabetes, CPP, and thrombin-induced platelet-fibrin clot strength, and were included in the MAGMA-ischemia score. The MAGMA-ischemia score showed a c-statistic of 0.85 (95% Confidence Interval [CI] 0.80-0.87; p< 0.001) for the primary endpoint. In the subset of patients who underwent revascularization, the c-statistic was 0.90 (p< 0.001). Patients with MAGMA-ischemia score greater than 5 had highest risk to develop clinical events, hazard ratio for the primary endpoint: 13.9 (95% CI 5.8-33.1, p< 0.001) and for the secondary endpoint: 4.8 (95% CI 2.3-9.6, p< 0.001). When compared to previous models, the MAGMA-ischemia score yielded a higher discrimination.
   Conclusions: Inclusion of CPP and assessment of thrombogenicity in a novel score for patients with documented CAD enhanced the prediction of events. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Bliden, Kevin P.; Chaudhary, Rahul; Navarese, Eliano P.; Sharma, Tushar; Kaza, Himabindu; Tantry, Udaya S.; Gurbel, Paul A.] Inova Heart & Vasc Inst, Inova Ctr Thrombosis Res & Drug Dev, Fairfax, VA USA.
RP Gurbel, PA (reprint author), Inova Heart & Vasc Inst, Inova Ctr Thrombosis Res & Drug Dev, Intervent Cardiol & Cardiovasc Med Res, 3300 Gallows Rd, Falls Church, VA 22042 USA.
EM Paul.Gurbel@inova.org
OI Navarese, Eliano/0000-0002-2355-4589; Chaudhary,
   Rahul/0000-0002-3276-385X
FU AmgenAmgen; BayerBayer AG; DCRI; Haemonetics; Idorsia; Ionis;
   JanssenJohnson & Johnson USAJanssen Biotech Inc; MerckMerck & Company; 
   [P50HL110789-04]
FX Dr. Gurbel reports receiving grants from the National Institutes (Grant
   # P50HL110789-04), Amgen, Bayer, DCRI, Haemonetics, Idorsia, Ionis,
   Janssen, and Merck; receiving honoraria and payment for lectures,
   consultations, including service on speakers' bureaus from, Bayer,
   Janssen, Merck, Corgenix, and Aralez Pharmaceuticals. Dr. Gurbel is
   holding stock or stock options in Merck, Medtronic, and Pfizer; and
   holding patents in the area of personalized antiplatelet therapy and
   interventional cardiology. The other authors report no disclosures.
NR 37
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 55
EP 62
DI 10.1016/j.atherosclerosis.2017.11.018
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500008
PM 29175655
DA 2019-10-28
ER

PT J
AU Kubota, Y
   Folsom, AR
   Ballantyne, CM
   Tang, WH
AF Kubota, Yasuhiko
   Folsom, Aaron R.
   Ballantyne, Christie M.
   Tang, Weihong
TI Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis
   Risk in Communities study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Abdominal aortic aneurysm; Lipoprotein(a); Prospective study;
   Population-based study
ID CARDIOVASCULAR-DISEASE; RECOMMENDATION STATEMENT; STROKE; PLASMA;
   PROLIFERATION; METAANALYSIS
AB Background and aims: No prospective study has investigated whether elevated lipoprotein(a) concentrations are associated with an increased risk of abdominal aortic aneurysm (AAA). We aimed to prospectively investigate this association.
   Methods: In 1987-1989, the Atherosclerosis Risk in Communities study measured plasma lipoprotein(a) in 13,683 participants aged 45-64 years, without a history of AAA surgery. We followed them for incident, clinical AAA events through 2011.
   Results: During the 272,914 person-years of follow-up, over a median of 22.6 years, we documented 505 incident AAA events. The age-, sex-, and race-adjusted model showed that individuals in the highest quintile of plasma lipoprotein(a) had an increased risk of AAA. Further adjustment for the other potential confounding factors, including other plasma lipids (high-and low-density lipoprotein cholesterol and triglyceride concentrations), attenuated the association, but individuals in the highest versus lowest quintile of plasma lipoprotein(a) still had a significantly increased risk of AAA [hazard ratio (95% confidence interval): 1.57 (1.19e2.08)]. Interaction testing suggested no difference in the associations for whites and African Americans (p for interaction = 0.96). A restricted cubic spline analysis demonstrated a positive dose-response relation of plasma lipoprotein(a) with AAA, with a steep increase in AAA risk above the 75th percentile (p for overall association = 0.0086, p for non-linear association = 0.097).
   Conclusions: In this population-based cohort study, elevated lipoprotein(a) concentrations were independently associated with an increased risk of AAA. The association reflected a threshold of increased AAA risk at high lipoprotein(a) concentrations, rather than a steady monotonic association. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Kubota, Yasuhiko; Folsom, Aaron R.; Tang, Weihong] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, 1300 South 2nd St, Minneapolis, MN 55454 USA.
   [Ballantyne, Christie M.] Baylor Coll Med, Dept Med, Sect Cardiovasc Res, Houston, TX 77030 USA.
   [Ballantyne, Christie M.] Houston Methodist Debakey Heart & Vasc Ctr, Houston, TX USA.
RP Kubota, Y (reprint author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, 1300 South 2nd St, Minneapolis, MN 55454 USA.
EM kubot007@umn.edu
FU Nippon FoundationNippon Foundation; National Heart, Lung, and Blood
   Institute (NHLBI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]
FX The Nippon Foundation provided grants to support Dr. Kubota's fellowship
   at School of Public Health, University of Minnesota. The National Heart,
   Lung, and Blood Institute (NHLBI) supported ARIC via contracts
   HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, HHSN268201100012C, and the collection of AAA data via
   R01 HL103695.
NR 31
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 63
EP 67
DI 10.1016/j.atherosclerosis.2017.10.017
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500009
PM 29182987
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Mahajan, H
   Choo, J
   Masaki, K
   Fujiyoshi, A
   Guo, JC
   Hisamatsu, T
   Evans, R
   Shangguan, SY
   Willcox, B
   Okamura, T
   Vishnu, A
   Barinas-Mitchell, E
   Ahuja, V
   Miura, K
   Kuller, L
   Shin, C
   Ueshima, H
   Sekikawa, A
AF Mahajan, Hemant
   Choo, Jina
   Masaki, Kamal
   Fujiyoshi, Akira
   Guo, Jingchuan
   Hisamatsu, Takashi
   Evans, Rhobert
   Shangguan, Siyi
   Willcox, Bradley
   Okamura, Tomonori
   Vishnu, Abhishek
   Barinas-Mitchell, Emma
   Ahuja, Vasudha
   Miura, Katsuyuki
   Kuller, Lewis
   Shin, Chol
   Ueshima, Hirotsugu
   Sekikawa, Akira
TI Association of alcohol consumption and aortic calcification in healthy
   men aged 40-49 years for the ERA JUMP Study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Alcohol; Aorta; Atherosclerosis; Calcification; Men
ID CORONARY-ARTERY CALCIUM; CARDIOVASCULAR EVENTS; CAROTID ATHEROSCLEROSIS;
   ARCH CALCIFICATION; BINGE DRINKING; BLOOD-PRESSURE; HEART-DISEASE;
   RISK-FACTORS; ADULTS; HYPERTENSION
AB Background and aims: Several studies have reported a significant inverse association of light to moderate alcohol consumption with coronary heart disease (CHD). However, studies assessing the relationship between alcohol consumption and atherosclerosis have reported inconsistent results. The current study was conducted to determine the relationship between alcohol consumption and aortic calcification.
   Methods: We addressed the research question using data from the population-based ERA-JUMP Study, comprising of 1006 healthy men aged 40-49 years, without clinical cardiovascular diseases, from four race/ethnicities: 301 Whites, 103 African American, 292 Japanese American, and 310 Japanese in Japan. Aortic calcification was assessed by electron-beam computed tomography and quantified using the Agatston method. Alcohol consumption was categorized into four groups: 0 (non-drinkers), <= 1 (light drinkers), > 1 to <= 3 (moderate drinkers) and > 3 drinks per day (heavy drinkers) (1 drink - 12.5 g of ethanol). Tobit conditional regression and ordinal logistic regression were used to investigate the association of alcohol consumption with aortic calcification after adjusting for cardiovascular risk factors and potential confounders.
   Results: The study participants consisted of 25.6% nondrinkers, 35.3% light drinkers, 23.5% moderate drinkers, and 15.6% heavy drinkers. Heavy drinkers [Tobit ratio (95% CI) = 2.34 (1.10, 4.97); odds ratio (95% CI) = 1.67 (1.11, 2.52)] had significantly higher expected aortic calcification score compared to nondrinkers, after adjusting for socio-demographic and confounding variables. There was no significant interaction between alcohol consumption and race/ethnicity on aortic calcification.
   Conclusions: Our findings suggest that heavy alcohol consumption may be an independent risk factor for atherosclerosis. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Mahajan, Hemant; Guo, Jingchuan; Evans, Rhobert; Vishnu, Abhishek; Barinas-Mitchell, Emma; Ahuja, Vasudha; Kuller, Lewis; Sekikawa, Akira] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA.
   [Choo, Jina] Korea Univ, Coll Nursing, Dept Nursing, Seoul, South Korea.
   [Masaki, Kamal; Willcox, Bradley] Univ Hawaii, Kuakini Med Ctr, Dept Res, Honolulu, HI 96822 USA.
   [Masaki, Kamal; Willcox, Bradley] Univ Hawaii, John A Burns Sch Med, Dept Geriatr Med, Honolulu, HI 96822 USA.
   [Fujiyoshi, Akira; Miura, Katsuyuki; Ueshima, Hirotsugu] Shiga Univ Med Sci, Dept Publ Hlth, Seta Tsukinowa Cho, Otsu, Shiga, Japan.
   [Hisamatsu, Takashi] Shimane Univ, Fac Med, Dept Environm Med & Publ Hlth, Izumo, Shimane, Japan.
   [Shangguan, Siyi] Univ Pittsburgh, Dept Internal Med, Med Ctr, Pittsburgh, PA 15213 USA.
   [Okamura, Tomonori] Keio Univ, Sch Med, Dept Prevent Med & Publ Hlth, Shinjuku Ku, 35 Shinanomachi, Tokyo, Japan.
   [Shin, Chol] Univ Ansan Hosp, Dept Internal Med, Sleep & Crit Care Med, Ansan, South Korea.
RP Mahajan, H (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, 130 North Bellefield Ave,Suite 546, Pittsburgh, PA 15213 USA.
EM hdm12@pitt.edu
RI Okamura, Tomonori/L-1693-2013
OI Okamura, Tomonori/0000-0003-0488-0351; Sekikawa,
   Akira/0000-0002-7197-6321; Fujiyoshi, Akira/0000-0002-5790-7119; Guo,
   Jingchuan/0000-0001-9799-2592; Vishnu, Abhishek/0000-0003-3573-4090;
   Mahajan, Hemant/0000-0001-7874-9191; Ahuja, Vasudha/0000-0002-6736-8809
FU National Institutes of Health, USA (Bethesda, Maryland, USA)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [HL068200, HL071561]; Japanese Ministry of Education,
   Culture, Sports, Science and Technology (Tokyo, Japan)Ministry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT) [B
   16790335, A 13307016, 17209023, 21249043]
FX The work was supported by grants HL068200 and HL071561 from the National
   Institutes of Health, USA (Bethesda, Maryland, USA), B 16790335 and A
   13307016, 17209023, and 21249043 from the Japanese Ministry of
   Education, Culture, Sports, Science and Technology (Tokyo, Japan).
NR 50
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 84
EP 91
DI 10.1016/j.atherosclerosis.2017.11.017
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500012
PM 29195109
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Zhu, L
   Zhang, DY
   Zhu, H
   Zhu, JM
   Weng, SG
   Dong, L
   Liu, TT
   Hu, Y
   Shen, XZ
AF Zhu, Lin
   Zhang, Danying
   Zhu, Hong
   Zhu, Jimin
   Weng, Shugiang
   Dong, Ling
   Liu, Taotao
   Hu, Yu
   Shen, Xizhong
TI Berberine treatment increases Akkermansia in the gut and improves
   high-fat diet-induced atherosclerosis in Apoe(-/-) mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Berberine; Gut microbiota; Akkermansia; Inflammation
ID ENDOTOXEMIA-INDUCED INFLAMMATION; METABOLIC SYNDROME; INDUCED OBESITY;
   CORONARY-ARTERY; CROSS-TALK; MICROBIOTA; MUCINIPHILA; DISEASE;
   PHOSPHATIDYLCHOLINE; MACROPHAGES
AB Background and aims: Gut microbiota plays a major role in metabolic disorders. Berberine is used to treat obesity, diabetes and atherosclerosis. The mechanism underlying the role of berberine in modulating metabolic disorders is not fully clear because berberine has poor oral bioavailability. Thus, we evaluated whether the antiatherosclerotic effect of berberine is related to alterations in gut microbial structure and if so, whether specific bacterial taxa contribute to the beneficial effects of berberine.
   Methods: Apoe(-/-) mice were fed either a normal-chow diet or a high-fat diet (HFD). Berberine was administered to mice in drinking water (0.5 g/L) for 14 weeks. Gut microbiota profiles were established by high throughput sequencing of the V3-V4 region of the bacterial 16S ribosomal RNA gene. The effects of berberine on metabolic endotoxemia, tissue inflammation and gut barrier integrity were also investigated.
   Results: Berberine treatment significantly reduced atherosclerosis in HFD-fed mice. Akkermansia spp. abundance was markedly increased in HFD-fed mice treated with berberine. Moreover, berberine decreased HFD-induced metabolic endotoxemia and lowered arterial and intestinal expression of proinflammatory cytokines and chemokines. Berberine treatment increased intestinal expression of tight junction proteins and the thickness of the colonic mucus layer, which are related to restoration of gut barrier integrity in HFD-fed mice.
   Conclusions: Modulation of gut microbiota, specifically an increase in the abundance of Akkermansia, may contribute to the antiatherosclerotic and metabolic protective effects of berberine, which is poorly absorbed orally. Our findings therefore support the therapeutic value of gut microbiota manipulation in treating atherosclerosis. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Zhu, Lin; Hu, Yu] Fudan Univ, Zhongshan Hosp, Dept Geriatr, Shanghai, Peoples R China.
   [Zhang, Danying; Zhu, Jimin; Weng, Shugiang; Dong, Ling; Liu, Taotao; Shen, Xizhong] Fudan Univ, Zhongshan Hosp, Dept Gastroenterol, Shanghai, Peoples R China.
   [Zhu, Hong] Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Shanghai, Peoples R China.
   [Shen, Xizhong] Minist Educ & Hlth, Key Lab Med Mol Virol, Shanghai Inst Liver Dis, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
RP Shen, XZ (reprint author), Minist Educ & Hlth, Key Lab Med Mol Virol, Shanghai Inst Liver Dis, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM xizhongshen@126.com
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [81301820, 81472673, 81672720, 81672334]; fund of
   Shanghai Science and Technology Commission [16ZR1406100]; National
   Clinical Key Special Subject of China
FX This study was supported by National Nature Science Foundation of China
   (No. 81301820, No. 81472673, No. 81672720, No. 81672334), The fund of
   Shanghai Science and Technology Commission (16ZR1406100), The National
   Clinical Key Special Subject of China.
NR 49
TC 14
Z9 16
U1 6
U2 33
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 117
EP 126
DI 10.1016/j.atherosclerosis.2017.11.023
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500016
PM 29202334
DA 2019-10-28
ER

PT J
AU Hwang, IC
   Jin, KN
   Kim, HL
   Kim, YN
   Im, MS
   Lim, WH
   Seo, JB
   Kim, SH
   Zo, JH
   Kim, MA
AF Hwang, In-Chang
   Jin, Kwang Nam
   Kim, Hack-Lyoung
   Kim, You-Nui
   Im, Moon-Sun
   Lim, Woo-Hyun
   Seo, Jae-Bin
   Kim, Sang-Hyun
   Zo, Joo-Hee
   Kim, Myung-A
TI Additional prognostic value of brachial-ankle pulse wave velocity to
   coronary computed tomography angiography in patients with suspected
   coronary artery disease
SO ATHEROSCLEROSIS
LA English
DT Article
DE Arterial stiffness; Coronary artery disease; Coronary CT angiography;
   Prognosis
ID ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS; CALCIUM SCORE; SYMPTOMATIC
   PATIENTS; CT ANGIOGRAPHY; STIFFNESS; PREDICTION; RISK; DETERMINANTS;
   SOCIETY
AB Background and aims: Increased arterial stiffness is associated with a higher risk of future cardiovascular events. We aimed to investigate whether information about arterial stiffness provides additional prognostic value to coronary computed tomography angiography (CCTA) findings.
   Methods: A total of 523 consecutive patients (mean age, 58.0 +/- 10.3 years; male, 60.6%) with suspected coronary artery disease (CAD), who underwent CCTA and brachial-ankle pulse wave velocity (baPWV) measurement within a month, were retrospectively analyzed. A composite of cardiovascular death, nonfatal myocardial infarction (MI), coronary revascularization, nonfatal stroke, and hospitalization for cardiovascular causes was assessed.
   Results: During a median 43.9 months of follow-up (interquartile range, 11.6-66.9 months), the composite endpoint occurred in 66 patients (3 cardiovascular deaths, 1 nonfatal MI, 35 coronary revascularizations, 16 nonfatal strokes, and 45 hospitalizations for cardiovascular causes). After adjustment for clinical risk factors and CCTA findings, higher baPWV was an independent prognostic factor for the composite endpoint (adjusted hazard ratio, 4.717; 95% confidence interval, 2.675-8.319; p < 0.001). The addition of baPWV to clinical risk factors and CCTA findings significantly improved the prediction of cardiovascular events (global chi(2) score, from 132 to 154; p = 0.005).
   Conclusions: Arterial stiffness provides additional prognostic information to CCTA findings in patients with suspected CAD. The baPWV can serve as a useful clinical tool for risk stratification in this population. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Hwang, In-Chang; Kim, Hack-Lyoung; Kim, You-Nui; Im, Moon-Sun; Lim, Woo-Hyun; Seo, Jae-Bin; Kim, Sang-Hyun; Zo, Joo-Hee; Kim, Myung-A] Seoul Natl Univ, Coll Med, Boramae Med Ctr, Div Cardiol,Dept Internal Med, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
   [Jin, Kwang Nam] Seoul Natl Univ, Coll Med, Boramae Med Ctr, Dept Radiol, Seoul, South Korea.
RP Kim, HL (reprint author), Seoul Natl Univ, Coll Med, Boramae Med Ctr, Div Cardiol,Dept Internal Med, 20 Boramae Ro 5 Gil, Seoul 07061, South Korea.
EM khl2876@gmail.com
OI Kim, Sang-Hyun/0000-0001-8026-1582; Lim, Woo-Hyun/0000-0001-9298-8500
NR 35
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 127
EP 137
DI 10.1016/j.atherosclerosis.2017.11.026
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500017
PM 29216483
DA 2019-10-28
ER

PT J
AU Nishihira, K
   Shibata, Y
   Yamashita, A
   Kuriyama, N
   Asada, Y
AF Nishihira, Kensaku
   Shibata, Yoshisato
   Yamashita, Atsushi
   Kuriyama, Nehiro
   Asada, Yujiro
TI Relationship between thrombus age in aspirated coronary material and
   mid-term major adverse cardiac and cerebrovascular events in patients
   with acute myocardial infarction
SO ATHEROSCLEROSIS
LA English
DT Article
DE Aspiration; Coronary intervention; Thrombus; Pathology
ID 2011 ACCF/AHA/SCAI GUIDELINE; ASSOCIATION TASK-FORCE; 1-YEAR FOLLOW-UP;
   INDEPENDENT PREDICTOR; INTERVENTION; MORTALITY; MANAGEMENT; OUTCOMES;
   UPDATE
AB Background and aims: Recent studies have shown that coronary thrombus histopathology is associated with impaired myocardial reperfusion and poor clinical outcome in patients with acute myocardial infarction (AMI). We sought to investigate the age of thrombi aspirated during percutaneous coronary intervention (PCI) in patients with AMI and evaluate the relationship between histopathologic findings and major adverse cardiac and cerebrovascular events (MACCEs) defined as all-cause death, stroke, or myocardial infarction within 6 months of PCI.
   Methods: In this prospective 2-center observational study, coronary material was obtained during PCI from 305 patients with AMI within 24 h of symptom onset. Thrombi were morphologically classified as either only fresh or older (lytic changes or organization).
   Results: MACCE occurred in 38 (12.5%) patients. Only fresh thrombi were observed in 114 (37%) of 305 patients; older thrombi were identified in 191 (63%). The rate of MACCE was significantly higher among patients with older thrombus (p = 0.011). Multivariate analysis also showed the presence of older thrombus [odds ratio (OR) 3.03, 95% confidence interval (CI) 1.122-9.522] is an independent predictor of MACCE within 6 months of PCI, as well as age (OR 1.051, 95% CI 1.013-1.094) and creatine kinase concentration (OR 1.025, 95% CI 1.013-1.037). The prevalence of slow flow or distal embolization during PCI and peak creatine kinase concentration were significantly higher in the older thrombus group (p < 0.05, respectively).
   Conclusions: Older thrombus found in aspirated coronary material is associated with impaired myocardial reperfusion and is an independent predictor of mid-term MACCE in patients with AMI. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Nishihira, Kensaku] Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.
   [Shibata, Yoshisato; Kuriyama, Nehiro] Miyazaki Med Assoc Hosp, Dept Cardiol, Miyazaki, Japan.
   [Yamashita, Atsushi; Asada, Yujiro] Univ Miyazaki, Fac Med, Dept Pathol, Miyazaki, Japan.
RP Nishihira, K (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Cardiovasc Med, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.
EM nishihira@ncvc.go.jp
NR 20
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 138
EP 144
DI 10.1016/j.atherosclerosis.2017.12.001
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500018
PM 29223872
DA 2019-10-28
ER

PT J
AU Gjodesen, CU
   Jorgensen, ME
   Bjerregaard, P
   Dahl-Petersen, IK
   Larsen, CVL
   Noel, M
   Melbye, M
   Cohen, AS
   Lundqvist, M
   Hougaard, DM
   Helge, JW
   Nielsen, NO
AF Gjodesen, Camilla U.
   Jorgensen, Marit E.
   Bjerregaard, Peter
   Dahl-Petersen, Inger K.
   Larsen, Christina V. L.
   Noel, Martin
   Melbye, Mads
   Cohen, Arieh S.
   Lundqvist, Marika
   Hougaard, David M.
   Helge, Jorn W.
   Nielsen, Nina O.
TI Associations between vitamin D status and atherosclerosis among Inuit in
   Greenland
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Carotid intima media thickness; Vitamin D; Inuit;
   Greenland
ID INTIMA-MEDIA THICKNESS; SUBCLINICAL ATHEROSCLEROSIS;
   CARDIOVASCULAR-DISEASE; 25-HYDROXYVITAMIN D; CAROTID ATHEROSCLEROSIS;
   INSULIN-RESISTANCE; RISK; PREVALENCE; DIET; POPULATION
AB Background and aims: Low levels of vitamin D are suspected to be a risk factor for cardiovascular disease and atherosclerosis. The aim of this study was to assess the prevalence of subclinical atherosclerosis among Inuit in Greenland, and to evaluate the association with vitamin D status. We hypothesized that low vitamin D status could be associated with higher carotid intima-media thickness (IMT) as a marker of atherosclerosis.
   Methods: 756 adults from the Inuit Health in Transition (IHIT) study carried out in Greenland in the period 2005-2010 were included. A blood sample donated in 1987 was available for a sub-sample of 102 individuals. Serum 25(OH) D3 from the IHIT study and the 1987 survey was used as a measure of vitamin D status. IMT measurements were conducted by ultrasound scanning. The prevalence of atherosclerosis was estimated, and the association between serum 25(OH) D3 and IMT measurements was examined by linear regression.
   Results: The overall prevalence of subclinical atherosclerosis was 20.1% (n = 152). The linear regression analyses indicated a weak positive association between serum 25(OH) D3 level and IMT measurements from the IHIT study, though not statistically significant after adjustment for potential confounders (beta = 0.35% per 10 nmoL/L 25(OH) D3, p = 0.06). Linear regression analyses of the association between serum 25(OH) D3 level in the 1987 survey and IMT measurements also indicated a positive, though not statistically significant, association after adjustment (beta = 0.07% per 10 nmoL/L 25(OH) D3, p = 0.86).
   Conclusions: Our findings did not support the hypothesis of an association between low vitamin D levels and risk of atherosclerosis. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Gjodesen, Camilla U.; Jorgensen, Marit E.; Bjerregaard, Peter; Dahl-Petersen, Inger K.; Larsen, Christina V. L.; Nielsen, Nina O.] Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark.
   [Jorgensen, Marit E.] Steno Diabet Ctr Copenhagen, Gentofte, Denmark.
   [Jorgensen, Marit E.; Bjerregaard, Peter] Univ Greenland, Greenland Ctr Hlth Res, Nuuk, Greenland.
   [Noel, Martin] Univ Laval, Laval, PQ, Canada.
   [Melbye, Mads] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark.
   [Melbye, Mads] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
   [Melbye, Mads] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
   [Cohen, Arieh S.; Lundqvist, Marika; Hougaard, David M.] Statens Serum Inst, Dept Congenital Disorders, Copenhagen, Denmark.
   [Helge, Jorn W.] Univ Copenhagen, Ctr Hlth Aging, Dept Biomed Sci, Copenhagen, Denmark.
   [Nielsen, Nina O.] Univ Coll Absalon, Ctr Nutr & Rehabil, Naestved, Denmark.
RP Gjodesen, CU (reprint author), Univ Southern Denmark, Natl Inst Publ Hlth, Copenhagen, Denmark.
EM cugjoedesen@hotmail.com
RI Helge, Jorn Wulff/I-7096-2012
OI Helge, Jorn Wulff/0000-0001-9724-5423; Dahl-Petersen,
   Inger/0000-0002-3157-8847; Jorgensen, Marit Eika/0000-0001-8356-5565;
   Larsen, Christina Viskum Lytken/0000-0002-6245-4222; melbye,
   mads/0000-0001-8264-6785
FU Government of Greenland's health department [2011-047012/2012-074239];
   Aase og Ejnar Danielsen's Foundation [10-000444]; Dagmar Marshalls
   Foundation; Karen Elise Jensens Foundation; Nuna Foundation
FX The study was supported by the Government of Greenland's health
   department (2011-047012/2012-074239), Aase og Ejnar Danielsen's
   Foundation (10-000444), Dagmar Marshalls Foundation, Karen Elise Jensens
   Foundation and Nuna Foundation. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
NR 46
TC 2
Z9 2
U1 2
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 145
EP 151
DI 10.1016/j.atherosclerosis.2017.11.028
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500019
PM 29227867
DA 2019-10-28
ER

PT J
AU Sohn, SM
   Choi, BG
   Choi, SY
   Byun, JK
   Mashaly, A
   Park, Y
   Jang, WY
   Kim, W
   Choi, JY
   Park, EJ
   Na, JO
   Choi, CU
   Lim, HE
   Kim, EJ
   Park, CG
   Seo, HS
   Oh, DJ
   Rha, SW
AF Sohn, Sung Min
   Choi, Byoung Geol
   Choi, Se Yeon
   Byun, Jae Kyeong
   Mashaly, Ahmed
   Park, Yoonjee
   Jang, Won Young
   Kim, Woohyeun
   Choi, Jah Yeon
   Park, Eun Jin
   Na, Jin Oh
   Choi, Cheol Ung
   Lim, Hong Euy
   Kim, Eung Ju
   Park, Chang Gyu
   Seo, Hong Seog
   Oh, Dong Joo
   Rha, Seung-Woon
TI Impact of alcohol drinking on acetylcholine-induced coronary artery
   spasm in Korean populations
SO ATHEROSCLEROSIS
LA English
DT Article
DE Coronary artery spasm; Acetylcholine; Alcohol; Angina
ID 3-YEAR FOLLOW-UP; PROVOCATION TEST; VARIANT ANGINA; CLINICAL-OUTCOMES;
   INFLAMMATORY MARKERS; VASOSPASTIC ANGINA; CONSUMPTION; DISEASE; HEALTH;
   PATHOPHYSIOLOGY
AB Background and aims: Generally, immoderate alcohol consumption is associated with variant angina and accepted as one of the risk factors for coronary artery spasm (CAS), but evidence is lacking in this regard. The aim of this study is to evaluate the impact of alcohol consumption and drinking pattern on CAS by acetylcholine (ACH) provocation test and long-term clinical outcomes.
   Methods: A total of 5491 patients with typical or atypical chest pain, without significant coronary artery disease, who underwent intracoronary ACH provocation test, were enrolled prospectively, and retrospectively analyzed in this study. They were divided into two groups according to their alcohol drinking status; the current alcohol (CA) drinking group (n = 1792), and non-CA group (n = 3699). To adjust for potential confounders, a propensity score matching (PSM) analysis was performed. The primary endpoint was incidence of CAS, and secondary endpoints were major adverse cardiac events (MACE) and recurrent angina requiring repeat coronary angiography (CAG) at 5 years.
   Results: After PSM analysis, alcohol consumption was a strong risk factor for CAS. Furthermore, excessive alcohol consumption was correlated with a higher risk for CAS. As compared with the non-CA group, the CA group showed worse angiographic and clinical findings, including higher incidence of CAS (58% vs. 62%, p = 0.016), spontaneous spasm (17% vs. 22%, p = 0.004), multi-vessel spasm (31% vs. 37%, p = 0.009), proximal epicardial spasm (39% vs. 46%, p = 0.002), ischemic electrocardiography changes such as Tinversion (0.4% vs. 1.2%, p < 0.001) and chest pain (42% vs. 46%, p = 0.047) during ACH provocation test. However, the status and pattern of alcohol drinking had no influence on long-term clinical outcomes such as MACE or recurrent angina.
   Conclusions: Alcohol consumption is a strong risk factor for CAS, and excessive alcohol consumption was correlated with a higher risk for CAS. Further well-designed studies are needed to confirm the results. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Sohn, Sung Min] Korea Univ, Dept Med, Coll Med, Seoul, South Korea.
   [Choi, Byoung Geol; Choi, Se Yeon; Byun, Jae Kyeong] Korea Univ, Grad Sch, Dept Med, Seoul, South Korea.
   [Mashaly, Ahmed; Park, Yoonjee; Jang, Won Young; Kim, Woohyeun; Choi, Jah Yeon; Park, Eun Jin; Na, Jin Oh; Choi, Cheol Ung; Lim, Hong Euy; Kim, Eung Ju; Park, Chang Gyu; Seo, Hong Seog; Oh, Dong Joo; Rha, Seung-Woon] Korea Univ, Guro Hosp, Cardiovasc Ctr, 148 Gurodong Ro, Seoul 08308, South Korea.
RP Rha, SW (reprint author), Korea Univ, Guro Hosp, Cardiovasc Ctr, 148 Gurodong Ro, Seoul 08308, South Korea.
EM swrha617@yahoo.co.kr
OI Choi, Byoung Geol/0000-0002-6090-869X
NR 36
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 163
EP 169
DI 10.1016/j.atherosclerosis.2017.11.032
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500022
PM 29227870
DA 2019-10-28
ER

PT J
AU Liljestrand, JM
   Paju, S
   Pietiainen, M
   Buhlin, K
   Persson, GR
   Nieminen, MS
   Sinisalo, J
   Mantyla, P
   Pussinen, PJ
AF Liljestrand, John M.
   Paju, Susanna
   Pietiainen, Milla
   Buhlin, Kare
   Persson, G. Rutger
   Nieminen, Markku S.
   Sinisalo, Juha
   Mantyla, Paivi
   Pussinen, Pirkko J.
TI Immunologic burden links periodontitis to acute coronary syndrome
SO ATHEROSCLEROSIS
LA English
DT Article
DE Periodontitis; Cardiovascular diseases; Acute coronary syndrome;
   Antibodies; Enzyme-linked immunosorbent assay; Molecular mimicry;
   Bacteria
ID SERUM ANTIBODY-LEVELS; ARTERY-DISEASE; CARDIOVASCULAR-DISEASE;
   ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; PORPHYROMONAS-GINGIVALIS;
   CHECKERBOARD ASSESSMENTS; MYOCARDIAL-INFARCTION; PATHOGEN BURDEN;
   ASSOCIATION; RISK
AB Background and aims: Periodontitis, a common polymicrobial inflammatory disease in the tooth supporting tissues, is a risk factor for coronary artery disease. One of the proposed underlying mechanisms is the systemic immune response to periodontal infection. We studied how serum antibodies against seven periodontal pathogens and their subgingival levels associate with each other, periodontitis, and coronary artery disease.
   Methods: The Parogene cohort included 505 Finnish patients (mean age 63 y) who underwent coronary angiography, and clinical and radiographic oral examinations. Coronary diagnosis was defined as no significant coronary artery disease (< 50% stenosis, n = 152), stable coronary artery disease (>= 50% stenosis, n = 184) and acute coronary syndrome (n = 169). Levels of subgingival Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Porphyromonas endodontalis, Prevotella intermedia, Tannerella forsythia, Campylobacter rectus, and Fusobacterium nucleatum were determined by checkerboard DNA-DNA hybridization. Serum antibody (IgA/IgG) levels were analyzed with enzyme-linked immunosorbent assay (ELISA). Aggregate IgA/IgG burdens were calculated by summing and standardizing the serum antibody levels.
   Results: Patients with active periodontitis were characterized by higher levels of subgingival bacteria and corresponding IgA/IgG response. Quartiles 2-4 of serum IgA/IgG burden indicated higher risk for acute coronary syndrome (OR 1.84, 95% CI 1.01-3.35 for IgA; OR 1.87, 95% CI 1.01-3.46 for IgG) independently of established cardiovascular risk factors, body mass index, number of teeth, subgingival bacterial levels and periodontal diagnosis.
   Conclusions: Our findings support the hypothesis that the association between periodontitis and cardiovascular diseases is partly mediated by the immunologic response for periodontal pathogens. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Liljestrand, John M.; Paju, Susanna; Pietiainen, Milla; Buhlin, Kare; Mantyla, Paivi; Pussinen, Pirkko J.] Univ Helsinki, Oral & Maxillofacial Dis, Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
   [Liljestrand, John M.; Paju, Susanna; Pietiainen, Milla; Buhlin, Kare; Mantyla, Paivi; Pussinen, Pirkko J.] Helsinki Univ Hosp, Haartmaninkatu 8, Helsinki 00290, Finland.
   [Buhlin, Kare] Karolinska Inst, Dept Dent Med, Div Periodontol, Huddinge, Sweden.
   [Persson, G. Rutger] Univ Washington, Dept Oral Med, Seattle, WA 98195 USA.
   [Persson, G. Rutger] Univ Washington, Dept Periodont, Seattle, WA 98195 USA.
   [Nieminen, Markku S.; Sinisalo, Juha] Helsinki Univ Hosp, Heart & Lung Ctr, Dept Cardiol, Dept Med, Helsinki, Finland.
   [Mantyla, Paivi] Univ Eastern Finland, Inst Dent, Kuopio, Finland.
RP Liljestrand, JM (reprint author), Univ Helsinki, Oral & Maxillofacial Dis, Biomed Helsinki 1,Haartmaninkatu 8,POB 63, FI-00014 Helsinki, Finland.
EM john.liljestrand@helsinki.fi
OI Paju, Susanna/0000-0002-2048-3420; Sinisalo, Juha/0000-0002-0169-5137;
   Mantyla, Paivi/0000-0003-2091-972X
FU Finnish Dental Society Apollonia; Ida Montin foundation; Otto A. Malm
   foundation; Academy of FinlandAcademy of Finland [1266053, 1296541];
   Paivikki and Sakari Sohlberg foundation; Yrjo Jahnsson foundation;
   Sigrid Juselius foundationSigrid Juselius Foundation
FX This study was supported by grants from the Finnish Dental Society
   Apollonia (JML), the Ida Montin foundation (JML), the Otto A. Malm
   foundation (JML), the Academy of Finland (1266053 to PJP; 1296541 to
   SP), the Paivikki and Sakari Sohlberg foundation ( to PJP), the Yrjo
   Jahnsson foundation (to PJP) and the Sigrid Juselius foundation (PJP).
NR 49
TC 9
Z9 9
U1 1
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 177
EP 184
DI 10.1016/j.atherosclerosis.2017.12.007
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500024
PM 29232563
OA Green Published
DA 2019-10-28
ER

PT J
AU Christodoulou, E
   Kadoglou, NPE
   Stasinopoulou, M
   Konstandi, OA
   Kenoutis, C
   Kakazanis, ZI
   Rizakou, A
   Kostomitsopoulos, N
   Valsami, G
AF Christodoulou, Ei.
   Kadoglou, N. P. E.
   Stasinopoulou, M.
   Konstandi, O. A.
   Kenoutis, C.
   Kakazanis, Z. I.
   Rizakou, A.
   Kostomitsopoulos, N.
   Valsami, G.
TI Crocus sativus L. aqueous extract reduces atherogenesis, increases
   atherosclerotic plaque stability and improves glucose control in
   diabetic atherosclerotic animals
SO ATHEROSCLEROSIS
LA English
DT Article
DE Saffron; Crocetin; Atherosclerosis; ApoE(-/-) mice; Matrix
   metalloproteinases; Inflammation
ID SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASES; CAROTID PLAQUES;
   SAFFRON; CROCETIN; SERUM; INFLAMMATION; CORONARY; DISEASE; MACROPHAGES
AB Background and aims: We aimed to evaluate a possible atheroprotective effect of saffron aqueous extract (SFE), and its potential anti-inflammatory mechanisms, in apoE knockout (ApoE(-/-)) mice.
   Methods: Fifty male, ApoE(-/-) mice, fed a high-fat diet (HFD) for 12 weeks, were randomized into 5 groups: (1) baseline group, euthanatized, without intervention, (2) three saffron groups, receiving HFD and 30,60,90 mg/kg/day of SFE, respectively, for four weeks, per os through gavage, after reconstitution in water for injection (WFI), (3) control group (COG), receiving daily HFD and the same volume of WFI (four weeks). After blood sampling and euthanasia, aortic roots were excised and analyzed for gene expression and/or percentage of aortic stenosis, relative content of macrophages, smooth muscle cells (SMCs), connective tissue, tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1), matrix metalloproteinases-2,-3,-9 (MMP-2,-3,-9) and their inhibitor (TIMP-2) and IL-6. SFE doses were determined by a pilot serum pharmacokinetic study in C57BL/6J wild-type mice.
   Results: SFE did not affect body weight and total cholesterol levels (p > 0.05), while high SFE dose significantly ameliorated glucose and triglycerides profiles compared to other groups (p < 0.05). SFE considerably decreased aortic stenosis in a dose-dependent manner (p < 0.05). Furthermore, increasing SFE doses proportionally reduced macrophages content and increased within plaques content of collagen, elastin, and SMCs, promoting more stable plaque phenotype compared to COG (p < 0.05). Those effects seemed to be associated with a considerable reduction (> 30%) in IL-6, TNF-alpha, MCP-1, MMP-2,-3,-9 (p < 0.05) and MMP-2/TIMP-2 ratio.
   Conclusions: SFE exerted dose-dependent anti-atherosclerotic and plaque-stabilizing effects in Apo-E-/- mice, probably mediated by a favorable modification of inflammatory mechanisms, which requires further investigation. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Christodoulou, Ei.; Rizakou, A.; Valsami, G.] Univ Athens, Sch Hlth Sci, Dept Pharm, Lab Biopharmaceut Pharmacokinet, Athens, Greece.
   [Kadoglou, N. P. E.] Univ Oxford, Oxford, England.
   [Stasinopoulou, M.; Kakazanis, Z. I.; Kostomitsopoulos, N.] Acad Athens, Biomed Res Fdn, Ctr Clin Expt Surg & Translat Res, Athens, Greece.
   [Konstandi, O. A.; Kenoutis, C.] Univ Athens, Sch Sci, Dept Biol, Sect Cell Biol & Biophys, Athens, Greece.
RP Valsami, G (reprint author), Univ Athens, Sch Hlth Sci, Dept Pharm, Lab Biopharmaceut Pharmacokinet, Athens, Greece.
EM valsami@pharm.uoa.gr
OI STASINOPOULOU, MARIANNA/0000-0003-3365-891X; Kostomitsopoulos,
   Nikolaos/0000-0003-4787-5106
FU INTERMED S.A. through the PABET research program (ESPA)
FX This work was financially supported by INTERMED S.A. through the PABET
   2013 research program (ESPA 2007-2013).
NR 52
TC 6
Z9 6
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 207
EP 214
DI 10.1016/j.atherosclerosis.2017.10.032
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500030
PM 29128090
DA 2019-10-28
ER

PT J
AU Kubota, Y
   Folsom, AR
   Matsushita, K
   Couper, D
   Tang, WH
AF Kubota, Yasuhiko
   Folsom, Aaron R.
   Matsushita, Kunihiro
   Couper, David
   Tang, Weihong
TI Prospective study of lung function and abdominal aortic aneurysm risk:
   The Atherosclerosis Risk in Communities study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Lung function; Abdominal aortic aneurysm; COPD; Epidemiology
ID OBSTRUCTIVE PULMONARY-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; VENOUS
   THROMBOEMBOLISM; SYSTEMIC INFLAMMATION; BIOMARKERS; COMORBIDITIES;
   ASSOCIATION; PREVALENCE; ACTIVATION; MORTALITY
AB Background and aims: No prospective study has investigated whether individuals with respiratory impairments, including chronic obstructive pulmonary disease (COPD) and restrictive lung disease (RLD), are at increased risk of abdominal aortic aneurysm (AAA). We aimed to prospectively investigate whether those respiratory impairments are associated with increased AAA risk.
   Methods: In 1987-1989, the Atherosclerosis Risk in Communities (ARIC) study followed 14,269 participants aged 45-64 years, without a history of AAA surgery, through 2011. Participants were classified into four groups, "COPD" [forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) < lower limit of normal (LLN)], "RLD" (FEV1/FVC >= LLN and FVC < LLN), "respiratory symptoms with normal spirometry" (without RLD or COPD), and "normal" (without respiratory symptoms, RLD or COPD, reference group).
   Results: During the 284,969 person-years of follow-up, 534 incident AAA events were documented. In an age, sex, and race-adjusted proportional hazards model, individuals with respiratory impairments had a significantly higher risk of AAA than the normal reference group. After adjustment for AAA risk factors, including smoking status and pack-years of smoking, AAA risk was no longer significant in the respiratory symptoms with normal spirometry group [HR (95% CI), 1.25 (0.98-1.60)], but was still increased in the other two groups [RLD: 1.45 (1.04-2.02) and COPD: 1.66 (1.34-2.05)]. Moreover, continuous measures of FEV1/FVC, FEV1 and FVC were associated inversely with risk of AAA.
   Conclusions: In the prospective population-based cohort study, obstructive and restrictive spirometric patterns were associated with increased risk of AAA independent of smoking, suggesting that COPD and RLD may increase the risk of AAA. (c) 2017 Elsevier B.V. All rights reserved.
C1 [Kubota, Yasuhiko; Folsom, Aaron R.; Tang, Weihong] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, 1300 South 2nd St, Minneapolis, MN 55454 USA.
   [Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Matsushita, Kunihiro] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
   [Couper, David] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA.
RP Kubota, Y (reprint author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, 1300 South 2nd St, Minneapolis, MN 55454 USA.
EM kubot007@umn.edu
OI Couper, David/0000-0002-4313-9235
FU Nippon FoundationNippon Foundation; National Heart, Lung, and Blood
   Institute (NHLBI)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [HHSN268201100005C, HHSN268201100006C,
   HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
   HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01 HL103695]
FX The Nippon Foundation provided grants to support Dr. Kubota's fellowship
   at School of Public Health, University of Minnesota. The National Heart,
   Lung, and Blood Institute (NHLBI) supported ARIC via contracts
   HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
   HHSN268201100008C, HHSN268201100009C, HHSN268201100010C,
   HHSN268201100011C, HHSN268201100012C, and R01 HL103695.
NR 39
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 225
EP 230
DI 10.1016/j.atherosclerosis.2017.10.013
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500032
PM 29079449
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Ruscica, M
   Ferri, N
   Corsini, A
   Sirtori, CR
AF Ruscica, Massimiliano
   Ferri, Nicola
   Corsini, Alberto
   Sirtori, Cesare R.
TI PCSK9 antagonists and inflammation
SO ATHEROSCLEROSIS
LA English
DT Letter
DE PCSK9; Inflammation
ID HIGH CARDIOVASCULAR RISK; ODYSSEY COMBO II; EFFICACY; SAFETY;
   METAANALYSIS; ALIROCUMAB; TRIALS
C1 [Ruscica, Massimiliano; Corsini, Alberto] Univ Milan, Dipartimento Sci Farmacol & Biomol, Milan, Italy.
   [Ferri, Nicola] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Padua, Italy.
   [Corsini, Alberto] Multimed IRCCS, Milan, Italy.
   [Sirtori, Cesare R.] ASST Grande Osped Metropolitano Niguarda, Dyslipidemia Ctr, Milan, Italy.
RP Sirtori, CR (reprint author), ASST Grande Osped Metropolitano Niguarda, Dyslipidemia Ctr, Milan, Italy.
EM cesare.sirtori@icloud.com
RI Ruscica, Massimiliano/K-7133-2012; ferri, nicola/K-7085-2019
OI Ruscica, Massimiliano/0000-0002-0195-7061; ferri,
   nicola/0000-0001-8898-7441
NR 11
TC 8
Z9 8
U1 4
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 235
EP 236
DI 10.1016/j.atherosclerosis.2017.10.022
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500035
PM 29102656
OA Green Published
DA 2019-10-28
ER

PT J
AU Docherty, CK
   Carswell, A
   Friel, E
   Mercer, JR
AF Docherty, Craig K.
   Carswell, Andy
   Friel, Elaine
   Mercer, John R.
TI Impaired mitochondrial respiration in human carotid plaque
   atherosclerosis: A potential role for Pink1 in vascular smooth muscle
   cell energetics
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Mitochondria; Oxidative phosphorylation; AMPK Pink-1;
   Glycolysis; Metabolism; Vascular smooth muscle cells
ID DNA-DAMAGE; REDUCES ATHEROSCLEROSIS; METABOLIC SYNDROME;
   GENE-EXPRESSION; RISK PLAQUES; MICE; MITOPHAGY; PROTECTS; FEATURES
AB Background and aims: DNA damage and mitochondrial dysfunction are thought to play an essential role in ageing and the energetic decline of vascular smooth muscle cells (VSMCs) essential for maintaining plaque integrity. We aimed to better understand VSMCs and identify potentially useful compensatory pathways that could extend their lifespan. Moreover, we wanted to assess if defects in mitochondrial respiration exist in human atherosclerotic plaques and to identify the appropriate markers that may reflect a switch in VSMC energy metabolism.
   Methods: Human plaque tissue and cells were assessed for composition and evidence of DNA damage, repair capacity and mitochondrial dysfunction. Fresh plaque tissue was evaluated using high resolution oxygen respirometry to assess oxidative metabolism. Recruitment and processing of the mitochondrial regulator of autophagy Pink1 kinase was investigated in combination with transcriptional and protein markers associated with a potential switch to a more glycolytic metabolism.
   Results: Human VSMC have increased nuclear (nDNA) and mitochondrial (mtDNA) damage and reduced repair capacity. A subset of VSMCs within plaque cap had decreased oxidative phosphorylation and expression of Pink1 kinase. Plaque cells demonstrated increased glycolytic activity in response to loss of mitochondrial function. A potential compensatory glycolytic program may act as energetic switch via AMP kinase (AMPK) and hexokinase 2 (Hex2).
   Conclusions: We have identified a subset of plaque VSMCs required for plaque stability that have increased mitochondrial dysfunction and decreased oxidative phosphorylation. Pink1 kinase may initiate a cellular response to promote a compensatory glycolytic program associated with upregulation of AMPK and Hex2. (C) 2017 The Authors. Published by Elsevier Ireland Ltd.
C1 [Docherty, Craig K.; Carswell, Andy; Friel, Elaine; Mercer, John R.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Univ Ave, Glasgow G12 8TA, Lanark, Scotland.
RP Mercer, JR (reprint author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Cardiovasc & Med Sci, Univ Ave, Glasgow G12 8TA, Lanark, Scotland.
EM john.mercer@glasgow.ac.uk
OI Docherty, Craig/0000-0001-9166-8695; Mercer, John/0000-0002-3204-7511
FU University of Glasgow [252-146123-001]
FX This work was supported by the University of Glasgow: Strategic fund
   252-146123-001.
NR 30
TC 5
Z9 6
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 1
EP 11
DI 10.1016/j.atherosclerosis.2017.11.009
PG 11
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500001
PM 29156421
OA Other Gold, Green Published, Green Accepted
DA 2019-10-28
ER

PT J
AU Airaghi, L
   Rango, M
   Maira, D
   Barbieri, V
   Valenti, L
   Lombardi, R
   Biondetti, P
   Fargion, S
   Fracanzani, AL
AF Airaghi, Lorena
   Rango, Mario
   Maira, Diletta
   Barbieri, Valentina
   Valenti, Luca
   Lombardi, Rosa
   Biondetti, Pietro
   Fargion, Silvia
   Fracanzani, Anna Ludovica
TI Subclinical cerebrovascular disease in NAFLD without overt risk factors
   for atherosclerosis
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cerebrovascular disease; Atherosclerosis; Metabolic syndrome;
   Non-alcoholic fatty liver disease (NAFLD); Cerebral blood flow; Magnetic
   resonance spectroscopy (MRS)
ID NONALCOHOLIC FATTY LIVER; METABOLIC SYNDROME; CARDIOVASCULAR EVENTS;
   DAMAGE; MR
AB Background and aims: Non-alcoholic fatty liver disease is recognized not only as part of the metabolic syndrome but also as an independent predictor of cardiovascular disease.
   Methods: In this study, NMR spectroscopy method, together with perfusion techniques, was used to detect subclinical brain vascular damage in subjects with NAFLD without overt atherosclerosis risk factors (i.e. hypertension, diabetes, hypercholesterolemia, obesity).
   Results: The results suggest that subjects with histologically proven NAFLD have a reduced cerebral perfusion (CBFr) confined to limited brain areas, i.e., left semioval center and posterior cingulate cortex. No statistically significant differences in CBFr values were found, dividing the NAFLD cohort into subgroups, considering NAS score, presence/absence of NASH/fibrosis, and degree of steatosis.
   Conclusions: Our data suggest that NAFLD per se may be involved in cerebral atherosclerotic disease. It will be interesting to draw longitudinal studies to determine whether these changes could evolve in more serious cerebral injury. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Airaghi, Lorena; Maira, Diletta; Valenti, Luca; Lombardi, Rosa; Fargion, Silvia; Fracanzani, Anna Ludovica] Univ Milan, IRCCS Ca Granda Osped Maggiore Policlin Fdn, Dept Internal Med, Milan, Italy.
   [Rango, Mario; Barbieri, Valentina] Univ Milan, IRCCS Ca Granda Osped Maggiore Policlin Fdn, Dept Neurosci & Mental Hlth, Milan, Italy.
   [Rango, Mario; Barbieri, Valentina] IRCCS Ca Granda Osped Maggiore Policlin Fdn, Excellence Ctr Adv MR Studies, Milan, Italy.
   [Biondetti, Pietro] IRCCS Ca Granda Osped Maggiore Policlin Fdn, Radiol Unit, Milan, Italy.
RP Airaghi, L (reprint author), IRCCS Ca Granda Osped Maggiore Policlin Fdn, Dept Internal Med, Via Francesco Sforza 35, I-2012 Milan, Italy.
EM lorena.airaghi@policlinico.mi.it
RI Lombardi, Rosa/AAB-8031-2019; Valenti, Luca/B-3695-2009
OI Lombardi, Rosa/0000-0001-6958-927X; Airaghi, Lorena/0000-0001-5466-8151;
   Valenti, Luca/0000-0001-8909-0345
FU Ricerca Finalizzata [RF 2013-02358519];  [MI-0059];  [C42F16000080001]
FX This study was funded by grants from Ricerca Finalizzata RF
   2013-02358519 (Early atherosclerosis in patients with steatosis and with
   chronic hepatitis C: role of visceral adiposity, procoagulant imbalance
   and endothelial dysfunction in vascular damage). Project n. MI-0059,
   C42F16000080001.
NR 25
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 27
EP 31
DI 10.1016/j.atherosclerosis.2017.11.012
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500004
PM 29175651
DA 2019-10-28
ER

PT J
AU Thompson, JC
   Wilson, PG
   Shridas, P
   Ji, AL
   de Beer, M
   de Beer, FC
   Webb, NR
   Tannock, LR
AF Thompson, Joel C.
   Wilson, Patricia G.
   Shridas, Preetha
   Ji, Ailing
   de Beer, Maria
   de Beer, Frederick C.
   Webb, Nancy R.
   Tannock, Lisa R.
TI Serum amyloid A3 is pro-atherogenic
SO ATHEROSCLEROSIS
LA English
DT Article
DE Inflammation; Atherosclerosis; Murine models
ID C-REACTIVE PROTEIN; APOLIPOPROTEIN; DISEASE; WOMEN
AB Background and aims: Serum amyloid A (SAA) predicts cardiovascular events. Overexpression of SAA increases atherosclerosis development; however, deficiency of two of the murine acute phase isoforms, SAA1.1 and SAA2.1, has no effect on atherosclerosis. SAA3 is a pseudogene in humans, but is an expressed acute phase isoform in mice. The goal of this study was to determine if SAA3 affects atherosclerosis in mice.
   Methods: ApoE(-/-)mice were used as the model for all studies. SAA3 was overexpressed by an adenoassociated virus or suppressed using an anti-sense oligonucleotide approach.
   Results: Over-expression of SAA3 led to a 4-fold increase in atherosclerosis lesion area compared to control mice (p = 0.01). Suppression of SAA3 decreased atherosclerosis in mice genetically deficient in SAA1.1 and SAA2.1 (p < 0.0001).
   Conclusions: SAA3 augments atherosclerosis in mice. Our results resolve a previous paradox in the literature and support extensive epidemiological data that SAA is pro-atherogenic. Published by Elsevier Ireland Ltd.
C1 [Thompson, Joel C.; Wilson, Patricia G.; Ji, Ailing; Webb, Nancy R.; Tannock, Lisa R.] Dept Vet Affairs, Lexington, KY 40502 USA.
   [Thompson, Joel C.; Wilson, Patricia G.; Shridas, Preetha; Ji, Ailing; de Beer, Frederick C.; Tannock, Lisa R.] Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA.
   [de Beer, Maria] Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA.
   [Webb, Nancy R.] Univ Kentucky, Dept Pharmacol & Nutr Sci, Lexington, KY 40536 USA.
   [Thompson, Joel C.; Wilson, Patricia G.; Shridas, Preetha; Ji, Ailing; de Beer, Maria; de Beer, Frederick C.; Webb, Nancy R.; Tannock, Lisa R.] Univ Kentucky, Barnstable Brown Diabet Ctr, Lexington, KY 40536 USA.
   [Thompson, Joel C.; Wilson, Patricia G.; Shridas, Preetha; Ji, Ailing; de Beer, Maria; de Beer, Frederick C.; Webb, Nancy R.; Tannock, Lisa R.] Univ Kentucky, Saha Cardiovasc Res Ctr, Lexington, KY 40536 USA.
RP Tannock, LR (reprint author), Room 553,Wethington Bldg,900 S Limestone St, Lexington, KY 40536 USA.
EM lisa.tannock@uky.edu
FU Department of Veterans AffairsUS Department of Veteran Affairs
   [CX000622, R01 HL134731]
FX This work was supported by funding from the Department of Veterans
   Affairs CX000622 (to LRT) and R01 HL134731 (to NRW, FCdB). There are no
   disclosures for any author.
NR 14
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 32
EP 35
DI 10.1016/j.atherosclerosis.2017.11.011
PG 4
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500005
PM 29175652
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Sun, JT
   Lundstrom, SL
   Zhang, B
   Zubarev, RA
   Steuer, J
   Gillgren, P
   Rahman, M
   Ajeganova, S
   Liu, AQ
   Frostegard, J
AF Sun, Jitong
   Lundstrom, Susanna L.
   Zhang, Bo
   Zubarev, Roman A.
   Steuer, Johnny
   Gillgren, Peter
   Rahman, Mizanur
   Ajeganova, Sofia
   Liu, Anquan
   Frostegard, Johan
TI IgM antibodies against phosphorylcholine promote polarization of T
   regulatory cells from patients with atherosclerotic plaques, systemic
   lupus erythematosus and healthy donors
SO ATHEROSCLEROSIS
LA English
DT Article
DE Antibodies; Phosphorylcholine; T regulatory cells; Atherosclerosis;
   Autoimmunity
ID PLATELET-ACTIVATING-FACTOR; LOW-DENSITY-LIPOPROTEIN; PROTECTIVE FACTORS;
   DENDRITIC CELL; OXIDIZED LDL; RISK-FACTORS; INHIBITION; AUTOIMMUNE;
   CYTOKINES; DISEASE
AB Background and aims: IgM antibodies against phosphorylcholine (anti-PC) are negatively associated with atherosclerosis, cardiovascular disease (CVD) and systemic lupus erythematosus (SLE), where the risk of CVD and atherosclerosis is high. We here study the effects of IgM anti-PC immune regulation.
   Methods: Mononuclear leukocytes were isolated from peripheral blood (PBMC) obtained from healthy blood donors, six SLE patients with age-and sex-matched controls, and symptom-giving human atherosclerotic plaques. The proportion of Th17 (CD4(+)CCR6(+)) and Treg (CD4(+)CD25(+)CD127(dim/-)) cells was determined by flow cytometry in CD4(+)T cells after 6 days of culture with Th17 or Treg-polarizing cytokines, with PMA and Ionomycin stimulation. IgM anti-PC were extracted from total IgM, with flowthrough IgM as controls. Dendritic cells (DC) were differentiated from PBMC. Antibody peptide/protein characterization was done by a proteomics de novo sequencing approach.
   Results: IgM anti-PC increased significantly the proportion of Tregs from healthy donors, SLE patients and atherosclerotic plaque cells while control antibodies did not. T cells from SLE patients had a significantly lower proportion of Tregs and a higher proportion of Th17 cells as compared to matched controls. IgM anti-PC, but not control antibodies, significantly reduced the production of IL-17 and TNF-alpha in cell cultures from SLE patients and atherosclerotic plaque cells. IgM anti-PC interacted with CD40 and kept DCs in an immature stage, potentially being tolerogenic. We observed differences in the IgM peptide expression levels in anti-PC compared to control antibodies.
   Conclusions: IgM anti-PC promote polarization of Tregs, which could represent a novel protective mechanism in atherosclerosis and autoimmune conditions as SLE. (C) 2017 Published by Elsevier Ireland Ltd.
C1 [Sun, Jitong; Rahman, Mizanur; Liu, Anquan; Frostegard, Johan] Karolinska Inst, Unit Immunol & Chron Dis, Inst Environm Med, Stockholm, Sweden.
   [Lundstrom, Susanna L.; Zhang, Bo; Zubarev, Roman A.] Karolinska Inst, Div Physiol Chem 1, Dept Med Biochem & Biophys, Stockholm, Sweden.
   [Steuer, Johnny; Gillgren, Peter] Karolinska Inst, Sect Vasc Surg, Inst Clin Sci & Educ, Dept Surg,Sodersjukhuset, Stockholm, Sweden.
   [Ajeganova, Sofia] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden.
   [Frostegard, Johan] Karolinska Univ Hosp, Div Emergency Med, Solna, Sweden.
RP Liu, AQ; Frostegard, J (reprint author), Karolinska Inst, Unit Immunol & Chron Dis, Inst Environm Med, Stockholm, Sweden.
EM anquan.liu@ki.se; johan.frostegard@ki.se
RI Zubarev, Roman A/W-7891-2018
OI Zubarev, Roman A/0000-0001-9839-2089; Zhang, Bo/0000-0001-8890-8416;
   Ajeganova, Sofia/0000-0001-9162-9717; Lundstrom,
   Susanna/0000-0003-2363-4287; Gillgren, Peter/0000-0003-0538-3496
FU Swedish Heart and Lung foundationSwedish Heart-Lung Foundation; Swedish
   Rheumatism Association; AFA; Torsten Soderbergs Foundation; King Gustav
   V:s 80-year fund
FX This study was supported by the Swedish Heart and Lung foundation, the
   Swedish Rheumatism Association, AFA, Torsten Soderbergs Foundation and
   King Gustav V:s 80-year fund.
NR 45
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 36
EP 48
DI 10.1016/j.atherosclerosis.2017.11.010
PG 13
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500006
PM 29175653
DA 2019-10-28
ER

PT J
AU Iwatsuka, R
   Matsue, Y
   Yonetsu, T
   O'uchi, T
   Matsumura, A
   Hashimoto, Y
   Hirao, K
AF Iwatsuka, Ryota
   Matsue, Yuya
   Yonetsu, Taishi
   O'uchi, Toshihiro
   Matsumura, Akihiko
   Hashimoto, Yuji
   Hirao, Kenzo
TI Arterial inflammation measured by F-18-FDG-PET-CT to predict coronary
   events in older subjects
SO ATHEROSCLEROSIS
LA English
DT Article
DE Framingham risk score; Coronary heart disease event; Prognosis
ID POSITRON-EMISSION-TOMOGRAPHY; ATHEROSCLEROTIC PLAQUE INFLAMMATION;
   CARDIOVASCULAR-DISEASE; COMPETING RISK; MARKERS; PET
AB Background and aims: Although 18F-fluorodeoxyglucose (FDG) uptake has emerged as a sensitive and reliable marker of atherosclerotic inflammation, its additive predictive value for future coronary disease in older subjects is unknown. The aim of this study was to test the prognostic value of aortic inflammation detected via FDG-positron emission tomography (PET)-computed tomography (CT) in older subjects.
   Methods: We retrospectively utilized the records of 309 subjects aged over 65 years, without a history of coronary artery disease, who underwent 18F-FDG-PET-CT mostly due to the clinical suspicion of cancer, but eventually turned out to be cancer-free. Target-to-background ratio (TBR) was calculated at the ascending aorta. The endpoint was occurrence of coronary heart disease (CHD) events.
   Results: During a median follow-up of 3.9 years, 28 subjects experienced CHD events and 12 patients died due to non-CHD causes. The highest TBR tertile was associated with a high CHD event rate, accounting for death due to non-CHD causes as a competing risk (Gray test, p = 0.005). In a Fine and Gray competing risk proportional hazard regression model, TBR was associated with significantly high CHD events independently of FRS, with a hazard ratio (HR) of 1.19 per 0.1 TBR increase (p < 0.001). Likewise, a significant increase in the area under the curve (from 0.57 to 0.73, p = 0.028) and a significant improvement in net reclassification (0.42, p = 0.038) were observed when TBR was added to the model with FRS alone.
   Conclusions: In older subjects with no history of malignant disease or overt coronary artery disease, arterial inflammation evaluated by FDG uptake provides information on future occurrence of coronary artery events. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Iwatsuka, Ryota; Matsue, Yuya; Matsumura, Akihiko; Hashimoto, Yuji] Kameda Med Ctr, Dept Cardiol, Kamogawa City, Chiba, Japan.
   [Iwatsuka, Ryota; Hirao, Kenzo] Tokyo Med & Dent Univ, Dept Cardiovasc Med, Tokyo, Japan.
   [Matsue, Yuya] Juntendo Univ, Dept Cardiovasc Med, Sch Med, Tokyo, Japan.
   [Yonetsu, Taishi] Tsuchiura Kyodo Gen Hosp, Div Cardiovasc Med, Ibaraki, Japan.
   [O'uchi, Toshihiro] Kameda Med Ctr, Dept Radiol, Chiba, Japan.
RP Iwatsuka, R (reprint author), Kameda Med Ctr, Dept Cardiol, Kamogawa City, Chiba, Japan.
EM ryotaiwtk@gmail.com
OI Yonetsu, Taishi/0000-0002-1798-5008
FU JSPS (Japan Society for the Promotion of Science) Overseas Research
   Fellowship
FX YM is supported by JSPS (Japan Society for the Promotion of Science)
   Overseas Research Fellowship, and received an honorarium from Otsuka
   Pharmaceutical Co. The other authors have nothing to disclose.
NR 27
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 49
EP 54
DI 10.1016/j.atherosclerosis.2017.11.016
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500007
PM 29175654
DA 2019-10-28
ER

PT J
AU Thompson, JC
   Wilson, PG
   Wyllie, AP
   Wyllie, AK
   Tannock, LR
AF Thompson, Joel C.
   Wilson, Patricia G.
   Wyllie, Alex P.
   Wyllie, Adrian K.
   Tannock, Lisa R.
TI Elevated circulating TGF-beta is not the cause of increased
   atherosclerosis development in biglycan deficient mice
SO ATHEROSCLEROSIS
LA English
DT Article
DE Atherosclerosis; Cholesterol; Proteoglycans; Extracellular matrix;
   Diabetes; Animal models
ID GROWTH-FACTOR-BETA; TO-RETENTION HYPOTHESIS; SMOOTH-MUSCLE-CELLS;
   TRANSFORMING GROWTH-FACTOR-BETA-1; DIABETIC-NEPHROPATHY; VASCULAR
   BIGLYCAN; PROTEOGLYCANS; ACCUMULATION; APOPTOSIS; LESIONS
AB Background and aims: Vascular biglycan contributes to atherosclerosis development and increased biglycan expression correlates with increased atherosclerosis. However, mice deficient in biglycan have either no reduction in atherosclerosis or an unexpected increase in atherosclerosis. Biglycan deficient mice have systemically elevated TGF-beta, likely due to lack of sequestration of TGF-beta in the extracellular matrix. The purpose of this study was to determine if prevention of TGF-beta elevations in biglycan deficient mice affected atherosclerosis development.
   Methods: Biglycan deficient mice were crossed to Ldlr deficient mice. Diabetes was induced via streptozotocin and all mice were fed a high cholesterol diet. Diabetic biglycan wild type and biglycan deficient Ldlr deficient mice were injected with the TGF-beta neutralizing antibody 1D11 or the irrelevant control antibody 13C4.
   Results: Biglycan deficient mice had significantly elevated plasma TGF-beta levels, which was further increased by diabetes, and significantly increased atherosclerosis. There was a significant correlation between TGF-beta concentrations and atherosclerosis. However, despite nearly complete suppression of plasma TGF-beta levels in mice treated with the TGF-beta neutralizing antibody 1D11, there was no significant difference in atherosclerosis between mice with elevated TGF-beta levels and mice with suppressed TGF-beta levels.
   Conclusions: The increased atherosclerosis in biglycan deficient mice does not appear to be due to elevations in TGF-beta. Published by Elsevier Ireland Ltd.
C1 [Thompson, Joel C.; Wilson, Patricia G.; Tannock, Lisa R.] Dept Vet Affairs, Lexington, KY USA.
   [Thompson, Joel C.; Wilson, Patricia G.; Wyllie, Alex P.; Wyllie, Adrian K.; Tannock, Lisa R.] Div Endocrinol & Mol Med, Lexington, KY USA.
   [Thompson, Joel C.; Wilson, Patricia G.; Tannock, Lisa R.] Univ Kentucky, Barnstable Brown Diabet Ctr, Lexington, KY 40536 USA.
RP Tannock, LR (reprint author), Univ Kentucky, Div Endocrinol & Mol Med, Room 553, Wethington Bldg, 900 S Limestone, Lexington, KY 40536 USA.
EM Lisa.Tannock@uky.edu
FU Merit Review Award from the Department of Veterans AffairsUS Department
   of Veteran Affairs [BX000622]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [P30 GM103527]
FX This work was supported by Merit Review Award BX000622 to LRT from the
   Department of Veterans Affairs, and used Cores supported by NIH P30
   GM103527. The contents of this publication are solely the responsibility
   of the authors and do not represent the views of the National Institutes
   of Health, the Department of Veterans Affairs or the United States
   Government.
NR 34
TC 2
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 68
EP 75
DI 10.1016/j.atherosclerosis.2017.11.005
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500010
PM 29182988
OA Green Accepted
DA 2019-10-28
ER

PT J
AU Haberka, M
   Lelek, M
   Bochenek, T
   Kowalowka, A
   Mlynarski, R
   Mizia-Stec, K
   Gasior, Z
AF Haberka, Maciej
   Lelek, Michal
   Bochenek, Tomasz
   Kowalowka, Adam
   Mlynarski, Rafal
   Mizia-Stec, Katarzyna
   Gasior, Zbigniew
TI Novel combined index of cardiometabolic risk related to periarterial fat
   improves the clinical prediction for coronary artery disease complexity
SO ATHEROSCLEROSIS
LA English
DT Article
DE Coronary artery disease; Syntax score; Fat; Obesity; Metabolic syndrome;
   Adventitia; Vascular index; Extra-media thickness; Intima-media
   thickness; PATIMA
ID INTIMA-MEDIA THICKNESS; PERIVASCULAR ADIPOSE-TISSUE; EPICARDIAL FAT;
   CARDIOVASCULAR-DISEASE; CAROTID-ARTERY; SYNTAX SCORE; ULTRASOUND;
   ATHEROSCLEROSIS; ANGIOGRAPHY; SEVERITY
AB Background and aims: Cardiovascular (CV) risk assessment based on conventional risk factors has a limited performance in the prediction of obstructive coronary artery disease (CAD). Therefore, our aim was to provide a complete assessment on the associations between single or combined cardiovascular ultrasound indexes and the complexity of CAD in high and very-high risk patients.
   Methods: Two hundred fifteen patients scheduled for elective coronary angiography were enrolled in the study (F/M: 80/135 pts; age: 61.8 +/- 7.9 years). Detailed clinical characteristics, including several obesity parameters, and the following ultrasound indexes were obtained: carotid intima-media thickness (IMT) and extra-media thickness (EMT), epicardial fat thickness (EFT) and intra-abdominal fat thickness (IAT). CAD severity and complexity were assessed based on the well-evidenced SYNTAX score (SS) algorithm.
   Results: The study patients (79% with a very high CV risk) had central obesity (77%), and arterial hypertension (81%), one-third (37%) had diabetes and most of the individuals (74%) were current or previous smokers. In the study group, male sex, higher number of CV risk factors, diabetes and increased carotid vascular indexes (IMT or EMT >= 900 mu m) were associated with significantly higher SS (p < 0.05). Paradoxically, obese patients revealed a significantly lower SS compared to non-obese individuals (3.65 +/- 6.66 vs. 5.93 +/- 8.8; p < 0.01), which was not explained by the number of CV risk factors or age. All the ultrasound indexes (except for visceral fat - IAT) revealed significant associations with the SS and the highest correlation coefficient was found for PATIMA combined index (r = 0.45; p < 0.01). Hence, none of the obesity-related clinical indexes showed any associations with CAD complexity. Multivariate regression analysis showed that male sex, chronic kidney disease and the PATIMA index were independently associated with the Syntax Score. The ROC analysis showed that the highest sensitivity (71% and 82%) and specificity (77% and 72%) in prediction of either SS > 1 or SS > 7 were found for the combined PATIMA index (negative predictive value = 92% for SS > 7).
   Conclusions: We present the first study showing that a combination of ultrasound indexes related to periarterial fat and vascular wall (PATIMA index) is associated with more complex CAD in high and very-high risk patients. PATIMA index revealed improved predictive value compared to other single ultrasound indexes and clinical risk assessment. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Haberka, Maciej; Gasior, Zbigniew] Med Univ Silesia, Sch Hlth Sci, Dept Cardiol, Katowice, Poland.
   [Lelek, Michal; Bochenek, Tomasz; Mizia-Stec, Katarzyna] Med Univ Silesia, Sch Med Katowice, Dept Cardiol 1, Katowice, Poland.
   [Kowalowka, Adam] Med Univ Silesia, Sch Med Katowice, Dept Cardiac Surg, Katowice, Poland.
   [Mlynarski, Rafal] Upper Silesian Heart Ctr, Dept Electrocardiol, Katowice, Poland.
RP Haberka, M (reprint author), Ziolowa 45-47, PL-40635 Katowice, Poland.
EM mhaberka@op.pl
OI Kowalowka, Adam/0000-0002-8239-9099; Mlynarski,
   Rafal/0000-0002-2697-3543; Gasior, Zbigniew/0000-0003-3616-8932;
   Mizia-Stec, Katarzyna/0000-0001-6907-2799; Bochenek,
   Tomasz/0000-0002-1065-2665
NR 45
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 76
EP 83
DI 10.1016/j.atherosclerosis.2017.09.015
PG 8
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500011
PM 29195108
DA 2019-10-28
ER

PT J
AU Maruhashi, T
   Soga, J
   Fujimura, N
   Idei, N
   Mikami, S
   Iwamoto, Y
   Iwamoto, A
   Kajikawa, M
   Matsumoto, T
   Oda, N
   Kishimoto, S
   Matsui, S
   Hashimoto, H
   Aibara, Y
   Yusoff, FM
   Hidaka, T
   Kihara, Y
   Chayama, K
   Noma, K
   Nakashima, A
   Goto, C
   Tomiyama, H
   Takase, B
   Kohro, T
   Suzuki, T
   Ishizu, T
   Ueda, S
   Yamazaki, T
   Furumoto, T
   Kario, K
   Inoue, T
   Koba, S
   Watanabe, K
   Takemoto, Y
   Hano, T
   Sata, M
   Ishibashi, Y
   Node, K
   Maemura, K
   Ohya, Y
   Furukawa, T
   Ito, H
   Ikeda, H
   Yamashina, A
   Higashi, Y
AF Maruhashi, Tatsuya
   Soga, Junko
   Fujimura, Noritaka
   Idei, Naomi
   Mikami, Shinsuke
   Iwamoto, Yumiko
   Iwamoto, Akimichi
   Kajikawa, Masato
   Matsumoto, Takeshi
   Oda, Nozomu
   Kishimoto, Shinji
   Matsui, Shogo
   Hashimoto, Haruki
   Aibara, Yoshiki
   Yusoff, Farina Mohamad
   Hidaka, Takayuki
   Kihara, Yasuki
   Chayama, Kazuaki
   Noma, Kensuke
   Nakashima, Ayumu
   Goto, Chikara
   Tomiyama, Hirofumi
   Takase, Bonpei
   Kohro, Takahide
   Suzuki, Toru
   Ishizu, Tomoko
   Ueda, Shinichiro
   Yamazaki, Tsutomu
   Furumoto, Tomoo
   Kario, Kazuomi
   Inoue, Teruo
   Koba, Shinji
   Watanabe, Kentaro
   Takemoto, Yasuhiko
   Hano, Takuzo
   Sata, Masataka
   Ishibashi, Yutaka
   Node, Koichi
   Maemura, Koji
   Ohya, Yusuke
   Furukawa, Taiji
   Ito, Hiroshi
   Ikeda, Hisao
   Yamashina, Akira
   Higashi, Yukihito
TI Brachial artery diameter as a marker for cardiovascular risk assessment:
   FMD-J study
SO ATHEROSCLEROSIS
LA English
DT Article
DE Baseline brachial artery diameter; Flow-mediated vasodilation;
   Atherosclerosis; Cardiovascular risk factor
ID FLOW-MEDIATED DILATION; ENDOTHELIAL FUNCTION; SHEAR-STRESS; OXIDATIVE
   STRESS; ATHEROSCLEROSIS; VASODILATION; WOMEN; ENLARGEMENT; COMMUNITY;
   DISEASE
AB Background and aims: Baseline brachial artery (BBA) diameter has been reported to be a potential confounding factor of flow-mediated vasodilation (FMD). The purpose of this study was to evaluate the relationships between BBA diameter and cardiovascular risk factors and compare the diagnostic accuracy of BBA diameter in subjects without cardiovascular risk factors and patients with cardiovascular disease (CVD) with that of FMD.
   Methods: We measured BBA diameter and FMD in 5695 male subjects. In addition, we retrospectively investigated the incidence of cardiovascular events using another population sample consisting of 440 male subjects, to compare the accuracy of BBA diameter with that of FMD in predicting cardiovascular events.
   Results: BBA diameter and FMD significantly correlated with age, body mass index, systolic blood pressure, diastolic blood pressure, triglycerides, high-density lipoprotein cholesterol, and glucose as well as Framingham risk score. The prevalence of cardiovascular risk factors and CVD increased with the increase in BBA diameter and FMD. Area under the curve (AUC) value of the receiver operating characteristic (ROC) curve for BBA diameter to diagnose subjects without cardiovascular risk factors (0.59 vs. 0.62, p = 0.001) or patients with CVD (0.58 vs. 0.64, p < 0.001) was significantly lower than that for FMD. In the retrospective study, the AUC value of the ROC curve for BBA diameter to predict first major cardiovascular events was significantly lower than that of FMD (0.50 vs. 0.62, p = 0.03).
   Conclusions: In men, BBA diameter was inferior to FMD for assessment of cardiovascular risk. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Maruhashi, Tatsuya; Soga, Junko; Fujimura, Noritaka; Idei, Naomi; Mikami, Shinsuke; Iwamoto, Yumiko; Iwamoto, Akimichi; Kajikawa, Masato; Matsumoto, Takeshi; Oda, Nozomu; Kishimoto, Shinji; Matsui, Shogo; Hashimoto, Haruki; Hidaka, Takayuki; Kihara, Yasuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Hiroshima, Japan.
   [Chayama, Kazuaki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Gastroenterol & Metab, Biomed Sci, Hiroshima, Japan.
   [Aibara, Yoshiki; Yusoff, Farina Mohamad; Noma, Kensuke; Higashi, Yukihito] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Cardiovasc Regenerat & Med, Hiroshima, Japan.
   [Noma, Kensuke; Nakashima, Ayumu; Higashi, Yukihito] Hiroshima Univ Hosp, Div Regenerat & Med, Hiroshima, Japan.
   [Goto, Chikara] Hiroshima Int Univ, Hiroshima, Japan.
   [Tomiyama, Hirofumi; Kohro, Takahide; Yamashina, Akira] Tokyo Med Univ, Dept Cardiol, Tokyo, Japan.
   [Takase, Bonpei] Natl Def Med Coll, Div Biomed Engn, Res Inst, Tokorozawa, Saitama, Japan.
   [Suzuki, Toru] Univ Leicester, Cardiovasc Med, Leicester, Leics, England.
   [Ishizu, Tomoko] Univ Tsukuba, Inst Clin Med, Cardiovasc Div, Ibaraki, Japan.
   [Ueda, Shinichiro] Univ Ryukyus, Dept Clin Pharmacol & Therapeut, Sch Med, Nishihara, Okinawa, Japan.
   [Yamazaki, Tsutomu] Univ Tokyo, Fac Med, Clin Res Support Ctr, Tokyo, Japan.
   [Furumoto, Tomoo] Hokkaido Univ, Dept Cardiovasc Med, Grad Sch Med, Sapporo, Hokkaido, Japan.
   [Kario, Kazuomi] Jichi Med Univ, Dept Cardiovasc Med, Sch Med, Shimotsuke, Tochigi, Japan.
   [Inoue, Teruo] Dokkyo Med Univ, Dept Cardiovasc Med, Mibu, Tochigi, Japan.
   [Koba, Shinji] Showa Univ, Dept Med, Sch Med, Div Cardiol, Tokyo, Japan.
   [Watanabe, Kentaro] Yamagata Univ, Dept Neurol, DNHMED, Sch Med, Yamagata, Japan.
   [Takemoto, Yasuhiko] Osaka City Univ, Dept Internal Med & Cardiol, Grad Sch Med, Osaka, Japan.
   [Hano, Takuzo] Wakayama Med Univ, Postgrad Sch Med, Dept Med Educ & Populat Based Med, Wakayama, Japan.
   [Sata, Masataka] Univ Tokushima, Inst Hlth Biosci, Dept Cardiovasc Med, Grad Sch, Tokushima, Japan.
   [Ishibashi, Yutaka] Shimane Univ, Dept Gen Med, Fac Med, Izumo, Shimane, Japan.
   [Node, Koichi] Saga Univ, Dept Cardiovasc & Renal Med, Saga, Japan.
   [Maemura, Koji] Nagasaki Univ, Dept Cardiovasc Med, Grad Sch Biomed Sci, Nagasaki, Japan.
   [Ohya, Yusuke] Univ Ryukyus, Dept Internal Med 3, Nishihara, Okinawa, Japan.
   [Furukawa, Taiji] Teikyo Univ, Dept Internal Med, Sch Med, Tokyo, Japan.
   [Ito, Hiroshi] Okayama Univ, Dept Cardiovasc Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan.
   [Ikeda, Hisao] Teikyo Univ, Fac Fukuoka Med Technol, Omuta, Japan.
RP Higashi, Y (reprint author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Cardiovasc Regenerat & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.
EM yhigashi@hiroshima-u.ac.jp
RI Higashi, Yukihito/G-5343-2019; chayama, Kazuaki/G-2917-2019; Nakashima,
   Ayumu/N-9158-2017
OI Nakashima, Ayumu/0000-0002-7838-1494; Suzuki, Toru/0000-0002-8371-664X
FU Ministry of Education, Science and Culture of JapanMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)
   [18590815, 21590898]; Japanese Arteriosclerosis Prevention Fund
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research from the Ministry of Education, Science and Culture of Japan
   (18590815 and 21590898) and a Grant in Aid of Japanese Arteriosclerosis
   Prevention Fund.
NR 29
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 92
EP 98
DI 10.1016/j.atherosclerosis.2017.11.022
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500013
PM 29195110
DA 2019-10-28
ER

PT J
AU Marz, W
   Dippel, FW
   Theobald, K
   Gorcyca, K
   Iorga, SR
   Ansell, D
AF Maerz, Winfried
   Dippel, Franz-Werner
   Theobald, Karlheinz
   Gorcyca, Katherine
   Iorga, Serban R.
   Ansell, David
TI Utilization of lipid-modifying therapy and low-density lipoprotein
   cholesterol goal attainment in patients at high and very-high
   cardiovascular risk: Real-world evidence from Germany
SO ATHEROSCLEROSIS
LA English
DT Article
DE Cardiovascular diseases; Diabetes mellitus; LDL-C; Lipid-lowering
   therapy; LDL-C goal attainment; Real-world evidence; Germany
ID STATIN-TREATED PATIENTS; CORONARY-HEART-DISEASE; LDL-CHOLESTEROL;
   GUIDELINES; METAANALYSIS; EFFICACY; PEOPLE; COHORT; TARGET
AB Background and aims: Elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for cardiovascular (CV) events. European guidelines recommend reducing LDL-C as the primary lipid target to reduce CV risk, using lifestyle modifications and lipid-lowering therapy (LLT). Many European patients do not achieve guideline-recommended LDL-C levels. The present database analysis aimed to assess LLT treatment patterns and LDL-C threshold attainment in Germany in a large, real-world cohort of patients.
   Methods: Patients from the Cegedim Longitudinal Practice Database in Germany who met selection criteria were included: (a) LDL-C measurement in 2013; (b) >= 20 years of age; (c) high or very-high CV risk conditions: recent acute coronary syndrome (ACS), other coronary heart disease (CHD), ischemic stroke, peripheral arterial disease (PAD) (atherosclerotic cardiovascular disease [ASCVD]) or diabetes mellitus (DM) (non-ASCVD). LDL-C threshold attainment was assessed based on LDL-C targets from 2011 European guidelines.
   Results: 42,767 patients met the inclusion criteria; 35% received current statin treatment, and 30% achieved guideline-recommended LDL-C targets. Attainment of LDL-C goals among ASCVD hierarchical categories was 46.7% for recent ACS, 35.8% for ischemic stroke, 34.9% for other CHD, and 26.9% for PAD. Among patients in the non-ASCVD group with DM, 23.6% achieved LDL-C goals. Similar results were observed when patients were grouped by prevalence (patients assigned to every risk group for which they qualified).
   Conclusions: In this high/very-high CV risk population in Germany, statin utilization was low; suggesting that LLTs are not prescribed as per European guidelines. These results highlight the need to increase LLT use among high-risk patients. (C) 2017 The Authors. Published by Elsevier Ireland Ltd.
C1 [Maerz, Winfried] Synlab Acad, Mannheim, Germany.
   [Maerz, Winfried] Heidelberg Univ, Med Fac Mannheim, Med Clin 5, Nephrol Hypertensiol Rheumatol Endocrinol Diabetol, Heidelberg, Germany.
   [Maerz, Winfried] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria.
   [Dippel, Franz-Werner] Sanofi Aventis Deutschland GmbH, Berlin, Germany.
   [Theobald, Karlheinz] Sanofi Aventis Deutschland GmbH, Frankfurt, Germany.
   [Gorcyca, Katherine] Sanofi US, Bridgewater, NJ USA.
   [Iorga, Serban R.] Regeneron Pharmaceut Inc, Tarrytown, NY USA.
   [Ansell, David] IMS Hlth, London, England.
RP Marz, W (reprint author), SYNLAB Acad, P5,7, D-68161 Mannheim, Germany.
EM Winfried.Maerz@synlab.com
FU SanofiSanofi-Aventis; Regeneron Pharmaceuticals, Inc.
FX This study was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc.
NR 28
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 99
EP 107
DI 10.1016/j.atherosclerosis.2017.11.020
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500014
PM 29197254
OA Green Published, Other Gold
DA 2019-10-28
ER

PT J
AU Courand, PY
   Harbaoui, B
   Fay, H
   Grandjean, A
   Milon, H
   Lantelme, P
AF Courand, Pierre-Yves
   Harbaoui, Brahim
   Fay, Helene
   Grandjean, Adrien
   Milon, Hugues
   Lantelme, Pierre
TI Aortic atherosclerosis is a key modulator of the prognostic value of
   postural blood pressure changes
SO ATHEROSCLEROSIS
LA English
DT Article
DE Diastolic blood pressure; Systolic blood pressure; Aortic
   atherosclerosis; Cardiovascular death; Blood pressure variability
ID CARDIOVASCULAR RISK-FACTOR; ORTHOSTATIC HYPOTENSION; VASCULAR
   CALCIFICATION; ORGAN DAMAGE; HYPERTENSION; STIFFNESS; ASSOCIATION;
   VARIABILITY; MORTALITY; CORONARY
AB Background and aims: Orthostatic blood pressure decrease or increase has been related to cardiovascular events in hypertensive patients. Large blood pressure changes after orthostatic stress are associated with autonomic and neurohormonal abnormalities; aortic atherosclerosis (ATS) may also play a role.
   Methods: We investigated the interaction of ATS on the prognostic value of postural blood pressure changes. In a cohort of 958 hypertensive patients with an aortography (mean +/- standard deviation age 44 +/- 11 years, 61% men, mean blood pressure 182/110 mmHg), blood pressure was measured after 10 min of rest in the supine position. Systolic blood pressure (SBP) was also measured in standing position, 1 min after the supine position. Blood pressure changes were calculated as supine SBP minus standing SBP and analyzed as absolute or arithmetic means. ATS was assessed using an aortography score.
   Results: After 15 years of follow-up, 280 all-cause and 167 cardiovascular deaths occurred. In a multivariable Cox regression analysis adjusted for major cardiovascular risk factors and stratified according to ATS status, SBP changes were statistically associated with all-cause and cardiovascular mortality only in the presence of ATS: tertile 3 versus 1, 2.99 (1.37-6.49) and 4.08 (1.55-10.72) respectively, tertile 3 versus 2, 2.89 (1.29-6.46) and 4.82 (1.79-12.98), respectively (p for interaction: 0.003 for all-cause and 0.003 for cardiovascular mortality) for absolute changes. The hazard associated with the magnitude of SBP changes was more important than that associated with its direction.
   Conclusions: The prognostic significance of postural SBP changes is markedly influenced by ATS in hypertensive patients. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Courand, Pierre-Yves; Harbaoui, Brahim; Fay, Helene; Grandjean, Adrien; Milon, Hugues; Lantelme, Pierre] Hop Croix Rousse, Cardiol Dept, European Soc Hypertens Excellence Ctr, F-69004 Lyon, France.
   [Courand, Pierre-Yves; Harbaoui, Brahim; Fay, Helene; Grandjean, Adrien; Milon, Hugues; Lantelme, Pierre] Hosp Civils Lyon, Hop Lyon Sud, F-69004 Lyon, France.
   [Courand, Pierre-Yves; Harbaoui, Brahim; Lantelme, Pierre] Univ Claude Bernard Lyon 1, Hosp Civils Lyon, CREATIS, CNRS UMR5220,INSERM U1044,INSA Lyon, Lyon, France.
RP Courand, PY (reprint author), Hop Croix Rousse, Cardiol Dept, 103 Grande Rue Croix Rousse, F-69004 Lyon, France.
EM pycourand@hotmail.com
RI Lantelme, Pierre/G-2708-2019; Courand, Pierre-Yves/O-1054-2016;
   Harbaoui, Brahim/AAA-4986-2019; HARBAOUI, Brahim/G-5667-2019
OI Courand, Pierre-Yves/0000-0003-3199-7977; 
NR 28
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 108
EP 116
DI 10.1016/j.atherosclerosis.2017.11.025
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500015
PM 29202333
DA 2019-10-28
ER

PT J
AU Indhirajanti, S
   van Daele, PLA
   Bos, S
   Mulder, MT
   Bot, I
   van Lennep, JER
AF Indhirajanti, Swasti
   van Daele, Paul L. A.
   Bos, Sven
   Mulder, Monique T.
   Bot, Ilze
   van Lennep, Jeanine E. Roeters
TI Systemic mastocytosis associates with cardiovascular events despite
   lower plasma lipid levels
SO ATHEROSCLEROSIS
LA English
DT Article
DE Systemic mastocytosis; Carotid plaques; Carotid intima media thickness;
   Cardiovascular disease; LDL-Cholesterol; Atherosclerosis
ID ACTIVATED MAST-CELLS; MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; RUPTURE;
   HYPERCHOLESTEROLEMIA; DESTABILIZATION; PLAQUES; SITE; MICE
AB Background and aims: Mast cells have been implicated in the development and progression of atherosclerosis in animal models and human autopsy studies. However, it is unknown whether long-term exposure to excess of mast cells is associated with cardiovascular disease (CVD) in humans. Our objective was to compare the prevalence of CVD and cardiovascular risk factors in patients with systemic mastocytosis (SM) and controls.
   Methods: In 50 patients with SM and 50 age and sex matched controls, the history of CVD and presence of cardiovascular risk factors were assessed. Carotid ultrasound was performed to assess carotid intimamedia thickness (C-IMT) and plaques presence.
   Results: CVD events were more prevalent in SM patients compared to controls (20% vs. 6%, p = 0.04). The prevalence of C-IMT and carotid plaques was similar between patients with SM and controls. In multivariate analysis, CVD events were significantly associated with SM (OR 7.0 (95% CI 1.3-37.6), p = 0.02) and hypertension (OR 9.5 (95% CI 1.9-48.7), p = 0.01). The prevalence of diabetes, hypertension, obesity and smoking was similar between the two groups. Total cholesterol and LDL-C levels were significantly lower in SM patients than in the control group. (5.1 +/- 1.1 vs. 5.9 +/- 0.9 mmol/l, p < 0.05 and 2.9 +/- 0.8 vs. 3.5 +/- 0.7 mmol/l, p < 0.05, respectively).
   Conclusions: Despite lower plasma total cholesterol and LDL-C, the prevalence of CVD is higher in patients with SM compared to healthy controls. Beyond the setting of SM, this study can be considered as a proof of concept study, indicating the contribution of mast cells to CVD in humans. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Indhirajanti, Swasti; Bos, Sven; Mulder, Monique T.; van Lennep, Jeanine E. Roeters] Erasmus MC, Div Vasc Med, Dept Internal Med, Rotterdam, Netherlands.
   [van Daele, Paul L. A.] Erasmus MC, Dept Internal Med, Div Immunol, Rotterdam, Netherlands.
   [van Daele, Paul L. A.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands.
   [Bot, Ilze] Leiden Univ, Div Biopharmaceut, Leiden Acad Ctr Drug Res, Leiden, Netherlands.
RP van Lennep, JER (reprint author), POB 2040, NL-3000 CA Rotterdam, Netherlands.; van Lennep, JER (reprint author), Sgravendijkwal 230,Room D-425, NL-3015 CE Rotterdam, Netherlands.
EM j.roetersvanlennep@erasmusmc.nl
FU Netherlands Heart FoundationNetherlands Heart Foundation [2012T083]
FX I. Bot is supported by a Dr. Dekker Senior Postdoc grant from the
   Netherlands Heart Foundation (2012T083).
NR 22
TC 7
Z9 7
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 152
EP 156
DI 10.1016/j.atherosclerosis.2017.11.030
PG 5
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500020
PM 29227868
OA Other Gold, Green Published
DA 2019-10-28
ER

PT J
AU Fryer, S
   Stone, K
   Dickson, T
   Faulkner, J
   Lambrick, D
   Corres, P
   Jerred, L
   Stoner, L
AF Fryer, Simon
   Stone, Keeron
   Dickson, Tabitha
   Faulkner, James
   Lambrick, Danielle
   Corres, Pablo
   Jerred, Lauren
   Stoner, Lee
TI Reliability of oscillometric central blood pressure responses to lower
   limb resistance exercise
SO ATHEROSCLEROSIS
LA English
DT Article
DE Resistance training; Pulse wave analysis; Augmentation index
ID PULSE-WAVE ANALYSIS; AMERICAN-HEART-ASSOCIATION; AUGMENTATION INDEX;
   CARDIOVASCULAR-DISEASE; CLINICAL-CARDIOLOGY; PHYSICAL-ACTIVITY;
   REPRODUCIBILITY; INDIVIDUALS; GUIDELINES; STATEMENT
AB Background and aims: Although it is well known that resistance training (RT) is beneficial for patients suffering from a variety of cardiovascular diseases, it remains underutilized as a rehabilitation tool as there is no reliable way to monitor the additional stress placed on the central organs. The current study aimed to determine between-day reliability of central haemodynamic indices using oscillometric pulse wave analysis (PWA) during progressive sub-maximal RT.
   Methods: Nineteen healthy young males were tested on 3 different mornings in a fasted state. Central hemodynamic variables including augmentation index (AIx), AIx normalized to a heart rate of 75 beats per minute (AIx@75), central systolic blood pressure (cSBP), forwards (Pf) and backwards (Pb) wave reflection were determined at rest, as well as during leg extension RT at 10, 15 and 20% of maximal volitional contraction (MVC), and following 1 min and 5 min passive recovery.
   Results: During RT at 10, 15 and 20% MVC, the intraclass correlation coefficient (ICC) values for AIx@75 (0.76-0.9), cSBP (0.74-0.78), Pf (0.75-0.82) and Pb (0.75-0.83) exceeded the criteria (0.75) for excellent reliability. During the 5 min recovery, the ICC values for AIx@75 (0.87-0.87), cSBP (0.69-0.7), Pf (0.63 -0.67) and Pb (0.63-0.66) indicated good to excellent reliability.
   Conclusions: Clinically meaningful changes in central hemodynamic indices can be obtained during resistance training using oscillometric PWA devices. This technology holds potential for advancing resistance training prescription guidelines for patients with overt cardiovascular diseases. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Fryer, Simon; Stone, Keeron; Dickson, Tabitha; Jerred, Lauren] Univ Gloucestershire, Sch Sport & Exercise, Cheltenham, Glos, England.
   [Faulkner, James] Univ Winchester, Dept Sport & Exercise, Winchester, Hants, England.
   [Lambrick, Danielle] Univ Southampton, Fac Hlth Sci, Southampton, Hants, England.
   [Corres, Pablo] Univ Basque Country, UPV EHU, Fac Educ & Sport, Dept Phys Educ & Sport, Araba Alava, Basque Country, Spain.
   [Stoner, Lee] Univ N Carolina, Dept Sport & Exercise, Chapel Hill, NC USA.
RP Fryer, S (reprint author), Univ Gloucestershire, Oxstalls Campus, Gloucester GL2 9HW, England.
EM dr.s.fryer@gmail.com
RI Stoner, Lee/C-8504-2011
OI Stoner, Lee/0000-0002-0682-2270; Fryer, Simon/0000-0003-0376-0104;
   Lambrick, Danielle/0000-0002-0325-6015; Stone,
   Keeron/0000-0001-6572-7874
NR 34
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 157
EP 162
DI 10.1016/j.atherosclerosis.2017.11.031
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500021
PM 29227869
DA 2019-10-28
ER

PT J
AU Li, TT
   Li, TH
   Peng, J
   He, B
   Liu, LS
   Wei, DH
   Jiang, ZS
   Zheng, XL
   Tang, ZH
AF Li, Ting-Ting
   Li, Tao-Hua
   Peng, Juan
   He, Bei
   Liu, Lu-Shan
   Wei, Dang-Heng
   Jiang, Zhi-Sheng
   Zheng, Xi-Long
   Tang, Zhi-Han
TI TM6SF2: A novel target for plasma lipid regulation
SO ATHEROSCLEROSIS
LA English
DT Review
DE Transmembrane 6 superfamily 2; Plasma lipids; Cardiovascular disease
ID NONALCOHOLIC FATTY LIVER; SUPERFAMILY MEMBER 2; C-REACTIVE PROTEIN;
   DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR RISK-FACTOR; E167K
   VARIANT; HEPATIC STEATOSIS; DISEASE; RS58542926; LOCI
AB Transmembrane 6 superfamily 2 (TM6SF2), a gene identified at the locus 19p12, has been recognized to regulate plasma lipids. Here, we provide an overview of the roles of TM6SF2 as a novel target for plasma lipid regulation. We first review the association of TM6SF2 variant with plasma lipid traits, cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD). Then, we present an overview about the in vivo validation of TM6SF2 as a regulator of plasma lipid levels using mice, with overexpression or knockdown/knockout of TM6SF2. Thereafter, we discuss the mechanisms underlying TM6SF2 regulation of lipid metabolism involving intestinal cholesterol absorption and hepatic cholesterol biosynthesis and transport.
   In conclusion, increasing evidence suggests that TM6SF2 may be a major regulator of plasma lipid levels and become a therapeutic target in cardiovascular disease. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Li, Ting-Ting; Li, Tao-Hua; Peng, Juan; He, Bei; Liu, Lu-Shan; Wei, Dang-Heng; Jiang, Zhi-Sheng; Tang, Zhi-Han] Univ South China, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China.
   [Peng, Juan; Zheng, Xi-Long; Tang, Zhi-Han] Univ Calgary, Hlth Sci Ctr, Libin Cardiovasc Inst Alberta, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
RP Tang, ZH (reprint author), Univ South China, Key Lab Arteriosclerol Hunan Prov, Inst Cardiovasc Dis, Hengyang 421001, Hunan, Peoples R China.
EM tangzhihan98@163.com
FU Fellowship Award of International atherosclerosis society; Educational
   Department of Hunan Province Fund for Distinguished Young Scholars
   [16B228]; Hunan Province Postgraduate Research and Innovation Project
   [CX2017B549]; Undergraduate Training Programs for Innovation and
   Entrepreneurship [20161055500, 2016-283-309]; Construct Program of the
   Basic Medicine Key Discipline in Hunan Province
FX This work was supported by the Fellowship Award of International
   atherosclerosis society (2017), the grants from the Educational
   Department of Hunan Province Fund for Distinguished Young Scholars
   (16B228), the Hunan Province Postgraduate Research and Innovation
   Project (CX2017B549), the Undergraduate Training Programs for Innovation
   and Entrepreneurship (20161055500, 2016-283-309), and the Construct
   Program of the Basic Medicine Key Discipline in Hunan Province.
NR 68
TC 4
Z9 4
U1 3
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 170
EP 176
DI 10.1016/j.atherosclerosis.2017.11.033
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500023
PM 29232562
DA 2019-10-28
ER

PT J
AU Pessentheiner, AR
   Ramms, B
   Gordts, PLSM
AF Pessentheiner, Ariane R.
   Ramms, Bastian
   Gordts, Philip L. S. M.
TI ANGPTL3 targeting: The power of versatile lipid-lowering
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE Hyperlipidemia; Triglycerides; Cholesterol; LDLR; RNAi; Atherosclerosis
ID HDL CHOLESTEROL; PLASMA; INACTIVATION; LIPOPROTEIN; INHIBITION; GENETICS
C1 [Pessentheiner, Ariane R.; Ramms, Bastian; Gordts, Philip L. S. M.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Ramms, Bastian] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   [Ramms, Bastian] Bielefeld Univ, Dept Chem, Biochem 1, Bielefeld, Germany.
RP Gordts, PLSM (reprint author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
EM pgordts@ucsd.edu
OI Pessentheiner, Ariane/0000-0002-5010-9528; Gordts,
   Philip/0000-0001-7224-4328
FU Erwin-Schrodinger Fellowship [FWF J4031-B21]; American Heart Association
   Predoctoral FellowshipAmerican Heart Association [17PRE33410619];
   American Heart AssociationAmerican Heart Association [15BGIA25550111];
   Fondation LeducqLeducq Foundation; National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [1 R21 HD089067-01A1]
FX Ariane R. Pessentheiner is supported by an Erwin-Schrodinger Fellowship
   (FWF J4031-B21), Bastian Ramms is supported by an American Heart
   Association Predoctoral Fellowship (17PRE33410619) and Philip L.S.M.
   Gordts is supported by the American Heart Association (15BGIA25550111),
   the Fondation Leducq and by the National Institutes of Health (1 R21
   HD089067-01A1).
NR 20
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 185
EP 187
DI 10.1016/j.atherosclerosis.2017.10.002
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500025
PM 29111225
DA 2019-10-28
ER

PT J
AU Mule, G
   Vadala, M
   Geraci, G
   Cottone, S
AF Mule, Giuseppe
   Vadala, Maria
   Geraci, Giulio
   Cottone, Santina
TI Retinal vascular imaging in cardiovascular medicine: New tools for an
   old examination
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
ID FRACTAL ANALYSIS; MICROVASCULAR STRUCTURE; HEART-DISEASE; RISK;
   DIMENSION
C1 [Mule, Giuseppe; Geraci, Giulio; Cottone, Santina] Univ Palermo, Dipartimento Biomed Med Interna & Specialist DIBI, Unit Nephrol & Hypertens, European Soc,Hypertens Excellence Ctr, Palermo, Italy.
   [Vadala, Maria] Univ Palermo, Ophthalmol Sect, Dipartimento Biomed Sperimentale & Neurosci Clin, Palermo, Italy.
RP Mule, G (reprint author), Via Mt San Calogero 29, I-90146 Palermo, Italy.
EM giuseppe.mule@unipa.it
RI Geraci, Giulio/U-5985-2019
OI Geraci, Giulio/0000-0003-3806-1151; Mule', Giuseppe/0000-0002-8500-8671
NR 20
TC 2
Z9 2
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 188
EP 190
DI 10.1016/j.atherosclerosis.2017.11.001
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500026
PM 29145994
DA 2019-10-28
ER

PT J
AU Stiebellehner, L
   Pesau, G
   Schernthaner, GH
AF Stiebellehner, Leopold
   Pesau, Gerfried
   Schernthaner, Gerit-Holger
TI Chronic lung disorders and abdominal aortic aneurysms: An old clinical
   observation now proven?
SO ATHEROSCLEROSIS
LA English
DT Editorial Material
DE COPD; RLD; AAA
C1 [Stiebellehner, Leopold] Med Univ Vienna, Div Pulmol, Med 2, Vienna, Austria.
   [Pesau, Gerfried; Schernthaner, Gerit-Holger] Med Univ Vienna, Div Angiol, Med 2, Vienna, Austria.
RP Schernthaner, GH (reprint author), Med Univ Vienna, Dept Internal Med 2, Div Angiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM gerit.schernthaner@meduniwien.ac.at
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JAN
PY 2018
VL 268
BP 191
EP 192
DI 10.1016/j.atherosclerosis.2017.11.004
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA FR5IF
UT WOS:000419099500027
PM 29157610
DA 2019-10-28
ER

EF